臨床腫瘍学 CLINICAL ONCOLOGY Third edition (日本臨床腫瘍学会編)

出版社： 癌と化学療法社
著者：
発行日： 2003-11-28
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784906225392
電子書籍版： 2003-11-28 （第1版第1刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

13,750 円(税込)

購入する

商品紹介

進月歩のがん研究と臨床をup-to-dateに理解できる教科書は急速に進歩を続ける臨床腫瘍学の教育と知識の普及に必須と思われ、編集した。

目次

  • 表紙
  • 執筆者一覧
  • レビュアー一覧
  • 目次
  • 序
  • I. Principles of oncology
  • 1. がんの分子生物学 ―総論ゲノムとがん―
  • 2. がん細胞のシグナル伝達
  • 3. 腫瘍免疫 ―総論―
  • 4. 染色体異常とがん
  • 5. 細胞周期
  • 6. がん遺伝子・がん抑制遺伝子
  • 7. アポトーシス
  • 8. がんの浸潤と転移
  • 9. 血管新生
  • 10. 発がん
  • 1. ウイルス発がん
  • 2. 化学発がん
  • 3. 物理因子
  • 11. 疫学研究の方法論とがんの統計
  • 12. 分子標的治療とトランスレーショナル・リサーチ
  • 13. がん研究における個別化とEBM
  • 14. 外科療法
  • 15. 放射線療法
  • 16. 化学療法
  • 17. Interventional radiology
  • 18. 抗悪性腫瘍薬の薬理学
  • 1. 薬物動態・薬力学
  • 2. がん細胞パネル ― 抗がん剤探索およびポストゲノム研究における活用
  • 3. DDS
  • 4. 殺細胞効果の分類と作用機序
  • a. トポイソメラーゼ阻害剤
  • b. 白金化合物
  • c. 代謝拮抗剤
  • d. 微小管に作用する抗がん剤
  • e. その他 (アルキル化剤, 抗がん抗生物質)
  • 19. 分子標的治療薬 (Biotherapyを含む)
  • 1. インターフェロン・インターロイキン
  • 2. ホルモン療法
  • 3. 分化誘導療法
  • 4. 抗体療法
  • 5. 分子標的治療薬 ― シグナル伝達阻害剤, 血管新生阻害剤, 細胞周期阻害剤
  • 20. 薬剤耐性
  • 21. 新しい治療戦略
  • 1. 遺伝子治療
  • 2. がんワクチン
  • 3. 内視鏡下手術・ロボット手術
  • 4. 荷電粒子線 (イオン線) 治療
  • 5. 内視鏡治療
  • 6. レーザー光化学治療
  • 22. 臨床試験
  • 1. 臨床試験に必要な組織と人
  • 2. 臨床試験のデザインと解析
  • 3. 行政からみた臨床試験
  • 4. がん診療における医療倫理とインフォームド・コンセント
  • 5. 臨床試験のデータマネージメント
  • II. Practice of oncology
  • 23. がん予防
  • 1. 禁煙・食事等
  • 2. がんの化学予防
  • 24. がん検診
  • 25. がん診断学
  • 1. CT・MRI・Functional imaging・RI診断・Ultrasound ―総論―
  • 2. 内視鏡診断学 ―消化器―
  • 3. 小型肺癌診断の進歩と問題点
  • 4. 分子診断学
  • 5. 病理診断学
  • 6. 腫瘍マーカー
  • <臓器別がん>
  • 26. 頭頸部がん
  • 27. 肺癌
  • 1. 小細胞肺癌
  • a. 内科
  • b. 限局型小細胞肺癌の化学放射線治療
  • 2. 非小細胞肺癌
  • a. 内科
  • b. 外科
  • 28. 縦隔腫瘍
  • 29. 食道癌
  • 1. 内科領域
  • 2. 食道癌の外科治療
  • 30. 乳癌
  • 31. 胃癌
  • 1. 内科
  • 2. 外科
  • 32. 結腸・直腸癌
  • 33. 原発性肝癌
  • 34. 膵癌
  • 1. 内科
  • 2. 外科
  • 35. 胆道系がん
  • 36. 腎・尿路上皮癌
  • 1. 腎細胞癌
  • 2. 尿路上皮癌
  • 37. 前立腺癌
  • 38. 精巣腫瘍
  • 39. 子宮癌
  • 1. 子宮頸癌・外陰癌
  • 2. 子宮体癌
  • 40. 卵巣癌・絨毛癌
  • 41. 悪性骨・軟部腫瘍の治療
  • 42. 皮膚癌
  • 1. 悪性黒色腫
  • 2. 皮膚癌 (その他)
  • 43. 脳腫瘍
  • 44. 内分泌系腫瘍
  • 45. (性腺外) 胚細胞腫瘍 (Extragonadal germ cell tumor)
  • 46. 小児固形がん
  • 47. 小児の白血病と悪性リンパ腫
  • 48. 白血病と類縁疾患
  • 49. 造血幹細胞移植
  • 50. 悪性リンパ腫
  • 1. ホジキンリンパ腫
  • 2. 非ホジキンリンパ腫
  • 51. 多発性骨髄腫 (Multiple myeloma:MM)
  • 52. 原発不明がん (Cancer of unknown primary)
  • 53. HIV感染と新生物
  • 54. 腫瘍随伴症候群
  • 55. がん性漿膜炎
  • 1. がん性胸膜炎
  • 2. 心嚢炎
  • 3. がん性腹膜炎・がん性腹水
  • 56. 転移がんの治療
  • 1. 肝転移
  • 2. がんの骨転移
  • 3. がんの脳転移 (転移性脳腫瘍)
  • 57. 腫瘍関連緊急対策
  • 1. 上大静脈症候群
  • 2. 悪性腫瘍に伴う高カルシウム血症
  • 3. 転移性脊椎腫瘍による脊髄麻痺
  • 4. 消化管悪性腫瘍に対する緊急手術
  • 5. 泌尿器科的対策
  • 6. がん関連感染症
  • 58. 支持療法
  • 1. 化学療法薬物有害反応の対策
  • 2. 栄養対策
  • 3. がん性疼痛対策
  • 4. がん性疼痛対策最新のガイドライン がん性疼痛対策の基本方針
  • 59. がん看護学
  • 60. サイコオンコロジー (Psycho-oncology)
  • 61. がん緩和医療学
  • 62. がん治療とQuality of Life
  • 索引
  • 日本臨床腫瘍「メディカルオンコロジー」学会会則
  • 日本臨床腫瘍学会専門医制度規則「附則I」
  • 日本臨床腫瘍学会専門医制度規則施行細則
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

P.13 掲載の参考文献
1) International Human Genome Sequencing Consortium : Initial sequencing and analysis of the human genome. Nature 409: 860-921, 2001.
PubMed
2) Venter JC, Adamas MD, Myers EW, et al: The sequence of the human genome. Science 291: 1304-1351, 2001.
 
3) Hogenesch JB, Ching KA, Batalov S, et al: A comparison of the Celera and Ensembl predicted gene sets reveals little overlap in novel genes. Cell . 106: 413-415, 2001.
PubMed
4) http://www. ncbi. nlm. nih. gov/genome/seq/
 
5) Mouse Genome Sequencing Consortium: Initial sequencing and comparative analysis of the mouse genome. Nature 420: 520-562, 2002.
PubMed
6) Collins FS: Shattuck Lecture-Medical and social consequences of the Human Genome Project. NEJM 341: 28-37, 1999.
 
7) Waterfield MD, Scrace GT, Whittle N, et al: Platelet-derived growth factor is structurally related to the putativetransforming protein p28 sis of simian sarcoma virus. Nature 304(5921) : 35-39, 1983. L
 
8) Land H, Parada LF and Weinberg RA: Cellular oncogenes and multistep carcinogenesis. Science 222(4625) : 771-778, 1983.
PubMed
9) Knudson AG: Mutation and cancer: astatistical study of retinoblastoma. PNS 68: 820-823, 1971.
 
10) Kuramochi M, Fukuhara H, Nobukuni T, et al: TSLCI is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 27(4) : 427-430, 2001.
PubMed
11) Collins FS: Positional cloning moves from perditional to traditional. Nat Genet 9(4) : 347-350, 1995.
PubMed
12) Sugimura T: Multistep carcinogenesis: al992 perspective. Science 258(5082) : 603-607, 1992.
PubMed
13) Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71(4) : 543-546, 1992.
 
14) Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
PubMed
15) Pollack JR, Perou CM, Alizadeh AA, et al: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23: 41-46, 1999.
PubMed
16) Monni O, Hyman E, Mousses S, et al: From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. Semin Cancer Bio111(5) : 395-401, 2001.
PubMed
17) TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by geneexpression monitoring. Science 286: 531-537, 1999.
 
18) Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expressionprofiling. Nature 403: 503-511, 2000.
PubMed
19) Bittner M, Meltzer P, Chen Y, et al: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536-540, 2000.
PubMed
20) Welsh JB, Zarrinkar PP, Sapinoso LM, et al: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98: 1176-1181, 2001.
PubMed
21) Okabe H, Satoh S, Kato T, et al: Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61: 2129-2137, 2001.
PubMed
22) Khan J, Wei JS, Ringner M, et al: Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7: 673-679, 2001
PubMed
23) Kihara C, Tsunoda T, Tanaka T, et al: Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 61: 6474-6479, 2001.
PubMed
24) Garber ME, Troyanskaya OG, Schluens K, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98(24) : 13784-13789, 2001.
PubMed
25) Bhattacharjee A, Richards WG, Staunton J, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98(24) : 13790-13795, 2001.
PubMed
26) van't Veer LJ, Dai H, van de Vijver M, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
 
27) Hippo Y, Taniguchi H, Tsutsumi S, et al: Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 62(1) : 233-240, 2002.
PubMed
28) Selaru FM, Xu Y, Yin J, et al: Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. Gastroenterology 122(3) : 606-613, 2002.
PubMed
29) Miura K, Bowman ED, Simon R, et al: Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking-and prognosis-related molecular profiles. Cancer Res 62: 3244-3250, 2002.
PubMed
30) Lin YM, Furukawa Y, Tsunoda T, et al: Molecular diagnosis of colorectal tumors by expression profiles of 50 genesexpressed differentially in adenomas and carcinomas. Oncogene 21(26) : 4120-4128, 2002.
 
31) Aoyagi K, Tatsuta T, Nishigaki M, et al: A faithful method for PCR-mediated global mRNA amplification and its integration into microarray analysis on laser-captured cells. Biochem Biophys Res Commun 300: 915-920, 2003.
 
32) Friend SH, Horowitz JM, Gerber MR, et al: Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci USA 84(24) : 9059-9063, 1987.
PubMed
33) Donis-Keller H, Dou S, Chi D, et al: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2(7) : 851-856, 1993.
PubMed
34) Hofstra RM, Landsvater RM, Ceccherini I, et al: Amutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367(6461) : 375-376, 1994
 
35) Nishisho I, Nakamura Y, Miyoshi Y, et al : Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253(5020) : 665-669, 1991.
PubMed
36) Chandrasekharappa SC, Guru SC, Manickam P, et al: Positional cloning of the gene for multiple endocrine neoplasia-type1. Science 276(5311) : 404-407, 1997.
 
37) Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 14(5) : 1730-1736, 1996. http://www. asco. org/
 
38) 遺伝学的検査に関するガイドライン(案) : 日本遺伝カウンセリング学会, 日本遺伝子診療学会, 日本産婦人科学会, 日本小児遺伝学会, 日本人類遺伝学会, 日本先天異常学会, 日本先天代謝異常学会, 家族性腫瘍研究会. 平成13年3月27日. http://cellbank. nihs. go. jp/information/ethics/documents/8 academic 2001. pdf
 
39) Pharoah PD, Antoniou A, Bobrow M, et al: Polygenic susceptibility to breast cancer and implications for prevention. NatGenet 31(1) : 33-36, 2002.
 
40) 鎌谷直之・編: ポストゲノム時代の遺伝統計学. 羊土社, 東京, 2001.
 
41) Risch N and Merikangas K: The future of genetic studies of complex human diseases. Science 273: 1516-1517, 1996.
PubMed
42) Weiss KM and Terwilliger JD: How many diseases does it take to map a gene with SNPs?Nat Genet 26(2) : 151-157, 2000.
PubMed
43) Lichtenstein P, Holm NV, Verkasalo PK, et al: Environmental and heritable factors in the causation of cancer. NEJM 343(2) : 78-85, 2000.
PubMed
44) Holtzman NA and Marteau TM: Will genetics revolutionize medicine? NEJM 343: 141-144, 2000.
PubMed
45) Kruglyak L and Nickerson DA: Variation is the spice of life. Nat Genet 27: 234-236, 2001.
PubMed
46) Liu H-X, Cartegni L, Zhang MQ, et al: A mechanism for exon skipping caused by nonsense or missense mutations in BRCA 1 and other genes. Nat Genet 27: 55-58, 2001.
PubMed
47) Ohnishi Y, Tanaka T, Ozaki K, et al: A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 46: 471-477, 2001.
PubMed
48) The International SNP map working group: A map of human genome sequence variation containing 1. 42 million single nucleotide polymorphisms. Nature 409: 928-933, 2001.
 
49) Marth G, Yeh R, Minton M, et al: Single-nucleotide polymorphisms in the public domain: how useful are they? Nat Genet 27: 371-373, 2001.
PubMed
50) Wilson JF, Weale ME, Smith AC, et al : Population genetic structure of variable drug response. Nat Genet 29: 265-269, 2001.
PubMed
51) Hirakawa M, Tanaka T, Hashimoto Y, et al: JSNP: Adatabase of common gene variations in the Japanese population. Nucleic Acids Res 30: 158-162, 2002.
PubMed
52) http://snp. ims. u-tokyo. ac. jp/index_ja. html
 
53) Goldstein DB: Islands of linkage disequilibrium. Nat Genet 29: 109-111, 2001.
PubMed
54) Patil N, Berno AJ, Hinds DA, et al: Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 294(5547) : 1719-1723, 2001.
PubMed
55) Gabriel SB, Schaffner SF, Nguyen H, et al: The structure of haplotype blocks in the human genome. Science 296 (5576) : 2225-2229, 2002.
 
56) Evans WE and Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286 (5439) : 487-491, 1999.
PubMed
57) Relling MV and Dervieux T: Pharmacogenetics and cancer therapy. Nat Rev Cancer 1: 99-108, 2001.
 
58) http://www2. ncc. go. jp/elsi/
 
P.25 掲載の参考文献
1) Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
PubMed
2) Hunter T: Signaling-2000 and beyond. Cell 100: 113-127, 2000.
PubMed
3) 宮園浩平・編: 特集「TGF-βシグナリングと癌」. 蛋白質 核酸 酵素 46: 101-129, 2001.
 
4) 田矢洋一・編: p53研究の新たな挑戦(新規ターゲット遺伝子, リン酸化とアセチル化, シグナル伝達, アポトーシスからがん治療まで) . 実験医学 19: 1045-1182, 2001.
 
5) Pawson T, Raina M and Nash P: Interaction domains: from simple binding events to complex cellular behavior. FEBS Lett 513: 2-10, 2002.
PubMed
6) Marshall MS: Ras target proteins in eukaryotic cells. Faseb J 9: 1311-1318, 1995.
PubMed
7) Hsuan JJ and Tan SH: Growth factor-dependent phosphoinositide signalling. Int J Biochem Cell Biol 29: 415-435, 1997.
PubMed
8) Toker A and Cantley LC: Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387: 673-676, 1997.
PubMed
9) Erpel T and Courtneidge SA: Src family protein tyrosine kinases and cellular signal transduction pathways. Curr Opin Cell Biol 7: 176-182, 1995.
PubMed
10) Linnekin D, Mou S, Deberry CS, et al: Stem cell factor, the JAK-STAT pathway and signal transduction. Leuk Lymphoma 27: 439-444, 1997.
PubMed
11) de Caestecker MP, Piek E and Roberts AB: Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 92: 1388-1402, 2000.
 
12) Akhurst RJ and Derynck R: TGF-beta signaling in cancer-a double-edged sword. Trends Cell Bio1 11: S44-51, 2001.
 
13) Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
PubMed
14) Leyland-Jones B: Trastuzumab: hopes and realities. Lancet Oncol 3: 137-144, 2002.
PubMed
15) Takahashi M, Asai N, Iwashita T, et al: Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations. Recent Results Cancer Res 154: 229-236, 1998.
 
16) Carlomagno F, Melillo RM, Visconti R, et al: Glial cell line-derived neurotrophic factor differentially stimulates retmutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. Endocrinology 139: 3613-3619, 1998.
PubMed
17) Bocciardi R, Mograbi B, Pasini B, et al: The multiple endocrine neoplasia type 2B point mutation switches the specificityof the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 15: 2257-2265, 1997.
 
18) Smith-Hicks CL, Sizer KC, Powers JF, et al: C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. Embo J 19: 612-622, 2000.
 
19) Acton DS, Velthuyzen D, Lips CJ, et al: Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 19: 3121-3125, 2000.
 
20) Taniguchi M, Nishida T, Hirota S, et al: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59: 4297-4300, 1999.
PubMed
21) Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001.
PubMed
22) Young MA, Gonfloni S, Superti-Furga G, et al: Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell 105: 115-126, 2001.
 
23) Irby RB, Mao W, Coppola D, et al: Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21: 187-190, 1999.
 
24) Laurent E, Talpaz M, Kantarjian H, et al: The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 61: 2343-2355, 2001.
PubMed
25) Pluk H, Dorey K and Superti-Furga G: Autoinhibition of c-Abl. Cell 108: 247-259, 2002.
PubMed
26) Sawyers C: Disabling Abl-Perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 1: 13-15, 2002.
 
27) Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001.
PubMed
28) Bromberg JF: Activation of STAT proteins and growth control. Bioessays 23: 161-169, 2001.
PubMed
29) Schwaller J, Parganas E, Wang D, et al: Stat 5 is essential for the myelo-and lymphoproliferative disease induced by TEL/JAK 2. Mol Cell 6: 693-704, 2000.
 
30) Rosa Santos SC, Dumon S, Mayeux P, et al: Cooperation between STAT 5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line. Oncogene 19: 1164-1172, 2000.
 
31) Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93: 1062-1074, 2001.
PubMed
32) Shields JM, Pruitt K, McFall A, et al: Understanding Ras: tit ain't over'til it's over'. Trends Cell Biol 10: 147-154, 2000.
 
33) McCormick F: Signalling networks that cause cancer. Trends Cell Biol 19: M53-56, 1999.
 
34) Fritz G, Just I and Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer 81: 682-687, 1999.
PubMed
35) Schnelzer A, Prechtel D, Knaus U, et al: Racl in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Raclb. Oncogene 19: 3013-3020, 2000.
 
36) Nobes CD and Hall A: Rho, rac, and cdc 42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81: 53-62, 1995.
 
37) Itoh K, Yoshioka K, Akedo H, et al: An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5: 221-225, 1999.
PubMed
38) Sahai E and Mershall CJ: Rho-GTPases and cancer. Nature Reviews 2: 133-142, 2002.
 
39) Adnane J, Bizouarn FA, Qian Y, et al: p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta-and Sp1-responsive element: involvement of the small GTPase rhoA. Mol Cell Biol 18: 6962-6970, 1998.
PubMed
40) Philp AJ, Campbell IG, Leet C, et al: The phosphatidylinositol 3'-kinase p85 alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61: 7426-7429, 2001.
 
41) Shayesteh L, Lu Y, Kuo WL, et al: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102, 1999.
PubMed
42) Jimenez C, Jones DR, Rodriguez-Viciana P, et al: Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. Embo J 17: 743-753, 1998.
PubMed
43) Vogt PK: PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med 7 : 482-484, 2001.
PubMed
44) Hidalgo M and Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686, 2000.
 
45) Daniels DL, Eklof Spink K and Weis WI: beta-catenin: molecular plasticity and drug design. Trends Biochem Sci 26: 672-678, 2001.
PubMed
46) Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-1851, 2000.
PubMed
47) Satoh S, Daigo Y, Furukawa Y, et al: AXINl mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24: 245-250, 2000.
PubMed
P.31 掲載の参考文献
1) Coley, William B: A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysipelas Post-graduate 8: 278-286, 1893.
 
2) Nauts HC: A review of the influence of bacterial infection and of bacterial products (Coley's toxin) on malignant tumors in man. Acta Med Scand Suppl 276: 1-103, 1953.
 
3) Steinman RM and Cohn ZA: Identification of a novel cell type inperipheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 137: 1142-1155, 1973.
 
4) Inaba K, Inaba M, Romani N, et al: Generation of large numbers of dendritic cells from bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693-1702, 1992.
PubMed
5) Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91: 3515-3519, 1994.
PubMed
6) Shichij o S, Nakao M, Imai Y, et al: Agene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187: 277-288, 1998.
 
7) Caux C, Dezutter DC, Schmitt D, et al: G M-CSF and TNF-alpha cooperate in the generation of dendritic Langhans cells. Nature 360: 258-261, 1992.
 
8) Sallusto F and Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is matintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and down regulated by tumor necrosis factor alpha. J Exp Med 179: 1109-1118, 1994.
 
9) Schuler-Thurner B, Schultz ES, Berger TG, et al: Rapid induction of tumor-specific type l T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195: 1279-1288, 2002.
 
10) Hillenbrand EE, Neville AM and Coventry BJ: Immunohistochemical localization of CD 1 a-positive putative dendritic cells in human breast tumours. Br J Cancer 79: 940-944, 1999.
 
11) Zeid NA and Muller HK: S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 25: 338-343, 1993.
PubMed
12) Matsuda H, Mori M, Tsujitani S, et al: Immunohistochemical evaluation of squamous cell carcinoma antigen and S-100 protein-positive cells in human malignant esophageal tissues. Cancer 65: 2261-2265, 1990.
PubMed
13) Tsujitani S, Kakeji Y, Watanabe A, et al: Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 66: 2012-2016, 1990.
PubMed
14) Noguchi Y, Richards EC, Chen YT, et al: Influence of interleukin 120n p 53 peptide vaccination against established Meth Asarcoma. Proc Natl Acad Sci USA 92: 2219-2223, 1995.
 
15) Mayordomo JI, Zorina T, Storkus WJ, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1: 1297-1302, 1995.
 
16) Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
PubMed
17) Lu L, Li W, Fu F, et al: Blockade of the CD 40-CD 40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survivaL Transplantation 64: 1808-1815, 1997.
 
18) Hirao M, Onai N, Hiroishi K, et al: CC chemokine receptor-70n dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 60: 2209-2217, 2000.
 
19) Specht JM, Wang G, Do MT, et al: Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 186: 1213-1221, 1997.
PubMed
20) Song W, Kong HL, Carpenter H, et al: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 186: 1247-1256, 1997.
 
21) Tueting T, Wilson CC, Martin DM, et al: Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th 1-biasing cytokines IL-12 and IFN-alpha. J Immunol 160: 1139-1147, 1998.
 
22) Nishioka Y, Robbins PD, Lotze MT, et al: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells geneticaUy modified to express interleukin 12. Cancer Res 59: 4035-4041, 1999.
PubMed
23) Maraskovsky E, Brasel K, Teepe M, et al: increase in the numbers of functionally mature dendritic cells in Flt 3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184: 1953-1962, 1996.
PubMed
P.42 掲載の参考文献
1) Rabbitts TH: Chromosomal translocation in human cancer. Nature 372(6502) : 143-149, 1994.
PubMed
2) Sugimoto N, Imoto I, Fukuda Y, et al: IQGAP 1, a negative regulator of cell-cell adhesion, is upregulated by gene amplification at 15 q 26 in gastric cancer cell lines HSC 39 and 40 A. J Hum Genet 46(1) : 21-25, 2001.
 
3) Imoto I, Yang ZQ, Pimkhaokham A, et al: Identification of cIAP l as a candidate target gene within an amplicon at 11 q 22 in esophageal squamous cell carcinomas. Cancer Res 61(18) : 6629-6634, 2001.
 
4) Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL genemutation or amplification. Science 293(5531) : 876-880, 2001.
PubMed
5) Wang P, Spielberger RT, Thangavelu M, et al: dic (5; 17) : arecurring abnormality in malignant myeloid disorders associated with mutations of TP 53. Genes Chromosomes Cancer 20(3) : 282-291, 1997.
 
6) Ferguson DO and Alt FW: DNA double strand break repair and chromosomal translocation: lessons from animal models. Oncogene 20(40) : 5572-5579, 2001.
PubMed
7) Li R, Sonik A, Stindl R, et al: Aneuploidy vs gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. Proc Natl Acad Sci USA 97(7) : 3236-3241, 2000.
PubMed
8) Jimbo T, Kawasaki Y, Koyama R, et al: Identification of a link between the tumour suppressor APC and the kinesin superfamily. Nat Cell Bio14(4) : 323-327, 2002.
 
9) Taniwaki M, Nishida K, Misawa S, et al: Correlation of chromosome abnormalities with clinical characteristics in thyroid lymphoma. Cancer 63(5) : 873-876, 1989.
PubMed
10) Schrock E, du Manoir S, Veldman T, et al: Multicolor spectral karyotyping of human chromosomes. Science 273(5274) : 494-497, 1996.
PubMed
11) Taniwaki M, Silverman GA, Nishida K, et al : Translocations and amplification of the BCL 2 gene are detected in interphase nuclei of non-Hodgkin's lymphoma by in situ hybridization with yeast artificial chromosome clones. Blood86(4) : 1481-1486, 1995.
 
12) Nomura K, Sekoguchi S, Ueda K, et al: Differentiation of follicular from mucosa-associated lymphoid tissue lymphomaby detection of t(14; 18) on single cell preparations and paraffin-embedded sections. Genes Chromosomes Cancer 33(2) : 213-216, 2002. Nomura K, Sekoguchi S, Ueda K, et al: Differentiation of follicular from mucosa-associated lymphoid tissue
 
13) van den Engh G, Sachs R, Trask BJ, et al: Estimating genomic distance from DNA sequence location in cell nuclei by a random walk model. Science 257(5075) : 1410-1412, 1992.
PubMed
14) Saitoh Y and Laemmli UK: Metaphase chromosome structure: bands arise from a differential folding path of the highly AT-rich scaffold. Cell 76(4) : 609-622, 1994.
PubMed
15) Zirbel RM, Mathieu UR, Kurz A, et al: Evidence for a nuclear compartment of transcription and splicing located at chromosome domain boundaries. Chromosome Res 1(2) : 93-106, 1993.
PubMed
16) Solovei I, Kienle D, Little G, et al: Topology of double minutes(dmins) and homogeneously staining regions(HSRs) in nucleiof human neuroblastoma cell lines. Genes Chromosomes Cancer 29(4) : 297-308, 2000.
 
17) Nikiforova MN, Stringer JR, Blough R, et al: Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290(5489) : 138-141, 2000.
PubMed
18) Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia(AML) : analysis of 1065 patients entered into the United Kingdom Medical Research CouncilAML l!trial. Blood 98(5) : 1312-1320, 2001.
 
19) Armstrong SA, Staunton JE, Silverman LB, et al: MLL translocations specify a distinct gene expression profile thatdistinguishes a unique leukemia. Nat Genet 30(1) : 41-47, 2002.
PubMed
20) Ueda C, Akasaka T, Kurata M, et al: The gene for interleukin-21 receptor is the partner of BCL 6 in
PubMed
21) Akagi T, Motegi M, Tamura A, et al: A novel gene, MALTI at 18 q 21, is involved in t(11; 18) (q 21; q21) found in lowgrade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18(42) : 5785-5794, 1999. 21
 
22) Taniwaki M, Nishida K, Takashima T, et al: Nonrandom chromosomal rearrangements of 14 q 32. 3 and 19 p 13. 3 and preferential deletion of l p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84(7) : 2283-2290, 1994.
 
23) Nishida K, Tamura A, Nakazawa N, et al: The immunoglobulin heavy chain gene is frequently involved in chromosomal trasnlocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90(2) : 526-534, 1997.
PubMed
24) Bergsagel PL and Kuehl WM: Chromosome translocations in multiple myeloma. Oncogene 20(40) : 5611-5622, 2001.
PubMed
25) 植田 豊, 谷脇雅史: FISH法によるEwing肉腫の染色体転座の検出. 小児外科 29(8) : 1082-1086, 1997.
 
26) Arvand A and Denny CT: Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20(40) : 5747-5754, 2001.
 
27) Laddanyi M: Fusion of the SYT and SSX genes in synovial sarcoma. Oncogene 20(40) : 5755-5762, 2001.
 
28) Barr FG: Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 20(40) : 5736-5746, 2001.
PubMed
29) Li QL, Ito K, Sakakura C, et al: Causal relationship between the loss of RUNX 3 expression and gastric cancer. Cell 109(1) : 113-124, 2002.
 
30) Melcher R, Steinlein C, Feichtinger W, et al: Spectral karyotyping of the human colon cancer cell lines SW 480 and SW 620. Cytogenet Cell Genet 88(1-2) : 145-152, 2000.
 
31) Wong N, Lai P, Pang E, et al: Acomprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping. Hepatology 32(5) : 1060-1068, 2000.
 
P.48 掲載の参考文献
1) Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348, 2001.
PubMed
2) Nurse P: Universal control mechanism regulating onset of M-phase. Nature 344: 503-508, 1990.
PubMed
3) King RW, Jackson PK and Kirschner MW: Mitosis in transition. Cell 79: 563-571, 1994.
PubMed
4) Sherr C: Mammalian G l cyclins. Cell 73: 1059-1065, 1993.
 
5) Hunter T: Braking the cycle. Cell 75: 839-841, 1993.
PubMed
6) Sherr CJ: G 1 phase progression: Cycling on cue. Cell 79: 551-555, 1994.
 
7) Hunter T and Pines J: Cyclins and Cancer II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
PubMed
8) De Bondt HL, Rosenblatt J, Jancarik J, et al: Crystal structure of cyclin-dependent kinase 2. Nature 363: 595-602, 1993.
PubMed
9) Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
PubMed
10) Nevins JR: E 2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424-429, 1992.
 
11) DePinho RA: The cancer-chromatin connection. Nature 391: 526-533, 1998.
 
12) Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
PubMed
13) Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
PubMed
14) Taipale J and Beacy PA: The Hedgehog and Wnt signalling pathways in cancer. Nature 411: 349-354, 2001.
PubMed
P.60 掲載の参考文献
1) Bishop JM: The molecular genetics of cancer. Science 235: 305-311, 1987.
PubMed
2) Ponder B: Gene losses in human tumours. Nature 335: 400-402, 1988.
PubMed
3) Kinzler KW and Vogelstein B: Gatekeepers and caretakers. Nature 386: 761-763, 1997.
PubMed
4) Bos JL: Ras oncogenes in human cancer; areview. Cancer Res 49: 4672-4689, 1989.
 
5) James GL, Goldstein JL, Brown MS, et al: Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 260: 1937-1942, 1993.
PubMed
6) Kohl NE, Mosser SD, deSolms J, et al: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934-1937, 1993.
 
7) Blackwell TK, Kretzner L, Blackwood EM, et al: Sequence-specific DNA binding by the c-myc protein. Science 250: 1149-1151, 1990.
 
8) Blackwood EM and Eisenman RN: Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with myc. Science 251: 1211-1217, 1991.
 
9) Schwab M and Amler LC: Amplification of cellular oncogenes: apredictor of clinical outcome in human cancer. Genes Chromosomes Cancer 1: 181-193, 1990.
 
10) Yarden Y and Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
PubMed
11) van Heyningen V: One gene-four syndromes. Nature 367: 319-320, 1994.
PubMed
12) Raitano AB, Whang YE and Sawyers CL: Signal transduction by wild-type and leukemogenic Abl proteins. Biochim Biophys Acta 1333: F201-216, 1997.
PubMed
13) Sherr CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695, 2000.
PubMed
14) Benedict WF, Xu H, Hu S, et al: Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 85: 988-993, 1990.
 
15) Helin K, Lees JA, Vidal M, et al: AcDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 70: 337-350, 1992.
 
16) Kaelin WG, Krek W, Sellers WR, et al: Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70: 351-364, 1992.
PubMed
17) Kamb A: Cyclin-dependent kinase inhibitors and human cancer. Curr Top Microbiol Immunol 227: 139-148, 1998.
PubMed
18) Merlo A, Herman JG, Mao L, et al: 5'CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTSI in human cancers. Nat Med 1: 686-692, 1995.
 
19) Dasika GK, Lin SC, Zhao S, et al: DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18: 7883-7899, 1999.
PubMed
20) Swift M, Morrell D, Massey RB, et al: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325: 1831-1836, 1991.
PubMed
21) Kastan MB and Lim DS: The many substrates and functions of ATM. Nat Rev Mol Cell Biol 1: 179-186, 2000.
 
22) Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
PubMed
23) Sherr CJ: The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2: 731-737, 2001.
PubMed
24) Bell DW, Varley JM, Szydlo TE, et al: Heterozygous germ line hCHK 2 mutations in Li-Fraumeni syndrome. Science 286: 2528-2531, 1999.
 
25) Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
PubMed
26) Szabo CI and King MC: Population genetics of BRCAI and BRCA2. Am J Hum Genet 60: 1013-1020, 1997.
 
27) Venkitaraman AR: Cancer susceptibility and the functions of BRCAI and BRCA2. Cell 108: 171-182, 2002.
 
28) Dikovskaya D, Zumbrunn J, Penman GA, et al: The adenomatous polyposis coli protein: in the limelight out at the edge. Trends Cell Biol 11: 378-384, 2001.
PubMed
29) Powell SM, Zilz N, Beazer-Barclay Y, et al: APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237, 1992.
PubMed
30) Morin PJ, Sparks AB, Korinek V, et al: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in betacatenin or APC. Science 275: 1787-1790, 1997.
 
31) Guilford P, Hopkins J, Harraway J, et al: E-cadherin germline mutations in familial gastric cancer. Nature 392: 402-405, 1998.
PubMed
32) Heldin CH, Miyazono K and ten Dijke P: TGF-βsignalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471, 1997.
 
33) Markowitz S, Wang J, Myeroff L, et al: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338, 1995.
 
34) Drummond IA, Madden SL, Rohwer-Nutter P, et al: Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 257: 674-678, 1992.
PubMed
35) Modrich P: Mismatch repair, genetic stability, and cancer. Science 266: 1959-1960, 1994.
PubMed
36) Parsons R, Li G, Longley MJ, et al: Hypermutability and mismatch repair deficiency in RER+tumor cells. Cell 75: 1 227-1236, 1993.
 
37) Friedberg EC, Walker GC and Siede W: DNA repair and Mutagenesis. ASM Press, Washington DC, 1995.
 
P.65 掲載の参考文献
1) 森島信裕: 実験医学増刊アポトーシス研究の新たな挑戦. 羊土社, 東京, 2001, pp57-62.
 
2) Enari M, Sakahira H, Yokoyama H, et al: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391: 43-50, 1998.
 
3) Sebbagh M, Renvoize C, Hamelin J, et al: Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol 3: 346-352, 2001.
 
4) 村川正男, 米原 伸: 実験医学増刊アポトーシス研究の新たな挑戦. 羊土社, 東京, 2001, pp 98-102.
 
5) Li H, Zhu H, Xu CJ, et al: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998.
PubMed
6) Kuida K, Haydar TF, Kuan CY, et al: Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 94: 325-337, 1998.
PubMed
7) Li P, Nijhawan D, Budihardjo I, et al: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997.
PubMed
8) Du C, Fang M, Li Y, et al: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42, 2000.
PubMed
9) Deveraux QL and Reed JC: IAP family proteins-suppressors of apoptosis. Genes Dev 13: 239-252, 1999.
PubMed
10) 田中知明, 田矢洋一: p53によるアポトーシス誘導能を制御するリン酸化. 実験医学 18: 2212-2218, 2000.
Medical*Online
11) Seimiya H, Mashima T, Toho M, et al: c-Jun NH 2-terminal kinase-mediated activation of interleukin-1 beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J Biol Chem 272: 4631-4636, 1997.
 
12) Tournier C, Hess P, Yang DD, et al: Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288: 870-873, 2000.
PubMed
13) Kharbanda S, Saxena S, Yoshida K, et al: Translocation of SAPK/JNK to mitochondria and interaction with Bcl-xl in response to DNA damage. J Biol Chem 275: 322-327, 2000.
 
14) Yamamoto K, Ichijo H and Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK 1/Jun N-terminal protein kinase pathway normally activated at G (2) /M. Mol Cell Biol 19: 8469-8478, 1999.
 
15) Soengas MS, Alarcon RM, Yoshida H, et al: Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284: 156-159, 1999.
PubMed
16) Tsujimoto Y, Cossman J, Jaffe E, et al: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443, 1985.
PubMed
17) LaCasse EC, Baird S, Korneluk RG, et al: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247-3259, 1998.
PubMed
18) McGahon A, Bissonnette R, Schmitt M, et al: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83: 1179-1187, 1994.
PubMed
19) Sumantran VN, Ealovega MW, Nunez G, et al: Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55: 2507-2510, 1995.
PubMed
20) Degterev A, Lugovskoy A, Cardone M, et al: Identification of small-molecule inhibitors of interaction between the BH 3 domain and Bcl-xL. Nat Cell Biol 3: 173-182, 2001.
 
21) Tzung SP, Kim KM, Basanez G, et al: Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 3: 183-191, 2001.
PubMed
P.80 掲載の参考文献
1) Fidler IJ: Selection of successive tumor line for metastasis. Nature (New Biol) 242: 148-149, 1973.
PubMed
2) Tsuro T, Yamori T, Naganuma K, et al: Characterization of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma. Cancer Res 43: 5437-5442, 1983.
 
3) Morikawa K, Walker SM, Jessup JM, et al: In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 48: 1943-1948, 1988.
PubMed
4) 鶴尾 隆: 特集「癌転移の基礎と臨床」実験癌の高転移クローンとその臓器選択性. Oncologia 3: 47-57, 1982.
 
5) Liotta LA: Tumor invasion and metastases-Role of the extracellular matrix. Cancer Res 46: 1-7, 1986.
 
6) Hart I and Fidler IJ: An in vitro quantitative assay for tumor cell invasion. Cancer Res 38: 3218-3224, 1978.
 
7) Nicoloson GL: Metastatic tumor cell attachment and invasion assay utilizing vascular endothelial cell monolayers. J Histochem Cytochem 30: 214-220, 1982.
 
8) Kramer RH, Bensch KK and Wong J: Invasion of reconstituted basement-membrane matrix by metastatic tumor cells. Cancer Res 46: 1080-1089, 1986.
 
9) Akedo H, Shinkai K, Mukai M, et al: Interaction of rat ascites hepatoma cells with cultured mesothelial cell layers: A model for tumor invasion. Cancer Res 46: 2416-2422, 1986.
 
10) del Regata JA: Pathways of metastatic spread of malignant tumors. Semin Oncol 4: 33-38, 1977.
 
11) Fisher B and Fisher ER: The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet 122: 791-798, 1966.
PubMed
12) Harmanek P and Sobin LH: TNM Classification of Malignant tumors. 4th Ed, Springer-Verlag, Berlin, 1987.
 
13) Ewing J: A Treatise on Tumors. 3rd Ed, WB Saunders, Philadelphia, 1920.
 
14) Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1: 571-573, 1989.
 
15) Zeidman I and Buss JM: Experimental studies on the spread of cancer in the lymphatic system: effectiveness of the lymphnode as a barrier to the passage of emnonic tumor cells. Cancer Res 14: 403-410, 1954.
 
16) Berg JW, Huvos AG, Axtell LM, et al: A new sign of favorable prognosis in mammary cancer: hyperplastic reactive lymphnodes in the apex of the axilla. Ann Surg 177: 8-15, 1973.
 
17) Hill RP: Metastasis. In The Basic Science of Oncology, (ed by Tannock IF and Hill RP) , Pergamon Press, New York, 1987, pp 160-175.
 
18) Tarin D and Price JE: Influence of microenvironment and vascular anatomy on "metastatic"colonization potential of mammary tumors. Cancer Res 41: 3604-3609, 1981.
PubMed
19) Hart IR and Fidler IJ: Role of organ selectivity in the determination of metastasis pattern of B 16 melanoma. Cancer Res 40: 2281-2287, 1980.
 
20) Nicolson GL: Organ specificity of tumor metastasis: role of preferential adhesion, invasion, and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7: 143-188, 1988.
PubMed
21) Hujanen ES and Terranova VP: Migration of tumor cells to organ-derived chemoattractants. Cancer Res 45: 3517-3521, 1985.
PubMed
22) Yamori T, Iida H, Tsukagoshi S, et al: Growth stimulating activity of lung extract on lung-extract on lung-colonization clone 26 clones and its partial-haracterization. Clin Exp Metastasis 6: 131-139, 1992.
 
23) Sugarbaker EV: Patterns of metastasis in human malignancy. Cancer Biol Rev 2: 235-278, 1981.
 
24) Fidler IJ and Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 197: 893-895, 1977.
PubMed
25) Glaves D: Correlation between circulating cancer cells and incidence of metastasis. Br J Cancer 48: 665-673, 1983.
PubMed
26) Glaves D, Huben RP and Weiss L: Hematogenous dissemination of cells from human renal adenocarcinomas. Br J Cancer 57: 32-35, 1988.
 
27) Fialkow PJ: The origin and development of human tumors studied with cell markers. N Engl J Med 291: 26-35, 1974.
PubMed
28) Vogelstein B, Fearon ER, Hamilton SR, et al: Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res 47: 4806-4813, 1987.
PubMed
29) Nowell PC: Mechanisms of tumor progression. Cancer Res 48: 2203-2207, 1988.
 
30) Nicolson GL: Tumor cell instability, diversification, and progression to the metastatic phenotype: From oncogene to oncofetal expression. Cancer Res 47: 1473-1487, 1987.
 
31) Feron ER and Vogelstein B: Agenetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
 
32) Dear TN, Ramshow JA and Kefford RF: Molecular oncogenetics of metastasis. Mol Aspects Med 11: 243-324, 1990.
 
33) Dear TN, Ramshow JA and Kefford RF: Differential expression of a novel gene, WDNM 1, in nonmetastatic rat mammary adenocarcinoma cells. Cancer Res 48: 5203-5209, 1989.
 
34) Dear TN, McDonald DA and Kefford RF: Transcriptional down-regulation of a rat gene WDNM 2, in metastatic DNMBA-8 cells. Cancer Res 49: 5323-5328, 1989.
 
35) Phillips SM, Bendal AJ and Ramshow IA: Isolation of gene associated with high metastatic potential in rat mammary adenocarcinoma. J Natl Cancer Inst 82: 199-203, 1990.
 
36) harp MGF, Adama SM, Elvin P, et al: Asequence previously identified as metastasis-related encodes an acidic ribosomal phosphoprotein, P2. Br J Cancer 61: 83-88, 1990.
 
37) Tulchinsky EM, Grigorian MS, Ebralidze AK, et al: Structure of gene mts 1, transcribed in metastatic mouse tumor cells. Gene 87: 219-225, 1990.
 
38) Pencil SD, Toh Y and Nicolson GL: Candidate metastasis-associated genes of the rat 1376 NF mammary adenocarcinoma. Breast Cancer Res Treat 25: 165-174, 1993.
 
39) Toh Y, Pencil SD and Nicolson GL: A novel candidate metastasis-associated gene, mta 1, differentially expressed in highly metastatic mammary adenocarcinoma cell line. J Biol Chem 268: 22958-22967, 1994.
 
40) Habets GGM, Scholtes EHM, Zuydeest D, et al: Identification of an invasive-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for rho-1ike protein. Cell 77: 537-546, 1994.
 
41) Steeg PS, Bevilacqua G, Kopper L, et al: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80: 200-204, 1988.
PubMed
42) Dong JT, Lamb PW, Rinker-Schaeffer CW, et al: KAI 1, a metastases suppressor gene for prostate cancer on human chromosome llp11. 2. Science 268: 884-886, 1995.
 
43) Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
PubMed
44) Zou Z, Anisowicz A, Hendrix MJ, et al: Maspin, a serpin with tumor-supPressing activity in human mammary epithelial cells. Science 263: 526-529, 1994.
PubMed
45) Davies BR, Davies MP, Gibbs FE, et al: Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p 9 Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene8: 999-1008, 1993.
 
46) Fidler IJ: Critical factors in the biology of human cancer metastasis. Cancer Res 50: 6130-6138, 1990.
PubMed
47) Morikawa K, Walker SM, Nakajima M, et al: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48: 6863-6871, 1988.
PubMed
48) Nicolson GL: Cancer progression and growth: Relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp Cell Res 202: 171-180, 1993.
 
49) Liotta LA, Steeg PS and Stetler-Stevenson GW: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
 
50) Weidner N, Semple Jp, Welch WR, et al: Tumor angiogenesis and metastasis-correlation in breast carcinoma. N Engl J Med 324: 1-8, 1991.
PubMed
51) Weidner LA, Carroll PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993.
 
52) Maeda K, Chung Y, Takatsuka S, et al: Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 13: 477-481, 1995.
PubMed
53) Weiss L and Ward PM: Cell detachment and metastasis. Cancer Metastasis Rev 2: 111-27, 1983.
PubMed
54) Behrens J, Mareel MM, Van Roy FM, et al: Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of unvomorulin-mediated cell-cell adhesion. J Cell Biol 108: 2435-2447, 1989.
PubMed
55) Frixen UH, Behrens J, Sachs M, et al: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113: 173-185, 1991.
 
56) Vleminckx K, Vakaet L, Mareel M, et al: Genetic manipulation of E-cadherin expression by epithelial tumor cells revealsan invasion suppressor. Cell 66: 107-119, 1991.
PubMed
57) Shimoyama Y, Nagafuchi A, Fujita S, et al: Cadherin dysfunction in a human cancer cell line: Possible involvement of loss ofα一catenin expression in reduced cell-cell adhesiveness. Cancer Res 52: 5770-5774, 1992.
 
58) Hirano S, Kimoto N, Shimoyama Y, et al: Identification of a neuralα-catenin as a key regulator of cadherin function and multicellular organization. Cell 70: 293-301, 1992.
 
59) Shimoyama Y and Hirohashi S: Expression of E-and P-cadherin in gastric carcinomas. Cancer Res 51: 2185-2192, 1991.
 
60) Shiozaki H, Tahara H, Oka H, et al: Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 139: 17-23, 1991
PubMed
61) Schipper JH, Frixen UH, Behrens J, et al: E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 51: 6328-6337, 1991.
PubMed
62) Umbas R, Isaacs WB, Aalders TW, et al: Decreased expression of E-cadherin in high grade prostate cancer. Cancer Res52: 5104-5108, 1992.
PubMed
63) Rasbridge SA, Gillet CE, Sampson SA, et al: Epithelial(E-) and placental(P-) cadherin cell adhesion molecule expressionin breast carcinoma. J Pathol 169: 245-250, 1993.
 
64) Bringuier PP, Umbas R, Schaafama HE, et al: Decreased E-cadherin immunoreactivity correlates with poor survival inpatients with bladder tumors. Cancer Res 53: 3241-3245, 1993.
 
65) Mattijssen V, Peters HM, Schalkwijk L, et al: E-cadherin expression in head and neck squamous-cell carcinoma isassociated with clinical outcome. Int J Cancer 55: 580-585, 1993. Shiozaki H, Iihara K, Oka H, et al: Immunohistochemical detection of a-catenin expression in human cancer. Am J Pathol 144: 1-8, 1994.
 
66) Shiozaki H, Iihara K, Oka H, et al: Immunohistochemical detection of 44: 1-8, 1994.
 
67) Rubinfeld B, Souza B, Albert I, et al: Association of the APC gene product with beta-catenin. Science 262: 1731-1734, 1993.
PubMed
68) Su LK, Vogelstein B and Kinzler KW: Association of the APC tumor suppressor protein with catenins. Science 262: 1734-1737, 1993.
PubMed
69) Anderssen AM, Moran N, Gaardavoll H, et al: Characterization of NCAM expression and function in BT 4C and BTCn glioma cells. Int J Cancer 47: 124-129, 1991.
 
70) Eghbali B, Kessler JA, Reid LM, et al: Involvement of gap junctions in tumorigenesis: Transfection of tumor cells with connexin 32 cDNA retards growth in vivo. Proc Natl Acad Sci USA 88: 10701-10705, 1991.
PubMed
71) Bechimal S, Fuks A and Jothy S: Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57: 327-334, 1989.
PubMed
72) Inohara H and Raz A: Functional evidence that cell surface Galectin-3 mediates homotypic cell adhesion. Cancer Res 55: 3267-3271, 1995.
PubMed
73) Ligtenberg MJL, Buijs F, Vos HL, et al: Suppression of cellular aggregation by high levels of episialin. Cancer Res 52: 2318-2324, 1992.
 
74) Jessup JM and Homas P: Carcinoembryonic antigen: function in metastasis by human colorectal carcinoma. Cancer Metastasis Rev 8: 263-280, 1989.
 
75) Zotter S, Philomena CH, Lossnitzer A, et al: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11-12: 55-101, 1988.
 
76) Nakamori S, Ota DM, Cleary KR, et al: MUC 1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 106: 353-361, 1994.
PubMed
77) Kramer RH and Nicolson GL: Interactions of tumor cells with vascular endothelial cell monolayers: A model for metastatic invasion. Proc Natl Acad Sci USA 76: 5704-5708, 1979.
 
78) Fidler IJ: Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-iod-2'-deozyuridine. J Natl Cancer Inst 45: 773-782, 1970.
 
79) Hilgard P: Anticoagulants and tumor growth: Pharmacological consideration. In Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects, (ed by Nicolson GL and Milas L) , Raven Press, New York, 1984, pp353-360.
 
80) Hill RP, Young SD, Cillo D, et al: Metastatic cell phenotypes: Quantitative studies using the experimental metastasis assay. Cancer Res 5: 118-151, 1986.
 
81) Saiki I: Review: Cell adhesion and cancer metastasis. Jpn J Pharmacol 75: 215-242, 1997.
PubMed
82) Gasic GJ: Role of plasma, platelets and endothelial cells and incidence of metastasis. Cancer Metastasis Rev 3: 665-673, 1983.
 
83) Tsuruo T, Kawabata H, Iida H, et al: Tumor-induced platelet aggregation and growth promoting factors as determinants for successful tumor metastasis. Clin Exp Metastasis 4: 25-33, 1986.
PubMed
84) Handa K, Nudelman E, Striud MR, et al: Selectin GMP-140(CD62; PADGEM) binds to sialosyl-Lex and sialosyl-Lea, and sulfated glycans modulate this binding. Biochem Biophys Res Commun 181: 1223-1230, 1991.
 
85) Magnani JL, Nilsson BO, Brockhaus M, et al: A monoclonal antibody-defined antigen associated with gastro-intestinal cancer in aganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 257: 14365-14369, 1982.
 
86) Fukishima K, Hirota M, Terasaki PI, et al: Characterization of sialosylated Lewisx as a new tumor-associated antigen. Cancer Res 44: 5279-5285, 1984.
 
87) Ruoslahti E and Gianocotti FG: Integrins and tumor cell dissemination. Cancer Cells 1: 119-126,
 
88) Haynes BF, Liao HX and Patton KL: The transmembrane hyaluronate receptor (CD 44) : Multiple functions multiple forms. Cancer Cells 3: 347-350, 1991.
 
89) Hanna N: Role of natural killer cells in host defense against cancer metastasis. In Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects, (ed by Nicolson GL and Milas L) , Raven Press, New York, 1984, pp309-319.
 
90) Nicolson GL, Belloni PN, Tressler RJ, et al: Adhesive, invasive, and growth properties of selected metastatic variants of amurine large-cell lymphoma. Invasion Metastasis 9: 102-116, 1989.
 
91) Springer TA and Laskey LA: Sticky sugars for selectins. Nature 349: 196-197, 1991.
 
92) Springer TA: Adhesion receptor of immune system. Nature 346: 425-434, 1990.
 
93) Lawrence MB and Springer TA: Leukocytes roll on a selectin at physiologic flow rates: Distinct from and prerequisite for adhesion through integrins. Cell 65: 859-873, 1991.
 
94) Picher LJ, Warnock RA, Burns AR, et al: The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. Cell 66: 921-933, 1991.
 
95) Huber AR, Kunkel SL, Todd RF, et al: Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 254: 99-102, 1991.
PubMed
96) Stetler-Stevenson WG, Aznavvrian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 9: 541-573, 1993.
 
97) Skinner MP, Lucas CM, Burns SGF, et al: GMP-140 binding to neutrophils is inhibited by sulfated glycans. J Biol Chem 266: 5371-5374, 1991.
 
98) Hynes RO: Integrins: A family of cell surface receptors. Cell 48: 549-554, 1987.
PubMed
99) Hynes RO: Integrins: Versatility, modulation, signaling in cell adhesion. Cell 69: 11-25, 1992.
PubMed
100) Rice GE and Bevilacqua MP: An inducible endothelial cell surface glucoprotein mediates melanoma adhesion. Science 246: 1303-1306, 1989.
 
101) Takada A, Ohmori k, Yoneda Y, et al: Contribution of carbohydrate antigens sialy LewisA and sialy Lewis X to adhesion of human cancer cells to vascular entothelium. Cancer Res 53: 354-361, 1993.
 
102) Izumi Y, taniuchi T, Tsuji T, et al: Characterization of human colon carcinoma variant cells selacted for sialy 1 Lex carbohydrate antigen: Liver colonization and adhesion to vascular endothelial cells. Exp Cell Res 216: 215-221. 1995.
 
103) Narita T, Funahashi H, Satoh Y, et al: Association of blood group-realated carbohydrate antigen with prognosis in breast cancer. Cancer 71: 3044-3049, 1993.
 
104) Kawai T, Suzuki M, Kase K, et al: Expression of carbohydrate antigens in human pulmonary adenocarcinoma. Cancer 72: 1581-1587, 1993.
PubMed
105) Nakamori S, Kaneyama M, Imaoka S, et al: Increased expression of sialy Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: Clinicopathological and immunohitochemical study. Cancer Res 53: 3632-3637, 1993.
 
106) Nakayama T, Watanabe M, Katsumata T, et al: Expression of sialy Lewisa as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer 75: 2051-2056, 1995.
 
107) Nakamori S, Furukawa H, Hiratsuka M, et al: expression of carbohydrate antigen sialy Lea: A new functional prognostic factor in gastric cancer. J Clin Oncol 15: 2051-2056, 1995.
 
108) Albelda SM, Mette SA, Buck CA, et al: Integrin distribution in malignant melanoma: association of the b3 subunit with tumor progression. Cancer Res 50: 6757-6764, 1990.
 
109) Kramer RH, Vu M, Cheng YF, et al: Integrin expression in maligant melanoma. Cancer Meyastasis Rev 10: 115-128, 1991.
 
110) Tomita Y, Saito T, Saito K, et al: PossibleIe significance VLA-4(α4β1) for hematogenous metastasis of renal-cellcancer. Int J Cancer 60: 753-758, 1995.
 
111) Fujita S, Watanabe M, Kubota T, et al: Alteration of expression in integrinβ1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett 91: 145-149, 1995.
 
112) Jalkanen S, Bargatze RF, de los Toyos J, et al: Homing receptors and the control of lymphocyte recognition. Immunol Rev 91: 39-60, 1986.
 
113) Afruffo A, Stamenkovic I, Melnick M, et al: CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313, 1990.
PubMed
114) Heider K-H, Hofmann M, Hors E, et al: A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 120: 227-233, 1993.
PubMed
115) Hofmann M, Rudy W, Zoller M, et al: CD44 splice variant of glycoprotein confer metastatic behavior in rat. Cancer Res 51: 5292-5297, 1991.
PubMed
116) Gunther U, Hofman M, Rudy W, et al: A new variant of glycoprotein CD44 confer metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991.
 
117) Rudy W, Hofmann M, Scfwartz-Albeyz R, et al: The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 53: 1262-1268, 1993.
 
118) Matsumura Y and Train D: Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340: 1053-1058, 1992.
 
119) Tanabe KT, Ellis LM and Daya H: Expression of CD44 R1 adhesion molecule in colon carcinoma and metastasis. Lancet 341: 725-726, 1993.
 
120) Mayer B, Jauch KW, Gunthert U, et al: De-novo expression of CD44 and survival in gastric cancer. Lancet 342: 1019-1022, 1993.
PubMed
121) Mackay CR, Terpe HJ, Stauder R, et al: Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 124: 71-72, 1994.
PubMed
122) Lieberbach BF and Sanderson RD: Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 269: 20013-20019, 1994.
 
123) Numa F, Hirabayashi K, Tsunaga N, et al: Elevated levels of syndecan-1 expression confer potent serum-dependent growth in human 293 T cells. Cancer Res 55: 4676-4680, 1995
 
124) Raz A and Lotan R: Endogenous galactoside-binding lectins: a new class of functional cell surface molecules related to metastasis. Cancer Rev 6: 433-452, 1987.
PubMed
125) Takeda K, Hatakeyama K, Tsuchiya Y, et al: A correlation between GM-CSF gene expression and metastases in murine tumors. Int J Cancer 47: 413-420, 1991.
PubMed
126) Takeda K, Fujii N, Nitta Y, et al: Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyteactivating cytokines interleukin-1 and/or-6. Jpn J Cancer Res 82: 1299-1308, 1991.
PubMed
127) Senger DR, Galli SJ, Dvorak Am, et al: Tumor cell secrete a vascular permeability factor that promote accumulation of ascites fluid. Science 219: 983-985, 1983.
 
128) Honn KV, Tang DG, Grossi I, et al: Tumor cell-derived 12(S) -hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction. Cancer Res 54: 565-574, 1994.
PubMed
129) Stoolman LM: Adhesion molecules controlling lymphocyte migration. Cell 56: 907-910, 1989.
PubMed
130) Sacchi A, Falcioni R, Kennel SJ, et al: Ligand-induced phosphorylation of murine tumor surface protein (TSP-180) associated with metastasis phenotype. Cancer Res 49: 2615-2620, 1989.
PubMed
131) Chan BM, Matsuura N, Hemler ME, et al: In vitro and in vivo consequences of VLA-2 expression on rabdomyosarcomas cells. Science 251: 1600-1602, 1991.
 
132) Humphries MJ, Olden K and Yamada KM: A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma. Science 233: 467-470, 1986
 
133) Saiki I, Iida J, Murata J, et al: Inhibition of the metastasis of murine malignant melanoma by synthetic polymeric peptides containing core sequences of cell-adhesive molecules. Cancer Res 49: 3815-3822, 1989
PubMed
134) Khokha R and Denhardt DT: Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 9: 391-405, 1989.
PubMed
135) Nakajima M and Chop AM: Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Semin Cancer Biol 2: 115-127, 1991.
PubMed
136) Sato H, Takino T, Okada Y, et al: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65, 1994.
PubMed
137) Khokha R, Waterhouse P, Yagel S, et al: Anti-sense RNA-induced reduction in murine TIMP levels confers oncogenicity in Swiss 3T3 cells. Science 243: 947-950, 1989.
PubMed
138) Alvarez OA, Carmichael DF and DeClerck YA: Inhibition of collagenolytic activity and metastasis of tumor cells by recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 82: 589-595, 1990.
PubMed
139) Lah TT, Kokali-Kunovar M, Strukelj B, et al: Stefins and lysosomal cathepsins B, L, and D in human breast carcinoma. Int J Cancer 50: 36-44, 1992.
 
140) Zucker S, Lysik RM, Zarrabi MH, et al: Mr 92, 000 collagenase in plasma of patients with colon cancer and breast cancer. Cancer Res 53: 140-146, 1993.
PubMed
141) Shuja S, Sheehan K and Murnane MJ: Cystein endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. Int J Cancer 49: 341-346, 1991
 
142) Nomura H, Sato H, Seiki M, et al: Expression of membrane-type matrix metalloproteinase in human gastric carcinoma. Cancer Res 55: 3263-3266, 1995.
PubMed
143) Tandon AK, Clark GM, Chamness GC, et al: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297-302, 1990.
PubMed
144) Kwaan HC: The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11: 291-311, 1992.
PubMed
145) Marutsuka K, Suzumiya J, Kataoka H, et al: Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells. Invasion Metastasis 11: 181-191, 1991.
PubMed
146) Hollas W, Blasi F and Boyd D: Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 51: 3690-3695, 1991.
PubMed
147) Ganeshi S, Sier CFM and Heerding MM: Urokinase receptor and colorectal cancer survival. Lancet 344: 401-402, 1994.
 
148) Bellusci S, Moens G, Gaudino G, et al: Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 9: 1091-1099, 1994.
PubMed
149) Fabra A, Nakajima M, Bucana CD, et al: Modulation of the invasive phenotype of human colon carcinoma cells by fibroblasts from orthotopic organs of nude mice. Differentiation 52: 101-110, 1992.
 
150) Kolega J: Effects of mechanical tension on protrusive activity and microfilament and intermediate filament organization in an epidermal epithelium moving in culture. J Cell Biol 102: 1400-1411, 1986.
 
151) Aznavoorian SA, Stracke ML, Krutzsch H, et al: Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol 110: 1427-1438, 1990.
 
152) McCarthy JB, Hager SJ and Furcht LT: Human fibronectin contains distinct adhesion-and motility promoting domains for metastatic melanoma cells. J Cell Biol 102: 179-188, 1986.
 
153) Mensing H, Albini A, Krieg T, et al: Enhanced chemotaxis of tumor-derived and virus-transformed cells to fibronectin and fibroblast conditioned medium. Int J Cancer 33: 43-48, 1985.
 
154) McCarthy JB, Basara ML, Palm SL, et al: The role of cell adhesion proteins laminin and fibronectin in the movement of malignant and metastatic cells. Cancer Metastasis Rev 4: 125-152, 1985.
PubMed
155) Stoker M and Gherardi E: Regulation of cell movement: The mitogenic cytokines. Biochim Biophys Acta 1072: 81-102, 1991.
 
156) Liotta LA, Mandler R, Murano G, et al: Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 83: 3302-3306, 1986.
PubMed
157) Grey AM, Schor AM, Rushton G, et al: Purification of the migration stimulating factor produced by fetal and breast cancer patient fibroblasts. Proc Natl Acad Sci USA 86: 2438-2442, 1989.
PubMed
158) Weidner KM, Arakaki N, Hartmann G, et al: Evidence for identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA 88: 7001-7005, 1991.
PubMed
159) Stracke ML, Krutzsch HC, Unsworth EJ, et al: Identification, purification, and partial sequence analysis of Autotaxin, a novel motility-stimulating protein. J Biol Chem 267: 2524-2529, 1992.
 
160) Wang M and Stearns M: Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in SCID mice. Differentiation 48: 115-121, 1991.
PubMed
161) Watanabe H, Takehara K, Date M, et al: Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 56: 2960-2963, 1996.
 
162) Nabi IR, Watanabe H and Raz A: Autocrine motility factor and its receptor: role in cell locomotion and metastasis. Cancer Metastasis Rev 11: 5-20, 1992.
PubMed
163) Watanabe H, Carmi P, Hogan V, et al: Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J Biol Chem 266: 13442-13448, 1991.
PubMed
164) Wanag M, Steans M and Stearns ME: Identification of the receptor for a novel Mr 78, 000 "Invasion stimulating factor" from metastatic human prostatic PC-3 ML clones. Cancer Res 54: 2492-2495, 1994.
 
165) Guiruis R, Schiffman E, Liu B, et al: Detection of autocrine motility factor in urine as a marker of baldder cancer. J Natl Cancer Inst 12: 1203-1211, 1988.
 
166) Picard M, Schor S, Grey AM, et al: Migration-stimulating activity in serum of breast cancer patients. Lancet 337: 130-133, 1991.
 
167) Otto T, Brichmeier W, Schmit U, et al: Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinoma. Cancer Res 54: 3120-3123, 1994.
 
168) Nakamori S, Watanabe H, Kaneyama M, et al: Expression of autocrine motility factor receptor in colorectal cancer as apredictor for disease recurrence. Cancer 74: 1855-1862, 1994.
 
169) Hamada J, Cavanaugh PG, Lotan O, et al: Separable growth and migration factor for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer 66: 349-353, 1992.
 
170) Isoai A, Giga-Hama Y, Shinkai, et al: Purification and characterization of tumor invasion-inhibiting factors. Jpn J Cancer Res 81: 909-914, 1990.
PubMed
171) Cerra RF and Nathanson SD: Organ-specific chemotactic factor present in lung extracellular matrix. J Surg Res 46: 422-426, 1989.
PubMed
172) Miyake M and Hakomori S: A specific cell surface glycoconjugate controlling cell motility: Evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry 340: 3328-3334, 1991.
 
173) Muller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
PubMed
174) Miyake M, Koyama M, Seno M, et al: Identification of the motility-related protein (MRP-1) , recognized by monoclonal antibody M 31-15, which inhibits cell motility. J Exp Med 174: 1347-1354, 1991.
 
175) Schaller MD, Borgman CA, Cobb BS, et al: pp 125FAK, a structurally distinctive protein-tyrosine kinase associated with focal adhesion. Proc Natl Acad Sci USA 89: 5192-5196, 1992.
 
176) Hanks SK, Calalb MB, Haaper MC, et al: Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci USA 89: 8487-8491, 1992.
 
177) Guan JL and Shalloway D: Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature 358: 690-692, 1992.
PubMed
178) Clark EA and Brugge JS: Integrins and signal transduction pathways: the road taken. Science 268: 233-239, 1995.
PubMed
179) Weiner TM, Liu ET, Craven R, et al: Expression of focal adhesion kinase gene and invasive cancer. Lancet 343: 1024-1025, 1993.
 
180) Nobes CD and Hall A: Rho, Rac, and cdc 42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, Lamelipodia, and filopodia. Cell 81: 53-62, 1995.
 
181) Nakamori S, Yoshioka K, Kameyama M, et al: Increased expression of RHOAp21 protein is involved in progression and metastasis of colorectal carcinoma. In Recent Advances in Gastroenterological Carcinogenesis I, (ed by Tahara E, Sugimachi K and Ohara T) , Monduzzi Editore, Bologna, 1966, pp901-904.
 
182) Schabel FM: Concepts for systemic treatment of micrometastasis. Cancer 35: 15-24, 1975.
 
183) Fidler IJ: The evolution of biological heterogeneity in metastatic neoplasms. In: Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects, (ed by Nicolson GL and Milas L) , Raven Press, New York, 1984, pp5-30.
 
184) Nicolson GL: Cancer metastasis; Tumor cell and host organ properties important in metastasis to specific secondary sites. Biochem Biophys Acta 948: 175-224, 1988.
PubMed
185) Yamori T, Iizuka Y, Takayama Y, et al: Insulin-like growth factor I induces tyrosine phosphorylation of Mr 150, 000 and Mr 160, 000 protein in highly metastatic mouse colon carcinoma 26 NL-17 cells. Cancer Res 51: 5859-5865, 1991.
 
186) Folkman J: Tumor angiogenesis: A possible control point in tumor growth. Ann Intern Med 82: 96-100, 1975.
PubMed
187) Holmgren L, Michael SO and Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1: 149-153, 1995.
 
188) Noguchi S, Aihara T, Nakamori S, et al: The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 74: 1595-1600, 1994.
PubMed
189) Schoenfeld A, Luqmani Y, Smith D, et al: Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 54: 2986-2990, 1994.
PubMed
190) Hayashi N, Arakawa H, Nagase H, et al: Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res 54: 3853-3856, 1994.
PubMed
191) Mori M, Mimorti K, Inoue H, et al: Detection of cancer micrometastases in lymph nodes by reverse transcriptasepolymerase chain reaction. Cancer Res 55: 3417-3420, 1995.
 
192) Sasaki A, Boyce BF, Story B, et al: Bisphonate risedrate reduces metastatic human breast cancer in bone in nude mice. Cancer Res 55: 3351-3357, 1995.
 
193) Yamaoka K, Yamamoto T, Sudo K, et al: Inhibition of tumor growth and metastasis of rodent Rumor by the angiogenesis inhibitor O-(choroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) . Cancer Res 53: 4262-4267, 1993.
 
194) Tanaka T, Konno H, Baba S, et al: Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 55: 836-839, 1995.
PubMed
195) Iishi H, Tatsuta M, Baba M, et al: Suppression by amiloride of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Int J Cancer 63: 716-719, 1995.
PubMed
196) Stacker S, Caesr C, Baldwin ME, et al: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186-191, 2001.
 
P.92 掲載の参考文献
1) Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
 
2) Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
PubMed
3) Hanahan D: Signaling vascular morphogenesis and maintenance. Science 277: 48-50, 1997.
PubMed
4) Asahara T, Murohara T, Sullivan A, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967, 1997.
PubMed
5) Asahara T, Masuda H, Takahashi T, et al: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85: 221-228, 1999.
PubMed
6) Reyes M, Dudek A, Jahagirdar B, et al: Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 109: 337-346, 2002.
PubMed
7) Shibuya M: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26: 25-35, 2001.
PubMed
8) Carmeliet P, Ferreira V, Breier G, et al: Abnormal blood vessel development and lethality in embryos lacking a singel VEGF allele. Nature 380: 435-439, 1996.
 
9) Ferrara N, Carver-Moore K, Chen H, et al: Heterozygous embrionic lethality induced by targeted inactivation of VEGF gene. Nature 380: 439-442, 1996.
 
10) Miquerol L, Gertsenstein M, Harpal K, et al: Multiple developmental roles VEGF suggested by a LacZ-tagged allele. Dev Biol 212: 307-322, 1999.
PubMed
11) Shalaby F, Rossant J, Yamaguchi TP, et al: Failure of blood-island formation and vasculogenesis in FLK-1-deficient mice. Nature 376: 62-66, 1995.
PubMed
12) Fong GH, Rossant J, Gertsenstein M, et al: Role of Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 370: 66-70, 1995.
 
13) Hiratsuka S, Minowa O, Kuno J, et al: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95: 9349-9354, 1998.
PubMed
14) Davis S, Aldrich TH, Jones PF, et al: Isolation of angiopoietin-1, a ligand for the TIE 2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169, 1996.
PubMed
15) Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for tie 2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997.
PubMed
16) Valenzuela DM, Griffiths JA, Rojas J, et al: Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96: 1904-1909, 1999.
PubMed
17) Witzenbichler B, Mainsonpierre PC, Jones P, et al: Chemotactic properties of angiopoietin-1 and-2, ligands for the endothelial-specific receptor tyrosine kinase Tie 2. J Biol Chem 273: 18514-18521, 1998.
 
18) Suri C, Jones PF, Patan S, et al: Requisite role of angiopoietin-1, a ligand for the TIE 2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180, 1996.
PubMed
19) Dumont DJ, Gradwohl G, Fong GH, et al: Dominant-negative and targeted null mutations in endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8: 1897-1909, 1994.
PubMed
20) Sato TN, Tazawa Y, Deutsch U, et al: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70-74, 1995.
 
21) Good DJ, Polverini PJ, Rastinejad F, et al: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87: 6624-6628, 1990.
PubMed
22) Adams JC: Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Bio117: 25-51, 2001.
PubMed
23) Volpert OV, Tolsma SS, Pellerin S, et al: Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 217: 326-332, 1995.
PubMed
24) O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of etastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
 
25) Ito H, Rovira II, Bloom ML, et al: Endothelial progenitor cells as putative targets for angiostatin. Cancer Res 59: 5875-5877, 1999.
PubMed
26) Lay AJ, Jiang XM, Kisker O, et al: Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 408: 869-873, 2000.
PubMed
27) Moser TL, Stack MS, Asplin I, et al: Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96: 2811-2816, 1999.
PubMed
28) Troyanovsky B, Levchenko T, Mansson G, et al: Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152: 1247-1254, 2001.
PubMed
29) Tarui T, Miles LA and Takada Y: Specific interaction of angiostatin with integrin αvβ3 in endothelial cells. J Biol Chem 276: 39562-39568, 2001.
 
30) O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
 
31) Wen W, Moses MA, Wiederschain D, et al: The generation of endostatin is mediated by elastase. Cancer Res 59: 6052-6056, 1999.
PubMed
32) Karumanchi SA, Jha V, Ramchandran R, et al: Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 7: 811-822, 2001.
PubMed
33) Rehn M, Veikkola T, Kukk-Valdre E, et al: Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 98: 1024-1029, 2001.
PubMed
34) Shichiri M and Hirata Y: Antiangiogenesis signals by endostatin. FASEB J 15: 1044-1053, 2001.
PubMed
35) Iwasaka C, Tanaka K, Abe M, et al: Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 169: 964-967, 1996.
 
36) Tanaka K, Oda N, Iwasaka C, et al: Induction of Ets-1 in endothelial cells during re-endothelialization after denuding injury. J Cell Physiol 176: 235-244, 1998.
 
37) Sato Y, Kanno S, Oda N, et al: Properties of two VEGF receptors, Flt-1 and KDR, in the signal transduction. Ann N Y Acad Sci 901: 201-207, 2000.
 
38) Oikawa M, Abe M, Kurosawa H, et al: Hypoxia induces transcription factor ETS-1 via the activity of hypoxia inducible factor-1. Biochem Biophys Res Commun 289: 39-43, 2001.
PubMed
39) Oda N, Abe M, and Sato Y: ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin β3. J Cell Physiol 178: 121-132, 1999.
 
40) Teruyama K, Abe M, Nakano T, et al: Neuropilin-1 is a downstream target of transcription factor Ets-1 in human umbilical vein endothelial cells. FEBS Lett 504: 1-4, 2001.
PubMed
41) Nakano T, Abe M, Tanaka K, et al: Angiogenesis inhibition by transdominant mutant Ets-1. J Cell Physiol 184: 255-262, 2000.
PubMed
42) Maxwell PH, Wiesener MS, Chang GW, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999.
PubMed
43) Zundel W, Schindler C, Haas-Kogan D, et al: Loss of PTEN facilties HIF-1-mediated gene expression. Genes Dev 14: 391-396, 2000.
 
44) Kieser A, Weich HA, Brandner G, et al: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9: 963-969, 1994.
PubMed
45) Dameron KM, Volpert OV, Tainsky MA, et al: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584, 1994.
PubMed
46) Yu JL, Rak JW, Coomber BL, et al: Effect of p53 status on tumor response to antiangiogenic therapy. Science 295: 1526-1528, 2002.
PubMed
47) Holash J, Maisonpierre PC, Compton D, et al: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994-1998, 1999.
PubMed
48) Maniotis AJ, Folberg R, Hess A, et al: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155: 739-752, 1999.
PubMed
49) Hendrix MJ, Seftor EA, Meltzer PS, et al: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 98: 8018-8023, 2001
PubMed
50) Skobe M, Hawighorst T, Jackson DG, et al: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7: 192-198, 2001.
PubMed
51) Mandriota SJ, Jussila L, Jeltsch M, et al: Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20: 672-682, 2001.
PubMed
52) Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571, 1999.
PubMed
53) Browder T, Butterfield CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000.
PubMed
P.101 掲載の参考文献
1) Beasley RP, Hwang LY, et al: Hepatocellular carcinoma and hepatitis B virus. Lancet ii: 1129-1133. 1981.
 
2) Brechot C, Hadchouel M, et al: State of hepatitis virus DNA in hepatocyte of patients with hepatitis B surface antigenpositive and-negative liver diseases. Proc Natl Acad Sci USA 78: 3906, 1981.
 
3) Takada S and Koike K: Trans-activation function of 3'truncated X gene-cell fusion product from integrated hepatitis B virus DNA in chronic hepatitis tissues. Proc Natl Acad Sci USA 87: 5628-5632, 1990.
PubMed
4) Takada S, Shirakata Y, et al: Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death. Oncogene 18: 6965-6973, 1999.
PubMed
5) Kobayashi M and Koike K: Complete nucleotide sequence of hepatitis B virus DNA of subtype adr and its conserved gene organization. Gene 30: 227-233, 1984.
PubMed
6) Koike K, Shirakata Y, et al: Oncogenic potential of hepatitis B virus. Mol Biol Med 6: 151-160, 1989.
PubMed
7) Wang GH and Seeger C: The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 71: 663-670, 1992.
 
8) Spandau DF and Lee C: trans-Activation of viral enhancers by the hepatitis B virus X protein. J Virol 62: 427-434, 1988.
 
9) Twu JS and Schloemer RH: Transcriptional trans-activating function of hepatitis B virus. J Virol 61: 3448-3453, 1987.
PubMed
10) Seto E, Yen TSB, et al: Trans-activation of the human immnodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc Natl Acad Sci USA 85: 8286-8290, 1988.
 
11) Kekule AS, Lauer U, et al: The preS 2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 343: 457-461, 1990.
 
12) Kekule AS, Lauer U, et al: Hapatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 361: 742-745, 1993.
 
13) Meyer M, Caselmann WH, et al: Hepatitis B virus transactivator MHBst: activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization. EMBO J 11: 2991-3001, 1992.
PubMed
14) Benn J and Schneider RJ: Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA 91: 10350-10354, 1994.
PubMed
15) Doria M, Klein N, et al: The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J 14: 4747-4757, 1995.
PubMed
16) Wang XW, Forrester K, et al: Hepatitis B virus X protein inhibits p 53 sequence-specific DNA binding, transcriptional activity, and association with transcriptional factor ERCC 3. Proc Natl Acad Sci USA 91: 2230-2234, 1994.
 
17) Takada S and Koike K: Hepatitis B virus X gene expression is activated by X protein but repressed by p53 tumor suppressor gene product in the transient expression system. Virology 216: 80-89, 1996.
PubMed
18) Shirakata Y, Kawada M, et al: The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH 3 T 3 cells. Jpn J Cancer Res 80: 617-621, 1989.
 
19) Hohne M, Schaefer S, et al: Malignant transformation of immortalized transgenic hepatocyte after transfection with hepatitis B virus. DNA 9: 1137-1145, 1990.
PubMed
20) Kim C, Koike K, et al: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351: 317-320, 1991.
PubMed
21) Shaul Y, et al: H human hepatitis B virus enhancer element. EMBO J 4: 427-430, 1985.
PubMed
22) Bulla GA and Siddiqui A: The hepatitis B virus enhancer modulates transcription of the hepatitis B virus surface antigen gene from an internal location. J Virol 62: 1437-1441, 1988.
PubMed
23) Yee TSB: A liver-specific enhancer in the core promoter region of human hepatitis B virus. Science 246: 658-661, 1989.
 
24) Summers Y and Mason WS: Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29: 403-415, 1982.
 
25) Siddiqui A, Gaynor R, et al: Trans-activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein. Virology 169: 479-484, 1989.
PubMed
26) Maguire HF, Hoeffer JP, et al: HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interaction. Science 252: 842-844, 1991.
 
27) Cheong J-H, Yi M-K, et al: Human RPB 5, a subunit shared by eukaryotic nuclear RNA polymerase, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J 14: 143-150, 1995.
 
28) Qadri I, et al: The hepatitis B virus transactivator protein, HBx, interacts with single-stranded DNA (ssDNA) . Biochemical characterizations of the HBx-ssDNA interactions. J Biol Chem 271: 15443-15450, 1996.
PubMed
29) Takada S, Kido S, et al: Interaction of hepatitis B virus X protein with a serine protease, tryptase TL 2, as an inhibitor. Oncogene 9: 341-348, 1994.
 
30) Thut CJ, Chen JL, et al: Science 267: 100-104, 1995.
PubMed
31) Scheffner M, Werness BA, et al: The E 6 oncoprotein encoded by human papillomavirus type 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136, 1990.
 
32) Hsu IC, et al: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428, 1991.
PubMed
33) Bressae B, Galvin M, et al: Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 1973-1977, 1990.
 
34) Takada S, Kaneniwa N, et al: Cytoplasmic retention of the p53 tumor suppressor gene product ls observed in the hepatitis B virus X gene-transfected cells. Oncogene 15: 1895-1901, 1997.
 
35) Chisari FV, et al: Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59: 1145-1156, 1989.
PubMed
36) Moriaty AM, Alexander H, Lerner RA, et al: Antibodies to peptides detect new hepatitis B antigen: Serological correlation with hepatocellular carcinoma. Science 227: 429-432, 1985.
 
37) Yang W, Mason WS, et al: Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus infected liver. J Virol 70: 4567-4575, 1996.
 
38) Yang W and Summers J: Integration of hepadnavirus DNA in infected liver: evidence for a linear precursor. J Virol 73: 9710-9717, 1999.
PubMed
39) 高田等子, 小池克郎: B型肝炎ウイルスと肝発癌. 蛋白質 核酸 酵素 35: 2089-2099, 1990.
 
40) Wollersheim M, Debelka U and Hofschneider PH: A transactivating function encoded in the hepatitis B virus X gene is conserved in the integrated state. Oncogene 3: 545-552, 1988.
PubMed
41) Brechot C, Hadchonuel M, Scotto J, et al: Detection of hepatitis B virus DNA in liver and serum: adirect appraisal of the chronic carrier state. Lancet ii: 765-768, 1981.
 
42) Koike K, Kobayashi M, et al: Structure and functions of integrated HBV DNA. In Hepadna Viruses, (ed by Robinson WS, et al) , Alan R Liss Inc, NewYork, 1987, pp263-286.
 
P.107 掲載の参考文献
1) Sugimura T: Overview of carcinogenic heterocyclic amines. Mutat Res 376: 211-219, 1997.
PubMed
2) Berenblum I and Shubik P: The role of croton oil applications associated with a single painting of a carcinogen in tumour induction in the mouse's skin. Br J Cancer 1: 379-383, 1947.
 
3) Ames BN, Durston WE, Yamasaki E, et al: Carcinogens are mutagens: asimple test system combining liver homogenates for activation and bacteria for detection. Proc Natl Acad Sci USA 70: 2281-2285, 1973.
 
4) Shimizu Y, Nakatsuru Y, Ichinose M, et al: Benzo [a] pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 97: 779-782, 2000.
PubMed
5) Guengerich FP and Shimada T: Activation of procarcinogens by human cytochrome P 450 enzymes. Mutat Res 400: 201-213, 1998.
PubMed
6) Clapper ML: Genetic polymorphism and cancer risk. Curr Oncol Rep 2: 251-256, 2000.
PubMed
7) Zarbl H, Sukumar S, Arthur AV, et al: Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 315: 382-385, 1985.
 
8) 荒木真理人, 益岡央豪, 花岡文雄: ヌクレオチド除去修復の分子機構. 蛋白質 核酸 酵素 44: 1845-1851, 1999.
 
9) Friedberg EC: How nucleotide excision repair protects against cancer. Nature Rev Cancer 1: 22-33, 2001.
 
10) Sarma DS, Rao PM and Rajalakshmi S: Liver tumour promotion by chemicals: models and mechanisms. Cancer Surv 5: 781-798, 1986.
PubMed
11) Tatematsu M, Takahashi M, Fukushima S, et al: Effects in rats of sodium chloride on experimental gastric cancers induced by N-methyl-N-nitro-N-nitrosoguanidine or 4-nitroquinoline-1-oxide. J Natl Cancer Inst 55: 101-106, 1975.
PubMed
12) Shimizu N, Ikehara Y, Inada K, et al: Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 60: 1512-1514, 2000.
PubMed
13) Ito N, Fukushima S, Shirai T, et al: Drugs, food additives and natural products as promoters in rat urinary bladder carcinogenesis. IARC Sci Publ, 1984, pp399-407.
PubMed
14) Ito N, Tsuda H, Tatematsu M, et al: Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rats-an approach for a new medium-term bioassay system. Carcinogenesis 9: 387-394, 1 988.
 
15) Tatematsu M, Furihata C, Katsuyama T, et al: Immunohistochemical demonstration of pyloric gland-type cells with lowpepsinogen isozyme 1 in preneoplastic and neoplastic tissues of rat stomachs treated with N-methyl-N'-nitro-Nnitrosoguanidine. J Natl Cancer Inst 78: 771-777, 1987.
 
16) Tsukamoto T, Kozaki K, Nishikawa Y, et al: Development and distribution of 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine(PhIP) -induced aberrant crypt foci in the rat large intestine. Jpn J Cancer Res 90: 720-725, 1999.
PubMed
17) Tsukamoto T, Fukami H, Yamanaka S, et al: Hexosaminidase-altered aberrant crypts, carrying decreased hexosaminidase αandβ subunit mRNAs, in colon of 1, 2-dimethylhydrazine-treated rats. Jpn J Cancer Res 92: 109-118, 2001.
 
18) Tatematsu M, Nagamine Y and Farber E: Redifferentiation as a basis for remodeling of carcinogen-induced hepatocyte nodules to normal appearing liver. Cancer Res 43: 5049-5058, 1983.
PubMed
19) Donehower LA, Harvey M, Slagle BL, et al: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221, 1992.
PubMed
20) Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
PubMed
21) Kakiuchi H, Watanabe M, Ushijima T, et al: Specific S'-GGGA-3'→5'-GGA-3'mutation of the Apc gene in rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine. Proc Natl Acad Sci USA 92: 910-914, 1995.
 
22) Furihata C, Tatematsu M, Saito M, et al: Rare occurrence of ras and p53 gene mutations in mouse stomach tumors induced by N-methyl-N-nitrosourea. Jpn J Cancer Res 88: 363-368, 1997.
 
23) Wistuba, II, Gazdar AF and Minna JD: Molecular genetics of small cell lung carcinoma. Semin Oncol 28: 3-13, 2001.
PubMed
24) Kobayashi T, Hirayama Y, Kobayashi E, et al: A germline insertion in the tuberous sclerosis (Tsc 2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 9: 70-74, 1995.
 
25) Ames BN, McCann J and Yamasaki E: Methods for detecting carcinogens and mutagens with the Salmonella/mammalianmicrosome mutagenicity test. Mutat Res 31: 347-364, 1975.
PubMed
26) Ostling O and Johanson KJ: Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem Biophys Res Commun 123: 291-298, 1984.
PubMed
27) Gossen JA, de Leeuw WJ, Tan CH, et al: Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo. Proc Natl Acad Sci USA 86: 7971-7975, 1989.
 
28) Kohler SW, Provost GS, Fieck A, et al: Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice. Proc Natl Acad Sci USA 88: 7958-7962, 1991.
PubMed
29) Nohmi T, Katoh M, Suzuki H, et al: A new transgenic mouse mutagenesis test system using Spi-and 6-thioguanine selections. Environ Mol Mutagen 28: 465-470, 1996.
PubMed
30) Jakubczak JL, Merlino G, French JE, et al: Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target. Proc Natl Acad Sci USA 93: 9073-9078, 1996.
 
31) Burkhart JG, Burkhart BA, Sampson KS, et al: ENU-induced mutagenesis at a single A: T base pair in transgenic mice containing phi X 174. Mutat Res 292: 69-81, 1993.
 
32) Leach EG, Narayanan L, Havre PA, et al: Tissue specificity of spontaneous point mutations in lambda supF transgenic mice. Environ Mol Mutagen 28: 459-464, 1996.
PubMed
33) Gondo Y, Shioyama Y, Nakao K, et al: A novel positive detection system of in vivo mutations in rpsL (strA) transgenic mice. Mutat Res 360: 1-14, 1996.
 
34) Dobrovolsky VN, Casciano DA and Heflich RH: Tk+/-mouse model for detecting in vivo mutation in an endogenous, autosomal gene. Mutat Res 423: 125-136, 1999.
 
35) Tatematsu M, Hasegawa R, Imaida K, et al: Survey of various chemicals for initiating and promoting activities in a shortterm in vivo system based on generation of hyperplastic liver nodules in rats. Carcinogenesis 4: 381-386, 1983.
 
36) Sakai H, Tsukamoto T, Yamamoto M, et al: Differential effects of partial hepatectomy and carbon tetrachloride administration on induction of liver cell foci in a model for detection of initiation activity. Jpn J Cancer Res 92: 1018-1025, 2001.
 
37) Sakai H, Tsukamoto T, Yamamoto M, et al: Summation of initiation activities in the Iiver after partial hepatectomy. Cancer Lett 176: 1-5, 2002.
 
38) Spalding JW, Momma J, Elwell MR, et al: Chemically induced skin carcinogenesis in a transgenic mouse line (TG. AC) carrying a v-Ha-ras gene. Carcinogenesis 14: 1335-1341, 1993.
 
39) Ando K, Saitoh A, Hino O, et al: Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. Cancer Res 52: 978-982, 1992.
 
40) Usui T, Mutai M, Hisada S, et al: CB 6 F 1-rasH 2 mouse: overview of available data. Toxicol Pathol 29: 90-108, 2001.
 
41) Asamoto M, Ochiya T, Toriyama-Baba H, et al: Transgenic rats carrying human c-Ha-ras proto-oncogenes are highly susceptible to N-methyl-N-nitrosourea mammary carcinogenesis. Carcinogenesis 21: 243-249, 2000.
 
42) Gondo Y, Nakamura K, Nakao K, et al: Gene replacement of the p53 gene with the lacZ gene in mouse embryonic stem cells and mice by using two steps of homologous recombination. Biochem Biophys Res Commun 202: 830-837, 1994.
PubMed
43) Ozaki K, Sukata T, Yamamoto S, et al: High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl) nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res 58: 3806-3811, 1998.
 
44) Shirai N, Tsukamoto T, Yamamoto M, et al: Elevated susceptibility of the p53 knockout mouse esophagus to methyl-namylnitrosamine carcinogenesis. Carcinogenesis 23: 1541-1547, 2002.
PubMed
45) Yamamoto M, Tsukamoto T, Sakai H, et al: p53 knockout mice(-/-) are more susceptible than(+/-) or(+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis 21: 1891-1897, 2000.
 
46) de Vries A and van Steeg H: Xpa knockout mice. Semin Cancer Biol 7: 229-240, 1996.
PubMed
47) van Kreijl CF, McAnulty PA, Beems RB, et al: Xpa and Xpa/p 53+/-knockout mice: overview of available data. Toxicol Pathol 29: 117-127, 2001.
 
P.115 掲載の参考文献
1) Thomassen MJ, Buoen LC, Brand I, et al: Foreign-body tumorigenesis in mice: DNA synthesis in surface-attached cells during preneoplasia. J Natl Cancer Inst 61: 359-363, 1978.
PubMed
2) Moizhessb TG and Vasiliev JM: Early and late stages of foreign-body carcinogenesis can be induced by implants of different shapes. Int J Cancer 44: 449-453, 1989.
 
3) Kane AB: Mechanisms of mineral fibre carcinogenesis. Mechanisms of fibre carcinogenasis. IARC Scientific Publicatios No. 140, IARC, Lyon, 1996, pp11-33
 
4) Brand KG, Johnson KH and Buoen LC: Foreign body tumorigenesis. CRC Crit Rev Toxicol 4: 353-394, 1976.
PubMed
5) Ribeiro U Jr, Posner MC, Safatle-Ribeiro AV, et al: Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg 83: 1174-1185, 1996.
PubMed
6) Uetsuji S, Okuda Y, Kwon AH, et al: Gallbladder cancer with a low junction of the cystic duct or an anomalous pancreaticobiliary junction. Eur J Gastroenterol Hepatol 8: 1213-1217, 1996.
PubMed
7) Marczynski B, Rozynek P, Kraus T, et al: Levels of 8-hydroxy-2'-deoxyguanosine in DNA of white blood cells from workers highly exposed to asbestos in Germany. Mutat Res 468: 195-202, 2000.
PubMed
8) Unfried K, Schurkes C and Abel J: Distinct spectrum of mutations induced by crocidolite asbestos: clue for 8-hydroxydeoxyguanosine-dependent mutagenesis in vivo. Cancer Res 62: 99-104, 2002.
PubMed
9) Liu KJ and Shi X: In vivo reduction of chromium(VI) and its related free radical generation. Mol Cell Biochem 222: 41-47, 2001.
PubMed
10) Beyersman D: Interactions in metal carcinogenicity. Toxicol Lett 72: 333-338, 1994.
 
11) Wu MM, Chiou HY, Wang TW, et al: Association of blood arsenic levels with increased reactive oxidants and decreased antioxidant capacity in a human population of northeastern Taiwan. Environ Health Perspect 109: 1011-1017, 2001.
 
12) Ahmad S, Kitchin KT and Cullen WR: Arsenic species that cause release of iron from ferritin and generation of activated oxygen. Arch Biochem Biophys 382: 195-202, 2000.
PubMed
13) Yamamoto S, Wanibuchi H, Hori T, et al: Possible carcinogenic potential of dimethylarsinic acid as assessed in rat in vivo models: a review. Mutat Res 386: 353-361, 1997.
PubMed
14) IARC: IARC Monografhs on the evaluation of carcinogenic risk of the chemicals to humans, some metals and metallic compounds, vol. 23, IARC, Lyon, 1980.
 
15) Reeves AL: Beryllium carcinogenesis: areview. Adv Exp Med Biol 91: 13-27, 1977.
 
16) Hirose T, Kondo K, Takahashi Y, et al: Frequent microsatellite instability in lung cancer from chromate-exposed workers. Mol Carcinog 33: 172-180, 2002.
PubMed
17) IARC: IARC Monografhs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Chromium, nickel and welding. vol. 49, IARC, Lyon, 1990.
 
18) Kawanishi S, Inoue S, Oikawa S, et al: Oxidative DNA damage in cultured cells and rat lungs by carcinogenic nickel compounds. Free Radic Biol Med 31: 108-116, 2001.
PubMed
19) Schwerdtle T, Seidel A and Hartwig A: Effect of soluble and particulate nickel compounds on the formation and repair of stable benzo[a]pyrene DNA adducts in human lung cells. Carcinogenesis 23: 47-53, 2002.
PubMed
20) Miller AC, Mog S, McKinney L, et al: Neoplastic transformation of human osteoblast cells to the tumorigenic phenotype by heavy metal-tungsten alloy particles: induction of genotoxic effects. Carcinogenesis 22: 115-125, 2001.
 
21) Toyokuni S, Tanaka T, Nishiyama Y, et al: Induction of renal cell carcinoma in male Wistar rats treated with cupricnitrilotriacetate. Lab Invest 75: 239-248, 1996.
PubMed
22) Liehr JG and Jones JS: Role of iron in estrogen-induced cancer: a review. Curr Med Chem 8: 839-849, 2001.
 
23) Toyokuni S and Sagripanti JL: Increased 8-hydroxydeoxy-guanosine in kidney and liver of rats continuously exposed to copper. Toxicol Appl Pharmacol 126: 91-97, 1994.
 
24) IARC: IARC Monografhs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Beryllium, cadmium, mercury, and exposures in the glass manufacturing industry. vol. 58, IARC, Lyon, 1993.
 
25) Huang C, Zhang Q, Li J, et al: Involvement of Erks activation in cadmium-induced AP-1 transactivation in vitro and in vivo. Mol Cell Biochem 222: 141-147, 2001.
 
26) Driscoll KE: Effects of fibers on cell proliferation, cell activation and gene expression. Mechanisms of fibre carcinogenasis. IARC Scientific Publicatios No. 140, IARC, Lyon, 1996, pp11-33.
 
27) IARC: IARC Monografhs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Asbestos. vol. 14, IARC, Lyon, 1977.
 
28) IARC: IARC Monografhs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Silica and silicates. 42, IARC, Lyon, 1987.
 
29) Unfried K, Schurkes C and Abel J: Distinct spectrum of mutations induced by crocidolite asbestos: clue for 8-hydroxydeoxyguanosine-dependent mutagenesis in vivo. Cancer Res 62: 99-104, 2002.
PubMed
30) Timblin CR, Guthrie GD, Janssen YW, et al: Patterns of c-fos and c-lun proto-oncogene expression, apoptosis, and proliferation in rat pleural mesothelial cells exposed to erionite or asbestos fibers. Toxicol Appl Pharmacol 151: 88-97, 1998.
PubMed
31) IARC: IARC Monografhs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Man-made mineral fibres and radon. vol. 43, IARC, Lyon, 1988.
 
32) Dopp E and Schiffmann D: Analysis of chromosomal alterations induced by asbestos and ceramic fibers. Toxicol Lett 96-97: 155-162, 1998.
 
33) Clayson DB and Pringle JA: The influence of a foreign body on the induction of tumours in the bladder epithelium of the mouse. Br J Cancer 20: 564-568, 1966.
PubMed
34) IARC: IARC Monografhs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Silica, some silicates, coal dusts and para-aramid fibrils. vol. 68, IARC, Lyon, 1997.
 
35) Leanderson P, Soderkvist P, Tagesson C, et al: Formation of DNA adduct 8-hydroxy-2'-deoxyguanosine induced by manmade mineral fibres. IARC Sci Publ 89: 422-424, 1988.
 
36) Iwai K, Adachi S, Takahashi M, et al: Early oxidative DNA damages and late development of lung cancer in diesel exhaust-exposed rats. Environ Res 84: 255-264, 2000.
PubMed
37) IARC: IARC Monografhs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Polynuclear aromatic compounds, Part 4, Bitumens, coal-tars and derived products, shale-oils and soots. vol. 35, IARC, Lyon, 1985.
 
38) Sera N, Tokiwa H and Miyata N: Mutagenicity of the fullerene C 60-generated singlet oxygen dependent formation of lipid peroxides. Carcinogenesis 17: 2163-2169, 1996.
 
39) Hahon N, Booth JA and Stewart JD: Interferon induction inhibition and mutagenic activity of nitrosated coal dust extract. Environ Res 45: 213-223, 1988.
PubMed
40) Palus J, Dziubaltowska E and Rydzynski K: DNA damage detected by the comet assay in the white blood cells of workersin a wooden furniture plant. Mutat Res 444: 61-74, 1999.
 
41) IARC: IARC Monografhs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Wood dust and fomaldehyde. vol. 62, IARC, Lyon, 1995.
 
42) Tsukahara Y, Fukamatsu Y, Hirabayashi T, et al: Adenocarcinoma of the endometrium following prolonged use of an intrauterine device. Nnippon sanka fujinka gakkai zasshi(Acta Obstet Gynaecol Japonica) 35: 339-343, 1983.
 
43) Baba N and Von Haam E: Squamous cell carcinoma of the rat endometrium produced by insertion of strings coated with paraffin and polymer. J Natl Cancer Inst 47: 675-685, 1971.
PubMed
44) Kuwashima Y, Nemoto N and Ishikawa T: Expression of proto-oncogenes and cytoskeletal actin gene in foreign body induced murine sarcomas. In Vivo 7: 139-142, 1993.
PubMed
45) Van Natta BW, Thurston JB and Moore TS: Silicone breast implants-Is there cause for concern? Indiana Medicine 83: 184-185, 1990.
PubMed
46) Brand KG: Do implanted medical devices cause cancer? (95 Refs) . J Biomater Appl 8: 325-343, 1994.
 
47) Dewan PA: Is injected polytetrafluoroethylene (Polytef) carcinogenic? [see comments]. Br J Urol 69: 29-33, 1992.
 
48) Dunn KW, Hall PN and Khoo CT: Breast implant materials: sense and safety [see comments]. Br J Plast Surg 45: 315-321, 1992.
 
49) Fukushima S, Tanaka H, Asakawa E, et al: Carcinogenicity of uracil, a nogenotoxic chemical, in rats and mice and its rationale. Cancer Res 52: 3789-3794, 1989.
 
50) Ishii A, Matsuoka H, Aji T, et al: Parasite infection and cancer: with special emphasis on Scistosoma japonicum infections (Trematoda) : a review. Mutat Res 305: 273-281, 1994.
 
51) Cohen SM, Cano M, Garland EM, et al: Urinary and urothelial effects of sodium salts in male rats. Carcinogenesis 16: 343-348, 1995.
PubMed
52) Segi M: Tea-gruel as a possible factor for cancer for the esophagus. Gann 66: 199-202, 1975.
PubMed
53) IARC: IARC Monografhs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Coffee, tea, mate, methylxanthines and methylglyoxal. vol. 51, IARC, Lyon, 1991.
 
54) Fonseca CA, Otto SS, Paumgartten FJ, et al: Nontoxic, mutagenic, and clastogenic activities of Mate-Chimarrao(Ilexparaguariensis) . J Environ Pathol Toxicol Oncol 19: 333-346, 2000.
 
55) Kuwashima Y, Nemoto N and Ishikawa T: Expression of proto-encogenes and cytoskeletal actin gene in foreign body-induced murine sarcomas. In Vivo 7: 139-142, 1993.
PubMed
P.126 掲載の参考文献
1) Silva IDS: Cancer Epidemiology: Principles and Methods. IARC, Lyon, 1999.
 
2) Parkin DM, Whelan SL, Ferlay J, et al(eds) : Cancer Incidence in Five Continents, Vol. VII. IARC Scientific Publication No 143, IARC, Lyon, 1997.
 
3) 大島 明, 味木和喜子, 北川貴子・他: 日本のがん罹患率と推移. がん・統計白書-罹患/死亡/予後-1999, (富永祐民, 大島 明, 黒石哲生, 他・編) , 篠原出版, 東京, 1999, pp 85-148.
 
4) Ajiki W, Tsukuma H, Oshima A, et al: Cancer incidence and incidence rates in Japan in 1997: Estimates based on data from 12population-based cancer registries. Jpn J Clin Oncol 32: 318-322, 2002.
 
5) 黒石哲生, 広瀬かおる, 田島和雄・他: 日本におけるがん死亡(1950-1995) . がん・統計白書-罹患/死亡/予後-1999, (富永祐民, 大島 明, 黒石哲生, 他・編) , 篠原出版, 東京, 1999, pp 1-84.
 
6) 厚生統計協会・編: 国民衛生の動向. 臨時増刊 49(9) : 2002.
 
7) 日本疫学会・編: 疫学ハンドブック 重要疾患の疫学と予防. 南江堂, 東京, 1998, pp 25-29.
 
8) Muir CS: International patterns of cancer. Cancer Prevention and Control, (ed by Greenwald P, Kramer BS and Weed DJ) , Marcel Dekker Inc, New York, 1995, pp 37-68.
 
9) Thomas D and Karagas MR: Migrant studies. Cancer Epidemiology and Prevention, (ed by Schottenfeld and Fraumeni JF Jr) , Oxford University Press, New York, 1996, pp236-254.
 
10) Fraumeni Jr JF, Devesa SS, Hoover RN, et al: Epidemiology of cancer. Cancer, Principles & Practice of Oncology, (ed by DeVita Jr VT, Hellman S and Rosenberg ST) , Lippincott Company, Philadelphia, 1993, pp150-181.
 
11) Higgison J, Muir CS and Munoz N: Human Cancer: Epidemiology and Environmental Causes. Cambridge Monographs on Cancer Research. Cambridge University Press, New York, 1992.
 
12) http://www. mc. pref. osaka. jp/ocr
 
13) 大島 明, 津熊秀明, 味木和喜子, 他・編: 大阪府におけるがん患者の生存率の動向1975-1989年. 篠原出版, 東京, 1998.
 
14) Hennekens CH and Buring JE: Epidemiology in Medicine. Little, Brown and Company, Boston, 1987.
 
15) Rothman KJ and Greenland S: Modern Epidemiology. Lippincott-Raven, Philadelphia, 1998.
 
P.137 掲載の参考文献
1) Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031, 2001.
PubMed
2) Huang ME, Ye YC, Chen SR, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567, 1988.
PubMed
3) Guidez F, Ivins S, Zhu J, et al: Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML-and PLZF-RAR alpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91: 2634, 1998.
PubMed
4) Lin RJ, Nagy L, Inoue S, et al: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811, 1998.
PubMed
5) Nakagawa K, Yamamoto N, Kudoh S, et al: A phase I intermittent dose-escalation trial of ZD 1839(Iressa) in Japanese patients with solid malignant tumours. Proc ASCO 19: 183a, 2000.
 
6) Hung MC and Lau YK: Basic science of HER-2/neu: a review. Semin Oncol 26: 51, 1999.
PubMed
7) Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med 344: 783, 2001.
 
8) McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD 20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825, 1998.
 
9) Tokuda Y, Okumura A, Ohta M, et al: A humanized anti-c-erbB-2 monoclonal antibody for the treatment of breast cancer. Breast Cancer 25: 269, 1997,
 
10) Sliwkowski MX, Lofgren JA, Lewis GD, et al: Nonclinical studies addressing the mechanism of action of trastuzumab(Herceptin) . Semin Oncol 26: 60-70, 1999.
PubMed
11) Christian MC, Pluda JM, Ho PT, et al: Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Semin Oncol 24: 219, 1997.
PubMed
12) Maloney DG, Smith B and Rose A: Rituximab: mechanism of action and resistance. Semin Oncol 29(1 Suppl 2) : 2, 2002.
 
13) Alas S, Emmanouilides C and Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7: 709, 2001.
PubMed
14) Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185, 1994.
PubMed
15) 矢野聖二, 曽根三郎: 肺がんの分子生物学. 癌と化学療法 26(14) : 2131-2138, 1999.
Medical*Online
16) Yuan A, Yu CJ, Kuo SH, et al: Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19: 432, 2001.
 
17) Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321, 1998.
PubMed
18) Childs R, Chernoff A, Contentin N, et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750-758, 2000.
PubMed
19) Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235, 2002.
 
20) Thiesing JT, Ohno-Jones S, Kolibaba KS et al: Efficacy of STI 571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96: 3195, 2000.
PubMed
21) Nakamura S and Suchi T: A clinicopathologic study of node-based, low-grade, peripheral T-cell lymphoma. Angioimmunoblastic lymphoma, T-zone lymphoma, and lymphoepithelioid lymphoma. Cancer 67: 2566, 1991.
PubMed
22) Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561, 1996.
PubMed
23) Heinrich MC, Griffith DJ, Druker BJ, et al: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925, 2000.
PubMed
24) Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052, 2001.
 
25) Izumi Y, Xu L, di Tomaso E, et al: Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416: 279, 2002.
PubMed
26) Wojtowicz-Praga S, Torri J, Johnson M, et al: Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced Iung cancer. J Clin Oncol 16: 2150, 1998.
 
27) Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD 20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaR III a gene. Blood 99: 754, 2002.
 
28) Weisberg E and Griffin JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI 571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95: 3498, 2000.
 
29) Gambacorti-Passerini C, Barni R, le Coutre P, et al: Role of alpha 1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI 571. J Natl Cancer Inst 92: 1641, 2000.
 
30) Hofmann WK, de Vos S, Elashoff D, et al: Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI 571 and gene-expression profiles: agene-expression study. Lancet 359: 481, 2002.
 
31) Nishizaki M, Fujiwara T, Tanida T, et al: Recombinant adenovirus expressing wild-type p53 is antiangiogenic: aproposedmechanism for bystander effect. Clin Cancer Res 5: 1015-1023, 1999.
PubMed
P.146 掲載の参考文献
1) Sackett DL, Haynes RB, Guyatt GH, et al: Clinical epidemiology, a basic science for clinical medicine, 2nd ed, Little, Brown and Company, Boston, 1991.
 
2) Sackett DL, Richardson WS, Rosenberg W, et al: Evidence-based medicine: how to practice and teach EBM, 2nd ed, Churchill Living-Stone, Edinburgh, 2000.
 
3) Dent DM, Madden MV and Price SK: Randomized comparison of R 1 and R 2 gastrectomy for gastric carcinoma. Br J Surg 75: 110-112, 1988.
 
4) Robertson CS, Chung SCS, Woods SDS, et al: Aprospective randomized trial comparing R l subtotal gastrectomy with R 3 total gastrectomy for antral cancer. Ann Surg 220: 176-182, 1994.
 
5) Bonenkamp JJ, Hermans J, Sasako M, et al: Extended lymph-node dissection for gastric cancer. N Engl J Med 340: 908-914, 1999.
PubMed
6) Cuschieri A, Weeden S, Fielding J, et al: Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 79: 1522-1530, 1999.
 
7) Brennan MF: Lymph-node dissection for gastric cancer. N Engl J Med 340: 956-958, 1999.
PubMed
8) Veronesi U, Saccozzi R, Del Vecchio M, et al: Comparing radical mastectomy with quandrantectomy, axillary dissection, and radiotherapy in patient with small cancers of breast. N Engl J Med 305: 6-11, 1981.
 
9) Veronesi U, Marubini E, Mariani L, et al: The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomized trial. Eur J Cancer 35: 1320-1325, 1999.
 
10) Turhan AG, Solary E, Vainchenker W, et al: Molecular pathophysiology of chronic myelogeneous leukemia. Hematol Cell Ther 40: 217-221, 1998.
PubMed
11) O'Dwyer ME and Druker BJ: STI 571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukemia. Lancet Oncol 1: 207-211, 2000.
 
12) Kantarjian H, Sawyers C, Hochhaus A, et al: The International STI 571 CML Study Group: Hematologic and cytogenetic responses to imatinib mesylate in chronicmyelogenous leukemia. N Engl J Med 346: 645-652, 2002.
 
13) Perez EA and Hortobagyi GN: Ongoing and planned adjuvant trials with trastuzumab. Semin Oncol 27: 26-32, 2000.
PubMed
14) Hortobaagyi GN: Overview of treatment results with trastuzumab(Herceptin) in metastatic breast cancer. Semin Oncol 28: 43-47, 2001.
 
15) Ciardiello F and Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958-2970, 2001.
PubMed
16) Hasan J and Jayson GC: VEGF antagonists. Expert Opin Biol Ther 1: 703-718, 2001.
 
17) DeRisi J, Penland L, Brown PO, et al: Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14: 457-460, 1996.
PubMed
18) Kihara C, Tsunoda T, Tanaka T, et al: Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene expression profiles. Cancer Res 61: 6474-6479, 2001.
PubMed
19) Paik S: Incorporating genomics into the cancer clinical trial process. Semin Oncol 28: 305-309, 2001.
PubMed
20) Brufman G, Colajori E, Ghilezan N, et al: Doubling epirubicin dose intensity(100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomized phase III study in metastatic breast cancer. The Epirubicin High Dose(HEPI O10) Study Group. Ann Oncol 8: 155-162, 1 997.
 
21) Poikonen P, Saarto T, Lundin J, et al: Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80: 1763-1766, 1999.
PubMed
22) Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrowsupported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: arandomized trial. Scandinavian Breast Group 9401 Study. Lancet 356: 1384-1391, 2000.
 
P.152 掲載の参考文献
1) 高山坦三: 西洋外科史. 現代外科学大系(1) , (木本誠二・監修) , 中山書店, 東京, 1973, pp 3-31.
 
2) Billroth T: Behandlung von verengerungen des verdauungs-traktes durch carcinom. Wien Med Wschr 31: 272-276, 1881.
 
3) 高山坦三: 日本外科史. 現代外科学大系(1) , (木本誠二・監修) , 中山書店, 東京, 1973, pp33-53.
 
4) Halsted WS: The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg 20: 497-555, 1894.
 
5) Patey DH and Dyson WH: The prognosis of carcinoma of the breast in relation to the type of operation performed. Br J Cancer 2: 7-13, 1948.
 
6) Auchincloss H: Significance of location and number of axillary metastasis in carcinoma of the breast. A justification for aconservative operation. Ann Surg 158: 37-46, 1967.
 
7) Tsuchiya R, Asamura H, Kondo H, et al: Extended resection of the left atrium, great vessels, or both for lung cancer. Ann Thorac Surg 57: 960-965, 1994.
PubMed
8) 大橋一郎, 高木国夫, 梶谷 環: 進行胃癌に対する左上腹部内臓全摘術の適応と方法. 消化器外科 7: 1535-1542, 1984.
 
9) 徳田 一, 高橋 滋, 竹中 温: 胃癌の超拡大郭清における適応と限界. 日外会誌 89: 1528-1530, 1988.
 
10) 愛甲 孝, 夏越祥次, 帆北修一: 進行胃癌に対する拡大手術-拡大手術の治療成績及び適応と今後の問題点-. 特集「胃癌治療の最近の進歩と今後の問題点」日外会誌 102: 764-769, 2001.
 
11) Hojo K and Koyama Y: The effectiveness of wide anatomical resection and radical lymphadenectomy for patients with rectal cancer. Jpn J Surg 12: 111-116, 1982.
PubMed
12) 土屋周二, 池 秀之, 大林繁男: 大腸癌の手術. 自律神経を温存する直腸癌手術. 手術 37: 1367-1373, 1983.
 
13) Heald RJ and Ryall RD: Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 28: 1479-1482, 1986.
 
14) Brunschwig A: Complete excision of pervic visera for advanced carcinoma; A one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer 1: 177-183, 1948.
 
15) Maddox WA, Carpenter JT Jr, Laws HL, et al: A randomized prospective trial of radical(Halsted) mastectomy versus modified radical mastectomy in 311 breast cancer patients. Ann Surg 198: 207-212, 1983.
PubMed
16) Fisher B, Redmond C, Poisson R, et al: Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320: 822-828, 1989.
PubMed
17) Fisher B, Radmond C, Fisher ER, et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312: 674-681, 1985.
PubMed
18) Noguchi M, Morikawa A, Kawasaki M, et al: Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75: 2844-2852, 1995.
PubMed
19) Tsubota N, Ayabe K, Doi O, et al: Ongoing prospective study of segmentectomy for small lung tumors. Study Group of Extended Segmentectomy for Small Lung Tumor. Ann Thorac Surg 66: 1787-1790, 1998.
 
20) Lung Cancer Study Group: Randomized trial of lobectomy versus limited resection for T 1 N O non-small cell lung cancer. Ann Thorac Surg 60: 615-623, 1995.
 
21) Maki T, Shiratori T, Hatafuku T, et al: Pylorus-preserving gastrectomy as improved operation for gastric ulcer. Surgery 61: 838-845, 1967.
PubMed
22) 三輪晃一, 松本 尚, 瀬川正考・他: 胃癌リンパ節郭清における迷走神経温存療法. 医学のあゆみ 159: 257-258, 1991.
 
23) Bonenkamp JJ, Hermans J, Sasako M, et al: Extended lymph node dessection for gastric cancer. N Engl J Ned 340: 908-914, 1999.
 
24) Cuschieri A, Weeden S, Fielding J, et al: Patient survival after DI and D2 resections for gastric cancer: Long term results of the MRC randomized surgical trial. Br J Cancer 79: 1522-1530, 1999.
 
25) 森 武生, 高橋慶一, 安野正道: 低位直腸癌における自律神経温存術. 日外会誌 98: 385-390, 1997.
 
26) 杉原健一, 赤須考之, 藤田 伸・他: 肛門機能括約筋温存術. 日外会誌 98: 391-395, 1997.
 
27) Kayikcioglu F, Kose MF, Boran N, et al: Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 11: 466-470, 2001.
PubMed
28) Jahne J: Principle and indications for debulking operation in peritoneal carcinosis. Kongressbd Dtsch Ges Chir Kongr 118: 209-212, 2001.
PubMed
29) 北川雄光, 大上正裕, 藤井博史・他: 消化器癌のセンチネルリンパ節検出; RI法と色素法の比較. 特集「消化器癌のセンチネルリンパ節」. 消化器外科 23: 1617-1624, 2000.
 
30) Early breast cancer trialists'collaborative group: Systemic treatment of early breast cancer by hormonal. cytotoxic, or immune therapy. 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: 71-85, 1992.
PubMed
31) Early Breast Cancer Trialist'Collaborative Group: Tamoxifen for early breast cancer. Cochrane Database Syst Rev 1: CD OOO486, 2001.
 
32) Early Breast Cancer Trialist'Collaborative Group: Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 1: CD OOO487, 2002.
 
33) 高嶋成光, 佐伯俊昭: 抗がん剤適正使用のガイドライン(案) -乳がん. 癌と化学療法 29: 1025-1046, 2002.
 
34) Hermans J, Bonenkamp JJ, Boon MC, et al: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11: 1441-1447, 1993.
PubMed
35) Earle CC and Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer 35: 1059-1064, 1999.
PubMed
36) Mari E, Floriani I, Tinazzi A, et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a metaanalysis of published randomized trials. A study of the GISCAD(Gruppo Italiano per lo Studio dei Carcunomi dell'Apparato Digerente) . Ann Oncol 12: 1178-1180, 2002.
 
37) Janunger KG, Hafstrom L, Nygren P, et al: A system atic overview of chemotherapy effects in gastric cancer. Acta Oncol 40: 309-326, 2001.
 
38) 峠 哲哉, 金 隆史, 吉田和弘・他: 抗がん剤適正使用のガイドライン(案) -胃がん, 大腸がんに対する術後補助療法. 癌と化学療法 29: 1015-1024, 2002.
 
39) Buyse M, Zeleniuch-Jacquotte A and Chalmers TC: Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 259: 3571-3578, 1988.
 
40) Meta-analysis Group In Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308, 1998.
PubMed
41) Non-small cell lung cancer collaborative group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909, 1995.
 
42) Felip E and Rosell R: Neoadjuvant chemotherapy in non-small cell lung cancer. Curr Med Chem 9: 893-898, 2002.
PubMed
43) Rosell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330: 153-158, 1994.
PubMed
44) Depierre A, Milleron B, Sibilot DM, et al: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I(except TlNO) , II, and IIIa non-small-cell lung cancer. J Clin Oncol 20: 247-253, 2002.
 
45) Fowler WC, Langer CJ, Curran WJ, et al: Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 55: 986-989, 1993.
PubMed
46) 北野正剛, 白石憲男: 内視鏡外科における癌の増殖・進展・転移. 特集「内視鏡外科の基礎と臨床」. 日外会誌 101: 526-530, 2000.
 
47) Nakajo A, Natsugoe S, Ishigami S, et al: Detection and prediction of micrometastasis in the lymph nodes of patients with pN O gastric cancer. Ann Surg Oncol 8: 158-162, 2001.
 
48) Funke I and Schraut W: Meta-analysis of studies on bone marrow micrometastasis: an independent prognostic impact remains to be substantiated. J Clin Oncol 16: 557-566, 1998.
 
P.167 掲載の参考文献
1) Chu E and DeVita VT Jr: Principles of cancer management: Chemotherapy. Cancer: Principles and Practice of Oncology, (ed by DeVita VT Jr, Hellman S and Rosengerg SA) , 6th edition, Lippincott Co, Philadelphia, 2001, pp289-306.
 
2) Donehower RC, Abeloff MD and Perry MC: Chemotherapy. Clinical Oncology, (ed by Abeloff MD, Armitage JO, Lichter AS, et al) , 1st edition, Churchill Livingstone Inc, New York, 1 995, pp201-218.
 
P.181 掲載の参考文献
1) Margulis AR: Interventional diagnostic radiology-A subspeciality. Am J Roentgenol 99: 761-762, 1967.
 
2) Wallace S: Interventional radiology. Cancer 37: 517-531, 1976.
PubMed
3) Martin HE and Ellis EB: Biopsy by needle and aspiration. Ann Surg 92: 169-181, 1930.
PubMed
4) Lindblom K: Percutaneous puncture of renal cyctes and tumors. Acta Radiol 27: 66, 1946.
PubMed
5) McFadzean AJS, Chang KPS and Wong CC: Solitary pyogenic abscess of liver treated by closed aspiration and antibiotics: A report of 14 consecutive cases with recovery. Br J Surg 41: 141, 1953.
 
6) Wiechel KL: Percutaneous transhepatic cholangiography: technique and application. Act Chir Scand 330(Suppl) : 1, 1964.
 
7) Dotter CT and Judkins MP: Transluminal treatment of arteriosclerotic obstruction. Description of a technique and a preliminary report of application. Circulation 30: 654-670, 1964.
 
8) Adam A and Hemingway AP: Interventional radiology. Oxford Textbook of Palliative Medicine, (ed by Doyle D, Hanks GWC and MacDonald N) , 2nd edition, Oxford University Press, Oxford, New York, Tokyo, 1998, pp239-248.
 
9) Aguayo A and Patt YZ: Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 28: 503-513, 2001.
PubMed
10) Sheu JC, Huang GT, Chen DS, et al: Small hepatocellular carcinoma: intratumor ethanol treatment using new needle and guidance systems. Radiology 163: 43-48, 1987.
PubMed
11) Livraghi T, Festi D, Monti F, et al: US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. Radiology 161: 309-312, 1986.
PubMed
12) Ohto M, Sugiura N, Ebara M, et al: Treatment of hepatocellular carcinoma by alcohol injection into tumor and irradiation to tumor. Gan To Kagaku Ryoho 13: 1625-1634, 1986.
PubMed
13) Sheu JC, Sung JL, Huang GT, et al: Intratumor injection of absolute ethanol under ultrasound guidance for the treatment of small hepatocellular carcinoma. Hepatogastroenterology 34: 255-261, 1987.
PubMed
14) Shiina S, Yasuda H, Muto H, et al: Percutaneous ethanol injection in the treatment of liver neoplasms. Am J Roentgenol 149: 949-952, 1987.
 
15) Seki T, Wakabayashi M, Nakagawa T, et al: Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 74: 817-825, 1994.
PubMed
16) Murakami R, Yoshimatsu S, Yamashita Y, et al: Treatment of hepatocellular carcinoma: value of percutaneous microwave coagulation. Am J Roentgenol 164: 1159-1164, 1995.
 
17) Jiao LR, Hansen PD, Havlik R, et al: Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors. Am J Surg 177: 303-306, 1999.
PubMed
18) Wood TF, Rose DM, Chung M, et al: Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 7: 593-600, 2000.
PubMed
19) Yamasaki T, Kurokawa F, Shirahashi H, et al: Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer 91: 1342-1348, 2001.
PubMed
20) Hall-Craggs MA and Vaidya JS:Minimally invasive therapy for the treatment of breast tumours. Eur J Radiol 42:52-57, 2002.
PubMed
21) Putnam JB Jr: New and evolving treatment methods for pulmonary metastases. Semin Thorac Cardiovasc Surg 14: 49-56, 2002.
PubMed
22) Mirza AN, Fornage BD, Sneige N, et al: Radiofrequency ablation of solid tumors. Cancer J 7: 95-102, 2001.
PubMed
23) Murphy DP and Gill IS: Energy-based renal tumor ablation: a review. Semin Urol Oncol 9: 133-140, 2001.
 
24) Wood BJ, Ramkaransingh JR, Fojo T, et al: Percutaneous tumor ablation with radiofrequency. Cancer 94: 443-451, 2002.
PubMed
25) Shibata T, Iimuro Y, Yamamoto Y, et al: Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 223: 331-337, 2002.
PubMed
26) Shiina S, Teratani T, Obi S, et al: Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 1: 64-68, 2002.
PubMed
27) Dupuy DE and Goldberg SN: Image-guided radiofrequency tumor ablation: challenges and opportunities-part II. J Vasc Interv Radiol 12: 1135-1148, 2001.
 
28) Nahum Goldberg S and Dupuy DE: Image-guided radiofrequency tumor ablation: challenges and opportunities-part I. J Vasc Interv Radiol 12: 1021-1032, 2001.
 
29) Poon RT, Fan ST, Tsang FH, et al: Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 235: 466-486, 2002.
 
30) Huang A, McCall JM, Weston MD, et al: Phase I study of percutaneous cryotherapy for colorectal liver metastasis. Br J Surg 89: 303-310, 2002.
PubMed
31) Muralidharan V, Malcontenti-Wilson C and Christophi C: Effect of interstitial laser hyperthermia in a murine model of colorectal liver metastases. J Gastrointest Surg 5: 646-657, 2001.
 
32) Usatoff V and Habib NA: Update of laser-induced thermotherapy for liver tumors. Hepatogastroenterology 48: 330-332, 2001.
PubMed
33) Yamamoto J, Okada S, Shimada K, et al: Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 34: 707-713, 2001.
PubMed
34) Livraghi T, Lazzaroni S and Meloni F: Radiofrequency thermal ablation of hepatocellular carcinoma. Eur J Ultrasound 13: 159-166, 2001.
PubMed
35) Vogl TJ, Muller PK, Mack MG, et al: Liver metastases: interventional therapeutic techniques and results, state of the art. Eur Radiol 9: 675-684, 1999.
PubMed
36) Curley SA: Radiofrequency ablation of malignant liver tumors. Oncologist 6: 14-23, 2001.
PubMed
37) Collins J: Pharmacologic rationale for regional drug delivery. J Clin Oncol 2: 498-504, 1984.
PubMed
38) Lang EK: Superselective arterial catheterization as a vehicle for delivering radioactive infarct particles to tumors. Radiology 98: 391-399, 1974.
 
39) Yamada R, Sato M, Nakatsuka H, et al: Hepatic arterial embolization in 120 patients with unresectable hepatoma. Radiology 148: 397-401, 1983.
PubMed
40) Nakamura H, Hashimoto T, Oi H, et al: Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 17: 783-786, 1989.
PubMed
41) Konno T, Maeda H, Iwai K, et al: Effect of arterial administration of high-molecular weight anticancer agent SMANCS with lopid lymphographic agent on hepatoma. A preliminary report. Eur J Cancer Clin Oncol 19: 1053-1065, 1983.
 
42) 田口鐵男, 斉藤達雄, 太田 潤・他: YM 881(ジノスタチン スチマラマー) 油性懸濁液の肝動注における第II相試験. 癌と化学療法 18: 1665-1675, 1991.
Medical*Online
43) Nakamura H, Hashimoto T, Oi H, et al: Treatment of hepatocellular carcinoma by segmental hepatic artery injection of adriamycin in oil emulsion with overflow to segmental portal veins. Acta Radiol 31: 347-349, 1990.
PubMed
44) Uchida H, Ohisi H, Matsuo N, et al: Transcatheter hepatic segmental arterial embolization using Lipiodol mixed with anticancer drug and gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 13: 140-145, 1990.
 
45) Uchida H, Matsuo N, Sakaguchi H, et al: Segmental embolotherapy for hepatic cancer: Keys to success. Cardiovasc Intervent Radiol 16: 67-71, 1993.
PubMed
46) 第9回全国原発性肝癌追跡調査報告(1986-1987) , 日本肝癌研究会, 1990.
 
47) 西村幸洋, 打田日出夫, 郭 啓勇・他: 肝細胞1075例に対する肝動脈塞栓術-特に累積生存率と3年以上生存9例からみた抗癌剤混入リピオドール併用の評価-. 日癌治療会誌 26: 2279-2289, 1991.
 
48) Ikeda K, Kumada H, Saitoh S, et al: Effect of repeated transcatheter arterial embolization of the survival time in patients with hepatocellular carcinoma. Cancer 68: 2150-2154, 1991.
PubMed
49) Yamamoto K, Masuzawa M, Kato M, et al: Analysis of prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Cancer Chemother Pharmacol 31(Suppl) : S77-S 81, 1992.
 
50) 高田恵二: 原発性肝癌に対する経カテーテル治療の適応と選択に関する研究. 肝臓 35: 496-508, 1992.
 
51) 畑中義美, 山下康行, 荒川昭彦・他: 1. 進行肝細胞癌に対するIVR(2) 切除不能肝細胞癌の肝動脈塞栓療法における予後因子. IVR 10: 253-256, 1995.
 
52) Lin DV, Liaw YF, Lee TY, et al: Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-arandomized controlled trial. Gastroenterology 94(2) : 453-456, 1988.
 
53) Pelletier G, Roche A, Ink O, et al: A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11(2) : 181-184, 1990.
PubMed
54) Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 332(19) : 1256-1261, 1995.
 
55) Bruix J, Llovet JM, Castells A, et al: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27(6) : 1578-1583, 1998.
 
56) Pelletier G, Ducureux M, Gay G, et al: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 29(1) : 129-134, 1998.
 
57) Okada S: Transcatheter arterial embolization for advanced hepatocellular carcinoma: the controversy continues. Hepatology 27(6) : 1743-1744, 1998.
PubMed
58) Camma C, Schepis F, Orlando A, et al: Transarterial chemoembolization for unresectable hepatocellular carcinoma: metaanalysis of randomized controlled trials. Radiology 224: 47-54, 2002.
PubMed
59) Yodono H, Sasaki T, Tarusawa K, et al: Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies. Cancer Chemother Pharmacol 31(Suppl) : S89-S 92, 1992.
 
60) Okuda K, Tanaka M, Shibata J, et al: Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 6: 587-591, 1999.
PubMed
61) Itamoto T, Nakahara H, Tashiro H, et al: Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 80: 143-148, 2002.
PubMed
62) Patt YZ: Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: The controversy continues. J Clin Oncol 11: 815-819, 1991.
 
63) Begos DG and Ballantyne GH: Regional chemotherapy for colorectal liver metastases: Thirty years without patient benefit. J Surg Oncol 56: 139-144, 1994.
PubMed
64) Hohn DC, Stagg RJ, Friedman MA, et al: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial. J Clin Oncol 7: 1646-1654, 1989.
 
65) Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Int Med 107: 459-465, 1987.
PubMed
66) Martin JK, O'Connel MJ, Wieand HS, et al: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 125: 1022-1027, 1990.
 
67) Chang AE, Schneider PD, Sugarbaker PH, et al: A prospective randomized trial of regional versus systemic continuous 5FU-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206: 685-693, 1987.
 
68) Kemeny MM, Goldberg D, Beatty JD, et al: Results of a prospective randomized trial of continuous regional chemotherapyand hepatic resection as treatment of hepatic metastases from colorectal cancer. Cancer 57: 492-498, 1986.
 
69) Rougier P, Laplanche A, Huguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of prospective randomized trial. J Clin Oncol 10: 1112-1118, 1992.
 
70) Allen Mersh TG, Earlam S, Fordy C, et al: Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255-1260, 1994.
PubMed
71) Meta-Analysis Group In Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88: 252-258, 1996.
PubMed
72) Harmans A, Rotstein LE and Langer B: Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 78: 1639-1645, 1996.
 
73) Arai Y, Inaba Y and Takeuchi Y: Interventional techniques for hepatic arterial infusion chemotherapy. Interventional Radiology, (ed by Casuterneda-Zuniga ER) , Third Edition, Wiliams & Wilkins, Baltimore, 1997, pp192-205.
 
74) Inaba Y, Arai Y, Matsueda K, et al: Right gastric artery embolization to prevent acute gastric mucosal lesions in patients undergoing repeated hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 12: 957-963, 2001.
 
75) Seki H, Kimura M, Yoshimura N, et al: Hepatic arterial infusion chemotherapy using percutaneous catheter placementwith an implantable port: assecement of factors affecting patency of the hepatic artery. Clin Radiol 54: 221-227, 1999.
PubMed
76) Tanaka T, Arai Y, Inaba Y, et al: Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 14: 63-68, 2003.
PubMed
77) Durand-Zaleski I, Roche B, Buyse M, et al: Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. J Natl Cancer Inst 89: 790-795, 1997.
PubMed
78) Arai Y, Inaba Y, Takeuchi Y, et al: Intermittent hepatic arterial infusion of high-dose 5 FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol 40: 526-530, 1997.
PubMed
79) Arai Y, Inaba Y, Matsueda K, et al: Weekly 5 hour hepatic arterial infusion of high-dose 5-FU for unresectable liver metastases from colorectal cancer in patients without extra-hepatic lesions. Proc ASCO 17: 285a, 1998.
 
80) Arai Y, Sone Y, Tohyama N, et al: Hepatic arterial infusion for unresectable liver metastases from gastric cancer. Proc ASCO 11: 176, 1992.
 
81) Kumada T, Arai Y, Itoh K, et al: Phase II study of combined administration of 5-fluorouraci1, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer. Oncology 57: 216-223, 1999.
PubMed
82) Arai Y, Sone Y, Inaba Y, et al: Hepatic arterial infusion chemotherapy for liver metastases from breast cancer. Cancer Chemother Pharmacol 33: S142-S 144, 1994.
 
83) Kemeny N, Huang Y, Cohen AM, et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341: 2039-2048, 1999.
PubMed
84) Kemeny N, Gonen M, Sullivan D, et al: Phase I study of hepatic arterial infusion of floxiuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 19: 2687-2695, 2001.
 
85) Seldinger SI: Catheter replacement of the needle in percutaneous arteriography. A new technique. Acta Radiol 39: 368-376, 1953.
PubMed
86) 荒井保明, 澤田 敏, 中島康雄・他: Non-vascular IVR-画像診断手技の治療への応用-, (木戸長一郎・監修) , 癌と化学療法社, 東京, 1991, pp143-151.
 
87) 蘆田 浩: 膿瘍ドレナージ. 放射線医学大系特別巻1インターベンショナルラジオロジー, (編集代表・坂 晧) , 中山書店, 東京, 1986, pp288-299.
 
88) 荒井保明: 8-26 Interventional radiologyの手技を用い療法の有効性についての研究. 厚生省がん研究助成金による研究報告書平成8年度, 国立がんセンター, 東京, 1996, pp422-426.
 
89) Wright KC, Wallace S, Charnsangavej C, et al: Percutaneous endovascular stents: an experimental evaluation. Radiology 156: 69-72, 1985.
PubMed
90) Palmaz JC, Sibbitt PP, Reuter SR, et al: Expandable intraluminal graft: apreliminary study. Radilogy 156: 73-77, 1985.
 
91) Rousseau H, Peul J, Joffre F, et al: Self-expanding endovascular prosthesis: an experimental study. Radiology 164: 709-714, 1987.
 
92) Uchida BT, Putman JS and Rosch J: Modification of Giantruco wire stents. Am J Roentogenol 150: 185-187, 1988.
 
93) Sawada S, Fujiwara Y, Koyama T, et al: Application of expandable metallic stent to the venous system. Acta Radiol 33: 156-159, 1992.
 
94) Furui S, Sawada S, Irie T, et al: Hepatic inferior vena obstruction; treatment of two types with Gianturco expandable metallic stents. Radiology 176: 665-670, 1990.
PubMed
95) 荒井保明: 6-30 Interventional Radiologyの手技を用いた治療法の有効性に関する研究. 厚生省がん研究助成金による研究報告集 平成7年度, 国立がんセンター, 東京, 1995, pp242-247.
 
96) Sawada S, Tanigawa N, Kobayashi M, et al: Malignant tracheobronchial obstructive lesions: Treatment with Gianturco expandable metallic stents. Radiology 188: 205-208, 1993.
PubMed
97) Maeda M, Timmermans HA, Uchida B, et al: In vitro comparison of the spiral Z stent and the Giantruco Z stent. J VIR 3: 565-569, 1992.
 
98) Yoshioka T, Sakaguchi H, Yoshimura H, et al: Expandable metallic biliary endoprostheses: Preliminary clinical evaluation. Radiology 177: 253-257, 1990.
PubMed
99) Coons H: Metallic stents for the treatment of biliary obstruction: Areport of 100 cases. Cardiovasc Intervent Radiol 15: 367-374, 1992.
 
100) Uchida H, Yoshioka T, Maeda M, et al: Use of original, modified, and spiral Z stents in the biliary system. Stents-state of the art and future development, (ed by Liermann DD) , Polyscienc Publication Inc, 1995, pp202-207.
 
101) Cwikiel W: Esophageal nitinol stents: long-term results-state of the art and future development, (ed by Liermann DD) , Polyscienc Publication Inc, 1995, pp218-221.
 
102) Song HY, Choi KC, Kwon HC, et al: Esophageal strictures: treatment with a new design of a modified Giantruco stent. Radiology 184: 729-734, 1992.
 
103) Schaer J, Katon RM, Ivancev K, et al: Treatment of malignant esophageal obstruction with silicone-coated metallic selfexpanding stent. Gastrointest Endosc 38: 7-11, 1992.
 
104) Watokinson A, Ellul J, Entwisle K, et al: Plastic covered metallic endoprostheses in the management of oesophageal perforation in patients with oesophageal carcinoma. Clin Radiol 50: 304-309, 1995.
PubMed
105) Knyrim K, Wagner HJ, Bethge N, et al: A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med 329: 1302-1307, 1993.
PubMed
106) Mauro MA, Koehler RE and Baron TH: Advances in gastrointestinal intervention: the treatment of gastroduodenal and colorectal obstructions with metallic stents. Radiology 215: 659-669, 2000.
PubMed
107) Rafanan AL and Mehta AC: Stenting of the tracheobronchial tree. Radiol Clin North Am 38: 395-408, 2000.
PubMed
108) Shimi SM: Self-expanding metallic stents in the management of advanced esophageal cancer: areview. Semin Laparosc Surg 7: 9-21, 2000.
 
109) Lo SK: Metallic stenting for colorectal obstruction. Gastrointest Endosc Clin N Am 9: 459-477, 1999.
PubMed
110) Akle CA: Endoprostheses for colonic strictures. Br J Surg 85: 310-314, 1998.
PubMed
111) Adam A, Ellul J, Watkinson AF, et al: Palliation of inoperable esophageal carcinoma: aprospective randomized trial of laser therapy and stent placement. Radiology 202: 344-348, 1997.
 
112) Lammer J, Hausegger KA, Fluckiger F, et al: Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. Radiology 201: 167-172, 1996.
PubMed
113) Watkinson AF, Ellul J, Entwisle K, et al: Esophageal carcinoma: initial results of palliative treatment with covered selfexpanding endoprostheses. Radiology 195: 821-827, 1995.
 
114) Smith AC, Dowsett JF, Russell RC, et al: Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 344: 1655-1660, 1994.
PubMed
115) 荒井保明: 8-26 Interventional radiologyの手技を用いた治療法の有効性についての研究. 厚生省がん研究助成金による研究報告書平成9年度, 国立がんセンター, 東京, 1996.
 
116) Toyoda H, Nakano S, Takeda I, et al: Transcatheter arterial embolization for massive bleeding from duodenal ulcers not controlled by endoscopic hemostasis. Endoscopy 27: 304-307, 1995.
PubMed
117) 関 竜夫, 白土桃子: 消化管出血に対するIVR(2) 腫瘍性出血. IVR 10: 18, 1995.
 
118) 山内栄五郎, 熊野玲子, 池田隆久: 磁石圧迫吻合術(山内法) . 組織培養工学 28: 16-19, 2002.
 
119) Takao S, Matsuo Y, Shinchi H, et al: Magnetic compression anastomosis for benign obstruction of the common bile duct. Endoscopy 33: 988-990, 2001.
PubMed
120) Deramond H, Depriester C, Toussaint P, et al: Percutaneous vertebroplasty. Semin Musculoskelet Radiol 1: 285-296, 1997.
 
121) Levine SA, Perin LA, Hayes D, et al: An evidence-based evaluation of percutaneous vertebroplasty. Manag Care 9: 56-60, 2000.
PubMed
122) Cotten A, Boutry N, Cortet B, et al: Percutaneous vertebroplasty: state of the art. Radiographics 18: 311-320, 1998.
PubMed
123) 石川 徹: Interventional radiologyの歴史と展望. Non-vascular Interventional Radiology手技と考え方, (石川 徹・編) , 中外医学社, 東京, 1993, pp1-8.
 
124) Smith EH: Complications of percutaneous abdominal fine-needle biopsy. Radiology 128: 253-258, 1991.
 
125) 中島康雄: 3. 胸部. 生検1. 経皮的穿刺-A. 肺. Non-vascular Interventional Radiology手技と考え方, (石川 徹・編) , 中外医学社, 東京, 1993, pp17-23.
 
126) 荒井保明: 3. 胸部. 生検1. 乳房および胸壁. Non-vascular Interventional Radiology手技と考え方, (石川 徹・編) , 中外医学社, 東京, 1993, pp44-48.
 
127) 林 信成: 4. 腹部I. 生検1. 腫瘤. Non-vascular lnterventional Radiology手技と考え方, (石川徹・編) , 中外医学社, 東京, 1993, pp72-79
 
128) 荒井保明: 6-30 Interventional Radiologyの手技を用いた治療法の有効性に関する研究. 厚生省がん研究助成金による研究報告集 平成6年度, 国立がんセンター, 東京, 1994, pp459-463
 
129) Dedrick CG, Olson RR and Athanasoulis CA: Transcatheter embolization of the spleen. Interventional Radiology, (ed by Athanasoulis CA, Pfister RC, Greene RE and Roberson GH) , WB Saunders, Philadelphia, 1982, pp223-227.
 
130) Nakao N, Miura K, Takahashi H, et al: Hepatocellular carcinoma: combined hepatic, arterial, and portal venous embolization. Radiology 161: 303-307, 1986.
PubMed
131) Rosch J, Uchida BT and Putnam JS: Experimental intrahepatic portacaval anastomosis: Use of expandable Gianturco stents. Radiology 162: 481, 1987.
PubMed
132) Kimura M, Sato M, Shioyama Y, et al: Long-term results of TIPS. Nippon Igaku Hoshasen Gakkai Zasshi 60: 255-260, 2000.
PubMed
133) Bosch J and Garcia-Pagan JC: Complications of cirrhosis. I. Portal hypertension. J Hepatol 32(Suppl 1) : 141-156, 2000.
 
134) Angermayr B, Cejna M, Schoder M, et al: Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood 99: 4246-4247, 2002.
PubMed
135) Bloom AI and Verstandig A: SCVIR 2002 Film Panel case 2: TIPS for bleeding varices in cystic fibrosis and liver cirrhosis. J Vasc Interv Radiol 13: 533-536, 2002.
PubMed
136) Chutaputti A: Management of refractory ascites and hepatorenal syndrome. J Gastroenterol Hepatol 17: 456-461, 2002.
PubMed
137) Grubel P, Pratt DS and Elhelw T: Transjugular intrahepatic portosystemic shunt for portal decompression before abdominal and retroperitoneal surgery in patients with severe portal hypertension. J Clin Gastroenterol 34: 489-490, 2002.
PubMed
138) Oishi H, Murata J and Kameoka S: Percutaneous transesophageal gastric-tube drainage-Development of the balloon catheter and future prospects. Nippon Geka Gakkai Zasshi 99: 275, 1998.
PubMed
P.193 掲載の参考文献
1) Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage, prospecitve evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
 
2) Minami H, Ando Y, Saka H, et al: Re, prediction of carboplatin clearance form standard morphological and biological and biochemical patient characteristics. J Natl Cancer Inst 89: 968-969, 1997.
 
3) Reece PA, Stafford I, Russell J, et al: Nonlinear renal clearance of ultrafiltrable platinum in patients treated with cisdichlorodiammineplatinum(II) . Cancer Chemother Pharmacol 15: 295-299, 1985.
PubMed
4) Forastiere AA, Belliveau JF, Goren MP, et al: Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head neck cancer patients. Cancer Res 48: 3869-3874, 1988.
PubMed
5) Chu X-Y, Kato Y and Sugiyama Y: Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 57: 1934-1938, 1997.
 
6) Sonnichsen DS and Relling MV: Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27: 256-269, 1994.
PubMed
7) Tobinai K, Kobayashi Y, Narabayashi M, et al: Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody(IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol 9: 527-534, 1998.
PubMed
8) Sausville EA, Arbuck SG, Messmann R, et al: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19: 2319-2333, 2001.
 
9) Karlsson MO, Molnar V, Bergh J, et al: A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63: 11-25, 1998.
 
10) Minami H, Sasaki Y, Saijo N, et al: Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64: 511-521, 1998.
PubMed
11) Stewart CF, Arbuck SG, Fleming RA, et al: Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 50: 385-393, 1991.
PubMed
12) Stewart CF, Arbuck SG, Fleming RA, et al: Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 8: 1874-1879, 1990.
PubMed
13) Benjamin RS, Wiernik PH and Bachur NR: Adriamycin chemotherapy, efficacy, safety and pharmacologic basis of an intermittent single high-dose schedule. Cancer Res 33: 19-27, 1974.
 
14) Bachur NR, Charles E, Riggs J, et al: Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay. Clin Pharmacol Ther 21: 70-77, 1977.
 
15) Chan KK, Chlebowski RT, Tong M, et al: Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 40: 1263-1268, 1980.
PubMed
16) Twelves CJ, Dobbs NA, Gillies HC, et al: Doxorubicin pharmacokinetics, the effect of abnormal iver biochemistry tests. Cancer Chemother Pharmacol 42: 229-234, 1998.
 
17) Sulkes A and Collins JM: Reappraisal of some dosage adjustment guidelines. Cancer Treat Rep 71: 229-233, 1987.
PubMed
18) Venook AP, Egorin MJ, Rosner GL, et al: Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction, Cancer and Leukemia Group B 9264. J Clin Oncol 16: 1811-1819, 1998.
 
19) Gauvin A, Pinguet F, Culine S, et al: Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 6: 2690-2695, 2000.
PubMed
20) Evans WE, Crom WR, Abromowitch M, et al: Clinical pharmacodynamics of high-dose methotrexate in acute lymphoblastic leukemia, identification of a relation between concentration and effect. N Engl J Med 314: 471-477, 1986.
 
21) Evans WE, Relling MV, Rodman JH, et al: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338: 499-505, 1998.
PubMed
22) Ando Y, Minami H, Saka H, et al: Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer. Jpn J Cancer Res 87: 200-205, 1996.
 
23) Tuchman M, Stoeckeler JS, Kiang DT, et al: Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313: 245-249, 1985.
PubMed
24) Diazio RB, Beavers TL and Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase, biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81: 47-51, 1988.
 
25) Kuilenburg ABPV, Vreken P, Abeling NGGM, et al: Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104: 104-109, 1999.
 
26) Relling MV, Hancock LM, Rivera GK, et al: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine Smethyltransferase gene locus. J Natl Cancer Inst 91: 2001-2008, 1999.
 
27) Lilleyman JS and Lennard L: Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 343: 1188-1190, 1994.
PubMed
28) Yates CR, Krynetski EY, Loennechen T, et al: Molecular diagnosis of thiopurine S-methyltransferase deficiency, genetic basis for azathiopurine and mercaptopurine intolerance. Ann Intern Med 126: 608-614, 1997.
 
29) McLeod HL, Pritchard SC, Githang'a J, et al: Ethnic differences in thiopurine methyltransferase pharmacogenetics, evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 9: 773-776, 1999.
 
30) Hiratsuka M, Inoue T, Omori F, et al: Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat Res 448: 91-95, 2000.
 
31) Iyer L, King CD, Whitington PF, et al: Genetic predisposition to the metabolism of irinotecan(CPT-11) . Role of uridine diphosphate glucuronosyltransferase isoform IAI in the glucuronidation of its active metabolite(SN-38) in human liver microsomes. J Clin Invest 101: 847-854, 1998.
 
32) Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity, a pharmacogenetic analysis. Cancer Res 60: 6921-6926, 2000.
PubMed
33) Liegler DG, Henderson ES and Hahn MA: The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 10: 849-857, 1969.
PubMed
34) Ronchera CL, Hernandez T, Peris JE, et al: Pharmacokinetic interaction between high-dose methotrexate and amoxycilin. Ther Drug Monit 15: 375-379, 1993.
 
35) Sulkes A, Benner SE and Canetta RMI Uracil-ftorafur, an oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 16: 3461-3475, 1998.
 
36) Shirasaka T, Nakano K, Takechi T, et al: Antitumor activity of 1 M tegafur-0. 4 M 5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate(S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996.
 
37) Grem JL, Hoth DF, Hamilton JM, et al: Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep 71: 1249-1264, 1987.
PubMed
38) Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692-1703, 1991.
PubMed
39) Rowinsky EK, Citardi MJ, Noe DA, et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119: 727-733, 1993.
PubMed
40) Rowinsky EK, Kaufmann SH, Baker SD, et al: Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14: 3074-3084, 1996.
PubMed
41) Grossman SA, Hochberg F, Fisher J, et al: Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. Cancer Chemother Pharmacol 42: 118-126, 1998.
PubMed
42) Minami H, Lad TE, Nicholas MK, et al: Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72hours in phase II studies. Clin Cancer Res 5: 1325-1330, 1999.
 
43) Durr D, Stieger B, Kullak-Ublick GA, et al: St John's Wort induces intestinal P-glycoprotein/MDR l and intestinal and hepatic CYP 3 A 4. Clin Pharmacol Ther 68: 598-604, 2000.
 
44) Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187-196, 1998.
 
P.202 掲載の参考文献
1) Shawver L K, Slamon D and Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1: 117-123, 2002.
 
2) 矢守隆夫, 安藤俊夫, 上原至雅・他: 制がん剤の分子標的スクリーニング成績-わが国における制がん剤候補物質のスクリーニング成績・第9報-. 癌と化学療法 29(Suppl II) : 225-415, 2002.
 
3) Scherf U, Ross D T, Waltham M, et al: A gene expression database for the molecular pharmacology of cancer [see comments]. Nat Genet 24: 236-244, 2000.
 
4) Monks A, Scudiero D, Skehan P, et al: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766, 1991.
PubMed
5) Yamori T, Matsunaga A, Sato S, et al: Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell Iine panel. Cancer Res 59: 4042-4049, 1999.
 
6) Naasani I, Seimiya H, Yamori T, et al: FJ 5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 59: 4004-4011, 1999.
PubMed
7) Dan S, Tsunoda T, Kitahara O, et al: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62: 1139-1147, 2002.
PubMed
8) Paull K D, Shoemaker R H, Hodes L, et al: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092, 1989.
PubMed
9) Hashimoto S, Xu Y, Masuda Y, et al: b-Hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases. Jpn J Cancer Res 93: 944-951, 2002.
 
P.209 掲載の参考文献
1) Matsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritopic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392, 1986.
 
2) Maeda H and Matsumura Y: Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6: 193-210, 1989.
PubMed
3) Muggia FM: Doxorubicin-polymer conjugates: Further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res 5: 7-8, 1999.
PubMed
4) 加藤将夫, 杉山雄一: DDSとファーマコキネティックス. 総合製剤学, (杉山雄一, 山本恵司・編) , 南山堂, 東京, 2000, pp 167-175.
 
5) Matsumura Y, Kimura M, Yamamoto T, et al: Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 79: 1327-1334, 1988.
PubMed
6) Matsumura Y, Maruo K, Kimura M, et al: Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn JCancer Res 82: 732-741, 1991.
 
7) Dvorak HF, Nagy JA, Dvorak JT, et al: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Patho1133: 95-109, 1988.
 
8) Dvorak HF: Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing. N Engl JMed 315: 1650-1659, 1986.
 
9) Gabizon A, Chemla M, Tzemach D, et al: Liposome longevity and stability in circulation: effects on the in vivo delivery to tumor and therapeutic efficacy of encapsulated anthracyclines. J Drug Targeting 3: 391-398, 1996.
PubMed
10) Sakakibara T, Chen F-A, Kida H, et al: Doxorubicin encapsulated in sterically stabilized liposomes in superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res 56: 3743-3746, 1996.
PubMed
11) Unezaki S, Maruyama K, Hosoda J-1, et al: Direct measurement of the extravasation of polyehyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int J Pharmaceut 144: 11-17, 1996.
 
12) Lasic D: Doxorubicin in sterically stabilized liposomes. Nature 561-562, 1996.
PubMed
13) Gabison A, Catane R, Uziely R, et al: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicine encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992, 1994.
 
14) Harrington KJ, Mohammadtaghi S, Uster PS, et al: Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7: 243-254, 2001.
PubMed
15) Koukourakis MI, Koukouraki S, Giatramanolaki A, et al: Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 17: 3512-3521, 1999.
PubMed
16) Northfelt DW, Martin FJ and Working P: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics. Tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36: 55-63, 1996.
PubMed
17) Safra T, Muggia F, Jeffers S, et al: Pegylated liposomal doxorubicin(doxil) : reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11: 1029-1033, 2000.
PubMed
18) Northfelt D, Dezube B, Thommes J, et al: Efficacy of pegylated-liposomal doxorubicin in the treatment of AID-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15: 653-659, 1997.
 
19) Harrison M, Tomlinson D and Stewart S: Liposomal-entarapped doxorubicin: an active agent in AIDS-related Kapos's sarcoma. J Clin Oncol 13: 914-920, 1995.
 
20) Cheung TW, Remick SC, Azarnia N, et al: AIDS-related Kaposi's sarcoma: a phase II study of liposomal doxorubicin. Clin Cancer Res 5: 3432-3437, 1999.
 
21) Tulpule A, Yung RC, Wernz J, et al: Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. J Clin Oncol 16: 3369-3374, 1998.
 
22) Ellerhorst J, Bedikian A, Ring S, et al: Phase II trial of doxil for patients with metastatic melanoma refractory to frontile therapy. Oncol Rep 6: 1097-1099, 1999.
PubMed
23) Tsiara S, Kapasali E, Christou L, et al: Administration of a modified chemotherapeutic regimen containing vincristine, 1iposomal doxorubicine and dexamethasone to multiple myeloma patients: preliminary data. Eur J Haematol 65: 118-122, 2000.
 
24) Toma S, Tucci A, Villani G, et al: Liposomal doxorubicin(Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group(ISG) . Anticancer Res 20: 485-491, 2000.
PubMed
25) Judson I, Radford JA, Harris M, et al: Randomized phase II trial of pegylated liposomal doxorubicin(DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37: 870-877, 2001.
PubMed
26) Samantas E, Kalofonos H, Linardou H, et al: Phase II study of pegylated liposomal doxorubicin: Inactive in recurrent small-cell lung cancer with sterically stabilized liposomal doxorubicin: Inactive in recurrent small-cell lung cancer. Ann Oncol 11: 1395-1397, 2000.
 
27) Ranson M, Carmicheal J, O'Byrne K, et al: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 16: 811-812, 1998.
 
28) Shapairo C, Ervin T, Welles L, et al: Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. J Clin Oncol 17: 1435-1441, 1999.
 
29) Valero V, Buzdar AU, Theriault RL, et al: Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 17: 1425-1434, 1999.
PubMed
30) Treat J, Greenspan A, Forst D, et al: Antitumor activity of liposome-encapsulated doxorubicin in advanced beast cancer: phase II study. J Natl Cancer Inst 82: 1706-1710, 1990.
 
31) Markeman M, Kennedy A, Webster K, et al: Phase II trial of liposomal doxorubicin in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78: 369-372, 2000.
 
32) Alan NG, Granai CO, Rose PG, et al: Phase II study of liposomal doxorubicin in platinum and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18: 3093-3100, 2000.
 
33) Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987-993, 1997.
PubMed
34) Batist G, Ramakrishnan G, Rao CS, et al: Reduced cardiotoxicity and preserved antitumor efficacy of liposome encapsulat- ed doxorubicin and cyclophospahmide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19: 1444-1454, 2001.
 
35) Northfelt DW, Dezube BJ, Thommes JA, et al: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16: 2445-2451, 1998.
PubMed
36) Stewart S, Jablonowski H, Goebel F, et al: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16: 683-691, 1998.
 
37) Gill PS, Wernz J, Scadden DT, et al: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14: 2353-2364, 1996.
PubMed
38) Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylat-ed liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322, 2001.
 
39) Ryan C, Fleming G, Janisch L, et al: A phase I study of liposomal doxorubicin(DOXIL) with topotecan. Am J Clin Oncol 23: 297-300, 2000.
 
40) Burstein HJ, Ramirez MJ, Petros WP, et al: Phase I study of doxil and vinorelbine in metastatic breast cancer. Ann Oncol 10: 1113-1116, 1999.
PubMed
41) Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147, 1997.
PubMed
42) Yokoyama M, Inoue S, Kataoka K, et al: Preparation of adriamycin-conjugated poly(ethylene glycol) -poly(aspartic acid) block copolymer. Makromol Chem Rapid Commun 8: 431-435, 1987.
 
43) Yokoyama M, Miyauchi M, Yamada N, et al: Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol) -poly(aspartic acid) block copolymer. Cancer Res 50: 1693-1700, 1990.
PubMed
44) Mizumura Y, Matsumura Y, Hamaguchi T, et al: Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res 92: 328-336, 2001.
PubMed
45) Matsumura Y, Yokoyama M, Kataoka K, et al: Reduction of the side effects of an antitumor agent, KRN 5500, by incorporation of the drug into polymeric micelles. Jpn J Cancer Res 90: 122-128, 1999.
PubMed
46) Kataoka K, Togawa A, Harada A, et al: Spontaneous formation of polyion complex micelles with narrow distribution from antisense oligonucleotide and cationic block copolymer in physiological saline. Macromolocules 29: 8556-8557, 1996.
 
47) Ogawa Y, Okada H, Yamamoto M, et al: In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acid or copoly(lactic/glycolic) acids and in vivo degradation of these polymers. Chem Pharm Bull 36: 2576-2581, 1988.
PubMed
48) Auclair C, Kelly PA, Coy DH, et al: Potent inhibitory activity of(D-Leu6, Des-Gly-NH2) LHRH ethylamide on LH/hCG and PRL testicular receptor levels in the rat. Endocrinology 101: 1890-1893, 1977.
PubMed
49) Redding TW, Schally AV, Tice TR, et al: Long-acting delivery systems for peptides: Inhibition of rat prostate tumors by controlled release of[D-Trp 6] luteinizing hormone-releasing hormone from injectable microcapsules. Proc Natl Acad Sci USA 81: 5945-5948, 1984.
 
50) Okada H, Sakura Y, Kawaji H, et al: Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide acetate) administered vaginally. Cancer Res 43: 1869-1874, 1983.
PubMed
51) Ichikawa T, Akimoto S, Shimazaki J, et al: Effect of leuprolide on growth of rat prostatic tumor(R 3327) and weight of male accessory sex organs. Endocrinol Jpn 35: 181-187, 1988.
PubMed
52) Takakura Y and Hashida M: Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm Res 13: 820-831, 1996.
PubMed
53) Hashida M, Mahato R, Kawabata K, et al: Pharmacokinetics and targeted delivery of proteins and genes. J Controlled Release 41: 91-97, 1996.
 
P.219 掲載の参考文献
1) Gellert M: DNA topoisomerases. Annu Rev Biochem 50: 879-910, 1981.
PubMed
2) Wang JC: DNA topoisomerases. Annu Rev Biochem 54: 665-697, 1985.
PubMed
3) Wang JC: Recent studies of DNA topoisomerases. Biochim Biophys Acta 909: 1-9, 1987.
PubMed
4) Schneider E, Hsiang YH and Liu L: DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21: 149-183, 1990.
 
5) Wang JC: DNA topoisomerases: why so many? JBiol Chem 266: 6659-6662, 1991.
 
6) Roca J: The mechanisms of DNA topoisomerases. Trends Biol Sci 20: 156-160, 1995.
 
7) Chen AY and Liu LF: DNA topoisomerases: essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 34: 191-218, 1994.
 
8) 安藤俊夫: DNAトポロジーの生物効果. 細胞工学 6: 830-838, 1987.
 
9) 安藤俊夫: DNAトポイソメラーゼの生物機能. 癌と化学療法 18: 1543-1555, 1991.
Medical*Online
10) Liu LF and Miller KG: Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA 78: 3487-3491, 1981.
PubMed
11) Wall ME, Wani MC, Cook CE, et al: Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
 
12) Li LH, Fraser TJ, Olin EJ, et al: Action of camptothecin on mammalian cells in culture. Cancer Res 32: 2643-2650, 1972.
PubMed
13) Drewinko B, Freireich EJ and Gottlieb JA: Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34: 747-750, 1974.
PubMed
14) Gallo RC, Whang-Peng J and Adamson RH: Studies on the antitumor activity mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46: 789-795, 1971.
PubMed
15) Gottlieb J, Guarino A, Call J, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880) . Cancer Chemother Rep 54: 461-470, 1970.
PubMed
16) Moertel CG, Schutt AJ, Reitemeier RJ, et al: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Treat Rep 56: 95-101, 1972.
 
17) Gottlieb JA and Luce JK: Treatment of malignant melanoma with camptothecin(NSC-100880) . Cancer Chemother Rep 56: 103-105, 1972.
PubMed
18) Creaven PJ, Allen LM and Muggia FM: Plasma camptothecin(NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 56: 573-578, 1972.
PubMed
19) Muggia FM, Creaven PJ, Hansen HH, et al: Phase I clinical trial of weekly and daily treatment with camptothecin(NSC-100880) : Correlation with preclinical studies. Cancer Chemother Rep 56: 515-521, 1972.
PubMed
20) Hsiang YH, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
PubMed
21) Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(1-piperidino) -1-piperidino] carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944-5947, 1987.
PubMed
22) Furuta T, Yokokura T and Mutai M: Antitumor activity of CPT-11 against rat Walker 256 carcinoma. Gan To Kagaku Ryoho 15: 2757-2760, 1988(in Japanese) .
PubMed
23) Bissery MC, Mathieu-Boue A and Lavelle F: Experimental antitumor activity of CPT-11 in vitro and in vivo. In Proceedings of the Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 82, 1992(Abstr) .
 
24) Matsuzaki T, Yokokura T, Mutai M, et al: Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21: 308-312, 1988.
PubMed
25) Kudoh S, Takada M, Masuda N, et al: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84: 203-207, 1993.
PubMed
26) Tsuruo T, Matsuzaki T, Matsushita M, et al: Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21: 71-74, 1988.
PubMed
27) Kaneda N, Nagata H, Furuta T, et al: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715-1720, 1990.
PubMed
28) Tsuji T, Kaneda N, Kado K, et al: CPT-11 converting enzyme from rat serum: Purification and some properties. J Pharmacobio-Dyn 14: 341-349, 1991.
PubMed
29) Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191, 1991.
PubMed
30) Furuta T and Yokokura T: Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative. Gan To Kagaku Ryoho 17: 121-130, 1990(in Japanese) .
PubMed
31) Atsumi R, Suzuki W and Hakusui H: Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21: 1159-1169, 1991.
PubMed
32) Taguchi T, Wakui A, Hasegawa K, et al: Phase I clinical study of CPT-11. Gan To Kagaku Ryoho 17: 115-120, 1990(in Japanese) .
PubMed
33) Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83: 1164-1168, 1991.
PubMed
34) Abigerges D, Chabot GG, Armand J-P, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210-221, 1995.
PubMed
35) Rothenberg ML, Kuhn JG, Burris HA III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11: 2194-2204, 1993.
 
36) Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino) -1-piperidino] carbonyloxycamptothecin(CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54: 427-436, 1994.
PubMed
37) Catimel G, Chabot GG, Guastalla JP, et al: Phase I and pharmacokinetic study of irinotecan(CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6: 133-140, 1995.
PubMed
38) de Forni M, Bugat R, Chabot GG, et al: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54: 4347-4354, 1994.
PubMed
39) Ohe Y, Sasaki Y, Shinkai T, et al: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84: 972-974, 1992.
PubMed
40) Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11: 909-913, 1993.
PubMed
41) Bugat R, Suc E, Rougier PH, et al: CPT-11(Irinotecan) as second line therapy in advanced colorectal cancer(CRC) : Preliminary results of a multicentric phase II study. Proc ASCO 13: 200, 1994(Abstr) .
 
42) Rougier Ph, Culine S, Bugat R, et al: Multicentric phase II study of first line CPT-11(Irinotecan) in advanced colorectal cancer(CRC) : Preliminary results. Proc ASCO 13: 200, 1994(Abstr) .
 
43) Bugat R, Rougier P, Douilland JY, et al: Efficacy of Irinotecan HCI(CPT-11) in patients with metastatic colorectal cancer after progression while receiving a 5 FU-based chemotherapy. Proc ASCO l4: 222, 1995(Abstr) .
 
44) Conti JA, Kemeny N, Saltz L, et al: Irinotecan(CPT-11) is active agent in untreated patients (pts) with metastatic colorectal cancer(CRC) . Proc ASCO 13: 195, 1994(Abstr).
 
45) Pitot HC, Wender D, O'Connell MJ, et al: Aphase II trial of CPT-11(Irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group(NCCTG) study. Proc ASCO 13: 197, 1994(Abstr) .
 
46) Rothenberg ML, Eckardt JR, Burris III HA, et al: Irinotecan(CPT-11) as second-line therapy for pts with 5-FU-refractory colorectal cancer. Proc ASCO 13: 198, 1994(Abstr) .
 
47) Takeuchi S, Takamizawa H, Takeda Y, et al: An early phase II study of CPT-11 for gynecologic cancers. Gan To Kagaku Ryoho 18: 579-584, 1991(in Japanese) .
PubMed
48) Takeuchi S, Dobashi K, Fujimoto S, et al: A late phase II study of CPT-11 0n uterine cervical cancer and ovarian cancer. Gan To Kagaku Ryoho 18: 1681-1689, 1991(in Japanese) .
 
49) Takeuchi S, Noda K, Yakushiji M, CPT-11 Study Group on Gynecologic malignancy: Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma(CC) . Proc ASCO 11: 224, 1992(Abstr) .
 
50) Kambe M, Wakui A and Nakao I: A late phase II study of irinotecan(CPT-11) in patients with advanced gastric cancer. Proc ASCO 12: 198, 1993(Abstr) .
 
51) Sakata Y, Wakui A and Nakao I: A late phase II study of irinotecan(CPT-11) , in advanced pancreatic cancer. Proc ASCO 12: 211, 1993(Abstr) .
 
52) Bonneterre J, Pion J, Adenis A, et al: A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients. Proc ASCO 12: 94, 1993(Abstr) .
 
53) Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907-1912, 1990.
PubMed
54) Tsuda H, Takatsuki K, Ohno R, et al: Treatment of adult T-cell leukemia-lymphoma with irinotecan hydrochloride(CPT-11) . Br J Cancer 70: 771-774, 1994.
PubMed
55) Nakai H, Fukuoka M, Furuse K, et al: An early phase II study of CPT-11 for primary lung cancer. Gan To Kagaku Ryoho 18: 607-612, 1991(in Japanese) .
PubMed
56) Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16-20, 1992.
 
57) Negoro S, Fukuoka M, Niitani H, et al: Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC) . Proc ASCO 10: 241, 1991(Abstr) .
 
58) Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225-1229, 1992.
PubMed
59) Sasaki Y, Yoshida Y, Sudo K, et al: Pharmacological correlation between total drug concentration and lactones of CPT-11and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 86: 111-116, 1995.
 
60) Chabot GG, Abigerges D, Gandia D, et al: Pharmacokinetic-pharmacodynamic relationships in patients administered with CPT-11, a new camptothecin analogue. Proc ASCO 33: 266, 1992(Abstr) .
 
61) Masuda N, Kudoh S and Fukuoka M: Irinotecan(CPT-11) : Pharmacology and clinical applications. Crit Rev Oncol Hematol 24: 3-26, 1996.
PubMed
62) Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54: 3723-3725, 1994.
PubMed
63) Gupta E, Mick R, Ramirez J, et al: Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15: 1502-1510, 1997.
PubMed
64) Ando Y, Saka H, Asai G, et al: UGT l A l genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9: 845-847, 1998.
 
65) Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921-6926, 2000.
PubMed
66) Ciotti M, Basu N, Brabgi N, et al: Glucuronidation of 7-ethyl-10-hydroxycamptothecin(SN-38) by human UDP-glucuronosyltransferases encoded at the UGT l locus. Biochem Biophys Res Commun 260: 199-202, 1999.
 
67) Rivory LP, Haaz M-C, Canal P, et al: Pharmacokinetic interrelationships of irinotecan(CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 3: 1261-1266, 1997.
PubMed
68) Johnson RK, McCabe FL, Faucette LF, et al: SKF-104864, a water-soluble analog of camptothecin with broad spectrum activity in preclinical models. Proc Am Assoc Cancer Res 30: 623, 1989(Abstr) .
 
69) Hertzberg RP, Caranfa MJ, Holden KG, et al: Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715-720, 1989.
PubMed
70) Kingsbury WD, Boehm JC, Jakas DR, et al: Synthesis of water-soluble(aminoalky1) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98-107, 1991.
PubMed
71) Burris HA III, Hanauske A-R, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84: 1816-1820, 1992.
 
72) Hendricks CB, Rowinsky EK, Grochow LB, et al: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan(SK & F104864) , a new camptothecin analogue. Cancer Res 52: 2268-2278, 1992.
 
73) Wall JG, Burris HA, Von Hoff DD, et al: A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan(SK & F104864) given as an intravenous bolus every twenty-one days. Anticancer Drugs 3: 337-345, 1992.
 
74) Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase Iinhibitor. J Clin Oncol 10: 647-656, 1992.
 
75) Haas NB, LaCreta FP, Walczak J, et al: Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 54: 1220-1226, 1994.
PubMed
76) ten Bokkel Huinink WW, Rodenhius S, Beijnen J, et al: Phase I study of the topoisomerase I inhibitor topotecan(SK & F10864) . Proc ASCO 11: 110, 1992(Abstr) .
 
77) Eckardt J, Burris H, Kuhn J, et al: Phase I and pharmacokinetic trial of continuous infusion topotecan in patients with refractory solid tumors. Proc ASCO 11: 138, 1992(Abstr) .
 
78) Sirott MN, Saltz L, Young C, et al: Phase I and clinical pharmacologic study of intravenous topotecan(T) . Proc ASCO 10: 104, 1991(Abstr) .
 
79) Saltz L, Sirott M, Young C, et al: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colonystimulating factor. J Natl Cancer Inst 85: 1499-1507, 1993.
 
80) Rowinsky EK, Startorius S, Grochow L, et al: Phase I and pharmacologic study of topotecan, an inhibitor of topoisomerase I, with granulocyte colony-stimulating factor(G-CSF) : toxicologic differences between concurrent and post-treatmentG-CSF administration. Proc ASCO 11: 116, 1992(Abstr) .
 
81) Schiller J, Kim K and Huston P: Phase II study of topotecan in patients with extensive stage small cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 14: 2345-2352, 1996.
 
82) Ardizzoni A, Hansen H, Dombernosky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 15: 2090-2096, 1997.
 
83) Beran M, Kantarjian H, O'Brien S, et al: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88: 2473-2479, 1996.
 
84) Creemers GL, Bolis G, Gore M, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14: 3056-3061, 1996.
 
85) Kudelka A, Tresukosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14: 1552-1557, 1996.
PubMed
86) Carmichael J, Gordon A, Malfetano J, et al: Topotecan, a new active drug, vs paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group Trial. Proc ASCO 15: 283, 1996(Abstr) .
 
87) Gordon A, Bookman M, Malmstrom H, et al: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial. Proc ASCO 15: 282, 1996(Abstr) .
 
88) Lynch TJ Jr, Kalish L, Strauss G, et al: Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12: 347-352, 1994.
PubMed
89) Perez-Soler R, Fossella FV, Glisson BS, et al: Phase II study of topotecan in patients with advanced non-small-cell lug cancer previously untreated with chemotherapy. J Clin Oncol 14: 503-513, 1996.
 
90) von Pawel J, Schiller J, Shepherd F, et al: Topotecan versus CAV for the treatment of recurrent small cell lung cancer. J Clin Oncol 17: 658-667, 1999.
PubMed
91) Vokes EE, Ansari RH, Masters GA, et al: Aphase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol 9: 1085-1090, 1998.
 
92) Takimoto CH and Thomas R: The clinical development of 9-aminocamptothecin. Ann N Y Acad Sci 922: 224-236, 2000.
 
93) Hinz HR, Harris NJ, Natelson EA, et al: Pharmacokinetics of the in vitro and in vivo conversion of 9-nitro-20(S) -camptothecin to 9-amino-20(S) -camptothecin in humans, dogs, and mice. Cancer Res 52: 3096-3100, 1994.
 
94) Verschraegen CF, Natelson EA, Giovanella BC, et al: A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 9: 36-44, 1998.
PubMed
95) DeJager R, Cheverton P, Tamanoi K, et al: DX-8951 f: summary of phase I clinical trials. Ann N Y Acad Sci 922: 260-273, 2000.
 
96) Rowinsky EK, Johnson TR, Geyer CE, et al: DX-8951 f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 18: 3151-3163, 2000.
 
97) Talbot DC, White S, Mattson KV, et al: Phase II study of exatecan mesylate(DX-8951 f) in advande NSCLC. Lung Cancer 29(S1) : 55, 2000.
 
98) Kohn KW and Pommier Y: Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors. Ann N Y Acad Sci 922: 11-26, 2000.
PubMed
99) Takano H, Kohno K, Matsuo K, et al: DNA topoisomerase-targeting antitumor agents and drug resistance. Anticancer Drugs 3: 323-330, 1992.
PubMed
100) Bojanowski K, Lelievre S, Markovits J, et al: Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci USA 89: 3025-3029, 1992.
PubMed
101) Wadler S, Fuks JZ and Wiernik PH: Phase I and II agents in cancer therapy: 1. Anthracyclines and related compounds. J Clin Pharmacol 26: 491-509, 1986.
 
102) Potmesil M, Hsiang YH, Liu LF, et al: Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48: 3537-3543, 1988.
PubMed
103) Robert J: Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 24: 275-288, 1993.
PubMed
104) Cersosimo RJ: Idarubicin: An anthracycline antineoplastic agent. Clin Pharm 11: 152-167, 1992.
PubMed
105) Stewart CF and Ratain MJ: Topoisomerase interactive agents. In Cancer. Principles and Practice of Oncology, (ed by Devita VT Jr, Hellman S and Rosenberg SA) , 5th ed, JB Lippincott Co, Philadelphia, 1997, pp 452-469.
 
106) Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717, 1979.
PubMed
107) Praga C, Beretta G, Vigo PL, et al: Adriamycin cardiotoxicity: Asurvey of 1273 patients. Cancer Treat Rep 63: 827-834, 1979.
 
108) Bristow MR, Billingham ME, Mason JW, et al: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 6: 873-879, 1978.
PubMed
109) Juret P, Heron JF, Couette JE, et al: Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: A5-year experience. Cancer Treat Rep 66: 1909-1916, 1982.
 
110) Rouesse JG, Le Chevalier T, Caile P, et al: Phase II study of elliptinium in advanced breast cancer. Cancer Treat Rep 69: 707-708, 1985.
 
111) Harvey VJ, Hardy JR, Smith S, et al: Phase II study of the amsacrine analogue CI-921(NSC 343499) in non-small cell lung cancer. Eur J Cancer 26: 1617-1620, 1991.
 
112) Sklarin NT, Wiernik PH, Grove WR, et al: A phase II trial of CI-921 in advanced malignancies. Invest New Drugs 10: 309-312, 1992.
PubMed
113) Grove WR, Fortner CL and Wiernik PH: Review of amsacrine, an investigational antineoplastic agent. Clin Pharm 1: 320-326, 1980.
 
114) Muggia FM and Burris HA: Clinical development of topoisomerase-interactive drugs. Adv Pharmacol 29 B: 1-31, 1994.
 
115) Ratain MJ, Mick R, Berezin F, et al: Paradoxical relationship between acetylator and amonafide toxicity. Clin Pharmacol Ther 50: 573-579, 1991.
PubMed
116) Hainsworth JD and Greco FA: Etoposide: twenty years later. Ann Oncol 6: 325-341, 1995.
PubMed
117) Sinha BK: Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 49: 11-19, 1995.
PubMed
118) Clark PI: Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. Semin Oncol 19: 20-27, 1992(Suppl) .
 
119) Joel SP, Hall M, Gaver RC, et al: Complete recovery of radioactivity after administration of 14C-etoposide in man. Proc ASCO 14: 168, 1995?(Abstr) .
 
120) Wolff SN, Grosh WW, Prater K, et al: In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 19: 246-249, 1987.
 
121) Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333-1340, 1989.
PubMed
122) Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial. J Clin Oncol 8: 1613-1617, 1990.
PubMed
123) Hainsworth JD: Chronic administration of etoposide in the treatment of non-Hodgkin's lymphoma. Leuk Lymphoma 10?(Suppl) : 65-72, 1993.
 
124) Medical Research Council Lung Cancer Working Party: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial. Lancet 348: 563-566, 1996.
PubMed
125) Souhami RL, Spiro SG, Rudd RM, et al: Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89: 577-580, 1997.
PubMed
126) Miller AA, Herndon JE, Hollis DR, et al: Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer. A randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 13: 1871-1879, 1995.
 
127) Morisada S, Yanagi Y, Noguchi T, et al: Antitumor activities of a novel 9-amino-anthracycline?(SM-5887) against mouse experimental tumors and human tumor xenografts. JPn J Cancer Res 80: 69-76, 1989.
 
128) Suzuki T, Minamide S, Iwasaki T, et al: Cardiotoxicity of a new anthracycline derivative?(SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 15: 219-225, 1997.
PubMed
129) Negoro S, Fukuoka M, Nakamura S, et al?: Phase I/II study of amrubicin?(SM-5887) , a novel 9-amino-anthracycline, by iv administration for 3 consecutive days in patients with advanced non-small cell lung cancer. Proc ASCO 14: 361, 1995.
 
130) Furuse K, Ikegami H and Ariyoshi Y: Two phase II studies of amrubicin(SM-5887) , a 9-amino-anthracycline, in patients with advanced non-small cell lung cancer(NSCLC) : West Japan Lung Cancer Group trials. Ann Oncol 9: 88, 1998.
 
131) Yana T, Negoro S, Takada Y, et al: Phase II study of amrubicin(SM-5887) , a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer(ES-SCLC) : a West Japan Lung Cancer Group trial. Proc ASCO 17: 1734, 1998.
 
132) Huchet M, Demarquay D, Coulomb H, et al: The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann N Y Acad Sci 922: 303-305, 2000.
PubMed
P.230 掲載の参考文献
1) Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542, 1998.
PubMed
2) Rosenberg B, VanCamp L and Krigas T: Inhibition of cell division in Escherichia coli by electrolysis oroducts from a platinum electrode. Nature 205: 698-699, 1965.
PubMed
3) Rosenberg B: Fundamental studies with cisplatin. Cancer 55: 2303-2316, 1985.
PubMed
4) Higby DJ, Wallace HJ Jr, Albert D, et al: Diamminedichloro-platinum in the chemotherapy of testicular tumors. J Urol 112: 100-104, 1974.
 
5) Wiltshaw E and Carr B: Cis-platinum diamminedichloride. In Platinum Coordination Complexes in Cancer Chemotherapy, (ed by Cornnos TA and Roberts JJ) , Springer, Heidelberg, 1974, pp 178-182.
 
6) Hayes D, Cuitkovic E, Goldberg R, et al: Amelioration of renal toxicity of high dose cis-platinum dimmine dichloride (CPDD) by mannitol induced diuresis, Proc Am Assoc Cancer 67: 169, 1976,
 
7) Merrin C: Anew method to prevent toxicity with high doses of cis diammine platinum (therapeutic efficacy in previously treated widespread and recurrent testicular tumors) . Proc ASCO 12: 243, 1976.
 
8) Einhorn LH and Donohue J: Cis-diamminedichloroplatinum. vinblastin and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293-298. 1977.
PubMed
9) Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: an review of randomized clinical trials. Br Med J 303: 884-893, 1991.
 
10) Stewart LA and Pignon JP: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual atients from 52 randomized clinical trials. Br Med J 311: 899-909, 1995.
 
11) Von Hoff DD and Rozencweig M: Cis-diamminedichloroplatinum (II) : a metal complex with significant anticancer activity. In Advances in Pharmacology and Chemotherapy, (ed by Garattini S, Goldin A, Hawking F and Kodin JJ) , Academic Press, New, York, 1979; 16, pp 273-298.
 
12) 菊池義公: 卵巣癌におけるシスプラチン耐性機序. Human Cell 14: 115-133, 2001.
 
13) Fichtinger-Schepman AMJ, van der Veer JL, den Hartog JHJ, et al: Adducts of the antitumor drug cis-diamminedichloro-platinum (II) with DNA: formation, identification, and quantitation. Biochemistry 24: 707-713, 1985.
 
14) Shiratori O, Kasai H, Uchida N, et al: Antitumor activity of 254-S, a platinum complex, in rodents. Proc Int Cong Chemother 14: 23-26, 1985.
 
15) Gorbunova VA, Smirunova NB, Orel NF, et al: A phase I and pharmacokinetic trial of cycloplatam in patients with refractory solid tumors. Proc NCI-EORTC Symp New Drugs Cancer Ther 8: 215, 1994.
 
16) Gorbunova VA, Smirnova NB and Orel NE: Phase II of cycloplatam in advanced ovarian carcinoma. Proc Int Cong Anti-Cancer Chemother 5: 382, 1995,
 
17) Drees M, Sengler WM, Hendriks HR, et al: Cycloplatam: anovel platinum compound exhibiting a different spectrum of anti-tumor activity to cisplatin. Eur J Cancer 31 A: 56-361, 1995.
 
18) Kim NK, Bang Y-J, Heo DS, et al: A phase I clinical and pharmacokinetic study of SKI 2053 R, a new platinum analog in patients with malignancies. Proc ASCO 14: 479, 1995.
 
19) Kim NK, Im SA, Jung CW, et al: An active new platinum analog SKI 2053 R in patients with advanced gastric adenocar cinoma: phase II clinical trial. Proc ASCO 16: 294 a, 1997.
 
20) Harrap KR: Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 12 (Suppl A) : 21-33, 1985.
 
21) Rose WC and Schurig JE: Preclinical antitumor and toxicologic profile of carboplatin. Caner Treat Rev 12 (Suppl A) : 1-19, 1985.
 
22) Canetta R, Bragman K, Amaldone L, et al: Carboplatin: current status and future prospects. Cancer Treat Rev 15 (Suppl B) : 17-32, 1988.
 
23) Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
PubMed
24) Jodrell DI, Egorin MJ, Canetta RM, et al: Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520-528, 1992.
PubMed
25) Fish RG, Shelly MD, Griffiths H, et al: A dosing scheme for carboplatin in adult cancer patients based upon pre-infusion renal function and platelet count. Anti Caner Drugs 5: 527-532, 1994.
 
26) Chatelut E, Canal P, Brunner V, et al: Prediction of carboplatin clearance from standard morphologies and biological patient characteristics. J Natl Cancer Inst 87: 573-580, 1995.
 
27) Kearns CM, Belani CP, Erkmen K, et al: Reduced platelet toxicity with combination carboplatin and paclitaxel; pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc ASCO 14: 170, 1995.
 
28) Creaven PJ, Raghavan D, Perez RP, et al: Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. Semin Oncol 6 (Suppl 16) : 26-31, 1996.
 
29) Fiebig HH, Mross K, Henss H, et al: Phase I study of the new platinum complex D 194660n a single intermittent schedule. Eur J Cancer (Suppl) : S197, 1991.
 
30) Gietema JA, de Vries EGE, Sleijfer DT, et al: A phase I study of 1, 2-diamminomethyl-cyclobutane-platinum (II) -lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer 67: 396-401, 1993.
 
31) Gietema JA, Guchelaar H-J, deVries EGE, et al: A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion. Anticancer Drugs 4: 51-55, 1993.
 
32) Gietema JA, Veldhuis G-J, Guchelaar H-J, et al: Phase II and pharmacokinetic study of lobaplatin in patients with relaosed ovariancancer. Br J Cancer 71: 1302-1307, 1995.
 
33) Kavanagh JJ, Fiunegan MB, Edwards CL, et al: A trial of lobaplatin (D-19466) in platinum resistant epithelial ovarian cancer. Proc Am Soc Cancer Res 36: 401, 1995.
 
34) Dejardin M, Armand Jp, Chevallier B, et al: A clinical screening cooperative group Phase II evaluation of lobaplatin (ASTAD-19466) in advanced head and neck cancer. Invest New Drugs 13: 253-255, 1995.
 
35) Feibig HH: Phase I and II studies with lobaplatin. Proc Int Symposium on Platinum and Other Metall Coodination Compounds in Cancer Chemotherapy 7: S127, 1995.
 
36) Sternbeg CN, de Mulder P, Fossa S, et al: Lobaplatin in advanced urothelial tract tumors. Ann Oncol 8: 695-696, 1997.
 
37) Schmoll HJ, Kohne CH, Papageorgiou E, et al: Single agent lobaplatin is active in patients with esophageal squamous cell carcinoma. A phase II evaluation. Proc ASCO 14: 201, 1995.
 
38) Rolland F, Douillard JY, Adenis A, et al: Lobaplatin in combination with 5-fluorouracil in patients with esophageal carcinoma: aphase I/II feasibility study. Proc Int Cong Anti-Cancer Treat 6: 320, 1996.
 
39) Mathe G, Kidani Y, Noji M, et al: Antitumor activity of 1-OHP in mice. Cancer Let 27: 135-143, 1985.
 
40) Mathe G, Kidani Y, Triana K, et al: Aphase I trial of trans-1-diaminocyclohexane oxalatoplatinum (1-OHP) . Biomed Pharmacother 40: 372-376, 1986.
 
41) Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 5: 299-303, 1990.
 
42) Eriguchi M, Sekiguchi M, Fujii Y, et al: Clinical study for a new platinum complex 1-OHP: oxalato (1-1, 2-diaminocyclo-hexane) platinum (II) against solid tumors. Proc NCI-EORTC Symp New Drugs Cancer Ther 7: 343, 1991.
 
43) Caussanel J-P, Levi F, Brienza S, et al: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046-1050, 1990.
 
44) Rotarski M, Brienza S, Gastiaburu J, et al: Oxaliplatin (1-OHP) : a new platinum analog: active in refractory/relapsed intermediate and low grade non-Hodgkin lymphoma. Proc ASCO 12: 375, 1993.
 
45) Garufi C, Nistico C, Brienza S, et al: Oxaliplatin (1-OHP) activity in anthracycline-resistant metastatic breast cancer. Proc ASCO 16: 170 a, 1997.
 
46) Gastiaburu J, Misset JL, Brienza S, et al: Early phase II trial of trans-1-diamino cyclohexane (1-OHP) in malignant melanoma, advanced ovarian cancer, low grade non-Hodgkin's lymphoma. Proc Am Assoc Cancer Res 33: 538, 1992.
 
47) Monnet I, Brienza S, Voisin S, et al: Phase II study of oxaliplatin (1-OHP) , transplatin in patients with advanced non small cell lung cancer: preliminary results. Proc NCI-EORTC Symp New Drugs Cancer Ther 8: 224, 1994.
 
48) Degardin M, Cappelaere P, Krakowski I, et al: Phase II trial of oxaliplatin (1-OHP) in locoregional advanced, recurrentand/or metastatic head and neck squamous cell carcinoma. Ann Oncol 5 (Suppl 8) : 119, 1994.
 
49) Chollet P, Bens maine MA, Brienza S, et al: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7: 1065-1070, 1996.
 
50) Levi F, Machover D, Marty JM, et al: Oxaliplatin (1-OHP) : summary of results in advanced colorectal cancer. Eur J Cancer 31 A (Suppl 5) : 154, 1995.
 
51) Levi FA, Zidani R, Vannetzel J-M, et al: Chronomodulated versus fixed-infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in tutional trial. J Natl Cancer Inst 86: 1608-1617, 1994.
 
52) Giacchetti S, Zidani R, Perpoint B, et al: Phase III trial of 5-fluorouracil, folinic acid, with or without oxaliplatin in previously untreated patients with metastatic colorectal cancer. Proc ASCO 16: 229 a, 1997.
PubMed
53) Perez-Soler R, Lopez-Berestein G, Lautersztain J, et al: Clinical development of liposomal platinum. J Liposome Res 1: 437-449, 1990.
 
54) Perez-Soler R, Lopez-Berestein G, Lauterstain J, et al: Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodexanoato-trans-R, R 1, 2. diaminocyclohexane platinum (II) . Cancer Res 50: 4254-4259, 1990.
 
55) Perez-Soler R, Siddik ZH, Chase J, et al: Phase I clinical and pharmacology study of liposome-entrapped cis-bis neodexanoato-trans-R, R-1, 2-diaminocyclohexane platinum (II) (1-NDDP) . Proc ASCO 12: 153, 1993.
 
56) Perez-Soler R, Shin DM, Siddik ZH, et al: Phase I clinical and pharmacological study of liposome-entrapped (L-NDDP) administered intrapleurally in patients with malignant pleural effusions. Proc ASCO 15: 492, 1996.
 
57) Mutoh M, Matsushita Y, Saito Y, et al: Antitumor activity of TRK-710, a new platinum complex having activity against cisplatin-resistant tumours. Proc Am Assoc Cancer Res 34: 399, 1993.
 
58) Inoue S and Mizuno S: Cytometric characterization of cisplatin and a new platinum analog, TRK-710. Proc Int Cong Anti-Cancer Chemother 5: 214, 1995.
 
59) Kelland LR, Abel G, McKeage MJ, et al: Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexane platinum (IV) : an orally active platinum drug. Cancer Res 53: 2581-2586, 1993.
 
60) Rose WC, Crosswell AR, Schruig JE, et al: Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemother Pharmacol 32: 197-203, 1993.
 
61) Harrap KR: Initiatives with platinum and quinazoline-based antitumor molecules. Fourtennth Bruce F. Cain Memorial Award Lecture. Cancer Res 55: 2761-2768, 1995.
 
62) Rose WC: Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chernother Pharmacol 40: 51-56, 1997.
PubMed
63) McKeage MJ, Mistry P, Ward J, et al: A phase I and pharmacology study of an oral platinum complex, JM-216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36: 451-458, 1995.
 
64) McKeage MJ, Raynaud F, Ward J, et al: Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15: 2691-2700, 1997.
 
65) Saraf N, Smith R, Brassard C, et al: Phase I trial of the oral platinum analog BMS-182751 (JM-216) in patients with refractory cancer. Proc ASCO 15: 485, 1996.
 
66) Fujii H, Sasaki Y, Tomura T, et al: A phase I and pharmacokinetic (PK) study of the oral platinum (Pt) analog JM 216. Proc ASCO 16: 215 a, 1997.
 
67) Pagani O, Bauer J, Borner M, et al: Phase I study of the oral platinum derivative JM 216 given daily for 14 days. Ann Oncol 7 (Suppl 5) : 125, 1996.
 
68) Groen HJM, Smit EF, Bauer J, et al: A phase II study of oral platinum JM-216 as first-line treatment in small cell lung cancer. Proc ASCO 15: 378, 1996.
 
69) Judson I, Cerny T, Epelbaum R, et al: Phase II trial of the oral platinum complex JM 216 in non-small cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 8: 604-606, 1997.
 
70) Peereboom DM, Wood L, Connell C, et al: Phase II trial of oral BMS-182751 (JM-216) in hormone refractory prostate cancer. Proc ASCO 16: 339 a, 1997.
 
71) Miglietta L, Cannobbio L and Boocardo F: Assessment of response of carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 15: 2825-2828, 1995.
 
72) Parker RJ, Vionner JA, Bostick-Bruton F, et al: Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin. Cancer Res 53: 242-247, 1993.
 
73) Farrell N, Qu Y, Bierbach U, et al: Structure-activity relationships within di-and trinuclear platinum phase-I clinical anticancer agents. In Cisplatin: chemistry and biochemistry of a leading anticancer drug, (ed by Lipper B) , Verlag Helvetica Chimica Acta, Zurich, Switzerland, 1999.
 
74) Manzotti C, Pratesi G, Menta E, et al: BBR 3464: A novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res 6: 2626-2634, 2000.
PubMed
P.240 掲載の参考文献
1) Rutman RJ, Cantarow A and Paschkis K: Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Res 14: 119, 1954.
PubMed
2) Duschinsky R, Pleven E and Heidelberger C: The synthesis of 5-fluoropyrimidines. J Am Chem Soc 79: 4559, 1957.
 
3) Wohlhueter RM, Mclvor RS and Plagemann PGW: Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 104: 309-319, 1980.
 
4) Yamamoto S and Kawasaki T: Active transport of 5-fluorouracil and its energy coupling in Ehrlich ascites tumor cells. JBiochem 90: 635-642, 1981.
PubMed
5) Schlemmer HP, Semmler W, Bachert P, et al: Evaluation of early response for in vivo 19F NMR spectroscopy in therapy monitoring of patients with liver metastases of colorectal carcinoma. Radiology 181: 210, 1991.
 
6) Reyes P and Guganig ME: Studies on a pyrimidine phosphoribosyltransferase from murine leukemia P1534 J. J Biol Chem 250: 5097-5108, 1975.
 
7) Niedzwicki JG, EL Kouni MH, Chu SH, et al: Structure activity relationship of ligands of the pyrimidine nucleoside phosphorylases. Biochem Pharmacol 32: 399-415, 1983.
PubMed
8) Diasio RB and Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215-237, 1989.
PubMed
9) Kufe DW and Major PP: 5-fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 256: 9802-9805, 1981.
PubMed
10) Santi DV, McHenry CS and Sommer A: Mechanisms of interactions of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13: 471-480, 1974.
 
11) Leichman CG, Lenz H-J, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.
PubMed
12) Major PP, Egan E, Herrick D, et al: 5-Fluorouracil incorporation in DNA of human breast carcinoma cells. Cancer Res 42: 3005-3009, 1982.
PubMed
13) Mauro DJ, De Riel JK, Tallarida RJ, et al: Mechanisms of excision of 5-fluorouracil by uracil DNA glycosylase in normal human cells. Mol Pharmacol 43: 854-857, 1993.
PubMed
14) Christophidis N, Vajda FJE, Lucas I, et al: Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 3: 330, 1978.
 
15) McDermott BJ, van der Berg HW and Murphy RF: Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol 9: 173-178, 1982.
 
16) McDermott BJ, Van der Berg HW and Murphy RF: Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Pharmacology 9: 173-178, 1982.
 
17) Takimoto CH, Yee LK, Venzon D, et al: High inter-and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res 5: 1347-1352, 1999.
PubMed
18) Mulkins MA and Heidelberger C: Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res 42: 965-973, 1982.
PubMed
19) Jiang W, Lu Z, He Y, et al: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma; implication for fluorouracil-based chemotherapy. Clin Cancer Res 3: 395-399, 1997.
PubMed
20) Copur S, Aiba K, Drake JC, et al: Thymidylate synthase gene amplification in human colon cancer cell line resistant to 5-fluorouracil. Biochem Pharmacol 49: 1419-1426, 1995.
PubMed
21) Antilla MI, Sotaniemi EA, Kaiaralcoma MI, et al: Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 10: 150-153, 1983.
 
22) Bjerkeset T and Fjosne HE: Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. Oncology 43: 212-215, 1986.
PubMed
23) Hortobagyi GN, Blumenschein GR, Tashima CK, et al: Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer. Cancer 44: 398-405, 1979.
PubMed
24) Queisser W, Schnitzler G, Schaefer J, et al: Comparison of ftorafur with 5-fluorouracil in combination chemotherapy of advanced gastrointestinal carcinoma. Recent Results Cancer Res 79: 82-92, 1981.
PubMed
25) Nakajima T, Takahashi T, Takagi K, et al: Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 2: 1366-1371, 1984.
PubMed
26) Fujii S, Kitano S, Ikenaka K, et al: Effect of coadrninistration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl) -5-fluorouracil and level of 5-fluorouracil in rodents. Gann 70: 209-214, 1979.
 
27) Douillard J-Y, Hoff PM, Skillings JR, et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605-3616,
PubMed
28) 上田孝典, 浦崎芳正: 抗腫瘍薬の新しい展開. 化学療法. 臨床医 28: 1640-1643, 2002.
 
29) Hoff PM: Capecitabine as first-line treatment for colorectal cancer (CRC) : integrated results of 1207 patients (pts) from 2 randomised, phase III studies. On behalf of the Capecitabine CRC Study Group. Ann Oncol 11 (suppl 4) : 60a, 2000.
 
30) Keyomarsi K and Moran R: Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 46: 5229-5235, 1986.
 
31) Cadman E, Davis L and Heimer R: Enhanced 5-fluorouracil nucleotide formation following methotrexate: biochemical explanation for drug synergism. Science 205: 1135-1137, 1979.
 
32) Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12: 960-969, 1994.
PubMed
33) Sawada N, Ishikawa T, Fukase Y, et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998.
PubMed
34) O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002.
 
35) Evans JS, Musser EA, Mengel GD, et al: Antitumor activity of 1-β-D-arabinofuranosylcytosine hydrochloride. Proc Soc Exp Biol Med 106: 350-353, 1961.
 
36) Ueda T, Nakamura T, Ando S, et al: Pharmacokinetics of N4-behenoyl-1-β-D-arabinofuranosylcytosine in patients with acute leukemia. Cancer Res 43: 3412-3416, 1983.
 
37) Ueda T, Kamiya K, Urasaki Y, et al: Clinical pharmacology of 1-β-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-β-D-arabinofuranosylcytosine. Cancer Res 54: 109-113, 1994.
 
38) Vesely J and Cihak A: 5-Azacytidine: mechanism of action and biological effects in mammalian cells. Pharmacol Ther 2: 813, 1978.
 
39) Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine (2', 2'-difluoro-2'-deoxycytidine) . Cancer Res 50: 4417-4422, 1990.
PubMed
40) Hanaoka K, Suzuki M, Kobayashi T, et al: Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-β-D-arabinopentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682) . Int J Cancer 82: 226-236, 1999.
 
41) Wiley JS, Taupin J, Jamieson GP, et al: Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 75: 632-642, 1985.
 
42) Griffiths M, Beaumont N, Yao SYM, et al: Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 3: 89-93, 1997.
 
43) Chabner BA, Johns DG, Coleman N, et al: Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest 53: 922-931, 1974.
 
44) Inagaki A, Nakamura T and Wakisaka G: Studies on the mechanism of action of 1-β-D-arabinofuranosylcytosine as an inhibitor of DNA synthesis in human leukemic leukocytes. Cancer Res 29: 2169-2176, 1969.
 
45) Kufe DW, Major PP, Egan EM, et al: Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 255: 8997-9000, 1980.
 
46) Ohno Y, Spriggs D, Matsukage A, et al: Effects of 1-β-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase β. Cancer Res 48: 1494-1498, 1988.
 
47) Leclerc JM and Cheng Y-C: Demonstration of activities in leukemic cells capable of removing 1'-d-arabinofuranosyl cytosine (araC) from araC incorporated DNA [abstract]. Proc Am Assoc Cancer Res 25: 19, 1984.
 
48) Fridland A: Effect of cytosine arabinoside on replicon initiation in human lymphoblasts. Biochem Biophys Res Commun 74: 72-78, 1977.
PubMed
49) Pourquier P, Takebayashi Y, Urasaki Y, et al: Induction of topoisomerase I cleavage complexes by 1-β-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci USA 97: 1885-1890, 2000.
 
50) Takauji R, Yoshida A, Iwasaki H, et al: Enhancement of Ca2+-dependent endonuclease activity in L1210 cells during apoptosis induced by 1-β-D-arabinofuranosylcytosine: Possible involvement of activating factor (s) . Jpn J Cancer Res 86: 677-684, 1995.
 
51) Ho DHW and Frei E III: Clinical pharmacology of 1-β-D-arabinofuranosylcytosine. Clin Pharmacol Ther 12: 944-954, 1971.
 
52) Kishi S, Goto N, Nakamura T, et al: Evaluation of cell-killing effects of 1-β-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. Cancer Res 59: 2629-2634, 1999.
 
53) Parker WB and Cheng YC: Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. Mol Pharmacol 31: 146-151, 1987.
PubMed
54) Bishop JF, Matthews JP, Young GA, et al: Arandomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87: 1710-1717, 1996.
 
55) Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331: 896-903, 1994.
PubMed
56) de Saint Vincent BR and Buttin G: Studies on 1-β-D-arabinofuranosyl cytosine-resistant mutants of Chinese hamster fibroblasts: IV. Altered regulation of CTP synthetase gerlerates arabinosylcytosine and thymidine resistance. Biochim Biophys Acta 610: 352, 1980.
 
57) de Saint Vincent BR, Dechamps M and Buttin G: The modulation of the thymidine triphosphate pool of Chinese hamster cells by dCMP deaminase and UDP reductase. J Biol Chem 255: 162-167, 1980.
PubMed
58) Steuart CD and Burke PJ: Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol 233: 109-110, 1971.
PubMed
59) Plunkett W, Iacoboni S, Estey E, et al: Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12: 20-30, 1985.
PubMed
60) Abe I, Saito S, Hori K, et al: Role of dephosphorylation in accumulation of 1-β-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Cancer Res 42: 2846-2851, 1982.
 
61) Dicioccio RA and Srivastava BIS: Kinetics of inhibition of deoxynucleotide-polymerizing enzyme activities from normaland leukemic human cells by 9-β-D-arabinofuranosyladenine 5'-triphosphate and 1-β-D-arabinofuranosylcytosine 5'-triphosphate. Eur J Biochem 79: 411-418, 1977.
 
62) Kataoka S, Naito M, Tomida A, et al: Resistance to antitumor agent-induced apoptosis in a mutant of human myeloid leukemia U 937 cells. Exp Cell Res 215: 199-205, 1994.
 
63) Wang S, Vrana JA, Bartimole TM, et al: Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-β-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol 52: 1000-1009, 1997.
 
64) Burris III HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: Arandomized trial. J Clin Oncol 15: 2403-2413, 1997.
 
65) Ruiz van Haperen VWT, Veerman G, Boven E, et al: Schedule dependence of sensitivity to 2', 2'-difluorodeoxycytidine gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 48: 1327-1339, 1994.
 
66) Heinemann V, Xu Y-Z, Chubb S, et al: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2', 2'-difluorodeoxycytidine. Mol Pharmacol 38: 567-572, 1990.
PubMed
67) Huang P, Chubb S, Hertel LW, et al: Action of 2', 2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
PubMed
68) Avramis VI, Wiersma S, Krailo MD, et al: Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res 4: 45-52, 1998.
 
69) Gandhi V, Kemena A, Keating MJ, et al: Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic Iymphocytic leukemia. Cancer Res 52: 897-903, 1992.
 
70) Ferrara F, Melillo L, Montillo M, et al: Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol 78: 380, 1999.
 
71) Perrino FW, Mazar DJ, Ward H, et al: Exonucleases and the incorporation of aranucleotides into DNA. Cell Biochem Biophys 30: 331-352, 1999.
 
72) Tidd DM and Patterson ARP: Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 34; 733-737, 1974.
 
73) Zimm S, Ettinger LJ, Holcenberg JS, et al: Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 45: 1869-1873, 1985.
PubMed
74) Weinshilboum RM: Methyltransferase pharmacogenetics. Pharmacol Ther 43: 77-90, 1989.
 
75) Zimm S, Collins JM, O'Neill D, et al: Chemotherapy: inhibition of first-pass metabolism in cancer interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 34: 810-817, 1983.
 
76) Otterness D, Szumlanski C, Lennard L, et al: Human thiopurine methyltransferase pharmacogenetics: gene sequences polymorphisms. Clin Pharmacol Ther 62: 60-73, 1997.
 
77) Balis FM, Holcenberg JS, Poplack DG, et al: Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia; a joint Children's Cancer Group and Pediatric Oncology Branch study. Blood 92: 3569-3577, 1998.
 
78) Huang P, Chubb S and Plunkett W: Incorporation of 9-d-arabinofuranosyl-2-fluoradenine into DNA and its chain termination effect on DNA synthesis. J Biol Chem 265: 16617-16625, 1990.
 
79) Tseng WC, Derse D, Cheng YC, et al: in vitro activity of 9-d-arabinofuranosyl-2-fluoradenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 21: 474-477, 1982.
 
80) Spriggs D, Robbins G, Mitchell T, et al: Incorporation of 9-d-arabinofuranosyl-2-fluoradenine into HL-60 dellular RNA and DNA. Biochem Pharmacol35: 247-252, 1986.
 
81) O'Dwyer PJ, Wagner B, Leyland-Jones B, et al: 2'-deoxycoformycin (Pentostatin) for lymphoid malignancies. Ann Intern Med 108: 733-743, 1988.
PubMed
82) Smyth JF, Paine RM, Jackman AL, et al: The clinical pharmacology of the adenosine deaminase inhibitor 2'deoxycoformycin. Cancer Chemother Pharmacol 5: 93-101, 1980.
PubMed
83) Huang M-C, Ashmun RA, Avery TL, et al: Effects of cytotoxicity of 2-chloro-2'-deoxyadenosine and 2-bromo-2'deox-yadenosine on cell growth, clonogenicity, DNA synthesis, and cell kinetics. Cancer Res 46: 2362-2368, 1986.
 
84) Parker WB, Bapat AR, Shen JX, et al: Interaction of 2-halogenated dATP analogs (F, Cl and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol34: 485-491, 1988.
 
85) Leoni LM, Chao Q, Cottam HB, et al: Induction of an apoptotic program in cell free extracts by 2-chloro-2'deoxyadenosine 5' triphosphate and cytochrome C. Proc Natl Acad Sci USA 95: 9567-9571, 1998.
PubMed
86) Farber S, Diamond LK, Mercer RD, et al: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin) . N Engl J Med 238: 787, 1948.
 
87) Antony AC: The biological chemistry of folate receptors. Blood 79: 2807-2820, 1992.
PubMed
88) Kumar P, Kisliuk RL, Gaumont Y, et al: Inhibition of human dihydrofolate reductase by antifolyl polyglutamates. Biochem Pharmacol 38: 541-543, 1989.
PubMed
89) Allegra CJ, Chabner BA, Drake JC, et al: Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260: 9720-9726, 1985.
PubMed
90) Bertino JR, Boothe BA, Cashmore A, et al: Studies of the inhibition of dihydrofolate reductase by the folate antagonists. J Biol Chem 239: 479, 1964.
 
91) Ackland SP and Schilsky RL: High-dose methotrexate: a critical reappraisal. J Clin Oncol 5: 2017-2031, 1987.
PubMed
92) Kessel D, Hall TC and Roberts DW: Modes of uptake of methotrexate by normal and leukemic human leukocytes in vitro and their relation to drug response. Cancer Res 28: 564-570, 1968.
 
93) Erttman R, Bielack S and Landbeck G: Kinetics of 7-hydroxy-methotrexate after high dose methotrexate therapy. Cancer Chemother Pharmacol 15: 101-104, 1985.
 
94) Valerino DM, Johns DG, Zaharko DS, et al: Studies of the metabolism of methotrexate by intestinal flora. Biochem Pharmacol 21: 821-831, 1972.
 
95) Schornagel JH and McVie JG: The clinical pharmacology of methotrexate. Cancer Treat Rev 10: 53-75, 1983.
PubMed
96) Balis FM, Savitch JL and Bleyer WA: Pharmacokinetics of oral methotrexate in children. Cancer Res 43: 2342-2345, 1983.
PubMed
97) Said HM and Hollander D: Inhibitory effect of bile salts on the enterohepatic circulation of methotrexate in the unanesthetized rat: inhibition of methotrexate intestinal absorption. Cancer Chemother Pharmacol 16: 121-124, 1986.
PubMed
98) Bleyer AR: The clinical pharmacology of methotrexate. Cancer 41: 6-51, 1978.
 
99) Jolivet J, Cowan KH, Curt GA, et al: The pharmacology and clinical use of methotrexate. N Engl J Med 369: 1094-1104, 1983.
 
100) Ettinger LJ, Chervinsky DS, Freeman AI, et al: Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma. Cancer 50: 1676-1682, 1982.
PubMed
101) Carman MD, Schornagel JH, Rivest RS, et al: Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 2: 16-20, 1984.
 
102) Dedhar S, Hartley D, Fitz-Gibbons D, et al: Heterogeneity in the specific activity and methotrexate sensitivity of dihydrofolate reductase from blast cells of acute myelogenous leukemia patients. J Clin Oncol 3: 1545-1552, 1985.
PubMed
103) Gorlick R, Goker E, Trippett T, et al: Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89: 1013-1018, 1997.
PubMed
104) Whitehead VM, Vuchich MJ, Lauer SJ, et al: Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdipoid (50 chromosomes) B-lineage acute lymphoblastic leukemia: apediatric oncology group study. Blood 80: 1316-1323, 1992.
 
P.251 掲載の参考文献
1) Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16: 2459-2465, 1998.
 
2) Kobayashi M, Natsume T, Tamaoki S, et al: Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88: 316-327, 1997.
PubMed
3) Arioka H, Nishio K, Heike Y, et al: In vitro and in vivo modulation byrhizoxin of non-P-glycoprotein-mediated vindesine resistance. J Cancer Res Clin Oncol 123: 195-200, 1997.
 
4) Ohta S, Krishan A, Nishio K, et al: Effect of taxol on vinblastine sulfate-induced crystallization of tubulin. Anticancer Res 13: 873-877, 1993.
PubMed
5) Giannakakou P, Gussio R, Nogales E, et al: A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 97: 2904-2909, 2000.
PubMed
6) Nishio K, Nakamura T, Koh Y, et al: Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells. Cancer 91: 1494-1499, 2001.
PubMed
7) Ohta S, Nishio K, Kubota N, et al: Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 85: 290-297, 1994.
PubMed
8) Giannakakou P, Sackett DL, Kang YK, et al: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118-17125, 1997.
PubMed
9) Tsurutani J, Komiya T, Uejima H, et al: Mutational analysis of the beta-tubulin gene in lung cancer. Lung Cancer 35: 11-16, 2002.
PubMed
10) Scatena CD, Stewart ZA, Mays D, et al: Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 273: 30777-30784, 1998.
PubMed
11) Ohmori T, Podack ER, Nishio K, et al: Apoptosis of lung cancer cells caused by some anti-cancer agents(MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 192: 30-36, 1993.
PubMed
12) Yamamoto N, Tamura T, Kamiya Y, et al: Correlation between docetaxel clearance and estimated cytochrome P 450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol18: 2301-2308, 2000.
 
13) Nakamura T, Saito Y, Murayama N, et al: Apparent low frequency of sequence variability within the proximal promoter region of the cytochrome P 450(CYP) 3 A 5 gene in established cell lines from Japanese individuals. Biol Pharm Bull 24: 954-957, 2001.
 
14) Cavalli SA, Hirata MH and Hirata RD: Detection of Mbo II polymorphism at the 5'promoter region of CYP 3 A 4. Clin Chem 47: 348-351, 2001.
 
15) Kuehl P, Zhang J, Lin Y, et al: Sequence diversity in CYP 3 A promoters and characterization of the genetic basis of polymorphic CYP 3 A 5 expression. Nat Genet 27: 383-391, 2001.
 
16) Ando Y, Tateishi T, Sekido Y, et al: Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP 3 A 4. J Natl Cancer Inst 91: 1587-1590, 1999.
 
17) Joshi HC and Cleveland D W: Diversity among tubulin subunits: toward what functional end? Cell Motil Cytoskeleton l6: 159-163, 1990.
 
18) Tatsumi Y, Arioka H, Ikeda S, et al: Enhancement of in vivo antitumor activity of a novel antimitotic 1-phenylpropenone derivative, AM-132, by tumor necrosis factor-alpha or interleukin-6. Jpn J Cancer Res 92: 768-777, 2001.
PubMed
19) Derry WB, Wilson L, Khan IA, et al: Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 36: 3554-3562, 1997.
PubMed
20) Jaffrezou Jp, Dumontet C, Derry WB, et al: Novel mechanism of resistance to paclitaxel(Taxol) in human K 562 leukemia cells by combined selection with PSC 833. Oncol Res 7: 517-527, 1995.
 
21) Kavallaris M, Kuo DY, Burkhart CA, et al: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282-1293, 1997.
PubMed
22) Ranganathan S, Dexter DW, Benetatos CA, et al: Increase of beta(III) -and beta(IV a) -tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56: 2584-2589, 1996.
 
23) Ranganathan S, Benetatos CA, Colarusso PJ, et al: Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77: 562-566, 1998.
PubMed
24) Behar A, Pujade-Lauraine E, Maurel A, et al: The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 43: 653-658, 1997.
 
25) Cavaletti G, Cavalletti E, Montaguti P, et al: Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 18: 137-145, 1997.
PubMed
26) Cavaletti G, Cavelletti E, Oggioni N, et al: Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 221: 389-393, 2000.
 
27) McKeage MJ, Haddad GG, Ding L, et al: Neuroprotective interactions in rats between paclitaxel and cisplatin. Oncol Res 11: 287-293, 1999.
PubMed
28) Behar A, Pujade-Lauraine E, Maurel A, et al: The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 43: 653-658, 1997.
 
29) Nadella P, Shapiro C, Otterson GA, et al: Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 20: 2616-2623, 2002.
PubMed
30) Nukatsuka M, Fujioka A, Nakagawa F, et al: The antimetastatic and anticancer effects of oral fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer that spontaneously metastasizes to the lungs. Proc Am Assoc Cancer Res: Abstr 795, 2002.
 
31) Naruse I, Ohmori T, Ao Y, et al: Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) Iressa(ZD 1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 98: 310-315, 2002.
 
32) Montgomery RB, Guzman J, O'Rourke DM, et al: Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 275: 17358-17363, 2000.
 
P.259 掲載の参考文献
1) 前原喜彦, 杉町圭蔵: DNA修復機構と抗癌剤感受性. 癌の薬剤耐性とその克服-基礎と臨床-, (大沼尚夫, 竹村 譲・編) , 宇宙堂八木書店, 東京, 2001, pp 84-96.
 
2) Erickson LC, Laurent G, Sharkey NA, et al: DNA cross-linking and monoadduct repair in nitrosourea-treated human tumor cells. Nature 288: 727-729, 1980.
PubMed
3) Radman M: Mismatch repair and the fidelity of genetic recombination. Genome 31: 68-73, 1989.
PubMed
4) Pourquier P, Waltman JL, Urasaki Y, et al: Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguaninidine: Trapping of topoisomerase I by the O6-methylguanine. Cancer Res 61: 53-58, 2001.
 
5) Okamoto R, Takano H, Okamura T, et al: 06-methylguanine-DNA methyltransferase(MGMT) as a determinant of resistance to camptothecin derivatives. JPn J Cancer Res 93: 93-102, 2002.
 
6) Colvin M and Chabner BA: Alkylating agents. In: Cancer Chemotherapy: Principles and Practice, (ed by Chabner BA and Collins JM) , JB Lippincott, Philadelphia, 1990, pp 276-313.
 
7) Chaney SG and Sancar A: DNA repair. Enzymatic mechanism and relevance to drug response. J Natl Cancer Inst 88: 1346-1360, 1996.
 
8) Gilman A: The clinical trial of nitrogen mustard. Am J Surg 105: 574-578, 1963.
PubMed
9) 藤井喜一郎: アルキル化剤. 医薬品の化学と作用, (藤井喜一郎・著) , 第3刷, 薬業時報社, 東京, 1999, pp 343-348.
 
10) 持田 泰, 早川 浩, 桑野信彦: アルキル化剤. 癌の薬剤耐性とその克服-基礎と臨床-, (大沼尚夫, 竹村 譲・編) , 宇宙堂八木書店, 東京, 2001, pp 233-241.
 
11) Chabner BA: Miscellaneous agents. In: Cancer: Principles and Practice of Oncology, (ed by De Vita VT Jr, Hellman S and Rosenberg SA) , 4th Edition, JB Lippincott, Philadelphia, 1993, pp 385-389.
 
12) 涌井 昭: アルキル化剤, 特にニトロソウレア. 臨床成人病 24: 1869-1875, 1994.
 
13) Ewig RA and Kohn KW: DNA damage and reapir in mouse leukemia L 1210 cells treated with nitrogen mustard, 1, 3-bis (2-chloroethyl) -1-nitrosourea, and other nitrosoureas. Cancer Res 37: 2114-2122, 1977.
 
14) Wu ZN, Chan CL, Eastman A, et al: Expression of human O6-methyl-transferase in a DNA excision repair-deficient Chinese hamster ovary cell line and its response to certain alkylating agents. Cancer Res 52: 32-35, 1992.
 
15) Dolan ME, Mitchell RB, Mummert C, et al: Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 51: 3367-3372, 1991.
 
16) Grombacher T, Einchorn U, Kina B: p 53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase(MGMT) by DNA damaging agents. Oncogene 17: 845-851, 1998.
 
17) 横山康宏: アンソラサイクリン系抗腫瘍剤. 癌の薬剤耐性とその克服-基礎と臨床-, (大沼尚夫, 竹村 譲・編) , 宇宙堂八木書店, 東京, 2001, pp 269-277.
 
18) Charies JB, Dattagupta N and Crothers DM: Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. Biochemistry 21: 3933-3940, 1982.
 
19) Nittis JL and Beck WT: Antitopoisomerase drug action and resistance. Eur J Cancer 32 A: 958-966, 1996.
 
20) Bacher NR, Yu F, Johmson R, et al: Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol 41: 993-998, 1992.
 
21) Hortobagyi GN: Anthracyclines in the treatment of cancer. An overview. Drugs 54: 1-7, 1997.
PubMed
22) Wingard LB Jr, Tritton TR and Egler KA: Cell surface effects of adriamycin and carminomycin immobilized on crosslinked polyvinyl alcohol. Cancer Res 45: 3529-3536, 1985.
 
23) Friesen C, Herr I, Krammer PH, et al: Involvement of the CD 95(APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2: 574-577, 1996.
 
24) Di Marco A, Gaetani M, Dorigotti L, et al: Daunomycin: A new antibiotics with antitumor activity. Cancer Chemother Re 38: 31-38, 1964.
 
25) Di Marco A, Gaetani M, Scarpinato B, et al: Adriamycin(NSC-123, 127) , anew antibiotics with antitumor activity. Cancer Chemother Rep 53: 33-37, 1969.
 
26) Oki T, Matsuzawa Y, Yoshimoto A, et al: New antitumor antibiotics aclacinomycins A and B. Jpn J Antibiot 28: 830-834, 1975.
 
27) Erei E 3d: the clinical use of actinomycin. Cancer Chemother Rep 58: 49-54, 1974.
 
28) Boland MP, Fitzgerald KA and O'Neill LAJ: Topoisomerase II is required for mitoxantrone to signal nuclear factorκB activation in HL 60 cells. J Biol Chem 275: 25231-25238, 2000.
 
29) Crooke ST and Bradner WT: Mitomycin C. A review. Cancer Treat Rev 3: 12H39, 1976.
PubMed
30) owis G: Metabolism and reactions of quinoid anticancer agents. Pharmacol Ther 35: 57-62, 1987.
 
31) Nishiyama M, Suzuki K, Kumazaki T, et al: Molecular targeting of mitomycin C chemotherapy. Int J Cancer 72: 649-656, 1997.
PubMed
32) Petering DH, Byrnes RW, Antholine WE, et al: The role of redox-active metals in the mechanism of action of bleomycin. Chem Biol Interact 73: 133-182, 1990.
PubMed
33) Hecht SM: Bleomycin: new perspectives on the mechanism of action. J Nat Prod 63: 158-168, 2000.
PubMed
34) Kuo HM, Lee Chao PD and Chin DH: Delocalized electronic structure of the thiol sulfur substantially prevents nucleic acid damage induced by neocarzinostatin. Biochemistry 41: 897-905, 2002.
 
35) Iguchi K, Hirano K and Ishida R: Activation of caspase-3, proteolytic cleavage of DFF and no oligonucleosomal DNA fragmentation in apoptotic Molt-4 cells. J Biochem 131: 469-475, 2002.
 
P.268 掲載の参考文献
1) Yamaue H, Tanimura H, Iwahashi M, et al: Role of interleukin-2 and interferony in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK-432. Cancer Immunol Immunother 29: 79-86, 1989.
 
2) Rosenberg SA, Lotze MT and Yang JC: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85: 622-632, 1993.
 
3) Rosenberg SA, Sepiess P, Latreniere RA, et al: A new approach to the adoptive immunotherapy of cancer with TIL. Science 233: 1318-1321, 1986.
 
4) Rosenberg SA, Packard BS, Aebeersold PM, et al: Use of tumor-infiltrating lymphocytes and IL-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676-1680, 1988.
 
5) Yamaue H, Tanimura H, Tsunoda T, et al: Functional and phenotypical analyses of IL-2-activated tumor-infiltrating lymphocytes. Biotherapy 2: 247-259, 1990.
 
6) Tsunoda T, Tanimura H, Yamaue H, et al: Clinical efficacy of adoptive immunotherapy by IL-4-activated tumorinfiltrating lymphocytes in patients with advanced cancer. Int J Clin Oncol 2: 202-207, 1997.
 
7) Yamaue H, Tanimura H, Mizobata S, et al: Multidisciplinary treatment for gastric cancer patients by chemoimmunotherapy. Hepatogastroenterology 46: 620-625, 1999.
PubMed
8) Bruggen PVD, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
 
9) Greiner JW, Guadagni F, Goldstein D, et al: Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 10: 735-746, 1992.
 
10) Sartori S, Nielsen I, Tassinari D, et al: Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2 b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology 61: 192-196, 2001.
 
11) Frreeman RS, Kudelka AP, Kavanagh JJ, et al: Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 6: 2268-2278, 2000.
 
12) Nishiguchi S, Shiomi S, Nakatani S, et al: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis Cand cirrhosis. Lancet 357: 196-197, 2001.
 
13) Ikeda K, Arase Y, Saitoh S, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32: 228-232, 2000.
PubMed
14) Kubo S, Nishiguchi S, Hirohashi K, et al: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134: 963-967, 2001.
 
15) Cascinelli N, Belli F, MacKie RM, et al: Effect of long-term adjuvant therapy with interferon alpha-2 a in patients with regional node metastasis from cutaneous melanoma: arandomized trail. Lancet 358: 66-869, 2001.
 
16) Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alpha-2 b significantly prolongs relapse-free and overall survival compared with the GM 2-KLH/QS-21 vaccine in patients with resected stage II B-III melanoma: results of intergroup trial E 1694/S 9512/C 509801. J Clin Oncol 19: 2370-2380, 2001.
 
17) Flanigan RC, Salmon SE, Blumenstein BA, et al: Nephrectomy followed by interferon alpha-2 b compared with interferon alfa-2 b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655-1659, 2001.
 
18) Mickisch GH, Garin A, van Poppel H, et al: Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: arandomized trial. Lancet 358: 966-970, 2001.
 
19) Fountzilas G, Zisiadis A, Dafni U, et al: Fluorouracil and leucovorin with or without interferon alpha-2 a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Oncology 58: 227-236, 2000.
 
20) Patt YZ, Hassan MM, Lozano RD, et al: Phase II trial of cisplatin, interferon alpha-2 b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 7: 3375-3380, 2001.
 
21) Nukui Y, Picozzi VJ and Traverso LW: Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 179: 367-371, 2000.
PubMed
22) Ridolfi R, Chiarion-Sileni V, Guida M, et al: Cisplatin, Dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2 b in advanced melanoma outpatients: Results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20: 1600-1607, 2002.
 
23) Buzio C, Andrulli S, Santi R, et al: Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer 92: 2286-2296, 2001.
PubMed
24) Presant CA, Wolf W, Waluch V, et al: Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive(19) F-magnetic resonance spectros・ copy. J Clin Oncol 18: 255-261, 2000.
 
25) Grimm EA, Mazumder A, Zhang HZ, et al: Lymphokine-activated killer cell phenomenon. Lysis of NK-resistant fresh solid tumor cells by IL2 activated peripheral blood lymphocytes. J Exp Med 155: 1823-1841, 1982.
 
26) Smith KA: Interleukin-2: Inception, impact, and implications. Science 240: 1169-1176, 1988.
PubMed
27) Hatakeyama M, Tsudo M, Minamoto S, et al: Interleukin-2 receptorβchain gene: Generation of three receptor forms by cloned humanαandβchain cDNAs. Science 244: 551-556, 1989.
 
28) Takeshita T, Ohtani K, Asao H, et al: An association molecule, p 64, with IL-2 receptorβchain: Its possible involvement in formation of the functional IL-2 receptor complex. J Immunol 148: 2154-2158, 1992.
 
29) Takeshita T, Asao H, Ohtani K, et al: Cloning of the y chain of the human IL-2 receptor. Science 257: 379-382, 1992.
 
30) Gratama JW, Bruin RJ, Lamers CHJ, et al: Activation of the immune system of cancer patients by continuous i. v. recombinant IL-2(rIL-2) therapy is dependent on dose and schedule of rIL-2. Clin Exp Immunol 92: 185-193, 1993.
 
31) Schneekloth C, Kerfer A, Hadam M, et al: Low dose IL-2 in combination with IFN-α effectively modulates biological response in vivo. Acta Haematol 89: 13-21, 1993.
 
32) Lotze MT, Custer MC, Sharrow SO, et al: In vivo administration of purified IL-2 to patients with cancer: development of IL-2 receptor following IL-2 administration. Cancer Res 47: 2188-2195, 1987.
PubMed
33) Gooding R, Riches P, Dadian G, et al: Increased soluble IL-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer 721452-455, 1995.
 
34) Howard M, Farrar J, Hilfiker M, et al: Identification of a T cell derived B-cell growth factor distinct for IL-2. J Exp Med 155: 914-923, 1982.
 
35) Noma Y, Sideras P, Naito T, et al: Cloning of cDNA encoding the murine IgG 1 induction factor by a novel strategy using SP 6 promoter. Nature 319: 640-646, 1986.
 
36) Mosmann TR, Cherwinski H, Bond MW, et al: Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986.
PubMed
37) Gilleece MH, Scarffe JH, Ghosh A, et al: Recombinant human IL-4 given as daily subcutaneous injections-a phase I dose toxicity trial. Br J Cancer 66: 204-210, 1992.
PubMed
38) Prendiville J, Thatcher N, Lind R, et al: Recombinant human IL-4 administered by intravenous and subcutaneous routes in patients with advanced cancer-a phase I toxicity study and pharmacokinetic analysis. Eur J Cancer 29: 1700-1707, 1993.
 
39) Tsunoda T, Tanimura H, Yamaue H, et al: The promotive effect of IL-4 with IL-2 in the proliferation of tumorinfiltrating lymphocytes from patients with malignant tumor. Biotherapy 4: 9-15, 1992.
 
40) Tsunoda T, Tanimura H, Yamaue H, et al: Clonal and functional analysis for the augmentation of tumour-infiltrating lymphocytes by interleukin 4. Br J Cancer 74: 1085-1089, 1996.
PubMed
41) Tepper RI: The eosinophil-mediated antitumor activity of interleukin-4. J Allergy Clin Immunol 94: 1225-1231, 1994.
PubMed
42) Kobayashi M, Fitz L, Ryan M, et al: Identification and purification of natural killer cell stimulatory factor(NKSF) , a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170: 827-845, 1989.
PubMed
43) Sieburth D, Jabs EW, Warrington JA, et al: Assignment of genes encoding a unique cytokine(IL 12) compared of two unrelated subunits to chromosomes 3 and 5. Genomics 14: 59-66, 1992.
 
44) Gearing DP and Cosman D: Homology of the p 40 subunit of natural killer cell stimulatory factor(NKSF) with the extracellular domain of the interleukin-6 receptor. Cell 66: 9-13, 1991.
 
45) Taga T and Kishimoto T: Cytokine receptors and signal transduction. FASEB J 7: 387-394, 1993.
 
46) Trinchieri G: Interleukin-12: Acytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84: 4008-4027, 1994.
PubMed
47) Ohno R, Yamaguchi Y, Toge T, et al: Adose-escalation and pharmacokinetic study of subcutaneously administered recombinant human Interleukin 12 and its biological effects in Japanese patients with advanced malignancies. Clin Cancer Res 6: 2661-2669, 2000.
 
48) Gollob JA, Mier JW, Veenstra K, et al: Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6: 1678-1692, 2000.
PubMed
49) Lee P, Wang F, Kuniyoshi J, et al: Effects of interleukin-120n the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 15: 3836-3847, 2001.
 
50) Gajewski TF, Fallarino F, Ashikari A, et al: Immunization of HLA-A 2+ melanoma patients with MAGE-30r Melan A peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 7: 895-901, 2001.
 
51) Manetti R, Parronchi P, Giudizi MG, et al: Natural killer cell stimulatory factor(NKSF/IL-12) induces Th 1-type specific immune responses and inhibits the development of IL-4 producing Th cells. J Exp Med 177: 1199-1207, 1993.
 
52) Manetti R, Gerosa F, Giudizi MG, et al: Interleukin-12 induces stable prirning for interferon-g(IFN-y) production during differentiation of human T helper(Th) cells and transient IFN-y production in established Th 2 cell clones. J Exp Med 179: 1141-1150, 1994.
 
53) Scott P: IL-12: Initiation cytokine for cell-mediated immunity. Science 260: 496, 1993.
PubMed
54) Young MRI, Wright MA, Mattews JP, et al: Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-βand nitric oxide. J Immunol 156: 1916-1922, 1996.
 
55) Rosenberg SA, Yang JC, Schwartzentruberg DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998.
 
56) Irvine KR, Roa RB, Rosenberg SA, et al: Cytokine enhancement of DNA immunization leads to treatment of established pulmonary metastases. J Immunol 154: 4282-4292, 1995.
 
57) Noguchi Y, Richard EC, Chen YT, et al: Influence of interleukin 12 on p 53 peptide vaccination against established Meth Asarcoma. Proc Natl Acad Sci USA 92: 2219-2223, 1995.
 
58) Gansbacher B, Zier K, Daniels B, et al: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1227, 1990.
PubMed
59) Fearon ER, Pardoll DM, Itaya T, et al: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403, 1990.
PubMed
60) Conner J, Bannerji R, Saito S, et al: Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 177: 1127-1135, 1993.
 
61) Yannelli JR, Hyatt C, Johnson S, et al: Characterization of human tumor cell lines transduced with the cDNA encoding either TNF-αor IL2. J Immunol Methods 161: 77-90, 1993.
 
62) Yamaue H, Kashmiri SVS, De Filippi R, et al: Enhanced IL-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated IL-2 gene. J Immunother 16: 262-274, 1994.
 
63) Tahara H, Gubler U, Wolf SF, et al: Fibroblasts genetically engineered to secrete IL-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54: 182-189, 1994.
PubMed
64) Fakhrai H, Shawler DL, Gjerset R, et al: Cytokine gene therapy with IL-2 transduced fibroblasts: Effect of IL-2 dose on anti-tumor immunity. Human Gene Ther 6: 591-601, 1995.
 
65) Terasawa H, Tanimura H, Nakamori M, et al: Antitumor effects of interleukin-2 gene-modified fibroblasts in an orthotopic colon cancer model. Jpn J Cancer Res 90: 1000-1006, 1999.
 
66) Nishioka Y, Hirano M, Robbins PD, et al: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 59: 4035-4041, 1999.
 
P.277 掲載の参考文献
1) Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2: 104-107 (part I) , 162-165(part 2) , 1894.
 
2) Huggins C and Hodges CV: Studies on prostatic cancer. The effect of castration, of estrogen and androgen injection onserum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297, 1941.
 
3) Jordan VC: The development of tamoxifen for breast cancer: atribune to the late Arthur L. Wadpole. Breast Cancer ResTreat 11: 197-209, 1988.
 
4) Labrie F: Intracrinology. Mol Cell Endocrinol 78: C113-118, 1991.
PubMed
5) Jensen EV and DeSombre ER: Estrogen-receptor interaction. Science 182: 126-134, 1973.
PubMed
6) Hollenberg SM, Weinberger C, Ong ES, et al: Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 318: 635-641, 1985.
PubMed
7) Green S, Walter P, Kumar V, et al: Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320: 134-139, 1986.
 
8) Chang CS, Kokontis J and Liao ST: Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240: 324-326, 1988.
PubMed
9) Lubahn DB, Joseph DR, Sullivan PM, et al: Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240: 327-330, 1988.
 
10) Misrahi M, Atger M, d'Auriol L, et al: Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. Biochem Biophys Res Commun 143: 740-748, 1987.
PubMed
11) Tanenbaum DM, Wang Y, Williams SP, et al: Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci USA 95: 5998-6003, 1998.
PubMed
12) Brzozowski AM, Pike AC, Dauter Z, et al: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-758, 1997.
PubMed
13) Mangelsdorf DJ and Evans RM: The RXR heterodimers and orphan receptors. Cell 83: 841-850, 1995.
 
14) McKenna NJ, Lanz RB and O'Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20: 321-344, 1999.
 
15) Knobil E: The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 36: 53-78, 1980.
PubMed
16) Belchetz PE, Plant TM, Nakai Y, et al: Hypophysial responses to continuous and intermittent delivery of hypothalamicgonadotropin-releasing hormone. Science 202: 631-633, 1978.
PubMed
17) Taylor CW, Green S, Dalton WS, et al: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16: 994-999, 1998.
PubMed
18) Kaisary AV, Tyrrell CJ, Peeling WB, et al: Comparison of LH-RH analogue(Zoladex) with orchiectomy in patients withmetastatic prostatic carcinoma. Br J Urol 67: 502-508, 1991.
 
19) Thompson IM, Zeidman EJ and Rodriguez FR: Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 144: 1479-1480, 1990.
PubMed
20) Waxman J, Man A, Hendry WF, et al: Importance of early tumour exacerbation in patients treated with long actinganalogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J Clin Res 291: 1387-1388, 1985
 
21) Corbin CJ, Graham-Lorence S, McPhaul M, et al: Isolation of a full-length cDNA insert encoding human aromatase systemcytochrome P-450 and its expression in nonsteroidogenic cells. Proc Natl Acad Sci USA 85: 8948-8952, 1988.
PubMed
22) Harada N: Cloning of a complete cDNA encoding human aromatase: immunochemical identification and sequence analysis. Biochem Biophys Res Commun 156: 725-732, 1988.
PubMed
23) Chen SA, Besman MJ, Sparkes RS, et al: Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. DNA 7: 27-38, 1988.
PubMed
24) Pasqualini JR, Chetrite G, Blacker C, et al: Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81: 1460-1464, 1996.
PubMed
25) Castagnetta LA, Lo Casto M, Granata OM, et al: Estrogen content and metabolism in human breast tumor tissue and cells. Ann NY Acad Sci 784: 314-324, 1996.
PubMed
26) DeJong PC, ven de Ven J, Nortier HW, et al: Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res 57: 2109-2111, 1997.
 
27) Simpson ER and Davis SR: Aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 142: 4589-4594, 2001.
PubMed
28) Griffiths CT, Hall TC, Saba Z, et al: Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31-37, 1973.
PubMed
29) The ATAC Trialists'Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvanttreatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002.
 
30) Fisher B, Costanitino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: findingsfrom the National Surgical Adjuvant Breast and Bowel Project(NSABP) B-14. J Natl Cancer Inst 86: 527-537, 1994.
 
31) White IN, de Matteis F, Davies A, et al: Genotoxic potential of tamoxifen and analogues in female Fischer F 344/n rats, DBA/2 and C 57 BL/6 mice and in human MCL-5 cells. Carcinogenesis 13: 2197-2203, 1992.
 
32) Hard GC, Iatropoulos MJ, Jordan K, et al: Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Ctr: CD(BR) rats. Cancer Res 53: 4534-4541, 1993.
 
33) Mouridsen H, Palshof T, Patterson J, et al: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131-141, 1978.
PubMed
34) Howell A, DeFriend D, Robertson J, et al: Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breastcancer. Lancet 345: 29-30, 1995.
 
35) Knuth UA, Hano R and Nieschlag E: Effect of flutamide or cyproterone acetate on pituitary and testicular hormones innormal men. J Clin Endocrinol Metab 59: 963-969, 1984.
PubMed
36) Marchetti B and Labrie F: Characteristics of flutamide action on prostatic and testicular functions in the rat. J Steroid Biochem 29: 691-698, 1988.
 
37) Neri RO: Antiandrogens. Adv Sex Horm Res 2: 233-262, 1976.
PubMed
38) Veldscholte J, Berrevoets CA, Brinkmann AO, et al: Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31: 2393-2399, 1992.
PubMed
39) Mattsson W: Current status of high dose progenstin treatment in advanced breast cancer. Breast Cancer Res Treat 3: 231-235, 1983.
PubMed
40) Hortobagyi GN, Buzdar AU, Frye D, et al: Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 5: 321-326, 1985.
PubMed
41) Bruera E, Macmillan K, Kuehn N, et al: A controlled trial of megesterol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66: 1279-1282, 1990.
 
42) Labrie F, Belanger A, Simard J, et al: Combination therapy for prostate cancer. Endocrine and biologic basis of its choiceas new standard first-line therapy. Cancer 71: 1059-1067, 1993.
PubMed
43) Matsumoto K, Sakamoto G and Nomura Y: International comparisons concerning breast cancer and steroid receptors. Anticancer Res 6: 621-624, 1986.
PubMed
44) Ciocca DR and Elledge R: Molecular markers for predicting response to tamoxifen in breast cnacer patients. Endocrine13: 1-10, 2000.
 
P.284 掲載の参考文献
1) Honma Y, Kasukabe T, Okabe J, et al: Prolongation of survival time of mice inoculated with myeloid leukemia cells by inducers of normal differentiation. Cancer Res 39: 3167-3171, 1979.
PubMed
2) 穂積本男: 癌細胞の分化誘導から制癌へ. 治療 64: 509-516, 1983.
 
3) 本間良夫: In vivoにおける分化誘導と治療. 癌細胞の分化誘導と制癌, (穂積本男, 高久史麿・編) , ソフトサイエンス社, 東京, 1985, pp 80-89.
 
4) Warell RP Jr, He LZ, Richon V, et al: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90: 1621-1625, 1998.
 
5) Huang ME, Ye YC, Chen SR, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572, 1988.
PubMed
6) Frankel SR, Eardley A, Lauwers G, et al: The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117: 292-296, 1992.
PubMed
7) 大野竜三: レチノイン酸による急性前骨髄球性白血病の分化誘導療法. 医学のあゆみ 184: 424-427, 1998.
Medical*Online
8) Takeshita A, Sakamaki H, Miyawaki S, et al: Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. Cancer 76: 602-608, 1995.
PubMed
9) 竹下昭裕: レチノイン酸耐性急性前骨髄球性白血病の治療戦略. 最新医学 54: 246-252, 1999.
 
10) Neildez-Nguyen T, Chapel A, Arock M, et al: Gamma-irradiation does not impair ATRA-induced maturation of myeloidleukaemic cells: implication for combined radiation and differentiation therapy. Br J Haematol 103: 79-86, 1998.
 
11) Head D, Kopecky KJ, Weick J, et al: Effect of aggressive daunomycin therapy on survival in acute promyelocyticIeukemia. Blood 86: 1717-1728, 1995.
 
12) Estey E, Thall PF, Pierce S, et al: Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15: 483-490, 1997.
PubMed
13) Niitsu N, Ishii Y, Matsuda A, et al: Induction of differentiation of acute promyelocytic leukemia cells by a cytidinedeaminase-resistant analogue of 1-β-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-β-D-erythro-pentofuranosyl) cytidine. Cancer Res 61: 178-185, 2001.
 
14) Han ZT, Zhu XX, Yang RY, et al: Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate(TPA) inpatients with myelocytic leukemia: Preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci USA 95: 5357-5361, 1998.
 
15) Han ZT, Tong YK, He LM, et al: 12-0-Tetradecanoylphorbol-13-acetate(TPA) -induced increase in depressed whiteblood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs. Proc Natl Acad Sci USA 95: 5362-5365, 1998.
 
16) 本間良夫: 固形癌の分化誘導療法. KARKINOS 6: 1175-1181, 1993.
 
17) Sato M, Harada K, Yura Y, et al: Induction of tumour differentiation and apoptosis and Ley antigen expression intreatment with differentiation-inducing agent, vesnarinone, of a patient with salivary adenoid cyctic carcinoma. Apoptosis2: 106-113, 1997.
 
18) Lippman SM, Parkinson DR, Itri LM, et al: 13-cis retinoic acid and interferonα-2 a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84: 235-241, 1992.
 
19) Tong W-M, Bises G, Sheinin Y, et al: Establishment of primary cultures from human colonic tissue during tumor Progression. Int J Cancer 75: 467-472, 1998.
PubMed
20) Ricchi P, Pignata S, Popolo AD, et al: Effect of aspirin on cell proliferation and differentiation of colon adenocarcinomacaco-2 ells. Int J Cancer 73: 880-884, 1997.
 
21) Tontonoz P, Singer S, Forman BM, et al: Terminal differentiatin of human liposarcoma cells induced by ligands forperoxisome proliferator-activated receptorγand the retinoid X receptor. Proc Natl Acad Sci USA 94: 237-241, 1997.
 
22) Demetri GD, Fletcher CDM, Mueller E, et al: Induction of solid tumor differentiation by the peroxisome proliferator activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96: 3951-3956, 1999.
 
23) Elstner E, MUIIer C, Koshizuka K, et al: Ligands for peroxisome proliferator-activated receptor γ and retinoic acidreceptor inhibit growth and induce apoptosis of human breast cancer cells in vitro nd in BNX mice. Proc Natl Acad SciUSA 95: 8806-8811, 1998.
 
24) Mueller E, Sarraf P, Tontonoz P, et al: Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1: 465-470, 1998.
 
25) Kitamura S, Miyazaki Y, Shinomura Y, et al: Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 90: 75-80, 1999.
 
26) Chang T-H and Szabo E: Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activatedreceptorγin non-small cell lung cancer. Cancer Res 60: 1129-1138, 2000.
 
27) 本間良夫: 固形癌における分化誘導による制癌. 現代医療 32: 2437-2441, 2000.
 
28) Goto I, Yamamoto-Yamaguchi Y and Honma Y: Enhancement of sensitivity of human lung adenocarcinoma cells togrowth-inhibitory activity of interferonαby differentiation-inducing agents. Br J ancer 74: 546-554, 1996.
 
29) Kasukabe T, Rephaeli A and Honma Y: An anti-cancer derivative of utyric acid(pivalyloxymethyl butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukemia cells. Br J Cancer 75: 850-854, 1997.
PubMed
30) Niitsu N, Kasukabe T, Okabe-Kado J, et al: Anticancer derivative of butyric acid(pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol Pharmacol 58: 27-36, 2000.
PubMed
P.292 掲載の参考文献
1) Kohler G and Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975.
PubMed
2) Nadler LM, Stashenko P, Hardy R, et al: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40: 3147-3154, 1980.
PubMed
3) Miller RA, Maloney DG, Warnke R, et al: Treatment of B-cell lymphoma with anti-idiotype antibody. N Engl J Med 306: 517-522, 1982.
PubMed
4) Meeker T, Lowder J, Cleary ML, et al: Emergence of idiotype variants during therapy of B cell lymphoma with anti-idiotype antibodies. N Engl J Med 312: 1658-1665, 1985.
PubMed
5) Davis TA, Maloney DG, Czerwinski DK, et al: Anti-idiotype can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92: 1184-1190, 1998.
PubMed
6) Press OW, Appelbaum F, Ledbetter JA, et al: Monoclonal antibody IF 5(anti-CD 20) serotherapy of human B cell Iymphomas. Blood 69: 584-591, 1987.
 
7) Grossbard ML, Freedman AS, Ritz J, et al: Serotherapy of B-cell neoplasms with anti-B 4-blocked ricin: A phase I trial of daily bolus infusion. Blood 79: 576-585, 1992.
PubMed
8) Grossbard ML, Lambert JM, Goldmacher VS, et al: Anti-B 4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11: 726-737, 1993.
PubMed
9) Hu E, Epstein AL, Naeve GS, et al: A phase I a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 7: 155-166, 1989.
PubMed
10) Miller RA, Oseroff AR, Stratte PT, et al: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62: 988-995, 1983.
 
11) Knox SJ, Levy R, Hodgkinson S, et al: Observations on the effect of chimeric anti-CD 4 monoclonal antibody in patients with mycosis fungoides. Blood 77: 20-30, 1991.
 
12) Knox S, Hoppe RT, Maloney D, et al: Treatment of cutaneous T-cell lymphoma with chimeric anti-CD 4 monoclonal antibody. Blood 87: 893-899, 1996.
 
13) Waldman TA, Goldman CK, Bongiovanni KF, et al: Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 72: 1805-1816, 1988.
 
14) Waldmann TA, White JD, Goldman CK, et al: The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia. Blood 82: 1701-1712, 1993.
 
15) Kreitman RJ, Wilson WH, Bergeron K, et al: Efficacy of the anti-CD 22 recombinant immunotoxin BL 22 in chemotherapy-resistant hairy cell leukemia. N Engl J Med 345: 241-247, 2001.
 
16) Sievers EL, Larson RA, Stadtmauer EA, et al: Efficacy and safety of gemtuzumab ozogamicin in patients with CD 33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19: 3244-3254, 2001.
 
17) Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antobody to CD 20. Blood 84: 435-445, 1994.
 
18) Stashenko P, Nadler LM, Hardy R, et al: Characterization of a human B lymphocyte-specific antigen. J Immunol 125: 1678-1685, 1980.
 
19) Ono N, Sato S, Tedder TF: CD 20 workshop panel report. In Leukocyte Typing VI, (ed by Kishimoto T, et al) , Garland Publishing Inc, New York, 1997, pp135-137.
 
20) Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD 20 monoclonal antibody(IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84: 2457-2466, 1994.
 
21) Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15: 3266-3274, 1997.
PubMed
22) Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997.
PubMed
23) McLaughlin P, Grillo-Lopez, Link BK, et al: Rituximab chimeric anti-CD 20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients responded to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998.
 
24) Tobinai K, Kobayashi Y, Narabayashi M, et al: Feasibility and pharmacokinetic study of a chimeric anti-CD 20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol 9: 527-534, 1998.
 
25) Igarashi T, Kobayashi Y, Ogura M, et al : Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: A Japanese phase II study. Ann Oncol 13: 928-943, 2002.
PubMed
26) Demidem A, Lam T, Alas S, et al: Chimeric anti-CD 20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12: 177-186, 1997.
 
27) Taji H, Kagami Y, Okada Y, et al: Growth inhibition of CD 20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD 20 monoclonal antibody. Jpn J Cancer Res 89: 748-756, 1998.
 
28) Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD 20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268-276, 1999.
 
29) Magni M, Nicola MD, Devizzi L, et al: Successful in vivo purging of CD 34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 96: 864-869, 2000.
 
30) Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD 20 monoclonal antibody) for treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92: 1927-1932, 1998.
PubMed
31) Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002.
PubMed
32) Vose JM, Link BK, Grossbard, et al: Phase II study of rituximab in combination with CHOP chemotherapy in patients withp reviously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19: 389-397, 2001.
 
33) DeNardo GL, DeNardo SJ, Goldstein DS, et al: Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16: 3246-3256, 1998.
 
34) O'Donnell RT, DeNardo GL, Kukis DL, et al: 67 Copper-21 T-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. Clin Cancer Res 10: 3330 s: 3336 s, 1999.
 
35) Parker BA, Vassos AB, Halpers SE, et al: Radioimmunotherapy of human B-cell lymphoma with Y-90-conjugated antiidiotype monoclonal-antibody. Cancer Res 50: S1022-S1028, 1990.
 
36) Vose JM, Wahl RL, Saleh M, et al: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18: 1316-1323, 2000.
 
37) Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD 20+B-cell non-Hodgkin's lymphoma. J Clin Oncol 17: 3793-3803, 1999.
 
38) Czuczman MS, Sraus DJ, Divgi CR, et al: Phase I dose escalation of iodine 131-labelled monoclonal antibody OKB 7 inpatients with non-Hodgkin's lymphoma. J Clin Oncol 11: 2021-2029, 1993.
 
39) Juweid M, Sharkey RM, Markowitz A, et al: Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL 2, an anti-CD 22 monoclonal antibody. Cancer Res 55: 5899 s-5907s, 1995.
PubMed
40) Kaminski MS, Fig LM, Zasadny KR, et al: Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD 37 antibody in B-cell lymphoma. J Clin Oncol 10: 1696-1711, 1992.
 
41) Illidge TM and Johnson PWM: The emerging role of radioimmunotherapy in haematological malignancies. Br J Haematol 108: 679-688, 2000.
 
42) Kaminski MS, Zasadny KR, Francis IR, et al: Radioimmunotherapy of B-cell lymphoma with 1311 anti-B1 (anti-CD 20) antibody. N Engl J Med 329: 459-465, 1993.
 
43) Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-BI radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14: 1974-1981, 1996.
 
44) Kaminski MS, Estes J, Zasadny KR, et al: Radioimmunotherapy with iodine 1311 tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 96: 1259-1266, 2000.
PubMed
45) Horning SJ, Lucas JB, Younes A, et al: Iodine-131 tositumomab for non-Hodgkin's lymphoma patients who progresse dafter treatment with rituximab: Results of a multicenter phase II study. Blood 96: 508a, 2000.
 
46) Knox S, Goris M, Trisler K, et al: Yttrium-90-labeled anti-CD 20 monoclonal antibody therapy of recurrent B-celllymphoma. Clin Cancer Res 2: 457-470, 1996.
 
47) Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients withrituximab-refractory non-Hodgkin's lymphoma. J Clin Oncol 20: 3262-3269, 2002.
PubMed
48) Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17: 1244-1253, 1999.
 
49) Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetanradioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463, 2002.
 
50) Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled antibody therapy of B-cell lymphoma with autologous bonemarrow support. N Engl J Med 329: 1219-1224, 1993.
 
51) Press OW, Eary JF, Appelbaum FR, et al: Phase II trial of 131 I-B1 (anti-CD 20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346: 336-340, 1995.
 
52) Liu SY, Eary JF, Petersdorf SH, et al: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16: 3270-3278, 1998.
PubMed
53) Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER 2 monoclonal antibody in women who have HER 2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
PubMed
54) Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med 344: 783-792, 2001.
 
55) Ozaki S, Kosaka M, Wakatsuki S, et al: Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM 1. 24. Blood 90: 3179-3186, 1997.
 
56) Ozaki S, Kosaka M, Wakahara Y, et al: Humanized anti-HM 1. 24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood 93: 3922-3930, 1999.
 
57) Margolin K, Gordon MS, Holmgren E, et al: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19: 851-856, 2001.
 
58) Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C. 225 alone and in combination with cisplatin. J Clin Oncol 18: 904-914, 2000.
 
59) 山口俊晴: モノクローナル抗体による癌治療. Drug Delivery Syst 17: 29-34, 2002.
 
P.301 掲載の参考文献
1) Saijo N, Tamura T, Yamamoto N, et al: New strategies for cancer therapy in the 21st century. Cancer Chemother Pharmacol 48(suppl) : s102-s106, 2001.
 
2) Kari C, Chan TO, Rocha de Quadros M, et al: Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63: 1-5, 2003.
PubMed
3) Grunwald V and Hidalgo M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95: 851-867, 2003.
PubMed
4) Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20 (suppl) : 1S-13S, 2002.
 
5) Ciardiello F and Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin Cancer Res 7: 2958-2970, 2001.
PubMed
6) Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250, 1999.
PubMed
7) Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380, 2002.
 
8) Shibuya M: Vascular endothelial growth factor receptor family genes: when did the three genes phylogenetically segregate? Biol Chem 383: 1573-1579, 2002.
PubMed
9) Toi M, Matsumoto T and Bando H: Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2: 667-673, 2001.
PubMed
10) Veikkola T, Karkkainen M, Claesson-Welsh L, et al: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60: 203-212, 2000.
PubMed
11) Kurokawa H and Arteaga CL: Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 12 (suppl) : 4436s-4442s, 2001.
 
12) Neve RM, Lane HA and Hynes NE: The role of overexpressed HER 2 in transformation. Ann Oncol 12(suppl 1) : S9-13, 2001.
 
13) Bange J, Zwick E and Ullrich A: Molecular targets for breast cancer therapy and prevention. Nat Med 7: 548-552, 2001.
PubMed
14) Yamauchi H, Stearns V and Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19: 2334-2356, 2001.
 
15) Olayioye MA, Neve RM, Lane HA, et al: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
 
16) Revillion F, Bonneterre J and Peyrat Jp: ERBB 20ncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791-808, 1998.
PubMed
17) Hill CS and Treisman R: Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 180: 199-211, 1995.
 
18) Fontanini G, Vignati S, Bigini D, et al: Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 31 A: 178-183, 1995.
 
19) Mukaida H, Toi M, Hirai T, et al: Clinical significance of the expression of epidermal growth factor and its receptor inesophageal cancer. Cancer 68: 142-148, 1991.
PubMed
20) Neal DE, Marsh C, Bennett MK, et al: Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1 (8425) : 366-368, 1985.
PubMed
21) Sainsbury JR, Farndon JR, Needham GK, et al: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1 (8547) : 1398-1402, 1987.
PubMed
22) Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37 (suppl 4) : S9-S15, 2001.
 
23) Wakeling AE, Guy SP, Woodburn Jr, et al: ZD 1839 (Iressa) : an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754, 2002.
PubMed
24) Baselga J and Averbuch SD: ZD 1839 ('lressa') as an anticancer agent. Drugs 60 (suppl 1) : 33-40, 2000.
 
25) Tortora G, Caputo R, Damiano V, et al: Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antian・giogenic activity. Clin Cancer Res 7: 4156-4163, 2001.
 
26) Ciardiello F, Caputo R, Bianco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells byZD 1839 (Iressa) , aselective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459-1465, 2001.
 
27) Negoro S, Nakagawa K, Fukuoka M, et al: Final results of a Phase I intermittent dose-escalation trial of ZD 1839 ('Iressa') in Japanese patients with various solid tumours. Proc ASCO 20: abstr 1292, 2001.
 
28) Fukuoka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD 1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1) . Proc ASCO 21: abstr 1188, 2002.
 
29) Kris MG, Natale RS, Herbst RS, et al: A phase II trial of ZD 1839 ('Iressa') in advanced non-small-cell lung cancer(NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2) . Proc ASCO 21: abstr 1166, 2002.
 
30) Giaccone G, Johnson DH, Manegold C, et al: A phase III clinical trial of ZD 1839('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer(INTACT 1) . Ann Oncol 13(suppl 5) : abstr 40, 2002.
 
31) Johnson DH, Herbst RS, Giaccone G, et al: ZD 1839 ('Iressa') in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer(NSCLC) : Results from a phase III clinical trial (INTACT 2) . Ann Oncol 13(suppl 5) : abstr 4680, 2002.
 
32) Inoue A, Saijo Y, Maemondo M, et al: Severe acute interstitial pneumonia and gefitinib. Lancet 361 (9352) : 137-139, 2003.
PubMed
33) Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267-3279, 2001.
 
34) Perez-Soler R, Chachoua A, Huberman M, et al: A phase II trial of the epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patient (pts) with advanced, EGFR-expressing, nonsmall cell lung cancer( NSCLC) . Proc ASCO 20: abstr 1235, 2001.
 
35) Shin DM, Donato NJ, Perez-Soler R, et al: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin inpatients with head and neck cancer. Clin Cancer Res 7: 1204-1213, 2001.
 
36) Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C 225alone and in combination with cisplatin. J Clin Oncol 18: 904-914, 2000.
 
37) Saltz L, Rubin M, Hochster H, et al: Cetuximab (IMC-C 225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) . Proc ASCO 20: abstr 7, 2001.
 
38) Robert F, Ezekiel MP, Spencer SA, et al: Phase I study of anti-epidermal growth factor receptor antibody cetuximab incombination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234-3243, 2001.
 
39) Baselga J: New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 18(21 suppl) : 54 S-59 S, 2000.
 
40) Kruh GD, King CR, Kraus MH, et al: A novel human gene closely related to the abl proto-oncogene. Science 234 (4783) : 1545-1548, 1986.
 
41) Yokota J, Yamamoto T, Toyoshima K, et al: Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1 (8484) : 765-767, 1986.
PubMed
42) van de Vijver M, van de Bersselaar R, Devilee P, et al: Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 7: 2019-2023, 1987.
 
43) Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (4905) : 707-712, 1989.
PubMed
44) Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of theHER-2/neu oncogene. Science 235 (4785) : 177-182, 1987.
PubMed
45) McKeage K and Perry CM: Trastuzumab: areview of its use in the treatment of metastatic breast cancer overexpressingHER 2. Drugs 62: 209-243, 2002.
 
46) Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment ofHER 2-overexpressing metastatic breast cancer. J Clin Oncol 20(3) : 719-726, 2002.
 
47) Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER 2monoclonal antibody in women who have HER 2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9) : 2639-2648, 1999.
 
48) Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER 2 for metastaticbreast cancer that overexpresses HER 2. N Engl J Med 344: 783-792, 2001.
 
49) Burstein HJ, Kuter I, Campos SM, et al: Clinical activity of trastuzumab and vinorelbine in women with HER 2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722-2730, 2001.
 
50) Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer withanalysis of efficacy by HER 2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595, 2001.
 
51) Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinanthumanized anti-p 185 HER 2/neu monoclonal antibody plus cisplatin in patients with HER 2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671, 1998.
 
52) Burstein HJ, Harris LN, Gelman R, et al: Preoperative therapy with trastuzumab and paclitaxel followed by sequentialadjuvant doxorubicin/cyclophosphamide for HER 20verexpressing stage II or III breast cancer: apilot study. J Clin Oncol21: 46-53, 2003.
 
53) Leyland-Jones B: Trastuzumab: hopes and realities. Lancet Oncol 3: 137-144, 2002.
PubMed
54) Croom KF and Perry CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 63: 513-522, 2003.
PubMed
55) Savage DG and Antman KH: Imatinib mesylate-a new oral targeted therapy, N Engl J Med 346: 683-693, 2002.
PubMed
56) Deininger MW, O'Brien SG, Ford JM, et al: Practical management of patients with chronic myeloid leukemia receivingimatinib. J Clin Oncol 21: 1637-1647, 2003.
 
57) Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronicmyeloid leukemia. N Engl J Med 344: 1031-1037, 2001.
PubMed
58) Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blastcrisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med344: 1038-1042, 2001.
 
59) Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronicmyelogenous leukemia. N Engl J Med 346: 645-652, 2002.
PubMed
60) Heinrich MC, Griffith DJ, Druker BJ, et al: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selectivetyrosine kinase inhibitor. Blood 96: 925-932, 2000.
PubMed
61) Mauro MJ, O'Dwyer M, Heinrich MC, et al: STI 571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 20: 325-334, 2002.
 
62) Joensuu H, Fletcher C, Dimitrijevic S, et al: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3: 655-664, 2002.
PubMed
63) Heinrich MC, Blanke CD, Druker BJ, et al: Inhibition of KIT tyrosine kinase activity: anovel molecular approach to thetreatment of KIT-positive malignancies. J Clin Oncol 20: 1692-16703, 2002.
 
64) Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998.
PubMed
65) Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI 571 in a patient with ametastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-1056, 2001.
 
66) Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinalstromal tumors. N Engl J Med 347: 472-480, 2002.
 
67) Dagher R, Cohen M, Williams G, et al: Approval summary: imatinib mesylate in the treatment of metastatic and/orunresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8: 3034-3038, 2002.
PubMed
68) Rowinsky EK, Windle JJ and Von Hoff DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17: 3631-3652, 1999.
PubMed
69) Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 49: 4682-4689, 1989.
 
70) Haluska P, Dy GK and Adjei AA: Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer 38: 1685-1700, 2002.
PubMed
71) Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93: 1062-1074, 2001.
PubMed
72) Johnston SR: Farnesyl transferase inhibitors: anovel targeted therapy for cancer. Lancet Oncol 2: 18-26, 2001.
 
73) Rowinsky EK, Windle JJ and Von Hoff DD: Ras protein farnesyltransferase: Astrategic target for anticancer therapeuticdevelopment. J Clin Oncol 17: 3631-3652, 1999.
 
74) Cortes J, Albitar M, Thomas D, et al: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemiaand other hematologic malignancies. Blood 101: 1692-1697, 2003.
PubMed
75) Johnston SR, Hickish T, Ellis P, et al: Phase II study of the farnesyl transferase inhibitor R 115777 in patients withadvanced non-small-cell lung cancer. J Clin Oncol 21: 1760-1766, 2003.
 
76) Cohen SJ, Ho L, Ranganathan S, et al: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 21: 1301-1306, 2003.
PubMed
77) Fidler IJ: Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 87: 1588-1592, 1995.
PubMed
78) Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
PubMed
79) Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
 
80) Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20: 3906-3927, 2002.
PubMed
81) Herbst RS and Fidler IJ: Angiogenesis and lung cancer: potential for therapy. Clin Cancer Res 6: 4604-4606, 2000.
PubMed
82) Karkkainen MJ and Petrova TV: Vascular endothelial growth factor receptors in the regulation of angiogenesis andlymphangiogenesis. Oncogene 19: 5598-5605, 2000.
 
83) Bevacizumab: Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D 3: 28-30, 2002. Review.
PubMed
84) Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) /leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65, 2003.
 
85) Hurwitz H, Fehrenbacher L, Cartwright T, et al: Bevacizumab (a monoclonal antibody to vascular endothelial growthfactor) prolongs survival in first-line colorectal cancer(CRC) : Results of a phase III trial of bevacizumab in combinationwith bolus IFL(irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO22: abstr 3646, 2 003.
 
86) Johnson DH, DeVore R, Kabbinavar F, et al: Carboplatin (C) + Paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc ASCO 20: abstr 1256, 2 001.
 
87) O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression ofmetastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
 
88) O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
 
89) Herbst RS, Mullani NA, Davis DW, et al: Development of biologic markers of response and assessment of antiangiogenicactivity in a clinical trial of human recombinant endostatin. J Clin Oncol 20: 3804-3814, 2002.
 
90) Herbst RS, Hess KR, Tran HT, et al: Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20: 3792-3803, 2002.
PubMed
91) Thomas JP, Arzoomanian RZ, Alberti D, et al: Phase I pharmacokinetic and pharmacodynamic study of recombinanthuman endostatin in patients with advanced solid tumors. J Clin Oncol 21: 223-231, 2003.
PubMed
92) Eder Jp Jr, Supko JG, Clark Jw, et al: Phase I clinical trial of recombinant human endostatin administered as a shortintravenous infusion repeated daily. J Clin Oncol 20: 3772-3784, 2002.
 
93) DeMoraes ED, Fogler WE, Grant D, et al: Recombinant human angiostatin(rhA) : aphase I clinical trial assessing safety, pharmacokinetics(PK) and Pharmacodynamics (PD) . Proc ASCO 20, abstr 10, 2001.
 
94) Nelson AR, Fingleton B, Rothenberg ML, et al: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
PubMed
95) Nagase H and Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 274: 21491-2144, 1999.
PubMed
96) Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-1392, 2002.
PubMed
97) Vihinen P and Kahari VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer99: 157-166, 2002.
 
98) Hidalgo M and Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst93: 178-193, 2001.
 
99) Shepherd FA, Giaccone G, Seymour L, et al: Prospective, randomized, double-blind, placebo-controlled trial of marimastatafter response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Instituteof Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20: 4434-4439, 2002.
 
100) Smylie M, Mercier R, Aboulafia D, et al: Phase III study of the matrix metalloprotease(MMP) inhibitor prinomastat inpatients having advanced non-small cell lung cancer(NSCLC) . Proc ASCO 20: abstr 1226, 2001.
 
101) Carnero A: Targeting the cell cycle for cancer therapy. Br J Cancer 87: 129-133, 2002.
PubMed
102) Senderowicz AM and Sausville EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J NatlCancer Inst 92: 376-387, 2000.
PubMed
103) Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
PubMed
104) Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G 1-phase progression. Genes Dev 13: 1501-1512, 1999.
 
105) Grana X and Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases(CDKs) , growthsuppressor genes and cyclin-dependent kinase inhibitors(CKIs) . Oncogene 11: 211-219, 1995.
 
106) Pardee AB: Multiple molecular levels of cell cycle regulation. J Cell Biochem 54: 375-378, 1994.
PubMed
107) Wang HK: Flavopiridol. National Cancer Institute. Curr Opin Investig Drugs 2: 1149-1155, 2001.
PubMed
108) Carlson BA, Dubay MM, Sausville EA, et al: Flavopiridol induces G 1 arrest with inhibition of cyclin-dependent kinase(CDK) 2and CDK 4 in human breast carcinoma cells. Cancer Res 56: 2973-2978, 1996.
 
109) Kaur G, Stetler-Stevenson M, Sebers S, et al: Growth inhibition with reversible cell cycle arrest of carcinoma cells byflavone L 86-8275. J Natl Cancer Inst 84: 1736-1740, 1992.
 
110) Senderowicz AM, Headlee D, Stinson SF, et al: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependentkinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16: 2986-2999, 1998.
PubMed
111) Schwartz GK, O'Reilly E, Ilson D, et al: Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combinationwith paclitaxel in patients with advanced solid tumors. J Clin Oncol 20: 2157-2170, 2002.
 
112) Kouroukis CT, Belch A, Crump M, et al: Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phaseII study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21: 1740-1745, 2 003.
PubMed
113) Shapiro GI, Supko JG, Patterson A, et al: A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patientswith previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7: 1590-1599, 2001.
 
114) Schwartz GK, Ilson D, Saltz L, et al: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered topatients with advanced gastric carcinoma. J Clin Oncol19: 1985-1992, 2001.
 
115) Stadler WM, Vogelzang NJ, Amato R, et al: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renalcancer: aUniversity of Chicago Phase II Consortium study. J Clin Oncol 18: 371-375, 2000.
 
116) Akinaga S, Sugiyama K and Akiyama T: UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: anewgeneration of anti-cancer agents for the new century?Anticancer Drug Des 15: 43-52, 2000.
PubMed
117) Akiyama T, Yoshida T, Tsujita T, et al: G 1 phase accumulation induced by UCN-01 is associated with dephosphorylationof Rb and CDK 2 proteins as well as induction of CDK inhibitor p 21/Cip 1/WAF 1/Sdi 1 in p 53-mutated human epidermoid carcinoma A 431 cells. Cancer Res 57: 1495-1501, 1997.
 
118) Busby EC, Leistritz DF, Abraham RT, et al: The radiosensitizing agent 7-hydroxystaurosporine(UCN-01) inhibits theDNA damage checkpoint kinase hChk 1. Cancer Res 60: 2108-2112, 2000.
 
119) Fuse E, Tanii H, Kurata N, et al: Unpredicted clinical pharmacology of UCN-01 caused by specific binding to humanalpha 1-acid glycoprotein. Cancer Res 58: 3248-3253, 1998.
 
120) Saijo N, Tamura T and Nishio K: Problems in the development of target-based drugs. Cancer Chemother Pharmacol46(supp1) : 43, 2000.
 
121) Schilsky RL: End points in cancer clinical trials and the drug approval process. Clin Cancer Res 8: 935-938, 2002.
PubMed
122) Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol19: 265-272, 2001.
 
123) Gelmon KA, Eisenhauer EA, Harris AL, et al: Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?JNatl Cancer Inst 91: 1281-1287, 1999.
PubMed
124) Eisenhauer EA: Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The MichelClavel Lecture, held at the 10 th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. Ann Oncol 9: 1047-1052, 1998.
 
P.316 掲載の参考文献
1) Deshirst NW: Angiogenesis and blood flow in solid tumors. In Drug resistance in oncology, (ed by Teicer BA) , Marcel Dekker, New York, 1993, pp3-24.
 
2) 秋山伸一: 新しい薬剤耐性のメカニズムと克服-今後の展望. 実験医学 19: 137-142, 2001.
 
3) Chen C-J, Chin JE, Ueda K, et al: Internal duplication and homology with bacterial transport proteins in the MDR 1 (p-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389, 1986.
 
4) 秋山伸一: ABCトランスポータと多剤耐性および疾病, 分子生物学で病気を織るシリーズ5, チャンネルとトランスポータその働きと病気, (岡田安伸, 清野 進・編) . Medical View, 東京, 1997, pp119-114.
 
5) Ueda K, Okumura N, Tanigawa Y, et al: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone but not progesterone. J Boil Chem 267: 24248-24252, 1992.
 
6) Mizoguchi T, Yamada K, Akiyama S, et al: Expression of the MDR 1 gene in human gastric and colorectal carcinomas. JNatl Cancer Inst 82: 1679-1683, 1990.
 
7) Kuwazuru Y, Hanada S, Akiyama S, et al: Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 76: 2065-2071, 1990.
 
8) Chin K-V, Ueda K, Pastan I, et al: Modulation of the activity of the promoter of the human MI) R 1 gene by Ras and p53. Science 255: 459-462, 1992.
 
9) 河野公俊, 和水弘人, 桑野信彦: 転写因子YB-1の核内局在と癌の薬剤耐性. Cancer Frontier 3: 68-73, 2001.
 
10) Tsuruo T, Iida H, Tsukagoshi S, et al: Overcoming of vincristine resistance in P 388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1957-1972, 1981.
 
11) Cole SPC, Bhardwaj G, Deeley RG, et al: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
 
12) Jedlistchky G, leier I, bucholz U, et al: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56: 988-994, 1996.
 
13) Loe DW, Almquist KC, Deeley RG, et al: Multidrug resistance protein (MRP) -mediated transport of leukotriene C 4 and chemotherapeutic agents in membrane vesicles: demonstration of glutathione-dependent vincristine transport. J Biol Chem 271: 9675-9682, 1996.
PubMed
14) Norris MD, Bordow SB, Haber M, et al: Association between high levels of expression of the multidrug resistance-associated protein(MRP) and poor outcome in primary human neuroblastoma. N Engl J Med 334: 231-2381, 1996.
PubMed
15) Nooter K, Westerman AM, flens MJ, et al: Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1: 1301-1310, 1995.
 
16) Ohno N, Tani A, Chen ZS, et al: Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res 7: 3120-3126, 2001.
PubMed
17) 秋山伸一: 抗癌剤排出ポンプ. 特集: 抗癌剤耐性に関する最近の進歩. 組織培養工学 25(10) : 1999.
 
18) Doyle LA, Yang W, Abruzzo LV, et al: Amultidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670, 1998.
PubMed
19) Rabindran SK, Ross DD, Doyle LA, et al: Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60: 47-50, 2000.
PubMed
20) Scheper RJ, Broxterman HJ, Scheffer GL, et al: Overexpression of a M(r) 110, 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-1479, 1993.
 
21) Scheffer GL, Wijngaard PL, Flens MJ, et al: The drug resistance-related protein LRP is the human major vault protein. Nat Med 1: 578-582, 1995.
 
22) Kickhoefer VA, Stephen AG, Harrington L, et al: Vaults and telomerase share a common subunit, TEP 1. J Biol Chem 274: 32712-32717, 1999.
 
23) Izquierdo MA, Scheffer GL, Flens MJ, et al: Broad distribution of the multidrug resistance-related vault lung resistanceprotein in normal human tissues and tumors. Am J Pathol 148: 877-887, 1996.
PubMed
24) Izquierdo MA, Shoemaker RH, Flens MJ, et al: Overlapping phenotypes of multidrug resistance among panels of humancancer cell lines. Int J Cancer 65: 230-237, 1996.
PubMed
25) Izquierdo MA, van der Zee AG, Vermorken JB, et al: Drug resistance-associated marker Lrp for prediction of responseto chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 87: 1230-1237, 1995.
 
26) List AF, Spier CS, Grogan TM, et al: Overexpression of the major vault transporter protein LRP predicts treatmentoutcome in acute myeloid leukemia. Blood 87: 2464-2469, 1996.
 
27) Izquierdo MA, Shoemaker RH, Flens MJ, et al: Overlapping phenotypes of multidrug resistance among panels of humancancer-cell lines. Int J Cancer 65: 230-237, 1996.
PubMed
28) Rome L, Kedersha N, Chugani D: Unlocking vaults: organelles in search of a function. Trends Cell Biol 1: 47, 1991.
 
29) Moran E, Cleary I, Larkin AM, et al: Co-expression of MDR-associated markers, including P-170, MRP and LRP andcytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW 42. Eur J Cancer 33: 652-660, 1997.
 
30) Kickhoefer VA, Rajavel KS, Scheffer GL, et al: Vaults are up-regulated in multidrug-resistant cancer cell lines. J BiolChem 273: 8971-8974, 1998.
 
31) Akiyama S, Chen ZS, Sumizawa T, et al: Resistance to cisplatin. Anticancer Drug Des 14: 143-151, 1999.
PubMed
32) 和田守正, 藤 賢史, 内海 健・他: ABCトランスポーターと体質性黄疸, 胆内胆汁うっ滞. 最新医学 54: 390-398, 1999.
 
33) Komatsu M, Sumizawa T, Mutoh M, et al: Copper transporting P-type ATPase(ATP 7B) is associated with cisplatinresistance. Cancer Res 60: 1312-1316, 2000.
 
34) 秋山伸一: 抗がん剤のはたらき-課題と展望. 共立出版, 東京, 1991, pp 1-119.
 
35) Pullarkat ST, Stoehlmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response andtoxicity of 5-FU chemotherapy. Pharmacogenomics J 1: 65-70, 2001.
 
36) Yamaguchi K, Arai Y, Kanda Y, et al: Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 92: 337-342, 2001.
PubMed
37) Radparvar S, Houghton PJ and Houghton JA: Effect of polyglutamylation of 5, 10-methylenetetrahydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 38: 335-342, 1989.
PubMed
38) Wang FS, Aschele C, Sobrero A, et al: Decreased folylpolyglutamate synthetase expression: anovel mechanism offluorouracil resistance. Cancer Res 53: 3677-3680, 1993.
 
39) Berger SH, Jenh CH, Johnson LF, et al: Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 28: 461-467, 1985.
PubMed
40) Barbour KW, Berger SH and Berger FG: Single amino acid substitution defines a naturally occurring genetic variant ofhuman thymidylate synthase. Mol Pharmacol 37: 515-518, 1990.
 
41) Chu E, Koeller DM, Casey JL, et al: Autoregulation of human thymidylate synthase messenger RNA translation bythymidylate synthase. Proc Natl Acad Sci USA 88: 8977-8981, 1991.
PubMed
42) Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: apharmacogenetic analysis. Cancer Res 60: 6921-6926, 2000.
PubMed
43) Beck WT and Dalton WS: Mechanisms of drug resistance. In Cancer: Principles&Practice of Oncology, (ed by Devita Jr, Hellman S and Rosenberg SA) , 5th Edition, Lippincott-Raven, Philadelphia, 1997, pp498-512.
 
P.324 掲載の参考文献
1) Cavazzana-Calvo M, Hacein-Bey S, Fischer A, et al: Gene therapy of human severe combined immunodeficiency (SCID) -Xldisease. Science 288: 669-672, 2000.
PubMed
2) Touraine RL, Vahanian N, Ramsey WJ, et al: Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther 9: 2385-2391, 1998.
PubMed
3) Rainov NG: Aphase III clinical evaluation of herpes simplex virus type l thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389-2401, 2000.
 
4) Trask TW, Trask RP, Aguilar-Cordova E, et al: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 1: 195-203, 2000.
 
5) Simons JW, Jaffee EM, Weber CE, et al: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57: 1535-1546, 1997.
 
6) Simons JW, Mikhak B, Chang JF, et al: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony stimu-1ating factor using ex vivo gene transfer. Cancer Res 59: 5160-5168, 1999.
 
7) Abonour R, Williams DA, Einhorn L, et al: Efficient retrovirus-mediated transfer of the multidrug resistance l gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 6: 652-658, 2001.
 
8) Bonini C, Ferrari G, Verzeletti S, et al: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719-1724, 1997.
PubMed
9) Verzeletti S, Bonini C, Marktel S, et al: Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther 9: 2243-2251, 1998.
PubMed
10) Kodaira H, Kume A, Ogasawara Y, et al: Fas and mutant estrogen receptor chimeric gene: anovel suicide vector for tamoxifen-inducible apoptosis. Jpn J Cancer Res 89: 741-747, 1998.
 
11) Khuri FR, Nemunaitis J, Ganly I, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885, 2000.
PubMed
12) Hanenberg H, Xiao XL, Dilloo D, et al: Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 2: 876-882, 1996.
PubMed
13) Naldini L, Blmer U, Gallay P, et al: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267, 1996.
 
14) Miyoshi H, Smith KA, Mosier DE, et al: Transduction of human CD34+cells that mediates long-term engraftment of NOD/SCID mice by HIV vectors. Science 283: 682-686, 1999.
 
15) Nakajima T, Nakamaru K, Ido E, et al: Development of novel simian immunodeficiency virus vectors carrying a dual gene expression system. Hum Gene Ther 11: 1863-1874, 2000.
PubMed
16) Okada T, Ramsey WJ, Munir J, et al: Efficient directional cloning of recombinant adenovirus vectors using DNA-protein complex. Nucleic Acids Res 26: 1947-1950, 1998.
PubMed
17) Mizuguchi H and Kay MA: A simple method for constructing E1-and El/E4 deleted recombinant adenoviral vectors. Hum Gene Ther 10: 2013-2017, 1999.
 
18) Sato M, Suzuki S, Kubo S, et al: Replication and packaging of helper-dependent adenoviral vectors. Gene Ther 9: 472-476, 2002.
PubMed
19) Russell DW and Kay MA: Adeno-associated virus vectors and hematology. Blood 94: 864-874, 1999.
PubMed
20) Nakai H, Storm TA and Kay MA: Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecularjoining of two complementary vectors. Nat Biotechnol 18: 527-532, 2000
PubMed
21) Surosky RT, Urabe M, Godwin SG, et al: Adeno-associated virus Rep proteins target DNA sequences to a unique locusin the human genome. J Virol 71: 7951-7959, 1997.
 
22) Davidson BL, Stein CS, Heth JA, et al: Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variantcell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 97: 3428-3432, 2000.
PubMed
23) Chao H, Liu Y, Rabinowitz J, et al: Several log increase in therapeutic transgene delivery by distinct adeno-associatedviral serotype vectors. Mol Ther 2: 619-623, 2000.
PubMed
24) Rabinowitz JE, Rolling F, Li C, et al: Cross-packaging of a single adeno associated virus (AAV) type 2 vector genome intomultiple AAV serotypes enables transduction with broad specificity. J Virol 76: 791-801, 2002.
PubMed
25) Kuo CJ, Farnebo F, Mulligan RC, et al: Comparative evaluation of the antitumor activity of antiangiogenic proteinsdelivered by gene transfer. Proc Natl Acad Sci USA 98: 4605-4610, 2001.
PubMed
26) Hasumi Y, Mizukami H, Urabe M, et al: Soluble Flt-1 expression suppresses carcinomatous ascites in nude mice bearingovarian cancer. Cancer Res 62: 2019-2023, 2002.
PubMed
27) Saga Y, Mizukami H, Ozawa, M, et al: Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitonealdissemination and extends host survival. Gene Ther 8: 1450-1455, 2001.
 
28) Kanazawa T, Urabe M, Mizukami H et al: γ-Rays enhance rAAV-mediated transgene expression and cytocidal effect ofAAV-HSVtk/ganciclovir on cancer cells. Cancer Gene Ther 8: 99-106, 2001.
 
29) Nakamura T, Sato K and Hamada H: Effective gene transfer to human melanomas via integrin-targeted adenoviralvectors. Hum Gene Ther 13: 613-626, 2002.
PubMed
P.333 掲載の参考文献
1) van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytotoxic T lymphocytes on ahuman melanoma. Science 254: 1643-1647, 1991.
 
2) Sahin U, Tureci O, Schmitt H, et al: Human neoplasm elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92: 11810-11813, 1995.
PubMed
3) Traversari C, van der Bruggen P, Luescher IF, et al: A nonapeptide encoded by human gene MAGE-1 is restricted on334 HLA-A 1 by cytolytic T lymphocytes directed against tumor antigen MZ 2-E. J Exp Med 176: 1453-1457, 1992.
 
4) Guilloux Y, Lucas S, Brichard VG, et al: A peptide recognized by human cytotoxic T lymphocytes on HLA-A 2 melanomais encoded by an intron sequence of the N-acetylglucosaminyl transferase V gene. J Exp Med 183: 1173-1183, 1996.
 
5) Gaugler B, Van den Eynde B, van der Bruggen P, et al: Human gene MAGE-3 codes for an antigen recognized on amelanoma by autologous cytotoxic T lymphocytes. J Exp Med l79: 921-930, 1994.
 
6) Boel P, Wildmann C, Sensi ML, et al: BAGE: A new gene encoding an antigen recognized on human melanoma by cytotoxicTlymphocytes. Immunity 2: 167-175, 1995.
 
7) Van den Eynde B, Peeters O, Backer O, et al: A new family of genes coding for an antigen recognized by autologouscytolitic T lymphocytes on a human melanoma. J Exp Med 182: 689-698, 1995.
PubMed
8) Jager E, Chen YT, Drijfhout JW, et al: Simultaneous humoral and ce11ular immune response against cancer-testis antigenNY-ESO 1-1: Definition of human histocompatibility leukocyte antigen (HLA) -A 2-binding peptide epitope. J Exp Med 187: 265-270, 1998.
 
9) Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognizedby autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91: 3515-3519, 1994.
 
10) Kawakami Y, Eliyahu S, Delgado CH, et al: Identification of a human melanoma antigen recognized by tumor-infiltratinglymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91: 6458-6462, 1994.
PubMed
11) Brichard V, Van Pel A, Wolfel T, et al: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A 2 melanomas. J Exp Med 178: 489-495, 1993.
PubMed
12) Lupetti R, Pisarra P, Verrecchia A, et al: Translation of a retained intron in tyrosinase-related protein(TRP) 2mRNAgenerates a new cytotoxic T lymphocyte (CTL) -defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med 188: 1005-1016, 1998.
 
13) Coulie PG, Brichard V, Van Pel A, et al: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A 2 melanomas. J Exp Med 180: 35-42, 1994.
 
14) Wang RF, Parkhurst MR, Kawakami Y, et al: Utilization of an alternative open reading frame of a normal gene ingenerating a novel human cancer antigen. J Exp Med 183: 1131-1140, 1996.
 
15) Correale P, Walmsley K, Zaremba S, et al: Generation of human cytolytic T lymphocyte lines directed against prostatespecific antigen(PSA) employing a PSA oligoepitope peptide. J Immunol 161: 3186-3194, 1998,
 
16) Peshwa MV, Shi JD, Ruegg C, et al: Induction of prostate tumor-specific CD 8+cytotoxic T-lymphocytes in vitro usingantigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 36: 129-138, 1998.
 
17) Fong L, Ruegg CL, Brockstedt D, et al: Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphataseimmunization: implications for immunotherapy of prostate cancer. J Immunol 159: 3113-3117, 1997.
PubMed
18) Albert ML, Darnell JC, Bender A, et al: Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 4: 1321-1324, 1998.
PubMed
19) Robbins PF, El-Gamil M, Li YF, et al: A mutated beta-catenin gene encodes a melanoma-specific antigen recognized bytumor infiltrating lymphocytes. J Exp Med 183: 1185-1192, 1996.
 
20) Wolfel T, Hauer M, Schneider J, et al: A p161NK 4 a-insensitive CDK 4 mutant targeted by cytolytic T lymphocytes inahuman melanoma. Science 269: 1281-1284, 1995.
 
21) Coulie PG, Lehmann F, Lethe B, et al: A mutated intron sequence codes for an antigenic peptide recognized by cytolyticTlymphocytes on a human melanoma. Proc Natl Acad Sci USA 92: 7976-7980, 1995.
PubMed
22) Brandle D, Brasseur F, Weynants P, et al: Amutated HLA-A 2 molecule recognized by autologous cytotoxic Tlymphocytes on a human renal cell carcinoma. J Exp Med 183: 2501-2508, 1996.
 
23) Mandruzzato S, Brasseur F, Andry G, et al: A CASP-8 mutation recognized by cytolytic T lymphocytes on a human headand neck carcinoma. J Exp Med 186: 785-793, 1996.
 
24) Robbins PF, el-Gamil M, Li YF, et al: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLAA24-restricted tumor-infiltrating lymphocytes. J Immunol 154: 5944-5950, 1995.
 
25) Peoples GE, Goedegebuure PS, Smith R, et al: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize thesame HER 2/neu-derived peptide. Proc Natl Acad Sci USA 92: 432-436, 1995.
 
26) Yoshino I, Goedegebuure PS, Peoples GE, et al: HER 2/neu-derived peptides are shared antigens among human non-smallcell Iung cancer and ovarian cancer. Cancer Res 54: 3387-3390, 1994.
 
27) Ioannides CG, Fisk B, Jerome KR, et al: Cytotoxic T cells from ovarian malignant tumors can recognize polymorphicepithelial mucin core peptides. J Immunol 151: 3693-3703, 1993.
PubMed
28) Dolstra E, Fredrix H, Maas F, et al: A human minor histocompatibility antigen specific for B cell acute lymphoblasticleukemia. J Exp Med 189: 301-308, 1999.
 
29) Trivedi P, Cuomo L, Christensson B, et al: Augmentation of leukocyte infiltration in murine tumors expressing B-cellderived but not nasopharyngeal carcinoma derived EBV membrane protein LMP 1. J Med Virol60: 417-424, 2000.
 
30) de The G and Kazanji M: An HTLV-1/II vaccine: from animal models to clinical trials?JAcquir Immune Defic SyndrHum Retrovirol 13(supple 1) : S191-198, 1996.
 
31) Lehtinen M and Paavonen J: Efficacy of preventive human papilloma virus vaccination. Int J STD AIDS 12: 771-776, 2001.
PubMed
32) Shichijo S, Nakao M, Imai Y, et al: A gene encoding antigenic peptides of human squamous cell carcinoma recognized bycytotoxic T lymphocytes. J Exp Med 187: 277-288, 1998.
PubMed
33) Seki N, Hoshino T, Kikuchi M, et al: HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytesof patients with non-small cell lung cancer. Cell Immunol 175: 101-110, 1997
PubMed
34) Gohara R, Nakao M, Ogata Y, et al: Histocompatibility leukocyte antigen-A 2402-restricted cytotoxic T lymphocytes recognizing adenocarcinomas in tumor-infiltrating lymphocytes of patients with colon cancer. Jpn J Cancer Res 88: 198-204, 1997.
 
35) Hoshino T, Seki N, Kikuchi M, et al: HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int J Cancer 70: 631-638, 1997.
 
36) Kikuchi M, Nakao M, Inoue Y, et al: Identification of a SART-1-derived peptide capable of inducing HLA-A 24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 181: 459-466, 1999.
 
37) Marchand M, Weynants P, Rankin E, et al: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63: 883-885, 1995.
PubMed
38) Marchard M, van Baren N, Weynants O, et al: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A 1. Int J Cancer 80: 219-230, 1999.
 
39) Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998.
PubMed
40) Atkins MB, Kunkel L, Sznol M, et al: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(Suppl 1) : S11-14, 2000.
 
41) Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
PubMed
42) Rosenberg SA, Zhai Y, Yang JC, et al: Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-10r gp 100 melanoma antigens. J Natl Cancer Inst 90: 1894-1900, 1998.
 
43) Soiffer R, Lynch T, Mihm M, et al: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Immunology 95: 13141-13146, 1998.
PubMed
44) Sondak VK, Liu PY, Tuthill RJ, et al: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20: 2058-2066, 2002.
 
45) Harris JE, Ryan L, Hoover HC Jr, et al: Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E 5283. J Clin Oncol 18: 148-157, 2000.
 
46) Fong L, Hou Y, Rivas A, et al: Alterd peptide ligand vaccination with Flit 31igand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 98: 8809-8814, 2001.
 
47) Simons JW, Mikhak B, Chang JF, et al: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocytemacrophage colony-stimu-lating factor using ex vivo gene transfer. Cancer Res 59: 5160-5168, 1999.
 
48) Slovin SF and Scher HI: Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man-clinical trials at Memorial Sloan-Kettering Cancer Center. Semin Oncol 26: 448-454, 1999.
PubMed
49) Tjoa BA, Simmons SJ, Elgamal A, et al: Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40: 125-129, 1999.
PubMed
50) Simmons SJ, Tjoa BA, Rogers M, et al: GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 39: 291-297, 1999.
 
51) Fong L, Brockstedt D, Benike C, et al: Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. JImmunol 167: 7150-7156, 2001.
 
52) Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696, 1995.
PubMed
53) Simons JW, Jaffee EM, Weber CE, et al: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57: 1537-1546, 1997.
PubMed
54) Plautz GE, Bukowski RM, Novick AC, et al: T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology 54: 617-623, 1999.
PubMed
55) Schwaab T, Heaney JA, Schned AR, et al: A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha 2 B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol l63: 1322-1327, 2000.
 
56) Rieser C, Ramoner R, Holtl L, et al: Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int 63: 151-159, 2000.
 
57) Kugler A, Stuhler G, Walden P, et al: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6: 332-336, 2000.
PubMed
58) Simon JW, Jafee EM, Weber CE, et al: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57: 1537-1546, 1997.
 
59) Witjes WP, Konig M, Boeminghaus FP, et al: Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-native patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol 36: 576-581, 1999.
 
60) Grant SC, Kris MG, Houghton AN, et al: Long survival of patients with small cell lung cancer after adluvant treatment with the anti-idiotypic antibody BEC 2 plus Bacillus Calmette-Guerin. Clin Cancer Res 5: 1319-1323, 1999.
 
61) van Driel WJ, Ressing ME, Kenter GG, et al: Vaccination with HPV 16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35: 946-952, 1999.
 
62) Tsunoda T, Tanimura H, Yamaue H, et al: Tumor specific CTL therapy for advanced cancer and development for cancer vaccine. Hepatogastroenterology 46 (Suppl 1) : 1287-1292, 1999.
 
63) Yang D, Nakao M, Shichijo S, et al: Identification of gene coding for a protein possessing shared tumor epitopes capableof inducing HLA-A 24-restricted cytotoxic T Iymphocytes in cancer patients. Cancer Res 59: 4056-4063, 1999.
 
64) Gomi S, Nakao M, Niiya F, et al: A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A 24-restricted andtumor-specific CTLs. J Immunol 163: 4994-5004, 1999.
 
65) Nakao M, Shichijo S, Imaizumi T, et al: Identification of a gene coding for a new squamous cell carcinoma antigenrecognized by the CTL. J Immunol 164: 2565-2574, 2000.
PubMed
66) Harashima N, Tanaka K, Sasatomi T, et al: Recognition of the lck tyrosine kinase as a tumor antigen by cytotoxic Tlymphocytes of cancer patients with distant metastasis. Eur J Immunol 31: 323-332, 2001.
 
67) Hida N, Maeda Y, Katagiri K, et al: A simple culture protocol to detect peptide-specific cytotoxic T lymphocyteprecursors in the circulation. Cancer Immunol Immunother 51: 219-228, 2002.
PubMed
68) Zamai L, Ahmad M, Bennett IM, et al: Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fasligand by immature and mature primary human NK cells. J Exp Med 188: 2375-2380, 1998.
 
69) Toh U, Yamana H, Sueyoshi S, et al: Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 6: 4663-4673, 2000.
PubMed
P.343 掲載の参考文献
1) 日本内視鏡外科学会: 内視鏡外科手術に関するアンケート調査-第5回集計結果報告-. 日鏡外会誌 5: 569-647, 2000.
 
2) Ohgami M, Otani Y, Kumai K, et al: Curative laparoscopic surgery for early gastric cancer: Five year experience. W J Surg 23: 187-193, 1999.
 
3) 渡邊昌彦, 大上正裕, 寺本龍生・他: 早期大腸癌に対する縮小手術の理論と実際. 腹腔鏡下大腸切除術. 臨外 51: 647-652, 1996.
 
4) Bouvet M, Mansfield PF, Skibber JM, et al: Clinical, pathologic and economic parameters of laparoscopic colon resection for cancer. Am J Surg 176: 554-558, 1998.
PubMed
5) Poulin EC, Mamazza J, Schlachta CM, et al: Laparoscopic resection does not adversely affect early survival curves in patients undergoing surgery for colorectal adenocarcinoma. Ann Surg 229: 487-492, 1999.
 
6) Milsom JW, Bohm B, Hammerhofer KA, et al: A prospective randomized trial comparing laparoscopic versus conventional techniques in colorectal cancer surgery: apreliminary report. J Am Coll Surg 187: 46-54, 1998.
 
7) Adachi Y, Suematsu T, Shiraishi N, et al: Quality of life after laparoscopy-assisted Billroth 1 gastrectomy. Ann Surg 229: 49-54, 1999.
PubMed
8) Shiraishi N, Adachi Y, Kitano S, et al: Indication for and outcome of laparoscopy-assisted Billroth I gastrectomy. Br J Surg 229: 541-544, 1999.
 
9) Kitagawa Y, Kubota T, Ando N, et al: The role of the sentinel lymph node in gastrointestinal cancer. Surg Clin North Am80: 1799-1809, 2000.
 
10) 阪 眞, 笹子三都留, 佐野 武・他: 早期胃癌の治療法の変遷. 胃と腸 36: 1633-1638, 2 001.
 
11) 日本胃癌学会・編: 胃癌治療ガイドライン 医師用. 2001年3月版, 金原出版, 東京, 2001.
 
12) Gotoda T, Yanagisawa A, Sasako M, et al: Incidence of lymph node metastasis from early gastric cancer. The estimationusing a large number of cases in two large centers. Gastric Cancer 3: 219-225, 2000.
PubMed
13) 古川俊治, 大谷吉秀, 吉田 昌・他: 早期胃癌の腹腔鏡下切除の適応基準. 胃と腸 36: 1639-1645, 2001.
 
14) Uyama I, Sugioka A, Fujita J, et al: Completely laparoscopic proximal gastrectomy with jejunal interposition andlymphadenectomy. J Am Coll Surg 191: 114-119, 2000.
PubMed
15) 日本内視鏡外科学会: 内視鏡下外科手術施行にあたってのガイドライン. 日鏡外会誌 1: 290, 1996.
 
16) Kavoussi LR, Moore RG, Adams JB, et al: Comparison of robotic versus human laparoscopic camera control. J Urol154: 2134-2136, 1995.
PubMed
17) Okada S, Tanaba Y, Yamauchi H, et al: Single-surgeon thoracoscopic surgery with a voice-controlled robot. Lancet 351: 1249, 1998.
PubMed
18) 西原俊作, 菅野伸彦, 西井 孝・他: ROBODOCシステムを用いた大腿骨掘削の精度評価. 日本コンピュータ外会誌 8: 30, 2000.
 
19) Chitwood WR: Endoscopic robotic coronary surgery-is this reality or fantasy? J Thorac Cardiovasc Surg 118: 1-3, 1999.
 
20) Reichenspurner H, Damiano RJ, Mack M, et al: Use of the voice-controlled and computer-assisted surgical system ZEUSfor endoscopic coronary artery bypass grafting. J Thorac Cardiovasc Surg 118: 11-16, 1999.
PubMed
21) Carpentier A, Loulmet D, Aupecle B, et al: Computer-assisted cardiac surgery. Lancet 353: 379-380, 1999.
PubMed
22) Shennib H, Bastawisy A, Mack MJ, et al: Computer-assisted telemanipulation: an enabling technology for endoscopiccoronary artery bypass. Ann Thorac Surg 66: 1060-1063, 1998.
PubMed
23) 古川俊治, 小澤壯治, 北島政樹: Robotic Surgery-胃食道逆流性疾患・食道アカラシアに対する腹腔鏡下手術-. 臨外 55: 1213-1218, 2000.
 
24) 古川俊治, 若林 剛, 小澤壯治・他: Robotic Surgery-腹腔鏡下胆嚢摘出術・腹腔鏡下ソケイヘルニア根治術-. 臨外 55: 1361-1366, 2000.
 
25) Abbou CC, Hoznek A, Salomon L, et al: Laparoscopic radical prostatectomy with a remote controlled robot. J Urol 165: 1964-1966, 2001.
PubMed
26) Furukawa T, Morikawa Y, Ozawa S, et al: The revolution of computer-aided surgery-the dawn of robotic surgery. MinInvas Ther Allied Technol 10: 283-288, 2001.
 
27) Ogata H, Furukawa T, Nakajima T, et al: Microvascular anastomosis with master-slave type surgical manipulator. J Reconstr Microsurg (in press)
 
28) 伊関 洋, 堀 智勝: 医療情報の可視化と医用三次元画像. 医学のあゆみ 195: 1020-1022, 2000.
Medical*Online
29) Iddan G, Meron G, Glukhovsky A, et al: Wireless capsule endoscopy. Nature 405: 417, 2000.
PubMed
30) Marescaux J, Leroy J, Gagner M, et al: Transatlantic robot-assisted telesurgery. Nature 413: 379-380, 2001.
PubMed
P.354 掲載の参考文献
1) Urtasun RC: Does improved depth dose characteristics and treatment planning correlate with a gain in therapeutic results. Int J Radiat Oncol Biol Phys 22: 235-239, 1991.
 
2) Suit HD and Westgate SJ: mpact of improved local control on survival. Int J Radiat Oncol Biol Phys 12: 453-458, 1986.
 
3) Leibel SA, Ling CC, Kutcher GJ, et al: The biological basis for conformal three dimentional radiation therapy. Int J RadiatOncol Biol Phys 21: 805-811, 1991.
 
4) Conquest of Cancer, Report of the National Panel of Consultants of the Committee on Labor and Public Welfare UnitedStates Senate, November 1970, p51.
 
5) 辻井博彦: 線量集中照射法の可能性について. 癌の臨床 43: 215-220, 1997.
Medical*Online
6) Chen GTY, Castro JR and Quivey JM: Heavy charged particle radiotherapy. Ann Rev Biophys Bioeng 10: 499-529, 1981.
 
7) Raju MR: Heavy Particle Radiotherapy. Academic Press, New York, 1980.
 
8) Larsson B: The new radiations in cancer therapy. Hadrontherapy in Oncology, (ed by Amaldi U and Larsson B) , Elsevier Science BV, Amsterdam, 1994, pp33-44.
 
9) Amaldi U: he Italian hadrontherapy project, (ed by Amaldi U and Larsson B) , Elsevier Science BV, Amsterdam, 1994, pp45-58.
 
10) Petti PL and Lennox AJ: Hadronic radiotherapy. Ann Rev Nucl Part Sci 44: 155-197, 1994.
 
11) Kogeinik HD: Hadrontherapy-do we need it? Advances in Hadrontherapy, (ed by Amaldi U, Larsson B and Lemoigne Y) , Elsevier Science BV, Austria, 1997, pp12-28.
 
12) Withers HR, Taylor JM and Maciejewski B: Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys 14: 751-759, 1988.
PubMed
13) Kraft G: TumorTherapy with Heavy Charged Particles. Prog Part Nucl Phys 45: 473-544, 2000.
 
14) Leith JT: Heavy-ion radiobiology: Normal tissue studies. Adv Radiol Biol 10: 191-236, 1983.
 
15) Hall E: New radiation modalities, Radiobiology for the Radiologist, (ed by Hall EJ) , 4th ed, JB Lippincott Co, Philadelphia, 1994, pp231-244.
 
16) Suit HD and Goitein M: Rationale for use of carged-particle and fast neutron beams in radiation therapy. In RadiationBiology in Cancer Res, (ed by Meyn RE) , Raven Press, New York, 1980, pp547-565.
 
17) Chapman JD, Blakely EA, Smith KC, et al: Radiobiological characterization of the inactivating events produced in mammalian cells by helium and heavy ions. Int J Radiat Oncol Biol Phys 3: 97-102, 1977.
PubMed
18) Field SB, Hornsey S and Kutsutani Y: Effects of fractionated irradiation on mouse lung and a phenomenon of slow repair. Br J Radiol 49: 700-707, 1976.
 
19) Wambersie A: Is there any future for high-LET radiation? Strahlenther Oncol 165: 348-356, 1989.
 
20) Griffin TW: Fast neutron radiation therapy. Crit Rev Oncol/Hematol13: 17-31, 1992.
PubMed
21) Laramore GE: The use of neutrons in cancer therapy: Ahistorical perspective through the modern era. Semin Oncol 24: 672-685, 1997.
 
22) Lillis-Hearne PK and Castro JR: Indications for heavy ions-Lesson from Berkeley. Ion Beams in Tumor Therapy, (ed byLinz U) , Chapman & Hall, London, 1995, pp133-141.
 
23) Linstadt DE, Castro JR, phillips TL: Neon ion radiotherapy: results of the phase I/II clinical trial. Int J Radiat Oncol Biol Phys 20: 761-769, 1991.
PubMed
24) Castro JR: Future research strategy for heavy ion radiotherapy. Progress in Radio-Oncology, (ed by Kogeinik HD) , Monduzzi Editore, Italy, 1995, pp643-648.
 
25) Tobias JS: Clinical practice of radiotherapy. Lancet 339: 159-163, 1992.
PubMed
26) Parsons JT, Mccarty PJ, Rao PV, et al: on the definition of local control. Int J Radiat Oncol Biol Phys 18: 705-706, 1990.
PubMed
27) Fagundes H, Perez GA, Grigsby PW, et al: Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 24: 197-204, 1992.
 
28) Fuks SA, Leibel K, Waliner, et al: The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 1251 implantation. Int J Radiat Oncol Biol Phys 21: 537-547, 1991.
 
29) Merino OR, Lindberg RD and Fletcher GH: An analysis of distant metastases from squamous cell carcinoma of the upperrespiratory and digestive tracts. Cancer 40: 145-151, 1977.
 
30) Bryant Ph, Kogeinik HD, Pavlovic M, et al: Ion cancer therapy research as part of the AUSTRON project. Hadrontherapyin Oncology, (ed by Amaldi U and Larsson B) , Elsevier Sciences BV, Netherlands, 1994, pp390-399.
 
31) Slater JM, Miller DN, Archambeau JO, et al: Development of a hospital-based proton beam treatment center. Int J RadiatOncol Biol Phys 14: 761-775, 1988.
 
32) Goitein M: Application of computed tomography in radiotherapy treatment planning. In Progress in Medical RadiationPhysics, (ed by Orton CG) , Plenum Pub Co, 1982, pp195-293.
 
33) Endo M, Ito H, Minohara S, et al: HIPLAN-A heavy ion treatment planning system at HIMAC. J Jpn Soc Ther Radiol Oncol 8: 231-238, 1996.
 
34) Boone ML, Lawrence JH, Connor WG, et al: Introduction to the use of protons and heavy ions in radiation therapy: Historical Perspective. Int J Radiat Oncol Biol Phys 3: 65-69, 1977.
 
35) Wilson RR: Radiological use of fast protons. Radiology 47: 487-491, 1946.
PubMed
36) Sisterson J: Worldwide charged particle patient totals. Particles Number 29: 15, 2002.
 
37) Suit HD and Urie M: Proton beams in radiation therapy. JNCI 84: 155-159, 1992.
 
38) Peters LJ, Fischer JJ, Fuks Z, et al: Proton beam therapy: Rationale, current status, future prospects and economicimplications. A report of the NCAB by a select panel appointed by the Board of Scientific Counsellors, Division of Cancer Treatment, 1992.
 
39) Tsujii H, Tsuji H, Inada T, et al: Clinical results of fractionated proton therapy at Tsukuba. Int J Radiat Oncol Biol Phys25: 49-60, 1993.
 
40) Castro JR, Chen GTY and Blakely EA: Current consideration in charged-particle radiotherapy. Radiat Rev 104: S263-S271, 1985.
 
41) Dennekamp J: Neutron radiobiology revised. Acta Oncol 3: 233-240, 1994.
 
42) Tsujii H, Morita S, Miyamoto T, et al: Experiences of carbon ion radiotherapy at NIRS. Prog Radio-Oncol VII: 393-405, 2002.
 
43) Tsujii H, Morita S, Miyamoto T, et al: Preliminary results of Phase I/II carbon-ion therapy. J Brachyther Int 13: 1-8, 1997
 
P.362 掲載の参考文献
1) 黒澤 進, 中村孝司: 内視鏡治療 消化器. 臨床腫瘍学, (日本臨床腫瘍研究会・編) , 第2版, 癌と化学療法社, 東京, 1999, pp856-867.
 
2) 多田正弘, 村田 誠, 村上不二夫・他: Strip-off biopsyの開発. Gastroenterol Endosc 26: 833-839, 1984.
 
3) 平尾雅紀, 小林多加志, 長谷良志男・他: 胃の腫瘍性病変に対する内視鏡的切除法. Gastroenterol Endosc 25: 194-195, 1983.
 
4) 細川浩一, 吉田茂昭: 早期胃癌の内視鏡的粘膜切除術. 癌と化学療法 25(4) : 476-483, 1998.
Medical*Online
5) 小野裕之, 後藤田卓志, 近藤 仁・他: ITナイフを用いたEMR-適応拡大の工夫-. 消内視鏡 11(5) 675-681, 1999.
 
6) Yokoyama A, Ohmori T, Muramatsu T, et al: Cancer screening of upper aerodigestive tract in Japanese alcoholics with reference to drinking and smoking habits and aldehyde dehydrogenase-2 genotype. Int J Cancer 68(3) : 313-316, 1996.
PubMed
7) 幕内博康: 食道粘膜癌に対する内視鏡の治療の適応と限界. 日消外会誌 24: 2599-2603, 1991.
 
8) 大倉康男, 西澤 護, 細井薫三: 食道粘膜癌の病型分類と深達度. 胃と腸 29: 263-271, 1994.
 
9) Kodama M and Kakegawa T: Treatment of superficial cancer of the esophagus: Asummary of responces to a questionnaire on superficial cancer of the esophagus in Japan. Surgery 123: 432-439, 1988.
 
10) Ohtsu A, Boku N, Muro K, et al: Definitive chemoradiotherapy for T 4 and/or M l lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17(9) : 2915-2921, 1999.
 
11) 室 圭, 新井達広, 濱中久尚: 食道sm2/sm3癌に対する放射線・化学療法の治療成績. 胃と腸 37: 1305-1314, 2002.
 
12) 門馬久美子, 吉田 操, 山田義也・他: 早期食道癌に対する内視鏡的粘膜切除術の実際. 胃と腸 28: 141-151, 1993.
 
13) 幕内博康, 町村貴郎, 水谷郷一・他: 早期食道癌に対する内視鏡的粘膜切除術-EEMR-tube法の実際. 胃と腸 28: 153-159, 1993.
 
14) 井上晴洋, 遠藤光夫, 竹下公矢・他: 透明プラスチックキャップを用いた内視鏡的食道粘膜切除術(EMRC) . Gastroenterol En-dosc 34: 2378-2390, 1992.
 
15) 小山恒男, 菊池勇一, 宮田佳典・他: 食道癌に対するEMRの選択方法; 新しいEMR手技-Hooking EMR methodの有用性. 臨消内科 16: 1609-1615, 2001.
 
16) 日本胃癌学会編: 胃癌治療ガイドライン(医師用) . 金原出版, 東京, 2001, p8.
 
17) 後藤田卓志, 小野裕之, 近藤 仁・他: 胃癌EMRの一括切除による治癒切除の判定基準. 胃と腸 33: 1567-1572, 1998.
 
18) 小野裕之, 吉田茂昭: 内視鏡からみた深達度診断. 胃と腸 36: 334, 2001.
 
19) 長南明道, 望月福治, 池田 卓・他: 早期胃癌治療のための精密検査-深達度を読む. 胃と腸28: 57, 1993.
 
20) Gotoda T, Sasako M, Yanagisawa A, et al: Incidence of lymph node metastasis from early gastric cancer-estimation with a large number of cases at two large centers. Gastric Cancer 3: 219, 2000.
 
21) 加藤真子, 矢作直久, 藤城光弘・他: 細径スネアとICC 200を用いたexfoliative EMRにて一括切除しえたハウストラ上の径40mmLSTの一例. 消内視鏡の進歩 61: 73, 2002.
 
22) Yamamoto H, Sekine Y, Higashizawa T, et al: Successful en bloc resection of a large superficial gastric cancer by using sodium hyaluronate and electrocautery incision forceps. Gastrointest Endosc 54: 629-632, 2001.
PubMed
23) 日本消化器内視鏡学会偶発症対策委員会 金子榮藏, 原田英雄, 春日井達造・他: 消化器内視鏡関連の偶発性に関する第3回全国調査報告-1993年より1997年までの5年間. Gastroenterol Endosc 42(3) : 308-313, 2000.
 
24) 小野裕之: 胃・十二指腸疾患に対するEMR施行時の穿孔の治療. 消内視鏡 14: 187-192, 2002.
 
25) Morson B C and Dawson I M P: The polyp-cancer sequence. Gastrointestinal Pathology. Blackwell Scientific, London, 1972, pp542-547.
 
26) 鶴田 修, 豊永 純, 重松聡松・他: 大腸微小腫瘍性病変の内視鏡診断とその取り扱い. 胃と腸 30: 1499-1506, 1995.
 
27) 工藤i進英, 林 俊一, 三浦宏二・他: 平坦・陥凹型早期大腸癌の内視鏡診断と治療. 胃と腸 24: 317-329, 1989.
 
28) Kudo S: Early colorectal cancer: detection of depressed types of colorectal carcinoma. Igakushoin Ltd, Tokyo, New York, 1996.
 
29) 工藤進英, 藤井隆広, 日下尚志・他: 大腸の内視鏡的粘膜切除法. 治療 73: 73-80, 1991.
Medical*Online
30) Nivatvongs S, Snover DC and Fang DT: Piecemeal snare excision of large sessile colon and rectal polyps: Is it adequate? Gastrointest Endosc 30: 18-20, 1984.
 
31) 五十嵐正広, 横山 薫, 高橋裕之・他: 粘膜摘除(EMR) 例における局所遺残の検討. 早期大腸癌 6: 639-645, 1998.
 
32) 田中信治, 春日 賢, 永田信二・他: リンパ節転移からみた早期大腸癌EMRの適応と限界. 早期大腸癌 6: 655-662, 1998.
 
33) 日本内視鏡外科学会学術委員会: 内視鏡外科手術に関するアンケート調査-第6回集計結果報告. 日鏡外会誌 7(5) : 479-567, 2002.
 
34) 北野正剛, 板東登志雄, 吉田隆典・他: Lapaloscopic Surgery Today Advanced Surgery への応用 Laparoscopy Assisted Surgery (LAS) の有効性. 消化器内視鏡 6: 1301-1310, 1994.
 
35) Antonio M Lacy, Juan C Garcia Valdecasas, Salvadora D, et al: Laparoscopy-assisted colectomy versus open colectomy for treatment non-metastatic colon cancer: arandomized trial. Lancet 359: 29, 2002.
 
36) Nagai N, Toli F, Oi I, et al: Continuous endoscopic pancreatocholedochal catheterization. Gastrointest Endosc 23: 78-81, 1976.
PubMed
37) Soehendra N and Reynders-Frederix V: Palliative biliary duct drainage. A new method for endoscopic introduction of a new drain. Dtsch Med Wochenschr 104: 206-207, 1979.
PubMed
38) 齋藤博哉, 真口宏介: PTCS所見からみたEMS再閉塞の機序. 消化器診療プラクティス(11) 肝・胆・膵疾患の内視鏡治療の実際, (木村 健・編) , 第1版, 文光堂, 東京, 1995, pp 85-89.
 
39) 後藤昌弘, 室 圭, 山田康秀・他: 放射線化学療法後の進行食道癌に対するExpandable Metalic Stentの問題点. 日癌治療会誌34: 434, 1999.
 
40) Wiersema MJ and Wiersema LM: Endosonography-guided celiac plexus neurolysis. Gastrointest Endosc 44: 656-662, 1996.
PubMed
P.368 掲載の参考文献
1) Kriegmair M, Baumgartner R, Lumper W, et al: Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol 77: 667-671, 1996.
PubMed
2) Barr H, Shepherd NA, Dix A, et al: Eradication of high-grade dysplasia in columner-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 348: 584-585, 1996.
 
3) Ruck A, Beck G, Bachor R. et al: Dynamic fluorescence changes during photodynamic therapy in vivo and in vitro of hydrophilic Al(III) phthalocyanine tetrasulphonate and lipophilic Zn (II) phthalocyanine administered in liposomes. J Photochem Photobiol B 36: 127-133, 1996.
 
4) Katsumi T, Aizawa K, Kuroiwa Y, et al: Photodynamic therapy with a diode laser for implanted fibrosarcoma in mice employing mono-L-aspertyl chlorin e 6. Photochem Photobiol 64: 671-675, 1996.
 
5) Mori M, Sakata I, Hirano T, et al: Photodynamic therapy for experimental tumors using ATX-SIO (Na) , ahydrophilic chlorin photosensitizer, and diode laser. Jpn J Cancer Res 91: 753-759, 2000.
 
6) Schmidt-Erfurth U, Flotte TJ, Gragoudas ES, et al: Benzoporphyrin-lipoprotein-mediated photodestruction of intraocular tumors. Exp Eye Res 62: 1-10, 1996.
PubMed
7) Husain D, Miller JW, Michaud N, et al : Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 114: 978-985, 1996.
PubMed
8) Steiner RA, Tadir Y, Tromberg B, et al: Benzoporphyrin derivative mono acid for photodynamic therapy of the en- dometrium. Geburtshilfe Frauenheilk 56: 1-7, 1996.
 
9) Pandy RK, Sumlin AB, Constantine S, et al: Alkyl ether analogs of chlorophyll-a derivatives: Part 1. Synthesis, photo- physical properties and photodynamic efficacy. Photochem Photobiol 64: 194-204, 1996.
 
10) Payne JT, McCaw DL, Casteel SW, et al: Pharmacokinetics of pyropheophorbide-a-hexyl ether in the dog. Lasers Surg Med 18: 406-409, 1996.
PubMed
11) Orenstein A, Kostenich G, Roitman L, et al: A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e 6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model. Br J Cancer 73: 937-944, 1996.
 
12) Okunaka T, Kato H, Konaka C, et al: A comparison between argon-dye and excimer-dye laser for photodynamic effect in transplanted mouse tumor. Jpn J Cancer Res 83: 226-231, 1992.
PubMed
13) Katsumi T, Aizawa K, Okunaka T, et al: Photodynamic therapy using a diode laser with mono-L-aspartyl chlorin e 6 for implanted fibrosarcoma in mice. Jpn J Cancer Res 85: 1165-1170, 1994.
 
14) Gomer CJ, Ryter SW, Ferrario A, et al: Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res 56: 2355-2360, 1996.
PubMed
15) Kick G, Messer G, Plewig G, et al : Strong and prolonged induction of c-jun and c-fos proto-oncogenes by photodynamic therapy. Br J Cancer 74: 30-36, 1996.
 
16) Tao J, Sangehera JS, Pelech SL, et al: Stimulation of stress-activated protein kinase and p38 H0 G1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative. J Biol Chem 271: 27107-27115, 1996.
 
17) Chan WS, Brasseur N, La Madeleine C, et al: Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulfonated alminum phthalocyanine or photofrin: tumor cell survival and blood flow. Anticancer Res 16: 1887-1892, 1996.
PubMed
18) Webber J, Luo Y, Crilly R, et al: An apoptotic responce to photodynamic therapy with endogenous protoporphyrin in vivo. JPhotochem Photobiol B 35: 209-211, 1996.
 
19) Luo Y, Chang CK and Kessel D: Rapid initiation of apoptosis by photodynamic therapy. Photochem Photobiol63: 528-534, 1996.
PubMed
20) Korbelik M, Krosl G, Krosl J, et al: The role of host lymphoid populations in the response of mouse EMT 6 tumor tophotodynamic therapy. Cancer Res 56: 5647-5652, 1996.
 
21) Okunaka T and Kato H: Photodynamic therapy for lung cancer: State of the art and expanded indications. Nippon Geka Gakkai Zasshi 103: 258-262, 2002.
PubMed
22) Shimao H and Hiki Y: Photodynamic therapy for esophageal cancer. Gan To Kagaku Ryoho 23(1) : 36-40, 1996.
PubMed
23) Mimura S, Ito Y, Nagayo T, et al: Cooperatve clinical trial of photodynamic therapy with Photofrin II and excimer dyelaser for early gastric cancer. Lasers Surg Med 19: 168-172, 1996.
 
24) Muroya T, Suehiro Y, Umayahara K, et al: Photodynamic therapy (PDT) for early cervical cancer. Gan To Kagaku Ryoho 23(1) : 47-56, 1996.
PubMed
25) Wilson BD, Mang TS, Cooper M, et al: Use of photodynamic therapy for the treatment of extensive basal cell carcinomas. Facial Plastic Surg 6: 185-189, 1989.
 
26) Cairnduff F, Stringer MR, Hudson EJ, et al: Superficial photodynamic therapy with topical 5-aminolaevulinic acid forsuperficial primary and secondary skin cancer. Br J Cancer 69: 605-608, 1994.
PubMed
27) 金子貞男, 松本亮二, 小濱好彦: 悪性腫瘍患者に対する光線力学療法の治療成績. 第15回日本レーザー医学会大会 45-48, 1994.
 
28) Konaka C, Usuda J and Kato H: Preoperative photodynamic therapy for lung cancer. Nippon Geka Gakkai Zasshi 101: 486-489, 2000.
PubMed
29) Chang SC, Buonaccorsi GA, MacRobert AJ, et al: Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX. Prostate 32: 89-98, 1997.
PubMed
30) Fielding DI, Buonaccorsi GA, MacRobert AJ, et al: Fine-needle interstitial photodynamic therapy of the lung parenchyma: photosensitizer distribution and morphologic effects of treatment. Chest 115: 502-510, 1999.
PubMed
P.388 掲載の参考文献
1) ヘルシンキ宣言-ヒトを対象とする医学研究の倫理的原則: 日本医師会ホームページhttp://www. med. or. jp/wma/helsin-ki00_j. html
 
2) デイヴィッド・ロスマン: 医療倫理の夜明け, (酒井忠昭・監訳) , 晶文社, 東京, 2000, p16.
 
3) 津谷喜一郎, 光石忠敬, 栗原千絵子・訳: ベルモント・レポート. 臨床評価 28(3) : 559-568, 2001. (原本はhttp://ohrp. osophs. dhhs. gov/humansubjects/guidance/belmont. htm)
 
4) 佐藤俊哉: 20世紀の臨床試験で統計家はなにをしてきたか, 21世紀の臨床試験で生物統計家はなにをすべきか. 臨床研究・生物統計研誌 22(1) : 61-69, 2002.
 
5) 砂原茂一: 無作為化試験(RCT) の歴史. 臨床医学研究序説, 医学書院, 東京, 1988, pp78-87.
 
6) Green S, Benedettei J and Crowley J: Introduction. Clinical trials in oncology, Chapman&Hall, London, 1997, pp1-8.
 
7) Clinical Trials Cooperative Group Program: http://ctep. cancer. gov/resources/coop2. html
 
8) About EORTC: http://www. eortc. be/
 
9) Shimoyama M, Fukuda H, Saijo N, et al: Japan Clinical Oncology Group(JCOG) : Jpn J Clin Oncol 28(3) : 158-162, 1998.
PubMed
10) Description of the Cancer Centers Program: http://www3. cancer. gov/cancercenters/description. html
 
11) 砂原茂一: 人間研究倫理の発展. 臨床医学研究序説, 医学書院, 東京, 1988, pp137-145.
 
12) The European Parliament and the Council of the European Union: Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medical products forhuman use. Official Journal of the European Communities 2001; L121/34-L 121/44. (http://www. eortc. be/のDocuments-European directive for the implementation of GCPよりダウンロード可
 
13) Protection of Human Subjects: Code of federal regulations, title 45, public welfare department of health and human services, national institutes of health, office for protection from research risks, part 46: http://ohrp. osophs. dhhs. gov/humansubjects/guidance/45cfr46. htm
 
14) 医薬品の臨床試験の実施の基準に関する省令: http://www. nihs. go. jp/dig/ich/efficacy/e6/e6. html
 
15) Human Participant Protections Education for Research Teams: http://cme. nci. nih. gov/
 
16) Office of Public Health and Sciences, and National Institute of Health, Office of the Director: Statement of Organization, Functions, and Delegations of Authority. Federal Register 2000; 65(114) : 37136-37137 (http://ohrp. osophs. dhhs. gov/)
 
17) The NIH AImanac-appropriations: http://www. nih. gov/about/almanac/appropriations/index. htm
 
18) NCI Organizational Structure: http://www. nci. nih. gov/about_nci/organization/
 
19) Division of Cancer Treatment and Diagnosis (DCTD) : http://www3. cancer. gov/dctd/
 
20) The Investigator's Handbook: http://ctep. cancer. gov/handbook/index. html
 
21) Cancer Therapy Evaluation Program: http://ctep. cancer. gov/
PubMed
22) ICHガイドラインと関連情報: http://www. nihs. go. jp/dig/ich/ichindex. htm
 
23) Disqualified/Restricted/Assurances Lists for Clinical Investigators: http://www. fda. gov/ora/compliance_ref/bimo/dis_resassur. htm
 
24) 佐藤恵子: 人体実験から臨床試験へ. これからの臨床試験, (椿 広計, 藤田利治, 佐藤俊哉・編) , 朝倉書店, 東京, 1999, pp 35-52.
 
25) Van Der Putten E and Boon MC: Data Managers, Skills and Training. Data Management And Clinical Trials, by EORTC Study Group on Data Management, Elsevier Science Publishers, Amsterdam, 1989, pp51-55.
 
26) デボラ・ノリス: スタディ・コーディネータ・ハンドブック, (酒井弘憲, 吉田純朗・共訳) , サイエンティスト社, 東京, 1998.
 
27) Pocock SJ: 組織作りと計画. クリニカルトライアル, (コントローラー委員会・監訳) , 篠原出版, 東京, 1989, pp 40-70.
 
28) Cummings SW: Introduction. Clinical Data Management, (ed by Rondel RK, Varley SA and Webb CF) , John Wiley&Sons, Chichester, 1993, pp1-8: (古川敏仁, 他・訳) , クリニカル・データ・マネジメント, サイエンティスト社, 東京, 1998, pp1-7.
 
29) Green S, Benedettei J and Crowley J: Interim Analysis and Data Monitoring Committee. Clinical Trials in Oncology, Chapman&Hall, London, 1997, pp79-99.
 
30) 治験中に得られる安全性情報の取り扱いについて: http://www. nihs. go. jp/dig/ich/efficacy/e2a/e2a. html
 
P.396 掲載の参考文献
1) Green S, Benedetti J and Crowley J: Clinical trials in oncology. Chapman and Hall, 1997.
 
2) Piantadosi S: Clinical trials. A methodologic perspective. John Wiley and Sons, Inc., 1997.
 
3) ICH-E 8: 臨床試験の一般指針についてhttp://www. nihs. go. jp/dig/ich/eindex. html
 
4) 抗悪性腫瘍薬の臨床評価ガイドライン作成に関する研究班(班長 末桝恵一・他) : 抗悪性腫瘍薬の臨床評価方法に関するガイドライン. 新薬臨床評価ガイドライン, (日本公定書協会・編) , 薬事日報社, 1992, pp313-366.
 
5) Crowley J: Handbook of statistics in clinical oncology. Marcel Dekker, NY, 2001.
 
6) Ishizuka N and Ohashi Y: The continuous reassessment method and its applications: aBayesian methodology for phase I cancer clinical trials. Stat Med 20: 2661-2681, 2001.
 
7) Simon R: Optimal two-stage designs for phase II clinical trials. Contol Clin Trials 10: 1-10, 1989.
 
8) 福田治彦, 山本精一郎: がんの多施設共同臨床試験の中間解析における問題点. 計量生物学 21: 59-69, 2000.
 
9) Green S and Dahlberg S: Planned versus attained design in Phase II clinical trials. Stat Med 11: 853-862, 1992.
PubMed
10) Simon R, Wittes RE and Ellenberg SS: Randomized phase II clinical trials. Cancer Treat Rep 69: 1-3, 1985.
 
11) ICH-E 9: 「臨床試験のための統計的原則」について http://www. nihs. go. jp/dig/ich/eindex. html
 
12) Noda K, Yamamoto S, et al: Randomized phase III study of irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive-disease small-cell lung cancer; Japan Clinical Oncology Group Study (JCOG 9511) . N Engl J Med 346: 85-91, 2002.
 
P.406 掲載の参考文献
1) 藤原康弘: 日本における新抗癌剤の承認審査. 癌と化学療法 26: 196-203, 1999.
Medical*Online
2) 藤原康弘: 本邦における抗がん薬の承認までの過程. 最新医学 2001年3月増刊号, pp187-204.
 
3) Fujiwara Y and Kobayashi K: Oncology drug clinical development and approval in Japan: the role of the Pharmaceuticals and Medical Devices Evaluation Center. Crit Rev Oncol Haematol 42: 145-155, 2002.
 
4) 藤原康弘: 2000年に承認された新薬と外国臨床データの利用について-適応外使用とブリッジング試験を巡って-. 医薬品研究 32: 639-651, 2001.
 
5) 藤原康弘: 日本の抗がん剤臨床開発におけるICH E 5ガイドラインの意義. Cancer Frontier 3: 157-161, 2001.
 
6) 藤原康弘: Japanese Experience on Bridging Studies through PMDEC's Review of NDAs. 臨床評価 29 (suppl XVII) : 19-33, 2002.
 
7) Kalb PE and Koehler KG: Legal issues in scientific research. JAMA 287: 85-91, 2002.
PubMed
8) Morin K, et al: Managing conflicts of interest in the conduct of clinical trial. JAMA 287: 78-84, 2002.
PubMed
9) Gelijns AC and Their SO: Medical innovation and institutional interdependence. JAMA 287: 72-77, 2002.
PubMed
10) 藤原康弘: トランスレーショナルリサーチを成功させる秘訣-臨床研究のインフラストラクチャー整備-. 医学のあゆみ 200: 544-548, 2002.
 
11) The NIH Director's Panel on Clinical Research Report to the Advisory Committee to the NIH Director, December, 1997. (http://www. nih. gov/news/crp/97report/index. htm)
 
12) Nathan DG: Clinical Research. Perceptions, reality, and proposed solutions. JAMA 280: 1427-1431, 1998.
PubMed
13) Schechter AN: The crisis in clinical research. Endangering the half-century National institute of Health consensus. JAMA 280: 1440-1442, 1998.
PubMed
14) Shine KL: Encouraging clinical research by physician scientists. JAMA 280: 1442-1444, 1998.
 
15) Nathan DG and Varmus HE: The National Institute of Health and clinical research: aprogress report. Nat Med 6: 1201-1204, 2000.
PubMed
16) Gelband H: Prepared for the National Cancer Policy Board, Institute of Medicine, National Research Council: A report on the sponsors of cancer treatment clinical trials and their approval and monitoring mechanisms. National Academy Press, Washington DC, 1999. (http://www. nap. edu/books/NIOOO611/html/)
 
17) National Bioethics Advisory Commission: Ethical and policy issues in research involving human participants. U. S. Department of Commerce, Technology Administration, National Technical Information Service, Springfield, 2001. (http://www. ntis. gov/product/featured/bioethics. htm)
 
18) 松村真司・他: 臨床試験に関する一般住民の全国意識調査. 日本医事新報 3962(2000年4月1日) : 14-19, 2000.
 
19) Committee on Assessing the System for Protecting Human Research Subjects: Board on Health Science Policy, Instituteof Medicine: Preserving public trust. National Academy Press, Washington DC, 2001. (http://www. nap. edu/books/0309073286/htm1/)
 
20) National Center for Research Resources: Guidelines for the General Clinical Research Centers Program (M O1) . (http://www. ncrr. nih. gov/clinical/crguide2001/)
 
21) Committee on Routine Patient Care Costs in Clinical Trials for Medicare Beneficiaries, Institute of Medicine: Extending Medicare reimbursement in clinical trials. National Academy Press, Washington DC, 2000. (http://www. nap. edu/books/0309068894/html/)
 
22) Kneller R: Technology transfer: a review for biomedical researchers. Clin Cancer Res 7: 761-774, 2001.
PubMed
P.417 掲載の参考文献
1) Beecher HK: Ethics and clinical research. N Engl J Med 274: 1354-1360, 1966.
PubMed
2) Goldberg RJ: Disclosure of information to adult cancer patients: Issues and update. J Clin Oncol 2: 948-955, 1984.
PubMed
3) Appelbaum PS, Lidz CW, Meisel A: インフォームド・コンセント, (杉山弘行・訳) , 文光堂, 東京, 1994.
 
4) Faden RR and Beauchamp TL: A History and theory of informed consent. Oxford University Press, Inc, NY, 1986. (酒井 忠昭, 秦 浄一・訳: インフォームド・コンセント-患者の選択. みすず書房, 1994.)
 
5) Pocok SJ: クリニカルトライアル, (コントローラー委員会・監訳) , 篠原出版, 東京, 1989.
 
6) 砂原茂一: 臨床医学研究序説方法論と倫理. 医学書院, 東京, 1988.
 
7) 伊藤道哉: 生命と医療の倫理学 現代社会の倫理を考える2. 丸善, 東京, 2002.
 
8) 星野一正: 医療の倫理(岩波新書201) . 岩波書店, 東京, 1991.
 
9) 田沢公樹, 中島宏昭, 石原潤一・他: わが国の肺癌化学療法におけるinformed consent全国アンケート調査. J Jpn Soc Cancer Ther 21: 2454-2459, 1986.
 
10) 久保昭仁, 中川和彦, 宮本裕介・他: 肺癌患者におけるinformed consent. 大阪市立羽曳野病院第2内科における現状. J Jpn Soc Cancer Ther 30: 664-679, 1995.
 
11) The Neuremberg Code, Ethics in Medicine: Historical perspectives and comtemporary concerns, (ed by Reiser SJ, Dyck AJ and Curren WJ) , MIT Press, Cambridge, Mass, 1977, pp272-273.
 
12) Declaration of Helsinki: Recommendations guiding medical doctors in biochemical research involving human subjects. (光 石忠敬・訳: ヘルシンキ宣言-世界医師会総会. ヘルシンキ1964, 東京1975, ベニス1983, ホンコン1989改訂版. 臨床評価 22: 289-291, 1994.)
 
13) The Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO) , International ethical guidelines for biomedical research involving human subjects, Geneva, 1993. (光 石忠敬・訳: 国際医科学評議会(世界保健機関協力) 被験者に対する生物医学研究についての国際的倫理指針(1993年ジュネー ブ) . 臨床評価 22: 261-288, 1994.)
 
14) The Council for International Organizations of Medical Sciences (CIOMS) , International guidelines for ethical review of epidemiological studies, Geneva, 1991. (光石忠敬・訳: 国際医科学評議会疫学研究の倫理審査のための国際的指針(1991年 ジュネーブ) . 臨床評価 20: 563-578, 1992.)
 
15) President's Commission for the study of ethical problems in medicine at biochemical and behavioral research: Final report on studies of the ethical and legal problems in medicine and biomedical and behavioral research-summing up-, 1993. (医 務局医事課・監訳, 牛場大蔵・他・訳: アメリカ大統領委員会 生命倫理総括レポート. 篠原出版, 1984.)
 
16) 加藤尚武: 環境倫理学のすすめ(丸善ライブラリー032) . 丸善, 東京, 1991, pp1-226.
 
17) 日本医師会生命倫理懇談会報告: 「説明と同意」についての報告. 日本医事新報 3430: 109-112, 3431: 112-113, 3432: 118-119, 1990年1月, 2月.
 
18) 柳田邦男・編: 元気の出るインフォームドコンセント. 中央法規, 東京, 1995.
 
19) 厚生省薬務局審査第一課・監修: GCPハンドブック医薬品の臨床試験の実施に関する基準. 薬業時報社, 東京, 1990
 
20) International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use-Guideline for good clinical practice-ICH Expert working group, ICH Steering Committee IFPMA, Geneva May, 1995. (医薬品の臨床試験の実施に関する基準(GCP) のガイドライン(案) . 平成7年7月厚生省薬務局審査課. 臨床評価 23: 369-484, 1995.)
 
21) 厚生省令第28号, 薬務局長通知430号, 審査課長通知445号, 安全課長通知68号: 新GCP関連資料集, (日本製薬工業会医薬品評価委員会・編) , ミクス, 東京, 1997, pp89-342.
 
22) 厚生省令10号: 平成9年3月10日
 
23) 下山正徳・他: 臨床試験の作成と実施, ならびに結果の統計解析とその評価に関するガイドライン(改訂第3版) . 癌の臨床 42: 339-352, 1996.
 
24) OPRR Protecting Human Research Subjects, Institutional Review Board Guidebook. US Department of Health and Human Services, Pubic Health Service, National Institute of Health, 1993.
 
25) 下山正徳: 抗悪性腫瘍薬臨床評価方法に関するガイドライン解説 新薬臨床評価ガイドライン 1994, (日本公定書協会・編) , 薬業日報社, 東京, 1994, pp358-377.
 
26) 島田安博: 進行胃癌グループのプロトコール研究におけるICの実態 薬物療法を主体とする固形癌の集学的治療の臨床試験研 究, (垣添忠生, 下山正徳・監修) , 協和企画通信, 東京, 1991.
 
27) 江口研二・編: がん医療での臨床試験のインフォームドコンセント. 南江堂, 東京, 1998.
 
28) Girgis A and Sanson-Fisher RW: Breaking bad news: consensus guidelines for medical practitioners. J Clin Oncol 13: 2449-2456, 1995.
PubMed
29) Okamura H, Uchitomi Y, Kakizoe T, et al: Guidelines for Telling the Truth to Cancer Patients. Jpn J Clin Oncol 28: 1-4, 1998.
PubMed
30) 兵頭一之介, 江口研二・共訳: がん患者・家族との会話技術Talking to Cancer Patients and Their Relatives, (ed by Faulkner A and Maguire P) , 南江堂, 東京, 2002.
 
31) 内藤周幸, 光石忠敬: 医学実験無作為化臨床試験の論理と倫理. 篠原出版, 東京, 1987.
 
32) Leventhal BG and Wittes RE: Research methods in clinical oncology. Raven Press, New York, 1988.
 
33) The physician and unorthodox cancer therapies. ASCO special article JCO 15: 401-406, 1997.
 
34) 浜島信之: 無作為化割付臨床試験. 癌と化学療法社, 東京, 1993.
 
35) 遺伝子解析研究に付随する倫理問題等に対応するための指針: 厚生科学審議会先端医療技術評価部会, 平成12年4月.
 
36) ヒトゲノム研究に関する基本原則について: 科学技術会議声明倫理委員会, 平成12年6月.
 
37) ヒトゲノム・遺伝子解析研究に関する倫理指針の施行について: 12文科振第266号 科発第146号 平成13・03・27製局第3号およびヒトゲノム・遺伝子解析研究に関する倫理指針平成13年3月29日, 文部科学省, 厚生労働省, 経済産業省.
 
38) 疫学研究の倫理指針: 文部科学省・厚生労働省告示第2号 平成14年7月.
 
39) 遺伝子治療研究に関する臨床指針: 文部科学省厚生労働省告示第1号 平成14年3月.
 
40) Bruera E, Sweeney C, Calder K, et al: Patient preferences versus physician perceptions of treatment decisions in cancer care. J Clin Oncol 19: 2883-2885, 2001.
 
41) Gattellari M, Voigt K, Butow PN, et al: When the treatment goal is not cure: Are cancer patients equipped to make informed decisions? J Clin Oncol20: 503-513, 2002.
 
42) Koedoot CG, de Haes JCJM, Heisterkamp SH, et al: Palliative chemotherapy or watchful waiting? Avignettes study among oncologists. J Clin Oncol 20: 3658-3664, 2002.
PubMed
43) Morita T, Akechi T, Sugawara Y, et al: Practices and attitudes of Japanese oncologists and palliative care physicians concerning terminal sedation: A nationwide survey. J Clin Oncol 20: 758-764, 2002.
PubMed
44) Mathijssen RHJ, Verweij J, de Bruijn P, et al: Effects of St John's wort on irinotecan metabolism J Natl Cancer Inst 94: 1247-1249, 2002.
 
P.426 掲載の参考文献
1) Pocock SJ: The historical development of clinical trials. Clinical Trials. John Wiley&Sons Ltd, Chichester, 1983, pp14-27.
 
2) Rondel RK, Varley SA and Webb CF: Clinical data management. John Wiley & Sons Ltd, Baffins Lane, 1993, pp 1-8, pp189-212.
 
3) Vanderputten E, Boon M, Vantongelen K, et al: Local data management. Data management and clinical trials, (ed by Rotmensz N) , Elsevier, Amsterdam, 1989, pp49-106.
 
4) Hageman D and Reeves DM: Research data management. Cancer principles&practice of oncology, (ed by Devita VT, Hellman S and Rosenberg S) , 6th Edition, Lippincott Williams&Wilkins, Philadelphia, 2001, pp539-545.
 
5) Calvert WS and Ma JM: Introduction to research data management. Concepts and case studies in data management. SAS Institute Inc, Cary, 1996, pp 3-12, pp113-131.
 
6) 福田治彦: 臨床試験の方法論-総論, 臨床試験の倫理と科学. 分子がん治療 1(1) : 63-68, 2000.
 
7) 新美三由紀, 福田治彦, 山本精一郎・他: 臨床試験入門講座-データセンターにおけるデータマネージメント. 癌と化学療法 25(2) : 253-259, 1998.
 
8) Green S, Benedetti J and Crowley J: Data management and quality control. Clinical trials in oncology. Chapman&Hall, Cambridge, 1997, pp 101-132.
 
9) Niimi M, Fukuda H, Yamamoto S, et al: The influence of handling censored data on estimating progression-free survival in cancer clinical trials(JCOG 9913-A) . Jpn J Clin Oncol 32(1) : 19-26, 2002.
 
10) 日本製薬工業協会医薬品評価委員会: 本邦におけるスタディコーディネーターの必要性について. 臨床医薬 13(21) : 5439-5450, 1997.
 
11) Spilker B and Schoenfelder J: Creating data collection forms. Data collection forms in clinical trials. Raven Press, New York, 1991, pp1-49.
 
12) 福田治彦, 新美三由紀: 多施設共同臨床試験とデータマネージメント. 新GCP下での治験データマネージメント, (植松俊彦・編) , ライフサイエンス出版, 1999, pp 69-77.
 
13) Hiiner J E: Quality controI of dietary data collection in the CARDIA study. Control Clin Trials 13: 156-169, 1992.
 
P.437 掲載の参考文献
1) Peto J: Cancer epidemiology in the last century and the next decade. Nature 411: 390-395, 2001.
PubMed
2) Parkin DM, Whelan SL, Ferlay J, et al: Cancer Incidence in Five Continents, Vol VII. In: IARC SCI Publ, No l43, International Agency for Research on Cancer, Lyon France, 1997.
 
3) Lichtenstein P, Holm NV, Verkasalo PK, et al: Environmental and Heritable Factors in the Causation of Cancer-Analysesof Cohorts of Twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78-85, 2000.
 
4) Doll R and Peto R: The causes of cancer. Oxford University Press, New York, 1981.
 
5) Harvard Center for Cancer Prevention. Harvard Report on Cancer Prevention, Vol. 1: Causes of Human Cancer. Cancer Causes Control 7 (Suppl 1) : S3-S59, 1996.
 
6) Tominaga S: An estimate of the potential for cancer prevention in Japan. Asian Pacific J Cancer Prev 2: 287-292, 2001.
 
7) 喫煙と健康問題に関する検討会: 新版喫煙と健康-喫煙と健康問題に関する検討会報告書保健同人社, 東京, 2002, pp109-121.
 
8) Thun MJ, Day-Lally CA, Calle EE, et al: Excess mortality among cigarette smokers: Change in a 20-year interval. Am J Public Health 85: 1223-1230, 1995.
 
9) Sobue T, Yamamoto S, Hara M, et al: Cigarette smoking and subsequent risk of lung cancer by histologic type in middleaged Japanese men and women: The JPHC. Int J Cancer 99: 245-251, 2002.
 
10) Bartsch H, Nair U, Risch A, et al: Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier oftobacco-related cancers. Cancer Epidemiol Biomarker Prev 9: 2-28, 2000.
PubMed
11) Brennan P: Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it. Carcinogenesis 23: 381-387, 2002.
PubMed
12) US Department of Health and Human Services: The Health Benefits of Smoking Cessation. A Report of the Surgeon General. DHHS Publication No (CDC) 90-8416, (ed by Rockville MD) , US Government Printing Office, 1990, pp107-186.
 
13) Hirayama T: Life-style and mortality, a large-scale census-based cohort study in Japan. Basel, Kargel, 1990.
 
14) Sobue T, Suzuki T, Fujimoto I, et al: Lung cancer risk among exsmokers. Jpn J Cancer Res 82: 273-279, 1991.
PubMed
15) Gao C, Tajima K, Kuroishi T, et al: Protective effects of raw vegetables and fruit against lung cancer among smokers and ex-smokers: acase-control study in the Tokai area of Japan. Jpn J Cancer Res 84: 594-600, 1993.
 
16) Wakai K, Seki N, Tamakoshi A, et al: Decrease in risk of lung cancer death in males after smoking cessation by age at quitting: Findings from the JACC study. Jpn J Cancer Res 92: 821-828, 2001.
PubMed
17) Sobue T, Yamaguchi N, Suzuki T, et al: Lung cancer incidence rate for male ex-smokers according to age at cessation of smoking. Jpn J Cancer Res 84: 601-607, 1993.
PubMed
18) Halpern MT, Gillespie BW and Warner KE: Patterns of absolute risk of lung cancer mortality in former smokers. J NatlCancer Inst 85: 457-464, 1993.
PubMed
19) Wingo PA, Ries LAG, Giovino GA, et al: Annual Report to the Nation on the Status of Cancer, 1973-1996, With a Special Section on Lung Cancer and Tobacco Smoking. J Natl Cancer Inst 91: 675-690, 1999.
 
20) Stat Bite: Lung cancer incidence in California, 1988-1997. J Natl Cancer Inst 93: 1371, 2001.
 
21) Lancaster T, Stead L, Silagy C, et al: Effectiveness of interventions to help people stop smoking: findings from theCohchrance Library. Br Med J 321: 355-358, 2000.
 
22) 中村正和: 医療機関(禁煙外来を含む) での指導の実際. 日医雑誌 127: 1025-1030, 2002.
 
23) World Cancer Research Fund and American Institute for Cancer Research: Food, Nutrition and the Prevention of Cancer: a global perspective, 1997.
 
24) 日本がん疫学研究会がん予防指針検討委員会: 生活習慣と主要部位のがん, 九州大学出版会, 福岡, 1998.
 
25) 坪野吉孝: 食べ物とがん予防. 文藝春秋, 東京, 2002, pp70-76, 87-101.
 
26) Schatzkin A, Lanza E, Corle D, et al: Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. NEngl J Med 342: 1149-1155, 2000.
 
27) Alberts DS, Martinez ME, Roe DJ, et al: Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. N Engl J Med 342: 1156-1162, 2000.
PubMed
28) Tsubono Y, Nishino Y, Komatsu S, et al: Green tea and the risk of gastric cancer in Japan. N Engl J Med 344: 632-636, 2001.
PubMed
29) 国立がんセンター. 「がんを防ぐための12ヵ条」 http://www. ncc. go. jp/jp/ncc-cis/pub/index/about. html
 
30) 健康・体力づくり事業財団. 健康日本21. http://www. kenkounippon21. gr. jp/
 
31) Tobacco Free Initiative. http://www5. who. int/tobacco/
 
P.442 掲載の参考文献
1) Fujimaki Y: Formation of gastric carcinoma in albino rats fed on deficiant diets. J Cancer Res 10: 469-477, 1926.
 
2) Lasnitzki I: The influence of a hypervitaminosis on the effect of 20-methylcholanthrene on mouse prostaglands grown in vitro. Br J Cancer 9: 434-441, 1955.
PubMed
3) Saffiotti U, Momtesano R, Sellakumar AR, et al: Exprimental cancer of the lung. Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumous. Cancer 20: 857-864, 1967.
 
4) Bollag W: Effects of vitamin A acid on transplantable and chemically induced tumors. Cancer Chemother Rep 55: 53-58, 1971.
PubMed
5) Muto Y, Morikawa H, Ninomiya M, et al: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334: 1561-1567, 1996.
 
6) Peto R, Doll R, Buckley JD, et al: Can dietaryβ-carotene materially reduce human cancer rates? Nature 290: 201-208, 1981.
 
7) Murakoshi M, Nishino H, Satomi Y, et al: Potent preventive action of carotene against carcinogenesis: Spontaneous liver carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by-carotene than byβ-carotene. Cancer Res 52: 6583-6587, 1992.
 
8) The Alfa-Tochopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 30: 1029-1035, 1994.
 
9) Omenn GS, Goodman GE, Thornquist MD, et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150-1155, 1996.
PubMed
10) Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
PubMed
11) Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993.
PubMed
12) Jaffe BM: Prostaglandins and cancer: an update. Prostaglandins 6: 453-461, 1974.
PubMed
13) Bennett A and Del Tacca M: Proceedings: Prostaglandins in human colonic carcinoma. Gut 16: 409, 1975.
PubMed
14) Bennett A, Del Tacca M, Stamford IF, et al: Prostaglandins from tumours of human large bowel. Br J Cancer 35: 881-884, 1997.
 
15) Nakatsugi S, Fukutake M, Takahashi M, et al: Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mece. Jpn J Cancer Res 88: 1117-1120, 1997.
 
16) Narisawa T, Sato M, Tani M, et al: Inhibition of development of methyinitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 41: 1954-1957, 1981.
PubMed
17) Beazer-Barclay Y, Levy DB, Moser AR, et al: Sulinduc suppresses tumorigenesis in the Min mouse. Carcinogenesis 17: 1757-1760, 1996.
PubMed
18) Jacoby RF, Marshall DJ, Newton MA, et al: Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56: 710-714, 1996.
 
19) Oshima M, Dinchuk JE, Kargman SL, et al: Suppression of intestinal polyposis in Apc△716 knockout mice by inhibition of cyclooxygenase 2 (COX 2) . Cell 87: 803-809, 1996.
 
20) Huang MT, Ma W, Yen P, et al: Inhibitory effects of topical application of low doses of curucumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis 18: 83-88, 1997.
 
21) Baba M, Asano R, Takigami I, et al: Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis, BiolPharm Bull 25: 247-250, 2002.
PubMed
22) Newmark TM and Schulick P: Beyond Aspirin, Hohm Press, 2000, pp1-316.
 
P.448 掲載の参考文献
1) Ota J, Horino T, Taguchi T, et al: Mass screening for breast cancer: Comparison of the clinicalstages and prognosis of breast cancer detected by mass screening and in out-patient clinics. Jpn J Cancer Res 80: 1028-1034, 1989.
PubMed
2) 久道 茂: がん検診のはなし. 新企画出版社, 東京, 1998.
 
3) Shapiro S, Venet W, Strax P, et al: Ten-to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 69: 349-355, 1982.
PubMed
4) Alexander FE, Anderson TJ, Brown HK, et al: The Edinburgh randomised trial of breast cancer screening: results after 10 years of followup. Br J Cancer 70: 542-548, 1994.
 
5) Kerlikowske K: Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr 22: 79-86, 1997.
PubMed
6) Gotzsche PC and Olsen O: Is screening for breast cancer with mammography justifiable? Lancet 355: 129-134, 2000.
PubMed
7) Olsen O, Go-tzsche PC: Cochrane review of screening for breast cancer with mammography. Lancet 358: 1340-1342, 2001.
 
8) Miettinen OS, Henschke CI, Pasmantier MW, et al: Mammographic screening: no reliable evidence?Lancet 359: 404-406, 2002.
PubMed
9) Mandel JS, et al: Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328: 1365-1371, 1993.
PubMed
10) Miller AB, et al: Canadian National Breast Cancer Study 1: breast cancer detection rates among women aged 40 to 49 years. Can Med Assoc J 147: 1459-1476, 1992.
 
11) Miller AB, et al: Canadian National Breast Cancer Study 2: breast cancer detection rates among women aged 50 to 59 years. Can Med Assoc J 147: 1477-1488, 1992.
 
12) Kopans DB and Feig SA: The Canadian national breast screening study: A critical review. Am J Raiol 161: 755-760, 1993.
 
13) Kanemura S, Tsuji I, Ohuchi N, et al: A case control study on the effectiveness of breast cancer screening by clinical breast examination in Japan. Jpn J Cancer Res 90: 607-613, 1990.
 
14) Fukao A, et al: The evaluation of screening for gastric cancer in Miyagi Prefecture, japan: a population based case-control study. Int J Cancer 60: 45-48, 1995.
PubMed
15) Makino H, Sato S, Yajima A, et al: Evaluation of the effectiveness of cervical cancer screening: acase-control study in Miyagi, Japan. Tohoku J Exp Med 175: 171-178, 1995.
 
16) Nishii K, Ueoka H, Kiura K, et al: A case-control study of lung cancer screening in Okayama Prefecture, Japan. Lung Cancer 34: 325-332, 2001.
PubMed
17) Tsukada H, Kurita Y, Yokoyama A, et al: An evaluation of screening for lung cancer in Niigata Prefecture, Japan: a population-based case-control study. Br J Cancer 85: 1326-1331, 2001.
PubMed
18) Sagawa M, Tsubono Y, Saito Y, et al: A case-control study for evaluating the efficacy of mass screening program for lung cancer in Miyagi Prefecture, Japan. Cancer 9: 588-594, 2001.
 
19) Kuroishi T, Hirose K and Tominaga S: Evaluation of the efficacy of mas screening for the uterine cancer in Japan. Jpn J Cancer Res 77: 399-405, 1986.
 
20) 篠田正昭, 石丸良三: 僻地における乳腺集団検診について. 診断と治療 37: 1406-1412, 1962.
 
21) 池田 誠: 僻地集団検診からみた乳腺検診の実態. 日臨外医会誌 26: 187-190, 1965.
 
22) 伊藤庸二, 池内准次, 河村純郎・他: 乳腺集団検診におけるX線撮影の応用. 癌の臨床 11: 668-669, 1965.
 
23) 泉雄 勝, 川井忠和, 藤井孝尚: 乳癌の集団検診-8年間の経験. 癌の臨床 19: 710-714, 1973
 
24) 田口鐵男, 中野陽典, 上田進久・他: 乳癌の集団検診. 癌と化学療法 5: 37-44, 1978.
Medical*Online
25) 岡崎邦泰・他: 乳癌の集団検診. 臨床医 3: 1586-1587, 1979.
 
26) Japan Cancer Society Conference on the Masst Examination of Breast Cancer: Japan Cancer Society, 1974.
 
27) 久道 茂・編: がん検診の有効性評価に関する研究班報告書. 日本公衆衛生協会, 東京, 1998.
 
28) Shapiro S, Coleman A, Broeders M, et al: Breast cancer screening programmes in 22 countries: current policies, a dministration and guidelines. Int J Epidemiol 27: 735-742, 1998.
 
29) 大内憲明, 遠藤登喜子, 辻 一郎・他: マンモグラフィー導入による乳がん検診の精度管理の確立に関する研究(7-8) . 厚生省がん研究助成金による研究報告. 平成8年度, 国立がんセンター, 東京, 1997, pp101-106.
 
30) 大内憲明, 遠藤登喜子, 辻 一郎・他: マンモグラフィーを導入した乳がん検診システムの確立に関する研究(9-6) . 厚生省がん研究助成金による研究報告. 平成10年度, 国立がんセンター, 東京, 1999, pp642-644.
 
31) 大内憲明: 遠藤登喜子, 東田善治・他: マンモグラフィによる乳癌検診を実施するにあたっての実態調査: 厚生省班研究報告. 日乳癌検診会誌 8: 15-22, 1999.
 
32) 大内憲明: 老人保健強化推進特別事業から学んだマンモグラフィ検診のあり方. INNERVISION 15: 21-23, 2000.
 
33) 大内憲明・編: マンモグラフィによる乳がん検診の手引き-精度管理マニュアル. 改定第2版, 日本医事新報社, 東京, 2001.
 
34) 久道 茂・編: がん検診の適正化に関する調査研究-新たながん検診手法の有効性評価-報告書. 日本公衆衛生協会, 東京, 2001.
 
35) 大森 芳, 大内憲明, 辻 一郎: がん検診精度管理のためのコンピュータシステムの開発. 日乳癌検診会誌 12: 16-25, 2003.
Medical*Online
P.456 掲載の参考文献
1) Katada K: Current status and future prospects of multislice CT. Med Rev 71: 1-11, 2000.
 
2) Kaneko M, Eguchi K, Ohmatsu H, et al: Peripheral lung cancer: Screening and detection with low-dose spiral CT versus radiography. Radiology 201(3) : 798-802, 1996.
PubMed
3) Murakami T, Kim T, Takamura M, et al: Useful of double arterial phase imaging of multislice helical CT for the detection of hypervascular. Hepatocellular Carcinoma 213: 126, 1999.
 
4) Jara H, Barish MA, Yucel EK, et al: MR hydrography: theory and practice of static fluid imaging. AJR 170: 873-882, 1998.
PubMed
5) 磯貝 聡, 竹原康雄, 礒田治夫・他: MR hydrographyの臨床応用. MRCP画像診断 19(7) : 718-730, 1999.
 
6) Strauss LG and Conti PS: The application of PET in clinical oncology. J Nucl Med 32: 623-648, 1991.
 
7) 中井勝彦, 井出 満, 高橋若生・他: 癌検診におけるFDG-PET. 臨床放射線 47(9) : 1137-1148, 2002.
 
P.467 掲載の参考文献
1) 長廻 紘: 消化器内視鏡をそだてた人々. 金原出版, 東京, 2001, pp2-3.
 
2) Hirshowitz BI, Curtis LE, Peter CW, et al: Demonstration of a new gastroscope, the fiberscope. Gastroenterology 35: 50, 1958.
 
3) 宇治達郎: 胃粘膜写真撮影装置. 日臨外会誌 12: 60, 1951.
 
4) Classen M and Phillip J: Electronic endoscopy of the gastrointestinal tract. Initial experience with a new type of endoscope that has no fiberoptic bundle for imaging. Endoscopy 16: 16-19, 1984.
 
5) Matek W, Lux G, Riemann JF, et al: Initial experience with the new electronic endoscope. Endoscopy 16: 20-21, 1984.
PubMed
6) Sivak MV and Fleischer DE: Colonoscopy with a video endoscope; preliminary experience. Gastrointest Endosc 30: 1-5, 1984.
PubMed
7) 清水誠治, 多田正大, 清田啓介・他: ビデオ内視鏡(WAVEシステム) の使用経験. Gastroenterol Endosc 27: 1813-1821, 1985.
 
8) 苅田幹夫, 有山重美, 安武隆二郎・他: Video-Endoscopeの使用経験. Gastroenterol Endosc 27: 2052-2057, 1985.
 
9) 竹本忠良: 電子内視鏡(electronic endoscope) . 胃と腸 20: 316, 1985.
 
10) 郡 大裕, 加藤卓次, 鈴木邦夫: 電子スコープの原理と画像処理の実際. 消化器内視鏡 1: 437-444, 1989.
 
11) 日本食道疾患研究会・編: 食道癌取扱い規約. 第9版, 金原出版, 東京, 1999.
 
12) 幕内博康, 島田英雄, 千野 修・他: m3, sm1食道癌に対するEMRの可能性. 胃と腸 33: 993-1002, 1998.
 
13) 星原芳雄, 木暮 喬, 福地創太郎・他: 下部食道縦走血管の内視鏡観察とその臨床的意義. Gastroenterol Endosc 28: 941-946, 1986.
 
14) Guelrud M, Herrera I, Essenfeld H, et al: Enhanced magnification endoscopy a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 53: 559-565, 2001.
 
15) Endo T, Arakawa T, Takahashi H, et al: TCIassification of Barrett's epithelium by magnifying endoscopy. Gastrointest Endosc 55: 641-647, 2002,
 
16) Leathem Van JL, Cremer M and Peny MO: Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression; immediate and mid term results. Gut 43: 747-751, 1998.
 
17) 斎藤奈々子, 藤崎順子, 新井弥生・他: short segment Barretts esophagus内に発生し内視鏡的粘膜切除術にて切除された早期食道癌の1例. Gastroenterol Endosc 44: 11-15, 2002.
 
18) 大芝 玄, 幕内博康, 島田英雄: short segment Barrett's esophagusから発生し, 異形成を伴う早期Barrett's食道癌の1例. 胃と腸34: 189-194, 1999.
 
19) 星原芳雄, 山本 敬, 橋本光代・他: 狭いshort segment Barrett's esophagusに発生したBarrett腺癌の1例. 胃と腸 34: 195-198, 1999.
 
20) 日本胃癌学会・編: 胃癌取扱い規約. 第13版, 金原出版, 東京, 1999.
 
21) 田尻久雄, 藤崎順子, 仲吉 隆・他: 胃癌-内視鏡診断の最先端. 胃と腸 38: 21-29, 2003.
 
22) 青野茂昭, 永尾重昭, 川口 淳・他: 適応型構造強調処理-上部消化管での有用性-. 臨牀消化器内科 12: 924-927, 1997.
 
23) 辻 晋吾, 佐藤信紘, 川野 淳: 臓器反射スペクトル. 消化管血流の画像解析. 消化器電子内視鏡と画像処理, (木村 健, 他・編) , 医学書院, 東京, 1991, pp93-99.
 
24) 榊 信廣, 飯田洋三, 斎藤 満・他: 胃粘膜微細模様の新しい拡大観察. Gastroenterol Endosc 22: 377-383, 1980.
 
25) 田尻久雄, 仲吉 隆, 藤崎順子: 内視鏡画像解析による消化管癌の診断. ポストゲノム時代の内視鏡学, (伊東 進, 田尻久雄・編) , 中山書店, 東京, 2002, pp79-86.
 
26) 相部 剛: 超音波内視鏡による消化管壁の層構造に関する基礎的, 臨床的研究. (1) 胃壁の層構造について. Gastroenterol Endosc 26: 1465-1773, 1984.
 
27) Yamanaka T: JGES consensus meeting report in DDW Japan 2000, Kobe; Interpretation of the layerd structure of gastrointestinal wall with endoscopic ultrasonography. Dig Endosc 14: 39-40, 2002.
 
28) 藤崎順子, 望月恵子, 桂 俊司・他: 食道癌-胃癌における三次元表示の意義. 消化器内視鏡 13: 1061-1068, 2001.
 
29) 村田洋子, 井手博子, 秋本 伸・他: 食道癌における腹腔内転移リンパ節の超音波内視鏡診断. 日消外会誌 14: 1005-1015, 1981.
 
30) 有馬美和子, 田崎健太郎, 飛田浩司・他: 食道縦隔疾患に対する超音波内視鏡下穿刺生検法の検討. Proceeding DDW-Japan 1999. 消化管超音波診断の進歩. メディカルビュー社, 東京, 1999, pp69-83.
 
31) 藤崎順子, 増田勝紀, 大政良二・他: 胃早期胃癌の内視鏡的胃粘膜切除術の適応決定における超音波内視鏡(プローブ型) の有用性. 消化器内視鏡 5: 1207-1213, 1993.
 
32) 芳野純治, 中沢三郎: 超音波内視鏡による胃癌の深達度診断. 胃と腸ハンドブック, (胃と腸編集委員会・編) , 医学書院, 東京, 1992, pp173-181.
 
33) 芳野純治, 中沢三郎, 中村常哉・他: 陥凹型早期胃癌の深達度診断. X線診断と超音波内視鏡の対比. 胃と腸 22: 169-177, 1987.
 
34) 長南明道, 望月福治, 池田 卓・他: 潰瘍合併. IIc型早期胃癌の超音波内視鏡(EUS) による深達度診断能の検討. Gastroenterol Endosc 32: 1981-1990, 1990.
 
35) 木田光宏, 西元寺克礼, 岡部治弥: 超音波内視鏡による胃癌の深達度診断に関する臨床病理学的研究-陥凹型胃癌を中心に. Gas-troenterol Endosc 31: 1141-1155, 1989.
 
36) 楡山 護: 胃悪性リンパ腫の診断と生検. 胃と腸 8: 165-175, 1973.
 
37) Isaacson PG and Wright DH: Malignant lymphoma of mucosa associated lymphoid tissue. Cancer 52: 1410-1416, 1983.
 
38) Montalban C, Manzanal A, Boixeda D, et al: Helicobacter ptlori eradication for the treatment of low grade gastric MALT lymphoma-follow-up together with sequentioal molecular studies. Ann Oncol 8 (Suppl 2) : 37-39, 1997.
 
39) Sackmann M, Morgner A, Rudolph B, et al: Regression of gastric MALT lymphoma after eradication Helicobacter pylon' is predicted by endosonographic staging. Gastroenterology 113: 1087-1090, 1997.
 
40) Neubauer A, Thiede C, Morgner A, et al: Cure of Helicobacter Pylori infection and duration of remission of low-grade gastric mucosa assosiated lymphoid tissue lymphoma. J Natl Cancer Inst 89: 1350-1355, 1997.
 
41) 小田一郎, 小野裕之, 乾 哲也・他: 胃MALTLymphoma-Helicobacter pylori除菌で効果が期待できる内視鏡像の特徴. 消化器内視鏡 13: 797-804, 2001.
 
42) Fenlon HM, Nunes DP, Schroy PC, et al: A comparison of virtual and conventional colonoscopy for detection of colorectal polyps. N Engl J Med 341: 1496-1503, 1999.
PubMed
43) 松本啓一, 東 征樹, 若原成行・他: ヘリカルCTによるVirtual Endoscopyの現状と展望. J Colon Exam 18: 31-33, 2001.
 
44) 須田浩晃, 吉本一哉, 村上省吾・他: バーチャルエンドスコピーの限界と応用. J Colon Exam 18: 28-30, 2001.
 
45) Sonnenberg A, Delco F, Bauerfeind P, et al: Is virtual colonoscopy a cost-effective option to screen for colorectal cancer? Am J Gastroenterol 94: 2268-2274, 1999.
PubMed
46) 斉藤征史, 伊東浩志, 古谷正伸・他: 隆起型早期大腸癌の内視鏡的深達度診断-m・sm1とsm2・sm3の鑑別-. 消化器内視鏡 9: 175-179, 1997.
 
47) 池上雅博, 下田忠和, 小牧稔之・他: 大腸sm癌の肉眼的特徴とその診断. 胃と腸 29: 1237-1247, 1994.
 
48) 下田忠和: 1 診断に必要な病理. 図説消化器病シリーズ8 大腸癌・大腸ポリープ, (飯田三雄・編) , メディカルビュー社, 東京, 2001, pp8-21.
 
49) 渡辺英伸, 味岡洋一: 大腸良・悪性境界病変の病理. 病理と臨床 6: 1280-1292, 1988.
 
50) 工藤進英, 樫田博史, 田村 智・他: 5 大腸ポリープの治療 (1) どこまでポリペクトミーをすべきか. b. 陥凹型とflat adenoma, IIa+depの相違. 臨床消化器内科 11: 635-649, 1996.
 
51) 斉藤 豊, 藤井隆広, 神津隆弘・他: 5 結節集蔟様病変の摘除法の選択. 大腸癌治療マニュアル, (小西文雄, 藤井隆広・編) , 南江堂, 東京, 2001, pp80-86.
 
52) 工藤進英, 三浦宏一, 高野征雄・他: 微小大腸癌の診断-実体顕微鏡所見を含めて. 胃と腸 25: 801-812, 1990.
 
53) 山野泰穂, 工藤進英: 4 表面型早期大腸癌の診断. 内視鏡検査. 図説消化器病シリーズ8 大腸癌・大腸ポリープ, (飯田三雄・編) , メディカルビュー社, 東京, 2001, pp66-77.
 
54) 松永厚生, 藤田直孝, 富永 現・他: 細径超音波プローブによる大腸sm癌の深達度診断-内視鏡診断との比較-. 消化器内視鏡 9: 201-209, 1997.
 
55) 大井 至: Fiberduodenoscope (FDS-L 6) による内視鏡的膵管造影. 日消病会誌 66: 880, 1969.
 
56) 池田靖洋, 松本伸二, 吉本英夫・他: 内視鏡下留置バルーンカテーテルによる膵管充満造影法-背臥位圧迫撮影の膵性差における有用性-. 胃と腸19: 1231-1242, 1984.
 
57) Tanaka M, Yokohata K, Konomi H, et al: Segmental balloon cytology for preoperative localization of in sitza pancreatic cancer. Gastrointest Endosc 46: 447-449, 1997.
PubMed
58) 井上寛巳, 土田 明, 岩尾年康・他: 膵液中のtelomerase活性検討による膵癌診断. 胆と膵 20: 765-769, 1999.
 
59) Izuishi K, Ryu M, Tajiri H, et al: Preoperative imaging for the location of intraductal pancreatic tumor and pancreatic duct using ERP-CT. Proc World Congress Int College Surgeon 15: 685-689, 1996.
 
60) 山雄健次, 中澤三郎, 内藤靖夫・他: 粘液産生膵腫瘍に対する経口的膵管鏡の有用性. Gastroenterol Endosc 30: 563-569, 1988.
 
61) 小林正彦, 田尻久雄: 細径膵管内視鏡検査. 別冊 医学のあゆみ 消化器疾患 Ver. 2-state of arts II. 肝・胆・膵, (玉熊正悦, 石井裕正・編) . 医歯薬出版, 東京, 1999, pp 209-240.
 
62) 小林正彦, 田尻久雄: 膵管鏡-内視鏡像のポイント. 消化器内視鏡New Procedure肝・胆・膵, (山中桓夫・編) , メディカルレビュー社, 東京, 2000, pp154-155.
 
63) Hunt GC and Faigel DO: Assessment of EUS for diagnosing, staging, and determining respectability of pancreatic cancer. A review. Gastrointest Endosc 55: 232-237, 2002.
 
64) Tierney WM, Fendrick AM, Hirth RA, et al: The clinical economic impact of alternative staging strategies for adenocarcinoma of the pancreas. Am J Gastroenterol 95: 1708-1713, 2000.
PubMed
65) Wiersema MJ and Wiersema LM: Endosonography-guided celiac plexus neurolysis. Gastrointest Endosc 44: 656-662, 1996.
PubMed
66) Vilmann P, Khattar S and Hancke S: Endoscopic ultrasound examination of the upper gastrointestinal tract using a curved-array transducer. A preliminary report. Surg Endosc 5(2) : 79-82, 1991.
PubMed
67) Matsuda K and Hawes RH: EUS-FNA for diagnosing malignant lymph node invasion. 消化器内視鏡 12(3) : 295-305, 2000.
 
68) Williams D, Sahai A, Aabakken L, et al: Endoscopic ultrasound guided fine needle aspiration biopsy: alarge single center experience. Gut 44: 720-726, 1999.
 
69) Ciaccia D, Onken J, Chappo J, et al: Endoscopic ultrasound guided fine needle aspiration in the diagnosis of chronicpancreatitis. Gastrointest Endosc 45: AB 170, 1997.
 
70) 戸田勝久, 安田一朗, 富田栄一・他: EUS-FNAが診断に有用であった自己免疫性膵炎の1例. 膵臓 16(5) : 495-501, 2001.
 
71) Silverstein FE, Martin RW, Kimmery MB, et al: Experimental evaluation of an endoscopic ultrasound probe: in vitro and in vivo canine studies. Gastroenterology 96: 1058-1062, 1989.
 
72) 乾 和郎, 中澤三郎, 芳野純治・他: 超音波内視鏡を用いた胆管癌の早期診断. 胆と膵 12: 373-377, 1991.
 
73) Tamada K, Inui K and Menzel J: Intraductal ultrasonography of the bile duct system. Endoscopy 33: 878-885, 2001.
PubMed
74) 古川 剛, 内藤靖夫, 廣岡芳樹・他: 細径超音波プローブによる新たなる展開. 消化器内視鏡 7: 1127-1134, 1995.
 
75) 田尻久雄: コンセンサス・ミーティング 5 膵嚢胞性疾患の取り扱い. Gastroenterol Endosc 43(6) : 1098-1100, 2001.
 
76) Hirooka Y, Goto H, Ito A, et al: Contrast-enhanced endoscopic ultrasonography inpancreatic diseases: a preliminary study. Am J Gastroenterol 93(4) : 632-635, 1998.
 
77) 吉田達也, 井上晴洋, 岩井武尚: 消化管粘膜の仮想生検(virtual biopsy) に向かって. J Colon Exam 18: 17-21, 2001.
 
P.475 掲載の参考文献
1) Kaneko M, Eguchi K, Ohmatsu H, et al: Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 201: 798-802, 1996.
PubMed
2) Sobue T, Moriyama N, Kaneko M, et al: Screening for lung cancer with low-dose helical computed tomography: Anti-Lung Cancer Association project. J Clin Oncol 20: 911-920, 2002.
PubMed
3) Sone S, Li F, Yang ZG, et al: Characteristics of lung cancers invisible on conventional chest radiography and detected by population based screening using spiral CT. Br J Radiol 73: 137-145, 2000.
 
4) 村松禎久, 秋山典子, 花井耕造: 螺旋状(ヘリカル) スキャンを用いた肺がんスクリーニングCTの医療被曝について. 日放技誌 52: 1-8, 1996.
 
5) Noguchi M, Morikawa A, Kawasaki M, et al: Small adenocarcinoma of the lung: Histologic characteristic and prognosis Cancer 75: 2844-2855, 1995.
 
6) Kuriyama K, Seto M, Kasugai T, et al: Ground-glass opacity on thin-section CT: value in differentiating subtypes of adenocarcinoma of the lung. AJR 173: 465-469, 1999.
PubMed
7) 奥泉美奈: 径20mm以下の限局性すりガラス濃度領域を呈する肺野病変の鑑別診断-HRCT所見と病理像との対比-. 日医放 60: 419-427, 2000.
 
8) 楠本昌彦, 立石宇貴秀, 金子昌弘・他: 単純X線写真で描出されない肺癌とその境界病変のCT像. 画像診断 21: 749-758, 2001.
 
9) Kitamura H, Kameda H, Ito T, et al: Atypical adenomatous hyperplasia of the lung; implication for the pathogenesis of peripheral lung adenocarcinoma. Am J Alin Pathol 111: 610-622, 1999.
 
10) Shimosato Y, Noguchi M, Matsuno Y, et al: Adenocarcinoma of the lung: its development and malignant progression. Lung Cancer 9: 99-108, 1993.
 
11) 児玉哲郎, 松本武夫, 横瀬智之・他: 肺腺癌の前癌病変: 異型腺腫様過形成の病理学的特徴と臨床像. 日胸 55: 785-792, 1996.
 
12) 松本祥一, 足立秀治, 河野通雄・他: CTで偶然発見された肺の異型腺腫様過形成の1例. 肺癌 37: 887-891, 1997.
 
13) Kushihashi T, Munechika H, Ri K, et al: Bronchioloalveolar adenoma of the lung: CT-pathologic correlation. Radiology 193: 789-793, 1994.
 
14) 楠本昌彦, 森山紀之, 仁木利郎・他: 異型腺腫様過形成との鑑別が問題となる肺腺癌. 臨床画像 16: 950-953, 2000.
 
P.486 掲載の参考文献
1) Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767. 1990.
PubMed
2) Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
PubMed
3) O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al: Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development (Recommendations of the AACR Task Force on the treatment and prevention of intraepithelial neoplasia) . Clin Cancer Res 8: 314-346. 2002.
PubMed
4) Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000.
PubMed
P.493 掲載の参考文献
1) 阿部令彦: IV用語集. (日本癌治療学会癌の治療に関する合同委員会癌規約総論委員会・編) , 金原出版, 東京, 1991, pp 60-70.
 
2) 真鍋俊明: 外科病理学入門. 医学書院, 東京, 1986.
 
3) 石川栄世: 外科病理学. まえがき, (石川栄世, 遠城寺宗知・編) , 第3版, 文光堂, 東京, pp 1-3.
 
4) 愛甲 孝, 太田惠一郎, 加藤 洋・他: 腹腔細胞診. 胃癌取扱い規約, (日本胃癌学会・編) , 第13版, 金原出版, 東京, 1999, pp 52-56.
 
5) 胃癌術中洗浄液細胞診ガイドライン: 日臨細胞会誌 40: 93-98, 2001.
 
6) Rosai J: Some considerations on the origin, evaluation, and outlook of American Surgical Pathology. Guiding the Surgeon's Hand, (ed by Rosai J) , American Registry of Pathology. Washington DC, 1997, pp 1-3.
 
7) 真鍋俊明: カラーアトラス肺腫瘍の病理診断. 金芳堂, 京都, 1991.
 
8) Brawer MK, Peehl DM, Stamey TA, et al: Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 45: 3663-3667, 1985.
PubMed
9) Hendrick L, Cheng L and Epstein JI: Use of keratin 903 as adjunct in the diagnosis of prostate carcinomas. Am J Surg Pathol 13: 389-396, 1989.
 
10) Lazard D, Sastre X, Frid MG, et al: Expression of smooth muscle specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant breast tissue. Proc Natl Acad Sci USA 90: 999-1003, 1993.
PubMed
11) True LD: Myoglobin. Atlas of Diagnostic Immunohistopathology, (ed by True LD) , Lippincott, Philadelphia, 1990.
 
12) True LD: Vascular antigens. Atlas of Diagnostic Immunohistopathology. (ed by True LD) , Lippincott, Philadelphia, 1990.
 
13) Miettinen, Lindenmayer AE and Chaubal A: Endothelial cell markers CD 31, CD 34, and BNH 9 antibodies to H-and Y-antigens: evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Villibrand factor. Mod Pathol 7: 82-90, 1994.
 
14) Barwick KW: S-100 protein. Atlas of Diagnostic Immunohistopathology. (ed by True LD) , Lippincott, Philadelphia, 1990.
 
15) Caplan AI, Fiszman MY, Eppenberger HM, et al: Molecular and cell isoforms during development. Science 221: 921-927, 1983.
PubMed
16) Salli O, Gabbiani G, Babai F, et al: Intermediate filament proteins and actin isoforms as markers for soft tissue tumor differentiation and origin. II Rabdomyosarcoma. Am J Pathol 130: 515-531, 1988.
 
17) 五條理志, 梅澤明弘: 間葉系幹細胞の分化制御機構(特集: 幹細胞) . 炎症と免疫 10: 13-18, 2001.
 
18) 長谷川匡: GISTの病理学的特徴(特集: 消化管の間葉系腫瘍) . 病理と臨床 20: 141-147, 2002.
 
19) Miettinen MM, Sarlomo-Rikala M, Kovatich AJ, et al: Calponin and h-Caldesmon in soft tissue tumors: consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates tratits of smooth muscle differentiation. Mod Pathol 12: 756-762, 1999.
 
20) Thomson W and MacKie RM: Comparison of five antimelanoma antibodies for identification of melanocytic cells on tissue sections in routine dermatopathology. J Am Acad Dermatol 21: 1280-1284, 1989.
PubMed
21) Sturtz CL and Dabbs DJ: Angiomyolipomas: the nature and expression of the HMB 45 antigen. Mod Pathol 7: 842-845, 1994.
 
22) Chu P, Wu E and Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 13: 962-972, 2000.
 
23) Mizutani Y, Nakajima T, Morinaga S, et al: Immunohistochernical localization of pulmonary surfactant apolipoproteins in various tumors Special reference to nonmucinous producing lung adenocarcinomas. Cancer 61: 532-537, 1988.
 
24) 渡辺英伸, 加藤法導, 渕上忠彦・他: 微小胃癌からみた胃癌の発育経過-病理形態学的解析-. 胃と腸 27: 59-67, 1992.
 
25) 片桐耕吾, 渡辺英伸, 味岡洋一・他: 高分化型進行大腸癌の高・低異型度による生物学的悪性度の差について. 胃と腸 29: 841-849, 1994.
 
26) Tsuda H, Hirohashi S, Shimosato Y, et al: Correlation between histologic grade and copy number of c-erbB 2 gene in breast carcinoma. Cancer 65: 1794-1800, 1990.
PubMed
27) Hasebe T, Tsuda H, Hirohashi S, et al: Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. Jpn J Cancer Res 87: 385-394, 1996.
PubMed
28) Nishimura R, Hasebe T, Tsubono Y, et al: The finrotic focus in advanced colorectal carcinoma: a hithrto unrecognized histological predictor for liver metastasis. Virchows Arch 433: 517-522 1998.
PubMed
29) Watanabe H, Enjoji M and Imai T: Gastric carcinoma with lymphoid stroma. Its morphologic characteristics and Prognostic correlations. Cancer 38: 232-243, 1976.
PubMed
30) 平戸純子: 髄膜腫特集-脳腫瘍の病理と臨床-. 病理と臨床 18: 1088-1096, 2000.
 
31) Tsuda H, Tani Y, Hasegawa T, et al: Concordance in judgements among c-erbB 2(HER 2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by southern blot hybridization in breast carcinoma. Pathol Int 51: 26-32, 2001.
 
32) Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116, 1985.
 
33) Yasui W, Yokozaki H, Shimamoto F, et al: Molecular-pathological diagnosis of gastrointestinal tissues and its contribution to cancer. Pathol Int 49: 763-774, 1999.
PubMed
34) Yasui W, Oue N, Kuniyasu H, et al: Molecular diagnosis of gastric cancer: present and future. Gastric Cance 4: 113-121, 2001.
 
35) 則松良明, 森谷卓也, 香田浩美・他:「新しい分類による子宮内膜増殖症の細胞診」子宮内膜増殖症および類内膜腺癌G1の細胞像に関する検討細胞集塊の形態異常を中心に. 日臨細胞会誌 37: 650-659, 1998.
 
36) 岩本俊之, 梶岡みゆき, 安原真由美・他: 乳腺穿刺吸引細胞診について. 日臨細胞会広島会報 13: 1-4, 1992.
 
37) Motomura K, Inaji H, Komoike Y, et al: Intraoperative sentinel nodes examination by imprint cytology and frozen section during breast surgery. Br J Surg 87: 597-601, 2000.
PubMed
38) 松野吉宏: がん治療の多施設共同研究における病理診断の精度管理. 特集-病理診断の精度管理-. 病理と臨床 19: 1335-1339, 2001.
 
P.501 掲載の参考文献
1) Woods WG, Gao R-N, Shuster JJ, et al: Screening of infants and mortality due to neuroblastoma. N Engl J Med 346: 1041-1046, 2002.
PubMed
2) Schilling FH, Spix L, Berthold F, et al: Neuroblastoma screening at one year of age. N Engl J Med 346: 1047-1053, 2002.
 
3) Perron L, Moore L, Bairati I, et al: PSA screening and prostate cancer mortality. CMAJ 166: 586-591, 2002.
PubMed
4) Taketa K, Endo Y, Sekiya C, et al: A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 53: 5419-5423, 1993.
PubMed
5) Mallory LD and Satomura S: AFP-L 3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 313: 15-19, 2001.
 
6) Narimatsu H, Iwasaki H, Nakayama F, et al: Lewis and Secretor gene dosages affect CA 19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 58: 512-518, 1998.
 
7) Sugano K, Usiama M, Fukutomi T, et al: Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitiv tumor marker for monitoring tumor relapse. Int J Cancer 89: 329-336, 2000.
 
8) 菅野康吉: p53による癌の分子診断. 実験医学(増刊) 19: 1176-1182, 2001.
 
9) Lubin R, Zalcman G, Bouchet L, et al: Serum p53 antibodies as early markers of lung cancer. Nat Med 1: 701-702, 1995.
 
10) Shimada H, Nakajima K, Ochiai T, et al: Detection of serum p53 antibodies in patient with esophageal squamous cell carcinoma: Correlation with clinicopathologic features and tumor markers. Oncology Rep 5: 871-874, 1998.
PubMed
P.502 掲載の参考文献
石井 勝・編: 腫瘍マーカーハンドブック. 医薬ジャーナル社, 大阪, 2001.
 
P.513 掲載の参考文献
1) 神奈川県衛生部: 神奈川のがん-1995-. 神奈川県悪性新生物登録事業年報 23: 63-109, 1999.
 
2) Schottenfeld D: Epidemiology, etiology, and pathogenesis of head and neck cancer. Head and Neck Cancer. (ed by Chretien PB and Johns ME) . vol 1, BC Decker, Philadelphia, 1985. pp 15-18.
 
3) 日本頭頸部腫瘍学会・編: 病理組織分類. 頭頸部癌取扱い規約. 改訂第3版, 金原出版, 東京, 2001, pp 64-65.
 
4) Stokkel MPM, Moons KGM, Broek FW, et al: 18 F-fluorodeoxyglucose dual-head positron emission tomography as a procedure fo detecting simultaneous primary tumors in cases of head and neck cancer. Cancer 86: 2370-2377, 1999.
 
5) Martino ED, Nowak B, Hassan HA, et al: Diagnosis and staging of head and neck cancer. Arch Otolaryngol Head Neck Surg 126: 1457-1461, 2000.
 
6) Teknos TN, Rosenthal EL, Lee D, et al: Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 23: 1056-1060, 2001.
PubMed
7) Schechter NR, Gillenwater AM, Byers RM, et al: Can positron emission tomography improve the quality of care for head and neck cancer patients? Int J Radiat Oncol Biol Phys 51(1) : 4-9, 2001.
PubMed
8) 山本逸雄, 三浦裕晃, 木上裕輔・他: 骨転移発見における血中I型コラーゲンC端テロペプチドの経時的測定の意義. 核医学 33: 423-429, 1996.
Medical*Online
9) Neel HB, Pearson GR, Weiland LH, et al: Application of Epstein-Barr virus serology to the diagnosis and staging of north American patients with nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 91: 255-262, 1983.
 
10) UICC: TNM classification of malignant tumors. Fifth revised edition, Springer-Verlag, Berlin, New York, Tokyo, 1997.
 
11) Gamel JW and Jones AS: Squamous carcinoma of the head and neck: cured fraction and median survival time as functions of age, sex, histologic type, and node status. Br J Cancer 67: 1071-1075, 1993.
 
12) Koivunew P, Rantala N, Hyrynkangas K, et al: The impact of patient and professional diagnostic delays on survival in pharyngeal cancer. Cancer 92: 2885-2891, 2001.
PubMed
13) Leborgne F, Leborgne JH, Fowler JF, et al: Advanced head and neck carcinoma in women. Cancer 91: 2353-2360, 2001.
PubMed
14) Mick R, Vokes EE, Weicheselbsum RR, et al: Prognostic factors in advanced head and neck cancer patients undergoing multi-modality therapy. Otolaryngol Head Neck Surg 105: 62-73, 1991.
 
15) Littelewood TJ: The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 28: 49-53, 2001.
 
16) List MA, Mumby P, Haraf D, et al: Plerformance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck. Qual Life Res 6: 274-284, 1997.
PubMed
17) Strone M, Clark JR, Fried MP, et al: T cell subsets and natural killer cell function with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 113: 1090-1093, 1996.
 
18) 佃 守: 頭頸部癌治療の現況. 免疫能と免疫療法. 癌と化学療法 23(3) : 283-290, 1996.
 
19) Lundy J, Raaf JH, Deakins S, et al: The acute and chronic effects of alcohol on the human immune system. Surg Gynecol Obstet 141: 212-218, 1975.
PubMed
20) 竹内 実: 喫煙と免疫機能. 臨床免疫 36(6) : 843-850, 2001.
 
21) Fortin A, Couture C, Doucet R, et al: Does histologic grade have a role in the management of head and neck cancers? J Clin Onlcol 19: 4107-4116, 2001.
 
22) 堀内正敏, 田村嘉之, 相原 均・他: 舌癌の深達度測定の臨床的意義. 口腔咽頭科 4: 171-177, 1992.
 
23) 木村結紀, 柳沢昭夫, 鎌田信悦・他: 舌部分切除後にリンパ節転移をきたしたpT1舌癌症例の臨床病理学的比較検討. 頭頸部腫瘍 21: 50-55, 1995.
 
24) Leeman CR, Tiwari R, Nauto JJ, et al: Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 71: 452-456, 1993.
 
25) Mamelle G, Pumpurik J, Luboinski B, et al: Lymphnode prognostic factors in head and neck squamous cell carcinoma. Am J Surg 168: 494-498, 1994.
 
26) Canter RL, Bliss JM, Soo KC, et al: Radical neck dissections for squamous carcinomas: pathological findings and their clinical implications with particular reference to transcapsular spread. Int J Radiat Oncol Biol Phys 13: 825-832, 1987.
 
27) Richard JM, Sancho-Garnier S, Micheau C, et al: Prognostic factors in cervical lymph node metastasis in upper respiratory and digestive tract carcinomas: study of 1713 cases during a 15-year period. Laryngoscope 97: 97-101, 1987.
 
28) Spector JG, Sessions DG, Haughey BH, et al: Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope 111: 1079-1087, 2001.
PubMed
29) Akerall JA, Michalides RJAM, Mineta H, et al: Amplification of cyclinD1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 99: 380-389, 1997.
 
30) Kyomoto R, Kumazawa H, Toda Y, et al: CyclinD1-gene amplification is a more potent prognostic factor than its protein over-expression in human head and neck squamous cell carcinoma. Int J Cancer 94: 576-581, 1997.
 
31) Fan GK, Fujieda S, Sunaga H, et al: Expression of protein p 27 is associated with progression and prognosis in laryngeal cancer. Laryngoscope 109: 815-820, 1999.
 
32) Mineta H, Miura K, Suzuki I, et al: Low p 27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer 85: 1011-1017, 1999.
 
33) Xie X, Clausen OP, De Angelis P, et al: The prognostic value of spontaneous apoptosis. Bax, Bcl-2, and p 53 in oral squamous cell carcinoma of the tongue. Cancer 86(6) : 913-920, 1999.
 
34) Smith BO, Smith GL, Carter D, et al: Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18: 2046-2052, 20003.
 
35) O-charoenrat P, Rhys-Evans P and Eccles SA: Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92: 556-568, 2001.
PubMed
36) O-charoenrat P, Rhys-Evans PH and Eccles SA: Expression of matrix metalloproteinase and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127: 813-820, 2001.
PubMed
37) Yoshizaki T, Maruyama Y, Sato H, et al: Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 9: 44-50, 2001.
 
38) 佃 守: 頭頸部癌における染色体, 遺伝子研究の現況. 耳鼻・頭頸外科 68(9) : 751-766, 1996.
 
39) Vaupel P, Kelleher , DK and Mockel M: Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28: 29. 35, 2001.
 
40) Teshima T, Inoue T, Chatani M, et al: Incidence of other primary cancers in 1569 patients with pharyngolaryngeal cancer and treated with radiation therapy. Strahlenther Onkol 168: 213-218, 1992.
PubMed
41) Chen TY, Emrich LJ, Driscoll DL, et al: The clinical significance of pathological findings in surgically in head and neck carcinoma. Int J Radiat Oncol Biol Phys 13: 833-837, 1987.
PubMed
42) Al-Saraf M and Hussein M: Head and neck cancer: present status and future prospects of adjuvant chemotherapy. Cancer Invest 13(1) : 41-53, 1995.
 
43) Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355: 949-955, 2000.
PubMed
44) Leon X, Quer M, Onu's C, et al: Histologically negative specimens after induction chemotherapy: frequency and impact on survival. Head Neck 22: 808-813, 2000.
 
45) Gillison ML and Forastiere AA: Larynx preservation in head and neck cancers. Hematol Oncol Clin North Am 13(4) : 699-719, 1999.
PubMed
46) 佃 守, 小笠原寛, 金子省三・他: 無作為化比較試験による頭頸部癌補助化学療法におけるUFTの有用性検討. 癌と化学療法 21(8) : 1169-1177, 1994.
Medical*Online
47) Dulguerov P, Jacobsen MS, Allal AS, et al: Nasal and paranasal sinus carcinoma. Are We Making Progress? Cancer 92: 3012-3029, 2001.
PubMed
48) Lewis JS: Cancer of the nasal cavity and paranasal sinuses. J Laryngol Otol 86: 255-286, 1972.
PubMed
49) 田崎瑛生: 放射線治療. 頭頸部II. 副鼻腔癌, 放射線医学, 第2版, 医学書院, 東京, 1967, p 340.
 
50) 佐藤靖雄, 森田 守: 上顎癌-併用療法による治療効果. 癌の臨床 23: 1118-1123, 1979.
 
51) Nishino H, Miyata M, Morita M, et al: Combined therapy with conservative surgery, radiotherapy, and regional chemotherapy for maxillary sinus carcinoma. Cancer 89: 1925-1932, 2000.
PubMed
52) Hayashi T, Nonaka S, Bandoh N, et al: Treatment outcome of maxillary sinus squamous cell carcinoma. Cancer 92: 1495-1503, 2001.
PubMed
53) 犬山征夫: 頭頸部癌に対するneoadjuvant chemotherapy. 耳鼻臨床 82: 1043-1050, 1989.
 
54) 今野昭義, 花沢 秀, 岡本美孝・他: 頭頸部がんの集学的治療. 上顎洞癌の集学的治療. 癌と化学療法 14(6) : 1772-1780, 1987.
 
55) 三谷浩樹, 鎌田信悦, 苦瓜知彦・他: 上顎癌治療法の変遷と成績. 耳鼻展望 44: 180-189, 2001.
 
56) 鎌田信悦: 鼻副鼻腔癌に対する頭蓋底外科. 癌の臨床 44: 1309-1315, 1998.
Medical*Online
57) 犬山征夫: 頭頸部癌治療における化学療法の役割. 東京医学社, 東京, 1997, pp 168-184.
 
58) 行木英生: 上顎癌治療における頭蓋底外科とその手術手技. 頭頸部腫瘍 24: 423-428, 1998.
 
59) 横山純吉: 頭頸部癌の超選択的動注化学療法. JOHNS 17: 94-97, 2001.
 
60) 新谷 悟, 松浦秀博, 長谷川泰久: 舌癌における原発巣の深さは転移予知因子となりえるか. 頭頸部腫瘍 22: 180-184, 1996.
 
61) 木村幸紀, 柳澤昭夫, 鎌田信悦・他: 舌癌手術後のリンパ節転移の予知因子について-舌部分切除単独治療症例を用いての検討-. 頭頸部腫瘍 22: 78-82, 1996.
 
62) 林 隆一, 海老原敏: 11. 舌癌 Practical Otolaryngology. 文光堂, 東京, 2001, pp 112-115
 
63) 鎌田信悦, 吉本世一: 舌癌III・IV期の治療-舌癌III・IV期の治療方針. JOHNS 16: 607-610, 2000.
 
64) 朝蔭孝宏, 海老原敏, 岸本誠司・他: 手術を主体とした舌癌の治療成績. 頭頸部腫瘍 25: 118-122, 1999.
 
65) 佐竹文介, 静 隆男, 牧野総太郎・他: Stage I, II症例の治療放射線治療を中心に. 耳喉頭頸 63: 599-603, 1991.
 
66) 鎌田信悦, 川端一嘉, 中溝宗永・他: Stage III, IV症例の治療 癌研究会附属病院の場合. 耳鼻・頭頸外科 63: 609-616, 1991.
 
67) 西川邦男, 永田基樹, 門田伸也・他: 進行舌癌の治療-再建を含めた治療の適応と選択-. 耳鼻 47(補1) S63-S70, 2001.
 
68) Geara FB, Glisson BS, Sanquineti G, et al: Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 79: 1279-1286, 1997.
 
69) Al-Saraf M, LeBlanc M, Shanker Giri PG, et al: Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergruoup study OO99. J Clin Oncol 16: 1310-1317. 1998.
 
70) 佃 守: 上咽頭癌におけるneo-adjuvant chemotherapy の役割. JOHNS 14(11) : 1587-1591, 1998.
 
71) International nasopharynx cancer study group: VUMCA trial: Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (≧N 2, MO) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radia Oncol Biol Phys 35(3) : 463-469, 1996.
 
72) Fu KK: Combined radiotherapy and chemotherapy for nasopharyngeal carcinoma. Semin Radiat Oncol 8(4) : 247-253, 1998.
PubMed
73) King WWK, Ku PKM, Mok C, et al: Nasopharyngectomy in the treatment of recurrent nasopharyngeal carcinoma: a twelve-year experience. Head Neck 22: 215-222, 2000.
 
74) Yen KL, Hsu LP, Sheen TS, et al: Salvage neck dissection for cervical recurrence of nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 123(7) : 725-729, 1997.
PubMed
75) 苦瓜知彦, 鎌田信悦, 川端一嘉・他: 中咽頭癌再発例の検討. 頭頸部腫瘍 25: 75-80, 1999.
 
76) 柘植勇人, 長谷川泰久, 松浦秀博・他: 中咽頭扁平上皮癌における治療法選択の検討. 日耳鼻 97: 1631-1642, 1994.
 
77) 今西順久, 藤井正人, 徳丸裕・他: 中咽頭扁平上皮癌の臨床統計学的検討-予後因子の解析および治療方針の評価-. 日耳鼻 101: 602-614, 1998.
 
78) Mendenhall WM, Amdur J, Stringer SP, et al: Radiation therapy for squamous cell carcinoma of the tonsillar region: A preferred alternative to surgery? J CIin Oncol 18: 2219-2225, 2000.
 
79) 真島一彦, 小野 勇, 海老原敏・他: 中咽頭側壁悪性腫瘍の臨床像. 日耳鼻 85: 1553-1561, 1982.
 
80) 佃 守: Chemoradiation の臨床 頭頸部癌. 癌と化学療法 24(14) : 2049-2057, 1997.
 
81) Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 9: 2081-2086. 1999.
 
82) Gehanno P, Depondt J, Guedon C, et al: Primary and salvage surgery for cancer of the tonsillar region: A retrospective study of 120 patients. Head Neck 15: 185-189, 1993.
PubMed
83) Hicks WL, Kuriakose MA, Loree TR, et al: urgery versus radiation therapy as single-modality treatment of tonsillar fossa carcinoma: The Roswell Park Cancer Institute experience (1971-1991) . Laryngoscope 108: 1014-1019, 1998.
 
84) Pernot M, Malissard L, Hoffstetter S, et al: Influence of tumoral, radiobiological, and general factors on local (control and survival of a series of 361 tumors of the velotonsi11ar area treated by exclusive irradiation (external beam irradiation 十 brachytherapy or brachytherapy alone) . Int J Radia Oncol Biol Phys 30: 1051-1057, 1994.
 
85) Gwozdz JT, Morrison WH, Garden AS, et al: Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. Int J Radiat Oncol Biol Phys 39: 127-135. 1997.
PubMed
86) Hermans R, Opde beek, Van den Bogaert W, et al: The radiation of CT-determined tumor parameters of tonsillar cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 50: 37-45, 2001.
 
87) 苦瓜知彦, 鎌田信悦, 川端一嘉・他: 中咽頭側壁扁平上皮癌の予後を左右する因子の解析. 日耳鼻 99: 1190-1199, 1996.
 
88) Wang CC, Montgomery W and Efird J: Local control of oropharyngeal carcinoma by irradiation alone. Laryngoscope 105: 529-533, 1995.
PubMed
89) Mendenhall WM, Stringer SP, Amdur RJ et al: Is radiation therapy a preferred alternative to surgery for squamous carcinoma of the base of tongue? J Clin Oncol 18: 35-42, 2000.
 
90) Weber RS, Gidley P, Morrison WH, et al: Treatment selection for carcinoma of the base of tongue. Am J Surg 160: 415-419, 1990.
PubMed
91) Erkal HS, Serin M, Amdur RJ, et al: Squamous cell carcinomas of the soft palate treated with radiation therapy alone or followed by planned neck dessection. Int J Radiat. Oncol Biol Phys 50: 359-366, 2001.
PubMed
92) 稲上憲一, 佐藤武男, 吉野邦俊・他: 中咽頭癌の治療-とくに原発巣の制御について-. 頭頸部腫瘍 25: 163-168., 1999.
 
93) 苦瓜知彦, 鎌田信悦, 川端一嘉・他: 中咽頭癌の頸部リンパ節転移に対する治療方針. 日耳鼻 103: 803-811, 2000.
 
94) 村上 泰: 下咽頭癌の腫瘍特性. 耳鼻臨床 88(2) : 133-146, 1995.
 
95) Marks SC, Lolachi CM, Shamsa F, et al: Outcome of Pyriform sinus cancer: a retrospective institutiona review. Laryngoscope 106: 27-31, 1996.
 
96) Hoffman HT, Karnell LH, Shah JP, et al: Hypopharyngeal cancer patient care evaluation. Laryngoscope 107: 1005-1017, 1997.
PubMed
97) 榎本浩幸, 佃 守, 堀内長一・他: 当科における進行下咽頭癌症例の治療成績. 耳鼻 46: 75-81, 2000.
 
98) Lefebure JL: What is the role primary surgery in the treatment of laryngeal and hypopharyngeal cancer? Arch Otolaryngol Head Neck Surg 126: 285-288, 2000.
 
99) Clayman GL, Weber RS, Guillamondegui O et al: Laryngeal preservation for advanced laryngeal and hypopharyngeal cancers. Arch Otolaryngol Head Neck Surg 121: 219-223, 1995.
PubMed
100) Beauvillain L. Mahe'M, Bourdin S, et al: Final results of a randomized trial comparing plus surgery plus radiotherapy in locall advance dresectable hypopharyngeal carcinomas. Laryngoscope 107: 648-653, 1997.
 
101) Zelefsky MJ, Kraus DH, Pfister DG, et al: Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head Neck 1: 405-411, 1996.
 
102) Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: preliminary results of an European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group J Natl Cancer Inst 88: 890-899, 1996.
 
103) Kies MS, Haraf DJ, Vokes EE, et al: Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol 16: 2715-2721, 1998.
PubMed
104) 藤本伊三郎, 花井彩, 大島 明・他: 大阪府におけるがんの罹患と死亡 1963-1989. 大阪成人病予防協会, 篠原出版, 東京, 1993, pp 105-107.
 
105) 藤井 隆, 佐藤武男, 吉野邦俊・他: 大阪府立成人病センターにおける喉頭癌1079例の臨床統計. 日耳鼻 100: 856-863, 1997.
 
106) Smee R, Bridger GP, Williams J, et al: Early glottic carcinoma: Results of treatment by radiotherapy. Radiat Oncol 44: 53-59, 2000.
 
107) Mendenhall WM, Amdur RJ, Morris CG, et al: T1-T2 N 0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 19: 4029-4036, 2001.
 
108) Harwood AR: Cancer of the larynx-the Toront experience. J Otolaryngol 11 (Supple) : 1-21, 1982.
 
109) Haraf DJ and Weichselbaum RR: Treatment selection in T 1 and T 2 vocal cord carcinoma. Oncology (Williston Park) 2 (10) : 41-50, 1988.
 
110) Mendenhall WM, Persons JT, Stringe SP, et al: T1-T2 vocal cord carcinoma: a basis for comparing the results of radiotherapy and surgery. Head Neck Surg 10: 373-377, 1988.
 
111) Steiner W: Results of curative laser microsurgery of laryngeal carcinomas. Am J Otolaryngol 14: 116-121, 1993.
PubMed
112) Blakeslee D, Vaughan CW, Shapshay, et al: Excisional biopsy in the selective management of T 1 glottic cancer: a three-year follow-up study. Laryngoscope 94: 488-494, 1984.
 
113) Kaufman JA: The endoscopic management of early squamous cell carcinoma of the vocal cord with the carbon dioxide surgical laser: clinical experience and a proposed subclassification. Otolaryngol Head Neck Surg 95: 531-537, 1986.
 
114) Urken ML and Biller HF: Management of early vocal cord carcinoma. Oncology (Williston Park) 2 (4) : 48-62, 1988.
PubMed
115) Nibu K: Partial laryngectomy in the treatment of radiation-failure of early glottic carcinoma. Head Neck 19: 116-120, 1997.
 
116) Hirano M, Kurita S and Matsuoka H: Vocal function following hemilaryngectomy. Ann Otol Rhinol Laryngol 96: 586-589, 1987.
PubMed
117) MacKenzie RG, Franssen E, Balogh JM, et al: Comparing treatment outcomes of limited to patients eligible for surgery. Int J Radiat Oncol Biol Phys 47 (1) : 65-75, 2000.
PubMed
118) Bryant GP, Poulsen MG, Tripcony L, et al: Treatment decisions in T 3 N 0 M 0 glottic carcinoma. Int J Radiat Oncol Biol Phys 31(2) : 285-293, 1995.
 
119) Jones AS, Cook JA, Phillips DE, et al: Treatment of T 3 carcinoma of the larynx by surgery or radiotherapy. Clin Otolaryngol 17(5) : 433-436, 1992.
PubMed
120) Mendenhall WM, Parsons JT, Mancuso AA, et al: Radiotherapy for squamous cell carcinoma of the supraglottic larynx: an alternative to surgery. Head Neck 18(1) : 24-35, 1996.
PubMed
121) Shimm DS and Coulthard SW: Radiation therapy for squamous cell carcinoma of the supraglottic larynx. Am J Clin Oncol 12(1) : 17-23, 1989
PubMed
122) Crus C, Leon X, Vega M, et al: Initial treatment of the early stages (I, II) of supraglottic squamous cell carcinoma: partial laryngectomy versus radiotherapy. Eur Arch Otorhinolaryngol 257(9) : 512-516, 2000.
 
123) Finizia C, Geterud A, Holmberg E, et al: Advanced laryngeal cancer T3-T4 in Sweden: a retrospective study 1986-1990. Survival and locoregional control rellated to treatment. Acta Otolaryngo 116: 906-912, 1996.
 
124) Donald GS, Joseph HO, Marvin PF, et al: arcinoma of the subglottic area. Laryngoscope 85: 1417-1423, 1975.
 
125) Nguyen-Tan PF, Le QT, Quivey JM, et al: Treatment results and prognostic factors of advanced T 3-4 laryngeal carcinoma: The University of California. San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys 50(5) : 1172-1180, 2001.
 
126) 日本TNM分類委員会頭頸部小委員会: 頭頸部TNM分類研究資料. 国立がんセンター頭頸科, 1993, pp 41-60.
 
127) 吉野邦俊, 佐藤武男, 藤井 隆・他: 喉頭癌に対する頸部郭清術. 頭頸部外科 5: 85-94, 1995
 
128) Myers EN and Alivi A: Management of carcinoma of the supraglottic larynx: evolution, current, concepts, and future trends. Laryngoscope 106: 559-567, 1996
 
P.523 掲載の参考文献
1) Aisner J, Alberto P, Bitran J et al: Role of chemotherapy in small cell lung cancer: a consensu report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep 67: 37-43, 1983.
 
2) Turrisi III AT, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265-271, 1999.
 
3) Morita T and Sugano H: A statistical analysis of lung cancer registered in the annual of pathological autopsy cases in Japan between 1958 and 1987. with special reference to the characteristics of lung cancer in Japan. Acta Pathol Jpn 40: 665-675, 1990.
 
4) Murren J, Glatstein E and Pass H: Small cell lung cancer. In Cancer: Principles and Practice of Oncology, (ed by DeVita VT Jr. Hellman S and Rosenberg SA) , 6th Edition, JB Lippincott Co. Philadelphia, 2001, pp 983-1018.
 
5) Travis WD, Linder J and Mackay B: Classification, histology, cytology, and electron microscopy. In Lung Cancer: Principles and Practice, (ed by Pass HI, Mitchell JB, Johnson DH, et al) , Lippincott-Raven, Philadelphia, 2000 pp 453-495,
 
6) 西脇 裕: 肺癌X線診断ハンドブック. 協和企画通信, 東京, 1984.
 
7) 関戸好孝: 肺癌細胞における分子生物学的アプローチ. 日本臨床 58: 1036-1040, 2000.
Medical*Online
8) 増田 彰, 高橋 隆: 癌遺伝子および癌抑制遺伝子. 肺癌, (福岡正博, 西條長宏・編) , 南江堂, 東京, 1998, pp 180-183.
 
9) Janne PA and Johnson BE: The role of myc, jun, and fos oncogenes. In Lung Cancer: Principles and Practice, (ed by Pass HI, Mitchell JB, Johnson DH, et al) , Lippincott-Raven, Philadelphia, 2000, pp 98-119.
 
10) Veronese ML, Sozzi G, Huebner K, et al: The role of the FHIT gene in the pathogenesis of lung cancer. In Lung Cancer: Principles and Practice. (ed by Pass HI, Mitchell JB, Johnson DH, et al) , Lippincott-Raven, Philadelphia, 2000, pp 156-169.
 
11) 厚生省大臣官房統計情報部・編: 平成11年人口動態統計. 厚生省大臣官房統計情報部, 東京, 2001.
 
12) がんの統計編集委員会・編: がんの統計'01. 財団法人癌研究振興財団, 東京, 2001
 
13) 森田豊彦: 肺癌の疫学. 臨床医 22: 1904-1909, 1996.
 
14) Hanai A, Benn T, Fujimoto I, et al: Comparison of lung cancer incidence rates by histological type in high and low incidence countries, with reference to the limited role of smoking. Jpn J Cancer Res 79: 445-452, 1988.
 
15) 日本肺癌学会・編: 臨床・病理, 肺癌取扱い規約. 改訂第5版, 金原出版, 東京, 1999.
 
16) World Health Organization: histological typing of lung tumours, 2nd ed, International Histological Classification of tumours, No. 1 World Health Organization, Geneva, 1981.
 
17) Travis WD, Colby TV, Corrin B, et al: Histological typing of lung and pleural tumours, World Health Organization International Histological Classification of Tumours, 3rd ed. Springer. Berlin, 1999.
 
18) 下里幸雄: 肺腫瘍の新しいWHO分類について. 肺癌の臨床 2: 277-285, 1999.
Medical*Online
19) 下里幸雄: WHO肺ならびに胸膜腫瘍組織分類第三版の解説: 肺上皮性腫瘍について. 肺癌 40: 1-10, 2000.
 
20) Travis WD, Linnoila RI, Tsokos MG, et al: Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma, An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 15: 529-553, 1991.
PubMed
21) Kraut M and Wozniak A. Clinical presentation. In Lung Cancer: Principles and Practice. (ed by Pass HI, Mitchell JB, Johnson DH, et al) , Lippincott-Raven, Philadelphia, 2000. pp 522-534.
 
22) 国兼浩嗣, 渡辺古志郎: 病状・理学的所見から見た肺癌. 日内会誌 86: 4-9, 1997.
 
23) 北村 諭, 坂東政司: 肺がんの初発症状. 総合臨床 43: 1479-1484, 1994.
 
24) Yamaguchi K, Aoyagi K, Urakami K, et al: Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res 86: 698-705, 1995.
PubMed
25) Takada M, Kusunoki Y, Masuda N, et al: Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br J Cancer 73: 1227-1232, 1996.
PubMed
26) Niho S, Nishiwaki Y, Goto K, et al: Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 27: 159-167, 2000.
PubMed
27) Fukuoka M, Furuse K, Saijo N, etal: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83: 855-861, 1991.
PubMed
28) Kudoh S, Fujiwara Y, Takada Y, et al: for the West Japan Lung Cancer Group: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 16: 1068-1074, 1998.
PubMed
29) Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002.
PubMed
30) Pignon Jp, Arriagada R, Ihde DC, et al: Ameta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327: 1618-1624, 1992.
 
31) Warde P and Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? Ameta-analysis. J Clin Oncol 10: 890-895, 1992.
 
32) Medical Research Council: Comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet ii: 979-986, 1966.
 
33) Miller AB, Fox W and Tall R: Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet ii: 501-505, 1969.
PubMed
34) Fox W and Scadding JG: Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet ii: 63-65, 1973.
PubMed
35) Shields TW, Higgins Jr GA, Matthews MJ, et al: Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 84: 481-488, 1982.
 
36) Shepherd FA, Ginsberg RJ, Evans WK, et al: Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer. J Thorac Cardiovasc Surg 86: 498-506, 1983.
PubMed
37) Meyer JA, Comis RL, Ginsberg SJ, et al: The prospect of disease control by surgery combined with chemotherapy in stage I and stage II small cell carcinoma of the lung. Ann Thorac Surg 36: 37-41, 1983.
 
38) Shepherd FA, Ginsberg RJ, Patterson GA, et al: A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. University of Toronto Lung Oncology Group stud. J Thorac Cardiovasc Surg 97: 77-186, 1989.
 
39) Yamada K, Saijo N, Kojima A, et al: A retrospective analysis of patients receiving surgery after chemotherapy for small cell lung cancer. Jpn J Clin Oncol 21: 39-45, 1991.
PubMed
40) Takei H, Ohe Y, Tamura T, et al: Indication of surgery for small cell lung cancer based on clinical stage. Proc ASCO 16: 485a, 1997.
 
41) Suzuki K, Tsuchiya R, Ichinose Y, et al: Phase II trial of postoperative adjuvant cisplatin/etoposide(PE) in patients with completely resected stage I-III A small cell lung cancer(SCLC) : The Japan Clinical Oncology Lung Cancer Study Group Trial(JCOG 9101) . Proc ASCO 19: 492a, 2000.
 
42) Greco FA, Richardson RL, Snell JD, et al: Small cell lung cancer. Complete remission and improved survival. Am J Med 66: 625-630, 1979.
PubMed
43) Evans WK, Shepherd FA, Feld R, et al: VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3: 1471-1477, 1985.
PubMed
44) Aisner J, Whitacre M, Van Echo DA, et al: Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. Cancer Treat Rep 66: 221-230, 1982.
PubMed
45) Thatcher N. Ifosfamide/carboplatin/etoposide(ICE) regimen in small cell lung cancer. Lung Cancer 9(Suppl 1) : s51-67, 1993.
 
46) Skarlos DV, Samantas E, Kosmidis P, et al: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 5: 601-607, 1994.
 
47) Goldie JH, Coldman AJ and Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66: 439-449, 1982.
PubMed
48) Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 107: 451-458, 1987.
PubMed
49) Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10: 282-291, 1992.
 
50) Murray N, Shah A, Osoba D, et al: Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9: 1632-1638, 1991.
PubMed
51) Furuse K, Fukuoka M, Nishiwaki Y, et al: Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. J Clin Oncol 16: 2126-2132, 1998.
PubMed
52) Murray N, Livingston RB, Shepherd FA, et al: Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17: 2300-2308, 1999.
 
53) Klasa RJ, Murray N and Coldman AJ: Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 9: 499-508, 1991.
PubMed
54) Arriagada R, Le Chevalier T, Pignon JP, et al: Initial chemotherapeutic doses and survival in patients with limited smallcell lung cancer. N Engl J Med 329: 1848-1852, 1993.
 
55) Le Chevalier T, Alain R, Jean Pierre P, et al: Is there an optimal dose for frontline chemotherapy(CT) in limited small cell lung cancer(SCLC) ? Results of a randomized trial in 295 patients from the French Cancer Centers Group. Proc ASCO 21: 294a, 2002.
 
56) Armitage JO: Bone marrow transplantation. N Engl J Med 330: 827-838, 1994.
PubMed
57) Lazarus HM: Autologous bone marrow transplantation for the treatment of lung cancer. Semin Oncol 20(Suppl 6) : 72-79, 1993.
 
58) Elias AD, Ayash L, Frei III E, et al: Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst 85: 559-566, 1993.
 
59) Elias A, Ibrahim J, Skarin AT, et al: Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 17: 1175-1184, 1999.
PubMed
60) Brugger W, Frommhold H, Pressler K, et al: Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer. Semin Oncol 22(Suppl 2) : 3-8, 1995.
 
61) The Medical Research Council by its Lung Cancer Working Party: Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 59: 584-590, 1989.
PubMed
62) Spiro SG, Souhami RL, Geddes DM, et al: Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 59: 578-583, 1989.
PubMed
63) Giaccone G, Dalesio O, McVie GJ, et al: Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J Clin Oncol 11: 1230-1240, 1993.
 
64) Jett JR, Maksymiuk AW, Su JQ, et al: Phase III trial of recombinant interferon gamma in complete responders with smallcell lung cancer. J Clin Oncol 12: 2321-2326, 1994.
 
65) Schiller JH, Adak S, Cella D, et al: Topotecan versus observation after cisplatin plus etoposide in extensive-stage smallcell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19: 2114-2122, 2001.
 
66) Shepherd FA, Giaccone G, Seymour L, et al: Prospective randomized double-blind placebo-controlled trial of Marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institutte of Canada-Clinical Trials Group and the Europeun Organization for Research and Treatment of Cancer. J Clin Oncol 20(22) 4434-4439, 2002.
 
67) he Y and Saijo N: Topoisomerase I targeting agents in small-cell lung cancer. Curr Oncol Rep 3: 170-178, 2001.
 
68) Kelly K, Pan Z, Wood ME, et al: A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Clin Cancer Res 5: 3419-3424, 1999.
PubMed
69) Kelly K, Lovato L, Bunn PA Jr, et al: Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: aphase II trial of the Southwest Oncology Group. Clin Cancer Res 7: 2325-2329, 2001.
 
70) Glisson BS, Kurie JM, Perez-Soler R, et al: Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 17: 2309-2315, 1997.
PubMed
71) Bremnes RM, Sundstrom S, Vilsvik J, et al: Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol 19: 3532-3538, 2001.
 
72) Mavroudis D, Papadakis E, Veslemes M, et al: A multicenter randomized clinical trial comparing paclitaxel-cisplatinetoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 12: 463-470, 2001.
PubMed
73) Niell HB, Herndon JE, Miller AA, et al: Randomized phase III intergroup trial(CALGB 9732) of etoposide(VP-16) and cisplatin(DDP) with or without paclitaxel(TAX) and G-CSF in patients with extensive stage small cell lung cancer(EDSCLC) . Proc ASCO 21: 293a, 2002.
 
74) Yana T, Negoro S, Takada Y, et al: Phase II study of amrubicin(SM-5887) , a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer(ES-SCLC) : awest Japan lung cancer group trial. Proc ASCO 17: 450a, 1998.
 
75) van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib(STI 571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421-1423, 2001.
PubMed
76) Heinrich MC, Blanke CD, Druker BJ, et al: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20: 1692-1703, 2002.
 
77) Johnson BE, Fisher B, Fisher T, et al: Phase II study of STI 571(Gleevec) for patients with small cell lung cancer. Proc ASCO 21: 293a, 2002.
 
78) Eberhardt W, Stamatis G, Stuschke M, et al: Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages I B to III B: long-term results of a phase II trial. Br J Cancer 81(7) : 1206-1212, 1999.
 
79) Auperin A, Arriagada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 341: 476-484, 1999.
PubMed
80) Jeremic B, Shibamoto Y, Nikolic N, et al: Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol 17: 2092-2099, 1999.
PubMed
81) Siu LL, Shepherd FA, Murray N, et al: Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 14: 821-828, 1996.
PubMed
82) Yuen AR, Zou G, Turrisi AT, et al: Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma, Cancer 89: 1953-1960, 2000.
PubMed
83) Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94: 173-181, 2002.
 
84) Sakuragi T, Oshita F, Nagashima S, et al: Retrospective analysis of the treatment of patients with small cell lung cancer showing Poor performance status. Jpn J Clin Oncol 26: 128-133, 1996.
PubMed
85) Ohe Y, Yamamoto S, Suzuki K, et al: Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 37: 54-63, 2001.
PubMed
86) Girling DJ: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 348: 563-566, 1996.
PubMed
87) Souhami RL, Spiro SG, Rudd RM, et al: Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89: 577-580, 1997.
PubMed
88) Oshita F, Kurata T, Kasai T, et al: Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 86: 1198-1202, 1995.
PubMed
89) Okamoto H, Watanabe K, Nishiwaki Y, et al: Phase II study of area under the plasma Concentration-versus-time curvebased carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 11: 3540-3545, 1999.
PubMed
90) Greco FA: Treatment options for patients with relapsed small cell lung cancer. Lung Cancer 9(Suppl 1) : S85-S 89, 1993.
 
91) Smit EF, Fokkema E, Biesma B, et al: A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77(2) : 347-351, 1998.
PubMed
92) Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel(Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 30 A(8) : 1058-1060, 1994.
 
93) Negoro S, Fukuoka M, Niitani H, et al: Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer(SCLC) . Proc ASCO 10: 241, 1991.
 
94) Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: anew derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225-1229, 1992.
PubMed
95) DeVore RF, Blanke CD, Denham CA, et al: Phase II study of irinotecan(CPT-11) in patients with previously treated small-cell lung cancer(SCLC) . Proc ASCO 17: 451a, 1998.
 
96) von Pawel J, Schiller JH, Shepherd FA, et al: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17: 658-667, 1999.
PubMed
97) Kubota K, Nishiwaki Y, Kakinuma R, et al: Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 15: 292-296, 1997.
PubMed
98) Masuda N, Matsui K, Negoro S, et al: Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16: 3329-3334, 1998.
 
99) Goto K, Sekine I, Nishiwaki Y, et al: Phase II study of weekly cisplatin, etoposide and irinotecan(PE/CPT) for relapsed small cell lung cancer(SCLC) . Proc ASCO 21: 316a, 2002.
 
100) Green RA, Humphrey E, Close H, et al: Alkylating agents in bronchogenic carcinoma. Am J Med 46: 516-525, 1969.
PubMed
101) Takada M, Fukuoka M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20(14) : 3054-3060, 2002.
 
102) Jeremic B, Shibamoto Y, Acimovic L, et al: Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 15(3) : 893-900, 1997.
PubMed
103) Feld R, Sagman U and LeBlanc M: Staging and prognostic factors for small cell lung cancer. In Lung Cancer: Principles and Practice, (ed by Pass HI, Mitchell JB, Johnson DH, et al) , Lippincott-Raven, Philadelphia, 2000, pp 612-627.
 
104) Albain KS, Crowley JJ, LeBlanc M, et al: Determinants of improved outcome in small-cell lung cancer: an analysis of the 2, 580-patient Southwest Oncology Group data base. J Clin Oncol 8: 1563-1574, 1990
 
105) Sagman U, Maki E, Evans WK, et al: Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol 9: 1639-1649, 1991.
PubMed
106) Richardson GE, Tucker MA, Venzon DJ, et al: Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 119: 383-390, 1993.
PubMed
107) Tucker MA, Murray N, Shaw EG, et al for the Lung Cancer Working Cadre: Second primary cancers related to smoking and treatment of small-cell lung cancer. J Natl Cancer Inst 89: 1782-1788, 1997.
PubMed
P.534 掲載の参考文献
1) Pignon Jp, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327: 1618-1624, 1992.
PubMed
2) Warde P and Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10: 890-895, 1992.
PubMed
3) Morris DE, Socinski MA and Detterbeck: Limited stage small cell lung cancer. In: Diagnosis and Treatment of Lung Cancer; An Evidence-Based Guide for the Practicing Clinician, (ed by Detterbeck, et al) , Saunders, Philadelphia, 2001, pp 341-359.
 
4) Komaki R: Management of limited small-cell lung cancer. Int J Clin Oncol 5: 205-216, 2000.
 
5) Curran Jr WJ: Combined-modality therapy for limited-stage small cell lung cancer. Semin Oncol 28(suppl 4) : 14-22, 2001.
 
6) Fox W and Scadding JG: Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus: Ten-year follow-up. Lancet ii(820) : 63-65, 1973.
PubMed
7) Murray N: Treatment of small cell lung cancer: the state of the art. Lung Cancer 17(suppl 1) : S75-S 89, 1997.
 
8) Perry MC, Eaton WL, Propert KJ, et al: Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316: 912-918, 1987.
 
9) Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11: 336-344, 1993.
PubMed
10) Jeremic B, Shibamoto Y, Acimovic L, et al: Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 15: 893-900, 1997.
PubMed
11) Takada M, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20: 3054-3060, 2002.
 
12) 西村恭昌: 化学放射線療法: Neoadjuvant chemotherapy versus concurrent chemotherapy. 癌の臨床 46(3) : 273-277, 2000.
 
13) Tannock IF: Treatment of cancer with radiation and drugs. J Clin Oncol 14: 3156-3174, 1996.
PubMed
14) Coy P, Hodson I, Payne DG, et al: The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian multicenter randomized trial. Int J Radiat Oncol Biol Phys 14: 219-226, 1988.
PubMed
15) Arriagada R, Chevalier TL, Ruffie P, et al: Alternating radiotherapy and chemotherapy in 173 consecutive patients with limited small cell lung carcinoma. Int J Radiat Oncol Biol Phys 19: 1135-1138, 1990.
 
16) Choi NC, Herndon II JE, Rosenman J, et al: Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 16: 3528-3536, 1998.
 
17) 西村恭昌: 線量時間関係の基礎と臨床. 癌の放射線治療, (田中敬正, 他・編著) , 金芳堂, 京都. 1998, pp 190-198.
 
18) Turrisi AT, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265-271, 1999.
PubMed
19) Bonner JA, Sloan JA, Shanahan TG, et al: Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small cell lung carcinoma. J Clin Oncol 17: 2681-2691, 1999.
PubMed
20) Ariyoshi Y, Fukuoka M, Furuse K, et al: Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited stage small-cell lung cancer. Jpn J Clin Oncol 24: 275-281, 1994.
PubMed
21) Macbeth FR, Wheldon TE, Girling DJ, et al: Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. Clin Oncol8: 176-181, 1996.
PubMed
22) Auperin A, Arriagada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 341: 476-484, 1999.
PubMed
23) Suwinski R, Lee SP and Withers HR: Dose-response relationship for prophylactic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 40: 797-806, 1998.
PubMed
24) Komaki R, Meyers CA, Shin DM, et al: Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 33: 179-182, 1995.
PubMed
P.554 掲載の参考文献
1) 祖父江友孝: 21世紀の肺癌の動向. Annual Review呼吸器2002, (工藤翔二, 土屋了介, 金沢 実, 他・編) , 中外医学社, 東京, 2002, pp 118-125.
 
2) Sobue T, Ajiki W, Tsukuma H, et al: Trends of lung cancer incidence by histologic type: a population-based study in Osaka, Japan. Jpn J Cancer Res 90(1) : 6-15, 1999.
PubMed
3) Villeneuve PJ and Mao Y: Lifetime probability of developing lung cancer, by smoking status, Canada. Can J Public Health 85(6) : 385-388, 1994.
 
4) Halpern MT, Gillespie BW and Warner KE: Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 85(6) : 457-464, 1993.
PubMed
5) Lam S, Lam B and Petty TL: Early detection for lung cancer. New tools for casefinding. Can Fam Physician 47: 537-544, 2001.
PubMed
6) Hirayama T: Non-smoking wives of heavy smokers have a higher risk of lung cancer: astudy from Japan. Br Med J(Clin Res Ed) 282: 183-185, 1981.
 
7) Hackshaw AK, Law MR and Wald NJ: The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 315(7114) : 980-988, 1997.
PubMed
8) Travis WD, Colby TV, Corrin B, et al: World Health Organization international histological classification of tumours. Histological typing of lung and pleural tumors. 3rd ed. Springer, Berlin Heidelberg, New York, 1999.
 
9) Beckles MA, Spiro SG, Colice GL, et al: Initial evaluation of the patient with lung cancer: symptom, signs, Iaboratory tests, and praneoplastic syndromes. CHEST 123: 97 S-104 S, 2003.
 
10) Pretreatment evaluation of non-small-cell lung cancer: this official statement of the American Thoracic Society and the European Respiratory Society was adopted by the ATS board of directors, March 1997 and by the ERS executive committee, April 1997 and endorsed by the American college of chest physicians board of regents. Am J Respir Crit Care Med 156: 320-332, 1997.
 
11) Poe RH, Israel RH, Marin MG, et al: Utility of fiberoptic bronchoscopy in patients with hemoptysis and a nonlocalizing chest roentgenogram. Chest 93(1) : 70-75, 1988.
 
12) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15(8) : 2996-3018, 1997.
 
13) Silvestri GA, Tanoue LT, Margolis ML, et al: The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 123: 147S-156 S, 2003.
 
14) Colice GL, Birkmeyer JD, Black WC, et al: Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest 108(5) : 1264-1271, 1995.
PubMed
15) Investigating extrathoracic metastatic disease in patients with apparently operable lung cancer. The Canadian Lung Oncology Group. Ann Thorac Surg 71(2) : 425-433, 2001.
PubMed
16) Pujol JL, Boher JM, Grenier J, et al: Cyfra 21-1, neuron specific enolase and prognosis of non-small cell cancer: prospective study in 621 patients. Lung Cancer 31(2-3) : 221-231, 2001.
PubMed
17) Sugama Y, Kitamura S, Kawai T, et al: Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res 85(11) : 1178-1184, 1994.
PubMed
18) Rastel D, Ramaioli A, Cornillie F, et al: CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur J Cancer 30 A(5) : 601-606, 1994.
PubMed
19) Pujol JL, Grenier J, Parrat E, et al: Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 154(3 Pt 1) : 725-733, 1996.
 
20) Bombardieri E, Seregni E, Bogni A, et al: Evaluation of cytokeratin 19 serum fragments(CYFRA 21-1) in patients with lung cancer: results of a multicenter trial. Int J Biol Markers 9(2) : 89-95, 1994.
PubMed
21) Laroche C, Fairbairn I, Moss H, et al: Role of computed tomographic scanning of the thorax prior to bronchoscopy in the investigation of suspected lung cancer. Thorax 55(5) : 359-363, 2000.
PubMed
22) Dales RE, Stark RM and Raman S: Computed tomography to stage lung cancer. Approaching a controversy using metaanalysis. Am Rev Respir Dis 141(5 Pt 1) : 1096-1101, 1990.
 
23) Toloza EM, Harpole L and McCrory DC: Noninvasive staging of non-small cell lung cancer: Areview of the current evidence. Chest 123(1 Suppl) : 137 S-146 S, 2003.
 
24) Investigation for mediastinal disease in patients with apparently operable lung cancer. Canadian Lung Oncology Group. Ann Thorac Surg 60(5) : 1382-1389, 1995.
PubMed
25) Bogot NR and Shaham D: Semi-invasive and invasive procedures for the diagnosis and staging of lung cancer. II. Bronchoscopic and surgical procedures. Radiol Clin North Am 38(3) : 535-544, 2000.
PubMed
26) Davis PC, Hudgins PA, Peterman SB, et al: Diagnosis of cerebral metastases: double-dose delayed CT vs contrastenhanced MR imaging. AJNR Am J Neuroradiol 12(2) : 293-300, 1991.
PubMed
27) Earnest F 4th, Ryu JH, Miller GM, et al: Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection-pilot study. Radiology 211(1) : 137-145, 1999.
PubMed
28) Yokoi K, Kamiya N, Matsuguma H, et al: Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest 115(3) : 714-719, 1999.
PubMed
29) Michel F, Soler M, Imhof E, et al: Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax 46: 469-473, 1991.
PubMed
30) Silvestri GA, Littenberg B and Colice GL: The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. Am J Respir Crit Care Med 152(1) : 225-230, 1995.
PubMed
31) Ettinghausen SE and Burt ME: Prospective evaluation of unilateral adrenal masses in patients with operable non-smallcell lung cancer. J Clin Oncol 9(8) : 1462-1466, 1991.
 
32) Hillers TK, Sauve MD and Guyatt GH: Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer. Thorax 49(1) : 14-19, 1994.
PubMed
33) Gould MK, Maclean CC, Kuschner WG, et al: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: ameta-analysis. JAMA 285(7) : 914-924, 2001.
 
34) Pieterman RM, van Putten JW, Meuzelaar JJ, et al: Preoperative staging of non-small-cell lung cancer with positronemission tomography. N Engl J Med 343(4) : 254-261, 2000.
PubMed
35) Dwamena BA, Sonnad SS, Angobaldo JO, et al: Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 213(2) : 530-536, 1999.
PubMed
36) Yun M, Kim W, Alnafisi N, et al: 18 F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42(12) : 1795-1799, 2001.
PubMed
37) Kalff V, Hicks RJ, MacManus MP, et al: Clinical impact of(18) Ffluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: aprospective study. J Clin Oncol 19(1) : 111-118, 2001.
 
38) van Tinteren H, Hoekstra OS, Smit EF, et al: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359(9315) : 1388-1393, 2002.
PubMed
39) Lacasse Y, Wong E, Guyatt GH, et al: Transthoracic needle aspiration biopsy for the diagnosis of localised pulmonary lesions: ameta-analysis. Thorax 54(10) : 884-893, 1999.
 
40) Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111(6) : 1710-1717, 1997.
PubMed
41) 白日高歩, 小林紘一: 肺癌切除例の全国集計に関する報告. 日呼外会誌 16(6) : 77-88, 2002.
 
42) Breathnach OS, Freidlin B, Conley B, et al: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19(6) : 1734-1742, 2001.
 
43) Soria JC and Le Chevalier T: Is cisplatin still the best platinum compound in non-small-cell lung cancer? Ann Oncol 13(10) : 1515-1517, 2002.
PubMed
44) Bunn PA Jr: Treatment of advanced non-small-cell lung cancer with two-drug combinations. J Clin Oncol 20(17) : 3565-3567, 2002.
PubMed
45) Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2) : 92-98, 2002.
PubMed
46) 福岡正博, 多田弘人: 非小細胞肺癌. 臨床腫瘍学, (有吉 寛, 西條長宏, 佐々木康綱, 他・編) , 第2版, 癌と化学療法社, 東 京, 1999.
 
47) Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899-909, 1995.
 
48) Souquet PJ, Chauvin F, Boissel P, et al: Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 342: 19-21, 1993.
 
49) Marino P, Pampallona S, Preatoni A, et al: Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest 106: 861-865, 1994.
PubMed
50) Grilli R, Oxman AD and Julian JA: Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough? J Clin Oncol 11: 1866-1872, 1993.
PubMed
51) Stephens RJ, Fairlamb D, Gower N, et al: The Big Lung Trial(BLT) : determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer(NSCLC) . Preliminary results in the supportive care setting. Proc ASCO 21: 291 a, 2002.
 
52) Ranson M, Davidson N, Nicolson M, et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92(13) : 1074-1080, 2000.
PubMed
53) Roszkowski K, Pluzanska A, Krzakowski M, et al: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer(NSCLC) . Lung Cancer 27(3) : 145-157, 2000.
 
54) The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91(1) : 66-72, 1999.
 
55) Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17: 3188-3194, 1999.
PubMed
56) Thongprasert S, Sanguanmitra P, Juthapan W, et al: Relationship between quality of life and clinical outcome in advanced non-small cell lung cancer: best supportive care(BSC) versus BSC plus chemotherapy. Lung Cancer 24: 17-24, 1999.
PubMed
57) Helsing M, Bergman B, Thaning L, et al: Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomized phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 34: 1036-1044, 1998.
PubMed
58) Anderson H, Hopwood P, Stephens RJ, et al: Gemcitabine plus best supportive care(BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 83(4) : 447-453, 2000.
PubMed
59) Marino P, Preatoni A, Cantoni A, et al: Single-agent chemotherapy versus combination chemotherapy in advanced nonsmall cell lung cancer: aquality and meta-analysis study. Lung Cancer 13(1) : 1-12, 1995.
 
60) Lilenbaum RC, Langengerg P, Dickersin K, et al: Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. A meta-analysis of response, toxicity, and survival. Cancer 82: 116-126, 1998.
 
61) Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: aSouthwest Oncology Group study. J Clin Oncol 16: 2459-2465, 1998.
 
62) Sandler AB, Nemunaitis J, Denham C, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18(19) : 122-130, 2000.
PubMed
63) von Pawel J, von Roemeling R, Gatzemeier U, et al: Tirapazamine plus cisplatin versus cisplatin in advanced non-small cell lung cancer: Areport of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 18(6) : 1351-1359, 2000.
 
64) Gatzemeier U, von Pawel J, Gottfried M, et al: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 18(19) : 3330-3339, 2000.
 
65) Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612patients. J Clin Oncol 12(2) : 360-367, 1994.
PubMed
66) Depierre A, Chastang C, Quoix E, et al: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 5(1) : 37-42, 1994.
PubMed
67) Masuda N, Fukuoka M, Negoro S, et al: Randomized trial comparing cisplatin(CDDP) and irinotecan(CPT-11) versus CDDP and Vindesine(VDS) versus CPT-11 alone in advanced non-small cell lung cancer(NSCLC) , amulticenter phase III study. Proc ASCO 18: 459 a, 1999.
 
68) Lilenbaum RC, Herndon J, List M, et al: Single-agent(SA) versus combination chemotherapy(CC) in advanced non-small cell lung cancer(NSCLC) : aCALGB randomized trial of efficacy, quality of life(QOL) , and cost-effectiveness. Proc ASCO 21: 1a, 2002.
 
69) Sederholm C: Gemcitabine(G) compared with gemcitabine plus carboplatin(CG) in advanced non-small cell lung cancer(NSCLC) : aphase III study by the Swedish Lung Cancer Study Group(SLUSG) . Proc ASCO 21: 291 a, 2002.
 
70) Georgoulias V, Ardavanis A, Agelidou M, et al: Preliminary analysis of a multicenter phase III trial comparing docetaxel(D) versus docetaxel/cisplatin(DC) in patients with inoperable advanced and metastatic non-small cell lung cancer(NSCLC) . Proc ASCO 21: 291 a, 2002.
 
71) Crino L, Tonato M, Darwish S, et al: A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer(NSCLC) : astudy of the Umbrian Lung Cancer Group. Cancer Chemother Pahrmacol 26: 52-56, 1990.
 
72) Dhingra HM, Valdivieso M, Carr DT, et al: Randomized trial of three combinations of cisplatin with vindesine and/or VP 16-213 in the treatment of advanced non-small cell lung cancer. J Clin Oncol 3: 176-183, 1985.
PubMed
73) Weick JK, Crowley J, Natale RB, et al: A randomized trial of five cisplatin-containing treatments in with metastatic non-small-cell lung cancer: ASouthwest Oncology Group Study. J Clin Oncol 9: 1157-1162, 1991.
 
74) Shinkai T, Eguchi K, Sasaki Y, et al: A randomized clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J Cancer 27: 571-575, 1991.
 
75) Fukuoka M, Masuda N, Furuse K, et al: A randomized trial in inoperable non-small cell lung cancer: Vindesine and cisplatin versus mitomycin, vindesine and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 9: 606-613, 1991.
PubMed
76) Sculier J-P, Paesmans M, Thiriaux J, et al: Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. J Clin Oncol 16: 1388-1396, 1998.
 
77) Comella P, Frasci G, Panza N, et al: Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer. Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 18(7) : 1451-1457, 2000.
 
78) Comella P: Southern Italy Cooperative Oncology Group: Phase III trial of cisplatin/gemcitabine with or without vinorel-bine or paclitaxel in advanced non-small cell lung cancer. Semin Oncol 28(2 Suppl 7) : 7-10, 2001.
 
79) Alberola V, Camps C, Proven M, et al: Cisplatin/gemcitabine(CG) vs cisplatin/gemcitabine/vinorelbine(CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosphamide/vinorelbine(GV/IV) in advanced non-small cell lung cancer(NSCLC) : results of a Spanish Lung Cancer Group Phase III Trial(GEPC/98-02) . Proc ASCO 20: 308 a, 2001.
 
80) Thompson D, Hainsworth J, Burris III H, et al: Prospective randomized study of four third generation chemotherapy regimens in patients(pts) with advanced non-small cell lung cancer: aMinnie Pearl Cancer Research Network Trial. Proc ASCO 20: 314 a, 2001.
 
81) Tan E, Souquet P, Pereira J, et al: Glob 1: Final results of a prospective randomized phase III trial comparing vinorelbine and cisplatin(NP) versus vinorelbine, ifosphamide, and cisplatin(NIP) in metastatic non small cell lung cancer(NSCLC) patients(pts) . Proc ASCO 20: 326 a, 2001.
 
82) Vansteenkiste JF, Vandebroek JE, Nackaerts KL, et al: Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomized phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 12(9) : 1221-1230, 2001.
PubMed
83) Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: astudy of the Eastern Cooperative Oncology Group. J Clin Oncol 7(11) : 1602-1613, 1989.
 
84) Fukuoka M, Nagao K, Ohashi Y, et al: Impact of irinotecan(CPT-11) and cisplatin(CDDP) on survival in previously untreated metastatic non-small cell lung cancer(NSCLC) . Proc ASCO 19: 495 a, 2000.
 
85) Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631, 2000.
 
86) Giaccone G, Splinter TA, Debruyne C, et al: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The Eeuropean Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16: 2133-2141, 1998.
 
87) Cardenal F, Lopez-Cabrerizo MP, Anton A, et al: Randomized phase III study of gemcitabine-cisplatin versus etoposidecisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17: 12-18, 1999.
 
88) Crino L, Scagliotti GV, Ricci S, et al: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer project. J Clin Oncol 17: 3522-3530, 1999.
PubMed
89) Rudd RM, Gower NH, James LE, et al: Phase III randomized comparison of gemcitabine and carboplatin(GC) with mitomycin, ifosfamide and cisplatin(MIP) in advanced non-small cell lung cancer(NSCLC) . Proc ASCO 21: 292 a, 2002.
 
90) Kubota K, Watanabe K, Kunitoh H, et al: Final results of a randomized phase III trial of docetaxel and cisplatin versus vindesine and cisplatin in stage IV non-small cell lung cancer(TAX-JP-301) . Proc ASCO 21: 296 a, 2002.
 
91) Yana T, Takada M, Origasa H, et al: New chemotherapy agent plus platinum for advanced non-small cell lung cancer: ameta-analysis. Proc ASCO 21: 328 a, 2002.
 
92) Kelly K, Crowley J, Bunn PA, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer(NSCLC) : aSouthwest Oncology Group. J Clin Oncol 19(13) : 3210-3218, 2001.
 
93) Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2) : 92-98, 2002.
PubMed
94) Scagliotti GV, De Marinis F, Rinaldi M, et al: Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20(21) : 4285-4291, 2002.
PubMed
95) Rodriguez J, Pawel J, Pluzanska A, et al: A multicenter, randomized phase III study of docetaxel+cisplatin(DC) and docetaxel+carboplatin(DCB) vs. vinorelbine+cisplatin(VC) in chemotherapy-naive patients with advanced non-small cell lung cancer. Proc ASCO 20: 314 a, 2001.
 
96) Rosell R, Gatemeier U, Betticher DC, et al: Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 13: 1539-1549, 2002.
PubMed
97) Novakova L, Novakova L, Petruzelka L, et al: Gemcitabine plus cisplatin(GCis) versus gemcitabine plus carboplatin(GCarb) in patients with stage IIIB and IV non-small cell lung cancer(NSCLC) : final results of Czech Lung Cancer Cooperative Group phase III randomized trial. Proc ASCO 21: 307 a, 2002.
 
98) Thomas PA, Robinet G, Sylvie G, et al: Randomized phase II study of carboplatin/gemcitabine versus cisplatin/vinorelbine in advanced non-small cell lung cancer(NSCLC) . (GFPC 99-01) . Proc ASCO 21: 336 a, 2002.
 
99) Van Meerbeeck JP, Smit EF, Lianes P, et al: AEORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer. Proc ASCO 20: 308 a, 2001.
 
100) Gridelli C, Shepherd F, Perrone F, et al: Gemvin III: aphase III study of gemcitabine plus vinorelbine(GV) comparing to cisplatin plus vinorelbine or gemcitabine chemotherapy(PCT) for stage IIIb or IV non-small cell lung cancer(NSCLC) : an Italo-Canadian study. Proc ASCO 21: 292 a, 2002.
 
101) Georgoulias V, Papadakis E, Alexopoulos A, et al: Platinum-based and nonplatinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial. Lancet 357(9267) : 1478-1484, 2001.
 
102) Satouchi M, Takada K, Takeda K, et al: Randomized phase II study of docetaxel(DOC) plus cisplatin(CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer(NSCLC) ; aWest Japan Thoracic Oncology Group(WJTOG) study. Proc ASCO 20: 329 a, 2001.
 
103) Kosmidis P, Mylonakis N, Nicolaides C, et al: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: aphase III randomized trial. J Clin Oncol 20: 3578-3585, 2002.
 
104) Chen YM, Perng RP, Lee YC, et al: Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: arandomize phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 13: 108-115, 2002.
PubMed
105) Smith IE, O'Brien ME, Talbot DC, et al: Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19(5) : 1336-1343, 2001.
 
106) Socinski MA, Schell MJ, Peterman A, et al: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20(5) : 1335-1343, 2002.
PubMed
107) Buccheri GF, Ferringno D, Curcio A, et al: Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 63(3) : 428-432, 1989.
PubMed
108) Frasci G, Lorusso V, Panza N, et al: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18(13) : 2529-2536, 2000.
PubMed
109) Gridelli C, Perrone F, Cigolari S, et al: The MILES(Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: gemcitabine+vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients. Proc ASCO 20: 308 a, 2001.
 
110) Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94: 173-181, 2002.
 
111) Kelly K, Giarritta S, Hayes S, et al: Should older patients(pts) receive combination chemotherapy for advanced stage non-small cell lung cancer(NSCLC) ? An analysis of Southwest Oncology trials 9509 and 9308. Proc ASCO 20: 329 a, 2001.
 
112) Oshita F, Kurata T, Kasai T, et al: Prospective evaluation of the feasibility of cisplatin based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 86: 118-122, 1995.
 
113) O'Connell Jp, Kris MG, Gralla RJ, et al: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 4: 1604-1614, 1986.
 
114) Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-stage non-small cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9: 1618-1626, 1991.
 
115) Paesmans M, Sculier JP, Libert P, et al: Prognostic factors for survival in advanced non-small cell lung cancer: Univariate and multivariate analysis including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party. J Clin Oncol 13: 1221-1230, 1995.
 
116) Johnson DH, Schiller J, Belani CP, et al: E1594-A randomized phase III trial in metastatic non-small cell lung cancer(NSCLC) -outcome of PS 2 patients(Pts) : an Eastern Cooperative Group Trial(ECOG) . Proc ASCO 18: 461 a, 1999.
 
117) Sweeney CJ, Zhu J, Sandler A, et al: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group study E 1594. A phase III trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 92: 2639-2647, 2001.
 
118) Fossella, FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosphamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18(12) : 2354-2362, 2000.
PubMed
119) Shepherd FA, Dancey J, Ramlau R, et all Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
 
120) Mukohara T, Takeda K, Miyazaki M, et al: Japanese experience with second-line chemotherapy with low-dose(60 mg/m2) docetaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Oncol 48(5) : 356-360, 2001.
 
121) Crino L, Mosconi AM, Scagliotti G, et al: Gemcitabine as second-line treatment for advanced non-small-cell lung cancer. A phase II trial. J Clin Oncol 17(7) : 2181-2185, 1999.
 
122) Rossi A, Perrone F, Barletta E, et al: Activity of gemcitabine(GEM) in cisplatin pretreated patients with advanced nonsmall cell lung caner(NSCLC) : aphase 2 trial. Proc ASCO 18: 484 a, 1999.
 
123) Baas P, Codrington H, Muller M, et al: Second line gemcitabine(G) therapy in non-small cell lung caner(NSCLC) stage IIIb and IV. Proc ASCO 18: 495 a, 1999.
 
124) Reddy GR, Gandara DR, Edelman MJ, et al: Gemcitabine(GEM) in platinum(PLAT) treated non-small cell lung cancer(NSCLC) . Proc ASCO 18: 521 a, 1999.
 
125) Johnson DH, Einhorn LH, Bartolucci A, et al: Thoracic radiotherapy does not prolong survival in patients with locally advanced unresectable non-small cell lung cancer. Ann Intern Med 113: 33-38, 1990.
PubMed
126) Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323: 940-945, 1990.
PubMed
127) Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: seven-year follow up of Cancer And Leukemia Group B(CALGB) 8433 trial. J Natl Cancer Inst 88: 1210-1215, 1996.
 
128) Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group(RTOG) 88-08 and Eastern Cooperative Oncology Group(ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 88: 198-205, 1995.
 
129) Sause W, Kolesar P, Taylor S IV, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: 358-364, 2000.
 
130) Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83: 417-423, 1991.
PubMed
131) Arriagada R, Le Chevalier T, Rekacewicz C, et al: Cisplatin-based chemotherapy in patients with locally advanced nonsmall cell lung cancer: Late analysis of a French randomized trial. Proc ASCO 17: 446 a, 1997.
 
132) Sahhake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326: 524-530, 1992.
 
133) Jeremic B, Shibamoto Y, Milicic B, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14: 1065-1070, 1996.
 
134) Pritchard R and Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125: 723-729, 1996.
PubMed
135) Marino P, Preatoni A and Canton A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76: 593-601, 1995.
 
136) Kubota K, Furuse K, Kawahara M, et al: Role of radiotherapy in combined modality treatment of locally advanced nonsmall-cell lung cancer. J Clin Oncol12: 1547-1552, 1994.
 
137) Sculier Jp, Paesmans M, Lafitte JJ, et all A randomized phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. Ann Oncol 10: 295-303, 1999.
 
138) Mattson RF, Holsti LR, Holsti P, et al: Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 24: 477-482, 1988.
PubMed
139) Morton RF, Jett JR, McGinnis WL, et al: Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. Ann Intern Med 115: 737-739, 1991.
 
140) Gregor A, Macbeth FR, Paul J, et al: Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: A randomized trial. J Natl Cancer Inst 85: 997-999, 1993.
 
141) Trovo MG, Minatel E, Veronesi A, et al: Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma: a randomized study. Cancer 65: 400-414, 1990.
PubMed
142) Blanke C, Ansari R, Mantravadi R, et al: Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: AHooiser Oncology Group Protocol. J Clin Oncol 13: 1425-1429, 1995.
PubMed
143) Soresi E, Clerici M, Grilli R, et al: A randomized clinical trial comparing radiation therapy vs radiation therapy plus cisdichlorodiammine platinum(II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol 15(6 suppl 7) : 20-25, 1988.
 
144) Trovo MG, Zanelli GD, Minstel E, et al: Radiotherapy versus radiotherapy enhance by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 24: 11-15, 1992.
 
145) Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17: 2692-2699, 1999.
PubMed
146) Curran WJ Jr, Scott C, Langer C, et al: Phase III comparison of sequential vs concurrent chemoradiation for PTS with unresectable stage III non-small cell lung cancer(NSCLC) : initial report of Radiation Therapy Oncology Group(RTOG) 9410. Proc ASCO 19: 484 a, 2000.
 
147) Pierre F, Maurice P, Gilles R, et al: A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer(NSCLC) (GLOT-GFPC NPC 95-01 study) . Proc ASCO 20: 312a, 2001.
 
148) Vokes EE, Herndon II JE, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20: 4191-4198, 2002.
 
149) Zatloukal PV, Petruzelka L, Zemanova M, et al: Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin(V-P) in locally advanced non-small cell lung cancer. A randomized phase II study. Proc ASCO 21: 290 a, 2002.
 
150) Choy H, Curran WJ, Scott CB, et al: Preliminary report of locally advanced multimodality protocol(LAMP) : ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation(TRT) for patients with locally advanced non-small cell lung cancer(LA-NSCLC) . Proc ASCO 21: 291 a, 2002.
 
151) Yamamoto N, Fukuoka M, Negoro S, et al: aphase II study of induction chemotherapy(IND CT) with CPT-11 and cisplatin followed by thoracic radiation(TRT) combined with weekly CPT-11 in patients with unresectable stage III nonsmall cell lung cancer(NSCLC) . Proc ASCO 19: 499 a, 2000.
 
152) Iizasa T, Fujisawa T, Suzuki M, et al: Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 5(1) : 149-153, 1999.
PubMed
153) Karameris A, Panagou P, Tsilalis T, et al: Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. Am J Respir Crit Care Med 156(6) : 1930-1936, 1997.
PubMed
154) Smylie M, Mercier R, Aboulafia D, et al: Phase III study of the matrix metalloprotease(MMP) inhibitor Prinomastat in patients having advanced non-small cell lung cancer(NCSLC) . Proc ASCO 20: 307 a, 2001.
 
155) Bissett D, O'Byrne KJ, von Powel J, et al: Phase III study of the matrix metalloprotease(MMP) inhibitor prinomastat(P) in combination with gemcitabine(G) and cisplatin(C) in non-small cell lung cancer(NSCLC) . Proc ASCO 21: 296 a, 2002.
 
156) Ohta Y, Endo Y, Tanaka M, et al: Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 2(8) : 1411-1416, 1996.
PubMed
157) Tsao MS, Liu N, Nicklee T, et al: Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res 3(10) : 1807-1814, 1997.
 
158) DeVore RF, Fehrenbacher L, Herbst RS, et al: A randomized phase II trial comparing rhumab VEGF(recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel(CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc ASCO 19: 485 a, 2000.
 
159) Fukuoka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD 1839('Iressa') for patients with advanced non-small-cell lung cancer(IDEAL 1) . Proc ASCO 21: 298 a, 2002.
 
160) Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD 1839('Iressa') in advanced non-small cell lung cancer(NSCLC) patients who had failed platinum-and docetaxel-based regimens(IDEAL 2) . Proc ASCO 21: 292 a, 2002.
 
161) Giaccone G, Johnson D, Manegold C, et al: A phase III clinical trial of ZD 1839("Iressa") in combination with gemcitabine and cisplatin in chemotherapy-nai've patients with advanced non-small-cell lung cancer(INTACT 1) . Ann Oncol 13(Suppl 5) : 2-3, 2002.
 
162) Johnson D, Herbst R, Giaconne G, et al: ZD 1839("Iressa") in combination with paclitaxel & carboplatin in chemotherapynaive patients with advanced non-small-cell lung cancer(NSCLC) : results from a phase III clinical trial(INTACT 2) . Ann Oncol 13(Suppl 5) : 127-128, 2002.
 
163) Perez-Soler R, Chachoua A, Huberman A, et al: A phase II trial of the epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients(pts) with advanced, EGFR-expressing, nonsmall cell lung cancer(NSCLC) . Proc ASCO 20: 310 a, 2001.
 
P.568 掲載の参考文献
1) Vansteenkiste JF, Stroobants SG, De Leyn PR, et al: Lymph node staging in non-small-cell lung cancer with FDG-PET scan: aprospective study on 6901ymph node stations from 68 patients. J Clin Oncol 16: 2142-2149, 1998.
 
2) Denoix P: Enquete permanent dans les centres anticancereux. Bull Inst Nat Hyg(Paris) 1: 70-75, 1946.
 
3) UICC: Committee on TNM classification"TNM general rules". Livre de Poche, Geneva, 1969.
 
4) Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
PubMed
5) Naruke T, Goya T, Tsuchiya R, et al: Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 96: 440-447, 1988.
PubMed
6) Deslauriers J, Brisson J, Cartier R, et al: Carcinoma of the lung. Evaluation of satellite nodules as a factor influencing prognosis after resection. J Thorac Cardiovasc Surg 97: 504-512, 1989.
PubMed
7) Shimizu N, Ando A, Date H, et al: Prognosis of undetected intrapulmonary metastases in resected lung cancer. Cancer 71: 3868-3872, 1993.
PubMed
8) Mountain CF and Dresler CM: Regional lymph node classification for lung cancer staging. Chest 111: 1718-1723, 1997.
PubMed
9) 日本肺癌学会・編: 肺癌取扱い規約. 金原出版, 東京, 1999.
 
10) Asamura H, Suzuki K, Kondo H, et al: Where is the boundary between N l and N 2 stations in lung cancer? Ann Thorac Surg 70: 1839-1845 (discussion 1845-1846) , 2000.
 
11) Piehler JM, Pairolero PC, Weiland LH, et al: Bronchogenic carcinoma with chest wall invasion: factors affecting survival following en bloc resection. Ann Thorac Surg 34: 684-691, 1982.
PubMed
12) Trastek VF, Pairolero PC, Piehler JM, et al: En bloc(non-chest wall) resection for bronchogenic carcinoma with parietal fixation. Factors affecting survival. J Thorac Cardiovasc Surg 87: 352-358, 1984.
PubMed
13) Pitz CC, Brutel de la Riviere A, Elbers HR, et al: Surgical treatment of 125 patients with non-small cell lung cancer and chest wall involvement. Thorax 51: 846-850, 1996.
PubMed
14) Downey RJ, Martini N, Rusch VW, et al: Extent of chest wall invasion and survival in patients with lung cancer. Ann Thorac Surg 68: 188-193, 1999,
PubMed
15) Naruke T, Tsuchiya R, Kondo H, et al: Implications of staging in lung cancer. Chest 112: 242 S-248 S, 1997.
 
16) Inoue K, Sato M, Fujimura S, et al: Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993. J Thorac Cardiovasc Surg 116: 407-411, 1998.
PubMed
17) Feld R, Abratt R, Graziano S, et al: Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer 17(Suppl 1) : S3-10, 1997.
 
18) Lopez Encuentra A: Criteria of functional and oncological operability in surgery for lung cancer: amulticenter study. The Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery(GCCB-S) . Lung Cancer 20: 161-168, 1998.
 
19) Laurent F, Drouillard J, Dorcier F, et al: Bronchogenic carcinoma staging: CT versus MR imaging. Assessment with surgery. Eur J Cardiothorac Surg 2: 31-36, 1988.
PubMed
20) Webb WR, Gatsonis C, Zerhouni EA, et al: CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 178: 705-713, 1991.
 
21) Suzuki N, Saitoh T and Kitamura S: Tumor invasion of the chest wall in lung cancer: diagnosis with US. Radiology 187: 39-42, 1993.
PubMed
22) Lewis JW Jr, Pearlberg JL, Beute GH, et al: Can computed tomography of the chest stage lung cancer? Yes and no. Ann Thorac Surg 49: 591-595(discussion 595-596) , 1990.
 
23) Watanabe Y, Shimizu J, Oda M, et al: Aggressive surgical intervention in N 2 non-small cell cancer of the lung. Ann Thorac Surg 51: 253-261, 1991.
 
24) Dillemans B, Deneffe G, Verschakelen J, et al: Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. Eur J Cardiothorac Surg 8: 37-42, 1994.
PubMed
25) Suzuki K, Nagai K, Yoshida J, et al: Clinical predictors of N 2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. J Thorac Cardiovasc Surg 117: 593-598, 1999.
 
26) Coughlin M, Deslauriers J, Beaulieu M, et al: Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann Thorac Surg 40: 556-560, 1985.
PubMed
27) Hammoud ZT, Anderson RC, Meyers BF, et al: The current role of mediastinoscopy in the evaluation of thoracic disease. JThorac Cardiovasc Surg 118: 894-899, 1999.
PubMed
28) Salvatierra A, Baamonde C, Llamas JM, et al: Extrathoracic staging of bronchogenic carcinoma. Chest 97: 1052-1058, 1990.
PubMed
29) Quint LE, Tummala S, Brisson LJ, et al: Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 62: 246-250, 1996.
PubMed
30) Ichinose Y, Hara N, Ohta M, et al: Preoperative examination to detect distant metastasis is not advocated for asymptomatic patients with stages l and 2 non-small cell lung cancer. Preoperative examination for lung cancer. Chest 96: 1104-1109, 1989.
PubMed
31) Tanaka K, Kubota K, Kodama T, et al: Extrathoracic staging is not necessary for non-small-cell lung cancer with clinical stage T 1-2 N 0. Ann Thorac Surg 68: 1039-1042, 1999.
PubMed
32) Healy ME, Hesselink JR, Press GA, et al: Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology 165: 619-624, 1987.
PubMed
33) Sze G, Shin J, Krol G, et al: Intraparenchymal brain metastases: MR imaging versus contrast-enhanced CT. Radiology 168: 187-194, 1988.
PubMed
34) Bury T, Barreto A, Daenen F, et al: Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25: 1244-1247, 1998.
PubMed
35) Weder W, Schmid RA, Bruchhaus H, et al: Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 66: 886-892(discussion 892-893) , 1998.
 
36) Saunders CA, Dussek JE, O'Doherty MJ, et al: Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 67: 790-797, 1999.
 
37) Marom EM, McAdams HP, Erasmus JJ, et al: Staging non-small cell lung cancer with whole-body PET. Radiology 212: 803-809, 1999.
PubMed
38) Ginsberg RJ and Rubinstein LV: Randomized trial of lobectomy versus limited resection for T 1 N 0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60: 615-622(discussion 622-623) , 1995.
 
39) Naruke T, Goya T, Tsuchiya R, et al: The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 46: 603-610, 1988.
PubMed
40) Watanabe Y, Hayashi Y, Shimizu J, et al: Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Chest 100: 422-428, 1991.
PubMed
41) Pearson FG, DeLarue NC, Ilves R, et al: Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 83: 1-11, 1982.
PubMed
42) Martini N, Flehinger BJ, Zaman MB, et al: Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 198: 386-397, 1983.
PubMed
43) Tsuchiya R, Asamura H, Kondo H, et al: Extended resection of the left atrium, great vessels, or both for lung cancer. Ann Thorac Surg 57: 960-965, 1994.
PubMed
44) Tsuchiya R, Goya T, Naruke T, et al: Resection of tracheal carina for lung cancer. Procedure, complications, and mortality. J Thorac Cardiovasc Surg 99: 779-787, 1990.
PubMed
45) Mathisen DJ and Grillo HC: Carinal resection for bronchogenic carcinoma. J Thorac Cardiovasc Surg 102: 16-22 (discussion 22-23) , 1991.
 
46) Dartevelle P and Macchiarini P: Carinal resection for bronchogenic cancer. Semin Thorac Cardiovasc Surg 8: 414-425, 1996.
PubMed
47) Magilligan DJ Jr, Duvernoy C, Malik G, et al: Surgical apProach to lung cancer with solitary cerebral metastasis: twenty-five years'experience. Ann Thorac Surg 42: 360-364, 1986.
PubMed
48) Read RC, Boop WC, Yoder G, et al: Management of nonsmall cell lung carcinoma with solitary brain metastasis. J Thorac Cardiovasc Surg 98: 884-890 (discussion 890-891) , 1989.
 
49) Burt M, Wronski M, Arbit E, et al: Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. J Thorac Cardiovasc Surg 103: 399-410(discussion 410-411) , 1992.
 
50) Patchell RA, Tibbs PA, Regine WF, et al: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280: 1485-1489, 1998.
 
51) Alexander E, 3rd, Moriarty TM and Loeffler JS: Radiosurgery for metastases. J Neurooncol 27: 279-285, 1996.
PubMed
52) Auchter RM, Lamond JP, Alexander E, et al: A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 35: 27-35, 1996.
 
53) Van Houtte P, Rocmans P, Smets P, et al: Postoperative radiation therapy in lung caner: acontrolled trial after resection of curative design. Int J Radiat Oncol Biol Phys 6: 983-986, 1980.
 
54) Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group. N Engl J Med 315: 1377-1381, 1986.
 
55) Stephens RJ, Girling DJ, Bleehen NM, et al: The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T 1-2, N 1-2, M 0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer 74: 632-639, 1996.
 
56) Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 352: 257-263, 1998.
PubMed
57) Slack NH: Bronchogenic carcinoma: nitrogen mustard as a surgical adjuvant and factors influencing survival. University surgical adjuvant lung Project. Cancer 25: 987-1002, 1970.
PubMed
58) Brunner KW, Marthaler T and Muller W: Effects of long-term adjuvant chemotherapy with cyclophosphamide(NSC-26271) for radically resected bronchogenic carcinoma. Cancer Chemother Rep [3]4: 125-132, 1973.
PubMed
59) Shields TW, Higgins GA Jr, Humphrey EW, et al: Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung. Cancer 50: 1713-1721, 1982.
PubMed
60) Holmes EC and Gail M: Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol4: 710-715, 1986.
 
61) Lad T: The comparison of CAP chemotherapy and radiotherapy to radiotherapy alone for resected lung cancer with positive margin or involved highest sampled paratracheal node(stage IIIA) . LCSG 791. Chest 106: 302 S-306 S, 1994.
PubMed
62) Feld R, Rubinstein L and Thomas PA: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. J Natl Cancer Inst 85: 299-306, 1993.
 
63) Niiranen A, Niitamo-Korhonen S, Kouri M, et al: Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol 10: 1927-1932, 1992.
PubMed
64) Ohta M, Tsuchiya R, Shimoyama M, et al: Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group. J Thorac Cardiovasc Surg 106: 703-708, 1993.
 
65) Wada H, Hitomi S and Teramatsu T: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery(see comments) . J Clin Oncol 14: 1048-1054, 1996.
 
66) Kato H, Tsuboi M, Ohta M, et al: A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I(T1N0M0, T2N0M0) adenocarcinoma of the lung. Proc ASCO#2498, 2003.
 
67) Keller SM, Adak S, Wagner H, et al: A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 343: 1217-1222, 2000.
 
68) Chemotherapy in non-small cell lung cancer: ameta-analysis using updated data on individual patients from 52 randomisedclinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311: 899-909, 1995.
 
69) Lechevalier T: Results of the Randomized International Adjuvant Lung Cancer Trial(IALT) : cisplatinbased chemotherapy(CT) vs no CT in 1867 patients(pts) with resected non-small celllung cancer(NSCLC) , Proc ASCO#6, 2003.
 
70) Martini N, Kris MG, Flehinger BJ, et al: Preoperative chemotherapy for stage IIIa(N 2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55: 1365-1373(discussion 1373-1374) , 1993.
 
71) Burkes RL, Ginsberg RJ, Shepherd FA, et al: Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. J Clin Oncol 10: 580-586, 1992.
PubMed
72) Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N 2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13: 1880-1892, 1995.
 
73) Strauss GM, Herndon JE, Sherman DD, et al: Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 10: 1237-1244, 1992.
 
74) Choi NC, Carey RW, Daly W, et al: Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 15: 712-722, 1997.
PubMed
75) Eberhardt W, Wilke H, Stamatis G, et al: Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 16: 622-634, 1998.
PubMed
76) Rosell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330: 153-158, 1994.
PubMed
77) Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86: 673-680, 1994.
PubMed
78) Depierre A, Milleron B, Moro-Sibilot D, et al: Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I(Except T 1 N 0) , II, and IIIa Non-Small-Cell Lung Cancer. J Clin Oncol 20: 247-253, 2002.
 
79) Pisters KM, Ginsberg RJ, Giroux DJ, et al: Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 119: 429-439, 2000.
PubMed
80) Feld R, Arrriagada R, Ball D, et al: Prognostic factors in non-small cell lung cancer: aconsensus report. Lung Cancer 7: 3-5, 1991.
 
81) Feld R, Borges M, Giner V, et al: Prognostic factors in non-small cell lung cancer. Lung Cancer 11(suppl 3) : S19-23, 1994.
 
82) Ichinose Y, Hara N, Ohta M, et al: Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer? Amultivariate prognostic factor analysis of l51 patients. J Thorac Cardiovasc Surg 106: 90-94, 1993.
 
83) Macchiarini P, Fontanini G, Hardin MJ, et al: Blood vessel invasion by tumor cells predicts recurrence in completely resected T 1 N 0 M 0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 106: 80-89, 1993.
 
84) Kessler R, Gasser B, Massard G, et al: Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. Ann Thorac Surg 62: 1489-1493, 1996.
PubMed
85) Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al: Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 16: 2468-2477, 1998.
 
86) Zimmerman PV, Hawson GA, Bint MH, et al: Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet 2: 530-533, 1987.
PubMed
87) Volm M, Hahn EW, Mattern J, et al: Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res 48: 2923-2928, 1988.
PubMed
88) Slebos RJ, Kibbelaar RE, Dalesio O, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561-565, 1990.
PubMed
89) Mitsudomi T, Steinberg SM, Oie HK, et al: Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51: 4999-5002, 1991.
PubMed
90) Graziano SL, Gamble GP, Newman NB, et al: Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 17: 668-675, 1999.
 
91) Carbone DP, Mitsudomi T, Chiba I, et al: p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 106: 377 S-381 S, 1994.
 
92) Lee JS, Yoon A, Kalapurakal SK, et al: Expression of p 53 Oncoprotein in non-small-cell lung cancer: afavorable prognostic factor. J Clin Oncol 13: 1893-1903, 1995.
 
93) Quinlan DC, Davidson AG, Summers CL, et al: Accumulation of p 53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828-4831, 1992.
 
94) Pappot H, Francis D, Brunner N, et al: p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis. Clin Cancer Res 2: 155-160, 1996.
PubMed
95) Goldstraw P, Mannam GC, Kaplan DK, et al: Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis(N 2 disease) . JThorac Cardiovasc Surg 107(19-27; discussion 27-28) , 1994.
 
96) Miller DL, McManus KG, Allen MS, et al: Results of surgical resection in patients with N 2 non-small cell lung cancer. Ann Thorac Surg 57: 1095-1100(discussion 1100-1101) , 1994.
 
97) Darwish S, Minotti V, Crino L, et al: Neoadjuvant cisplatin and etoposide for stage IIIA(clinical N 2) non-small cell lung cancer. Am J Clin Oncol 17: 64-67, 1994.
 
98) Elias AD, Skarin AT, Leong T, et al: Neoadjuvant therapy for surgically staged IIIA N 2 non-small cell lung cancer(NSCLC) . Lung Cancer 17: 147-161, 1997.
 
99) Sugarbaker DJ, Herndon J, Kohman LJ, et al: Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA(N 2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 109: 473-483(discussion 483-485) , 1995.
 
100) Rice TW, Adelstein DJ, Koka A, et al: Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer. Ann Thorac Surg 60: 586-591(discussion 591-592) , 1995.
 
P.581 掲載の参考文献
1) Leyvraz S, Henle W, Chahinian AP, et al: Association of Epstein-Barr virus with thymic carcinoma. N Engl J Med 312: 1296-1299, 1985.
PubMed
2) Shimosato Y and Mukai K: Tumors of the mediastinum. AFIP, Bethesda, 1997, pp 120-158.
 
3) Mario M and Muller-Hermelink HK: Thymoma and thymic carcinoma epithelial cells to the cortical and medullary differentiation of thymus. Virchow Arch 407: 119-149, 1985.
 
4) Quintanilla-Martinez L, Wilkins EW, Choi N, et al: Thymoma. Histologic subclassification is an independent prognositic facotr. Cancer 74: 606-617, 1994.
 
5) Kirchner T, Schalke B, Buchwald J, et al: Well-differentiated thymic carcinoma: An organotypical low-grade carcinoma with relationship to cortical thymoma. Am J Surg Pathol 16: 1153-1169, 1992.
PubMed
6) Histological typing of tumours of the thymus. Juan Rosai, 2nd ed, Springer, Berlin, 1999.
 
7) Okumura M, Ohta M, Tateyama H, et al: The World Health Organization histologic classification system reflects the oncologic behavior of thymoma. A clinical study of 273 patients. Cancer 94: 624-632, 2002.
PubMed
8) Masaoka A, Monden Y, Nakahara K, et al: Follow-up study of thymomas with special reference to their clinical stages. Cancer 48: 2485-2492, 1981.
PubMed
9) Maggi G, Casadio C, Cavallo A, et al: Thymoma: Results of 241 Operated cases. Ann Thorac Surg 51: 152-156, 1991.
PubMed
10) Pescarmona E, Rendina EA, Venuta F, et al: Analysis of prognostic factors and clinicopathological staging of thymoma. Ann Thorac Surg 50: 534-538, 1990.
PubMed
11) Koga K, Matsuno Y, Noguchi M, et al: Areview of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 44: 359-367, 1994.
 
12) Pan CC, Wu HP, Yang CF, et al: The clinicopathological correlation of epithelial subtyping in thymoma. A study of 112 consecutive cases. Hum Pathol 25: 893-899, 1994.
PubMed
13) Blumberg D, Port JL, Weksler B, et al: Thymoma: amultivariate analysis of factors predicting survival of factors predicting survival. Ann Thorac Surg 60: 908-914, 1995.
 
14) Regnard JF, Magdeleinat P, Dromer C, et al: Prognostic factors and long-term results after thymoma resection: a case of 307 patients. J Thorac Cardiovasc Surg 112: 376-384, 1996.
 
15) Wilkins KB, Sheikh E, Green R, et al: Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 230: 562-574, 1999.
PubMed
16) Curran JW, Kornstein M, Brooks JJ, et al: Invasive thymoma: The role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 6: 1722-1727, 1988.
PubMed
17) Pollack A: Thymoma: treatment and prognosis. Int J Radiat Oncol Biol Phys 23: 1037-1043, 1992.
PubMed
18) Fornasiero A: Chemotherapy of invasive thymoma. J Clin Oncol 8: 1419-1423, 1990.
PubMed
19) Loehrer PJ, Kim K, Aisner SC, et al: Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of a intergroup trial. J Clin Oncol 12: 1164-1168, 1994.
PubMed
20) Oshita F: Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide etoposide and colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results. Jpn J Clin Oncol 25: 208-212, 1995.
PubMed
21) 浅村尚生, 森永正二郎, 下里幸雄・他: 縦隔原発びまん性硬化性大細胞型悪性リンパ腫の3例. 病理と臨床 6: 81-87, 1988.
 
22) Perrone T, Frizzera G and Rosai J: Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am J Surg Pathol 10: 176-191, 1986.
PubMed
23) Isaacson PG, Chan JKC, Tang C, et al: Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue arising in the thymus. A thymic lymphoma mimicking myoepithelial sialadenitis. Am J Surg Patho 114: 342-351, 1990.
 
24) Bajorin D, Katz A, Chan E, et al: Comparison of criteria for assigning germ cell tumor patients to"good risk" and "poor risk"studies. J Clin Oncol 6: 786-792, 1988.
PubMed
25) Ozols RF: A randomized trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6: 1031-1040, 1988.
 
26) Wright CD, Kesler KA, Nichols CR, et al: Primary mediastinal nonseminomatous germ cell tumors. Results of a multimodality approach. J Thorac Cardiovasc Surg 99: 210-217, 1990.
PubMed
27) Saxman S, Nichols CR, Williams SD, et al: Mediastinal yolk sac tumor. J Thorac Cardiovasc Surg 102: 913-916, 1991.
PubMed
28) Bush SE, Martinez A and Bagshaw MA: Primary mediastinal seminoma. Cancer 48: 1877-1882, 1981.
PubMed
29) Hurt RD, Bruckman JE and Farrow GM: Primary anterior mediastinal seminoma. Cancer 49: 1658-1663, 1982.
PubMed
30) Hainsworth JD and Greco FA: Mediastinal germ cell neoplasms. In Thoracic Oncology, (ed by Roth JA, Ruckdeschel JC and Weisenburger TH) , W B Saunders, Philaderlphia, 1989, pp 478-489.
 
31) Shimosato Y and Mukai K: Tumors of the mediastinum. AFIP, Bethesda, 1997, pp 263-267.
 
P.592 掲載の参考文献
1) Parkin M, Muir C, Whelan S, et al: Cancer incidence in five continents, vol 6, International Agency for Research on Cancer, Lyon, France, 1992.
 
2) Yang CS: Research on esophageal cancer in China: areview. J Thorac Cardiovasc Surg 40: 2633, 1980.
 
3) Zeng W, Jin F, Devesa SS, et al: Declining incidence is greater for esophageal than gastric cancer in Shanghai, People's Republic of China. Br J Cancer 68: 978-982, 1993.
 
4) Day NE and Varghese C: Oesophageal cancer. Cancer Surv 19/20: 43-54, 1994.
 
5) Blot WJ, Devesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287-1289, 1991.
PubMed
6) Blot WJ: Cancer of the esophagus: its causes and changing patterns of occurrence. Proc ASCO 16: 159-163, 1997.
 
7) がんの統計編集委員会・編: がんの統計 1999.
 
8) Blot WJ: Esophageal cancer trends and risk factors. Semin Oncol 21: 403-410, 1994.
PubMed
9) Munoz N and Day NE: Esophageal cancer. In Cancer epidemiology and prevention, (ed by Schottenfeld D and Fraumeni JJr) , 2nd ed, NY Oxford University Press, New York, 1996, PP 681-706.
 
10) Blot WJ: Alcohol and cancer. Cancer Res 52: 2119 s-2123 s, 1992.
 
11) Yokoyama A, Muramatsu T, Ohmori T, et al: Multiple primary esophageal and concurrent upper aerodigestive tract cancer and the aldehyde dehydrogenase-2 genotype of Japanese alcoholics. Cancer 77: 1986-1990, 1996.
PubMed
12) Matsuo K, Hamajima N, Shinoda M, et al: Gene-environment interaction between an aldehyde dehydrogenase-2(ALDH 2) polymorphism and alcohol consumption for the risk of esophageal cancer. Carcinogenesis 22: 913-916, 2001.
 
13) Yang WX, Pu J, Lu SH, et al: Studies on the exposure level of nitrosamines in the gastric juice and its inhibition in high risk areas of esophageal cancer. Chin J Oncol 14: 407-410, 1992.
 
14) Li MH, Ji C and Cheng SJ: Occurrence of nitroso compounds in fungi-contained foods: areview. Nutr Cancer 8: 63-69, 1986.
 
15) Togawa K, JaskiewiczK, Takahasi, H, et al: Human papilloma virus DNA sequences in esophageal squamous cell carcinoma. Gastroenterology 107: 128-136, 1994.
 
16) Spechler SJ: Barret's esophagus. Semin Oncol 21: 435-437, 1994.
 
17) Brown LM, Silverman DS, Pottern LM, et al: Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control 5: 333-341, 1994.
 
18) Brown LM, Swanson CA, Gridely G, et al: Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 87: 104-109, 1995.
 
19) Gamrnon MD, Schoenberg JB, Ahsan H, et al: Tobbaco, alcohol, and socioeconomic status and adenocarcinoma of the esophagus. J Natl Cancer Inst 89: 1277-1284, 1997.
 
20) Shu YJ: Cytopathology of the esophagus: an overview of esphageal cytopathology in China. Acta Cytol 27: 7-16, 1983.
 
21) Froelicher G and Miller G: The European experience with esophageal cancer limited to the mucosa and submucosa. Gastrointest Endosc 32: 88-90, 1986.
 
22) Yokoyama A, Ohmori T, Makuuchi H, et al: Successful screening for early esophageal cancer in alcoholics using endoscopy and mucosal iodine staining. Cancer 76: 928-934, 1995.
PubMed
23) Meyer V, Burtin P, Bour B, et al: Endoscopic detection of early cancer in a high-risk population: does Lugol staining improve videoendoscopy? Gastrointest Endosc 45: 480-484, 1997.
 
24) Shiozaki H, Tahara H, Kobayashi K, et al: Endoscopic screening of early esophageal cancer with the lugol dye method in patients with head and neck cancers. Cancer 66: 2068-2071, 1990.
PubMed
25) 食道疾患研究会・編: 臨床・病理食道癌取り扱い規約. 第9版, 金原出版, 東京, 1999.
 
26) Watanabe H, Jass JR and Sobin LH: Histological typing of oesophageal and gastric tumours. WHO's international histological classification of tumours. Springer-Verlag, Berlin, 1990.
 
27) Bedi DG and Shaw MT: Oat cell carcinoma of the esophagus: unusual radiologic appearance. Eur J Radiol 6: 233-237, 1986.
 
28) 食道疾患研究会, 国立がんセンター: 全国食道がん登録調査報告. 第12号(昭和59年症例) 69, 1992.
 
29) Kelsen DP, Weston E and Kurtz R: Small cell carcinoma of the esophagus: treatment by chemotherapy alone. Cancer 45: 1558-1561, 1980.
PubMed
30) Rosenthal SN, Jemkin T: Multiple small cell carcinoma of the esophagus. Cancer 51: 1944-1946, 1983.
 
31) Iyomasa S, Kato H, Tachimori Y, et al: Carcinosarcoma of the esophagus: atwenty-case study. Jpn J Clin Oncol 20: 99-106, 1990.
 
32) Matsusaka T, Watanabe H, Enjoji M, et al: Pseudosarcoma and carcinosarcoma of the esophagus. Cancer 31: 1546-1555, 1976.
 
33) Osamura RY, Shimamura K and Hata J: Polypoid carcinoma of the esophagus. A unifying term for "carcinosarcoma" and "pseudosarcoma". Am J Surg Pathol 2: 201-208, 1978.
PubMed
34) 小玉正智, 掛川輝夫: 食道表在癌の治療-第49回食道疾患研究会食道表在癌アンケート集計報告. 日外会誌 97: 683-690, 1996.
 
35) 井出博子, 野上 厚, 葉梨智子・他: 食道sm癌の臨床診断と予後. 胃と腸 25: 1067-1074, 1990.
 
36) 吉田 操, 室井正彦, 門馬久美子・他: 食道m・sm癌の質的診断ならびに鑑別診断. 胃と腸 25: 1059-1066, 1990.
 
37) Murata Y, Hayashi K, Kobayashi A, et al: Preoperative staging of esophageal carcinoma by ultrasound. Asian J Surg 17: 200-207, 1994.
 
38) Sugimachi K, Ohno S, Fujishima H, et al: Endoscopic ultrasonographic detection of carcinomatous invasion and lymph nodes in the thoracic esophagus. Surgery 107: 366-371, 1990.
PubMed
39) Rankin SC, Taylor H, Cook GJ, et al: Computed tomography and positron emission tomography in the preoperative staging of the esophageal carcinoma. Clin Radiol 53: 659-665, 1998.
 
40) Luketich JD, Friedman DM, Weigel TL, et al: Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Tholac Surg 68: 1133-1137, 1999.
PubMed
41) Kole AC, Plukker JT, Nieweg OE, et al: Positron emission tomography for oesophageal and gastroesophageal malignancy. Br J Cancer 78: 521-527, 1998.
PubMed
42) Picus D, Balfe DM, Koeler RE, et al: Computed tomography in the staging of esophageal carcinoma. Radiology 146: 433-438, 1983.
 
43) Takashima S, Takeuchi N, Shiozaki H, et al: Carcinoma of the esophagus: CT versus MR imaging in determining respectability. Am J Roentgenol 156: 297-302, 1991.
 
44) Lerut T, Flamen P, Ectors N, et al: Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 232: 743-752, 2000.
PubMed
45) Flamen P, Lerut E, Van Custem W, et al: Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol18: 3202-3210, 2000.
 
46) 吉田 操, 葉梨智子, 出江洋介・他: 食道表在癌の治療. 臨床外科 57: 147-152, 2002.
 
47) Makuuchi H, Shimada H, Mizutani K, et al: Endoscopic criteria for invasive depth of superficial esophageal cancer. Dig Endosc 9: 110-115, 1995.
 
48) Makuuchi H: Endoscopic mucosal resection for early esophageal cancer. -indications and techniques-. Dig Endosc 8: 175-179, 1996.
 
49) Lambert R: Endoscopic treatment of esophagogastric tumors. Endoscopy 28: 27-37, 1996.
 
50) Dawsey SM, Yu Y, taylor PR, et al: Esophageal cytology and subsequent risk of esophageal cancer: a prospective followup study from Linxian, China. Acta Cytol 38: 183-192, 1994.
PubMed
51) 門馬久美子, 吉田 操, 山田義也・他: 早期食道癌に対する内視鏡的粘膜切除の実際-2チャンネル法-. 胃と腸 28: 141-151, 1993.
 
52) 井上晴洋, 竹下公矢, 長浜雄志・他: 早期食道癌に対する内視鏡的粘膜切除の実際-EMRTとEMRC-. 胃と腸 28: 161-169, 1993.
 
53) 小山恒男, 宮田佳典, 岡庭信司・他: 内視鏡的食道粘膜切除後の局所再発. 胃と腸 31: 1217-1233, 1996.
 
54) 門馬久美子, 吉田 操, 加藤久人・他: 内視鏡的食道粘膜切除後にm3・sm1と判明した癌への対応. 胃と腸 28: 1207-1215, 1996.
 
55) Kodama M and Kakegawa T: Treatment of superficial cancer of the esophagus: asummary of responses to a questionnaire on superficial cancer of the esophagus in Japan. Surgery 123: 432-439, 1998.
 
56) 幕内博康, 島田英雄, 千野修・他: 食道m3-sm1癌の治療成績. 胃と腸 37: 53-63, 2002.
 
57) 小山恒男, 宮田佳典, 島谷茂樹・他: 第46回食道色素研究会アンケート調査報告. 胃と腸 37: 71-74, 2002.
 
58) Newaishy GA, Read GA, Duncan W, et al: Results of radical radiotherapy of squamous cell carcinoma of the esophagus. Clin Radiol 33: 347-352, 1989.
 
59) Okawa T, Kita M, Tanaka M, et al: Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 17: 49-54, 1. 989.
 
60) De-Ren S: Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys 16: 329-334, 1989.
 
61) Slevin NJ and Stout R: Carcinoma of the esophagus: areview of 108 cases treated by radical radiotherapy. Clin Radiol 40: 200-203, 1989.
 
62) Harrison L, Fogel T, Picone J, et al: Radiation therapy for squamous cell carcinoma of the esophagus. J Surg Oncol 37: 40-43, 1988.
PubMed
63) Shrump DS, Altorki NK, Forastiere AA, et al: Cancer of the esophagus. Cancer; principles and practice of oncology, (ed by Devita V T, et al) , 6th ed, Lippincott-Raven, Philadelphia, 2000, pp 1051-1091.
 
64) Herskovic A, Martz K, Sarraf MA, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598, 1992.
 
65) Al-Sarraf M, Martz K, Herskovic A, et al: Progress report of combined chemoradio-therapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15: 277-284, 1997.
 
66) Armstrong JG: High dose rate remote after loading brachytherapy for lung and esophageal cancer. Sem Radiat Oncol 4: 270, 1993.
 
67) Jager JJ, Pannebakker M, Rijken J, et al: Palliation in esophageal cancer with a single session of intraluminal irradiation. Radiother Oncol 25: 134-136, 1992.
PubMed
68) Hareyama M, Nishio M, Kagami Y, et al: Intracavitary brachytherapy combined with external-beam irradiation for squamous cell carcinoma of the thoracic esophagus. Int J Radiat Oncol Biol Phys 24: 235-240, 1992.
PubMed
69) Sander R, Hagenmueler F, Sander C, et al: Laser versus laser plus afterloading with iridium-192 in the palliative treatment of malignant stenosis of the esophagus: aprospective, randomized, and control study. Gastrointest Endosc 37: 433-438, 1991.
 
70) Sur RK, Singh DP and Sharma SC: Radiation therapy of esophageal cancer: role of high dose rate brachytherapy. Int J Radiat Oncol Biol Phys 22: 1043-1046, 1992.
 
71) Gasper LE, Qian C, Kocha WI, et al: A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in Iocalized cancer of the esophagus(RTOG 9207) : preliminary toxicity report. Int J Radiat Oncol Biol Phys 37: 593-599, 1997.
 
72) Nishimura Y, Ono K, Tsutsui K, et al: Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation. Int J Radiat Oncol Biol Phys 30: 1099-1105, 1994.
PubMed
73) Coia L, Engstrom P, Paul A, et al: Long-term results of infusional 5-FU, mitomycin-C, and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 20: 29-36, 1991.
PubMed
74) Nihei K, Ishikura S, Ohtsu A, et al: Long-term survival and toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. Proc ASCO 21: 144 a, 2002.
 
75) Ajani JA: Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol 21: 474-482, 1994.
PubMed
76) Scanlon K J, Newman Y L and Priest D G: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923-8925, 1986.
 
77) Byfield JE: Combined modality infusional chemotherapy with radiation. In Cancer chemotherapy by infusion, (ed by Lokich JJ) , 2nd ed, Percepta Press, Chicago, 1990, pp 521-551.
 
78) Douple EB and Richmond RC: Areview of interactions between platinum coordination complexes and ionizing radiation: implication for cancer therapy. In cisplatin; current status and new developments, (ed by Prestayko AW, Crooke ST and Karter SK) , FL Academic, Orland, 1980, pp125-147.
 
79) Edzinli EZ, Gelber R, Desai DV, et al: Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 46: 2149-2153, 1980.
 
80) Lokich JJ, Shea M and Chaffey J: Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction. Cancer 60: 275-279, 1987.
PubMed
81) Engstrom PF, Lavin PT and Klassen DJ: Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Chemother Rep 67: 713-715, 1983.
 
82) Wittes RE, Adrianza ME, Parsons R, et al: Compilation of phase II results with single antineoplastic agents. Cancer Treatment Symposia 4: 91-130, 1985.
 
83) Murthy SK, Prabhakaran PS, Chandashekar M, et al: Neoadjuvant cis-DDP in esophageal cancers: An experience at a regional center, India. J Surg Oncol 45: 173-176, 1990.
 
84) Bleiberg H, Jacob J, Bedenne L, et al: Randomized phase II trial of 5-fluorouracil and cisplatin versus cisplatin alone in advanced esophageal cancer. Proc ASCO 10: 145, 1991(abstr) .
 
85) Whittington R and Close H: Clinical experience with mitomycin-C. Cancer Chemother Rep 54: 195-198, 1970.
PubMed
86) Bonadonna G, de Lena M, Monfardini S, et al: Clinical trial with bleomycin in lymphomas and in solid tumors. Eur J Cancer 8: 205-215, 1972.
 
87) Ravry M, Moertel CG, Schutt AJ, et al: Treatment of advanced squamus cell carcinoma of the gastrointestinal tract with bleomycin(NSC 125066) . Cancer Chemother Rep 57: 493-495, 1973.
 
88) Yagoda A, Mukherji B, Young C, et al: Bleomycin, an antitumor antibiotic: clinical experience in 274 patients. Ann Intern Med 77: 861-870, 1972.
PubMed
89) Kelsen DP, Bains M, Cvitkovic E, et al: Vindesine in the treatment of esophageal carcinoma: aphase II study. Cancer Treat Rep 63: 2019-2021, 1979.
 
90) Bedikian AY, Valdivieso M, Bodey GP, et al: Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors. Cancer Chemther Pharmacol 2: 263-266, 1979.
PubMed
91) Bezwoda WR, Derman DP, Weaving A, et al: Treatment of esophageal cancer with vindesine: an open trial. Cancer Treat Rep 68: 783-785, 1984.
PubMed
92) Kolaric K, Maricic Z, Roth A, et al: Adriamycin alone and in combination with radiotherapy in the treatment of inoperable esophageal cancer. Tumori 63: 485-491, 1977.
PubMed
93) Sternberg C, Kelsen D, Dukemen M, et al: Carboplatin: anew platinum analog in the treatment of epidermoid carcinoma of the esophagus. Cancer Treat Rep 69: 1305-1307, 1985.
 
94) Coonley CJ, Bains M, Heelan R, et al: Phase II study of etoposide in the treatment of esophageal carcinoma. Cancer Treat Rep 67: 397-398, 1983.
PubMed
95) Alberts AS, Falkson G, Badata M, et al: Trimetrexate in advanced carcinoma of the esophagus. Invest New Drugs 6: 319-324, 1988.
PubMed
96) Nanus DM, Kelsen DP, Lipperman R, et al: Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpected severe toxicity. Invest New Drugs 6: 239-243, 1988.
 
97) Ajani JA, Ilson DH, Daughetry K, et al: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86: 1086-1091, 1994.
 
98) Ohtsu A, Muro K, Chin K, et al: A phase II study of docetaxel in patients with metastatic esophageal cancer: response comparison of RECIST with traditional WHO criteria. Proc ASCO 21: 166 a, 2002.
 
99) Conroy T, Etienne PL, Adenis A, et al: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 14: 164-170, 1996.
PubMed
100) 田口鐵男, 涌井 昭, 鍋谷欣市・他: 254-S(Cis-diammine glycolate platinum) の消化器癌に対する第II相臨床試験. 癌と化学療法 19: 483-488, 1992.
 
101) Kelsen D, Hilaris B, Coonley C, et al: Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Am J Med 75: 645-652, 1983.
 
102) Dinwoodie WR, Bartolucci AA, Lyman GH, et al: Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: ASoutheastern Cancer Study Group trial. Cancer Treat Rep 70: 267-270, 1986.
 
103) Hilgenberg AD, Carey RW, Wilkins EW, et al: Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann Thorc Surg 45: 357-363, 1988.
 
104) Ajani JA, Ryan B, Rich TA, et al: Prolonged chemotherapy for localized squamous cell carcinoma of the esophagus. Eur J Cancer 28 A: 880-884, 1992.
 
105) Iizuka T, Kakegawa T, Ide H, et al: Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: aJapanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22: 172-176, 1992.
PubMed
106) Feliu J, Baron G, Giron G, et al: Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. Am J Clin Oncol 19: 577-580, 1996.
 
107) Wadler S, Haynes H, Beitler JJ, et al: Phase II clinical trial with 5-fluorouracil, recombinant interferon-α-2 a, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. Cancer 78: 30-34, 1996.
 
108) Temeck BK, Liebman JE, Theodossiou C, et al: Phase II trial of 5-fluorouracil, Leucovorin, Interferon-α-2 a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma. Cancer 77: 2432-2439, 1996.
 
109) Van der Gaast A, Kok TC, Vos R, et al: A phase I dose finding study of biweekly schedule of a fixed dose of cisplatin with increasing dose of paclitaxel in patients with advanced esophageal cancer. Semin Oncol 24: S82-S 85, 1997.
 
110) Costa F, Ilson D, Forastiere A, et al: Phase II study of paclitaxel and cisplatin in patients with advanced adenocarcinoma (A) and squamous cell(S) carcinoma of the esophagus. Proc ASCO 16: 262 a, 1997.
 
111) Ilson DH, Ajani JA, Bhalla K, et al: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16: 1826-1834, 1998.
 
112) Javed T, Reed C, Walle T, et al: Aregimen of paclitaxel(P) , cisplatin(C) , and 5-fluorouracil(FU) followed by G-CSF is highly active against epidermoid and adenocarcinoma of the esophagus. Proc ASCO 14: 456, 1995.
 
113) Belani CP, Luketich JD, Landreaneau RJ, et al: Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. Semin Oncol 24: S89-S 92, 1997.
 
114) Enzinger PC, Kulke MH, Clark JW, et al: Phase II trial of CPT-11 in previously untreated patients with advanced adenocarcinoma of the esophagus and stomach. Proc ASCO 19: 315 a, 2000.
 
115) Lin L and Hecht JR: A phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal(GE) junction. Proc ASCO 19: 298 a, 2000.
 
116) Ilson DH, Saltz L, Enzinger P, et al: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17: 3270-3275, 1999.
PubMed
117) Muro K, Shirao K, Shimada Y, et al: A phase I-II study of nedaplatin and 5-fluorouracil in patients with advanced esophageal cancer. Proc ASCO 18: 991, 1999.
 
118) Leichman, L, Steiger, Z, Seidel, HG, et al: Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: apotentially curative apProach. J Clin Oncol 2: 75-79, 1984.
 
119) Leichman L, Herskovic A, Leichman CG, et al: Nonoperative therapy for squmous-cell cancer of the esophagus. J Clin Oncol 5: 365-370, 1987.
 
120) Coia LR, Engstrom PS and Paul A: Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy. J Clin Oncol 5: 1783-1790, 1987.
 
121) Forastier, AA, Orringer MB, Perez-Tamayo C, et al: Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 11: 1118-1123, 1993.
 
122) Seitz JF, Giovannini M, Padaut-Cesana J, et al: Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy(5-fluorouracil and cisplatin) and radiation therapy. Cancer 66: 214-219, 1990.
PubMed
123) Coia LR, Engstrom PS, Paul A, et al: Long-term results of infusional 5-FU, and mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 20: 29-36, 1991.
 
124) Roussel A, Bleiberg H, Dalesio O, et al: Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: final results of a controlled clinical trial. Int J Radiat Oncol Biol Phys 16: 67-72, 1989.
PubMed
125) Araujo CMM, Souhami L, Gil RA, et al: A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 67: 2258-2261, 1991.
 
126) Smith TJ, Ryan LM, Douglass HO, et al: Combine chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus.: astudy of the Eastern Cooperative Oncology Group. Oncol Biol Phys 42: 269-274, 1998.
 
127) Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial(RTOG 85-01) . JAMA 281: 1623-1627, 1999,
PubMed
128) Coia LR, Minsky BD, Berkey BA, et al: Outcomes of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 patterns of care study. J Clin Oncol 18: 455-462, 2000.
PubMed
129) Nygaard K, Hagen S, Hansen HS, et al: Preoperative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized multicenter study of preoperative radiotherapy and chemotherapy. World J Surg 16: 1104-1109, 1992.
PubMed
130) Le Prise E, Etienne P, Meunier B, et al: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73: 1779-1784, 1994.
PubMed
131) Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337: 16H67, 1997.
PubMed
132) Walsh TN, Noonan N, Hollywood D, et al: Acomparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335: 462-467, 1996.
 
133) Wilke H and Fink U: Multimodal therapy for adenocarcinoma of the esophagus and esophagogastric junction. N Engl J Med 335: 509-510, 1996.
PubMed
134) Urba S, Orringer M, Turrisi R, et al: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313, 2001.
 
135) Burmeister BH, Smithers BM, Fitzgerald L, et al: A randomized phase III trial of preoperative chemoradiation followed by surgery(CR-S) versus surgery alone(S) for localized respectable cancer of the esophagus. Proc ASCO 21: 130 a, 2002.
 
136) Kelsen DP: Preoperative chemoradiotherapy for esophageal caner. J Clin Oncol 19: 283-285, 2001.
 
137) Bedenne L, Michel P, Bouche O, et al: Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone(FFCD 9102) . Proc ASCO 21: 130 a, 2002.
 
138) Poplin EA, Khanuja PS, Kraut MJ, et al: Chemoradiotherapy of esophageal carcinoma. Cancer 74: 1217-1224, 1994.
PubMed
139) Poplin EA, Jacobson J, Herskovic A, et al: Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. Cancer 78: 1851-1856, 1996.
 
140) Ganem G, Dubray B, Raoul Y, et al: Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus. J Clin Oncol 15: 701-711, 1997.
PubMed
141) Meluch AA, Hainsworth JD, Thomas M, et al: Preoperative therapy with paclitaxel, carboplatin, 5-FU, and radiation yields 69% pathologic complete response(CR) rate in the treatment of local esophageal carcinoma. Proc ASCO 16: 927, 1997.
 
142) Minsky BD, Neuberg D, Kelsen DP, et al: Final report of intergroup trial 0122(ECOG PE-289, RTOG 90-12) : phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 43: 517-523, 1999.
PubMed
143) Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123(Radiation Therapy Oncology Group 94-05) phase III trial of combined modality therapy for esophageal cancer: high dose versus standard dose radiation therapy. J Clin Oncol 20: 1167-1174, 2002.
PubMed
144) Hironaka S, Ohtsu A, Boku N, et al: Non-randomized comparison between definitive chemoradiotherapy(CRT) and surgery(S) in patients(pts) with T 2-3 M O squamous cell carcinoma of the esophagus. Proc ASCO 20: 159 a, 2001.
 
145) Chan A and Wong A: Is combined chemotherapy and radiation therapy equally effective as surgical resection in locarized esophageal carcinoma? Int J Radiat Oncol Biol Phys 45: 265-270, 1999.
 
146) Meyer RJ: Esophageal cancer: primary management of local-regional disease. Proc ASCO(Educational Book) : 207-211, 2002.
 
147) O'Reilly S and Forastier A: Is surgery necessary with multimodal treatment of esophageal cancer? Ann Oncol 6: 519-521, 1995.
 
148) Ohtsu A, Yoshida S, Boku N, et al: Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol 25: 261-266, 1995.
PubMed
149) Ohtsu A, Boku N, Muro K, et al: Definitive chemoradiotherapy for T 4 and/or M l lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17: 2915-2921, 1999.
 
150) Yamada S, Takagi Y, Ogawa Y, et al: Radiotherapy for malignant fistula to other tract. Cancer 64: 1026-1028, 1989.
 
151) Arlington A and Bohorquez J: Irradiation of carcinoma of the esophagus containing a tracheoesophageal fistula. Cancer 71: 3808-3812, 1993.
PubMed
152) Malik SM, Krasnow SH and Waldreigh RG: Closure of tracheoesophageal fistula with primary chemotherapy in patients with esophageal cancer. Cancer 73: 1321-1323, 1994.
 
153) Ohtsu A, Yoshida S, Boku N, et al: Small cell carcinoma of the esophagus with an esophago-mediastinal fistula successfully treated by chemoradiotherapy and intubation. Jpn J Clin Oncol 23: 372-377, 1993.
 
154) Muro K, Ohtsu A, Boku N, et al: Treatment for locally advanced esophageal carcinoma complicated by fistula: case reports. Int J Clin Oncol 1: 176-181, 1996.
 
155) Muto M, Ohtsu A, Miyamoto S, et al: Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistula. Cancer 86: 1406-1413, 1999.
PubMed
156) Mera K, Ohtsu A, Boku N, et al: Definitive chemoradiotherapy(CRT) for T 4 squamous cell carcinoma of the esophagus. Proc ASCO 20: 161 a, 2001.
 
157) Seitz JF, Monges G, Perrier H, et al: Abscence of surexpression of protein p53 is a powerful and independent predictor of response to treatment of squamous cell esophageal cancer by concurrent radiochemotherapy: Proc ASCO 13: 193, 1994.
 
158) Yang B, Rice TW, Adelstein DJ, et al: Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma. Mod Pathol 12: 251-256, 1999.
PubMed
159) Kitamura K, Saeki H, Kawaguchi H, et al: Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. Hepatogastroenterology 47: 419-423, 2000.
PubMed
160) Hickey K, Grehan D, Reid IM, et al: Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal carcinoma to chemoradiotherapy. Cancer 74: 1693-1698, 1994.
PubMed
161) Samejima R, Kitajima Y, Yunotani S, et al: Cyclin D l is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res 19: 5515-5521, 1999.
 
162) Torres C, Wang H, Turner J, et al: Prognostic significance and effect of chemoradiotherapy on microvessel density(angiogenesis) in esophageal Barret's esophagus associated adenocarcinoma and squamous cell carcinoma. Hum Pathol 30: 753-758, 1999.
 
163) Tominaga K, Arakawa T, Imano M, et al: Complete regression of recurrent esophageal carcinoma with reduced expression of glutathione S-transferase一πby treatment with continuous infusion of 5-fluorouracil and low-dose cisplatin infusion. Am J Gastroenterol 94: 1664-1668, 1999.
 
164) Hironaka S, Hasebe T, Kamijo T, et al: Biopsy specimen microvessel density is a useful prognostic marker in patients with T2-4 M O esophageal cacner treated with chemoradiotherapy. Clin Cancer Res 8: 124-130, 2002.
 
165) Shih C, Ozawa S, Ando N, et al: Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 6: 1161-1168, 2000.
PubMed
166) Isaac JR, Sim EK, Ngoi SS, et al: Safe and rapid palliation of dysphagia for carcinoma of the esophagus. Am Surg 57: 245-249, 1991.
PubMed
167) Siegel HI, Laskin KJ, Dabezies MA, et al: The effect of endoscopic laser therapy on survival in patients with squamouscell carcinoma of the esophagus: further experience. J Clin Gastroenterol 13: 142-145, 1991.
 
168) Alderson D and Wright PD: Laser recanalization versus endoscopic intubation in the palliation of malignant dysphagia. Br J Surg 77: 1151-1156, 1990.
PubMed
169) Barr H, Krasner N, Raouf A, et al: Prospective randomized trial of laser therapy only and laser therapy followed by endoscopic intubation for the palliation of malignant dysphagia. Gut 31: 252-256, 1990.
PubMed
170) Domschke W, Foerster EC, Matek W, et al: Self-expanding mesh stent for esophageal cancer stenosis. Endoscopy 22: 134-136, 1990.
PubMed
171) Knylrim K, Wagner HJ, Bethge N, et al: Acontrolled trial of an expansive metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med 329: 1302-1307, 1993.
 
172) Vakil N and Bethge N: Metal stent for malignant esophageal obstruction. Am J Gastroentero191: 2471-2476, 1996.
 
173) Spivak H, Katariya K, Lo AY, et al: Malignant tracheo-esophageal fistula: use of esophageal prosthesis. J Surg Oncol 63: 65-70, 1996.
PubMed
174) Klinsman KJ, DeGregrio BT, Katon RM, et al: Prior radiation and chemotherapy increase the risk of Iife-threatening complications after insertion of metallic stents for esophagogastric malignancies. Gastrointest Endosc 43: 196-203, 1996.
 
175) Bethge N, Sommer A, Kleist D, et al: Aprospective trial of self-expanding metal stents in the palliation of malignant esophageal obstruction after failure of primary curative therapy. Gastrointest Endosc 44: 283-286, 1996.
 
176) Muto M, Ohtsu A, Miyata Y, et al: Self-expandable metallic stents for patients with recurrent esophageal carcinoma after failure of primary chemoradiotherapy. Jpn J Clin Oncol 31: 270-274, 2001.
PubMed
P.609 掲載の参考文献
1) UICC International Union Against Cancer: TNM Classification of Malignant Tumours, (ed by Sobin LH and Wittekind C) , 5th ed, Wiley-Liss, New York, 1997.
 
2) 日本食道疾患研究会・編: 食道癌取扱い規約. 第9版, 金原出版, 東京, 1999.
 
3) UICC International Union Against Cancer: TNM CIassification of Malignant Tumours, (ed by Hermanek P and Sobin LH) , 4th ed, Springer-Verlag, Berlin, 1987.
 
4) Whyte RI: Advances in the Staging of Intrathoracic Malignancies. World J Surg 25: 167-173, 2001.
PubMed
5) 飯塚紀文, 小野田忠: 食道がんのTNM分類. 癌と化学療法 24(7) : 893-901, 1997.
Medical*Online
6) 渡辺 寛: 「食道癌取扱い規約」改訂の要点. 日消外会誌 31: 124-127, 1998.
 
7) The Registration Committee for Esophageal Cancer: Comprehensive Registry of Esophageal Cancer in Japan(1988-1994) . 1st Ed, The Japanese Society for Esophageal Disease, 2000.
 
8) Lerut T, De Leyn P, Coosemans W, et al: Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg 216: 583-590, 1992.
PubMed
9) Baba M, Aikou T, Yoshinaka H, et al: Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 219: 310-316, 1994.
PubMed
10) Lieberman MD, Shriver CD, Bleckner S, et al: Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg 109: 130-138(discussion 139) , 1995.
 
11) Ando N, Ozawa S, Kitagawa Y, et al: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 232: 225-232, 2000.
PubMed
12) Iizuka T, Isono K, Kakegawa T, et al: Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Japanese Committee for Registration of Esophageal Carcinoma Cases. Chest 96: 1005-1011, 1989.
PubMed
13) Vigneswaran WT, Trastek VF, Pairolero PC, et al: Extended esophagectomy in the management of carcinoma of the upper thoracic esophagus. J Thorac Cardiovasc Surg 107: 901-906(discussion 906-907) , 1994.
 
14) Kato H, Tachimori Y, Watanabe H, et al: Thoracic esophageal carcinoma above the carina: a more formidable adversary? J Surg Oncol 65: 28-33, 1997.
 
15) Holscher AH, Bollschweiler E, Schneider PM, et al: Prognosis of early esophageal cancer. Comparison between adeno-and squamous cell carcinoma. Cancer 76: 178-186, 1995.
PubMed
16) Sarbia M, Porschen R, Borchard F, et al: Incidence and prognostic significance of vascular and neural invasion in squamous cell carcinomas of the esophagus. Int J Cancer 61: 333-336, 1995.
PubMed
17) Brucher BL, Stein HJ, Werner M, et al: Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer 92: 2228-2233, 2001.
PubMed
18) Itakura Y, Sasano H, Shiga C, et al: Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74: 795-804, 1994.
PubMed
19) Kitagawa Y, Ueda M, Ando N, et al: Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2: 909-914, 1996.
PubMed
20) Shimada Y, Imamura M, Watanabe G, et al: Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 80: 1281-1288, 1999.
PubMed
21) Iihara K, Shiozaki H, Tahara H, et al: Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 71: 2902-2909, 1993.
PubMed
22) Takeuchi H, Ozawa S, Ando N, et al: Altered p 16/MTS 1/CDKN 2 and cyclin D 1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 3: 2229-2236, 1997.
 
23) Roncalli M, Bosari S, Marchetti A, et al: Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. Lab Invest 78: 1049-1057, 1998.
PubMed
24) Shinozaki H, Ozawa S, Ando N, et al: Cyclin D l amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res 2: 1155-1161, 1996.
 
25) Sarbia M, Porschen R, Borchard F, et al: p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 74: 2218-2223, 1994.
PubMed
26) Shimaya K, Shiozaki H, Inoue M, et al: Significance of p 53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Virchows Arch A Pathol Anat Histopathol 422: 271-276, 1993.
PubMed
27) Xing EP, Yang GY, Wang LD, et al: Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer. Clin Cancer Res 5: 1231-1240, 1999.
PubMed
28) Hashimoto N, Tachibana M, Dhar DK, et al: Expression of p53 and RB proteins in squamous cell carcinoma of the esophagus: their relationship with clinicopathologic characteristics. Ann Surg Oncol 6: 489-494, 1999.
PubMed
29) Kobayashi S, Koide Y, Endo M, et al: The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability. Am J Surg 177: 497-502, 1999.
PubMed
30) 塩崎 均, 井上雅智, 矢野雅彦・他: 頸部食道癌に対するQOLを考慮した喉頭温存術式. 外科治療 82: 255-260, 2000.
Medical*Online
31) Kelley DJ, Wolf R, Shaha AR, et al: Impact of clinicopathologic parameters on patient survival in carcinoma of the cervical esophagus. Am J Surg 170: 427-431, 1995.
PubMed
32) 野崎幹弘, 佐々木健司, 竹内正樹・他: 遊離空腸移植による咽喉食摘後の食道・音声同時再建. 頭頸部腫瘍 23: 547-552, 1997.
 
33) 川原英之, 井上 聡, 河地茂行・他: 下咽頭・頸部食道癌手術-発生のための手術手技的工夫-. 手術 50: 2007-2015, 1996.
 
34) 小澤壮治, 安藤暢敏, 北川雄光・他: 頸部食道癌に対する喉頭温存術式. 手術 52: 1803-1807, 1998.
 
35) 林 隆一, 海老原敏, 吉積 隆: 頸部食道癌に対する合理的手術. 手術 52: 1809-1814, 1998.
 
36) Omura K, Urayama H, Kanehira E, et al: Larynx-preserving resection of the cervical esophagus for cervical esophageal carcinoma limited to the submucosal layer. J Surg Oncol 69: 113-116, 1998.
 
37) 西野暢彦, 青木克憲, 今野裕之・他: 転移, 再発, 合併症からみた頸部食道癌の手術. 手術 52: 1815-1821, 1998.
 
38) Saito R, Suzuki H, Motoyama S, et al: Aclinical study of surgical treatment of patients with carcinoma of the cervical esophagus extending to the thoracic esophagus. J Thorac Cardiovasc Surg 48: 417-423, 2000.
 
39) Kuwano H, MasudaN, Kato H, et al: The subepithelial extension of esophageal carcinoma for determining the resection margin during esophagectomy: Aserial histopathologic investigation. Surgery 131: S14-S21, 2002.
PubMed
40) Akiyama H, Tsurumaru M, Udagawa H, et al: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 220: 364-373, 1994.
PubMed
41) 磯野可一, 小出義雄: 胸部食道癌-3領域リンパ節郭清を伴った食道癌根治手術. 消化器外科 17: 476-481, 1994.
 
42) Tsurumaru M, Kajiyama Y, Udagawa H, et al: Outcomes of extended lymph node dissection for squamous cell carcinoma of the thoracic esophagus. Ann Thorac Cardiavasc Surg 7: 325-329, 2001.
PubMed
43) 梶山美明, 鶴丸昌彦: 進行食道癌の手術; 胸部上部食道癌. 消化器外科 23: 1001-1007, 2000.
 
44) 井垣弘泰, 日月裕司, 加藤抱一: II胸部上部食道癌 (1) 胸部上部食道扁平上皮癌における3領域郭清. 外科 62: 748-752, 2000.
 
45) 舟波 裕, 落合武徳: II胸部上部食道癌 (2) 胸部上部食道癌におけるリンパ節転移と再発部位からみた至適リンパ節郭清術. 外科 62: 753-756, 2000.
 
46) 松原敏樹, 植田 守, 甲斐崎祥一・他: III. 胸部中部食道癌 (2) 胸部中部食道癌における合理的リンパ節郭清. 外科 62: 762-767, 2000.
 
47) 鶴丸昌彦, 梶山美明, 服部公昭・他: I. 胸部食道癌に対する郭清 (2) 3領域郭清. 外科 62: 4-7, 2000.
 
48) 川口 晃, 小玉正智, 谷 徹・他: 胸部食道癌におけるリンパ節転移, 郭清に関する臨床病理学的検討. 日臨外会誌 61: 1661-1669, 2000.
 
49) 甲 利幸, 土岐祐一郎, 石川 治・他: III. 胸部中部食道癌 (1) とくに頸部上縦隔リンパ節郭清について. 外科62: 757-761, 2000.
 
50) 渡辺 寛: 討論(2) 食道癌の総合的癌進展を考慮したリンパ節郭清. 外科 62: 856-860, 2000.
 
51) Udagawa H and Akiyama H: Surgical treatment of esophageal cancer: Tokyo experience of the three-field technique. Dis Esophagus 14: 110-114, 2001.
PubMed
52) 馬場政道, 夏越祥次, 草野 力・他: 進行食道癌の手術; 胸部下部食道癌. 消化器外科 23: 1017-1022, 2000.
 
53) 鶴丸昌彦, 宇田川晴司, 梶山美明・他: III. 術前リンパ節転移状況を配慮したT2, T3症例の合理的リンパ節郭清 4. 腹部リンパ節転移陽性胸部下部食道癌(Ei) のリンパ節郭清. 日外会誌 98: 755-760, 1997.
 
54) 細川正夫: III. 術前リンパ節転移状況を配慮したT2, T3症例の合理的リンパ節郭清 3. 上縦隔リンパ節陰性胸部下部食道癌 (Ei) のリンパ節郭清. 日外会誌 98: 751-754, 1997.
 
55) 神津照雄, 磯野可一: 胸部食道全摘後の胃管による食道再建. 手術 46: 691-698, 1992.
 
56) 宇田川晴司, 鶴丸昌彦, 秋山 洋: 結腸による食道再建術. 手術 53: 1559-1564, 1999.
 
57) 松田裕之, 杉町圭蔵: 結腸を用いた食道再建術式. 手術 46: 387-395, 1992.
 
58) 安藤暢敏小澤壮治, 今津嘉広・他: 胸部食道全摘後の結腸による食道再建. 手術 46: 707-715, 1992.
 
59) 平山 克, 森 昌造: 有茎空腸による食道再建術. 手術 46: 369-379, 1992.
 
60) 宮崎修吉, 西平哲郎: 胸部食道全摘後の有茎空腸による食道再建. 手術 46: 717-723, 1992.
 
61) 野口 剛, 内田雄三, 和田伸介・他: 左開胸・開腹による下部食道・噴門部癌手術. 手術 53: 1517-1524, 1999.
 
62) 鍋谷欣市, 本島悌司: 食道再建術 1. 食道 再建経路および再建臓器の種類と特徴, (陣内伝之助, 他・編) , 食道手術のすべて(下巻) , 金原出版, 東京, 1988, pp 208-215.
 
63) 井手博子, 江口礼紀, 中村 努・他: 胸部食道癌における再建経路の選択. 手術 46: 725-730, 1992.
 
64) 藤田博正, 末吉 晋, 山名秀明・他: 食道切除後の再建経路(3) 胸壁前経路. 外科 62: 14-16, 2000.
 
65) 日月裕司, 加藤抱一, 井垣宏康・他: 食道切除後の再建経路(2) 胸骨後. 外科 62: 11-13, 2000.
 
66) Van Lanschot JJ, Blankenstein M, Oei HY, et al: Randomized comparison of prevertebral and retrosternal gastric tube reconstruction after resection of oesophageal carcinoma. Br J Surg 86: 102-108, 1999.
PubMed
67) 馬場政道, 愛甲 孝, 浅谷倫代・他: 胸部食道癌再建術後の問題点と対策-後縦隔経路と胸骨後経路の優劣. 日消外会誌 28: 2047-2051, 1995.
 
68) 高木 巌, 篠田雅幸: 胸部下部食道癌における胸部食道亜全摘右胸腔内高位食道胃吻合術. 臨床外科 44: 933-939, 1989.
 
69) 内田雄三, 村上信一, 松本克彦・他: 胸部食道全摘後の高位胸腔内吻合術. 手術 46: 731-736, 1992.
 
70) 幕内博康, 島田英雄, 千野 修・他: 右開胸開腹連続切開による下部食道噴門部癌切除術. 手術 53: 1525-1531, 1999.
 
71) 加藤抱一: 胸部食道全摘後の用手による食道吻合法. 手術 46: 737-745, 1992.
 
72) 甲 利幸, 今岡真義, 平塚正弘・他: 用手による食道胃吻合術-食道癌における頸部での食道胃吻合-. 手術 47: 737-741, 1993.
 
73) 永田松夫, 渡辺一男, 本田一郎・他: 三角法による頸部における食道胃端端吻合術. 手術 55: 2077-2081, 2001.
 
74) Law S, Fok M, Chu KM, et al: Comparison of hand-sawn and strapled esophagogastric anastomosis after esophageal resection for cancer; aprospective randomized controlled trial. Ann Surg 226: 169-173, 1997.
 
75) Daly JM, Karnell LH and Menck HR: National Cancer Data Base report on esophageal carcinoma. Cancer 78: 1820-1828, 1996.
PubMed
76) Daly JM, Fry WA, Little AG, et al: Esophageal cancer: Results of an American college of surgeon patient care evaluation study. J Am Coll Surg 190: 562-573, 2000.
PubMed
77) Schrump DS, Altorki NK, Forastiere AA, et ai: Cancer of the esophagus. Cancer. Principles & practice of oncology, (ed by DeVita VT Jr, et al) , 6th edition, Lippincott Williams & Wilkins, Philadelphia, 2001, pp 105HO91.
 
78) Orringer MB: Transthoracic versus transhiatal esophagectomy: What difference does it make? Ann Thorac Surg 44: 116-118, 1987.
PubMed
79) Roth JA, Lichter AS, Putnam JB, et al: Cancer of the esophagus. Cancer. principles & practice of oncology, (ed by DeVita VT jr, et al) , 4th ed, Lippincott Co, Philadelphia, 1993, p792.
 
80) Orringer MB, Marshall B and Iannettoni MD: Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 230: 392-403, 1999.
PubMed
81) Gelfand GA, Finley RJ, Nelems B, et al: Transhiatal esophagectomy for carcinoma of the esophagus and cardia. Arch Surg 127: 1164-1167, 1992.
PubMed
82) Gertsch P, Vauthey JN, Lustenberger AA, et al: Long-term results of transhiatal esophagectomy for esophageal carcinoma. A multivariate analysis of prognostic factors. Cancer 72: 2312-2319, 1993.
PubMed
83) Vigneswaran WT, Trastek VF, Pairolero PC, et al: Transhiatal esophagectomy for carcinoma of the esophagus. Ann Thorac Surg 56: 838-846, 1993.
PubMed
84) Law SY, Fok M, Cheng SW, et al: Acomparison of outcome after resection for squamous cell carcinoma and adenocarcinoma of the esophagus and cardia. Surg Gynecol Obset 175: 107-112, 1992.
 
85) Putnam JB, Suell DM, McMurtrey MJ, et al: Comparison of three techniques of esophagectomy within a residency training program. Ann Thorac Surg 57: 319-325, 1994.
PubMed
86) Swisher SG, Hunt KK, Holmes EC, et al: Changes in the surgical management of esophageal cancer from 1970 to 1993. Am J Surg 169: 609-614, 1995.
PubMed
87) Adam DJ, Craig SR, Sang CT, et al: Esophagogastrectomy for carcinoma in patients under 50 years of age. J R Coll Surg Obset 41: 371-373, 1996.
 
88) Sharpe DA and Moghissi K: Resectional surgery in carcinoma of the esophagus and cardia: what influence long-term survival? Eur J Cardiothorac Surg 10: 359-363, 1996.
PubMed
89) Ellis FH Jr: Standard resection for cancer of the esophagus and cardia. Surg Oncol Clin North Am 8: 279-293, 1999.
 
90) Skinner DB: En bloc resection for neoplasms of the esophagus and cardia. J Thorac Cardiovasc Surg 85: 59-71, 1983.
 
91) Nigro JJ, DeMeester TR, Hagen JA, et al: Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. J Thorac Cardiovasc Surg 117: 960-968, 1999.
PubMed
92) Altorki NK, Girardi L and Skinner DB: En bloc esophagectomy improves survival for stage III esophageal cancer. J Thorac Cardiovasc Surg 114: 948-956, 1997.
PubMed
93) Hagen JA, Peters JH and DeMeester TR: Superioerity of extended en bloc esophagogastrectomy for carcinoma of the lower esophagus and cardia. J Thorac Cardiovasc Surg 106: 850-859, 1993.
 
94) Altorki NK: The rationale for radical resection. Surg Oncol Clin North Am 8: 295-305, 1999.
 
95) Altorki NK and Skinner DB: Occult cervical nodal metastasis in esophageal cancer: preliminary results of three-field lymphadenectomy. J Thorac Cardiovasc Surg 113: 540-544, 1997.
PubMed
96) Lerut T, Coosemans W, Leyn PD, et al: Reflections on three foeld lymphadenectomy in carcinoma of the esophagus and gastroesophageal junction. Hepatogastroenterology 46: 717-725, 1999.
 
97) Co-operative Clnical Study Group for esophageal carcinoma: Preliminary Report on Multidisciplinary treatment for esophageal carcinoma. Jpn J Clin Oncol 10: 215-220, 1980.
 
98) Iizuka T, Ide H, Kakegawa T, et al: Preoperative radioactive therapy for esophageal carcinoma: randomized evaluation trial in eight institutions. Chest 93: 1054-1058, 1988.
PubMed
99) Japanese Esophageal Oncology Group: AComparison of chemotherapy and radiotherapy as adjuvant treatment to surgery for esophageal carcinoma. Chest 104: 203-207, 1993.
 
100) Ando N, Iizuka T, Kakegawa T, et al: A randomized trial of surgery with and without chemotherapy for localized squamous cell carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 114: 205-209, 1997.
 
101) Ando N, Iizuka T, Ide H, et al: A randomized trial of surgery alone vs surgery plus postoperative chemotherapy with cisplatin and 5-fluorouracil for localized squamous carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study(JCOG 9204) . Proc ASCO 18: 269 a, 1999.
 
102) Pouliquen X, Levard H, Hay JM, et al: 5-fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized triaL Ann Surg 223: 127-133, 1996.
PubMed
103) Kelsen DP, Ginsberg R, Pajak TF, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer[see comments]. NEngl J Med 339: 1979-1984, 1998.
 
104) Kok TC, Lanschot JV, Siersema PD, et al: Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: final report of a phase III multicenter randomized controlled trial. Proc ASCO 16: 277 a, 1997.
 
105) Leichman L, Steiger Z, Seydel HG, et al: Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: apotentially curative apProach. J Clin Oncol 2: 75-79, 1984. .
 
106) Poplin E, Fleming T, Leichman L, et al: Combined therapies for squamous-cell carcinoma of the esophagus, a southwest oncology group study(SWOG-8037) . J Clin Oncol 5: 622-628, 1984.
 
107) Forastiere AA, Orringer MB, Perez-Tamayo C, et al: Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol 8: 119-127, 1990.
PubMed
108) Forastiere AA: Treatment of locoregional esophageal cancer. Semin Oncol 19: 57-63, 1992.
 
109) Naunheim KS, Petruska PJ, Roy TS, et al: Preoperative chemotherapy and radiotherapy for esophageal carcinoma. J Thorac Cardiovasc Surg 103: 887-895, 1992.
 
110) Urba SG, Orringer MB, Perez-Tamayo C, et al: Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma. Cancer 69: 285-291, 1992.
PubMed
111) Bates BA, Detterbeck FC, Bernard SA, et al: Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 14: 156-163, 1996.
PubMed
112) Malhaire JP, Labat JP, Lozac'h P, et al: Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients. Int J Rad{at Oncol Biol Phys 34: 429-437, 1996.
 
113) Stahl M, Wilke H, Fink U, et al: Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer: interim analysis of a phase II trial. J Clin Oncol 14: 829-837, 1996.
PubMed
114) Forastiere AA, Heitmiller RF, Lee DJ, et al: Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. Cancer J Sci Am 3: 144-152, 1997.
PubMed
115) Jones DR, Detterbeck FC, Egan TM, et al: Induction chemoradiotherapy followed by esoophagectomy in patients with carcinoma of the esophagus. Ann Thorac Surg 64: 185-192, 1997.
PubMed
116) Adelstein DJ, Rice TW, Becker M, et al: Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 80: 1011-1020, 1997.
PubMed
117) Posner MC, Gooding WE, Landreneau RJ, et al: Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. Cancer J Sci Am 4: 237-246, 1998.
PubMed
118) Raoul JL, Prise EL, Meunier B, et al: Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma. Int J Radiat Oncol Biol Phys 42: 29-34, 1998.
 
119) Keller SM, Ryan LM, Coia LR, et al: High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction. Results of a phase II study of the eastern cooperative oncology group. Cancer 83: 1908-1916, 1998.
PubMed
120) Heath EI, Burtness BA, Heitmiller RF, et al: Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18: 868-876, 2000.
PubMed
121) Urba S, Orringer M, Turrisi A, et al: Randomized trial of preoperative chemoradiation versus surgery alone in patients with localregional esophageal carcinoma. J Clin Oncol 19: 305-313, 2001.
 
122) Walsh TN, Noonan N, Hollywood D, et al: Acomparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335: 462-467, 1996.
 
123) Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337: 161-167, 1997.
PubMed
124) Nesbitt J, Ajani A, Komaki R, et al: Preoperative taxol-based chemotherapy(CT) followed by chemoradiation therapy(CTRT) in patients(PTS) with potentially respectable esophageal carcinoma(EC) . Proc ASCO 17: 282 a, 1998.
 
125) Safran H, Gaissert H, Akerman P, et al: Neoadjuvant paclitaxe1, cisplatin and radiation for esophageal cancer. Proc ASCO 17: 259a, 1998.
 
P.637 掲載の参考文献
1) がんの統計編集委員会: がんの統計'01. 財団法人がん研究振興財団, 2001.
 
2) Parkin DM, Whelan SL, Ferlay J, et al: Cancer incidence in five continents. No 143. Vol VII. International Agency for Research on Cancer Scientific Publications, Lyons, France, 1997.
 
3) Tominaga S, Aoki K, Fujimoto I, et al: Cancer mortality and morbidity stastics: Japan and the world-1994. Japan Scientific Societies Press, Tokyo, 1994.
 
4) Kelsey JL, Gammon MD and John EM: Reproductive factors and breast cancer. Epidemiol Rev 15: 233-243, 1993.
 
5) Garland M, Hunter DJ, Colditz GA, et al: Menstrual cycle characteristics and history of ovulatory infertility in relation to breast cancer risk in a large cohort of women. Am J Epidemiol 147: 636-643, 1998.
 
6) Rosner B and Colditz G: Extended mathematical model of breast cancer incidence in the Nurses'Health Study. J Natl Cancer Inst 88: 359-364, 1996.
PubMed
7) Gordon A and Nelson L: Characteristics and outcomes of WIC participants and non-participants: analysis of the 1988 National Maternal and Infant Health Survey. Alexandria, VA: US Department of Agriculture, 1995.
 
8) Palmer J, Rosenberg L and Rao R: Induced and spontaneous abortion in relation to risk of breast cancer(United States) . Cancer Causes Control 8: 841-849, 1997.
PubMed
9) Trichopoulos D, MacMahon B and Cole P: Menopause and breast cancer risk. J Natl Cancer Inst 48: 605-613, 1972.
 
10) Hankinson SE, Willett WC, Manson JE, et al: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90: 1292-1299, 1998.
PubMed
11) Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53, 297 women with breast cancer and 100, 239 women without breast cancer-from 54 epidemiological studies. Lancet 47: 1713-1727, 1996.
 
12) Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, et al: Menopausal hormone replacement therapy and breast cancer: ametaanalysis. Obstet Gynecol 79: 286-294, 1992.
PubMed
13) Colditz GA, Willett WC, Hunter DJ, et al: Family history, age, and risk of breast cancer. JAMA 270: 338-343, 1993.
PubMed
14) Hall JM, Lee MK, Newman B, et al: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988) : 1684, 1990.
PubMed
15) Wooster R, Neuhausen SL, Mangion J, et al: Location of a breast cancer susceptibility gene, BRCA 2, to chromosome 13 q12-13. Science 265: 2088, 1994.
 
16) Li FP and Fraumeni JF: Soft-tissue sarcomas, breast cancer, and other neoplasms: familial syndrome? Ann Intern Med 71: 747, 1969.
PubMed
17) Brownstein MH, Wolf M and Bikowski JB: Cowden's disease: acutaneous marker of breast cancer. Cancer 41: 2393, 1978.
 
18) Swift M, Reltnauer PJ, Morrell D, et al: Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316: 1289, 1987.
 
19) Martin-Moreno JM, Willett WC, Gorgojo L, et al: Dietary fat, olive oil intake and breast cancer risk. Int J Cancer 58: 774-780, 1994.
PubMed
20) London SJ, Colditz GA, Stampfer MJ, et al: Prospective study of relative weight, height and the risk of breast cancer. JAMA 262: 2853-2858, 1989.
PubMed
21) Prentice RL, Kakar F, Hursting S, et al: Aspects of the rational for the Women's Health Trial. J Natl Cancer Inst 80: 802-814, 1988.
 
22) Howe GR, Hirohata T, Hislop TG, et al: Dietary N factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst 82: 561-569, 1990.
 
23) Cohen LA, Kendall ME, Zang E, et al: Modulation of N-nitrosomethylurea-induced mammary tumor promotion by dietary fiber and fat. J Natl Cancer Inst 83: 496-501, 1991.
 
24) Hunter DJ and Willett WC: Diet, body size, and breast cancer. Epidemiol Rev 15: 110-132, 1993.
 
25) Smith-Warner SA, Spiegelman D, Yaun S-S, et al: Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 279: 535-540, 1998.
PubMed
26) Hunter DJ and Willett WC: Diet, body size, and breast cancer. Epidemiol Rev 15: 110-132, 1993.
 
27) Biesecker BB, Boehnke M, Calzone K, et al: Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 269: 1970-1973, 1993.
PubMed
28) Wooster R, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792, 1995.
PubMed
29) Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90: 1371-1388, 1998.
PubMed
30) Delmas PD, Bjarnason NH, Mitlak BH, et al: Effects of raloxifene on bone mineral density, serunm cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647, 1997.
 
31) Baker L: Breast Cancer Detection Demonstration Project: five year summary report. CA Cancer J Clin 32: 196, 1982.
 
32) 福田 譲: 乳癌集団検診の現状と問題点. 乳癌の臨床 5: 374, 1990.
 
33) Ota J: Mass screening for breast cancer. Comparison of the clinical stages and prognosis of breast cancer detected by mass screening and in out-patients clinic. Jpn J Cancer Res 80: 1028, 1989.
 
34) Leitch AM, Dodd GD, Costanza M, et al: American Cancer Society guidelines for the early detection of breast cancer: update 1997. CA Cancer J Cline 47: 150, 1997.
 
35) National Cancer Institute. Statement from the National Cancer Institute on the National Cancer Advisory Board recommendations on mammography. Bethesda, MD: National Cancer Institute, 1997.
 
36) US Preventive Services Task Force. Guide to clinical preventive services. Williams & Wilkins, Baltimore, 1996.
PubMed
37) 大内憲明・他: 「マンモグラフィによる乳がん検診の適正実施のための研究」研究報告書, がん検診の適正化に関する調査研究「新たながん検診手法の有効性評価」分担研究, 2001.
 
38) American Joint Committee on Cancer. Breast: AJCC cancer staging manual, 5th ed, Philadelphia, Lippincott-Raven, 1997, p171.
 
39) 日本乳癌学会・編: 乳癌の臨床的記載法に関する規約. 臨床・病理乳癌取扱い規約, 第14版, 金原出版, 東京, 2000.
 
40) 岩田広治, 三浦重人, 岩瀬拓士: 規約改訂案に基づくTNMシミュレーション. 乳癌の臨床 16: 28-33, 2001.
 
41) Goldhirsch A, Glick JH, Gellber RD, et al: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 19(18) : 3817-3827, 2001.
 
42) Bast RC, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of clinical oncology. J Clin Oncol 19(6) : 1865-1878, 2001.
 
43) Clark GM: Prognostic and predictive factors, Diseases of the Breast, (ed by Harris JR) , 2nd ed, Lippincott Williams & Wilkins, Philadelphia, 2000, pp 489-514.
 
44) Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124(7) : 966-978, 2000.
PubMed
45) Raju GC and Wee A: Spindle cell carcinoma of the breast. Histopathology 16(5) : 487-499, 1990.
 
46) Adair F, Berg J, Joubert L, et al: Long-term follow-up of breast cancer patients; The 30-year report. Cancer 33: 1145-1150, 1974.
 
47) Fisher B, Bauer M, Wickerham L, et al: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer 52: 1551-1557, 1983.
 
48) 三浦重人: 予後因子としての腋窩リンパ節転移. 乳癌の臨床 10: 452-459, 1995.
Medical*Online
49) 渡辺 亨, 勝俣範之: 乳がん. 臨床腫瘍学, (有吉 寛, 他・編) , 第1版, 癌と化学療法社, 東京, 1996, p867.
 
50) Disease of the breast: Lippincott Williams & Wilkins, Philadelphia, 2000, p491.
 
51) Axelesson CK, Mouriden HT and Zedeler K: Axillary dissection of level I and level II Iymph nodes is important in breast cancer patients. The Danish Breast Cancer Cooperative Group(DBCG) , Eur J Cancer 28 A: 1415-1418, 1992.
 
52) Noguchi S, Aihara T, Motomura K, et al: Detection of breast cancer micrometastases in axillary lymphnodes by means of reverse transcriptase-polymerase chain reaction: comparison between MUC-1 mRNA and keratin-19 mRNA ampllfication. Am J Pathol 148: 649-656, 1996.
 
53) Elston CW and Ellis IO: Pathological prognostic factors in breast cancer: experience from a long-term follow up. Histopathology 19: 403-410, 1991.
 
54) Tsuda H, Hirohashi S, Shimosato Y, et al: Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer 65: 1794-1800, 1990.
PubMed
55) 加藤茂明, 清水孝雄・編: 細胞膜・核内レセプターと脂溶性シグナル分子. 実験医学 18(増刊) : 223-260, 2000.
 
56) 野村雍夫: 乳癌の予後因子としてのホルモンレセプター. Breast Cancer Today 6(2) : 2-10, 1990.
 
57) 岩瀬弘敬, 小林俊三, 佐本常男・他: 乳癌におけるestrogen receptorの免疫組織化学的局在とhormone療法の効果. 内分泌外科2: 479-483, 1985.
 
58) NIH consensus development conference on steroid receptors in breast cancer. Cancer 46: 2759-2763, 1980.
PubMed
59) Mosselman S, Polman J and Dijkema R: ER一β: identification and characterization of a novel human estrogen receptor. FEBS Lett 392: 49-53, 1996.
 
60) Iwase H, Omoto Y, Toyama T, et al: Clinical significance of estrogen receptorβin breast cancer. Breast Cancer 6(4) : 325-330, 1999.
 
61) Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
PubMed
62) Yamashita H, Kobayashi S, Iwase H, et al: Analysis of oncogenes and tumor suppressor genes in human breast cancer. Jpn J Cancer Res 84: 871-878, 1993.
PubMed
63) Perez EA, Roche PC, Jenkins RB, et al: HER2 testing in patients with breast cancer: poor correlation between week positivity by immunohistochemistry and gene amplification by fluorescent in situ hybridization. Mayo Clini Proc 77(2) : 148-154, 2002.
 
64) Yamauchi H, Stearns V and Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19: 2334-2356, 2001.
 
65) Iwase H, Kobayashi S, Itoh Y, et al: Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer. Breast Cancer Res Treat 28: 215-221, 1993.
PubMed
66) 津田 均, 広橋説雄: 悪性腫瘍とp53遺伝子: 遺伝子診断と遺伝子治療. 現代化学増刊23, (村松正実, 平井久丸・編) , 東京化学同人, 東京, 1994, pp 177-184.
 
67) Clahsen PC, van de Velde CJ, Duval C, et al: p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 16(2) : 470-479, 1998.
PubMed
68) van Diest PJ, Michalides RJ, Jannink L, et al: Cyclin Dl expression in invasive breast cancer. Correlation and prognostic value. Am J Pathol 150(2) : 705-711, 1997.
 
69) Leong AC, Hanby AM, Potts HW, et al: Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast. Int J Cancer 89(1) : 26-31, 2000.
PubMed
70) Kenny FS, Hui R, Musgrove EA, et al: Overexpression of cyclin DI messenger RNA predicts for poor prognosis in estrogen receptor positive breast cancer. Clin Cancer Res 5: 2069-2076, 1999.
PubMed
71) Ohta T, Fukuda M, Wanebo HJ, et al: Behavior of the cell cycle-associated proteins in an unusual GO-arrestable cancer cell line. Exp Cell Res 225(1) : 85-92, 1996.
 
72) Umemura S, Komaki K, Noguchi S, et al: Prognostic factors for node-negative breast cancers: Results of a study program by the Japanese Breast Cancer Society. Breast Cancer 5(3) : 243-249, 1998.
PubMed
73) Van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling Predicts clinical outcome of breast cancer. Nature 415(6871) : 530-536, 2000.
 
74) 阿部力哉: 乳癌手術の歴史的変遷-HalstedからFisherへ-. 外科 57: 523-529, 1995.
 
75) Fisher B, Redmond C and Fisher ER: The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology-an overview of findings. Cancer 46: 1009-1025, 1980.
 
76) The Japanese Breast Cancer Society: Results of Questionnaires concerning Breast Cancer Surgery in Japan: An update in 2000. Breast Cancer 9: 1, 2002.
 
77) Lacour J, Bucalossi P, Cacers E, et al: Radical mastectomy versus radical mastectomy plus internal mammary dissection. Five-year results of an international cooperative study. Cancer 37: 206-214, 1976.
PubMed
78) 日本乳癌学会・編: 臨床・病理乳癌取扱い規約, 第14版, 金原出版, 東京, 2000, pp 3-4.
 
79) Fisher B, Redmond C, Fisher ER, et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312: 674-681, 1985.
PubMed
80) Fisher B, Anderson S, Redmond C, et al: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333(22) : 1456-1461, 1995.
PubMed
81) Veronesi U, Banfi A, Salvadori B, et al: Breast conservation is the treatment of choice in small breast cancer: Iong-term results of a randomized trial. Eur J Cancer 26: 668-670, 1990.
 
82) Ohuchi N, Harada Y, Ishida T, et al: Breast-coserving surgery for primary breast cancer: Immediate volume replacement using lateral tissue flap. Breast Cancer 4: 135-141, 1997.
PubMed
83) 山形基夫, 長谷川哲夫, 三上 元・他: 内視鏡円状部分切除と郭清術. 外科治療 83: 665-671, 2000.
 
84) Fisher B, Dignam J, Wolmark N, et al: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16: 441-452, 1998.
PubMed
85) 西村令喜: 乳房温存手術後の乳房内再発(炎症性型か否か) と放射線治療および臨床病理学的因子との関連について. 乳癌の臨床 13: 427-433, 1998.
Medical*Online
86) Cabanas R: An approach for the treatment of penile carcinoma. Cancer 39(2) : 456-466, 1977.
PubMed
87) Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127(4) : 392-399, 1992.
PubMed
88) Krag DN, Weaver DL, Alex JC, et al: Surgical resection and radio-localization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 2: 335-340, 1993.
 
89) Giuliano AE, Kirgan DM, Guenther JM, et al: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220: 391-401, 1994.
PubMed
90) 岩田広治: センチネルリンパ節生検. 乳癌診療の実際, (小林俊三・監修, 岩瀬弘敬・編) , 新興交易出版, 東京, 2002, p146.
 
91) Noguchi M, Tsugawa K, Kawahara F, et al: Dye-guided sentinel lymphadenectomy in clinically node-negative and nodepositive breast cancer patients. Breast Cancer 5(4) : 381-387, 1998.
PubMed
92) Sato K, Hiraide H, Uematsu M, et al: Efficacy and significance of sentinel lymph node identification with technetium-99 m-labeled tin colloid for breast cancer. Breast Cancer 5(4) : 389-393, 1998.
 
93) 野口昌邦: 乳癌・リンパ節郭清とセンチネルリンパ節生検. 協和企画, 東京, 2000.
 
94) McMasters KM, Tuttle TM, Carlson DJ, et al: Sentinel lymph node biopsy for breast cancer. A suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18(13) : 2560-2566, 2000.
 
95) Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52: 2127, 1992.
PubMed
96) Goldhirsch A, Glick JH, Gelber RD, et al: Meeting Hilights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol 18: 3817-3827, 2002.
 
97) Early Breast Cancer Trialist's Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: 71-85, 1992.
PubMed
98) Early Breast Cancer Trialist's Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352: 930-942, 1998.
 
99) Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405-410, 1976.
PubMed
100) Fisher B, Dignam J, Mamounas EP, et al: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from national surgical adjuvant breast and bowel project(NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate and fluorouracil. J Clin Oncol 14: 1982-1992, 1996.
 
101) Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89: 1673-1682, 1997.
PubMed
102) Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52: 2127, 1992.
PubMed
103) Tancini G, Bonadonna G, Valagussa P, et al: Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1: 2, 1983.
 
104) Falkson HC, Gray R, Wolberg WH, et al: Adjuvant trial of 12 cycles of CMFPT follwed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group Phase III study. J Clin Oncol 8: 599, 1990.
PubMed
105) Early Breast Cancer Trialists'Collaborative Group: Polychemotherapy for early breast cancer: an overview of therandomised trials. Lancet 352: 930, 1998.
 
106) National Institutes of Health Consensus: Statement on the adjuvant therapy of breast cancer. Available at: http://adp. od. nih. gov/consensus/cons/114/114-statement. htm
 
107) Fumoleau P, Bremond A and Kerbrat P: Better outcome of pre-menopausal node-positive(N-F) breast cancer patients(pts) treated with 6 cycle vs 3 cycle of adjuvant chemothearapy: Eight year follow-up results of FASG OI. Proc ASCO 18: 67a(abstract 252) , 1999.
 
108) Henderson IC, Berry D, Demetri G, et al: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with nodepositive primary breast cancer. Proc ASCO 17: 101 a, 1998.
PubMed
109) Azzopardi JG, Chepick OF, Hartmann WH, et al: The World Health Organization histological typing of breast tumors, second edition. Am J Clin Pathol 78: 806, 1982.
 
110) Yamauchi H, Stearns V and Hayes D: When is a tumor marker ready for prime time? A case study of c-erb-B 2 as a predicitive factor in breast cancer. J Clin Oncol 19: 2334-2356, 2001.
 
111) 福富隆志, 明石-田中定子: 日本における臨床試験-n0乳がんのハイリスクグループに対する術後補助療法の妥当性と問題点に ついて. 乳癌の臨床 17: 20-26, 2002.
 
112) Fisher B, Dignam J, Mamounas EP, et al: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project(NSABP) B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14: 1982, 1996.
PubMed
113) Budd GT, Green S, O'Bryan RM, et al: Short-course FAC-M versus 1-year of CMFVP in node-positive, hormone receptornegative breast cancer: an intergroup study. J Clin Oncol 13: 831, 1995.
 
114) Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and Tamoxifen compared with Tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to Tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8: 1005-1018, 1990.
PubMed
115) Fisher B, Redmond C, Wickerham DL, et al: Doxorubicin-containing regiments for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7: 572, 1989.
 
116) Early Breast Cancer Trialist'Collaborative Group: Analysis of overview results. Presented at the fifth meeting of Early Breast Cancer Trialist'Collaborative Group, Oxford, United Kingdom, September 21-23, (abstract) , 2000.
 
117) Wood W, Budman D, Korzun A, et al: Dose and dose intensity trial of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253-1259, 1994.
PubMed
118) Thor AD, Berry DA, Budman DR, et al: ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998.
PubMed
119) Budman D, Berry D, Cirrincione C, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90: 1205-1211, 1994.
 
120) Fisher B, Anderson S, Wickerham D, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicincyclophosphamide regimen for the treatment of the primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15: 1858-1869, 1997.
 
121) Fisher B, Anderson S, DeCillis A, et al: Further evaluation of intensified and increased total dose of cyclophosphamide in adoxorubicin-cyclophosphamide regimen for the treatment of the primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17: 3374-3388, 1999.
PubMed
122) Levine MN, Bramwell VH, Prichard PI, et al: Randomized trial of intensive cyclophosphamide, Epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with nodepositive breast cancer. J Clin Oncol 16: 2651-2658, 1998.
 
123) Coombes RC, Bliss JM, Morvan F, et al: Adjuvant cyclophosphamide, methotrexate and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol 14: 35-45, 1996.
 
124) Bonneterre J, Roche H, Bremond A, et al: Results of a randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 in high risk node-positive breast cancer patients. Proc ASCO 17: 124 a(abstract 473) , 1998.
 
125) Adachi I, Watanabe T and Abe K: Randomized comparison of sequential endocrine and chemotherapy versus combined chemoendocrine therapy in patients with advanced breast cancer, (ed by Kimura K, Carter SK and Griswold DP) , Chemotherapy Challenges for Future 5: 276-287, 1990.
 
126) 神田和弘, 山県 淳, 竹中賢治: 再発, 進行乳癌に対する5-FU, Adriamycin, Cyclophosphamide(FAC療法) の効果. 癌と化学療法 8: 749-756, 1981.
Medical*Online
127) 冨永 健, 北村正次, 野村雍夫・他: 共同研究によるEpirubicinの乳癌に対するPhase II Study. 癌と化学療法 13: 2187-2192, 1986.
Medical*Online
128) Fumoleau P, Bremond A and Kerbrat P: Better outcome of pre-menopausal node-positive(N+) breast cancer patients(pts) treated with 6 cycle vs 3 cycle of adjuvant chemothearapy: Eight year follow-up results of FASGOI. Proc ASCO 18: 67a(abstract 252) , 1999.
 
129) Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer. The results of 20 years of follow-up. N Engl J Med 332: 901-926, 1995.
 
130) 野村雍夫, 冨永 健, 安達 勇・他: 原発進行・再発乳癌に対するCyclophosphamide, Methotrexate, 5-fluorouracil(CMF) 併用療法の臨床的検討. 癌と化学療法 21: 1949-1956, 1994,
Medical*Online
131) Abe O: The role of chemoendocrine agents in postoperative adjuvant therapy for breast cancer: meta-analysis of the 1st collaborative studies of postoperative adjuvant chemotherapy for breast cancer(ACETBC) . Breast Cancer 1: 1-9, 1994.
 
132) Morimoto T, Ogawa M, Orita K, et al: Postoperative adjuvant randomized trial comparing chemoendocrine therapy for patients with stage II breast cancer: 5-year results from the Nishinihon cooperative study group of adjuvant chemoendocrine therapy for breast cancer(ACETBC) of Japan. Eur J Cancer 32: 235-242, 1996.
 
133) Toi M, Tominaga T, Abe O, et al: Role of Thimidine phosphorylase for predicting the prognosis and therapeutic effect of 5'-DFUR-5-fluorouridine, A intermediate form of Capecitabine, in ealy breast cancer patients; findings from a randomized controlled trial. Proc ASCO 20: 31 a(abstract #120) , 2001.
 
134) Early Breast Cancer Trialist's Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351: 1451-1467, 1998.
 
135) Fisher B, Anderson N, Wolmark E, et al: Chemotherapy with or without tamoxifen for patients with ER negative breast cancer and negative nodes: Results from NSABP B23. Proc ASCO 19: 72a(abstract 277) , 2000.
 
136) Early Breast Cancer Trialist's Collaborative Group: Ovalian ablation in early breast cancer: an ovsre view of the randomized trials. Lancet 348: 1189-1196, 1996.
 
137) Scottish Cancer Trials Breast Group and ICRF Breast Unit: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Lancet 341: 1293-1298, 1993.
PubMed
138) Kaufmann M, Jonat W, Kleeberg U, et al: Goserelin, a depot gonadotropin-releasing hormone against in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7: 1113-1119, 1989.
 
139) Boccard F, Rubagotti D, Perrotta D, et al: Ovarian ablation versus goserelin with or without Tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of multicentric Italian study. Ann Oncol 5: 337-342, 1994.
PubMed
140) Boccard F, Rubagotti D, Perrotta Amoroso D, et al: Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group O2 Randomized Trial. J Clin Oncol 18: 2718-2727, 2000.
 
141) Taylor CW, Green S, Dalton WS, et al: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An inter group study. J Clin Oncol 16: 994-999, 1998.
 
142) Davidson N, O'Neil A, Vukov A, et al: Effect of chemohormonal therapy in pre-menopausal, node(+) , receptor(+) breast cancer: Eastern cooperative oncology group phase III intergroup trial. Proc ASCO 18: 67 a, 1999.
 
143) Jakesz R, Hausemaninger H, Samonigg H, et al: Comparison of Adjuvant therapy with Tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four year results of Austrian Breast Cancer Study Group(ABCSG) Trial 5. Proc ASCO 18: 67 a, 1999.
 
144) Ejlertsen B, Dombernowsky P, Mouridsen HT, et al: Comparable effect of ovarian ablation versus CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients. Proc ASCO 18: 66 a(abstract #248) , 1999.
 
145) Roche HH, Kerbrat K, Bonneterre J, et al: Complete hormonal blockade versus chemotherapy in premenopausal earlystage breast cancer patients with positive hormone-receptor and 1-3 node-positive tumor: Results of the FASG O6 trial. Proc ASCO 19: 72 a(abstract #279) , 2000.
 
146) Jonat W for the Zoladex Early Breast Cancer Re Association: Zoladex vs CMF as adjuvant therapy in pre-/perimenopausal early breast cancer: Preliminary efficacy-QOL, and BMD results from the ZEBRA study. Breast Cancer Res Treat 64: 13, 2000.
 
147) Rutqvist LE: Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomized trial by the Cancer Research Campaign(CRC) Breast Cancer Trial Group, the Stpckholm Brest Cancer Trial Group, The South-East Sweden Brest Cancer Group and the Gruppo Intersdisciplinare Valtazione Interventi in Oncologia. Proc ASCO 18: 67 a, (abstract #251) , 1999.
 
148) Baum M, et al: The ATAC(Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal(PM) women. Breast Cancer Res Treat 69(3) : abstract #8, 2001.
 
149) Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and Tamoxifen compared with Tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to Tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8: 1005-1018, 1990.
PubMed
150) International Breast Cancer Study Group: Effectiveness of adjuvant chemotherapy in combination with Tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15: 1385-1394, 1997.
 
151) Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol 15: 2483-2493, 1997.
PubMed
152) Mauriac L, Durand M and Dilhuydy AJM: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol2: 347-354, 1991.
 
153) Falkson G, Gelman RS, Leone L, et al: Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer 66: 1621, 1990.
 
154) Greenberg P, Hortobagyi G, Smith T, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197, 1996.
PubMed
155) Bloom H, Richardson W and Harrier EJ: Natural history of untreated breast cancer. BMJ 2: 213, 1962.
 
156) Yamamoto N, Watanabe T, Katsumata N, et al: Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16: 2401, 1998.
PubMed
157) Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339: 974-984, 1998.
PubMed
158) Fossali R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: Asystemic review of published randomized trials involving 31, 510 wimen. J Clin Oncol 16: 3439-3460, 1998.
 
159) Greenberg PAC, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197-2202, 1996.
 
160) Paterson AHG, Szafran O and Cornish F: Effect of chemotherapy on survival in metastatic breast cancer. Breast Cancer Res Treat 1: 357-363, 1982.
 
161) Smalley RV, Murphy S, Hunguley CM, et al: Combination versus sequential five-drug chemotherapy on metastatic carcinoma of the breast. Cancer Res 36: 3911-3916, 1976.
 
162) Hoogstraten B, George SL, Samal B, et al: Combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38: 13-20, 1976.
PubMed
163) Lena MD, Zucali R and Viganotti G: Combined chemotherapy-radiotherapy approach in locally advanced breast cancer. Cancer Chemother Parmaco1 1: 53-59, 1978.
 
164) Cooper RG: Combination chemotherapy in hormone resistant breast cancer. Proc Am Assoc Cancer Res 10: 15, 1969.
 
165) Tranum BL, McDonald B and Thigpen T: Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study. Cancer 49: 835-839, 1982.
 
166) Segaloff A, Hankey BF, Carter AC, et al: An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotorexate, and predonine in advanced breast cancer. Breast Cancer Res Treat 5: 311-319, 1985.
 
167) Tormey DC, Gelman R, Band PR, et al: Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer 50: 1235-1244, 1982.
PubMed
168) Henderson IC and Harris JR: Principles in the management of metastatic disease, Breast Disease, (by ed Henderson IC and Harris Jr) , 2nd ed, Lippincott, New York, 1990, pp 547-677.
 
169) Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377-1387, 1988.
PubMed
170) Muss HB, White DR, Cooper MR, et al: Combination chemotherapy in advanced breast cancer: a randomized trial comparing a three-vs a five-drug program. Arch Intern Med 137: 1711-1714, 1977.
 
171) Chlebowski RT, Weiner JM, Luce J, et al: Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. Cancer Res 41: 4399-4403, 1981.
 
172) Taguchi T: A phase II study of CPT-11 in advanced breast cancer. Int J Oncol 5: 404-405, 1994.
 
173) Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14: 422-428, 1996.
 
174) Hudis C, Seidman AD, Crown JPA, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cacner. J Clin Oncol 14: 58-65, 1996.
 
175) Valero V, Holmes FA, Waters RS, et al: Phase II trial of docetaxel: Anew, highly effective antineoplastic agent in the management of patients with Anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886-2894, 1995.
 
176) Mamouse E, Brown A, Fisher B, et al: 3-hour high-dose taxol infusion in advanced breast cancer: an NSABP phase II study. Proc ASCO 15: abstract 206, 1995.
 
177) Bishop J, Dewar J, Tattesall M, et al: A randomized phase III study of Taxol vs CMFP in untreated patients with metastatic breast cancer. Proc ASCO 15: abstract 107, 1996.
 
178) 田口鐵男, 平田公一, 國井康男・他: RP 56976(Docetaxel) の乳癌に対する前期第II相臨床試験. 癌と化学療法 21: 2453-2460, 1994.
Medical*Online
179) Jean-Marc A, Nabholtz, et al: A phase III trial comparing docetaxel and doxorubicin(AT) vs doxorubicin and cyclophosphamide(AC) in first line metastatic breast cancer(MBC) . Proc ASCO 18: 127 a(abstract 485) , 1999.
 
180) Buzdar AU, Singletary SE, Theriault RL, et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, cyclophosphamide(FAC) as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17: 3412-3417, 1999.
PubMed
181) Pouillart P, Fumoleau P, Romieu G, et al: Final results of a phase II randomized, parallel study of doxorubicin/cyclophosphamide(AC) and doxorubicin/paclitaxel(AT) as neoadjuvant treatment of local-regional breast cancer. Proc ASCO 18: 73a(abstract 275) , 1999.
 
182) Hainsworth JD, Burris III HA, Erland JB, et al: Phase I trial of Docetaxel administered by weekly infusion in patients with advanced reflactory cancer. J Clin Oncol 16: 2164-2168, 1998.
 
183) Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: results of CALGB 9342. Proc ASCO 17: 101 a(abstract 388) , 1998.
 
184) Loffler TM: Is There a place for"Dose-Dense"weekly schedules of Taxoids? Semin Oncol 12: 32-34, 1998.
 
185) 木村盛彦, 小井田時廣, 柳田康弘: 進行・再発乳癌に対するPaclitaxel Weekly投与の臨床経験-特にShort Premedicationによる外来治療の可能性について-. 癌と化学療法 27: 1703-1708, 2000.
 
186) Ando M, Watanabe T, Nagata K, et al: Efficacy of Docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of Anthracycline resistance. J Clin Oncol 19: 336-342, 2001.
 
187) Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618, 1998.
PubMed
188) Howell A, Downey S and Anderson E: New Endocrine therapies for breast cancer. Eur J Cancer 32: 576-588, 1996.
 
189) Buzdar AU, Jonat W, Howell A, et al: Anastorozole versus megesterol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Cancer 83: 1142-1152, 1998.
 
190) Jonat W, Howell A, Blomqvist C, et al: A randomized trial comparing two doses of the new selective aromatase inhibitor anastorozole(Arimedex) with MA in postmenopausal patients with advanced breast cancer. Eur J Cancer 32: 404-412, 1996.
 
191) Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Doubleblind randomized trial showing a dose effect and improved efficacy and torelability compared with MA. J Clin Oncol 16: 453-461, 1998.
 
192) Gershanovich M, Chaudi HA, Campos D, et al: Letrozole, a new oral aromatase inhibitor: Randomized trial comparing 2. 5mg daily, 0. 5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Annal Oncol 9: 639-645, 1998.
 
193) Kaufmann M, Bajetta E, Dirix LY, et al: Examestane is superior to MA after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. J Clin Oncol 18: 1399-1411, 2000.
 
194) Thurlimann B, Paridaens R, Roche M, et al: Examestane in postmenopausal pretreated advanced breast cancer: a multicenter pahse II study in patients aminoglutethimide(AG) failure. Proc Eur Soc Med Oncol 5: abstract #144, 1994.
 
195) Buzdar A, Nabholtz JM, Robertson JF, et al: Anastrozole(Arimedex) versus Tamoxifen as First-line therapy for advanced breast cancer in postmenopausal women-Combined analysis from two identically designed multicenter trial. Proc ASCO 19: abstract #609 D, 2000.
 
196) Koyama H, Tominaga T, Asaishi K, et al: A randomized controlled cooperative study of oral medroxyprogesterone acetate 1200 and 600 mg in patients with advanced or recurrent breast cancer. Oncology 56: 283-290, 1999.
PubMed
197) Tominaga T, Abe O, Oshima A, et al: Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. Eur J Cancer 34: 959-964, 1994.
 
198) Kangas L, Kallio S, Blanco G, et al: Anew triphenylethylene compound, FC-1157 a: II, Antitumote effets. Cancer Chemother Pharmacol 17: 109-114, 1986.
 
199) Pyrjonen S, Valavaara R, Modig H, et al: Comparison of tremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomized double blind-The"Nordic"phase III study. Br J Cancer 76: 270-277, 1997.
 
200) Nomura Y, Tominaga T, Abe O, et al: Clinical evaluation of NK 622 in advanced or recurrent breast cancer: A comparative study by a double blind method with tamoxifen. Jpn J Cancer Chemother 20: 247-258, 1993.
PubMed
201) Gershanovich M, Hayes D, Ellmen J, et al: High dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology 11: 29-36, 1997.
PubMed
202) Holli K, Valavaara R, Blanco G, et al: Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. J Clin Oncol 18: 3487-3494, 2000.
PubMed
203) Cocconi G, di Blasio B, Bisagni G, et al: Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. Am J Clin Oncol13: 226, 1990.
 
204) Hortobagyi GN, Ames FC, Buzdar AU, et al: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507, 1988.
PubMed
205) Schwartz GF, Cantor RI and Biermann WA: Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast. Arch Surg 122: 1430, 1987.
PubMed
206) Lippman ME, Sorace RA, Bagley CS, et al: Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. NCI Monogr 1: 153, 1986.
 
207) Jaiyesimi IA, Buzdar AU and Hortobagyi G: Inflammatory breast cancer: areview. J Clin Oncol 10: 1014, 1992.
 
208) Taylor GW and Metzer A: Inflammatory carcinoma of the breast. Am J Cancer 33: 33, 1938.
 
209) Singletary SE, Ames FC and Buzdar AU: Management of inflammatory breast cancer. World J Surg 18: 87, 1994.
PubMed
210) Stadtmauer EA, O'Neil A, Goldstein LJ, et al: Chemotherapy compared with autologus stem cell transportation in the management of responding metastatic breast cancer. PBT-1. Proc ASCO 18: 1a, 1999.
 
211) Peters WP, Rosner G, Vredenburgh J, et al: Preliminary results of a randomized comparison of two doses of combination alkylating agents as consolidation after CAF in patients with primary breast cancer involving ten or more axillary lymphnodes. Proc ASCO 18: 1a, 1999.
 
212) Bergh J: Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc ASCO 18: 2a, 1999.
 
213) Takashima S, Saeki T, Adachi I, et al: A phase II study of high-dose epirubicin(EPI) plus cyclophosphamide(CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: Atrial of the Japan Clinical 0ncology Group. Jpn J Clin Oncol 27: 325-330, 1997.
 
214) Tokuda Y, Tajima T, Narabayashi M, et al: Randomized phase III study of high-dose chemotherapy(HDC) with autologus stem cell supPort as consolidation in high-risk postoperable breast cancer. Japan Clinical Oncology Group(JCOG 9208) . Proc ASOC 20: 38 a(abstract 148) , 2001.
 
215) The American Society of Clinical Oncology: American Society of Clinical Oncology recommendation for the use of hematopoietic colony-stimulating factors: Evidenced-based, clinical practice guidelines. J Clin Oncol 12: 2471-2508, 1994.
 
216) Hughes WT, Armstrong D, Bodey GP, et al: 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25: 551-573, 1997.
PubMed
217) Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82 b Trial. N Engl J Med 337: 949, 1997.
 
218) Overgaard M, Jensen M-B, Overgaard J, et al: Randomized controlled trial evaluating postoperative radiotherapy in highrisk postmenopausal breast cancer patients given tamoxifen: report from the Danish Breast Cancer Cooperative Group DBCG 82 c Trial. Lancet 353: 1641, 1999.
 
219) Nixon AJ, Manola J, Gelman R, et al: No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques. J Clin Oncol 16: 1374, 1998.
 
220) Hojris I, Overgaard M, Christensen JJ, et al: Morbidity and mortality of ischemic heart disease in 3083 high-risk breast cancer patients given adjuvant systemic treatment with or without postmastectomy irradiation. Radiother Oncol 48(suppl 1) : S120(abstract) , 1998.
 
221) Swedborg I and Wallgren A: The effect of pre-and post-mastectomy radiotherapy on the degree of edema, shoulder joint mobility, and gripping force. Cancer 47: 877, 1981.
 
222) Larson D, Weinstein M, Goldberg I, et al: Edema of the arm as a function of the extent of axillary surgery in patients with stage I and II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 12: 877, 1986.
 
223) Recht A, Come SE, Henderson IC, et al: The sequencing of chemotherapy and radiation therapy after conservative surgery for patients with early-stage breast cancer. N Engl J Med 334: 1356, 1996.
PubMed
224) Sutherland CM and Mather FJ: Long-term survival and prognostic factors in patients with regional breast(skin, muscle, and/or chest wall attachment) . Cancer 55: 1389-1397, 1985.
PubMed
225) Galicich JH, Sundaresan N, Arbt E, et al: Surgical treatment of brain metastasis. Cancer 55: 1382-1388, 1985.
 
226) 大川智彦, 喜多みどり, 西嶋博司・他: 転移性脳腫瘍に対する放射線治療の臨床的検討. 癌の臨床 34: 1139-1146, 1988.
 
227) Kida Y, Kobayashi T and Tanaka T: Radiotherapy of the metastatic brain tumors with gamma-knife. Acta Neurochir 63: 89-94, 1995.
 
228) Singer FR, Ritch PS, Lad TE, et al: Treatment of hypercalcemia of malignancy with intravenouse etidoronate. A controlled multicenter study. Arch Intern Med 151: 471-476, 1991.
 
229) O'Rourke NP, McCloskey EV, Vasikaran S, et al: Effective treatment of malignant hypercalcemia with a single infusion of clodronate. Bone 9: 123-130, 1993.
 
230) Body JJ and Dumon JC: Treatment of tumor-induced hypercalcemia with the bisphosphonate pamindronate: Doseresponse relationship and influence of the tumour type. Ann Oncol 5: 359-363, 1994.
 
231) Theriault RL, Lipton Allan, Hortobagyi GN, et al: Pamindronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. J Clin Oncol 17: 846-854, 1999.
 
232) Bloomfield DJ: Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 16: 1218-1225, 1998.
PubMed
233) DielIJ, Solomayer EF, Serban D, et al: Reduction in new metastasis in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363, 1998.
 
234) Body JJ, Bartl R, Burckharrdt P, et al: Current use of bisphosphonates in oncology. J Clin Oncol 16: 3890-3899, 1998.
 
235) Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamindronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. N Engl J Med 335: 1785-1791, 1996.
 
236) Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cacner that has progressed after chemotherapy. J Clin Oncol 17: 2639-2648, 1999.
 
237) Tokuda Y, Watanabe T, Omuro Y, et al: Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 81: 1419-1425, 1999.
PubMed
238) Norton L, Slamon D, Leyland-Jones B, et al: Overall survival advantage to simultaneouse chemotherapy plus the humanized anti-HER"monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer. Proc ASCO 18: 127a(abstract 483) , 1999.
 
239) Hudis C, Seidman A and Paton V: Characterization of cardiac dysfunction observed in the HERCEPTIN. Breast Cancer Res Treat 50: 232-235, 1998.
 
P.654 掲載の参考文献
1) 味木和喜子: 1995年 (平成7年) 全国癌罹患数, 罹患率の推定, 厚生省癌研究助成金, 地域癌登録の精度向上と活用に関する研究. 平成11年度報告書, (大島 明・編) , 大阪府立成人病センター, 2000, pp 35-44.
 
2) 黒石哲生: 世界各国の癌死亡の動向-33ヵ国における部位別癌の年齢調整死亡率 (1953-1992) . 癌・統計白書-罹患/死亡/予後-1999, (富永祐民, 他・編) , 篠原出版, 東京, 1999, p233, 251.
 
3) 厚生省大臣官房闘鶏情報部・編: 平成10年人口動態統計 (上巻) . 厚生統計協会, 東京, 2000, pp 284-290.
 
4) 黒石哲生: 日本における癌死亡 (1950-1995) . 癌・統計白書-罹患/死亡/予後-1999, (富永祐民, 他・編) , 篠原出版, 東京, 1999, pp 1-84.
 
5) World Cancer Research Fund and American Institute for Cancer Research: Food, nutrition and the prevention of cancer. aglobal perspective, American Institute for Cancer Research, Washington DC, 1997.
 
6) Kono S and Hirohata T: Areview on gastric cancer and life style. Jpn J Cancer Clin 36: 257-267, 1990.
 
7) Lopez-Carrillo L, et al: Chili pepPer consumption and gastric cancer in Mexico a case-control study. Am J Epidemiol 139: 263-271, 1994.
PubMed
8) Ji BT, Chow WH, Yang G, et al: Dietary habits and stomach cancer in Shanghai, China. Int J Cancer 76: 659-664, 1998.
PubMed
9) 吉野純典: ニンニク・タマネギと癌予防. 臨床栄養 91: 600, 1997.
 
10) 吉野純典: 緑茶と癌予防. 臨床栄養 90: 768, 1997.
 
11) Correa P: Ahuman model of gastric carcinogenesis. Cancer Res 48: 3554, 1998.
 
12) 滝澤登一郎, 小池盛雄: 病理形態学における微小胃癌-胃癌の組織発生再考-. 胃と腸 23: 791, 1988.
 
13) Honda S, Fujioka T, Tokieda M, et al: Development of Helicobacter pylori induced gastric carcinoma in Mongolian Gerbils. Cancer Res 58: 4255-4259, 1988.
 
14) Hirayama F, Takagi S, Kusuhara H, et al: Induction of gastric ulcer and intestinal metaplasia in the gastric mucosa of Mongolian gerbils infected with Helicobacter pylori. J Gastroenterol 31: 755-757, 1996.
PubMed
15) Sakaki N: Endoscopic diagnosis of gastritis in relation to Helicobacter pylori infection and subjective symptomes. J Clin Gastroenterol 21 (Suppl 1) : 135, 1995.
 
16) Sugiyama A, Maruta F, Ikeno T, et al: Helicobacter ptlori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in Mongolian gerbil. Cancer Res 58: 2067-2069, 1998.
PubMed
17) Kikuchi S, Nakajima T, Kobayashi O, et al: Effect of age on the relationship between gastric cancer and Helicobacter pylori Jpn J Cancer Res 91: 774-779, 2000.
PubMed
18) Tahara H, et al: Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res 1: 1245-1251, 1995.
 
19) 辻 一郎, 坪野吉孝, 久道 茂: 胃癌集団検診の現状. 日本臨床 59 (増刊4号) : 533-537, 2001.
 
20) 日本胃癌学会・編: 胃癌取扱い規約. 第13版, 金原出版, 東京, 1999.
 
21) 日本胃癌学会・編: 胃癌治療ガイドライン (医師用) . 金原出版, 東京, 2001.
 
22) Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in soid tumors. J Natl Cancer Inst 92: 205-216, 2000.
 
23) WHO handbook for reporting results of cancer treatment. Geneva (Switzerland) , World Health Organization. offset Publication 48, 1979.
 
24) 佐々木常雄, 岡元るみ子, 小室泰司: 胃癌, 大腸癌化学療法の効果判定法と生存期間. 第38回日本癌治療学会総会ワークショップ3. 日癌治療会誌 35: 243, 2000.
 
25) 小泉和三郎, 田辺 聡, 西之寺克禮・他: 進行胃癌における癌化学療法の効果判定と生存期間. 第38回日本癌治療学会総会ワークショップ3. 日癌治療会誌 35: 244, 2000.
 
26) Murad AM, Sntiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993.
 
27) Pyrhonen S, Kuitunen T, Nyandoto P, et al: Randamized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 71: 587-591, 1995.
 
28) Glimelius B, Hoffman K, Haglund U, et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5: 189-190, 1994.
PubMed
29) 中村 朗, 小尾俊太郎, 林田典子・他: 切除不能胃癌に対するbest supportive care (BSC) の長期成績. 日癌治療会誌 30: 1488 (示-283) , 1995.
 
30) 吉田元樹, 大津 敦, 朴 成和・他: 日本臨床腫瘍消化器内科グループ研究において化学療法を施行した切除不能胃癌の長期生存成績. 第11回癌臨床研究フォーラム抄録集, 2001, p50.
 
31) 佐々木常雄, 太田和雄, 井林 淳・他: 胃癌に対するメソトレキセート・5-FU交代療法と5-FU単独療法の比較試験-メソトレキセート・5-FU交代療法共同Phase III study-. 癌と化学療法 16 (8) : 2545-2555, 1989.
Medical*Online
32) Kurihara M, Izumi T, Yoshida S, et al: Acooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res 82: 613-620, 1991.
 
33) Koizumi W, et al: Combination therapy with cisplatin, 5'-deoxy-5-fluorouridine (5'-DFUR) and mitomycin C (MMC) in patients with inoperable, advanced gastric cancer: A randomized trial comparing two dosage regimens. Oncol Rep 3: 255-260, 1996.
 
34) Cullinan SA, Moertel CG, Fleming TR, et al: Acomparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253: 2061-2067, 1985.
 
35) Kim NK, Park YS, Heo DS, et al: phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813-3818, 1993.
PubMed
36) Cocconi G, Bella M, Zironi S, et al: Fluorouracil, doxorubicin, and mitomycin combination versus PFLF chemotherapy in advanced gastric cancer: Aprospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 12: 2687-2693, 1994.
 
37) Wils J, Klein HO, Wagener DJ, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A step ahead in the treatment of advanced gastric cancer: Atrial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9: 827-831, 1991.
 
38) Kelsen D, Atiq OT, Saltz L, et al: FAMTX versus etoposide, doxorubicin, and cisplatin: Arandom assignment trial in gastric cancer. J Clin Oncol 10: 541-548, 1992.
 
39) Cullinan SA, Moertel CG, Wieand HS, et al: Controlled evaluation of three drug combination regimens therapy of gastric cancer. J Clin Oncol 12: 412-416, 1994.
PubMed
40) Shimada Y, Shiro K, Ohtsu A, et al: Phase III study of UFT+MMC versus 5-FU+CDDP versus 5-FU alone in patients with advanced gastric cancer: JCOG Study 9205. Proc ASCO 18: 1043, 1999.
 
41) Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: Atrial of European Organization for Research and Treatment of Cancer Gastrointestial Tract Cancer Cooperative Group. J Clin Oncol 18: 2648-2657, 2000.
 
42) 大津 敦, 朴 成和, 藤井隆広・他: スキルス胃癌に対する5-FU+ADM+大量MTX (FAMTX) 併用療法の検討. 第66回胃癌研究会プログラム, 1996, p50.
 
43) MacDonald JS, Schein PS, Woolley P V, et al: 5-fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533-536, 1980.
PubMed
44) Klein HO: 5-fluorouracil (5-FU) , doxorubicin (ADM) , and methotrexate (MTX) : Acombination protoco1 (FAMTX) for treatment of metastatic stomach cancer. Proc ASCO 5: 84, 1986.
 
45) Preusser P, Wilke H, Achterrath W, et al: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastrlc cancer. J Clin Oncol 7: 1310-1317, 1989.
 
46) 田口鐵男, 太田 潤, 折野真哉・他: 進行胃癌に対するEtoposide, ADM, CDDP (EAP) 療法の共同研究. 癌と化学療法 17 (11) : 2191-2196, 1990.
Medical*Online
47) Nakajima T, Ota K, Ishihara S, et al: Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 4: 203-208, 1997.
PubMed
48) Cascinu S, Labianca R, Alessandroni P, et al: Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epidoxorubicin, 6 S-leucovorin, glutathione, and filgrastim: Areport from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 15: 3313-3319, 1997.
 
49) Yonemura Y, Sawa T, Kinoshita K, et al: Neoadjuvant chemother-apy for high-grade advanced gastric cancer. World J Surg 17: 256-261, 1993.
 
50) Boku N, Ohtsu A, Shimada Y, et al: Phase II study of a combination of irinotecan and cisplatin agalnst metastatic gastric cancer. J Clin Oncol 17: 319-323, 1999.
PubMed
51) 村上 稔, 太田和雄, 宮崎 保・他: 多施設共同研究によるメソトレキセート・5-FU交代療法の進行胃癌および結腸・直腸癌に対するPhase II study. 癌と化学療法 14 (8) : 2482-2490, 1987.
Medical*Online
52) 佐々木常雄, 太田和雄, 坂田 優・他: 多施設共同研究による大量Leucovorin・5-FU併用療法の進行胃癌および結腸・直腸癌に対するPhase II study. 癌と化学療法 17 (12) : 2361-2868, 1990.
Medical*Online
53) 佐藤 温, 長谷川浩一, 栗原 稔・他: 進行胃癌に対するUFTとCDDP併用療法 (UFTP療法) に関する検討. 癌と化学療法 22 (10) : 1355-1362, 1995.
Medical*Online
54) 赤沢修吾, 太田和雄, 栗原 稔: 多施設共同研究による1-leucovorin, 5-FU併用療法の進行胃癌に対する後期第II相試験. 日癌 治療会誌 30: 569-583, 1995.
 
55) 鄭 容錫, 山下好人, 仲田文造・他: 進行再発胃癌における5-FU持続静注とCDDP少量連日投与併用の臨床的効果. 癌と化学 療法 22 (11) : 149-151, 1995.
 
56) Sakata Y, Ohtsu A, Horikoshi N, et al: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafuro. 4mg gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 3: 1715-1720, 1998.
 
57) Koizumi W, Kurihara M, Nakano S, et al: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer: For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197, 2000.
 
58) 佐々木常雄, 前田義治, 栗原 稔・他: 胃癌の標準化学療法. 消化器外科 24: 1629-1636, 2001.
 
59) Ohtsu A, Boku N, Nagashima F, et al: APhase I/II Study of S-1 plus cisplatin (CDDP) in patients (pts) with advanced gastric cancer (AGC) . Proc ASCO 20: 656, 2001.
 
60) Joensuu J, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-1056, 2001.
 
61) 寺島雅典, 阿部 薫, 武田雄一郎・他: STI 571が著効した胃Gastrointestinal Stromal Tumorの1例. 癌と化学療法 29 (4) : 607-610, 2002.
 
62) Nakajima T, Nashimoto A, Kitamura M, et al: Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer a randomized trial. Lancet 354: 273-277, 1999.
PubMed
63) Hermans J, Bonenkamp JJ, Boon MC, et al: Adjuvant therapy after curative resection for gastric cancer meta-analysis of randomized trials. J Clin Oncol 11: 1441-1447, 1993.
PubMed
64) Earle CC and Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-asian patients revisiting a meta-analysis of randomized trials. Eur J Cancer 35: 1059-1064, 1999.
PubMed
65) Macdonald JS, Smalley S, Benedetti J, et al: Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and over all survival (OS) in resected adenocarcinoma of stomach and G. E. junction. Results of Intergroup Study INT-0116 (SWOG 9008) . Proc ASCO 19: 1a, 2000.
 
66) Sautner T, Hofbauer F, Depisch D, et al: Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 12: 970-974, 1994.
 
67) Gilly FN, Sayag AC, Carry PY, et al: Intraperitoneal chemo-hyperthermic (CHIP) : anew therapy in the treatment of the peritoneal seedings. Int Surg 76: 164-167, 1991.
 
68) Nakazato H, Koike A, Saji S, et al: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343: 1122-1126, 1994.
PubMed
69) Schuhmacher C, Fink U, Becker K, et al: Neoadjuvant chemotherapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatin. Cancer 91: 918-927, 2001.
PubMed
70) 坂本純一, 生越喬二, 合地 明・他: Evidence based medicineの観点からみた胃癌補助化学療法の評価. 臨床外科 53: 1291-1299, 1998.
 
71) Hamazoe R, Maeta M and Kaibara N: Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer: Final results of a randomized controlled study. Cancer 73: 2048-2052, 1994.
PubMed
72) 日本胃癌学会・編: 胃癌治療ガイドラインの解説 (一般用) . 金原出版, 東京, 2001.
 
P.667 掲載の参考文献
1) 日本胃癌学会・編: 胃癌取扱い規約. 第13版, 金原出版, 東京, 1999.
 
2) Japanese Gastric Cancer Associtaion: Japanese Classification of Gastric Carcinoma-2nd English Edition-. Gastric Cacncer 1: 10-24, 1998.
 
3) Aikou T and Mitsuru S: The new Japanese Classification of Gastric Carcinoma: Points to be revised. Gastric Cancer 1: 25-30, 1998.
 
4) Robertson CS, Chung SC, Woods SD, et al: Aprospective randomized trial comparing R l subtotal gastrectomy with R 3 total gastrectomy for antral cancer. Ann Surg 220: 176-182, 1994.
 
5) 貝原信明: 胃癌腹膜転移の予防と治療. 日外会誌 97: 308-311, 1996.
 
6) 日本胃癌学会・編: 胃癌治療ガイドライン 医師用. 金原出版, 東京, 2001.
 
P.681 掲載の参考文献
1) The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1995: Estimates based on data from nine population-based cancer registries. Jpn J Clin Oncol 30: 318-321, 2000.
 
2) 厚生統計協会・編: 国民衛生の動向. 厚生の指標 (臨時増刊) 47 (9) : 48-60, 2000.
 
3) 厚生省大臣官房統計情報部・編: 平成10年人口動態統計 上巻. 厚生統計協会, 東京, 2000, pp 284-299.
 
4) 松本主之, 檜沢一興, 飯田三雄: 内科100年のあゆみ (消化器) III. 主要疾患の歴史4. 大腸癌. 日本内科学会雑誌 創立100周年記念特集号 91 (2) : 95-99, 2002.
 
5) Ries LA, Wingo PA, Miller DS, et al: The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 88: 2398-2424, 2000.
 
6) 津熊秀明, 味木和喜子, 大島 明: 主要臓器癌の疫学研究の現状. わが国の主要部位のがん-死亡率・数と罹患率・数の推移-. 癌と化学療法28 (2) : 137-141, 2001.
 
7) World Cancer Research Fund/American Institute for Cancer Research: Food, Nutrition and the Prevention of Cancer: A GIobal Perspective. World Cancer Research Fund/American Institute for Cancer Research, 1997.
 
8) 玉腰浩司, 徳留信寛, 栗木清典・他: 主要臓器癌の疫学研究の現状. 大腸がんの疫学と予防. 癌と化学療法 28 (2) : 146-150, 2001.
 
9) Greegor DH: Diagnosis of large-bowel cancer in the asymptomatic patient. JAMA 201: 943-945, 1967.
PubMed
10) Hastings JB: Mass screening for colorectal cancer. Am J Surg l27: 228-233, 1974.
 
11) Winchester DP, Shull JH, Scanlon EF, et al: A mass screening program for colorectal cancer using chemical testing for occult blood in the stool. Cancer 45: 2955-2958, 1980.
PubMed
12) Hardcastle JD, Balfour TW and Amar SS: Screening for symptomless colorectal cancer by testing for occult blood in general practice. Lancet Apr 12: 791-793, 1980.
 
13) Heinrich HC: Occult blood tests. Lancet Apr 12: 822-823, 1980.
 
14) Knight KK, Fielding JE and Battista RN: Occult blood screening for colorectal cancer. JAMA 261: 586-593, 1989.
PubMed
15) Smart CR: Screening and early diagnosis. Cancer 70: 1246-1251, 1992.
PubMed
16) Winawer SJ, Fletcher RH, Miller L, et al: Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 112: 594-642, 1997.
PubMed
17) Frazier AL, Colditz GA, Fuchs CS, et al: Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284: 1954-1961, 2000.
PubMed
18) Podolsky DK: Going the distance-the case for true colorectal cancer screening. N Engl J Med 343: 207-208, 2000.
PubMed
19) Saito H, Soma Y, Kodea J, et al: Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer 61: 465-469, 1995.
PubMed
20) 大腸癌研究会・編: 大腸癌取扱い規約. 改訂第6版, 金原出版, 東京, 1998.
 
21) 板橋正幸: 肉眼的分類と組織学的分類. 大腸癌, (小黒八七郎, 吉田茂昭・編) , 日本メディカルセンター, 東京, 1996.
 
22) Kudo S: Endoscopic mucosal resection of flat and depressed types of early colorectal cancer. Endoscopy 7: 455-461, 1993.
PubMed
23) Watanabe H, Miwa H, Terai T, et al: Endoscopic ultrasonography for colorectal cancer using submucosal saline solution injection. Gastrointest Endosc 45: 508-511, 1997.
PubMed
24) 大腸癌研究会・編: 大腸癌取扱い規約. 改訂第6版, 金原出版, 東京, 1998.
 
25) Dukes CE: The classification of cancer of the rectum. J Pathol 35: 323-332, 1932.
 
26) Turnbull Rb Jr, Kyle K, Watson FR, et al: Cancer of the colon; The influence of the no-touch isolation technique on survival rates. Ann Surg 166: 420-427, 1967.
 
27) Astler VB and Coller FA: The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139: 846-851, 1954.
PubMed
28) TNM Classification of Malignant Tumours: (ed by Sobin LH and Wittekind Ch) , Sixth Edition, Wiley-Liss, New York, 2002.
 
29) Chapuis PH, Dent OF, Fisher R, et al: Amultivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 72 (9) : 698-702, 1985.
 
30) Hermanek P: Problems of pTNM classification of carcinoma of the stomach, colorectum and anal margin. Pathol Res Pract 181 (3) : 296-300, 1986.
PubMed
31) Coffey RJ: Cancer of the bowel in the young adult. Dis Colon Rectum 7: 491-492, 1964.
 
32) Van Langenberg A and Ong GB: Carcinoma of large bowel in the young. Br Med J 3 (823) : 374-376, 1972.
 
33) Pescatori M, Maria G, Beltrani B, et al: Site, emergency, and duration of symptoms in the prognosis of colorectal cancer. Dis Colon Rectum 25 (1) : 33-40, 1982.
PubMed
34) Wichman MW, MUller C, Hornung HM, et al: Gender differences in long-term survival of patients with colorectal cancer. Br J Surg 88 (8) : 1092-1098, 2001.
 
35) Beahrs OH and Sanfelippo PM: Factors in prognosis of colon and rectal cancer. Cancer 28 (1) : 213-218, 1971.
PubMed
36) Foster RS Jr, Costanza MC and Foster CB: Adverse relationship between blood transfusions and survival after colectomy for colon cancer. Cancer 55 (6) : 1195-1201, 1985.
PubMed
37) Marsh J, Donnan PT and Hamer-Hodges DW: Association between transfusion with plasma and the recurrence of colorectal carcinoma. Br J Surg 77 (6) : 623-626, 1990.
PubMed
38) Steinberg SM, Barkin JS, Stablein DM, et al: Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 57 (9) : 1866-1870, 1986.
 
39) Wolmark N, Wieand HS, Shibata H, et al: The prognostic significance of tumor location and bowel obstruction in Dukes Band C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg 198 (6) : 743-752, 1983.
 
40) 長谷川久美, 杉原健一, 榎本雅之・他: 閉塞性大腸癌の検討. 日消外会誌 33 (6) : 709-715, 2000.
 
41) Dwight RW, Higgins GW and Keehn RJ: Factors influencing survival after resection in cancer of the colon and rectum. Am J Surg 117 (4) : 512-522, 1969.
 
42) Freedman LS, Macaskill P and Smith AN: Multivariate analysis of prognostic factors for operable rectal cancer. Lancet 29: 2 (8405) : 733-736, 1984.
 
43) Muto T, Kotake K and Koyama Y: Colorectal cancer statistics in Japan: data from JSCCR registration, 1974-1993. Int J Clin Oncol 6 (4) : 171-176, 2001.
PubMed
44) Burrows L and Tartter P: Effect of blood transfusions on colonic malignancy recurrent rate. Lancet l8: 2 (8299) : 662, 1982.
 
45) Tartter PI: Perioperative blood transfusion and colorectal cancer recurrence: areview. J Surg Oncol 39 (3) : 197-200, 1988.
 
46) 大司俊郎, 森 武生, 安野正道・他: 結腸癌根治術施行症例における周術期同種血輸血が予後, 再発, 及び術後合併症に与えた影響. 日本大腸肛門病会誌 53 (4) : 197-205, 2000.
 
47) Evans JT, Mittelman A, Holyoke ED, et al: Pre-and postoperative uses of CEA. Cancer 42 (3 suppl) : 1419-1421, 1978.
 
48) Staab HJ, Anderer FA, Fischer R, et al: Prognostic value of preoperative serum CEA level compared to clinical staging. I. Colorectal carcinoma. Br J Cancer 44 (5) : 652-662, 1981.
PubMed
49) Szymendera JJ, Nowacki MP, Kaminska JA, et al: Predictive value of plasma CEA levels: preoperative prognosis and postoperative monitoring of patients with colorectal carcinoma. Dis Colon Rectum 25 (1) : 46-52, 1982.
PubMed
50) Minsky BD, Mies C, Chaffey JT, et al: Resectable adenocarcinoma of the rectosigmoid and rectum. 1. Patterns of failure and survival. Cancer 61 (7) : 1408-1416, 1988.
 
51) Minsky BD, Mies C, Chaffey JT, et al: Potentially curative surgery of colon cancer: patterns of failure and survival. J Clin Oncol 6 (1) : 106-118, 1988.
PubMed
52) Spratt JS Jr and Spjut HJ: Prevalence and prognosis of individual clinical and pathologic variables associated with colorectal carcinoma. Cancer 20 (11) : 1976-1985, 1967. No abstract available.
 
53) TepPer JE, O'Connell MJ, Mayer RJ, et al: Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 19 (1) : 157-163, 2001.
 
54) Prandi M, Lionetto R, Rosso R, et al: Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 235 (4) : 458-463, 2002.
 
55) Cohen AM, Wood WC, Shinrar M, et al: Pathological studies in rectal cancer. Cancer 15: 45 (12) : 2965-2968, 1980.
 
56) Wolmark N, Fisher ER, Fisher B, et al: The relationship of depth of penetration and tumor size to the number of positive nodes in Dukes C colorectal cancer. Cancer 53 (12) : 2707-2712, 1984.
 
57) Stahle E, Glimelius B, Pahlman L, et al: Preoperative prediction of outcome in patients with rectal and rectosigmoid cancer. Cancer 63 (9) : 1831-1837, 1989.
PubMed
58) 長谷和生, 望月英隆, 吉村一克・他: 直腸癌先進部組織型の臨床的意義に関する検討. 日本大腸肛門病会誌 50 (2) : 71-79, 1997.
 
59) Minsky BD, Mies C, Chaffey JT, et al: Potentially curative surgery of colon cancer: the influence of blood vessel invasion. J Clin Oncol 6 (1) : 119-127, 1988.
PubMed
60) Minsky BD, Mies C, Chaffey JT, et al: Resectable adenocarcinoma of the rectosigmoid and rectum. II. The influence of blood vessel invasion. Cancer 61 (7) : 1417-1424, 1988.
PubMed
61) Minsky BD, Mies C, Recht A, et al: Lymphatic vessel invasion is an independent prognostic factor for survival in colorectal cancer. Int J Radiat Oncol Biol Phys 17 (2) : 311-318, 1989.
PubMed
62) Michelassi F, Vannucci L, Block GE, et al: Local recurrence after curative resection of colorectal adenocarcinoma. Surgery 108 (4) : 787-792; discussion 792-793, 1990.
 
63) Symonds DA and Vickery AL: Mucinous carcinoma of the colon and rectum. Cancer 37 (4) : 1891-1900, 1976.
PubMed
64) Krasna MJ, Flancbaum L, Ben Ari G, et al: Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 61 (5) : 1018-1023, 1988.
PubMed
65) Quirke P, Durdey P, Wi11iams NS, et al: Local recurrence of rectal adenocarcinoma due to inadequate surgical resection, Histopathological study of lateral tumour spread and surgical excision. Lancet 2 (8514) : 996-999, 1986.
 
66) 長谷和生, 望月英隆, 宇都宮勝之・他: 大腸癌の浸潤増殖様式 (INF) の予後規定因子としての意義に関する検討. 日本大腸肛門病会誌 49 (6) : 463-469, 1996.
 
67) 諸冨雅之: 進行直腸癌における臨床病理学的研究; 術前生検材料からみたリンパ節転移程度の予測. 日外会誌 89: 352-364, 1988.
 
68) 長谷和生, 望月英隆, 小池聖彦・他: 直腸癌における腫瘍蔟出の予後規定因子としての意義に関する検討. 日消外会誌 25 (11) : 2765-2772, 1992.
 
69) Murray D, Hreno A, Hampson LG, et al: Prognosis in colon cancer: apathologic reassessment. Arch Surg 110 (8) : 908-913, 1975.
PubMed
70) Jass JR, Atkin WS, Todd IP, et al: The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 10 (5) : 437-459, 1986.
 
71) Carlon CA, Fabris G, Carniato S, et al: Prognostic correlations of operable carcinoma of the rectum. Dis Colon Rectum 28 (1) : 47-50, 1985.
PubMed
72) Andreyev HJ, Norman AR, Clarke PA, et al: Kirsten ras mutations in patients with colorectal cancer: the multicenter " RASCAL"study. J Natl Cancer Inst 90 (9) : 675-684, 1998.
PubMed
73) Kressner U, Inganas M, Lindmark G, et al: Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17 (2) : 593-599, 1999.
PubMed
74) Albano WA, Recabaren JA, Kimberling WJ, et al: Natural history of hereditary cancer of the breast and colon. Cancer 50 (2) : 360-363, 1982.
PubMed
75) Thibodeau SN, Bren G and Schaid D et al: Microsatellite instability in cancer of the proximal colon. Science 260 (5109) : 816-819, 1993.
PubMed
76) Lukish JR, Muro K, Hamilton SR, et al: Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 227 (1) : 51-56, 1998.
PubMed
77) Yamaguchi A, Urano T, Furukawa K, et al: Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 14 (4) : 1122-1127, 1996.
PubMed
78) Mohri Y: Prognostic significance of E-cadherin expression in human colorectal cancer tissue. Surg Today 27 (7) : 606-612, 1997.
PubMed
79) Hiraga Y, Tanaka S, Kohno N, et al: Immunoreactive MUC l expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 55 (4) : 307-319, 1998.
 
80) Takahashi Y, Kitadai Y, Ellis LM, et al: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55 (18) : 3964-3968, 1995.
PubMed
81) Osanai T, Ichikawa W, Sugihara K, et al: Expression of pyrimidine nucleoside phosphorylase (PyNPase) in colorectal cancer. Jpn J Clin Oncol 31 (10) : 500-505, 2001.
PubMed
82) Yamachika T, Nakanishi H, Tatematsu M, et al: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82 (1) : 70-77, 1998.
PubMed
83) Shibata D, Reale MA, Summerhayes IC, et al: The DCC protein and prognosis in colorectal cancer. N Engl J Med 335 (23) : 1727-1732, 1996.
PubMed
84) Reymond MA, Dworak O, Kockerling F, et al: DCC protein as a predictor of distant metastases after curative surgery for rectal cancer. Dis Colon Rectum 41 (6) : 755-760, 1998.
PubMed
85) 大腸癌研究会・編: 大腸癌取扱い規約. 第6版, 金原出版, 東京, 1998.
 
86) 勝又伴栄, 小林清典, 三富弘之・他: 大腸癌の治療法選択のための術前診断. 消化器内視鏡 13: 1535-1544, 2001.
 
87) 池上雅博, 江藤哲哉, 牛込新一郎・他: 大腸腫瘍の生検診断. 病理と臨床 17: 1163-1172, 1999.
Medical*Online
88) 武藤徹一郎・他: 大腸sm癌アンケート集計報告. 胃と腸 26: 911-918, 1991.
 
89) 寺本龍生, 渡邊昌彦, 北島政樹・他: 早期癌の外科的治療. 癌の臨床 40: 1435-1441, 1994.
Medical*Online
90) 工藤進英, 曽我 淳, 武藤輝一・他: 大腸sm癌のsm浸潤の分析と治療方針. 胃と腸 19: 1349-1356, 1984.
 
91) 森田隆幸, 今 充: 集学的治療からみた治療指針-早期癌, 進行癌-. 癌の臨床40: 1403-1409, 1994.
 
92) 正木忠彦, 武藤徹一郎: 早期癌の内視鏡的治療と手術. 癌の臨床 40: 1410-1415, 1994.
Medical*Online
93) 伊藤英明, 平田敬治, 永田直幹・他: 大腸癌治療の現況. 治療 83: 3185-3189, 2001.
Medical*Online
94) 加藤知行, 平井 孝: 治療成績からみた大腸早期癌の治療方針; とくにsm癌の治療方針について. 胃と腸19: 1349-1356, 1984.
 
95) 樋口哲郎, 榎本雅之, 杉原健一・ 他: 特集・消化器癌に対する標準的治療・21 進行結腸癌. 消化器外科 24: 1883-1887, 2001.
 
96) Morikawa E, Yasutomi M, Shindou K, et al: Distribution of metastatic lymph nodes in colorectal cancer by the modified clearing method. Dis Colon Rectum 37: 219-223, 1994.
PubMed
97) 泉本源太郎, 八田昌樹, 西山真一・他: クリアリング法による結腸癌リンパ節転移に関する研究. 日本大腸肛門病会誌 36: 523-531, 1983.
 
98) Lujan HJ, Plasencia G, Jacobs M, et al: Long-term survival after laparoscopic colon resection for cancer. Dis Colon Rectum 45: 491-501, 2002.
PubMed
99) Wexner SD, Cohen SM, Ulruch A, et al: Laparoscopic colorectal surgery; Are we being honest with our patients? Dis Colon Rectum 38: 723-727, 1995.
 
100) Ortega AE, Beart RW Jr, Steele GD Jr, et al: Laparoscopic bowel surgery registry; Preliminary results. Dis Colon Rectum 38: 681-686, 1995.
PubMed
101) Lord SA, Larach SW, Ferrera A, et al: Laparoscopic resections for colorectal carcinoma; Athree-year experience. Dis Colon Rectum 39: 148-154, 1996.
 
102) Falk PM, Beart RW Jr, Wexner SD, et al: Laparoscopic colectomy; Acritical appraisal. Dis Colon Rectum 36: 28-34, 1993.
 
103) Japanese Research Society for Cancer Colon and Rectum: Multi-Institutional Registry of Large Bowel Cancer in Japan vol. 23; cases treated in 1994, 2002.
 
104) 森谷宜晧: 大腸癌の治療成績は向上したか. CRC 2: 301-310, 1993.
 
105) Enker WE, Laffer UT and Block GE: Enhanced survival of patients with colon and rectal cancer is based upon wide anatomic resection. Ann Surg 190: 350-360, 1979.
PubMed
106) 加藤知行, 平井 孝: 腫瘍の局在と進行度からみた手術術式の選択. 消化器外科 13: 289-297, 1989.
 
107) 高橋 孝, 梶谷 鐶: 直腸癌における側方向リンパ節流への転移とその郭清の意義について. 日本大腸肛門病会誌 31: 207-219, 1978.
 
108) 加藤岳人, 高橋 孝, 太田博俊・他: 直腸癌側方リンパ節転移の検討. 日消外会誌 19: 963-968, 1989.
 
109) 大見良裕, 大木繁男, 江口英雄・他: 直腸癌のリンパ節転移の特徴; 拡大郭清による摘出リンパ節の検討. 日外会誌 81: 676-687, 1980.
 
110) 白井芳則, 斉藤典男, 布村正夫・他: 直腸癌側方リンパ節転移の態様と治療成績. 日本大腸肛門病会誌 44: 1061-1066, 1991.
 
111) 森 武生, 高橋慶一, 大植雅之・他: 特集・消化器癌に対する標準的治療・21 進行直腸癌. 消化器外科 24: 1897-1902, 2001.
 
112) 須田武保, 畠山勝義, 岡本春彦・他: 直腸癌における壁内進展. 日本大腸肛門病会誌 45: 421-426, 1992.
 
113) 小林宣昭: 直腸癌の病理組織学的研究 (第2報) ; 特に壁内進展について. 日本大腸肛門病会誌 30: 426-436, 1977.
 
114) Hughes TG, Jenevein EP and Poulos E: Intramural spread of colon carcinoma. Am J Surg 146: 697-699, 1983.
PubMed
115) Lazorthes F, Voigt JJ, Roques J, et al: Distal intramural spread of carcinoma of the rectum correlated with lymph nodal involvement. Surg. Gynecol Obstet 170: 45-48, 1990.
PubMed
116) Andreola S, Leo E, Beli F, et al: Distal spread in adenocarcinoma of the lower third of the rectum treated with total resection and coloanal anastomosis. Dis Colon Rectum 40: 25-29, 1997.
 
117) 仁丹利行: 直腸癌における肛門側壁内進展に関する臨床病理学的検討. 金沢医大誌 24: 145-153, 1999.
 
118) Williams NS, Dixon MF and Johnston D: Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum; Astudy of distal intramural spread and of patient's survival. Br J Surg 70: 150-154, 1983.
 
119) Kameda K, Furusawa M, Sugimachi K, et al: Proposed distal margin for resection of rectal cancer. Jpn J Cancer Res 81: 100-104, 1990.
PubMed
120) Hida J, Yasumoto M, Okuno K, et al: Lymph node metastases detected in the mesorectum distal to carcinoma of the rectum by the clearing method: Justification of total mesorectal excision. J Am Coll Surg 184: 584-588, 1997.
 
121) Ono C, Yoshinaga K, Sugihara K, et al: Discontinuous rectal cancer spread in the mesorectum and the optimal distal clearance margin in situ. Dis Colon Rectum 45: 744-749, 2002.
PubMed
122) 鈴木宏志, 山本純二, 石田智美・他: 直腸癌手術からみた排便機能. 臨床外科 51: 969-973, 1996.
 
123) Hallbook O, Nystrom P and Sjodahl R: Physiologic characteristics of straight and colonic J-pouch anastomoses after rectal excision for cancer. Dis Colon Rectum 40: 332-338, 1997.
PubMed
124) Ortiz H, De Miguel M, Armendariz P, et al: Coloanal anastomosis: Are functional results better with a pouch? Dis Colon Rectum 38: 375-377, 1995.
PubMed
125) Ramirez JM, Mortensen NJM, Takeuchi N, et al: Colonic J-pouch rectal reconstruction; Is it really a neorectum? Dis Colon Rectum 39: 1286-1288, 1996.
 
126) 酒井靖夫, 畠山勝義, 須田 保・他: J型結腸嚢肛門吻合術. 臨床外科 51: 1005-1011, 1996.
 
127) Hida J, Yasumoto M, Fujimoto K, et al: Functional outcome after low anterior resection with low anastomosis for rectal cancer using the colonic J-pouch. Dis Colon Rectum 39: 986-991, 1996.
 
128) 橋口陽二郎, 柳生利彦, 望月英隆・他: 直腸癌に対するパウチ手術. 消化器外科 24: 1203-1212, 2001.
 
129) Havenga K, Enker WE, Heald RJ, et al: Improved survival and local control after total mesorectal excision or D 3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol 25: 368-374, 1999.
PubMed
130) Hojo K, Koyama Y and Moriya Y: Lymphatic spread and its prognostic value in patients with rectal cancer. Am J Surg 144: 350-354, 1982.
PubMed
131) 森谷宜晧: 下部進行直腸癌に対する側方郭清の意義と問題点. 消化器癌 3: 357-363, 1993.
 
132) Enker WE, Heilweil ML, Hertz REL, et al: En bloc pelvic lymphadenectomy and sphincter preservation in the surgical management of rectal cancer. Ann Surg 203: 426-433, 1986.
 
133) Harnsberger JR, Vernava VM 3 rd and Longo WE: Radical abdominopelvic lymphadenectomy: Historic perspective and current role in the surgical management of rectal cancer. Dis Colon Rectum 37: 73-87, 1994.
 
134) 杉原健一, 榎本雅之: 直腸癌に対する側方郭清の意義. 外科 62: 930-932, 2000.
 
135) 鈴鹿伊智雄, 塩田邦彦, 清水信義: 直腸癌側方リンパ節転移例の特徴と予後からみた側方郭清の意義. 日外科系連会誌 23: 37-43, 1998.
 
136) Ueno H, Yamauchi C, Hase K, et al: Clinicopathological study of intrapelvic cancer spread to the iliac area in lower rectal adenocarcinoma by serial sectioning. Br J Surg 86: 1532-1537, 1999.
 
137) Sugihara K, Moriya Y, Akasu T, et al: Pelvic autonomic nerve preservation for patients with rectal carcinoma. Oncologic and functional outcome. Cancer 78: 1871-1880, 1996.
PubMed
138) 加藤知行, 平井 孝 : 直腸癌の拡大郭清はどこまで有効か-適応と転移陽性例の成績-. 外科 61: 957-961, 1999
 
139) 大木繁男, 池 秀之, 嶋田 紘・他: 自律神経温存術の適応と成績. 外科 61: 962-968, 1999.
 
140) 池 秀之, 山口茂樹, 嶋田 紘・他: 直腸癌に対する神経温存術. 消化器外科 24: 1213-1221, 2001.
 
141) 加藤知行, 平井 孝: 直腸癌・長期予後とQOLからみた神経温存手術の適応. 日臨外医会誌 56: 1079-1087, 1995.
 
142) 小山靖夫, 固武健二郎: TPEはどこまで有効か(1) 初回手術. 外科 61: 943-950, 1999.
 
143) Brunschwig A: Complete excision of pelvis viscera for advanced carcinoma: aone-stage abdominoperineal operation with colostomy and bilateral ureteral implantation into colon above the colostomy. Cancer 1: 177-183, 1948.
 
144) Lopez MJ, Standiford SB and Skibba JL: Total pelvic exenteration: A50-year experience at the Ellis Fischel Cancer Center. Arch Surg 129: 390-396, 1994.
 
145) 加藤知行, 平井 孝: 局所進行直腸癌に対する骨盤内臓器全摘術. 医学のあゆみ 172: 693-696, 1995.
 
146) Brophy PF, Hoffman JP and Eisenberg BL: The role of palliative pelvic exenteration. Am J Surg 167: 386-390, 1994.
PubMed
147) 第41回大腸癌研究会 (浜野恭一) : 骨盤内臓全摘術 (TPE) アンケート調査報告. 平成7年1月協和印刷株式会社 (東京) .
 
148) Williams LF Jr, Huddleston CB, McDougal SW, et al: Is total pelvic exenteration reasonable primary treatment for rectal carcinoma? Ann Surg 207: 670-678, 1988.
PubMed
149) Lopez MJ and Monafo WW: Role of extended resection in the initial treatment of locally advanced colorectal carcinoma. Surgery ll3: 365-372, 1993.
 
150) Hafner GH, Herrera L and Petrelli NJ: Patterns of recurrence after pelvic exenteration for colorectal adenocarcinoma. Ann Surg 126: 1510-1513, 1991.
 
151) Wanebo HJ, Koness RJ, Vezeridis MP, et al: Pelvic resection of recurrent rectal cancer. Ann Surg 220: 586-597, 1994.
PubMed
152) 固武健二郎, 小山靖夫, 本荘 哲: 大腸癌全国登録報告-1974-93年登録例の概要-. 厚労省がん研究助成金報告書.
 
153) Japanese Research Society for Cancer Colon and Rectum: Multi-Institutional Registry of Large Bowel Cancer in Japan vol. 23; cases treated in 1994, 2002,
 
154) Mettlin CJ, Menck HR, Winchester DP, et al: Acomparison of breast, colorectal, 1ung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results program. Cancer 79: 2052-2061, 1997.
 
155) Stearns MW, Deddish MR, Quan SH, et al: Preoperative roentgen therapy for cancer of the rectum Surg Gynecol Obstet 109: 225-229, 1959.
PubMed
156) Stearns MW, Deddish MR, Quan SH, et al: Preoperative roentgen therapy for cancer of the rectum and rectosigmoid. Surg Gynecol Obstet 138: 584-586, 1974.
PubMed
157) Steavens KS, Allen CV and Flecher WS: Pre-operative radiotherapy for adenocarcinoma of the rectosigmoid. Cancer 37: 2866-2874, 1976.
 
158) Minsky BD: Approaches to adjuvant therapy for rectal cancer. 37th annual meeting of American Society of Clinical Oncology Educational Book. 2001, pp 187-194.
 
159) Minsky BD, Cohen AM, Kemeny N, et al: Combined modality therapy of rectal cancer: Decreased acute toxicity with the pre-operative apProach. J Clin Oncol 10: 1218-1224, 1992.
 
160) Camma C, Giunta M, Fiorica F, et al: Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. JAMA 284: 1008-1015, 2000.
PubMed
161) Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in respectable rectal cancer. N Eng J Med 336: 980-987, 1997.
 
162) National Institutes of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444-1450, 1990.
 
163) Wolmark N, Wieand HS, Hyams DM, et al: Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 92: 388-396, 2000.
 
164) Anne P, Mitchel EP, Ahmad N, et al: Radiosensitization in locally advanced adenocarcinoma of the rectum using combined modality therapy (CMT) with CPT-11, 5-fluorouracil, concomitant irradiation. Proc ASCO 19: 250 a, 2000.
 
165) Kemeny MM, Goldberg DA, Browning S, et al: Experience with continuous regional chemotherapy and hepatic resectionas treatment of hepatic metastases from colorectal primaries. A prospective randomized study. Cancer 55: 1265-1270, 1985.
PubMed
166) Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107: 459-465, 1987.
PubMed
167) Chang AE, Schneider PD, Sugarbaker PH, et al: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206: 685-693, 1987.
PubMed
168) Hohn DC, Stagg RJ, Friedman MA, et al: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group Trial. J Clin Oncol 7: 1646-1654, 1989.
 
169) Martin JK, O'Connell MJ, Wieand HS, et al: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 125: 1022-1027, 1990.
 
170) Rougier P, Laplanche A, Huguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol10: 1112-1118, 1992.
 
171) Allen-Mersh TG, Earlam S, Fordy C, et al: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255-1260, 1994.
PubMed
172) Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88: 252-258, 1996.
PubMed
173) 荒井保明, 松枝 清, 稲葉吉隆・他: 動注療法の位置付けと展望. 肝転移に対する動注化学療法の位置付けと展望. 癌と化学療法29 (2) : 182-188, 2002.
 
174) Jonker DJ, Maroum JA, Kocha W, et al: Survival benefit of chemotherapy in metastatic colorectal cancer: ameta-analysis of randomized controlled trials. Br J Cancer 82: 1789-1794, 2000.
 
175) Colorectal cancer collaborative group: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 321: 531-535, 2000.
 
176) 下山正徳, 木村禧代二: 各種抗がん剤のin vitroにおける殺細胞効果について-L1210細胞を中心に. 最新医学 28: 1024-1040, 1973.
 
177) Lokich JJ, Ahlgren JD, Gullo JJ, et al: Aprospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: AMid-Atlantic Oncology Program Study. J Clin Oncol 7: 425-432, 1989.
 
178) Meta-analysis Group in Cancer: Efficacy of intra-venous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308, 1998.
 
179) Bertino JR, Sawicki WL, Lindquist CA, et al: Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 37: 327-328, 1977.
PubMed
180) Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967-1972, 1991.
 
181) Wadler S, Schwartz EL, Goldman M, et al: Fluorouracil and recombinant alpha-2 a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769-1775, 1989.
PubMed
182) Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
 
183) Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: evidence significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407-1418, 1989.
 
184) Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469-475, 1988.
 
185) DeMario M and Ratain M: Oral chemotherapy: Rationale and future directions. J Clin Oncol 16: 2557-2567, 1998.
PubMed
186) Meropol NJ: Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer 34: 1509-1513, 1998.
PubMed
187) Liu G, Franssen E, Fitch M, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115, 1997.
PubMed
188) Takiuchi H and Ajani JA: Uracil-Tegafur in gastric carcinoma. A comprehensive review. J Clin Oncol 16: 2877-2885, 1998.
PubMed
189) Pazdur R, Lassere Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12: 2296-2300, 1994.
PubMed
190) Douillard JY, Hoff PM, Schillings JR, et al: Multicenter phase III study of Uracil/Tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal carcinoma. J Clin Oncol 20: 3605-3616, 2002.
 
191) Carmichael J, Pooiela T, Radstone D, et al: Randomized comparative study of Tegafur/Uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617-3627, 2002.
 
192) Van Cutsem E, Sorensen J, Cassidy J, et al: International phase III study of oral eniluracil (EU) plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC) . Proc ASCO 20: 131 a (abstr 522) , 2001.
 
193) Schilsky RL, Levin J, West WH, et al: Randomized, open-lavel, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 20: 1519-15262002.
 
194) Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282-2292, 2001.
 
195) Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106, 2001.
 
196) Mayer RJ: Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. J Clin Oncol 19: 4093-4096, 2001.
 
197) Ohtsu A, Baba H, Sakata Y, et al: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83: 141-145, 2000.
 
198) Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11: 909-913, 1993.
 
199) Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol l4: 1128-1135, 1996.
PubMed
200) Cunningham D, Pyrhonen S, James RD, et al: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998.
PubMed
201) Rougier P, Van Cutsem E, Bajetta E, et al: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998.
PubMed
202) Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
 
203) Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: amulticentre randomized trial. Lancet 355: 1041-1047, 2000.
PubMed
204) Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801-3807, 2001.
 
205) Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95-98, 1996.
PubMed
206) De Gramont A, Figer M, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
PubMed
207) Saltz L, Rubin H, Hochster NS, et al: Cetuximab (IMC-C-225) plus irinotecan (CPT-11) is active in CPT-II-refractory colorectal cancer (CRC) that expresses epidemial growth factor receptor (EGFR) . Proc ASCO 20: 3a (abstr 7) , 2001.
 
P.702 掲載の参考文献
1) 日本肝癌研究会・編: 第15回全国原発性肝癌追跡調査報告.
 
2) 清澤研道: 日本の肝がんの特徴-世界の肝がんにおける位置づけ. 肝がん白書 平成11年度版, 日本肝臓学会, 東京, 1998, pp 5-9.
 
3) The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1992-93: Estimates based on data from seven population-based cancer registries. Jpn J Clin Oncol28: 641-647, 1998.
 
4) Kiyosawa K: Epidermiology of hepatitis C virus-associated hepatocellular carcinoma. In: Progress in Hepatology. He-patocellular Carcinoma, (ed by Yamanaka M) , vol 3, Elsevier, Tokyo, 1997, pp. HO.
 
5) Kiyosawa K, Tanaka E and Sodeyama T: Hepatitis C virus and hepatocellular carcinoma. In Hepatitis C Virus, (ed by Reesink HW) , Karger, Basel, 1998, pp 161-180.
 
6) 吉澤浩司: 肝炎ウイルスキャリアの動向. 肝がん白書 平成11年度版, 日本肝臓学会, 東京, 1998, pp 23-32.
 
7) 清澤研道: 前がん病変としての肝硬変の動向. 肝がん白書 平成11年度版, 日本肝臓学会, 東京, 1998, pp 33-37.
 
8) 神代正道: ヒトウイルス肝癌の形態学. 肝臓病学, (戸田剛太郎・編) , 医学書院, 東京, 1998, pp 758-766.
 
9) Kanai T, Hirohashi S, Upton Mp, et al: Pathology of small hepatocellular carcinoma: aproposal for a new gross classification. Cancer 67: 810-819, 1987.
 
10) Takayama T, Makuuchi M, Hirohashi S, et al: Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 336: 1150-1153, 1990.
PubMed
11) Sakamoto M, Hirohashi S and Shimosato Y: Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Human Pathol 22: 172-178, 1991.
PubMed
12) Takayama T, Makuuchi M, Hirohashi S, et al: Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 28: 1241-1246, 1998.
PubMed
13) 日本肝癌研究会・編: 原発性肝癌取扱い規約. 第4版, 金原出版, 東京, 2000.
 
14) Mita Y, Aoyagi Y, Yanagi M, et al: The usefulness of determining des-γ-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 82: 1643-1648, 1998.
 
15) Aoyagi Y, Suzuki Y, Isemura M, et al: The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. . Cancer 61: 769-774, 1988.
PubMed
16) Taketa K, Sekiya C, Namiki M, et al: Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular car cinoma and related conditions. Gastroenterology 99: 508-518, 1990.
 
17) Matsumura M, Niwa Y, Kato N, et al: Detection of α-fetoprotein m RNA, an indicator of hematogeneous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma. Hepatology 20: 1418-1425, 1994.
 
18) Ijichi M, Takayama T, Matsumura M, et al: α-fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: aprospective study. Hepatology 35: 853-860, 2002.
 
19) 幕内雅敏, 長谷川博, 山崎 晋・他: 肝腫瘍の超音波診断-特に質的診断の限界について-. 癌と化学療法 11 (5) : 1122-1133, 1984.
 
20) Ernst H, Hahn EG, Balzer T, et al: Color Doppler ultrasound of liver lesions: signal enhancement after intravenous injection of the ultrasound contrast agent Levovist(8) . J Clin Ultrasound 24: 31-35, 1996.
 
21) Wilson SR, Burns PN, Muradali D, et al: Harmonic hepatic US with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis. Radiology 215: 153-161, 2000.
PubMed
22) Nakayama A, Imamura H, Matsuyama Y, et al: Value of lipiodol computed tomography and digital subtraction angiography in the era of helical biphasic computed tomography as preoperative assessment of hepatocellular carcinoma. Ann Surg 234: 56-62, 2001.
PubMed
23) Choi D, Kim SH, Lim JH, et al: Preoperative detection of hepatocellular carcinoma: Ferumoxides-enhanced MR imaging versus combined helical CT during arterial portography and CT hepatic arteriography. AJR 176: 475-482, 2001.
 
24) Hayashi M, Matsui O, Ueda K, et al: Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR 172: 969-976, 1999.
PubMed
25) Takamori R, Wong LL, Dang C, et al: Needle-tract implantation from hepatocellular carcinoma: is needle biopsy of the liver always necessary? Liver Transplant 6: 67-72, 2000.
 
26) Torzilli G, Minagawa M, Takayama T, et al: Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 30: 889-893, 1999.
PubMed
27) Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 56: 918-928, 1985.
PubMed
28) The Cancer of the Liver Italian Program Investigators. A new prognostic system for hepatocellular carcinoma: aprospective study of 435 patients. Hepatology 28: 751-755, 1998.
 
29) Arii S, Yamaoka Y, Futagawa S, et al: Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: aretrospective and nationwide survey in Japan. Hepatology 32: 1224-1229, 2000.
 
30) Fan ST, Lo CM, Liu CL, et al: Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 229: 322-330, 1999.
PubMed
31) Torzilli G, Makuuchi M, Inoue K, et al: No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients. Is that a way? Aprospective analysis of our approach. Arch Surg 134: 984-992, 1999.
 
32) Azoulay D, Castaing D, Krissat J, et al: Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg 232: 665-672, 2000.
PubMed
33) Minagawa M, Makuuchi M, Takayama T, et al: Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 233: 379-384, 2001.
PubMed
34) Pugh RNH, Murray-Lyon IM, Dawson JL, et al: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646-649, 1973.
 
35) 幕内雅敏, 高山忠利, 山崎 晋・他: 肝硬変合併肝癌治療のStrategy. 外科診療 29: 1530-1536, 1987.
 
36) Makuuchi M, Kosuge T, Takayama T, et al: Surgery for small liver cancers. Semin Surg Oncol 9: 298-304, 1993.
PubMed
37) Makuuchi M, Hasegawa H and Yamazaki S: Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet 161: 346-350, 1986.
 
38) Regimbeau JM, Kianmanesh R, Farges O, et al: Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocallular carcinoma. Surgery 131: 311-317, 2002.
 
39) Imamura H, Matsuyama Y, Miyagawa Y, et al: Prognostic significance of anatomical resection and des-γ-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 86: 1032-1038, 1999.
 
40) Poon RT, Fan ST and Wong J: Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 194: 592-602, 2002.
 
41) Llovet JM, Bru C and Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338, 1999.
 
42) Sugimachi K, Maehara S, Tanaka S, et al: Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 8: 410-416, 2001.
PubMed
43) Grazi GL, Ercolani G, Pierangeli F, et al: Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 234: 71-78, 2001.
PubMed
44) Poon RT, Fan ST, Lo CM, et al: Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235: 373-382, 2002.
PubMed
45) Kumada T, Nakano S, Takeda I, et al: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25: 87-92, 1997.
PubMed
46) Sakamoto M, Hirohashi S, Tsuda H, et al: Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol 13: 1064-1067, 1989.
PubMed
47) Kawai S, Imazeki F, Yokosuka O, et al: Clonality in hepatocellular carcinoma: analysis of methylation pattern of polymorphic X-chromosome-linked phosphoglycerate kinase gene in females. Hepatology 22: 112-117, 1995.
PubMed
48) Chen YJ, Yeh SH, Chen JT, et al: Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 119: 431-440, 2000.
PubMed
49) Kakazu T, Makuuchi M, Kawasaki S, et al: Repeat hepatic resection for recurrent hepatocellular carcinoma. Hepatol Gastroenterology 40: 337-341, 1993.
 
50) Nakajima Y, Ko S, Kananuma T, et al: Repeat liver resection for hepatocellular carcinoma. J Am Coll Surg l92: 339-344, 2001.
 
51) Mazzaferro V, Regalia E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699, 1996.
PubMed
52) Yao FY, Ferrell L, Bass NM, et al: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33: 1394-1403, 2001.
 
53) Llovet JM, Fuster J, Bruix J, et al: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30: 1434-1440, 1999.
PubMed
54) Marcos A, FisherRA, Ham JM, et al: Right lobe living donor liver transplantation. Transplantation 68: 798-803, 1999.
PubMed
55) Fan ST, Lo CM, Liu CL, et al: Safety of donors in live donor liver transplantation using right lobe grafts. Arch Surg 135: 336-340, 2000.
PubMed
56) 日本肝癌研究会・編: 第12回全国原発性肝癌追跡調査報告.
 
57) Livraghi T, Goldberg SN, Lazzaroni S, et al: Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 214: 761-768, 2000.
PubMed
58) Livraghi T, Giorgio A, Marin G, et al: Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197101-108, 1995.
 
59) Livraghi T, Goldberg SN, Lazzaroni S, et al: Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210: 655-661, 1999.
PubMed
60) Shiina S, Tagawa K, Niwa Y, et al: Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR 160: 1023-1028, 1993.
PubMed
61) Giorgio A, Tarantino L, de Stefano G, et al: Ultrasound-guided percutaneous ethanol injection under general anesthesia for the treatment of hepatocellular carcinoma on cirrhosis long-term results in 268 patients. Eur J Ultrasound 12: 145-154, 2000.
PubMed
62) Meloni F, Lazzaroni S and Livraghi T: Percutaneous ethanol injection: single session treatment. Eur J UItrasound 13: 107-115, 2001.
 
63) Ishii H, Okada S and Nose H: Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 77: 1792-1796, 1996.
PubMed
64) Vilana R, Bruix J, Bru C, et al: Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 16: 353-357, 1992.
PubMed
65) Di Stasi M, Buscarini L, Livraghi T, et al: Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol 32: 1168-1173, 1997.
PubMed
66) Llovet JM, Vilan R, Br6 C, et al: Increase risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hapatology 33: 1124-1129, 2001.
 
67) Uchida H, Ohnishi H, Matsuo N, et al: Transcatheter hepatic segmental arterial embolization using Lipiodol mixed with an anticancer drug and Gelform particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 13: 140-145, 1990.
 
68) Takayasu K, Shima Y, Muramatsu Y, et al: Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 163: 345-351, 1987.
PubMed
69) Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire: Acomparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332: 1256-1261, 1995.
 
70) Bruix J, Llovet JM, Castells A, et al: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized controlled trial in a single institution. Hepatology 27: 1578-1583, 1998.
 
71) Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002.
PubMed
72) Llovet JM, Real MI, Montafia X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: arandomised controlled trial. Lancet 359: 1734-1739, 2002.
PubMed
73) Tanaka K, Nakamura S, Numata K, et al: Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization. Radiology 185: 457-460, 1992.
PubMed
74) Manjo PE, Adam R, Bismuth H, et al: Influence of preoperative transarterial Lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226: 688-703, 1997.
 
75) Roayaie S, Frischer JS, Emre SH, et al: Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235: 533-539, 2002.
PubMed
76) Oldhafer KJ, Chavan A, FrUhauf NR, et al: Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? JHepatol 29: 953-959, 1998.
PubMed
77) Uchida M, Kohno H, Kubota H, et al: Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 20: 326-331, 1996.
PubMed
78) Yamasaki S, Hasegawa H, Kinoshita H, et al: Aprospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 87: 206-211, 1996.
 
79) Lau WY, Leung TWT, Lai BS, et al: Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 233: 236-241, 2001.
 
80) Yamamoto M, Arii S, Sugahara K, et al: Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 83: 336-340, 1996.
PubMed
81) Huang YH, Wu JC, Lui WY, et al: Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. World J Surg 24: 551-555, 2000.
PubMed
82) Lai ECS, Lo CM, Fan ST, et al: Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma. Arch Surg 133: 183-188, 1998.
 
83) Ono T, Yamanoi A, Nazmy EI, et al: Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 91: 2378-2385, 2001.
 
84) Martinez Cerezo FJ, Tomas A, Donoso L, et al: Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 20: 702-706, 1994.
PubMed
85) CLIP Group (Cancer of the Liver Italian Programme) . Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled trial. Lancet 352: 17-20, 1998.
PubMed
86) Takayama T, Sekine T, Makuuchi M, et al: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 356: 802-807, 2000.
PubMed
87) Lau WY, Leung TWT, Ho SKW, et al: Adjuvant intra-arterial lipiodol-iodine-131 for respectable hepatocellular carcinoma: aprospective randomized trial. Lancet 353: 797-801, 1999.
 
88) Tarao K, Rino Y, Ohkawa S, et al: Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated with cirrhosis. Cancer 86: 589-595, 1999.
PubMed
89) Muto Y, Moriwaki H, Ninomiya M, et al: Prevention of second primary tumors by an acycric retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334: 156H567, 1996.
PubMed
90) Nishiguchi S, Kuroki T, Nakatani S, et al: Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis with cirrhosis. Lancet 346: 1051-1055, 1995.
 
91) Llovet J, Sala M, Castells L, et al: Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31: 54-58, 2000.
PubMed
92) Kubo S, Nishiguchi S, Hirohashi K, et al: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89: 418-422, 2002.
PubMed
93) Ikeda K, Arase Y, Saitoh S, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32: 228-232, 2000.
PubMed
94) Adachi E, Maeda T, Matsumata T, et al: Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 108: 768-775, 1995.
PubMed
95) Hasegawa S, Yamasaki N, Hiwaki T, et al: Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection. Cancer 86: 1682-1690, 1999.
PubMed
96) Fan ST, Ng IO, Poon RT, et al: Hepatectomy for hepatocellular carcinoma: the surgeon's role in long-term survival. Arch Surg 134: 1124-1130, 1999.
PubMed
97) Nagasue N, Ono T, Yamamori A, et al: Prognostic factors and survival after hepatic resection of hepatocellular carcinoma without cirrhosis. Br J Surg 88: 515-522, 2001.
 
98) Bilimoria MM, Lauwers GY, Doherty DA, et al: Underlying Iiver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 136: 528-535, 2001.
 
99) Koike Y, Shiratori Y, Sato S, et al: Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 32: 1216-1223, 2000.
PubMed
100) Okada S, Shimada K, Yamamoto J, et al: Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 106: 1618-1624, 1994.
PubMed
101) Ikeda Y, Shimada M, Hasegawa H, et al: Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 27: 1567-1571, 1998.
PubMed
102) Shirabe K, Kanematsu T, Matsumata T, et al: Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 14: 802-805, 1991.
PubMed
103) Yamamoto J, Kosuge T, Takayama T, et al: Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83: 1219-1222, 1996.
PubMed
104) Izumi R, Shmizu K, li T, et al: Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 106: 720-727, 1994.
 
105) Poon RT, Fan ST, Ng IO, et al: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89: 500-507, 2000.
PubMed
106) Lee CS, Sheu JC, Wang M, et al: Long-term outcome after surgery for asymptomatic small hepatocellular carcinoma. Br J Surg 83: 330-333, 1996.
PubMed
107) Hui AM, Takayama T, Sano K, et al: Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol 33: 975-979, 2000.
PubMed
108) Koike Y, Shiratori Y, Sato S, et al: Des-γ-Carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: aprospective analysis of 227 patients. Cancer 91: 561-569, 2001.
 
109) Chau GY, Lui WY, Tsay SH, et al: Prognostic significance of surgical margin in hepatocellular carcinoma resection: an analysis of 165 Child's A patients. J Surg Oncol 66: 122-126, 1997.
 
110) Yoshida Y, Kanematsu T, Matsumata T, et al: Surgical margin and recurrence after resection of hepatocellular carcinoma in patients with cirrhosis: further evaluation of limited hepatic resection. Ann Surg 209: 297-301, 1989.
PubMed
111) Poon RT, Fan ST, Ng IO, et al: Significance of resection margin in hepatectomy for hepatocellular carcinoma: acritical reappraisal. Ann Surg 231: 544-551, 2000.
 
112) Madariaga JR, Iwatsuki S, Todo S, et al: Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg 227: 70-79, 1998.
PubMed
113) Inoue K, Makuuchi M, Takayama T, et al: Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 127: 498-505, 2000.
PubMed
114) Uenishi T, Hirohashi K, Kubo S, et al: Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg 88: 969-974, 2001.
PubMed
115) Weber SM, Jarnagin WR, Klimstra D, et al: Intrahepatic cholangiocarcinoma: respectability, recurrence pattern, and outcomes. J Am Co11 Surg 193: 384-391, 2001.
 
116) Shimada M, Yamashita Y, Aishima S, et al: Value of lymph node dissection during resection of intrahepatic cholangiocar-cinoma. Br J Surg 88: 1463-1466, 2001.
 
117) Roayaie S, Guarrera JV, Ye MQ, et al: Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg 187: 365-372, 1998.
PubMed
118) Yamamoto M, Takasaki K, Otsubo T, et al: Recurrence after surgical resection for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 8: 154-157, 2001.
PubMed
119) Weimann A, Varnholt H, Schlitt HJ, et al: Retrospective analysis of prognostic factors after liver resection and transplan-tation for cholangiocellular carcinoma. Br J Surg 87: 1182-1187, 2000.
 
120) Meyer CG, Penn I, James L, et al: Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 69: 1633-1637, 2000.
PubMed
P.712 掲載の参考文献
1) Williamson RCN: Pancreatic cancer: the greatest oncological challenge. Br Med J 296: 445-446, 1988.
 
2) Gordis L and Gold EB: Epidemiology of pancreatic cancer. World J Surg 8: 808-821, 1984.
PubMed
3) 厚生労働省大臣官房統計情報部: 平成11年人口動態統計, 東京, 2001, pp 284-289.
 
4) Japanese Cancer Association: Cancer mortality and morbidity statistics. Japan and the world-1999. Japan Scientific Societies Press, Tokyo, 1999, pp 174-175.
 
5) Fuchs CS, Colditz GA, Stampfer MJ, et al: Aprospective study of cigarette and the risk of pancreatic cancer. Arch Intern Med 156: 2255-2260, 1996.
 
6) Duell EJ, Holly EA, Bracci PM, et al: A population-based, case-control study of polymorphisms in carcinogen-metaboliz-ing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst 94: 297-306, 2002.
 
7) Gullo L: Diabetes and the risk of pancreatic cancer. Ann Oncol 10 (Suppl 4) : 79-81, 1999.
 
8) Calle EE, Murphy TK, Rodriguez C, et al: Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 9: 403-410, 1998.
 
9) Everhart J and Wright D: Diabetes mellitus as a risk factor for pancreatic cancer. JAMA 273: 1605-1609, 1995.
PubMed
10) Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 328: 1433-1437, 1993.
 
11) Bansal P and Sonnenberg A: Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 109: 247-251, 1995.
PubMed
12) Karlson BM, Ekbom A, Josefsson S, et al: The risk of pancreatic cancer following pancreatitis: an association due to confounding? Gastroenterology 113 (2) : 587-592, 1997.
PubMed
13) Silverman DT, Brown LM, Hoover RN, et al: Alcohol and pancreatic cancer in blacks and whites in the United States. Cancer Res 55: 4899-4905, 1995.
PubMed
14) Ji BT, Chow WH, Hsing AW, et al: Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 70: 255-258, 1997.
PubMed
15) 松野正紀: 膵癌全国登録調査報告. 膵臓 16: 115-147, 2001.
Medical*Online
16) 日本膵臓学会・編: 膵癌取扱い規約. 第4版, 金原出版, 東京, 1993.
 
17) Reinhold C and Bret PM: MR cholangiopancreatography. Abdom Imaging 21: 105-116, 1996.
PubMed
18) Soto JA, Barish MA, Yucel EK, et al: Magnetic resonance cholangiography: Comparison with endoscopic retrograde cholangiopancreatography. Gastroenterology 110: 589-597, 1996.
PubMed
19) Adamek HE, Albert J, Breer H, et al: Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: aprospective controlled study. Lancet 356: 190-193, 2000.
 
20) Tada M, Omata M and Ohto M: Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 100: 233-238, 1991.
PubMed
21) Tada M, Omata M, Kawai S, et al: Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 53: 2472-2474, 1993.
PubMed
22) Kondo H, Sugano K, Fukayama N, et al: Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 73: 1589-1594, 1994.
 
23) Suzuki H, Yoshida S, Ichikawa Y, et al: Ki-ras mutations in pancreatic secretions and aspirates from two patients without pancreatic cancer. J Natl Cancer Inst 86: 1547-1548, 1994.
PubMed
24) Iguchi H, Sugano K, Fukayama N, et al: Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer. Gastroenterology 110: 221-226, 1996.
PubMed
25) Tada M, Ohashi M, Shiratori Y, et al: Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 110: 227-231, 1996.
PubMed
26) Castells A, Puig P, Mora J, et al: K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 17: 578-584, 1999.
PubMed
27) Hiyama E, Kodama T, Shinbara K, et al: Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 57: 1326-1333, 1997.
PubMed
28) Uehara H, Nakaizumi A, Tatsuta M, et al: Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutations. Am J Gastroenterol 94: 2513-2518, 1999.
 
29) Permert J, Larsson J, Westermark GT, et al: Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 330: 313-318, 1994.
PubMed
30) Chari ST, Klee GG, Miller LJ, et al: Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 121: 640-645, 2001.
 
31) Okada S, Yoshimori M and Kakizoe T: Pancreatic cancer: Medical aspects. Pancreas 16: 349-354, 1998.
PubMed
32) 日本癌治療学会固形がん化学療法効果判定基準. 日癌治療会誌 21: 929-942, 1986.
 
33) 膵癌の治療効果判定基準 (案) . 膵臓 7: 107-121, 1992.
 
34) Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumor. J Natl Cancer Inst 92: 205-216, 2000.
PubMed
35) Aoki K, Okada S, Moriyama N, et al: Accuracy of computed tomography in determining pancreatic cancer tumor size. Jpn J Clin Oncol 24: 85-87, 1994.
PubMed
36) Ishii H, Okada S, Okusaka T, et al: CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 44: 279-283, 1997.
 
37) Okusaka T, Okada S, Ishii H, et al: Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. Jpn J Clin Oncol 26: 215-220, 1996.
PubMed
38) Fisher BJ, Perera FE, Kocha W, et al: Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer, Int J Radiat Oncol Biol Phys 45: 291-295, 1999.
PubMed
39) Shibamoto Y, Manabe T, Ohshio G, et al: High-dose intraoperative radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 34: 57-63, 1996.
PubMed
40) Roldan GE, Gunderson LL, Nagorney DM, et al: External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 61: 1110-1116, 1988.
PubMed
41) TepPer JE, Noyes D, Krall JM, et al: Intraoperative radiation therapy of pancreatic carcinoma: Areport of RTOG-8505. Int J Radiat Oncol Biol Phys 21: 1145-1149, 1991.
 
42) Dobelbower RR, Konski AA, Merrick HW, et al: Intraoperative electron beam radiation therapy (10EBRT) for carcinoma of the exocrine pancreas. Int J Radiat Oncol Biol Phys 20: 113-119, 1991.
PubMed
43) Seydel HG, Stablein DM, Leichman LP, et al: Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group Experience. Cancer 65: 1478-1482, 1990.
 
44) Gastrointestinal Tumor Study Group: Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56: 2563-2568, 1985.
PubMed
45) Earle JD, Foley JF, Wieand HS, et al: Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 28: 207-211, 1994.
PubMed
46) Moertel CG, Gunderson LL, Mailliard JA, et al: Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. J Clin Oncol 12: 21-27, 1994.
PubMed
47) Ceha HM, van Tienhoven G, Gouma DJ, et al: Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 89: 2222-2229, 2000.
PubMed
48) Moertel CG, Childs DS, Reitemeier RJ, et al: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2: 865-867, 1969.
PubMed
49) Moertel CG, Frytak S, Hahn RG, et al: Therapy of locally unresectable pancreatic carcinoma. A randomized comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 Rads+5-fluorouracil) , and high dose radiation+5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer 48: 1705-1710, 1981.
 
50) Klaassen DJ, Maclntyre JM, Catton GE, et al: Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil. An Eastern Cooperative Oncology Group Study. J Clin Oncol 3: 373-378, 1985.
 
51) Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80: 751-755, 1988.
 
52) Ishii H, Okada S, Tokuuye K, et al: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79: 1516-1520, 1997.
PubMed
53) Okusaka T, Okada S, Tokuuye K, et al: Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. Cancer 91: 1384-1389, 2001.
PubMed
54) Safran H, Moore T, Iannitti D, et al: Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 49: 1275-1279, 2001.
PubMed
55) McGinn CJ, Zalupski MM, Shureiqi I, et al: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19: 4202-4208, 2001.
 
56) Ikeda M, Okada S, Tokuuye K, et al: A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 86: 1551-1554, 2002.
PubMed
57) Robert A, Wolff, Douglas B, et al: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7: 2246-2253, 2001.
 
58) Blackstock AW, Bernard SA, Richards F, et al: Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17: 2208-2212, 1999.
PubMed
59) Pipas JM, Mitchell SE, Barth RJ Jr, et al: Phase I study of twice-weekly gemcitabine and concomitant external-beamradiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 50: 1317-1322, 2001.
PubMed
60) Talamonti MS, Catalano pJ, Vaughn DJ, et al: Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: aregimen with unexpecte early toxicity. J Clin Oncol 18: 3384-3389, 2000.
PubMed
61) Kornek GV, Potter R, Selzer E, et al: Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int J Radiat Oncol Biol Phys 49: 665-671, 2001.
PubMed
62) Ishikawa O, Ohigashi H, Sasaki Y, et al: Liver Perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg 168: 361-364, 1994.
PubMed
63) Cantore M, Pederzoli P, Cornalba G, et al: Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann Oncol 11: 569-573, 2000.
PubMed
64) Louvet C, Beerblock K, Gramont A, et al: High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: apilot study. Eur J Cancer 29 A: 1217, 1993.
 
65) Pazdur R, Ajani JA, Abbruzzese JL, et al: Phase II evaluation of fluorouracil and recombinant α-2 a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 70: 2073-2076, 1992.
 
66) Ikeda M, Okada S, Ueno H, et al: A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer. Hepatogastroenterology 47: 862-865, 2000.
PubMed
67) Mani S, Kugler JW, Sciortino DF, et al: Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: aUniversity of Chicago phase II consortium study. Ann Oncol 9: 1035-1037, 1998.
 
68) Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2, 2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drug 12: 29-34, 1994.
PubMed
69) Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347-353, 1996.
PubMed
70) Burris HA 3 rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
 
71) Ulrich-Pur H, Kornek GV, Raderer M, et al: A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer 88: 2505-2511, 2000.
PubMed
72) Okada S, Ueno H, Okusaka T, et al: Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 31: 7-12, 2001.
PubMed
73) Crino L, Mosconi AM, Calandri C, et al: Gemcitabine in advanced pancreatic cancer: aphase II trial. Am J Clin Oncol 24: 296-298, 2001.
 
74) Wils JA, Kok T, Wagener DJTh, et al: Phase II trial with ifosfamide in pancreatic cancer. Eur J Cancer 29 A: 290, 1993.
 
75) Aoki K, Shimada Y, Okazaki N, et al: A phase II study of epirubicin in patients with advanced adenocarcinoma of the pancreas. Eur J Cancer 28: 1590, 1992.
 
76) Gebbia N and Gebbia V: Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma. Eur J Cancer 32 A: 1822-1823, 1996.
PubMed
77) Rougier P: Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Anticancer Drug 6 (Suppl 4) : 25-29, 1995.
 
78) Androulakis N, Kourousis C, Dimopoulos MA, et al: Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: amulticenter phase II study. J Clin Oncol 17: 1779-1785, 1999.
 
79) Okada S, Sakata Y, Matsuno S, et al: Phase II study of docetaxel in patients with metastatic pancreatic cancer: aJapanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer 80: 438-443, 1999.
PubMed
80) CPT-11 Study Group on Gastrointestinal Cancer: Alate phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. Jpn J Cancer Chemother 21: 1039-1046, 1994.
 
81) Wagener DJ, Verdonk HE, Dirix LY, et al: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 6: 129-132, 1995.
 
82) O'Reilly S, Donehower RC, Rowinsky EK, et al: A phase II trial of topotecan in patients with previously untreated pancreatic cancer. Anticancer Drugs 7: 410-444, 1996.
 
83) Scher RM, Kosierowski R, Lusch C, et al: Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drug 13: 347-354, 1996.
PubMed
84) Stevenson JP, Scher RM, Kosierowski R, et al: Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 34: 1358-1362, 1998.
PubMed
85) Oster MW, Gray R, Panasci L, et al: Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM) . Cancer 57: 29-33, 1986.
PubMed
86) The Gastrointestinal Tumor Study Group: Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. J Clin Oncol 4: 1794-1798, 1986.
 
87) Takada T, Kato H, Matsushiro T, et al: Comparison of 5-fluorouraci1, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 51: 396-400, 1994.
PubMed
88) Kelsen D, Hudis C, Niedzwiecki D, et al: A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68: 965-969, 1991.
PubMed
89) Moertel CG, Rubin J, O'Connell MJ, et al: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4: 1053-1057, 1986.
 
90) Cullinan S, Moertel CG, Wieand HS, et al: A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65: 2207-2212, 1990.
PubMed
91) Topham C, Glees J, Rawson NSB, et al: Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. Br J Cancer 64: 179-181, 1991.
 
92) Bartolomeo MD, Zampino MG, Leo AD, et al: Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma. Eur JCancer 29 A: 1215-1216, 1993.
 
93) Bukowski RM, Fleming TR, Macdonald JS, et al: Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group Study. Cancer 71: 322-325, 1993.
 
94) Rothman H, Cantrell JE, Lokich J, et al: Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. AMid-Atlantic Oncology Program study. Cancer 68: 264-268, 1991.
 
95) Rougier P, Zarba JJ, Ducreux M, et al: Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 4: 333-336, 1993.
PubMed
96) Nose H, Okada S, Okusaka T, et al: 5-fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: aJapanese Cooperative Study. Hepatogastroenterology 46: 3244-3248, 1999.
PubMed
97) Andre T, Lotz JP, Bouleuc C, et al: Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol 7: 73-78, 1996.
 
98) Evans TRJ, Lofts FJ, Mansi JL, et al: A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 73: 1260-1264, 1996.
 
99) Cascinu S, Frontini L, Comella G, et al: Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: areport from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) . Br J Cancer 79: 491-494, 1999.
 
100) Cascinu S, Silva RR, Barni S, et al: Acombination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) . Br J Cancer 80: 1595-1598, 1999.
 
101) Hidalgo M, Castellano D, Paz-Ares L, et al: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17: 585-592, 1999.
PubMed
102) Berlin JD, Adak S, Vaughn DJ, et al: A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E 3296) . Oncology 58: 215-218, 2000.
 
103) Heinemann V, Wilke H, Mergenthaler HG, et al: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11: 1399-1403, 2000.
PubMed
104) Brodowicz T, Wolfram RM, Kostler WJ, et al: Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs 11: 623-628, 2000.
PubMed
105) Philip PA, Zalupski MM, Vaitkevicius VK, et al: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92: 569-577, 2001.
PubMed
106) Scheithauer W, Kornek GV, Raderer M, et al: Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br J Cancer 80: 1797-1802, 1999.
PubMed
107) Cascinu S, Gasparini G, Catalano V, et al: A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: areport from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) . Ann Oncol 10: 1377-1379, 1999.
 
108) Stathopoulos GP, Mavroudis D, Tsavaris N, et al: Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: aphase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 12: 101-103, 2001.
 
109) Rocha Lima CS, Savarese D, Bruckner H, et al: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20: 1182-1191, 2002.
 
110) Berlin J, Catalano P, Thomas J, et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E 2297. J Clin Oncol 20: 3270-3275, 2002.
 
111) Wong A and Chan A: Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Cancer 71: 2200-2203, 1993.
PubMed
112) Taylor OM, Benson EA, McMahon MJ, et al: Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. Br J Surg 80: 384-386, 1993.
PubMed
113) Burch PA, Block M, Schroeder G, et al: Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: aNorth Central Cancer Treatment Group study. Clin Cancer Res 6: 3486-3492, 2000.
PubMed
114) Philip PA, Carmichael J, Tonkin K, et al: Hormonal treatment of pancreatic carcinoma: aphase II study of LHRH agonist goserelin plus hydrocortisone. Br J Cancer 67: 379-382, 1993.
 
115) Bramhall SR, Rosemurgy A, Brown PD, et al: Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol19: 3447-3455, 2001.
 
116) Nagasu T, Yoshimatsu K, RoweU C, et al: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B 956. Cancer Res 55: 5310-5314, 1995.
PubMed
117) Britten CD, Rowinsky EK, Soignet S, et al: A phase I and pharmacological study of the farnesyl protein transferase inhibitor l-778, 123 in patients with solid malignancies. Clin Cancer Res 7: 3894-3903, 2001.
PubMed
118) Eskens FALM, Awada A, Cutler DL, et al: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 19: 1167-1175, 2001.
 
119) Aoki K, Yoshida T, Sugimura T, et al: Liposome-mediated in vivo gene transfer of antisense K-ras contruct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 55: 3810-3816, 1995.
 
120) Bruns CJ, Harbison MT, Davis DW, et al: Epidermal growth factor receptor blockade with c 225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6: 1936-1948, 2000.
 
121) Bruns CJ, Solorzano CC, Harbison MT, et al: Blockade of the epidermal growth factor receptor signaling by a noveltyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926-2935, 2000.
PubMed
122) Buchler P, Reber HA, Buchler MC, et al: Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin) . J Gastrointest Surg 5: 139-146, 2001.
PubMed
123) Mulvihill S, Warren R, Venook A, et al: Safety and feasibility of injection with an EIB-55 kDa gene-deleted, replicationselective adenovirus (ONYX-015) into primary carcinomas of the pancreas: aphase I trial. Gene Ther 8: 308-315, 2001.
 
P.721 掲載の参考文献
1) 松野正紀: 膵癌全国登録調査報告 (1999年度症例の要約) . 膵臓 16: 115-147, 2001.
Medical*Online
2) 日本膵臓学会・編: 膵癌取扱い規約. 第5版, 金原出版, 東京, 2002.
 
3) 日本膵臓学会・編: 膵癌取扱い規約. 第4版, 金原出版, 東京, 2002.
 
4) Yeo CJ, Cameron JL, Sohn TA, et al: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990 s. Pathology, complications, and outcomes. Ann Surg 226: 248-260, 1997. treatment of ductal pancreatic carcinoma. Eur J Surg Oncol 17: 173-181, 1991,
 
5) Kubota K, Makuuchi M, Sakamoto Y, et al: Appraisal of two-staged pancreatoduodenectomy: Its technical aspects and outcome. Hepatogastroenterology 47: 269-274, 2000.
PubMed
6) 永川宅和, 太田哲生, 萱原正都・他: 膵癌に対する拡大手術. 肝胆膵 40: 475-481, 2000.
 
7) Gall FP, Kessler H and Hermanek P: Surgical the head of the pancreas. Ann Surg 228: 508-517, 1998.
 
8) Ishikawa O, Ohhigashi H, Sasaki Y, et al: Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 208: 215-220, 1988.
PubMed
9) Henne-Bruns D, Vogel I, Luttges J, et al: Ductal adenocarcinoma of the pancreas head: survival after regional versus extended Iymphadenectomy. Hepatogastroenterology 45: 855-866, 1998.
PubMed
10) Mukaiya M, Hitrata K, Satoh T, et al: Lack of survival benefit of extended lymph node dissection for ductal adenocar cinoma of the head of the pancreas: Retrospective multi-institutional analysis in Japan. World J Surg 22: 248-253, 1998.
 
11) 山本正博, 大橋 修, 斎藤洋一: 膵癌の標準手術と治療成績. 外科治療 78: 46-52, 1998.
Medical*Online
12) Pedrazzoli S, DiCarlo V, Dionigi R, et al: Standard versus extended lymphadenectomy associated with pan-creatoduodenectomy in the surgical treatment of adenocarcinoma of
 
13) Yeo CJ, Cameron JL, Sohn TA, et al: Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullaly adenocarcinoma. Comparison of morbidity and mortality and short term outcome. Ann Surg 229: 613-624, 1999.
 
14) Kawarada Y and Isaj i S: Modified standard (D1+α) pancreaticoduodenectomy for pancreatic cancer. J Gastrointest Surg 4: 227-228, 2000.
 
15) Nakao A, Kaneko T, Takeda S, et al: The role of extended radical operation for pancreatic cancer. Hepatogastroenterologyo 48: 949-952, 2001.
PubMed
16) Leach SD, Lee JE, Charnsangavej C, et al: Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 85: 611-617, 1998.
 
17) 尾形佳郎, 菱沼正一, 高橋 伸・他: 膵癌の治療-血行再建-. 日外会誌 98: 615-621, 1997.
 
18) Takada T, Yasuda H, Amano H, et al: Simultaneous hepatic resection with pancreatoduodenectomy for metastatic pancreatic cancer. Hepatogastroenterology 44: 567-573, 1997.
PubMed
P.731 掲載の参考文献
1) 富永佑民, 青木國雄, 花井 彩, 他. 編: 癌統計白書. 篠原出版, 東京, 1999.
 
2) 日本胆道外科研究会, 胆道癌登録事務局・編: 全国胆道癌登録調査報告. 1998年度症例, 2000.
 
3) 日本胆道外科研究会・編: 胆道癌取扱い規約. 第4版, 金原出版, 東京, 1997.
 
4) Papanikolaou N, Karantanas A, Maris T, et al: MR cholangiopancreatography before and after oral blueberry juice administration. J Comput Assist Tomogr 24(2) : 229-234, 2000.
PubMed
5) Soto JA, Alvarez O, Lopera JE, et al: Biliary obstruction: findings at MR cholangiography and cross-sectional MR imaging. Radiographics 20(2) : 353-366, 2000.
PubMed
6) Materne R, Van Beers BE, Gigot JF, et al: Extrahepatic biliary obstruction: magnetic resonance imaging compared with endoscopic ultrasonography. Endoscopy 32(1) : 3-9, 2000.
PubMed
7) Glasbrenner B, Ardan M, Boeck W, et al: Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. Endoscopy 31(9) : 712-717, 1999.
PubMed
8) Jailwala J, Fogel EL, Sherman S, et al: Triple-tissue sampling at ERCP in malignant biliary obstruction. Gastrointest Endosc 51(4 Pt 1) : 383-390, 2000.
 
9) Tascilar M, Sturm PD, Caspers E, et al: Diagnostic p 53 immunostaining of endobiliary brush cytology: preoperative cytology compared with the surgical specimen. Cancer 87(5) : 306-311, 1999.
 
10) 今井英夫, 堀口祐爾, 鈴木智博・他: 胆・膵悪性腫瘍の新しい超音波診断. 肝胆膵 40: 365-376, 2000.
 
11) Nimura Y and Kamiya J: Cholangioscopy. Endoscopy 30(2) : 182-188, 1998.
PubMed
12) 坂本英至, 二村雄次, 神谷順一・他: 肝門部胆管癌に対する肝管上流側切除範囲-PTBD造影およびPTCSによる進展範囲診断-. 日消外会誌 30: 2069-2073, 1997.
 
13) Nishio H, Kamiya J, Nagino M, et al: Biliobiliary fistula associated with gallblaadder carcinoma. Br J Surg 87: 1656-1657, 2000.
PubMed
14) 權 雅憲: ヘリカル(スパイラル) CTによる胆道癌の診断の動向-血管, 膵浸潤について-. 肝と膵 18: 729-738, 1997.
 
15) Bhuiya MR, Nimura Y, Kamiya J, et al: Clinicopathologic studies on perineural invasion of bile duct carcinoma. Ann Surg 215(4) : 344-349, 1992.
PubMed
16) Kosuge T, Yamamoto J, Shimada K, et al: Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 230(5) : 663-671, 1999.
PubMed
17) Nimura Y, Hayakawa N, Kamiya J, et al: Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J Surg 14(4) : 535-543(discussion 544) , 1990.
 
18) 上坂克彦, 二村雄次, 早川直和・他: 下部胆管癌に対する幽門輪温存膵頭部十二指腸切除術の適応-臨床病理学的検討-. 日消 外会誌 26: 1233-1238, 1997.
 
19) Hui AM, Cui X, Makuuchi M, et al: Decreased p 27(Kip 1) expression and cyclin D l overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma. Hepatology 30(5) : 1167-1173, 1999.
 
20) Li X, Hui A, Takayama T, et al: Altered p 21(WAF 1/CIP 1) expression is associated with poor prognosis in extrahepatic bile duct carcinoma. Cancer Lett 154(1) : 85-91, 2000.
 
21) Nimura Y, Kamiya J, Kondo S, et al: Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg 7(2) : 155-162, 2000.
PubMed
22) Cherqui D, Benoist S, Malassagne B, et al: Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. Arch Surg 135(3) : 302-308, 2000.
PubMed
23) Povoski SP, Karpeh MS Jr, Conlon KC, et al: Preoperative biliary drainage: impact on intraoperative bile cultures and infectious morbidity and mortality after pancreaticoduodenectomy. J Gastrointest Surg 3(5) : 496-505, 1999.
PubMed
24) 佐野 力, 神谷順一, 二村雄次: 胆膵領域の進行癌の治療肝門部胆管癌の手術. 消化器癌の外科治療 (上西紀夫, 田中雅夫・編) , 中外医学社, 東京, 2001, pp 238-244.
 
25) Tsao JI, Nimura Y, Kamiya J, et al: Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg 232(2) : 166-174, 2000.
 
26) Tamada K, Ido K, Ueno N, et al: Preoperative staging of extrahepatic bile duct cancer with intraductal ultrasonography. Am J Gastroenterol 90(2) : 239-246, 199. .
 
27) Sugiyama M, Hagi H, Atomi Y, et al: Diagnosis of portal venous invasion by pancreatobiliary carcinoma: value of endoscopic ultrasonography. Abdom Imaging 22(24) : 434-438, 1997.
 
28) 平田公一: 胆管癌に対する膵頭十二指腸切除術. 消化器癌の外科治療, (上西紀夫, 田中雅夫・編) , 中外医学社, 東京, 2001, pp 245-247.
 
29) Nomura M, Yamakado K, Nomoto Y, et al: Clinical efficacy of brachytherapy combined with external-beam radiotherapy and repeated arterial infusion chemotherapy in patients with unresectable extrahepatic bile duct cancer. Int J Oncol20(2) : 325-331, 2002.
 
30) Morganti AG, Trodella L, Valentini V, et al: Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 46(4) : 913-919, 2000.
PubMed
31) Miura Y, Endo I, Togo S, et al: Adjuvant therapies using biliary stenting for malignant biliary obstruction. J Hepatobiliary Pancreat Surg 8(2) : 113-117, 2001.
PubMed
32) Terzi C, Sokmen S, Seckin S, et al: Polypoid lesions of the gallbladder: report of 100 cases with special reference to operative indications. Surgery 127(6) : 622-627, 2000.
PubMed
33) Sugiyama M, Xie XY, Atomi Y, et al: Differential diagnosis of small polypoid lesions of the gallbladder: the value of endoscopic ultrasonography. Ann Surg 229(4) : 498-504, 1999.
PubMed
34) 乾 和郎, 中澤三郎, 芳野純治・他: ss胆嚢癌の診断はどこまで可能か: 超音波検査. 胆と膵 21: 293-296, 2000.
 
35) 本城和光: ss胆嚢癌のMRI. 胆と膵 21: 303-309, 2000.
 
36) 杉岡 篤, 竹下 元, 富岡和美・他: CTによる進行胆嚢癌の進展度診断. 消化器画像 1: 623-644, 1999.
 
37) Ogura Y, Mizumoto R, Isaji S, et al: Radical operations for carcinoma of the gallbladder: present status in Japan. World J Surg 15(3) : 337-343, 1991.
PubMed
38) Quan ZW, Wu K, Wang J, et al: Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 193(4) : 380-383, 2001.
PubMed
39) Hui AM, Li X, Shi YZ, et al: p27(Kip 1) expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: association with cancer progression and prognosis. Hepatology 31(5) : 1068-1072, 2000.
 
40) 二村雄次, 早川直和, 神谷順一・他: Stage IV胆嚢癌に対する拡大手術の意義. 日外会誌 88: 1343-1346, 1987
 
41) 中村 達, 鈴木晶八, 土屋泰夫: 肝浸潤, 他臓器浸潤を伴った進行胆嚢癌の手術成績. 消化器画像 1: 663-666, 1999.
 
42) Makuuchi M, Thai BL, Takayasu K, et al: Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: apreliminary report. Surgery 107(59) : 521-527, 1990.
 
43) Miyagawa S, Makuuchi M, Kawasaki S, et al: Outcome of major hepatectomy with pancreatoduodenectomy for advanced biliary malignancies. World J Surg 20(1) : 77-80, 1996.
PubMed
44) 柴本由香, 高木一郎: 微小管を標的とした抗癌剤のヒト胆嚢癌細胞に対する効果に関する基礎的研究. 胆道 14: 42-50, 2000.
Medical*Online
45) 辻 晃仁, 森田荘二郎, 堀見忠司・他: 手術不能進行・再発胆嚢癌に対する少量cisplatin・5-fluorouracil療法の初期成績. 癌と化学療法 27(2) : 233-237, 2000.
Medical*Online
46) Tio TL, Sie LH, Kallimanis G, et al: Staging of ampullary and pancreatic carcinoma: comparison between endosonography and surgery. Gastrointest Endosc 44(6) : 706-713, 1996.
PubMed
47) Itoh A, Goto H, Naitoh Y, et al: Intraductal ultrasonography in diagnosing tumor extension of cancer of the papilla of Vater. Gastrointest Endosc 45(3) : 251-260, 1997.
PubMed
48) 安田健治朗, 中島正継, 趙 栄済・他: 十二指腸乳頭部癌の診断, EUSの立場から. 胃と腸 32: 151-156, 1997.
 
49) Schwarz M, Pauls S, Sokiranski R, et al: Is a preoperative multidiagnostic approach to predict surgical resectability of periampullary tumors still effective? Am J Surg 182(3) : 243-249, 2001.
PubMed
50) 宮崎 亮, 池田靖洋, 岩永真一・他: 十二指腸乳頭部癌の外科治療, 幽門輪温存膵頭十二指腸切除術を中心に. 胃と腸 32: 173-179, 1997.
 
51) Talamini MA, Moesinger RC, Pitt HA, et al: Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg 225(5) : 590-599(discussion 599-600) , 1997.
 
52) Bottger TC, Boddin J, Heintz A, et al: Clinicopathologic study for the assessment of resection for ampullary carcinoma. World J Surg 21(4) : 379-383, 1997.
PubMed
53) Scarpa A, Di Pace C, Talamini G, et al: Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis. Gut 46(6) : 842-848, 2000.
PubMed
54) 日本胆道外科研究会, 胆道癌登録事務局・編: 全国胆道癌登録調査報告. 1996年度症例, 1997.
 
55) Yeo CJ, Sohn TA, Cameron JL, et al: Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 227(6) : 821-831, 1998.
PubMed
56) Lee JH, Whittington R, Williams NN, et al: Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 47(4) : 945-953, 2000.
PubMed
P.745 掲載の参考文献
1) Linehan WM, Zbar B, Bates SE, et al: Cancer of the kidney and ureter. In Cancer-Principles and practice of oncology, (ed by DeVita VT, Hellman S and Rosenberg SA) , 6th ed, JB Lippincott, Philadelphia, 2001, pp 1362-1356.
 
2) Aso Y and Homma Y: Asurvey on incidental renal cell carcinoma in Japan. J Urol 147: 340-343, 1992.
 
3) Thompson IM and Peek M: Improvement in survival of patients with renal cell carcinoma-The role of the sedendipitously detected tumor. J Urol 140: 487-490, 1988.
PubMed
4) 高山達也, 藤田公生: 本邦臨床統計集 腎癌. 日本臨床 59(増刊号7) : 373-378, 2001.
 
5) 富永裕民, 青木国雄, 花井 彩. 他: がん統計白書-罹患/死亡/予後-1993. 篠原出版, 東京, 1993.
 
6) McLaufhlin JK, Lindblad P and Mellemgaad A: International renal-cell carcinoma cancer study. I. Tabacco use. Int J Cancer 60: 194-198, 1995.
 
7) Yu MC, Mack TM, Hanish R, et al: Cigarette, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. JNCI 77: 351-356, 1986.
 
8) McLaufhlin JK, Chow WH, Mandel JK, et al: International renal-cell carcinoma cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer 63: 216-221, 1995.
 
9) Mandel JS, McLaughlin JK, Schlehofer B, et al: International renal-cell carcinoma cancer study. IV. Occupation. Int J Cancer 61: 601-605, 1995.
PubMed
10) Vogelzang NJ and Stadler WM: Kidney cancer. Lancet 352: 1691-1696, 1998 .
PubMed
11) Washecka R and Hanna M: Malignant renal tumors in tuberous sclerosis. Urology 37: 340-343, 1991.
PubMed
12) Ichikawa I: Uremic acquired renal cyst disease: natural history and complications. Nephron 58: 257-267, 1991.
 
13) Yao M and Shuin T: Familial renal cell carcinoma: review of recent molecular genetics. Int J Urol 2: 61-70, 1995.
PubMed
14) 執印太郎, 蘆田真吾, 矢尾正祐. 他: von Hippel-Lindau病. 日本臨床 58: 1448-1454, 2000.
Medical*Online
15) Maher EM, Yates JRW, Harriews R, et al: Clinial feartures and natural history of von Hippel-Lindau disease. . QJM 77: 1151-1163, 1990.
 
16) Shuin T, Kondo K, Torigoe S, et al: Frequent somatic mutations and loss of heterozygosity of the von Hoppel-Lindau disease tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54: 2852-2855, 1994.
 
17) Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet 16: 68-73, 1997.
PubMed
18) Zbar B, Alvord WG, Glenn G, et al: Risk of renal and colonic neoplasms and spontaneous pneumothorax in the birt-hoggdube syndrome. Cancer Epidemiol Biomarkers Prev 11: 393-400, 2000.
 
19) Takahashi A, Hayashi T, Yoshida O, et al: Renal cell carcinoma in the Birt-Hogg-dube syndrome: report of a case. Hinyokika Kiyo 47: 719-721, 2001.
PubMed
20) Lipponen P, Eskelinen M and Syrjanen K: Expression of tumour-suppressor gene RB, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer 71: 863-867, 1995.
 
21) Nanus DM, Mentle IR, Motzer RJ, et al: Infrequent ras oncogene point mutations in renal cell carcinoma. J Urol 143: 175-178, 1990.
PubMed
22) Brooks JD, Bova S, Mershall FF, et al: Tumor suppressor gene allelic loss in human renal cancers. J Urol 150: 1278-1283, 1993.
 
23) Uchida T, Wada C, Shitara T, et al: Infrequent involvement of p53 mutations and loss of heterozygosity of 17p in the tumorigenesis of renal cell cancer. J Urol 150: 1298-1301, 1993.
PubMed
24) Uhlman DL, Nguyen PL, Manivel C, et al: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patient with renal cell carcinoma. JNCI 86: 1470-1475, 1994.
 
25) Oda H, Nakatsuru Y and Ishikawa T: Mutation of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell cancer. Cancer Res 55: 658-662, 1995.
PubMed
26) Sporn MB and Todaro GJ: Autosecretion and malignant transformation of cell. N Engl J Med 303: 878-885, 1980.
 
27) Atlas I, Mendelsohn J, Baselga J, et al: Growth regulation of human renal carcinoma cells: role of transforming growth factor α. Cancer Res 52: 3335-3339, 1992.
 
28) Miki S, Iwano M, Miki Y, et al: Interleukin 6(IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250: 607-610, 1988.
 
29) Blay JY, Negrier S, Combaret V, et al: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322, 1992.
PubMed
30) Stadler WM, Richard JM, Vogelzang NJ, et al: Serum interleukin-6 levels in metastatic renal cancer: Correlation with survival but not an independent prognostic indicator. JNCI 84: 1835-1836, 1992.
 
31) Dosquet C, Schaetz A, Fraucher C, et al: Tumour necrosis factor-α, interleukin-1 and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 30 A: 162-167, 1994.
 
32) Horie S, Aruga S, Kawamata H, et al: Biological role of HGF/MET pathway in renal cell carcinoma. J Urol 161: 990-997, 1999.
PubMed
33) Fujimoto K, Ichimori Y, Kakizoe T, et al: Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun 180: 386-392, 1991.
PubMed
34) Takahashi A, Sasaki H, Kim SJ, et al: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54: 4223-4237, 1994.
 
35) Iliopoulos O, Levy AP, Jiang C, et al: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93: 10595-10599, 1996.
 
36) Gnarra JR, Zhou S, Merrill MJ, et al: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93: 10589-10594, 1996.
PubMed
37) 日本泌尿器科学会, 他・編: 腎癌取扱い規約. 第3版, 金原出版, 東京, 1999.
 
38) Storkel S, Eble JN, Adlakha K, et al: Classification of renal cell carcinoma. Cancer 80: 987-989, 1997.
PubMed
39) Boxer RJ, Waismann J, Lieber MM, et al: Non-metastatic hepatic dysfunction associated with renal carcinoma. J Urol 119: 468-471, 1978.
 
40) 三原修一: 超音波検診における腎細胞癌の早期発見. 日内超音波会誌 20: 24-32, 1993.
 
41) Kallman DA, King BF, Hattery RR, et al: Renal vein and inferior vena cava tumor thrombus in renal cell carcinoma: CT, US, MRI and venacavography. J Comput Assist Tomogr 16: 240-247, 1992.
PubMed
42) Studer UE, Scherz S, Scheidegger J, et al: Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastasis. J Urol 144: 243-245, 1990.
 
43) Koga S, Tsuda S, Nishikido M, et al: The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol 166: 2126-2128, 2001.
PubMed
44) Sekido N, Kawai K, Satoh M, et al: A case of angiomyolipoma diagnosed by thin-slice non-enhanced CT and needle biopsy. Int J Urol 3: 77-79, 1996.
PubMed
45) Bosniak MA: The current radiological approach to renal cysts. Radiology 158: 1-10, 1986.
PubMed
46) Wolf JS Jr: Evaluation and management of solid and cystic renal masses. J Urol 159: 1120-1133, 1998.
PubMed
47) Lieber MM: Renal oncocytoma: prognosis and treatment. Eur Urol 18(suppl 2) : 7-21, 1990.
 
48) Igarashi T, Tobe T, Nakatsu HO, et al: The impact of a 4cm cutoff point for stratification of TI NO MO renal cell carcinoma after radical nephrectomy. J Urol 165: 1103-1106, 2001.
 
49) Zisman A, Pantuck AJ, Chao D, et al: Reevaluation of the 1997 TNM classification for renal cell carcinoma: TI and T2 cutoff point at 4. 5rather than 7 cm better correlates with clinical outcome. J Urol66: 54-58, 2001.
 
50) 伊野宮秀志, 井坂茂夫, 岡野達弥・他: 転移のない腎細胞癌の予後因子解析. 日泌尿会誌 87: 1099-1104, 1996.
 
51) 里見佳昭: 腎癌の予後に関する臨床的研究-特に生体側の因子を中心に-. 日泌尿会誌 64: 195-216, 1973.
 
52) 里見佳昭: 腎癌の治療の現況と今後の課題. 日泌尿会誌 81: 1-13, 1990.
 
53) 大西哲朗, 大石幸彦, 増田富士男・他: 腎摘施行Stage 4B腎細胞癌の予後を左右する因子. 日泌尿会誌 85: 1664-1672, 1994.
 
54) Maldazys JD and DeKernion JB: Prognostic factors in metastatic renal carcinoma. J Urol 136: 376-379, 1986.
PubMed
55) 塚本泰司: 腎細胞癌の浸潤転移と血管新生. 日泌尿会誌 87: 1-12, 1996.
 
56) Saitoh H: Distant metastasis of renal adenocarcinoma. Cancer 48: 1487-1491, 1981.
PubMed
57) Saitoh H, Nakayama M, Nakamura K, et al: Distant metastasis of renal adenocarcinoma in nephrectomized cases. J Urol 127: 1092-1095, 1982.
 
58) Johnsen JA and Hellsten S: Lymphatogenous spread of renal cell carcinoma: An autopsy study. J Urol 157: 450-453, 1997.
PubMed
59) Cangiano T, Liao J, Naitoh J, et al: Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 17: 523-528, 1999.
PubMed
60) Chao D, Zisman A, Pantuck AJ, et al: Collecting duct renal ce11 carcinoma: Clinical study of a rare tumor. J Urol 167: 71-74, 2002.
 
61) Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540, 1999.
PubMed
62) Shimazui T, Oosterwijk E, Debruyne MJ, et al: Molecular prognostic factor in renal cell carcinoma. Semin Urol Oncol 14: 250-255, 1996.
 
63) Shimazui T, Tomobe M, Hattori K, et al: A prognostic significance of nucleolar organizer region(AgNOR) in renal cell carcinoma. J Urol 154: 1522-1526, 1995.
PubMed
64) Shimazui T, Oosterwijk E, Akaza H, et al: Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin absent renal cell carcinoma. Clin Cancer Res 4: 2419-2424, 1998.
 
65) Herrlinger A, Schrott KM, Schott G, et al: What are the benefits of extended dissection of the regional renal lymph nodes in the theraphy of renal cell carcinoma? J Urol 146: 1224-1227, 1991.
 
66) Blom JHM, van Poppel H, Marechal JM, et al: Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. Eur Urol 36: 570-575, 1999.
 
67) Shalev M, Cipolla B, Guille F, et al: Is ipsilateral adrenalectomy a necessary component of radical nephrectomy? J Urol 153: 1415-1417, 1995.
PubMed
68) Tsui KH, Shvarts O, Barbaric Z, et al: Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. J Urol 163: 437-441, 2000.
PubMed
69) Licht MR and Novick AC: Nephron sparing surgery for renal cell carcinoma. J Urol 149: 1-7, 1993.
PubMed
70) Poston CD, Jaffe GS, Lubensky IA, et al: Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol 153: 22-26, 1995.
PubMed
71) Herring JC, Enquist EG, Chernoff A, et al: Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 165: 777-781, 2001.
PubMed
72) Van Poppel H, Bamelis B, Oyen R, et al: Partial nephrectomy for renal cell carcinoma can achieve long-term tumor control. J Urol 160: 674-678, 1998.
PubMed
73) Fergany AF, Hafez KS and Novick AC: Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 163: 442-445, 2000.
PubMed
74) Uzzo RG and Novick AC: Nephron sparing surgery for renal tumors: Indications, techniques and outcomes. J Urol 166: 6-18, 2001.
PubMed
75) Ono Y, Kinukawa T, Hattori R, et al: The long-term outcome of laparoscopic radical nephrectomy for small renal cell carcinoma. J Urol 165: 1867-1870, 2001.
 
76) Tanaka M, Tokuda N, Koga H, et al: Hand assisted laparoscopic radical nephrectomy for renal carcinoma using a new abdominal wall sealing device. J Urol 164: 314-318, 2000.
 
77) Yoshimura K, Okubo K, Ichioka K, et al: Laparoscopic partial nephrectomy with a microwave tissue coagulator for small renal tumor. J Urol 165: 1893-1896, 2001.
PubMed
78) Skinner DG, Pritchett TR, Lieskovsky G, et al: Vena caval involvement by renal cell carcinoma surgical resection provides meaningful long-term survival. Ann Surg 210: 387-394, 1989.
PubMed
79) Libertino JA, Zinman L and Watkins E Jr: Long-term results of resection of renal cell cancer with extension into inferior vena cava. J Urol 137: 21-24, 1987.
PubMed
80) Hatcher PA, Anderson EE, Paulson DF, et al: Surgical management and prognosis of reanl cell carcinoma invading the vena cava. J Urol 145: 20-24, 1991.
 
81) Glazer AA and Novick AC: Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol 155: 448-450, 1996.
PubMed
82) Gohji K, Yamashita C, Ueno K, et al: Preoperative computerized tomography detection of extensive invation of the inferior vena cava by renal cell carcinoma: possible indication for resection with partial cardiopulmonary bypass and patch grafting. J Urol 152: 1993-1997, 1994.
 
83) 大園誠一郎, 岡島英五郎, 平尾佳彦: 進行癌に対する拡大手術. 癌の臨床 42: 1241-1263, 1996.
 
84) Naitoh J, Kaplan A and Dorey F: Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol 162: 46-50, 1999.
PubMed
85) Slaton JW, Balbay MD, Levy DA, et al: Nephrectomy and vena caval thrombectomy in patients with metastaticrenal cell carcinoma. Urology 50: 673-677, 1997.
PubMed
86) Mickisch GH, Garin A, van Poppel H, et al: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966-970, 2001.
PubMed
87) Flanigan RC and Yonover PM: The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol 0ncol 19: 98-102, 2001.
 
88) Fujikawa K, Matsui Y, Oka H, et al: Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol 162: 1934-1937, 1999.
 
89) Kavolius JP, Mastorakos DP, Pavlovich C, et al: Resection of metastatic renal cell carcinoma. J Clin Oncol 16: 2261-2266, 1998.
PubMed
90) Yogoda A, Abi-Rached B and Petrylak D: Chemotherapy for renal-cell carcinoma: 1983-1993. Semin Oncol 22: 42-60, 1995.
 
91) Motzer RJ and Russo P: Systemic therapy for renal cell carcinoma. J Urol 163: 408-417, 2000.
PubMed
92) 里美佳昭, 福田百邦: 腎癌治療の最前線-免疫療法. 癌の臨床 42: 1251-1264, 1996.
 
93) Wirth MP: Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283-295, 1993.
PubMed
94) MRC: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353: 14-17, 1999.
 
95) Pyrhonen S, Salminen E, Rutu M, et al: Prospective randomized trial of interferon alfa-2 a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859-2867, 1999.
 
96) Pizzocaro G, Piva L, Colavita M, et al: Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19: 425-431, 2001.
 
97) Gleave ME, Elhilali M, Fradet Y, et al: Interferon gamma-lb compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338: 1265-1271, 1998.
 
98) Fyfe G, Fischer RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696, 1995.
 
99) Stadler WM and Vogelzang NJ: Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol 22: 67-73, 1995.
PubMed
100) Yang JC and Rosenberg SA: An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 3(suppl 1) S79-84, 1997.
PubMed
101) Stahl M, Wilke HJ, Seeber S, et al: Cytokines and cytotoxic agents in renal cell carcinoma: A review. Semin Oncol l9 (Suppl 4) : 70-79, 1992.
 
102) Fujioka T, Hasegawa M, Ishikura K, et al: Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol 160: 247-251, 1998.
PubMed
103) Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-20r high-dose interleukin-2 slone. N Engl J Med 316: 889-897, 1987.
 
104) Pierce WC, Belldegrun A and Figlin RA: Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal cell carcinoma. Semin Oncol 22: 74-80, 1995.
PubMed
105) Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunctionwith lymphokine-activated killer cells for the treatment of patients with advanced cancer. JNCI 85: 622-632, 1993.
PubMed
106) Gaugler B, Brouwestijn N, Vantomme V, et al: A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal cell carcinoma. Immunogenetics 44: 323-330, 1996.
 
107) Brandle D, Brasseur F, Weynants P, et al: A mutated HLA-A2 molecule recognized by autologous cytotoxic Tlymphocytes on a human renal cell carcinoma. J Exp Med 183: 2501-2508, 1996.
 
108) Neumann E, Engelesberg A, Decker J, et al: Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and Glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based lmmunotherapies? Cancer Res 58: 4090-4095, 1998.
 
109) Figlin RA, Thompson JA, Bukowski RM, et al: Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17: 2521-2529, 1999.
PubMed
110) Liu SQ, Shiraiwa H, Kawai K, et al: Tumor-specific autologous cytotoxic T lymphocytes from tissue section. Nat Med 2: 1283, 1996.
 
111) Liu SQ, Kawai K, Akaza H, et al: High rate of induction of human autologous cytotoxic T lymphocytes against renal cell carcinoma cells cultured with an interleukin cocktail. Jpn J Cancer Res 89: 1195-1201, 1998.
PubMed
112) Kugler A, Stuhler G, Walden P, et al: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6: 332-336, 2000.
PubMed
113) Childs R, Chernoff A, Contentin N, et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750-758, 2000.
PubMed
114) Childs RW: Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma. Crit Rev Immunol 21: 191-203, 2001.
PubMed
115) Tani K, Nakazaki Y, Hase H, et al: Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer cells. Cancer Chemother Pharmacol 46(Suppl) : S73-76, 2000.
 
116) Kawai K, Tani K, Yamashita N, et al: Clinical course of an advanced renal cell carcinoma patient treated with GM-CSF gene therapy(GVAX) : The first experience of cancer gene therapy in Japan. Int J Urol 9: 462-466, 2002.
 
117) Simons JW, Jaffee EM, Weber CE, et al: Bioactivity of autologous irradiated renal ceil carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57: 1537-1546, 1997.
 
118) 谷憲三郎: GM-CSF遺伝子治療の経験から. 実験医学 20: 852-856, 2002.
 
119) Rini BI, Selk LM and Vogelzang NJ: Phase 1 study of direct intralesional gene transfer of HLA-B 7 into metastatic renal carcinoma lesions. Clin Cancer Res 5: 2766-2772, 1999.
 
120) Galanis E, Hersh EM, Stopeck AT, et al: Immunotherapy of advanced malignancy by direct gene transfer of an Interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience. J Clin Oncol 17: 3313-3323, 1999.
PubMed
121) Takahashi Y: Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. JNCI 87: 1262, 1995.
PubMed
P.766 掲載の参考文献
1) 日本泌尿器科学会, 日本病理学会・編: 膀胱癌取扱い規約. 第3版, 金原出版, 東京, 2001.
 
2) 日本泌尿器科学会, 日本病理学会・編: 腎孟・尿管癌取扱い規約. 第2版, 金原出版, 東京, 2002.
 
3) 垣添忠生・編: がんの統計'01. 財団法人がん研究振興財団, 東京, 2001.
 
4) Berenblum I: The cocarcinogenic action of craton resin. Cancer Res 1: 44-48, 1941.
 
5) Tsuji I: Environmental and industrial cancer of the bladder in Japan. Acta Unio 18: 662-666, 1962.
PubMed
6) UICC: TNM classification of malignant tumours, (ed by Sobin LH and Wittekind Ch) , 5th ed, Wiley-Liss, New York, Chichester, Weiheim, Brisbane, Singapore, Toronto, 1997.
 
7) Kinoshita H, Ogawa O, Kakehi Y, et al: Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 89: 724-730, 1997.
PubMed
8) Miyanaga N, Akaza H, Ishikawa S, et al: Clinical evaluation of Nuclear Matrix Protein 22(NMP 22) in urine as a novel marker for urothelial cancer. Eur Urol 31: 163-168, 1997.
 
9) Miyanaga N, Akaza H, Kameyama S, et al: Significance of the BTA test in bladder cancer: Amulticenter trial. Int J Urol (in press)
 
10) Carroll P, Raghavan D, Stein J, et al: Voided markers for bladder cancer diagnosis. In The treatment of bladder cancer-stage by stage, IC/PG and AM/PM Course Handouts in 96th Annual Meeting of AUA, 2001, p 20.
 
11) 服部一紀, 樋之津史郎, 島居 徹・他: 内視鏡用細径プローブを用いた膀胱腫瘍の経尿道的超音波診断. 超音波医学 20: 543-547, 1993.
Medical*Online
12) 津田 恭, 鳴海善文, 中村仁信・他: Dynamic(ダイナミック) MRIによる膀胱腫瘍の病期診断. 泌尿紀要 46: 835-839, 2000.
 
13) Hoshi S: Evaluation of neoadjuvant therapy in locally invasive bladder cancer: Core biopsy of bladder tumors and aspiration biopsy of regional nodes. In Evaluation of chemotherapy in bladder cancer, (ed by Villavicencio H and Fair WR) , Churchill Livingstone, Edinburgh, 1992, p 61.
 
14) Hopman AH, Moesker O, Smeets AW, et al: Numerical chromosome 1, 7, 9and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res 51: 644-651, 1991.
 
15) Sidransky D, von Eschenbach A, Tasi YC, et al: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706-709, 1991.
 
16) Cairns P, Shaw ME and Knowles MA: Initiation of bladder cancer may involve deletion of a tumor suppressor gene on chromosome. Oncogene 8: 1083-1085, 1993.
PubMed
17) Spruck CH III, Ohneseit PF, Conzalez-Zuluetta M, et al: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54: 784-788, 1994.
 
18) Esrig D, Elmajian D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331: 1259-1264, 1994.
PubMed
19) Cordon-Cardo C: Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147: 545-560, 1995.
PubMed
20) Stein J P, Ginsberg DA, Grossfeld GD, et al: Effect of p21 WAF 1/CIP 1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90: 1072-1079, 1998.
 
21) Bagchi S, Weinmann R and Raychaudhuri P: The retinoblastoma protein copurifies with E2 F-1, an EI A-regulated inhibitor of the transcription factor E2 F. Cell 65: 1063-1072, 1991.
 
22) Wang J Y, Knudsen ES and Welch PJ: The retinoblastoma tumor suppressor protein. Adv Cancer Res 64: 25-85, 1994.
PubMed
23) Esrig D, Shi SR, Bochner BH, et al: Prognostic importance of p53 and Rb alterations in transitional cell carcinoma of the bladder. J Urol 153(part 2) : 362A(abstr 536) , 1995.
 
24) Lerner S P, Linn D, Chakraborty S, et al: Correlation of p53 and retinoblastoma protein expression with established pathologic prognostic features in radical cystoprostatectomy specimens. J Urol 153(part 2) : 353 A(abstr 537) , 1995.
 
25) Sidransky D, Frost P, Von Eschenbach A, et al: Clonal origin bladder cancer. N Engl J Med 326: 737-740, 1992.
PubMed
26) Harris AL and Neal DE: Bladder cancer-field versus clonal origin. N Engl J Med 326: 759-761, 1992.
PubMed
27) Habuchi T, Takahashi R, Yamada H, et al: Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 342: 1087-1088, 1993.
PubMed
28) Mao L: Genetic alterations as clonal markers for bladder cancer detection in urine. J Cell Biochem(Suppl) 25: 191-196, 1996.
PubMed
29) Takahashi T, Habuchi T, Kakehi Y, et al: Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 58: 5835-5841, 1998.
PubMed
30) Volante M, Tizzani A, Casetta G, et al: Progression from superficial to invasive carcinoma of the bladder: genetic evidence of either clonal heterogeneous events. Hum Pathol 32: 468-474, 2001.
PubMed
31) Shimazui T, Ami Y, Miyanaga N, et al: Telomerase is upregulated in irreversible preneoplastic lesions during bladder carcinogenesis in Rats. Jpn J Cancer Res 93: 495-500, 2002.
PubMed
32) Shigyo M, Sugano K, Fukayama N, et al: Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt-end single-strand DNA conformation polymorphism. Int J Cancer 78: 425-429, 1998.
PubMed
33) Shigyo M, Sugano K, Tobisu K, et al: Molecular follow up of newly diagnosed bladder cancer using urine samples. J Urol 166: 1280-1285, 2001.
 
34) 香川 征: 泌尿器科腫瘍学における分子生物学. 日泌尿会誌 86: 963-978, 1995.
 
35) Decenzo J M, Howard P and Iris C E: Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma. J Urol 114: 874-878, 1975.
 
36) Newman AJ Jr, Carlton CE Jr and Johnson S: Cell surface A, B, or O(H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma. J Urol 124: 27-29, 1980.
 
37) Cordon-Cardo C, Reuter VE, Lioyd KO, et al: Blood group-related antigens in human urothelium: enhanced expression of precursor, LeX, and LeY determinants in urothelial carcinoma. Cancer Res 48: 4113-4120, 1988,
 
38) Sheinfeld J, Router VE, Melamed MR, et al: Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 143: 285-288, 1990.
 
39) Fontana D, Bellina M, Gubetta L, et al: Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma. J Urol 148: 1149-1151, 1992.
 
40) Tsujihashi H, Nakanishi A, Matsuda H, et al: Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining. J Urol 145: 846-849, 1991.
PubMed
41) Bush C, Price P, Norton J, et al: Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Br J Cancer 64: 357-360, 1991.
PubMed
42) Bringuier PP, Umbas R, Schaafama HE, et al: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53: 3241-3245, 1993.
 
43) Giroldi L A, Bringuier P P and Schalken J A: Defective E-adherin function in urological cancers: clinical implications and molecular mechanisms. Invasion Metastasis 14: 71-81, 1994.
 
44) Shimazui T, Schalken JA, Giroldi LA, et al: Prognostic value of cadherin-associated molecules(a-, b-, and g-catenins and p120 cas) in bladder tumors. Cancer Res 56: 4154-4158, 1996.
 
45) Liotta LA, Tryggvason K, Garbisa S, et al: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67, 1990.
 
46) Liotta LA: Tumor invasion and metastasis-Role of the extracellular matrix: Rhoads memorial award lecture. Cancer Res46: 1-7, 1986.
 
47) Jaeger TM, Weidner N, Chew K, et al: Tumor angiogenesis correlates with lymph node metastases in invasive bladder. Cancer. J Urol 154: 69-71, 1995.
PubMed
48) Bochner BH, Cote RJ, Weidner N, et al: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87: 1603-12, 1995.
PubMed
49) Li X and Eriksson U: Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol 33: 421-426, 2001.
PubMed
50) Herr HW: Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19: 89-93, 2001.
 
51) Akaza H, Koiso K, Kotake T, et al: Long-term results of intravesical chemotherapylaxis of superficial bladder cancer: experience of the Japanease Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 30(Suppl) : S15-S 20, 1992.
 
52) Maffezzini M, Aimonato A, Zanon M, et al: Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. J Urol 155: 91-93, 1996.
PubMed
53) Hinotsu S, Akaza H, Ohashi Y, et al: Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: acombined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 86: 1818-1826, 1999.
 
54) Morales A, Eidinger D and Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180-183, 1976.
PubMed
55) Akaza H, Hinotsu S, Aso Y, et al: Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Cancer 75: 552-559, 1995.
PubMed
56) Lamm DL, Blumenstein BA, Crawford ED, et al: Arandomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional cell carcinoma of the bladder. N Engl J Med 325: 1205-1209, 1991.
 
57) Akaza H, Iwasaki A, Ohtani M, et al: Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Guerin to bladder cancer cells. Cancer 72: 558-563, 1993.
PubMed
58) Zhang Y, Mahendran R, Yap LL, et al: The signalling pathway for BCG-induced interleukin-6 production in human bladder cancer cells. Biochem Pharmacol 63: 273-282, 2002.
PubMed
59) Iwasaki A, Kawai K, Hayashi H, et al: Immunological protection induced by bacillus Calmette-Guerin treatment in a murine bladder tumor model. Int J Urol 9: 219-224, 2002.
 
60) Lamm DL, Van der Meijden APM, Moreles A, et al: Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147: 596-600, 1992.
 
61) Martinez-Pineiro JA and Martinez-Pineiro L: BCG update: Intravesical therapy. Eur Urol 31: 31-41, 1997.
PubMed
62) Gruenwald IE, Stein A, TRashcovitsky R, et al: A 12 wersus 6-week course of bacillus calmetter-Guerin prophylaxis for the treatment of high risk superficial bladder cancer. J Urol 157: 487-491, 1997.
 
63) Davis JW, Sheth SI, Doviak MJ, et al: Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol 167(2 Pt 1) : 494-500(discussion 501) , 2002.
 
64) Pansadoro V, Emiliozzi P, de Paula F, et al: Long-term follow-up of G3 TI transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 59: 227-231, 2002.
 
65) Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 19: 666-675, 2001.
 
66) Kock NG, Nilson AE, Nilson LO, et al: Urinary diversion via a continent ileal reservoir: Clinical results in 12 patients. J Urol 128: 469-475, 1982. Rowland RG, Mitchell ME,
 
67) Rowland RG, Mitchell ME, Bihrle R, et al: Indiana continent urinary reservoir. J Urol 137: 1136-1139, 1987.
PubMed
68) Thuroff JW, Alken P, Riedmiller H, et al: The Mainz pouch(mixed augmentation ileum an cecum) for bladder augmentation and continent diversion. J Urol 136: 17-26, 1986.
PubMed
69) Hautmann RE, Egghart G, Frohneberg D, et al: The ileal neobladder. J Urol 139: 39-42, 1988.
PubMed
70) Studer U, Ackermann D, Casanova GA, et al: Anewer form of bladder substitute based on historical perspectives. Semin Urol 6: 57-65, 1988.
PubMed
71) Skinner DG, Boyd SD, Lieskovsky G, et al: Lower urinary tract reconstruction following cystectomy: experience and results in 126 patients using the Kock ileal reservoir with bilateral ureteroileal urethrostomy. Urology 146: 756-760, 1991.
PubMed
72) Skinner DG, Lieskovsky G and Boyd S: Continent urinary diversion. J Urol 141: 1323-1327, 1989.
PubMed
73) Studer UE, Danuser H, Merz VW, et al: Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment. J Urol 154: 49-56, 1995.
PubMed
74) Elmajian DA, Stein JP, Esrig D, et al: The Kock ileal neobladder: updated experience in 295 male patients. J Urol 156: 920-925, 1996.)
PubMed
75) Lampel A, Fisch M, Stein R, et al: Continent diversion with the Mainz pouch. World J Urol 14: 85-91, 1996.
PubMed
76) Bihrle R: The Indiana pouch continent urinary reservoir. Urol Clin North Am 24: 773-779, 1997.
PubMed
77) Hautmann RE, de Petriconi R, Gottfried HW, et al: The ileal neobladder: complications and functional results in 363 patients after ll years of followup. J Urol 161: 422-427(discussion 427-428) , 1999.
 
78) Logothetis CJ, Dexeus FM, Finn L, et al: Aprospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050-1055, 1990.
 
79) Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64: 2448-2458, 1989.
PubMed
80) Raghavan D, Shipley WU, Garnick MB, et al: Biology and management of bladder cancer. N Engl J Med 322: 1129-1138, 1990.
PubMed
81) Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: Arandomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: acooperative group study. J Clin Oncol 10: 1066-1073, 1992.
 
82) Levine EG and Raghavan D: MVAC for bladder cancer: time to move forward again. J Clin Oncol 11: 387-389, 1993.
PubMed
83) Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318: 1414-1422, 1988.
PubMed
84) cher HI, Yagoda A, Herr HW, et al: Neoadj uvant M-VAC(methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 139: 470-474, 1988.
 
85) Sternberg CN, de Mulder PH, Schornagel JH, et al: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin(MVAC) chemotherapy and recombinant human granulocyte colony-stimulatingfactor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19: 2638-2646, 2001.
 
86) Akaza H and Miyanaga N: Developing therapies for advanced bladder cancer. Expert Opin Investig Drugs 11: 109-115, 2002.
 
87) Roth BJ, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: aphase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264-2270, 1994.
 
88) McCaffrey JA, Hilton S, Mazumdar M, et al: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15: 1853-1857, 1997.
PubMed
89) von der Maase H: Gemcitabine in locally advanced and/or metastatic bladder cancer. Crit Rev Oncol Hematol 34: 175-183, 2000.
 
90) Burch PA, Richardson RL, Cha SS, et al: Phase II Trial of Combination Paclitaxel and Cisplatin in Advanced Urothelial Carcinoma(UC) . Proc ASCO 18: 329 a(abstr) , 1999.
 
91) Dreicer R, Manola J, Roth BJ, et al: Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 18: 1058-1061, 2000.
 
92) Vaughn DJ, Malkowicz SB, Zoltick B, et al: Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 16: 255-260, 1998.
PubMed
93) Pycha A, Grbovic M, Posch B, et al: Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Urology 53: 510-515, 1999.
PubMed
94) Sengelov L, Kamby C, Lund B, et al: Docetaxel and cisplatin in metastatic urothelial cancer: aphase II study. J Clin Oncol16: 3392-3397, 1998.
 
95) von der Maase H, Andersen L, Crino L, et al: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: aphase II clinical trial. Ann Oncol 10: 1461-1465, 1999.
 
96) Kaufman D, Raghavan D, Carducci M, et al: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18: 1921-1927, 2000.
 
97) Moore MJ, Winquist EW, Murray N, et al: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: aphase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17: 2876-2881, 1999.
 
98) von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077, 2000.
PubMed
99) Sternberg CN, Calabro F, Pizzocaro G, et al: Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92: 2993-2998, 2001.
PubMed
100) Smith Jr JA, Crawford EP and Paradelo JC: Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: Aphase III intergroup study. J Urol157: 805-808, 1997.
 
101) Shipley WU, Prout GRJr, Einstein AB, et al: Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258: 931-935, 1987.
PubMed
102) Kaufman DS, Shipley WU, Griffin PP, et al: Selective bladder preservation by combination treatment of invasive bladder cancer. N Eng J Med 329: 1377-1382, 1993.
 
103) Shipley WU, Winter KA, Kaufman DS, et al: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16: 3576-3583, 1998.
PubMed
104) Miyanaga N, Akaza H, Okumura T, et al: Abladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: aprospective study. Int J Urol 7: 41-48, 2000.
 
105) Sekido N, Miyanaga N, Kikuchi K, et al: Lower urinary tract function after intra-arterial chemotherapy with concurrent pelvic radiotherapy for invasive bladder cancer. Jpn J Clin Oncol 29: 479-484, 1999.
PubMed
106) Zietman AL, Grocela J, Zehr E, et al: Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 58: 380-385, 2001.
PubMed
107) Holmang S, Hedelin H, Anderstrom C, et al: The importance of depth of invasion in stage T l bladder carcinoma: a prospective cohort study. J Urol 157: 800-804, 1997.
 
108) Williams CB and Mitchell JP: Carcinoma of the ureter-a review of 54 cases-. Br J Urol 45: 377-387, 1973.
PubMed
109) Steffens J Nagel R: Tumours of the renal pelvis and ureter: Observation in 170 patients. Br J Urol 61: 277-283, 1989.
 
110) Sobin LH and Witteknd Ch, editors: International Union Against Cancer. TNM classification of malignant tumours. 6th ed, John Wiley&Sons Inc, New York, 2002.
 
111) Chen GL, ELGabry EA and Bagley DH: Surveillance of upper urinary tract transitional cell carcinoma: the role of ureteroscopy, retrograde pyelography, cytology and urinalysis. J Urol 164: 1901-1904, 2000.
 
112) Weeks SM, Brown ED, Brown JJ, et al: Transitional dell carcinoma of the upper urinary tract: staging by MRI. Abdom Imaging 20: 365-567, 1995.
 
113) Minowada S, Homma Y, Takeuchi T, et al: Long-term outcome of endoscopic biopsy and subsequent nephroureterectomy for upper urinary tract tumor. Int J Urol 8: 6-9, 2001.
PubMed
114) Dunn MD, Shalhav AL, McDougall EM, et al: Laparoscopic nephrectomy and nephroureterectomy for renal and upper tract transitional cell cancer. Semin Laparosc Surg 7: 200-210(Review) , 2000.
 
115) 溝口裕昭, 矢野 明, 橋本邦宏・他: 腎孟・尿管癌に対する腹腔鏡補助下腎尿管全摘除術. 日泌尿会誌 92: 554-559, 2001.
 
116) Stifelman MD, Hyman MJ, Shichman S, et al: Hand-assisted laparoscopic nephroureterectomy versus open nephroureterectomy for the treatment of transitional-cell carcinoma of the upper urinary tract. J Endourol 15: 391-395(discussion 397) , 2001.
 
117) Harada M: Ureteroscopic treatment of transitional cell carcinoma and fibroepithelial polyp of the upper urinary tract. Jap JEndourol ESWL 9: 43-46, 1996.
 
118) Schmeller NT and Hofstetter AG: Laser treatment of ureteral tumors. J Urol 141: 840-843, 1989.
PubMed
119) Plancke, HRF, Strijbos WEM and Delaere KPJ: Percutaneous endoscopic treatment of urothelial tumours of the renal pelvis. Br J Urol 75: 736-739, 1995.
 
120) Akaza H, Koiso K Niijima T: Clinical evaluation of urothelial tumors of the renal pelvis and ureter based on a new classification system. Cancer 59: 1369-1375, 1987.
PubMed
121) Freeman JA, Esrig D, Stein Jp, et al: Management of the patient with bladder cancer. Urethral recurrence. Urol Clin North Am 21: 645-651, 1994.
PubMed
122) Elmajian DA: Indications for urethrectomy. Semin Urol Oncol l9: 37-44(Review) , 2001.
 
123) Ray B and Grabstald H: Experience with primary carcinoma of the male urethra. J Urol 117: 591-594, 1977.
 
124) Zeidman EJ, Desmond P and Thompson I: Surgical treatment of carcinoma of the male urethra. Urol Clin North Am 19: 359-372, 1992.
 
125) Narayan P and Konety B: Surgical treatment of female urethral carcinoma. Urol Clin North Am 19: 373-382, 1992.
 
126) Grigsby PW and Corn BW: Localized urethral tumors in women: Indications for conservative versus exenterative therapoes. J Urol 147: 1516-1520, 1992.
PubMed
P.779 掲載の参考文献
1) 富永祐民, 青木國雄, 花井 彩・他: がん・統計白書-罹患/死亡/予後-1993. 篠原出版, 東京, 1993.
 
2) 厚生労働省がん研究助成金「地域がん登録の精度向上と活用に関する研究」平成12年度報告(主任研究者: 大島 明) .
 
3) Shiraishi T, Watanabe M, Matsuura H, et al: The Frequency of latent prostatic carcinoma in young males: the Japanese experience. In vivo 8: 445-447, 1994.
PubMed
4) 厚生省大臣官房統計情報部「人口動態統計」
 
5) Van Andel G, Vleeming R, Kurth K, et al: Incidental carcinoma of the prostate. Semin Surg Oncol 11: 36-45, 1995.
PubMed
6) Kabalin JN, McNeal JE, Price HM, et al: Unsuspected adenocarcinoma of the prostate in patients undergoing cystopros. tatectomy for other causes: incidence, histology and morphometric observations. J Urol 141: 1091-1094, 1989.
 
7) Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948-954, 1993.
PubMed
8) Potosky AL, Miller BA, Albertsen PC, et al: The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548-552, 1995.
PubMed
9) 日本泌尿器科学会, 日本病理学会・編: 前立腺癌取扱い規約. 第3版, 金原出版, 東京, 2001.
 
10) Gleason DF: Histologic granding of prostate cancer: aperspective. Hum Pathol23: 273-279, 1992.
 
11) Brawer MK: Prostatic intraepithelial neoplasia: apremalignant lesion. Hum Pathol23: 242-248, 1992.
PubMed
12) Keetch DW, Humphrey P, Stahl D, et al: Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 154: 347-351, 1995.
PubMed
13) Bostwick DG and Qian J: Atypical adenomatous hyperplasia of the prostate. Relationship with carcinoma in 217 whole-mount radical prostatectomies. Am J Surg Pathol 19: 506-518, 1995.
 
14) TNM CIassification of Malignant Tumours: (ed by Hermanek P and Sobin LH) , 4th ed, Springer-Verlag, 1992.
 
15) Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable(stageTlc) prostate cancer. JAMA 271: 368-374, 1994.
PubMed
16) Ohori M, Wheeler TM, Dunn JK, et al: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152: 1714-1720, 1994.
PubMed
17) Wirth MP and Frohmuller HG: Prostate-specific antigen and prostate acid phosphatase in the detection of early prostate cancer and prediction of regional lymph node metastasis. Eur Urol 22: 27-32, 1992.
PubMed
18) Lee F, Gray JM, McLeary RD, et al: Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology, and staging. Prostate 7: 117-129, 1985.
PubMed
19) Hodge KK, McNeal JE, Terris MK, et al: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142: 71-75, 1989.
PubMed
20) Coplen DE, Andriole GL, Yuan JJ, et al: The ability of systematic transrectal ultrasound guided biopsy to detect prostate cancer in men with the clinical diagnosis of benign prostatic hyperplasia. J Urol 146: 75-77, 1991.
PubMed
21) Armbruster DA: Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 39: 181-195, 1992.
 
22) Brawer MK, Chetner MP, Beatie J, et al: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147: 841-845, 1992.
PubMed
23) Catalona WJ, Hudson MA, Scardino PT, et al: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 152: 2037-2042, 1994.
PubMed
24) Kirby RS, Kirby MG, Feneley MR, et al: Screening for carcinoma of the prostate: aGP based study. Br J Urol 74: 64-71, 1994.
 
25) Yamamoto M, Hibi H and Miyake K: Prostate-soecific antigen levels in acute and chronic bacterial prostatits. Acta Urol Jpn(泌尿器科紀要) 39: 445-449, 1993.
 
26) Nadler RB, Humphrey PA, Smith DS, et al: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154: 407-413, 1995.
 
27) Bare R, Hart L and McCullough DL: Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy. Urology 43: 191-196, 1994.
PubMed
28) Smith DS and Catalona WJ: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 152: 163-1167, 1994.
 
29) Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
 
30) Zhou AM, Tewari PC, Bluestein BI, et al: Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 39: 2483-2491, 1993.
PubMed
31) Lilja H, Christensson A, Dahlen U, et al: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37: 1618-1624, 1991.
PubMed
32) Catalona WJ, Smith DS, Wolfert RL, et al: EvaIuation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
PubMed
33) Paul R, Breul J and Hartung R: Prostate-specific antigen density and age-specific prostate-specific antigen values: the solution of prostate cancer screening?Eur Urol 27: 286-291, 1995.
PubMed
34) Meshref AW, Bazinet M, Trudel C, et al: Role of prostate-specific antigen density after applying age-specific prostatespecific antigen reference ranges. Urology 45: 972-979, 1995.
 
35) Sutton MA, Gibbons RP and Correa RJ Jr: Is deleting the digital rectal examination a good idea? West J Med 155: 43-46, 1991.
PubMed
36) Smith DS and Catalona WJ: Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 45: 70-74, 1995.
PubMed
37) Flanigan RC, Catalona WJ, Richie Jp, et al: Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol 152: 1506-1509, 1994.
PubMed
38) Shinohara K, Wheeler TM and Scardino PT: The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J Urol 142: 76-82, 1989.
PubMed
39) Carter HB, Brem RF, Tempany CM, et al: Nonpalpable prostate cancer: detection with MR imaging. Radiology 178: 523-525, 1991.
PubMed
40) Engeler CE, Wasserman NF and Zhang G: Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives. Urology 40: 346-350, 1992.
 
41) Schnal1 MD, Lenkinski RE, Pollack HM, et al: Prostate: MR imaging with an endorectal surface coil. Radiology 172: 570-574, 1989.
 
42) Saitoh H, Hida M, Shimbo T, et al: Metastatic patterns of prostatic cancer. Correlation between sites and numer of organs involved. Cancer 54: 3708-3784, 1984.
 
43) Austenfeld MS: Treatment of stage A l prostate cancer: the case for observation. Semin Urol 11: 58-63, 1993.
 
44) Rossignol G, Leandri P, Ramon J, et al: Radical prostatectomy in the management of stage A carcinoma of the prostate. Eur Urol 21: 269-273, 1992.
 
45) Martzkin H, Patel Jp, Altwein JE, et al: Stage T l A carcinoma of prostate. Urology 43: 11-21, 1994.
 
46) Epstein JI, Walsh PC and Brendler CB: Radical prostatectomy for impalapable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection(stage T l A and T l B) and on needle biopsy(stage T l C) . JUrol 152: 1721-1729, 1994.
 
47) Stormont TJ, Farrow GM, Myers RP, et al: Clinical Stage B O or T l c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology 41: 3-8, 1993.
 
48) Johansson JE: Expectant management of early stage prostatic cancer: Swedish experience. J Urol 152: 1753-1756, 1994.
PubMed
49) Chodak GW, Thisted RA, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330: 242-248, 1994.
PubMed
50) Johansson JE: Result of conservative management of clinically localized prostate cancer. N Engl J Med 330: 242-248, 1994.
 
51) hodak GW: The role of watchful waiting in the management of localized prostate cancer. J Urol 152: 1766-1768, 1994.
 
52) Middleton RG, Thompson IM, Austenfeld MS, et al: Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol 154: 2144-2148, 1995.
PubMed
53) Smith JA Jr, Seaman Jp, Gleidman JB, et al: Pelvic lymph node metastasis from prostatic cancer: influence of tumor grade and stage in 452 consecutive patients. J Urol 130: 290-292, 1983.
PubMed
54) Soloway MS, Sharifi R, Wajsman Z, et al: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B 2(T 2 bNxM O) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154: 424-428, 1995.
 
55) Akakura K, Isaka S, Akimoto S, et al: Long-term results of a randomized trial for the treatment of Stages B 2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 54(2) : 313-318, 1999.
 
56) Soloway MS, Hachiya T, Civantos F, et al: Androgen deprivation prior to radical prostatectomy for T 2 b and T 3 prostate cancer. Urology 43(2 Suppl) : 52-56, 1994.
 
57) Van Poppel H, De Ridder D, Elgamal AA, et al: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T 2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 154: 429-434, 1995.
 
58) Oesterling JE, Andrews PE, Suman VJ, et al: Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 149: 779-782, 1993.
PubMed
59) Cher ML, Shinohara K, Breslin S, et al: High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Br J Urol 75: 771-777, 1995.
 
60) Myers RP, Larson Keller JJ, Bergstralh EJ, et al: Hormonal treatment at time of radical retropubic prostatectomy for stage D l prostate cancer: results of long-term followup. J Urol 147: 910-915, 1992.
 
61) Sgrignoli AR, Walsh PC, Steinberg GD, et al: Prognostic factors in men with stage D l prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol 152: 1077-1081, 1994.
 
62) Soloway MS, Hardeman SW, Hickey D, et al: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202, 1988.
PubMed
63) Herr HW, Kornblith AB and Ofman U: Acomparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71(3 suppl) : 1143-1150, 1993.
 
64) Labrie F, Dupont A, Cusan L, et al: Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer. Clin Invest Med 16: 493-498, 1993.
PubMed
65) Crawford ED, Eisenberger MA, Mcleod DG, et al: Acontrolled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321: 419-424, 1989.
 
66) a Silva FC: Quality of life in prostatic cancer patients. Cancer 72(12 suppl) : 3803-3806, 1993.
 
67) Cassileth BR, Solowy MS, Vogelzang NJ, et al: Patients'choice of treatment in stage D prostate cancer. Urology 33(5 suppl) : 57-62, 1989.
 
68) Droz JP, De Smedt E, Kattan J, et al: Phase I trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate. Prostate 24: 62-66, 1994.
PubMed
69) Sartor O, Cooper M, Weinberger M, et al: Surprising activity of flutamide withdrawal, when combined with aminogluteth. imide, in treatment of "hormone-refractory"prostate cancer. J Natl Cancer Inst 86: 222-227, 1994.
 
70) Nieh PT: Withdrawal phenomenon with the antiandrogen casodex. J Urol 153: 1070-1072, 1995.
PubMed
71) Bissada NK and Kaczmarek AT: Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol 153: 1944-1945, 1995.
PubMed
72) Villavicencio H: Quality of life of patients with advanced and metastatic prostatic carcinoma. Eur Urol 24(suppl 2) : 118-121, 1993.
 
73) World Health Organization: Cancer pain relief and palliative care. Technical Report Series No. 804, WHO, Geneva, 1990.
 
74) Crawford ED, Kozlowski JM, Debruyne FM, et al: The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology 44: 481-485, 1994.
PubMed
P.789 掲載の参考文献
1) Forman D and Moeller H: Testicular cancer. Cancer Surv 19: 323-341, 1994.
 
2) 日本泌尿器科学会, 日本病理学会・編: 泌尿器科・病理 精巣腫瘍取扱い規約. 第2版, 金原出版, 東京, 1997.
 
3) Bosl GJ and Motzer RJ: Testicular germ-cell cancer.
 
4) TNM Classification of Malignant Tumors.
 
5) Bosl GJ, Geller NL, Cirrincione cancer. Cancer Res 43(7) : 3403-3407, 1983.
PubMed
6) Birch R, Williams S, Cone 4(3) : 400-407, 1986.
PubMed
7) The International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: Aprognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15(2) : 594-603, 1997.
 
8) Donohue Jp, Thornhill JA, Foster RS, et al: Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience(1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31 A(10) : 1599-1604, 1995.
 
9) Bhatia S, Abonour R, Porce P, et al: High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18(19) : 3346-3351, 2000.
 
10) Rick O, Bokemeyer C, Beyer J, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19(1) : 81-88, 2001.
PubMed
11) Mostofi FK, Sesterhenn IA and Davis CJ: Developments in histopathology of testicular germ cell tumors. Semin Urology 6(3) : 171-188, 1988.
 
P.806 掲載の参考文献
1) 厚生省大臣官房総計情報部・編: 平成7年人口動態統計. (財) 厚生総計協会, 1997, p274.
 
2) 滝 一郎: 子宮癌登録委員会報告: 昭和56年度子宮頸癌患者数年報. 日産婦会誌 29: 1779-1791, 1977.
 
3) 植木 實: 婦人科腫瘍委員会報告: 1998年度子宮頸癌患者年報1998年子宮体癌患者年報. 日産婦会誌 53: 999-1037, 1997.
 
4) Christopherson WM and Parker JE: Relation of cervical cancer to early marriage and childbearing. N Engl J Med 273: 235-239, 1965.
 
5) Rotkin ID: Adolescent coitus and cervical cancer associations of related events with increased risk. Cancer Res 27: 603-617, 1967.
PubMed
6) Keighley E: Carcinoma of the cervix among prostitutes in a women's prison. Bt J Vener Dis 44: 245-255, 1968.
 
7) Schiffman MH, Bauer HM, Hoover RN, et al: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85: 958-964, 1993.
PubMed
8) Brisson J, Morin C, Fortier M, et al: Risk factors for cervical intra-epithelial neoplasia differences between low and high grade lesions. Am J Epidemiol 140: 700-710, 1994.
 
9) Tabara S, Saleh AM, Andersen WA, et al: The Bethesda classification for squamous intraepithelial lesions: Histologic, cytologic and viral correlates. Obstet Gynecol 79: 338-346, 1992.
 
10) Cuzick J, Terry G, Ho L, et al: Human papillomavirus type l6 DNA in cervical smears as predictor of high-grade cervical cancer. Lancet 339: 959-960, 1992.
 
11) Richart RM and Wright TC: Controversies in the management of low-grade cervical intraepithelial neoplasia. Cancer 71: 1413-1421, 1993.
PubMed
12) Koutsky LA, Holmes KK, Critchlow CW, et al: Acohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papilloma-virus infection. N Engl J Med 327: 1272-1278, 1992.
 
13) Bosch FX, Manos MM, Munoz N, et al: Prevalence of human papilloma virus in cervical cancer: aworldwide perspective. J Natl Cancer Inst 87: 796-802, 1995.
 
14) The atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study(ALTS) group: Human papilloma virus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 92: 397-402, 2000.
 
15) Barron BA and Richart RM: Statistical model of the natural history of cervical carcinoma. II. Estimates of the transition time from dysplasia to carcinoma in situ. J Natl Cancer Inst 45: 1025-1030, 1970.
PubMed
16) Kashigrarian M and Dunn JE: The duration of intraepithelial and preclinical squamous cell carcinoma of the uterine cervix. Am J Epidemiol 92: 221-222, 1970.
 
17) Cramer DW and Cuter SJ: Incidence and histopathology of malignancies of the female genital organs in the United States. Am J Obstet Gynecol 118: 443-460, 1974.
 
18) Koss LG, Stewart FW, Foote FW, et al: Some histological aspects of behavior of epidermoid carcinoma in situ and related lesions of the uterine cervix. Cancer 16: 1160-1211, 1963.
 
19) Clemesen J and Poulsen H: Report of the Ministry of the lnterior Document 3. Copenhagen, 1971.
 
20) 日本産科婦人科学会, 日本病理学会, 日本医学放射線学会・編: 子宮頸癌取扱い規約. 金原出版, 東京, 1997.
 
21) Creasman WT(Editorial) : New gynecologic cancer staging. Gynecol Oncol 58: 157-158, 1995.
PubMed
22) Delgado G, Bundy B, Zaino R, et al: Prospective surgical pathological study of disease-free interval in patients with stage IBsquamous cell carcinoma of the cervix: Gynecologic Oncology Group study. Gynecol Oncol 38: 352-357, 1990.
 
23) Zaino RJ, Ward S, Delgado G, et al: Histopathologic predictors of the behavior of surgically treated stage I B squamouscell carcinoma of the cervix. Cancer 69: 1750-1758, 1992.
 
24) Burghardt E, Baltzer J, Tulusan AH, et al: Results of surgical treatment of 1028 cervical cancers studied with volumetry. Cancer 70: 648-655, 1992.
PubMed
25) Stehman FB, Bundy BN, DiSaia PJ, et al: Carcinoma of the cervix treated with radiation therapy I: Amultivariate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 67: 2776-2785, 1991.
 
26) Fagundes H, Perez CA, Grigsby PW, et al: Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 24: 197-204, 1992.
PubMed
27) Eifel PJ, Morris M, Oswald MJ, et al: Adenocarcinoma of the uterine cervix: Prognosis and patterns of failure in 367 cases. Cancer 65: 2507-2514, 1990.
PubMed
28) Gallup Dg, Harper RH and Stock RJ: Poor prognosis in patients with adenosquamous cell carcinoma of the cervix. Obstet Gynecol 65: 416-422, 1985.
PubMed
29) Yazigi R, Sandstad J, Munoz AK, et al: Adenosquamous carcinoma of the cervix: Prognosis in stage I B. Obstet Gynecol75(6) : 1012-1015, 1990.
 
30) Bethwaiter P, Yeong ML, Holloway L, et al: The prognosis of adenosquamous carcinomas of the uterine cervix. Br Jobstet Gynecol 99: 745-750, 1992.
 
31) Maiman M, Fruchter RG, Guy L, et al: Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer71: 402-406, 1993
PubMed
32) Bourhis J, Le MG, Barrois M, et al: Prognostic value of c-myc protooncogene overexpression in early invasive carcinoma of the cervix. J Clin Oncol 8: 1789-1796, 1990.
 
33) Strang P, Eklund G, Stendahl B, et al: S-phase rate as a predictor of early recurrences in carcinoma of the uterine cervix. Anticancer Res 7: 807-810, 1987.
 
34) Alberts DS, Garcia D and Mason-Liddil N: Cisplatin in advanced cancer of the cervix: An update. Semin Oncol 18: 11-24, 1991.
PubMed
35) Sutton GP, Blessing JA, Adock L, et al: Phase II study of ifosfamide and mesna in patients with previously treated carcinoma of the cervix. A Gynecology Group study. Invst New Drugs 7: 341-343, 1989.
 
36) Wallace H, Hreshchshyn M, Eillbanks G, et al: Comparison of the therapeutic effect of advanced carcinoma of the cervix. Cancer Treat Rep 62: 1435-1441, 1978.
 
37) Thigpen JT: Single agent chemotherapy in carcinoma of the cervix. In Cervix Cancer, (ed by Surwit W and Alberts DS) , Martinus Nijhoff, Boston, 1987.
 
38) Krakoff IH, Cvitkovic E, Currie V, et al: Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion. Cancer 40: 2027-2037, 1977.
PubMed
39) 竹内正七, 土橋一慶, 藤本征一郎・他: 子宮頸癌および卵巣癌に対するCPT-11の後期第II相臨床試験. 癌と化学療法 18: 1681-1689, 1991.
Medical*Online
40) Wasserman T and Carter S: The integration of chemotherapy into combined modality treatment of solid tumors: VIII Cervical cancer. Cancer Treat Rev 4: 25-46, 1977.
PubMed
41) McGuire WP, Blessing JA, Moore D, et al: Paclitaxel has moderate activity in squamous cervix cancer: AGynecologic. Oncology Group study. J Clin Oncol 14: 792-795, 1996.
 
42) McGuire WP, Arseneau JC, Blessing JA, et al: Arandomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: AGynecologic Oncology Group study. J Clin Oncol 7: 1462-1468, 1989.
 
43) Panici PB, Scambia G, Baiocchi G, et al: Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Cancer 67: 372-379, 1991.
PubMed
44) Fontanelli R, Spatti G, Raspagliesi F, et al: Apreoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage I B/II carcinoma of the cervix. Ann Oncol 3: 117-121, 1992.
 
45) Friedlander ML, Atkinson K, Coppleson JVM, et al: The integration of chemotherapy into the management of locally advanced cervical cancer: Apilot study. Gynecol Oncol 19: 1-7, 1984
 
46) Kirsten F, Atkinson KH, Coppleson JVM, et al: Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer. Br J Obstet Gynecol 94: 583-588, 1987.
 
47) Sardi JE, Guillermo R, Paola D, et al: Apossible new trend in the management of the carcinoma of the cervix uteri. Gynecol Oncol 25: 139-149, 1986.
 
48) Kim DS, Moon Y, Kim KT, et al: Two-year survival: Preoperative adjuvant chemotherapy in the treatment of cervical cancer Stage I B and II with bulky tumor. Gynecol0ncol 33: 225-230, 1989.
 
49) Chang HC, Lai CH, Chou PC, et al: Neoadjuvant chemotherapy with cisplatin, vincristine, and bleomycin and radical surgery in early stage bulky cervical carcinoma. Cancer Chemother Pharmacol 30: 281-285, 1992.
PubMed
50) Sardi J, Sananes C, Giaroli A, et al: Neoadjuvant chemotherapy in Iocally advanced carcinoma of the cervix uterus. Gynecol Oncol 38: 486-493, 1990.
 
51) Rabinovich MG, Focaccia G, Ferreyra R, et al: Neoadjuvant chemotherapy for cervical carcinoma. Obstet Gynecol 78: 685-688, 1991.
PubMed
52) Symonds RE, Burnett RA, Habeshaw T, et al: The prognostic value of a response to chemotherapy given before radiotherapy in a advanced cancer of cervix. Br J Cancer 59: 473-475, 1989.
 
53) Weiner SA, Aristzabal S, Alberts DS, et al: Aphase II trial of mitomycin, vincristine, bleomycin(MOBP) as neoadjuvant therapy in high-risk cervical carcinoma. Gynecol Oncol 30: 1-6, 1988.
 
54) Lipsztein R, Kredentser D, Dottino P, et al: Combined chemotherapy and radiation therapy for advanced carcinoma of the cervix. Am J Clin Oncol(CCT) 10: 527-530, 1987.
 
55) Dottino PR, Plaxe SC, Beddoe AM, et al: Induction chemotherapy followed by radical surgery in cervical cancer. Gynecol Oncol 40: 7-11, 1991.
PubMed
56) Souhami L, Gil RA, Allan SE, et al: Randomized trial chemotherapy followed by peMc radiation therapy in Stage IIIB carcinoma of the cervix. J Clin Oncol 9: 970-977, 1991.
 
57) Patton T Jr, Kavanagh JJ, Delclos L, et al: Five-year survival in patients given intra-arterial chemotherapy prior to radiotherapy for advanced squamous carcinoma of the cervix and vagina. Gynecol Oncol 42: 54-59, 1991.
 
58) Deppe G, Malviya VK, Han I, et al: A preliminary report of combination chemotherapy with cisplatin and mitomycin-C followed by radical hysterectomy or radiation therapy in patients with locally advanced cervical cancer. Gynecol Oncol 42: 178-181, 1991.
PubMed
59) Panici PB, Scambia G, Baiocchi G, et al: Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Cancer 67: 372-379, 1991.
PubMed
60) Goldhirsch A, Greeiner R, Bleher A, et al: Combination of chemotherapy with methotrexate, bleomycin, and cisplatin, and radiation therapy for locally advanced carcinoma of the cervix. Am J Clin Oncol 9: 12-14, 1986.
 
61) Lara PC, Garcia-Puche JL and Pedraze V: Cisplatin-ifosfamide as neoadjuvant chemotherapy in Stage IIIB cervical uterine squamous-cell carcinoma. Cancer Chemother Pharmacol26: S36-S 38, 1990.
 
62) Kuhnle H, Meerpohl HG, Eiermann W, et al: Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer. Cancer Chemother Pharmacol 26: S33-S 35, 1990.
 
63) Tobias J, Buxton EJ, Blackledge G, et al: Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer. Cancer Chemother Pharmacol 26: S59-S 62, 1990.
 
64) 平林光司: 子宮頸癌neoadjuvant chemotheray. 図説産婦人科VIEW腫瘍 薬物療法. メジカルビュー社, 東京, 1994, p 4209.
 
65) Rose PG, Blessing JA, Gershenson DM, et al: Paclitaxel and cisplatin as first-1ine therapy in recurrent or advanced squamous cell carcinoma of the cervix: AGynecologic Oncology Group study. J Clin Oncol17: 2676-2680, 1999.
 
66) Burnett AF, Roman LD, Garcia AA, et al: Aphase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 76: 63-66, 2000.
PubMed
67) Nuovo J, Melnikow J, Willan AR, et al: Treatment outcomes for squamous intraepithelial lesions. Int J Gynaecol Obstet 68: 25-33, 2000.
PubMed
68) Kolstad P and Klem V: Long-term follow up of 1121 cases of carcinoma in situ. Obstet Gynecol 48: 125-129, 1976.
 
69) Creasnman WT and Rutledge F: Carcinoma in situ of the cervix. Obstet Gynecol 39: 373-380, 1972.
 
70) Boyes DA, Worth AJ and Fidler HK: The results of treatment of 4389 cases of preclinical cervical squamous carcinoma. J Obstet Gynaecol Br Commonw 77: 769-780, 1970.
PubMed
71) Bjerre B, Eliasson G, Linell F, et al: Conization as only treatment of carcinoma in situ of the uterine cervix. Am J Obstet Gynecol 15(125) : 143-152, 1976.
 
72) Krival TC, Rose GS, McBroom JW, et al: Cervical adenocarcinoma in situ: asystematic review of therapeutic options and predictors of persistent or recurrent disease. Obstet Gynecol Surv 56: 567-575, 2001.
PubMed
73) Soutter WP, Haidopoulous D, Gornall RJ, et al: ls conservative treatment for adenocarcinoma in situ of the cervix safe? Br J Obstet Gynaecol 108: 1184-1189, 2001.
 
74) Grigsby PW and Perex CA: Radiotherapy alone for medically inoperable carcinoma of the cervix: Stage I A and carcinoma in situ. Int J Radiat Oncol Biol Phys 21: 375-378, 1991.
 
75) Oster AG: Pandora's box or Aradine's thread?Definition and prognostic significance of microinvasion in the uterine cervix. Pathol Annu 30: 103-136, 1995.
 
76) Sevin BU, Nadji M, Averette HE, et al: Microinvasive carcinoma of the cervix. Cancer 15(70) : 2121-2178, 1992.
 
77) Kolstad P: Follow-up study of 232 patients with stage I A and 411 stage I A 2 squamous cell carcinoma of the cervix(microinvasive carcinoma) . Gynecol Oncol 33: 265-272, 1989.
 
78) Burghardt E, Girardi F, Lahousen M, et al: Microinvasive carcinoma of the uterine cervix(lnternational Federation of Gynecology and Obstetrics stage I A) . Cancer 67: 1037-1045, 1991.
 
79) Greer BE, Figge DC, Tamimi HK, et al: Stage I A 2 squamous carcinoma of the cervix: Difficult diagnosis and therapeutic dilemma. Am J Obstet Gynecol 162: 1406-1411, 1990.
 
80) Perez CA: Carcinoma of the uterine cervix. In Principles and Practice of Radiation Oncology, (ed by Perez CA and Brady LW) , 2nd ed, JB Lippincott, Philadelphia, 1992, pp 919-965.
 
81) Landoni F, Maneo A, Cormio G, et al: Class II versus class III radical hysterectomy in stage I B-IIA cervical cancer: a prospective randomized study. Gynecol Oncol 80(1) : 3-12, 2001.
 
82) Landoni F, Maneo A, Colombo A, et al: Randomized study of radical surgery versus radiotherapy for stage I b-II a cervical cancer. Lancet 350(9077) : 535-540, 1997.
 
83) Perez CA, Kurman RJ, Stehman FB, et al: Uterine Cervix, Ch 271n: Principles and Practice of Clinical Gynecologic Oncology, (ed by Hoskins WJ, Perez CA and Young RC) , 2nd ed, JB Lippincott, Philadelphia, 1992, pp 591-662.
 
84) Chang TC, Lai CH, Hong JH, et al: Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage I B and IIA cervical cancer. J Clin Oncol18: 1740-1747, 2000.
 
85) Sardi JE, Goarppo A, Samames C, et al: Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage I b squamous carcinoma of the cervix. Gynecol Oncol 67: 61-69, 1997.
 
86) Sedlis A, Bundy BN, Rotman MZ, et al: Arandomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage I B carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group study. Gynecol Oncol 73: 177-183, 1999.
 
87) Green JA, Kirwan JM, Tierney JF, et al: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: asystematic review and meta-analysis. Lancet 358(9284) : 781-786, 2001.
 
88) Peters WA, Liu PY, Barrett RJ, et al: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18: 1606-1613, 2000.
PubMed
89) Mendenhall WM, McCarty PJ, Margan LS, et al: Stage I B or IIA-B carcinoma of the intact uterine cervix≧6cm in diameter: Is adjuvant extrafacial hysterectomy beneficial?Int J Radiat Oncol Biol Phys 21: 899-904, 1991.
 
90) Keys HM, Bundy BN, Stehman FB, et al: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage I B cervical carcinoma. N Engl J Med 340: 1154-1161, 1999.
 
91) Whitney CW, Sause W, Bundy BN, et al: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage II B-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17: 1339-1348, 1999.
 
92) Morris M, Eifel PJ, Lu J, et al: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340: 1137-1143, 1999.
PubMed
93) Rose PG, Bundy BN, Watkins EB, et al: Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340: 1144-1153, 1999.
 
94) 植木 實: 婦人科腫瘍委員会第36回治療年報. 日産婦会誌 53: 1136-1154, 2001.
 
95) Hacker NF, Fifel P, MacGuire W, et al: Vulva. In Principles and Practice or Gynecologic Oncology, (ed by Hoskins WJ, Perez CA and Young RC) , JB Lippincott, Philadelphia, 1992, pp 537-566.
 
96) 杉森 甫, 工藤隆一(婦人科腫瘍委員会) : 本邦における外陰癌の臨床統計調査報告. 日産婦会誌 47: 685-693, 1992.
 
97) Crum CP, Liskow A, Pertas P, et al: Vulvar intraepithelial neoplasia(severe atypia and carcinoma in situ) . Cancer 54: 1429-1434, 1984.
 
98) Kaufman RH, Friearich EG Jr and Gardner HL: Benign diseases of the vulva and vagina. 3rd ed, Year-Book Medical Publishers, Chicago, 1989.
 
99) Karram M, Tabor B, Smotkin D, et al: Detection of human papilloma virus deoxyribonucleic acid from vulvar dystrophies and vulvar intraepithelial neoplastic lesions. Am J Obstet Gynecol 159: 22, 1988.
PubMed
100) Synopsis of Gynecologic Oncology, (ed by Morrow Cp, Curtin JP and Townsend DE) , 4th ed, Churchill Livingstone, New York, 1993.
 
101) Homesley HD, Bundy BN, Sedlis A, et al: Assessment of current International Federation of Gynecology and Obstetricsstaging of vulvar carcinoma related to prognostic factors for survival. A Gynecologic Oncology Group study. Am J Obstet Gynecol 164: 997-1004, 1991.
 
102) DiSaia PJ and Creasman WT: Clinical Gynecologic Oncology. 4th ed, Mosby-Year Book, St Louis, 1993.
 
103) Sedlis A, Homesley H, Bundy BN, et al: Positive groin lymph nodes in superficial squamous cell vulvar cancer. Am J Obstet Gynecol 156: 1159-1164, 1987.
PubMed
104) Boyce J, Fruchter RG, Kasambilides E, et al: Prognostic factors in carcinoma of the vulva. Gynecol Oncol 20: 364-377, 1985.
 
105) Plentl AA and Friedman EA: Clinical significance of vulvar lymphatics. In Lymphatic System of the Female Genitalia. WBSaunders, Philadelphia, 1971, pp 28-29.
 
106) Stehman FB, Burdy BN, Dvoretsky PM, et al: Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group. Obstet Gynecol 79: 490-497, 1992.
 
107) FIGO News, Modifications in the staging of Stage I vulvar and Stage I cervical cancer. Report of the FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet 50: 215-216, 1995.
 
108) Homesley HD, Bundy BN, Sedlis A, et al: Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol 68: 733-740, 1986.
PubMed
109) Homesley HD, Bundy BN, Sedlis A, et al: Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva. Gynecol Oncol 49: 279-283, 1993.
PubMed
110) Figge DC, Tamimi HK and Greer BE: Lymphatic spread in carcinoma of the vulva. Am J Obstet Gynecol 152: 387-394, 1985.
PubMed
111) Cavanagh D, Fiorica JV, Hoffman MS, et al: Invasive carcinoma of the vulva. Am J Obstet Gynecol 163: 1007-1015, 1990.
PubMed
112) Rutledge FN, Mitchell MF, Munsell MF, et al: Prognostic indicators for invasive carcinoma of the vulva. Gynecol Oncol 42: 239-244, 1991.
PubMed
113) Baggish MS and Dorsey JH: CO21aser for the treatment of vulvar carcinoma in situ. Obstet Gynecol 57: 371-375. 1981.
PubMed
114) Ferenczy A, Wright TC and Richart RM Jr: Comparison of CO21aser surgery and loop electrosurgical excision/fulguration procedure(LEEP) for the treatment of vulvar intraepithelial neoplasia(VIN) . Int J Gynecol Cancer 4: 22-28, 1994.
 
115) Kaufman RH: Intraepithelial neoplasia of the valva. Gynecol Oncol 56: 8-21, 1995.
 
116) Hacker NF, Berek JS, Lagasse LD, et al: Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol 63: 155-162, 1984.
 
117) Disaia PJ, Creasman WT and Rich WM: An alternate approach to early cancer of the vulva. Am J Obstet Gynecol 133: 825-832, 1979.
PubMed
118) Burger MPH, Hollema H and Bouma J: The side of groin node metastases in unilateral vulvar carcinoma. lnt J Gynecol Cancer 6: 318-322, 1996.
 
119) Stehman FB, Bundy BN, Thomas G, et al: Groin dissection versus groin radiation in carcinoma of the vulva: AGynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 24(2) : 389-396, 1992.
 
120) Petereit DG, Mehta MP, Buchler DA, et al: Inguinofemoral radiation of NO, N l vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. Int J Radiat Oncol Biol Phys 27(4: 963-967, 1993.
 
121) Boronow RC: Combined therapy as an alternative to exenteration for locally advanced vulvo-vaginal cancer. Cancer 49: 1085-1091, 1982.
PubMed
122) Moore DH, Thomas GM, Montana GS, et al: Preoperative chemoradiation for advanced vulvar cancer: Aphase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 42(1) : 79-85, 1998.
 
123) 須川 佶, 橋本正淑, 鈴木雅州・他: 本邦における外陰癌の発症ならびに治療の現況. 日産婦会誌 32: 177-186, 1980.
 
124) Torpe C, Jonsson JE, Larsson G, et al: Bleomycin alone or combined with mitomycin C in treatment of advanced or recurrent squamous cell carcinoma of the vulva. Cancer Treat Rep 64: 639, 1980.
 
125) 清水敬生, 荷見勝彦, 八木裕昭・他: FIGO IV期の外陰癌に対するBOMP療法. 日産婦会誌 41: 609-612, 1989.
 
126) Deppe G, Bruckner H and Cohen C: Adriamycin treatment of advanced vulvar carcinoma. Obstet Gynecol 50: 138, 1977.
 
127) Thomas G, Dembo A, De Petrillo A, et al: Concurrent radiation and chemotherapy in vulvar carcinoma. Gynecol Oncol 34: 263-267, 1989.
 
128) Levin W, Goldberg G, Altaras M, et al: The use of concomitant chemotherapy and radiotherapy prior to surgery in advanced stage carcinoma of the vulva. Gynecol0ncol 25: 20-25, 1986.
PubMed
129) Berek JS, Heaps JM, Fu YS, et al: Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol Oncol 42: 197-201, 1991.
PubMed
130) Russell AH, Mesic JB, Scudder SA, et al: Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva. Gynecol0ncol 47: 14-20, 1992.
PubMed
131) Sebag-Montefiore DJ, McLean C, Arnott SJ, et al: Treatment of advanced carcinoma of the vulva with chemotherapy. can exenterative be avoided?Int J Gynecol Cancer 4: 150-155, 1994.
PubMed
132) Han SC, Kim DH, Higgins SA, et al: Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiat Oncol Biol Phys 47(5) : 1235-1244, 2000.
PubMed
133) Cunningham MJ, Goyer RP, Gibbons SK, et al: Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the 'vulva. Gynecol Oncol 66(2) : 258-261, 1997.
PubMed
P.819 掲載の参考文献
1) Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17, 1983.
PubMed
2) Deligdisch L and Cohen CJ: Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 56: 1452-1455, 1985.
PubMed
3) Koss LG, Schreiber K, Oberlander SG, et al: Detection of endometrial cancer and hyperplasia in a symptomatic women. Obstet Gynecol 6: 1-11, 1984.
 
4) Robboy SJ and Bradley R: Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. Obstet Gynecol 54: 269-277, 1979.
PubMed
5) Robboy SJ, Miller AW and Kurman RJ: The pathologic features and behavior of endometrial carcinoma associated with exogenous estrogen administration. Pathol Res Pract 174: 237-256, 1982.
PubMed
6) Smith M and McCartney AJ: Occult, high-risk endometrial cancer. Gynecol Oncol 22: 154-161, 1985.
PubMed
7) Morrow CP, Curtin Jp, et al: Synopsis of Gynecologic Oncology, (ed by Morrrow CP, Curtin Jp and Townsend DE) , 4th ed, Churchill Livingstone, New York, 1993.
 
8) Hartz A, Fisheer M, Cassell E, et al: Obesity and endometrial cancer. Intern Med 6: 61-65, 1985.
 
9) Speroff L, Glass RH and Kase NG: Clinical gynecologic endocrinology and infertility. 4th ed, Williams and Wilkins Co, Baltimore, 1989.
 
10) Brakat RR, Park RC, Grigsby PW, et al: Corpus: Epithelial Tumors. In: Principles and Practice of Gynecologic Oncology(ed by Hoskins WJ, Perez CA and Young RC) , JB LipPincott, Philadelphia, 1997, PP 85-896.
 
11) Gambrell Jr RD: Role of hormones in the etiology and prevention of endometrial and breast cancer. Acta Obstet GynecolScand 106: 37-46, 1982.
 
12) Gambrell RD, Bagnell CA and Greenblatt RB: Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review. Am J Obstet Gynecol 146: 696-707, 1983.
PubMed
13) MacMahon B: Risk factors for endometrial cancer. Gynecol Onoc12: 122-129, 1974.
PubMed
14) Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel. Project(NSABP) B-14. J Natl Cancer Inst 86: 527-537, 1994.
PubMed
15) Jordan JC and Assikis VJ: Endometrial carcinoma and Tamoxifen: Clearing up a controversy. Clin Cancer Res 1: 467-472, 1995.
 
16) Ovarian Malignancies. Diagnostic and Therapeutic Advances, (ed by Piver MD) , Churchill Livingstone, New York, 1987.
 
17) Hacker NF: Uterine Cancer. In Practical Gynecologic Oncology, (ed by Bereck JS and Hacker NF) , Williams&Wilkinson, Baltimore, 285-326, 1996.
 
18) 婦人科腫瘍委員会第32回治療年報. 日産婦会誌 46: 935-1001, 1994.
 
19) 婦人科腫瘍委員会第34回治療年報. 日産婦会誌 49: 273-306, 1997.
 
20) 婦人科腫瘍委員会報告. 日産婦会誌 47: 177-211, 1995.
 
21) 婦人科腫瘍委員会第36回治療年報. 日産婦会誌 53: 1136-1169, 2001.
 
22) 婦人科腫瘍委員会報告. 日産婦会誌 54: 697-793, 2002.
 
23) DuBeshter B, Angel C, Lin J, et al: Gynecologic Physicians and Students, (ed by Rubin P) , 7th ed,
 
24) Kurman RJ, Kaminski PF and Norris HJ: The behavior of endometrial hyperplasia hyperplasia in 170 patients. Cancer 56: 403-412, 1985.
PubMed
25) Gal D: Hormonal therapy for lesions of the endometrium. Semin Oncol 13: 33-36, 1986.
PubMed
26) Ferenczy A and Gelfand M: The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 160: 126-131, 1989.
PubMed
27) Hawwa ZM, Nahhas WA and Copenhauer EH: Postmenopausal bleeding. Lahey Clin Foundation Bull 19: 61, 1970.
 
28) Pacheco JC and Kempers RD: Etiology of postmenopausal bleeding. Obstet Gynecol 32: 40-46, 1968.
PubMed
29) Granberg S, Wikland M, Karlsson B, et al: Endometrial thickness as measured by endovaginal ultrasonography foridentifying endometrial abnormality. Am J Obstet Gynecol 164: 47-52, 1991.
 
30) Chun M, Ball HG, Doherty F, et al: Uterine thickness determination using real-time ultrasonography: Aguide forintracavitary brachytherapy in the treatment of endometrial carcinoma. Gynecol Oncol 36: 176-180, 1990.
 
31) Fleischer AC, Kalemeris GC, Machin JE, et al: Sonographic depiction of normal and abnormal endometrium withhistopathologic correlation. J Ultrasound Med 5: 445, 1986.
PubMed
32) Gordon AN, Fleischer AC, Dudley BS, et al: Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by sonography(US) and magnetic resonance imaging(MRI) . Gynecol Oncol 34: 175-179, 1989
PubMed
33) 松浦佑介, 柏村正道, 篠原道興・他: 子宮体癌筋層浸潤の評価におけるMRIの有用性について. 日産婦会誌 44: 787-792, 1992.
 
34) Chen SS, Rumancik WM and Spiegel G: Magnetic resonance imaging in stage I endometrial carcinoma. Obstet Gynecol75: 274-277, 1990.
 
35) Powell MC, Wowmack C, Buckley J, et al: Preoperative magnetic resonance imaging of stage I endometrial adenocarcinoma Br J Obstet Gynecol 93: 353-360, 1986.
 
36) Yazigi R, Cohen J, Munoz AK, et al: Magnetic resonance imaging determination of myometrial invasion in endometriaIcarcinoma. Gynecol Oncol 34: 94-97, 1989.
PubMed
37) Joja I, Asakawa M, Asakawa T, et al: Endometrial carcinoma: dynamic MRI with turbo-FLASH technique. J Comput Tomogr 20: 878-887, 1996.
 
38) Niloff JM, Klug TL, Schaetsl E, et al: Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148: 1057-1058, 1984.
 
39) Patsner B, Mann WJ, Cohen H, et al: Predictive value of preoperative serum CA 1251evels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol 158: 399-402, 1988.
PubMed
40) 日本産科婦人科学会, 日本病理学会, 日本医学放射線学会・編: 子宮体癌取扱い規約. 第2版, 金原出版, 東京, 1996.
 
41) Boronow RC, Morrow CP, Creaseman WT, et al: Surgical staging in endometrial cancer: Clinical-pathologic findings of aprospective study. Obstet Gynecol 63: 825-832, 1984.
 
42) Creaseman WT, Morrow CP, Bundy BN, et al: Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 60: 2035-2041, 1987.
 
43) FIGO: Classification and staging of malignant tumors in the female pelvis. Int J Gynaecol Obstet 9: 172, 1971.
 
44) 西谷雅史, 櫻木範明, 田中俊誠・他: 子宮体癌のFIGO新進行期分類(1989) についての検討-旧進行期分類(1983) との比較ならびに予後因子の解析. 日産婦会誌 43: 451-457, 1991.
 
45) FIGO: Annual Report on the Results of Treatment in Gynecological Cancer. Vol21. Int J Gynecol Obstet 36(Suppl) : 1, 1991.
 
46) Wilson TO, Podratz KC, Gaffey TA, et al: Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 162: 418-426, 1990.
PubMed
47) Chambers SK, Kapp DS, Peschel RF, et al: Prognostic factors and sites of failure in FIGO stage I, grade 3 endometrial carcinoma. Gynecol Oncol 27: 180-188, 1987.
 
48) Sutton GP: The significance of positive peritoneal cytology in endometrial cancer. Oncology 4: 21, 1990.
PubMed
49) Wharton JT, Mikura JJ, Mettlin C, et al: Risk factors and current management in carcinoma of the endometrium. Surg Gynecol Obstet 162: 515-520, 1986.
 
50) Bucy GS, Mendenhall WM, Morgan LS, et al: Clinical stage I and II endometrial carcinoma treated with surgery and or radiation therapy: Analysis of prognostic and treatment-related factors. Gynecol Oncol 33: 290-295, 1989.
PubMed
51) 竹島信宏, 梅沢 聡, 山脇孝晴・他: 子宮体癌筋層浸潤欠如症例に関する研究. 日産婦会誌 46(6) : 553-558, 1995.
 
52) Hanson MB, van Nagell JR Jr, Powell DE, et al: The prognostic significance of lymph-vascular space invasion in stage Iendometrial cancer. Cancer 55: 1753-1757, 1985.
 
53) Sivridis E, Buckley CH and Fox I{: The prognostic significance of lymphatic vascular space invasion in endometrial adenocarcinoma. Br J Obstet Gynecol 94: 991-994, 1987.
 
54) 西谷雅史, 櫻木範明, 田中俊誠・他: 子宮体癌の組織学的予後判定因子についての検討. 日産婦会誌 44: 453-460, 1992.
 
55) McLellan R, Dillon MB, Currie JL, et al: Peritoneal cytology in endometrial cancer: Areview. Obstet Gynecol Surv 44: 711-719, 1989.
 
56) Konski A, Poulter C, Keys H, et al: Absence of prognostic significance, peritoneal dissemination and treatment advantage in endometrial cancer patients with positive peritoneal cytology. Int J Radiat Oncol Biol Phys 14: 49-55, 1988.
PubMed
57) Lurain JR, Rumsey NK, Schink JC, et al: Prognostic significance of positive peritoneal cytology in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 74: 175-179, 1989.
 
58) Yazigi R, Piver MS and Blumenson L: Malignant peritoneal cytology as prognostic indicators in stage I endometrial cancer. Obstet Gynecol 62: 359-362, 1983.
 
59) Turner DA, Gershenson DM, Arkinson N, et al: The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet Gynecol 74: 775-780, 1989.
 
60) Christopherson WM, Connelly PJ and Alberhasky RC: Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and stage I disease. Cancer 51: 1705-1709, 1983
 
61) Nielsen AL, Thomsen HK and Nyholm HCJ: Evaluation of the reproducibility of the revised 19881nternational Federation of Gynecology and Obstetrics grading system of endometrial cancers with special emphasis on nuclear grading. Cancer 68: 2303-2309, 1991.
 
62) Ambros RA and Kurman RJ: Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol 45: 235-239, 1992.
 
63) Iversen OE: Flow cytometric deoxyribonucleic acid index: aprognostic factor in endometrial carcinoma. Am J Obstet Gynecol 155: 770-776, 1986.
 
64) Stendahl U, Wagenuiis G, Strang P, et al: Flow cytometry in invasive endometrial carcinoma. Correlations between DNA content S-phase rate and clinical parameters. In Vivo 2: 123-127, 1988.
 
65) 塚本直樹: 婦人科癌に対する腹部大動脈周囲リンパ節廓清の適応と手技. 研修コーナー. 日産婦会誌 46: N103-N106, 1995.
 
66) Burke TW, Levenback C, Tornos C, et al: Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: Results of a pilot study. Gynecol Oncol62: 169-173, 1996.
PubMed
67) Mariani A, Webb MJ, Keeney GL, et al: Routes of lymphatic spread: Astudy of 112 consecutive patients with endometrial cancer. Gynecol Oncol 81: 100-104, 2001.
 
68) Landoni F, Maneo A, Cormio G, et al: Class II versus class III radical hysterectomy in stage I B-IIA cervical cancer: a prospective randomized study. Gynecol Oncol 80: 3-12, 2001.
 
69) Jones DA and Stout R: Results of intracavitary radium treatment for adenocarcinoma of the body of the uterus. Clin Radiol 37: 169-171, 1986.
PubMed
70) Greven K and Olds W: Radiotherapy in the management of endometrial carcinoma with cervical involvement. Cancer 60: 1737-1740, 1987.
PubMed
71) Larsen DM, Copeland LJ, Gallager HS, et al: The significance of residual tumor after preoperative pelvic irradiation for stage II endometrial carcinoma. Obstet Gynecol 70: 916-919, 1987.
 
72) Viaria M, Rosenman J, Halle J, et al: Primary radiation therapy for medically inoperable patients with endometrial carcinoma, stages I-II. Int J Radiat Oncol Biol Phys 13: 11-15, 1987.
 
73) Sears JD, Greven KM, Kathryn M, et al: Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer 74: 1303-1308, 1994.
 
74) Morgan JD III, Reddy S, Sarin P, et al: Isolated vaginal recurrences of endometrial carcinoma. Radiology 189: 609-613, 1993.
 
75) Kucera H, Vavra N and Weghaupt K: Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received post operative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol 38: 99-104, 1993.
 
76) Marchetti DL, Piver MS, TsukadaY, et al: Prevention of vaginal recurrence of stage I endometrial adenocarcinoma with postoperative vaginal radiation. Obstet Gynecol 67: 399-402, 1986.
 
77) Morrow CP, Bundy BN, Kurman RJ, et al: Relationship between surgical-pathologic risk factors and out come in clinical stage I and II carcinoma of the endometrium: aGynecologic Oncology Group study. Gynecol Oncol 40: 55-65, 1991.
 
78) Potish RA, Twiggs LB, Adock LL, et al: Role of whole abdominal radiation therapy in the management of endometrial cancer; prognostic importance of factors indicating peritoneal metastases. Gynecol Oncol 21: 80-86, 1985.
 
79) Kauppila A: Oestrogen therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations[Review]. Acta Obstet Gynecol Scand 63: 441, 1984.
PubMed
80) Ayoub J, Audet-Lapointe P, Maschio A, et al: Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol Oncol 31: 327-337, 1988.
 
81) Creasman WT, Soper JT, McCarty KS Jr, et al: Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 151: 922-932, 1985.
PubMed
82) Lewis GC, Slack NH, Mortel R, et al: Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol 2: 368-376, 1974.
PubMed
83) MacDonald RR, Thorogood J and Mason MK: Arandomized trial of progestogens in the primary treatment of endometrial carcinoma. Br J Obstet Gynecol 95: 166-174, 1988
 
84) Vergote I, Kjorstad K, Abeler V, et al: Arandomized trial of adjuvant progestogen in early endometrial cancer. Cancer 64: 1011-1016, 1989.
 
85) Lentz SS, Brady MF, Major FJ, et al: High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J CIin Oncol 14: 357-361, 1996.
PubMed
86) Swenerton KD: Treatment of advancer endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep 64: 805-811, 1981.
 
87) Moore TD, Phillips PH, Nerestone SR, et al: Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J CIin Oncol 9: 1071-1088, 1991.
 
88) Thigpen T, Brady MF, Homesley HD, et al: Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 19: 364-367, 2001.
PubMed
89) Pinelli DM, Fiorica JV, Roberts WS, et al: Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: Aphase II study. Gynecol Oncol 60: 462-467, 1996.
 
90) Fiorica J, Brunetto V, Hanjani P, et al: Aphase II study(GOG 153) of recurrent and advanced endometrial carcinoma treated with alternating courses of megestrol acetate and tamoxifen citrate. Proc ASCO: abstr#1499, 2000.
 
91) Thigpen JT, Buchsbaum HJ, Mangan C, et al: Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: AGynecologic Oncology Group study. Cancer Treat Rep 63: 21-27, 1979.
PubMed
92) ThigPen JT, Blessing JA, Lagasse LD, et al: Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am J CIin Oncol 7: 253-256, 1984.
PubMed
93) Thigpen JT, Blessing JA, Homesley HD, et al: Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Gynecol Oncol 33: 68-70, 1989.
 
94) Thigpen JT, Blessing JA, Homesley HD, et al: Phase III trial of doxorubicin+/-cisplatin in advanced or recurrent endometrial carcinoma: AGynecologic Oncology Group study. Proc ASCO 12: 261(abstr#830) , 1993.
 
95) ThigPen JT, Blessing JA, DiSaia PJ, et al: Arandomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: AGynecologic Oncology Group study. J CIin Oncol 12: 1408-1414, 1994.
 
96) Ball H, Blessing JA, Lentz S, et al: APhase II trial of Taxol in advanced and recurrent adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Proceedings of the Society of Gynecologic Ontologists Annual Meeting. abstr#69, 1995, p 102.
 
97) Fleming GF, Brunetto VL, Bentley R, et al: Randomized trial of doxorubicin(Dox) plus cisplatin(Cis) versus Dox plus paclitaxel(Tax) plus granulocyte colony-stimulating factor(G-CSF) in patients with advanced or recurrent endometrial cancer: aReport on Gynecologic Oncology Group(GOG) Protocol. Proc ASCO: abstr#1498, 2000.
 
98) Creasman WT, Henderson D, Hinshq W, et al: Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 46: 326-330, 1986.
 
P.838 掲載の参考文献
1) Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J CIin 50: 7-33, 2000.
 
2) 厚生統計協会: 国民衛生の動向2001. 厚生統計協会, 東京, pp 394-395.
 
3) Fiorca JV and Roberts WS: Screening for ovarian cancer. Cancer Control 3: 120-129, 1996.
 
4) Piver MS, Baker TR, Jishi MF, et al: Familial ovarian cancer: Areport of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 71(Supp12) : 582-588, 1993.
 
5) Bewtra C, Watson P, Conway T, et al: Hereditary ovarian cancer: Aclinicopathological study. Int J Gynecol Pathol 11: 180-187, 1992.
 
6) Lynch HT, Watson P and Lynch JF: Hereditary ovarian cancer: Heterogeneity in age at onset. Cancer 71: 573-581, 1993.
PubMed
7) Young RC, Perez CA and Hoskins WJ: Cancer of the ovary. In Cancer, (ed by Devita VT Jr, Hellman S and Rosenberg SA) , Principle&Practice of Oncology, 4th ed, JP Lippincott Co, Philadelphia, 1993, pp 1226-1263.
 
8) The WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol 18: 538-545, 1989.
PubMed
9) Rossing MA, Daling JR, Weiss NS, et al: Ovarian tumors in a cohort of infertile women. N Engl J Med 331: 765-771, 1994.
 
10) Gertig DM, Hunter DJ, Cramer DW, et al: Prospective study of talc use and ovarian cancer. J Natl Cancer Inst 92: 249-252, 2000.
PubMed
11) Rodriguez C, Patel AV and Calle EE: Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285: 1460-1465, 2001.
 
12) Palmer JR, Rao RS, Adams-Campbell LL, et al: Height and breast cancer risk: results from the Black Women's Health Study. Cancer Causes Control 12: 343-348, 2001.
 
13) Mori M, Nishida T, Sugiyama T, et al: Anthropometric and other risk factors for ovarian cancer in a case-control study. Jpn J Cancer Res 89: 246-253, 1998.
 
14) NIH Consensus Development Conference Panel. Ovarian Cancer: Screening, Treatment, and Follow-up. Washington DC, National Institute of Health, April 5-7, 1994, NIH Consensus Statement 12.
 
15) McFarlane C, Sturgis MD and Fetterman FC: Results of an experience in the control of cancer of the female pelvic organs: Areport of a 15-year research. Am J Obstet Gynecol 69: 294-301, 1956.
 
16) DePriest PD, van Nagel Jr, Gallion HH, et al: Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol Oncol 51: 205-209, 1993.
 
17) 佐藤重美, 須郷孝信, 丸山英俊・他: 経膣超音波断層法による卵巣癌の集団検診-二次検診におけるCAMPASの有用性に関する検討-. 日産婦誌 46: 1247-1253, 1994.
 
18) 小林 浩: 卵巣癌のスクリーニング. 産科と婦人科 66: 27-33, 1999.
Medical*Online
19) Marchbanks PA, McDonald JA, Wilson HG, et al: Oral contraceptive and the risk of breast cancer. N Engl J Med 346: 2025-2032, 2002.
PubMed
20) Narod SA, Sun P, Ghadirian P, et al: Tubal ligation and risk of ovarian cancer in carriers of BRCA l or BRCA 2 mutations: acase-control study. Lancet 357: 1467-1470, 2001.
 
21) Piver MS, Jishi MF, Tsukada Y, et al: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71: 2751-2755, 1993.
PubMed
22) Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA l or BRCA 2 mutation. N Engl J Med 346: 1609-1615, 2002.
PubMed
23) Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA l or BRCA 2 mutations. NEnglJMed 346: 1616-1622, 2002.
 
24) Sugiyama T, Kamura T, Kigawa J, et al: Clinical characteristics of clear cell carcinoma of the ovary. Cancer 88: 2584一2589, 2000.
 
25) Olson SH, Mignone L, Nakraseive C, et al: Symptoms of ovarian cancer. Obstet Gynecol 98: 212-217, 2001.
PubMed
26) Weiner Z, Thaler I, Beck D, et al: Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 79: 159-162, 1992.
PubMed
27) Pecorelli S, Odicino F, Maisonneuve P, et al: Annual Report on the Results of Treatment in Gynaecologic Cancer, vol 23. Milan, International Federation of Gynecology and Obstetrics. J Epidemiol Biostat 3: 75-102, 1998.
 
28) Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42: 101-104, 1975.
PubMed
29) Hoskins WJ, Bundy BN, Thigpen JT, et al: The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer: AGynecologic Oncology Group study. Gynecol Oncol 47: 159-166, 1992.
 
30) Hacker NF, Berek JS, Lagasse LD, et al: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol61: 413-420, 1983.
PubMed
31) Berek JS, Fu YS and Hacker NF: Ovarian Cancer. In Novak's Gynecology, (ed by Berek JS, Adashi EY and Hillard PA) , 12th ed, Williams&Wilkins, Baltimore, 1996, pp 1155-1230.
 
32) Friedlander ML, Hedley DW, Taylor IW, et al: Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res 44: 397-400, 1984.
PubMed
33) Levesque MA, Katsaros D, Yu H, et al: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75: 1327-1338, 1995.
PubMed
34) Young RC, Decker DG, Wharton JT, et al: Staging laparotomy in early ovarian cancer. JAMA 250: 3072-3076, 1983.
PubMed
35) Brown CL, Dharmendra B and Barakat RR: Preserving fertility in patients with epithelial ovarian cancer(EOC) : The role of conservative surgery in treatment of early stage disease. Gynecol Oncol 76: 240(abstr) , 2000.
 
36) Hoskins WJ: Epithelial ovarian carcinoma: Principle of primary surgery. Gynecol Oncol 55: S91-S 96, 1994.
 
37) Hoskins WJ, McGire WP, Brady MF, et al: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170: 974-979, 1994.
 
38) Piver MS, Lele SB, Marchetti DL, et al: The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J CIin Oncol 6: 983-989, 1988.
 
39) Eisenkop SM, Nalick RH and Teng NN: Modified posterior exenteration for ovarian cancer. Obstet Gynecol 78: 879-885, 1991.
PubMed
40) Burghardt E, Pickel H, Lahousen M, et al: Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Gynecol 155: 315-319, 1986.
 
41) Spirtos NM, Gross GM, Freddo JL, et al: Cytoreductive surgery in advanced epithelial cancer of the ovary: The impact of aortic and pelvic lymphadenectomy. Gynecol0ncol 56: 345-352, 1995.
PubMed
42) Potter ME, Partridge EE, Hatch KD, et al: Primary surgical therapy of ovarian cancer: how much and when. GynecoI Oncol 40: 195-200, 1991.
PubMed
43) Neijt JP, Ten Bokkel Huinink WW, Van der Burg MEL, et al: Long term survival in ovarian cancer: mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 27: 1367-1372, 1991.
 
44) Van der Burg MEL, Van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629-634, 1995.
 
45) Rose PG, Nerenstone S, Brady M, et al: Aphase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: aGynecologic Oncology Group study. Proc ASCO 21: 201a, 2002.
 
46) Nelson BE, Rosenfeld AT, Schwartz PE, et al: Preoperative abdominopelvic computed tomography prediction of optimaI cytoreduction in epithelial ovarian carcinoma. J CIin Oncol 11: 166, 1993.
 
47) 杉山 徹: Second look operation(SLO) の意義と問題点. 日産婦誌 50: N. 206-N. 209, 1998.
 
48) Gershenson DM: Advances in the management of early-stage epithelial ovarian cancer. Educational Book(American Society of Clinical Oncology) , PP 462-467, 2001.
 
49) Young RC, Brady MF, Nieberg RM, et al: Randomized clinical trial of adjuvant treatment of women with early(FIGO III A high risk) ovarian cancer. Proc ASCO 18: 357 a, 1999.
 
50) Vergote IB, Trimbos BJ, Guthrie D, et al: Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery. Proc ASCO 20: 201 a, 2001.
 
51) Kolomainen DF, A'Hern R and Gore M: Can patients with relapsed previously untreated stage I epithelial ovarian cancer(EOC) be salvaged?Proc ASCO 20: 201 a, 2001.
 
52) Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: Ameta-analysis. J CIin Oncol 9: 1668-1674, 1991.
 
53) Einzing AI, Wiernic PH, Sasloff J, et al: Phase II study and long term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J CIin Oncol 10: 1748-1753, 1992.
 
54) Trimble EL, Adams JD, Vena D, et al: Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1, 000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11: 2405-2410, 1993.
PubMed
55) ThigPen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy. A Gynecologic Oncology Group Study. J CIin Oncol 12: 1748-1753, 1994.
 
56) Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666, 1994.
PubMed
57) McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996,
PubMed
58) Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophos- phamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92: 699-708, 2000.
 
59) Sugiyama T, Yakushiji M, Aoki Y, et al: Paclitaxel-cisplatin combination in advanced ovarian cancer: aphase II study. Int J CIin Oncol 5: 85-88, 2000.
 
60) Ozols RF, Bundy BN, Fowler J, et al: Randomized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer: Gynecologic Oncology Group trial. Proc ASCO 18: 1373 a, 1999.
 
61) du Bois A, Lueck HJ, Meier W, et al: Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekolgische Onkologie study group trial. Proc ASCO 18: 1374 a, 1999.
 
62) 安田 允, 木村英三, 落合和徳・他: 卵巣癌に対するパクリタキセル(TAX) とカルボプラチン(CBDCA) の併用化学療法のpilot Study. 日癌治療会誌 33: 2471998.
 
63) 葛谷和夫, 石川尚武, 中西 透・他: 卵巣癌に対するCarboplatin+Paclitaxel併用化学療法の至適投与量の検討-Modified CRMによるPhase I Study. 日癌治療会誌 33: 247, 1998.
 
64) 波多江正紀, 大西義孝, 中村俊昭・他: 卵巣癌に対するパクリタキセル(TAX) とカルボプラチン(CBDCA) のPhase I Study. 日癌治療会誌 33: 248, 1998.
 
65) Kaye SB, Piccart M, Aapro M, et al: Phase II trials of docetaxel(Taxotere) in advanced ovarian cancer-an updated overview. Eur J Cancer 33: 2167-2170, 1997.
PubMed
66) Verschraegen CF, Sittisomwong T, Kudelka AP, et al: Docetaxel for patients with paclitaxel-resistant Mullerian car- cinoma. J CIin Oncol 18: 2733-2739, 2000.
 
67) Katsumata N, Tsunematsu R, Tanaka K, et al: Aphase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: AJapanese Cooperative Study. Ann Oncol 11: 1531-1536, 2000.
 
68) Vasey PA: Survival and long-term toxicity results of the SCOTROC study: docetaxel-carboplatin(DC) vs. paclitaxel- carboplatin(PC) in epithelial ovarian cancer(EOC) . Proc ASCO 21: 202 a, 2002.
 
69) Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: AGynecologic Oncology Group study. J CIin Oncol 18: 106-115, 2000.
PubMed
70) The International Collaborative Ovarian Neoplasm(ICON) Group: Paclitaxel plus carboplatin versus standard chemother- apy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON 3 randomised trial. Lancet 360: 505-515, 2002.
 
71) du BOis A, Weber B, Pfisterer J, et al: Epirubicin/paclitaxe1/carboplatin(TEC) vs. paclitaxel/carboplatin(TC) in first-line treatment of ovarian cancer FIGO stages IIb-IV. Interim results of an AGO-GINECO Intergroup Phase III Trial. Proc ASCO 20: 202 a, 2001.
 
72) Kristensen G, Vergote I, Stuart G, et al: First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/ epirubicin/carboplatin(TEC) vs. paclitaxel/carboplatin(TC) . Interim results of an NSGO-EORTC-NCIC CTG Gyne- cological Cancer Intergroup phase III trial. Proc ASCO 21: 202 a, 2002.
 
73) Blackledge G, Lawton F, Redman C, et al: Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patients treatment and the design of phase II trilas. Br J Cancer 59: 650-653, 1989.
 
74) Gore ME, Fryatt I, Wiltshaw E, et al: Treatment of relapsed carcinoma of the ovary: With cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36: 207-211, 1990.
PubMed
75) Markman M, Reichman B, Hakes T, et al: Response to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 9: 1801-1805, 1991.
PubMed
76) Thigpen T: Second-line therapy for ovarian carcinoma: General concepts. 1999 Educational Book(American Society of Clinical Oncology) , 1999, PP 564-566.
 
77) Markman M, Baker ME, Hall JB, et al: Phase 2 trial of weekly single agent paclitaxel(P) in platinum(PLAT) and Paclitaxel-refractory ovarian cancer(OC) . Proc ASCO 19: 396 a, 2000.
 
78) Andersson H, Boman K, Ridderheim M, et al: An updared analysis of a randomized study of single agent paclitaxel(P) given weekly vs every 3 weeks to patients(Pts) with ovarian cancer(OC) treated with prior platinum therapy. Proc ASCO 19: 380a, 2000.
 
79) Markman M, Iseminger KA, Hatch KD, et al: Tamoxifen in platinum-refractory ovarian cancer: AGynecologic Oncology Group ancillary report. Gynecol0ncol 62: 4-6, 1996.
 
80) Kavanagh JJ, Tresukosol D, Edwards C, et al: Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J CIin Oncol 13: 1584-1588, 1995.
 
81) Gordon AN, Fleagle JT, Guthrie D, et al: Interim analysis of a phase III randomized trial of doxil/caelyx(D) versus topotecan(T) in the treatment of patients with relapsed ovarian cancer. Proc ASCO 19: 380 a, 2000.
 
82) ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J CIin Oncol 15: 2183-2193, 1997.
 
83) 竹内正七, 土橋一慶, 藤本征一郎・他: 子宮頸癌および卵巣癌に対するCPT-11の後期第II相臨床試験. 癌と化学療法 18(10) : 1681-1689, 1991.
Medical*Online
84) Sugiyama T, Yakushiji M, Nishida T, et al: Irinotecan(CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 128: 211-218, 1998.
PubMed
85) Kigawa J, Takahashi M, Minagawa Y, et al: Topoisomerase-Iactivity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer. Int J Cancer 84: 521-524, 1999.
 
86) Katsumata N, Tsunemastu R, Hida K, et al: Phase I trial of irinotecan and carboplatin(CBDCA) in advanced ovarian cancer. Proc ASCO 18: 364 a, 1999.
 
87) Shimizu Y, Umezawa S, Utsugi K, et al: Combination of CPT-11 with mitomycin-C(MMC) for platinum-refractory clear cell(CCA) and mucinous(MCA) adenocarcinoma of the ovary. Proc ASCO 18: 361 a, 1999.
 
88) Itamochi H, Kigawa J, Sugiyama T, et al: Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100: 281-287, 2001.
 
89) Kottmeier HL: Presentation of therapeutic results in carcinoma of the female pelvis. Experience of the annual report on the results of treatment in carcinoma of the uterus, vagina and ovary. Gynecol Oncol 4: 13-19, 1976.
PubMed
90) Smith JP and Rutledge FN: Advances in chemotherapy for gynecologic cancer. Cancer 36: 669-674, 1975.
 
91) Einhorn LH and Donohue J: Cis-diamminedichloroplatinum, vinblastine, and bleomycin in disseminated testicular cancer. Ann Intern Med 87: 293-298, 1977.
PubMed
92) Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1436-1440, 1987.
 
93) de Wit R, Stoter G, Kaye SB, et al: Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: Arandomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J CIin Oncol 15: 1837-1843, 1997.
 
94) Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: Amultiinstitutional study. J CIin Oncol 11: 598-606, 1993.
 
95) Gershenson DM: Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol 6: 270-275, 1988.
PubMed
96) 東 政弘, 金澤浩二: 胚細胞性腫瘍治療後の妊孕性. Oncol Chemother 15: 251-256, 1999.
 
97) Lotz JP, Andre T, Donsimoni R, et al: High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 75: 874-885, 1995.
PubMed
98) Margolin BK, Doroshow JH, Ahn C, et al: Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 14: 2631-2637, 1996.
 
99) Mandanas RA, Saez RA, Epstein RB, et al: Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant 21: 569-576, 1998.
 
100) 半藤 保: 絨毛性疾患の疫学. 37. 絨毛性疾患, 新女性医学大系, (武谷雄二. 編) , 中山書店, 東京, 2000, pp 25-43.
 
101) Suzuki T, Goto S, Nawa A, et al: Identification of the pregnancy responsible for gestational trophoblastic disease by DNA analysis. Obstet Gynecol 82: 629, 1993.
PubMed
102) Fisher RA and Newlands ES: Molecular and genetic studies of gestational trophoblastic disease. J Reprod Med 43: 53, 1998.
PubMed
103) Fulop V, Mok SC, Genest DR, et al: p53, p21, RB and mdm 20ncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 43: 119, 1998.
 
104) Cheung AN, Zhang DK, Liu Y, et al: Telomerase activity in gestational trophoblastic disease. J CIin Pathol 52: 588-592, 1999.
 
105) Rotmensch S and Cole LA: False diagnosis and needless therapy of presumed malignant disease in women with falsepositive human chorionic gonadotropin concentrations. Lancet 355: 712-715, 2000.
 
106) Okamoto T, Nomura S, Nakanishi T, et al: Choriocarcinoma diagnostic score: Ascoring system to differentiate choriocarcinoma from invasive mole. Int J Gynecol Cancer 8: 128-132, 1998.
 
107) 後藤節子: 婦人科癌化学療法共同研究会: 絨毛性疾患委員会第2次研究の予後調査結果. Oncol Chemother 15(2) : 131-134, 1999.
 
108) Tham KF and Ratnum SS: The classification of gestational trophoblastic disease: scritical review. Int J Gynecol Obstet 60(1) : 39-49, 1998.
 
109) Hammond CB, Borchert LG, Tyrey L, et al: Treatment of metastatic trophoblastic disease: Good and poor prognosis. Am JObstet Gynecol 115: 451-457, 1973.
PubMed
110) Bolis G, Belloni C and Bonazzi C: EMA/CO regimen in high-risk gestational trophoblastic tumor. Obstet Gynecol Surv 44: 394-395, 1989.
 
111) Newlands ES, Mulholland PJ, Holden L, et al: Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D(EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 18: 854-859, 2000.
PubMed
P.855 掲載の参考文献
1) Silvermberg E and Lubera J: Cancer statistics 1987. CA 37: 2, 1987.
 
2) Malaer MM, Link MP and Donaldson SS: Sarcomas of bone in cancer: Principles and practice of oncology(ed by De Vita VT Jr, Hellman S and Rosenberg SA) . 5th ed, JB Lippincott, Philadelphia, 1997, pp 1789-1852.
 
3) 日本整形外科学会 骨・軟部腫瘍委員会・編: 全国骨腫瘍患者登録一覧表(平成7年度) . 国立がんセンター, 東京, 1996, pp 23-45.
 
4) Wingo PA, Tong T and Bolden S: Cancer statics 1995. CA 45: 12, 1995.
 
5) Brennan MF, Casper ES and Harrison LB: Soft tissue sarcoma. In Cancer: Principles and practice of oncology, (ed by De Vita VT Jr, Hellman S, Rosenberg SA) , 5th ed, JB Lippincott, Philadelphia, 1997, pp 1738-1788.
 
6) Cordon-Cardo C: CHAPTER 38. Sarcoma of the soft tissues and bone. Moleculara biology of sarcomas. Principles and practice of oncology, (ed by De Vita VT Jr, Hellman S and Rosenberg SA) , 5th ed, JB Lippincott, Philadelphia, 1997, pp 1731-1738.
 
7) 戸口田淳也: 遺伝子解析. 骨腫瘍の診断と治療, (平澤泰介・編) , OS Now 18, メジカルビュー社, 東京, 1995, pp 114-120.
 
8) Mertzer PS: Molecular genetics of soft tissue tumor. Soft tissue tumors, (ed by Enzinger&Weiss) , 4th ed, Mosby, St Louis, 2001, pp 103-123.
 
9) Kawaguchi N: Surgical treatment combined preoperative chemotherapy for musculoskeletal sarcoma. In Cancer chemotherapy challenges for the future, (et by Kimura K, Ota K, Yamada K and Ogawa M) , 10, Excerpta Medica, Tokyo, 1995, pp 248-256.
 
10) Enneking WF, et al: Asystem for the surgical staging of musculoskeletal sarcoma. Clin Orthop 153: 106-120, 1980.
 
11) Broders A: The microscopic grading of cancer. In Treatment of cancer and apllied diseases, (ed by Pack GT, et al) , Paul B, Hoeber, London, 1940, pp 19-41.
 
12) Enneking WF: Asystem for the functional evaluation of the surgical management of musculoskeletal tumors. In Limb salvage in musculoskeletal oncology, (ed by Enneking WF) , Churchill Livingstore New York, 1987, pp 5-16.
 
13) 柴田大法: 外科的治療. Surgical stagingとsurgical margin. 骨腫瘍の診断と治療, (平澤泰介・編) , OS Now 18, メジカル ビュー社, 東京, 1995, pp 158-163.
 
14) Coindre JM, Terrieer P, Bui NB, et al: Prognostic factors in adults patients with locally controlled soft tissue sarcoma: A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J CIin Oncol 14: 877-899, 1996.
 
15) Brennen MF: Staging of soft tissue sarcomas. Ann Surg Oncol 6: 8, 1999.
 
16) Bieling P, Rehan N, Winkler P, et al: Tumor size and prognosis in aggressively treated osteosarcoma. J CIin Oncol14: 848-858, 1996.
 
17) Rosen G, Caparros B, Huvos AG, et al: Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221-1230, 1982.
PubMed
18) Huvos AG: Bone tumors; Diagnosis, treatment and prognosis. 2nd ed. Philadelphia, London, Toronto, WB Saunders Co, 1991, pp 117-155.
 
19) Gehan EA, Nesbit ME, Burgert OE, et al: Prognostic factors in children with Ewing's sarcoma. Natl Cancer Inst Monogr 56: 273-278, 1981.
 
20) Pomeroy TC and Johnson RE: Prognostic factors for survival in Ewing's sarcoma. Am J Roentgenol Radium Ther Nucl Med 123: 598-606, 1975.
 
21) Glaubiger D, Makuch R, Wackenhut J, et al: Early results of current combined modarity therapy trials in Ewing's sarcoma at the NCI. Adjuvant chemotherapy of Cancer II, (ed by Jones Samon SE) , Grune and Stratton, New York, 1979, pp 409-412.
 
22) Wilkins R, Douglas MS, Pritchard J, et al: Ewing's sarcoma of bone: Experience with 140 patients. Cancer 58: 2551-2555, 1986.
 
23) Mendenhall CM, Marcus RB, Enneking WF, et al: The prognostic significance of soft tissue extension in Ewing's sarcoma. Cancer 51: 913-917, 1983.
 
24) Jurgen H, Exner U, Grander H, et al: Multidisciplinary treatment of primary Ewing's sarcoma of bone. Cancer 61: 23-32, 1988.
 
25) Nascimento AG: Clinicopathologic study of 20 cases of large-cell(atypical) Ewing's sarcoma of bone. Am J Surg PathoI14: 29-36, 1980.
 
26) Picci P, Rougraff BT, Bacci G, et al: Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J CIin Oncol 11: 1763-1769, 1993.
 
27) Verrill MW, Judson JR, Harmer CL, et al: Ewing's sarcoma and primitive neuroectodermal tumor in adults: Are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children?JClin Oncol 15: 2611-2621, 1997.
 
28) Ahrens S, Hoffmann C, Jabar S, et al: Evaluation of prognostic factors in a tumor volume adapted treatment strategy for localized Ewing's sarcoma of bone. The CESS experience. Med Pediatr Oncol 32: 186-195, 1999.
 
29) 日本整形外科学会骨, 軟部腫瘍委員会編: 骨, 軟部肉腫切除縁評価法. 金原出版, 東京, 1989, pp 31-36.
 
30) 日本整形外科学会骨, 軟部腫瘍委員会編: 整形外科. 病理悪性軟部腫瘍取扱い規約. 第2版, 金原出版, 東京, 1989, pp 59-67.
 
31) 岩本幸英: 上腕骨の再建. 広範骨欠損の再建手術, (安部宗昭・編) , 新OS NOW 5, メジカルビュー社, 東京, 2000, pp 60-65.
 
32) 和田卓郎, 薄井正道, 石井清一: 上腕骨近位部悪性骨腫瘍の患肢温存術: 遊離血管柄付き腓骨移植を用いたsling procedure. 広範骨欠損の再建手術, (安部宗昭・編) , 新OS NOW 5, メジカルビュー社, 東京, 2000, pp 60-65.
 
33) 土屋弘行, 櫻吉啓介, 富田勝郎: 膝関節の再建法: bone transport. 広範骨欠損の再建手術, (安部宗昭・編) , 新OS NOW 5, メジカルビュー社, 東京, 2000, pp 114-121.
 
34) 山崎 隆, 内田淳正: 制御型腫瘍用人工股関節による骨盤・股関節の再建法. 広範骨欠損の再建手術, (安部宗昭・編) , 新OS NOW 5, メジカルビュー社, 東京, 2000, pp 82-91.
 
35) 楠崎克之, 村田博昭: 骨盤・股関節の再建法: 創外固定術と骨延長術を併用した切除股関節形成術. 広範骨欠損の再建手術, (安部宗昭・編) , 新OS NOW 5, メジカルビュー社, 東京, 2000, pp 82-99.
 
36) 富田勝郎, 砂山千明: 骨肉腫の患肢温存療法. 骨腫瘍の診断と治療, (平澤泰介・編) , OS Now 18, メジカルビュー社, 東京, 1995, pp 36-41.
 
37) Kotz R and Salzer M: Rotation-Plasty for childhood osteosarcoma of the distal part of the femur. J Bone Joint Sug 64-A: 959-969, 1982.
 
38) 井上 治: 外科治療. Rotaion-Plasty(患四肢温存的回転形成術) の適応と方法. 骨腫瘍の診断と治療, (平澤泰介・編) , OS Now 18, メジカルビュー社, 東京, 1995, pp 203-209.
 
39) 米本 司, 館崎愼一郎: 膝関節周囲に発生した悪性骨腫瘍に対するknee rotaion-plasty. 広範骨欠損の再建手術, (安部宗昭・編) , 新OS NOW 5, メジカルビュー社, 東京, 2000, pp 122-126.
 
40) 鐙 邦芳: 骨盤輪の再建法. 広範骨欠損の再建手術, (安部宗昭・編) , 新OS NOW 5, メジカルビュー社, 東京, 2000, pp 100-107.
 
41) Brennan MF, Hikaris B, Shiu MH, et al: Local recurrence in adult soft-tissue sarcoma. A randomized trial of brachytherapy. Arch Surg 122: 1289-1293, 1987.
 
42) Pisters PWT, Harrison LB, Woodruff JM, et al: Aprospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk. J CIin Oncol 12: 1150-1155, 1994.
 
43) Tsuchiya H and Tomita K: Prognosis of osteosarcoma treated by limb-salvage surgery: the ten-year intergroup study in Japan. Jpn J CIin Oncol 22(5) : 347-353, 1992.
 
44) Enneking WF, Dunham W, Gebhardt M, et al: Asystem for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop 286: 241-246, 1993.
 
45) Bacci G, Picci P, Ferrari S, et al: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Cancer 72: 3227-3238, 1993.
PubMed
46) Bacci G, Ruggieri P, Picci P, et al: Intra-arterial versus intervenous cisplatinum(in addition to systemic adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the etremities: Results of randomized study. J Chemother 8: 70-81, 1996.
 
47) Jaffe N, Raymond AK, Carrasco H, et al: Effect of escalating courses of intraarterial cis-diamminedichloroplatinum-II(CDDP) on the primary tumor in pediatric osteosarcoma(OS) . Proc ASCO 6: 217-220, 1987.
 
48) Jaffe N, Smith D, Jaffe R, et al: Intraarterial cisplatin in the management of stage II B osteosarcoma in the pediatric and adolescent age group. Clin OrthoP 270: 15-21, 1991.
 
49) Benjamen RS, Chawla SP, Carrasco Ch, et al: Primary chemotherapy of patients with osteosarcoma of an extremity. Proc ASCO 5: 139, 1986.
 
50) Benjamen RS, Chawla SP, Carrasco C, et al: Arterial infusion in the treatment of osteosarcoma. In Recent Concepts in Sarcoma Treatment, (ed by Ryan JR, Baker LO) , Kluwer Academic Publishers, Dordrecht, 1988, pp 269-274.
 
51) Tuchiya H, Tomita K, et al: Intraarterial cisplatin and caffeine with or without doxorubicin for musculoskeletal highgrade spindle cell sarcoma. Oncol Rep 1: 27-36, 1984.
 
52) Cortes EP, Holland JF and Glidewell O: Amputation and adriamycin in primary osteosarcomas: A5year report. Cancer Treat Rep 62: 271-277, 1978.
PubMed
53) Jaffe N, Frei E, Link M, et al: Adjuvant chemotherapy of osteogenic sarcoma: 5-years experience. Cancer Treat Rep 62: 259-264, 1978.
 
54) Goorin A, Delorey M, Gelber R, et al: The Dana-Farber Cancer Institute/The children hospital adjuvant chemotherapy trials for osteosarcomas: Three sequential studies. Cancer Treat Symp 3: 155-159, 1985.
 
55) Goorin AM, Perez-Atayde A, Gebhardt M, et al: Weekly high dose methotrexate and doxorubicin for osteosarcoma: The Dana-Farber Cancer Institute/The Children's Hospital; Study III. J CIin Oncol 5: 1178-1184, 1987.
 
56) Sutow WW, Gehan EA, Dyment PG, et al: Multidrug adjuvant chemotherapy for osteosarcoma: Interm report of the Southwest Oncology Group Studies. Cancer Treat Rep 62: 265-269, 1978.
 
57) Furuse K, Maeyama I, Yamawaki S, et al: Adjuvant chemotherapy for osteosarcoma with adriamycin alone versus adriamycin vincristine and high dose methotrexate with citrovorum factor rescue. In Methotrexate in cancer therapy, (ed by Kimura K and Wang Y-M) , Raven Press, New York, 1986, pp 249-255.
 
58) Rosen G, Tan C, Sanmanechal A, et al: The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer 35: 936-945, 1975.
PubMed
59) Eilber Fp, Giuliano A and Eckardt K: Adjuvant chemotherapy for osteosarcoma: Arandomized prospective trial. J CIin Oncol 5: 21-26, 1987.
 
60) Ettinger LJ, Douglass HO, Higby DS, et al: Adjuvant adriamycin and cis-diamminedichloroplatinum(cisplatin) in primary osteosarcoma. Cancer 47: 248-254, 1981.
 
61) Jaffe N, Robertson R, Ayala A, et al: Comparison of cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J CIin oncol 3: 1101-1104, 1985.
 
62) Saeter G, Hoie J, Stenwig AE, et al: Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 75: 1084-1093, 1995.
PubMed
63) Winkler K, Beron G, Dellinger G, et al: Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial(COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6: 329-337, 1988.
 
64) Provisor AJ, Ettinger LJ, Nachman JB, et al: Treatment of nonmetastatic osteosarcoma of the exterimity with preoperative and postoperative chemotherapy: Areport from the children's cancer group. J CIin Oncol15: 76-84, 1997.
 
65) Meyers PA, Gorlick R, Heller G, et al: Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering(T 12) protocol. J CIin Oncol 16(7) : 2452-2458, 1998.
 
66) Meyers PA, Heller G and Vlamis V: Osteosarcoma of the extremities: chemotherapy experience at Memorial Sloan-Kettering. Cancer Treat Res 62: 309-322, 1993.
PubMed
67) Winkler K, Beron G, Kotz R, et al: Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German Austrian study. J CIin Oncol 2: 617-624, 1984.
 
68) Fuchs N, Bielack S, Epler D, et al: Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol9: 893-899, 1998.
 
69) 井須和男, 山脇慎也, 福間久俊・他: 骨肉腫に対するAdjuvant Chemotherapyにおける多施設共同研究の経験と将来への展望. 日整会誌 70: S999, 1996.
Medical*Online
70) 井須和男, 山脇慎也, 平賀博明・他: 骨肉腫補助化学療法における多剤併用療法の役割. 整形外科災害外科 43: 1067-1073, 2000.
 
71) Saeter G, Alvegard TA, Eloma L, et al: Treatment of osteosarcoma of the extremities with the T 10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: AScandinavian sarcoma group study. J Clin Oncol 9: 1766-1775, 1991.
 
72) Provisor A, Nachman J, Krailo M, et al: Treatment of non-metastatic osteogenic sarcoma(os) of the extremities with pre and post-operative chemotherapy. Proc ASCO 6: 217, 1987.
 
73) Bramwell VHC, Burgers M, Sneath R, et al: Acomparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European osteosarcoma intergroup. J CIin Oncol 10: 1579-1591, 1992.
 
74) Souhami RL, Craft AW, Van der Eijken JW, et al: Randomized trial of two regimens of chemotherapy in operable osteosarcoma: astudy of the European Osteosarcoma Intergroup. Lancet 350: 911-917, 1997.
 
75) Winkler K, Bielack S, De11ing G, et al: Effect of intraarterial versus intravenous cisplatin in adition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma(study COSS-86) . Cancer 66: 1703-1710, 1990.
 
76) Voute PA, Souhami RL, Nooij M, et al: Aphase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup(EOI) . Ann Oncol 10: 1211-1218, 1999.
 
77) Bacci G, Ferrari S, Mercuri M, et al: Neoadjuvant chemotherapy for extremity osteosarcoma: Preliminary results of the Rizzoli's 4th study. Acta Oncol 27: 41-48, 1998.
 
78) Meyers PA, Heller G, Healey J, et al: Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering Experience. J CIin Oncol 10: 5-15, 1992.
 
79) Ferrari S, Bacci G, Picci P, et al: Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 8: 765-771, 1997.
PubMed
80) Bielack S, Kempf-Bielack B, Schwenzer D, et al: Neoadjuvant therapy for Iocalized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients. Klin Padiatr 211: 260-270, 1999.
 
81) Ornadel D, Souhami RL, Whelan J, et al: Two-weekly doxorubicin and cisplatin with granulocyte colony stimulating factor as an adjuvant chemotherapy for osteosarcoma: Aphase II trial of the European Osteosarcoma Intergroup. J CIin Oncol 12: 1842-1848, 1994.
 
82) Lewis IJ, Weeden S, Machin D, et al: Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clin Oncol 18(24) : 4028-4037, 2000.
PubMed
83) Niederle N, Scheulen ME, Cremer M, et al: Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. Cancer Treat Rev 10: 129-135, 1983.
PubMed
84) Marti CH, Kroner T, Remagen W, et al: High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 69: 115-117, 1985.
 
85) Uchida A, Myoul A, Araki N, et al: Neoadjuvant for pediatric osteosarcoma patients. Cancer 79: 411-415, 1997.
PubMed
86) Miser J, Arndt C, Smithson W, et al: Treatment of high-grade osteosarcoma with ifosfamide, mesna, adriamycin, high dose methotrexate with or without cisplatin, abstracted. Proc Annu Meet Am Soc Clin Oncol 11: A1262, 1992.
 
87) Meyer WH, Prat BN, Rao X, et al: Curative therapy for osteosarcoma without cisplatin-preliminary results of SJCRH OS-91. Proc ASCO 16: 1844, 1997.
 
88) Edmonson , Green SJ, Ivins JC, et al: Acontrolled pilot study of high dose methotrexate as post-surgical adjuvant treatment for primary osteosarcoma. J CIin Oncol 2: 152-156, 1984.
 
89) Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse free survival in patients with osteosarcoma of the extremitiy. N Engl J Med 314: 1600-1606, 1986.
 
90) Link MP, Groorin AM, Horowitz M, et al: Adjuvant chemotherapy of high grade osteosarcoma of the extremity: Update results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relate Res 270: 8-14, 1991.
 
91) Kinsella T, Miser JS, Waller B, et al: Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys 20: 389-395, 1991.
 
92) Nesbit M, Gehan EA, Burgert O, et al: Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: Along follow-up of the first intergroup study. J CIin Oncol 8: 1664-1674, 1990.
 
93) Burgert EO, Nesbit ME, Gehan EA, et al: Multimodal therapy for the management of nonpelvic localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 8: 1514-1524, 1990.
 
94) Evans R, Nesbit M, Gehan EA, et al: Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: Areport from the second intergroup study. J CIin Oncol 9: 1173-1180, 1991.
 
95) Evans R, Nesbit M, Askin F, et al: Local recurrence rate and sites of metastases, and to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of pelvic bones. Int J Radiat Oncol Biol Phys 11: 129-136, 1985.
 
96) Oberlin O, Patte C, Demeocq F, et al: The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. Eur J Cancer Clin Oncol 21: 463-467, 1985.
 
97) Bacci G, Toni A, Avella M, et al: Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy. Cancer 63: 1477-1486, 1989.
 
98) Oberlin O, Habrand JL, Zucker M, et al: No benefit of ifosfamide in Ewing's sarcoma: Arandomized study of the French Society of pediatric oncology. J CIin Oncol 10: 1407-1412, 1992.
 
99) Jurgen H, Exner U, Grander H, et al: Multidisciplinary treatment of primary Ewing's sarcoma of bone. Cancer 61: 23-32, 1988.
 
100) Paulussen M, Ahrens, J, Dunst W, et al: Localized Ewing's tumor of bone: Final results of the cooperative Ewing's sarcoma study CESS 86. J CIin Oncol 19: 1818-1829, 2001.
 
101) Rosito P, Mancini AF, Rondelli R, et al: Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: apreliminary report of 6 years of experience. Cancer 86: 421-428, 1999.
 
102) Meyer WH, Kun L, Marina N, et al: Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. J CIin Oncol 10: 1737-1742, 1992.
 
103) Grier H, Krailo, Link M, et al: Improved outcome in non-metastatic Ewing's sarcoma and PNET of bone with the addition of ifosfamide and etoposide to vincristine, adriamycin, cyclophosphamide, and Pediatric Oncology Group(POG) report. Proc ASCO 19: 2286, 2000.
 
104) Wexler LH, Delaney TF, Tsokos M, et al: Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 78: 901-911, 1996.
 
105) Jurgens H, Ahrens P, Frohlich B, et al: European Intergroup Cooperative Ewing's sarcoma study(EICESS 92) : First results. Proc ASCO 19: 2286, 2000.
 
106) Kushner BH, Meyers PA, Gerald WL, et al: Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J CIin Oncol 13: 2796-2804, 1995.
 
107) Kinsella TJ, Glaubiger D, Disseroth A, et al: Intensive combined modality therapy including low-dose TBI in high-risk Ewing's sarcoma patients. Int J Radiat Oncol Biol Phys 9: 1955-1960, 1983.
 
108) Paulussen M, Ahrens S, Burdach S, et al: Primary metastatic(stage IV) Ewing's tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing's Sarcoma Studies. Ann Oncol 9: 275-281, 1998.
 
109) Frohlich B, Ahrens S, Burdach S, et al: High-dosage chemotherapy in primary metastazed and relapsed Ewing's sarcoma. (EICESS) . Klin Padiatr 211: 284-290, 1999.
 
110) Kushner BH and Meyers PA: How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow?The Memorial Sloan-Kettering experience and a literature review. J CIin Oncol 19: 870-880, 2001.
 
111) Burdach S, van Kaick B, Laws HJ, et al: Allogeneic and autologous stem-cell transplantation in advanced Ewing's tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 11: 1451-1462, 2000.
 
112) Bacci G, Ferrai S, Bertoni F, et al: Neoadjuvant chemotherapy in malignant fibrous histiocytoma and in osteosarcoma located in the exterimity: Analogies and differences between the two tumors. Ann Oncol 8: 1107-1115, 1997.
 
113) Bramwell VHC, Steward WP, Nooij M, et al: Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: AEuropean Osteosarcoma Intergroup study. J CIin Oncol 17: 3260-3269, 1999.
 
114) Huvos AG: Bone tumors; Diagnosis, treatment and prognosis. 2nd ed. Philadelphia, London, Toronto, W B Saunders Co, 1991, pp 514-517.
 
115) Shuman LS, Chuang VP, Wallance S, et al: Intra-arterial chemotherapy of malignant fibrous histiocytoma of the pelvis. Radiology 142: 343-346, 1982.
 
116) Urban Ch, Rosen G, Huvos AG, et al: Chemotherapy of malignant fibrous histiocytoma of bone. Cancer 51: 795-802, 1983.
 
117) Rosenberg SA: Adjuvant chemotherapy of adult patients with soft tissue sarcoma. In Important Advances by DeVita V, Hellman S and Rosenberg S) , Lippincott, Philadelphia, PA, 1985, pp 273-294.
 
118) Antman K, Ryan L, Borden E, et al: Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10 year results and review of literature. In Adjuvant Therapy of Cancer VI, (ed by Salmon SE) , PA, WB Saunders, Philadelphia, 1990, pp 529-543.
 
119) Alvegard TA, Sigurdsson H, Mouridsen H, et al: Adjuvant chemotherapy with doxorubicin in high grade soft tissue sarcoma: Arandomized trial of the Scandinavian Sarcoma Group. J Clin Oncol 7: 1504-1513, 1989.
 
120) Eilber FR, Guiliano AE, Huth JF, et al: Arandomized prospective trial using post-chemotherapy(Adriamycin) in high grade extreity soft-tissue sarcoma. Am J CIin Oncol 11: 39-45, 1988.
 
121) Gherlinzoni F, Bacci G, Picci P et al: Arandomized trial for the treatment of high grade soft tissue sarcomas of the extremities: Preliminary observations. J Clin Oncol 4: 552-558, 1986.
 
122) Gherlizoni F, Pignatti G, Fontana M, et al: Soft tissue sarcomas: The experience at the Istituto Ortopedic Rizzoli. Chir Organi Mov 75: 150-154, 1990.
 
123) Pisters PWT, Leuung DHY, Woodruff J, et al: Prognostic factors in adult patients with locally controlled soft tissue sarcoms of the extremities. J CIin Oncol 14: 1679-1689, 1996.
 
124) Benjamin RS, Terjanian TO, Genoglio CJ, et al: The importance of combination chemotherapy for adjuvant treatment of high risk patients with soft tissue sarcomas of the extremities. In Adjuvant Therapy of Caner V, (ed by Salmon SE) , Grune &Stratton, New York, NY, 1987, pp 735-744.
 
125) Edmonson JH, Fleming TR, Ivans JC, et al: Arandomized study of systemic chemotherapy following complete excision of nonosseous sarcoma. J Clin Oncol 2: 1390-1396, 1984.
 
126) Baker AR, Chang AE, Glastein E, et al: National Cancer institute experinece in the management of high grade extremity soft tissue sarcoma. In Recent concepts in Sarcoma Treatment, (ed by Ryan JR and Baker LO) , Kluwer Academic, Dordecht, Netherlands, 1988, pp 123-129.
 
127) Bui NB, Maree D, Coindre JM, et al: First results of a prospective randomized study of CYVADIC adjuvant chemotherapy in adults with operable high risk soft tissue sarcoma. Proc ASCO 8: 318, 1989.
 
128) Ravaud A, Bui NB, Coindre JM, et al: Adjuvant chemotherapy with CYVADIC in high risk soft tissue sarcoma: A randomized prospective trial. In Adjuvant Therapy of Caner VI, (ed by Salmon SE) , Grune&Stratton, New York, NY, 1990, pp 556-566.
 
129) Bramwell BV, Rouesse J, Steward W, et al: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-Reduced local recurrence but no improvement in survival; Astudy of the European Organization for Research and Treatment of cancer soft tissue and bone sarcoma group. J CIin Oncol 12: 1137-1149, 1994.
 
130) Sarcoma meta-analysis collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 350: 1647-1654, 1997.
PubMed
131) Frustaci S, Gherlinzoni F, De Paolli A, et al: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J CIin Oncol 19: 1238-1247, 2001.
 
132) Branmell VH: Adjuvant chemotherapy for adult soft tissue sarcoma: Is there a standard of care? JCIin Oncol 19: 1235-1237, 2001.
 
133) Gottlieb JA, Baker LH, Quagliana JM, et al: Chemotherapy of sarcomas with a combination of Adriamycin and diethyl triazeno imidazole-carboxamine. Cancer 30: 1632-1638, 1972.
 
134) Borden EC, Amato D, Rosenbaum C, et al: Randomized comparison of three adriamycin regimens for treatment of metastatic soft tissue sarcomas. J CIin Oncol 5: 840-850, 1987.
 
135) Omura GA, Major Fj, Blessing JA, et al: Arandomized study of adriamycin with and without dimethyletriazo imidazole carboxamine in advanced uterine sarcomas. Cancer 52: 626-632, 1983.
 
136) Pinedo HM, Bramwell VH, Mouridsen HT, et al: Cyvadic in advanced soft tissue sarcoma: Arandomized study comparing two schedules. Cancer 53: 1825-1832, 1984.
 
137) Schoenfeld DA, Rosenbaum C, Horton J, et al: Acomparison of adriamycin versus vincristine and adriamycin and cyclophosphamide versus vincristine actinomycin-D and cyclophosphamide for advanced sarcoma. Cancer 50: 2757-2762, 1982.
 
138) Baker L, Benjamin R, Fine G, et al: Combination chemotherapy in management of disseminated soft tissue sarcomas. Proc ASCO 20: 378, 1979.
 
139) Bramwell V, Mouridsen HT, Santoro A, et al: Cyclophosphamide vs ifosfamide and mesna: Final report of a randomized phase II trial in adult soft tissue sarcoma. Eur J Cancer Clin Oncol 7: 126-131, 1989.
 
140) Antman K, Crowley J, Balcerzak SP, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcoma. J CIin Oncol 11: 1276-1285, 1993.
PubMed
141) Santoro J, Mouridsen HT and Steward W: Arandomized Eortc study in advanced soft tissue sarcomas: ADM vs ADM+IFOS vs CYVADIC. Proc ASCO 9: 309, 1990.
 
142) Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11: 1269-1275, 1993.
PubMed
143) Nielsen OS, Judson I, van Hoesel Q, et al: Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36: 61-67, 2000.
PubMed
144) Le Cesne A, Judson I, Crowther D, et al: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: Atrial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J CIin Oncol 18(14) : 2676-2684, 2000.
 
145) Steward WP, Verweij J, Somers R, et al: The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 31(Suppl 2) : S241-244, 1993.
 
146) Verweij J, Lee SM, Ruka W, et al: Randomized phase II study of docetaxel versus doxorubicin in first and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: astudy of the European Organization for research and treatment of cancer soft tissue and bone sarcoma group. J CIin Oncol 18: 2081-2086, 2000.
PubMed
147) Verweij J: Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas. Anticancer Drugs 6(Suppl 4) : 19-24, 1995.
 
148) van Hoesel QG, Verweij J, Catimel G, et al: Phase II study with docetaxel(Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 5: 539-542, 1994.
PubMed
149) Mantravadi RV, Trippon MJ, Patel MK, et al: Limb salvage in extremity soft-tissue sarcoma: combined modality therapy. Radiology 152: 523-526, 1984.
PubMed
150) Denton JW, Dunham WK, Salter M, et al: Preoperative regional chemotherapy and rapid-fraction irradiation for sarcomas of the soft tissue and bone. Surg Gynecol Obstet 158: 545-551, 1984.
PubMed
151) Goodnight JE, Bargar WL, Voegeli T, et al: Limb-sparing surgery for extremity sarcomas after radiation therapy. Am J Surg 150: 109-113, 1985.
PubMed
152) Eileber FR, Mirra J, Eckart J, et al: Intraarterial adriamycin, radiation therapy, and surgical excision for extremity skeletal and soft tissue sarcomas. Dev Oncol 26: 141-152, 1984.
 
153) Hoekstra HJ, Koops SH, Molenaar WM, et al: Acombination of intraarterial chemotherapy, preoperative and post operative radiotherapy, and surgery as limb saving treatment of primarily unresectable high-grade soft tissue sarcomas of the extremities. Cancer 63: 59-62, 1989.
 
154) Dunst J, Sauer R, Burgers R, et al: Radiation therapy as local treatment in Ewing's sarcoma: Results of the cooperative Ewing's sarcoma studies CESS 81 and CESS 86. Cancer 67: 2818-2825, 1991.
 
155) 琴浦良彦, 坪山直生: 放射線療法, 術中照射の治療成績と問題点. 骨腫瘍の診断と治療, (平澤泰介・編) , OS Now 18, メジカルビュー社, 東京, 1995, pp 226-231.
 
156) Karakousis CP, Emrich LJ, Rao U, et al: Feasibity of limb salvage and survival in soft tissue sarcomas. Cancer 57: 484-491, 1986.
 
157) Abbatucci JS, Boulier N, DE Ranieri J, et al: Local control and survival in soft tissue sarcomas of the limbs, trunk walls and head and neck: astudy of 113 cases. Int J Radiat Oncol Biol Phys 12: 579-586, 1986.
 
158) Rosenberg SA, Tepper J, Glatstein E, et al: The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of(1) limb-sparing surgery plus radiation therapy compared with amputation and(2) the role of adjuvant chemotherapy. Ann Surg 196: 305-315, 1982.
PubMed
159) Brennan MF, Hikaris B, Shiu MH, et al: Local recurrence in adult soft-tissue sarcoma. A randomized trial of brachytherapy. Arch Surg 122: 1289-1293, 1987.
 
160) Pisters PWT, Harrison LB, Woodruff JM, et al: Aprospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk. J Clin Oncol 12: 1150-1155, 1994.
 
161) Pister PWT, Harrison L, Leung D, et al: Long-term results of prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J CIin Oncol 14: 859-868, 1996.
 
162) Yang JC, Chang AE, Baker AR, et al: Randomaized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremities. J CIin Oncol 16: 197-203, 1998.
 
P.872 掲載の参考文献
1) Grin-Jorgensen CM, Rigel DS and Friedman RJ: The worldwide incidence of malignant melanoma. Cutaneous Melanoma, (ed by Balch CM, et al) , 2nd ed, Lippincott, Philadelphia, 1992, pp 27-39.
 
2) 斎田俊明: 悪性黒色腫, (清水 宏, 他・編) , 最新皮膚科学大系11巻, 中山書店, 東京, 2002, pp 226-253.
 
3) Weinstock MA and Boyle MM: Melanoma incidence and mortality rates among US whites. The Year Book of Dermatol- ogy and Dermatologic Surgery(2000) , (ed by Thiers BH and Lang PG) , Mosby, St Louis, 2000, p 37.
 
4) Ishihara K, Saida T and Yamamoto A: Updated statistical data for malignant melanoma in Japan. Int J Clin Oncol 6: 109-116, 2001.
 
5) Wang SQ, Setlow R, Berwick M, et al: Ultraviolet A and melanoma: areview. J Am Acad Dermatol 44: 837-846, 2001.
 
6) Hearing VJ: Biochemical control of melanogenesis and melanosomal organization. J Invest Dermatol Symp Proc 4: 24-28, 1999.
 
7) Elwood JM, Gallagher RP, Hill GB, et al: Cutaneous melanoma in relation to intermittent and constant sun exposure: The Western Canada Melanoma Study. Int J Cancer 35: 427-433, 1985.
PubMed
8) Langley RGB, Fitzpatrick TB and Sober AJ: Clinical characteristics. Cutaneous Melanoma, (ed by Balch CM, et al) , 3rd ed, Quality Medical Publishing, St Louis, 1998, pp 81-101.
 
9) Ackerman AB: Malignant melanoma: Aunifying concept. Am J Dermatopathol 2: 309-313, 1980.
PubMed
10) 斎田俊明: メラノーマと色素細胞母斑の病理組織診断. メラノーマの病理組織診断: 症例検討から学ぶ診断のポイント, (斎田 俊明, 他. 編) , 文光堂, 東京, 2002, pp 1-16.
 
11) 斎田俊明: Spitz nevus: 組織像の多様性と悪性黒色腫との鑑別. 病理と臨床 10: 788-795, 1992.
 
12) Allen AC: Areorientation of the histogenesis and clinical significance of cutaneous melanomas. Cancer 2: 28-56, 1949.
PubMed
13) Clark WH, Elder DE, Guerry D, et al: Astudy of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15: 1147-1165, 1984.
 
14) Ackerman AB: The concept of malignant melanoma in situ. Pathobiology of Malignant Melanoma, (ed by Elder DE) , Karger, Basel, 1987, pp 205-210.
 
15) Ackerman AB: What naevus is dysplastic, a syndrome and the commonest precursor of malignant melanoma: Ariddle and an answer. Histopathology 13: 241-256, 1988.
 
16) Saida T: The concept of de novo origin of cutaneous malignant melanoma. Eur J Dermatol4: 252-254, 1994.
 
17) 斎田俊明: メラノサイトの増難病変としてのメラノーマと色素細胞母斑色素細胞. 機能と発生分化の分子機構から色素性疾患への対応を探る, (松本二郎, 他・編) , 慶應大学出版会, 東京, 2001, pp 249-265.
 
18) Healy E, Belgaid CE, Takata M, et al: Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res 56: 589-593, 1996.
PubMed
19) Bastian BC, LeBoit PE, Hamm H, et al: Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58: 2170-2175, 1998.
PubMed
20) Saida T: Recent advances in melanoma research. J Dermatol Sci 26: 1-13, 2001.
PubMed
21) 斎田俊明: ほくろはメラノーマになるか? 日皮会誌 111: 1790-1792, 2001.
 
22) Papp T, Pemsel H, Zimmermann R, et al: Mutational analysis of the N-ras, p53, p161NK4 a, CDK4, and MCIR genes in human congenital melanocytic naevi. J Med Genet 36: 610-614, 1999.
 
23) 斎田俊明: 悪性黒色腫の臨床所見と診断. 悪性黒色腫の診断・治療指針, (斎田俊明, 他・編) , 金原出版, 東京, 2001, pp 21-31.
 
24) 斎田俊明: メラノーマの早期病変をどう診断するか. 日皮会誌 111: 1673-1675, 2001.
 
25) Saida T: Malignant melanoma in situ on the sole of the foot: Its clinical and histopathologic characteristics. Am J Dermatopathol 11: 124-130, 1989.
PubMed
26) Saida T: Malignant melanoma on the sole: How to detect the early lesions efficiently. Pigment Cell Res 13(suppl 8) : 135-139, 2000.
 
27) Argenziano G, Soyer HP, Chimenti S, et al: Dermoscopy of pigmented skin Iesions: Results of a consensus meeting via the internet. J Am Acad Dermatol 48: 679-693, 2003.
 
28) Saida T, Oguchi S, Ishihara Y: In vivo observation of magnified features of pigmented lesions on volar skin using videomacroscope. Arch Dermatol 130: 298-304, 1994.
 
29) Oguchi S, Saida T, Koganehira Y, et al: Characteristic epiluminescent microscopic features of early malignant melanoma on glabrous skin: Avideomicroscopic analysis. Arch Dermatol 134: 563-568, 1998.
PubMed
30) Balch CM, Buzaid AC, Soong S-J, et al: Final version of the American Joint Committee on Cancer Staging System for cutaneous melanoma. J CIin Oncol 19: 3635-3648, 2001.
 
31) 日本皮膚悪性腫瘍学会・編: 悪性黒色腫, 皮膚悪性腫瘍取扱い規約. 第1版, 金原出版, 東京, 2002, pp 16-37.
 
32) Ringborg U, Andersson R, Eldh J, et al: Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of O. 8to 2. Omm. Cancer 77: 1809-1814, 1996.
 
33) Bono A, Bartoli C, Clemente C, et al: Ambulatory narrow excision for thin melanoma(<2mm) : Results of a prospective study. Eur J Cancer 33: 1330-1332, 1997.
PubMed
34) Heaton KM, Sussman JJ, Gershenwald JE, et al: Surgical margins and prognostic features in patients with thick(>4mm) primary melanoma. Ann Surg Oncol 5: 322-328, 1998.
 
35) Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Ann Surg 127: 392-399, 1992.
 
36) Balch CM: Surgical treatment of advanced melanoma. Cutaneous Melanoma, (ed by Balch CM, et al) , 3rd ed, Quality Medical Publishing, St Louis, 1998, pp 374-388.
 
37) Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferonα-2b adjuvant therapy of high-risk resected cutaneous melanoma: The ECOG Trial EST 1684. J Clin Oncol 14: 7-17, 1996.
 
38) 山本明史: フェロン・DAV併用療法の基礎と臨床. Skin Cancer 11: 358-366, 1996.
 
39) 宇原 久, 斎田俊明, 高田 実・他: 悪性黒色腫患者における重複癌についての調査結果. 日皮会誌 110: 2123-2126, 2000.
 
40) Cascinelli N, Herlyn M, Schneeberger A, et al: What is the most promising strategy for the treatment of metastasizing melanoma?Exp Dermatol 9: 439-451, 2000.
 
41) 斎田俊明, 宇原 久: 悪性黒色腫に対する抗がん剤の適正使用ガイドライン(試案) . Skin Cancer 16: 158-169, 2001.
 
42) Garbe C: Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3: 291-299, 1993.
PubMed
43) Buzaid AC, Bedikian A and Houghton AN: Systemic chemotherapy and biologic therapy. Cutaneous Melanoma, (ed by Balch CM, et al) , 3rd ed, Quality Medical Publishing, St Louis, 1998, pp 405-418.
 
44) McClay EF and McClay MET: Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 23: 744-753, 1996.
 
45) Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J CIin Oncol 17: 2745-2751, 1999.
 
46) 宇原 久, 斎田俊明: 進行期悪性黒色腫に対するdacarbazine, nimustine, cisplatin, tamoxifen併用療法(DAC-Tam療法: cisplatin 1回投与法) の治療成績. 日皮会誌 110: 979-982, 2000.
 
47) Richards JM, Gale D, Mehta N, et al: Combination of chemotherapy with interleukin-2 and interferonαfor the treatment of metastatic melanoma. J CIin Oncol 17: 651-657, 1999.
 
48) Johnston SR, Constenla DO, Moore J, et al: Randomized phase II trial of BCDT with or without interferonαand interleukin-2 in patients with metastatic melanoma. Br J Cancer 77: 1280-1286, 1998.
 
49) Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferonα一2b. J Clin Oncol 17: 968-975, 1999.
 
50) Eton O, Legha S, Bedikian A, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J CIin Oncol 20: 2045-2052, 2002.
 
51) Kawakami Y, Suzuki Y, Shofuda T, et al: Tcell immune response against melanoma and melanocytes in cancer and autoimmunity. Pigment Cell Res 13(suppl 8) : 163-169, 2000.
 
52) Nestle FO, Alijagic S, Gilliet M, et al: Vaccinination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
PubMed
53) Rosenberg SA, Yang JC, Schwarzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998.
 
54) Rosenberg SA: Gene therapy for cancer. JAMA 268: 2416-2419, 1992.
PubMed
P.882 掲載の参考文献
1) Stratton SP: Prevention of non-melanoma skin cancer. Curr Oncol Rep 3: 295-300, 2001.
PubMed
2) 石原和之, 斎田俊明, 山本明史: 悪性黒色腫(1987-91年) の統計調査による疫学, 予後因子, 10年生存率Skin Cancer 15: 99-107, 2000.
 
3) Ikegawa S, Saida T, Takizawa Y, et al: Vimentin-positive squamous cell carcinoma arising in a burn scar: ahighly malignant neoplasm composed of acantholytic round keratinocytes. Arch Dermatol 125: 1672-1676, 1989.
 
4) 斎田俊明: 皮膚癌の多段階発癌. Mol Med 36: 416-422, 1999.
 
5) 江川清文: Bowen病, bowenoid papulosis, verrucous carcinomaとHPV. 皮膚臨床 41: 1085-1099, 1999.
 
6) Rowe DE, Carroll RJ and Day CL: Prognostic factors for local recurrence, metastasis and survival rates in squamous cell carcinoma of the skin, ear and lip. J Am Acad Dermatol 26: 976-990, 1992.
 
7) Motley R, Kersey P, Lawrence C, et al: Multiprofessional guidelines for the management of the patients with primary cutaneous squamous cell carcinoma. Br J Dermatol 146: 18-25, 2002.
 
8) 日本皮膚悪性腫瘍学会・編: 有棘細胞癌, 皮膚悪性腫瘍取扱い規約. 第1版, 金原出版, 東京, 2002, pp 38-48.
 
9) 斎田俊明, 宇原 久: 皮膚有棘細胞癌に対する抗がん剤の適正使用ガイドライン(試案) . Skin Cancer 16: 170-173, 2001.
 
10) Al-Othman MO, Mendenhall WM and Amdur RJ: Radiotherapy alone for clinical T 4 skin carcinoma of the head and neck with surgery reserved for salvage. Am J Otolaryngol 22: 387-390, 2001.
 
11) Cherpelis BS, Marcusen C and Lang PG: Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg 28: 268-273, 2002.
PubMed
12) 池田重雄, 石原和之, 大浦武彦・他: 有棘細胞癌および悪性黒色腫に対する塩酸イリノテカン(CPT-11) の後期第II相臨床試験. Skin Cancer 8: 503-513, 1993.
 
13) Beham A, Egauer S, Soyer HP, et al: Keratoacanthoma: aclinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol 5: 269-280, 1998.
 
14) Yoshimura Y, Mishima K, Obara S, et al: Treatment modalities for oral verrucous carcinomas and their outcomes: contribution of radiotherapy and chemotherapy. Int J CIin Oncol 6: 192-200, 2001.
 
15) Argenziano G, Soyer HP, Chimenti S, et al: Dermoscopy of pigmented skin lesions: results of a consensus meetirlg via the internet. J Am Acad Dermatol 48: 679-693, 2003.
PubMed
16) 斎田俊明, 小口真司, 宮嵜 敦: ダーモスコピー(dermoscopy) : 色素性皮膚病変の革新的診断法. J Visual Dermatol 1: 76-87, 2002.
 
17) 小野友道: 基底細胞癌の診断と治療指針. Skin Cancer 9(Special issue) : 78-80, 1994.
 
18) Guthrie TH, Porubsky ES, Luxenberg MN, et al: Cisplatin-based chemotherapy in advanced basal and squamous cell carcinoma of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 8: 342-346, 1990.
PubMed
19) 石原和之: 全国アンケートの集計と説明. Skin Cancer 9(Special issue) : 80-83, 1994.
 
20) 大原國章, 大西泰彦, 川端康浩: 乳房外Paget病の診断と治療. Skin Cancer 8: 187-208, 1993.
 
21) 日本皮膚悪性腫瘍学会・編: 乳房外Paget病, 皮膚悪性腫瘍取扱い規約. 第1版, 金原出版, 東京, 2002, pp 58-71.
 
22) Oguchi S, Kaneko M, Uhara H, et al: Docetaxel induced durable response in advanced extramammary Paget's disease: a case report. J Dermatol 29: 33-37, 2002.
 
23) 日本皮膚悪性腫瘍学会・編: 皮膚付属器悪性腫瘍(毛包癌, 脂腺癌, 汗腺癌) , 皮膚悪性腫瘍取扱い規約. 第1版, 金原出版, 東京, 2002, pp 72-83.
 
24) 日本皮膚悪性腫瘍学会・編: Merkel細胞癌, 皮膚悪性腫瘍取扱い規約. 第1版, 金原出版, 東京, 2002, pp 84-87.
 
25) Mehrany K, Otley CC, Weenig RH, et al: Ameta-analysis of the prognostic significance of sentinel lymph node status in Merkel cell carcinoma. Dermatol Surg 28: 113-117, 2002.
 
26) Eich HT, Eich D, Staar S, et al: Role of postoperative radiotherapy in the management of Merkel cell carcinoma. Am J Clin Oncol 25: 50-56, 2002.
PubMed
27) Voog E, Biron P, Martin J-P, et al: Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85: 2589-2595, 1999.
PubMed
28) Tai PT, Yu E, Tonita J, et al: Merkel cell carcinoma of the skin. J Cutan Med Surg 4: 186-195, 2000.
PubMed
29) Feigenberg ST, Mendenhall NP and Reith JD: Angiosarcoma after breast-conserving therapy: experience with hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 52: 620-626, 2002.
 
30) Masuzawa M, Mochida N, Amano T, et al: Evaluation of recombinant interleukin-2 immunotherapy for human hemangiosarcoma in a SCID mice model. J Dermatol Sci 27: 88-94, 2001.
 
31) 日本皮膚悪性腫瘍学会・編: 肉腫, 皮膚悪性腫瘍取扱い規約. 第1版, 金原出版, 東京, 2002, pp 88-104.
 
32) 瀧川雅浩: リンパ腫の分類と治療. 日皮会誌 110: 1959-1961, 2000.
 
P.894 掲載の参考文献
1) 脳腫瘍全国統計委員会, 日本病理学会・編: 脳腫瘍取扱い規約; 臨床と病理カラーアトラス. 第2版, 金原出版, 東京, 2002, pp 3-12.
 
2) Kleihues P and Webster K: Cavenee: Pathology and genetics of tumours of the nervous system. IARC Press, 2000.
 
3) Kuratsu J and Ushio Y: Epidemiological study of primary intracranial tumors: aregional survey in Kumamoto Prefecture in the southern part of Japan. J Neurosurg 84: 946-950, 1996.
 
4) 日本脳腫瘍病理学会・編: 脳腫瘍臨床病理カラーアトラス. 第2版, 医学書院, 東京, 1999.
 
5) 脳腫瘍全国統計委員会・編: 脳腫瘍全国集計調査報告. vol. 9, 1996, pp 67-75.
 
6) Kinjo T, A1-Mefty O and Kanaan I: Grade zero removal of supratentorial convexity meningiomas. Neurosurgery 33: 394-399, 1993.
 
7) Adegbite AB, Khan MI, Paine KWE, et al: The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg 58: 51-56, 1983.
 
8) Kondziolka D, Lunsford LD, Coffey RJ, et al: Stereotactic radiosurgery of meningiomas. J Neurosurg 74: 552-559, 1991.
PubMed
9) Shin M, Kurita H, Sasaki T, et al: Analysis of treatment outcome after stereotactic radiosurgery for cavernous sinus meningioma. J Neurosurg 95: 435-439, 2001.
PubMed
10) Kobayashi T, Kida Y and Mori Y: Long-term results of stereotactic gamma radiosurgery of meningiomas. Surg Neurol 55: 325-331, 2001.
PubMed
11) Maxwell M, Galanopoulos T, Neville-Golden J, et al: Expression of androgen and progesteron receptors in primary human meningiomas. J Neurosurg 78: 456-462, 1993.
PubMed
12) Schrell UM, Rittig MG, Anders M, et al: Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86: 840-844, 1997.
PubMed
13) Kaba SE, DeMonte F, Bruner JM, et al: Treatment of recurrent unresectable and malignant meningioma with interferon alpha 2 b. Neurosurgery 40: 271-275, 1997.
 
14) Sanno N, Teramoto A and Osamura R: Clinical and cytofunctional classification of pituitary adenomas: proposal of a new classification. Acta Neurochir 38: 1186-1192, 1996.
 
15) Saito K, Kuwayama A, Yamamoto N, et al: The transsphenoidal removal of nonfunctioning pituitary adenomas with suprasellar extensions: The open sella method and intentionally staged operation. Neurosurgery 36(4) : 668-676, 1995.
PubMed
16) 景山直樹: 下垂体外科の歴史. 脳神経 54(7) : 565-573, 2002.
 
17) Kreuzer J, Vance ML, Lopes MRS, et al: Surgical management of GH-secreting pituitary adenomas: An outcome study using modern remission criteria. J CIin Endocrinol Metab 86: 4072-4077, 2001.
 
18) 小林達也, 木田義久, 森 美雅: ガンマナイフの長期治療成績. 脳神経 52(8) : 599-608, 2000.
 
19) Menon AG, Gusella JF and Seizinger BR: Progress toward the isolation and characterization of the genes causing neurofibromatosis. Brain Pathol 1: 33-40, 1990.
 
20) Ebersold MJ, Harner SG, Beatty CW, et al: Current results of the retrosigmoid apProach to acoustic neurinoma. J Neurosurg 76: 901-909, 1992.
PubMed
21) Pollack BE, Lunsford LD and Noren G: Vestibular schwannoma management in the next century: aradiosurgical perspec. tive. Neurosurgery 43: 475-483, 1998.
 
22) Baser ME, Makariou EV, Parry DM, et al: Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 96: 217-222, 2002.
PubMed
23) Kida Y, Kobayashi T, Tanaka T, et al: Radiosurgery for bilateral neurinomas associated with neurofibromatosis type 2. Surg Neurol 53: 383-390, 2000.
PubMed
24) Yoshida J, Shitara N, Takakura K, et al: Astatistical study of central neurofibromatosis in Japan. Tuberous sclerosis and neurofibromatosis. epidemiology, pathophysiology, biology and management, (ed by Ishibashi Y and Mori Y) , Elservier Science Publishers BV, 1990, pp 315-321.
 
25) Kobayashi T: Recent progress in the treatment of craniopharyngioma. Neurosurgeons 3: 101-112, 1984.
 
26) Lunsford LD: Stereotactic treatment of craniopharyngiomas. Intracavitary Irradiat and Radiosurg 11: 1-15, 1989.
 
27) Kobayashi T, Tanaka T and Kida Y: Stereotactic gamma radiosurgery of craniopharyngioma. Pediatr Neurosurg 21(Suppl 1) : 69-74, 1994.
 
28) Prasad D, Steiner M and Steiner N: Gamma knife surgery for craniopharyngioma. Acta Neurochir(Wien) 134(3-4) : 167-176, 1995.
 
29) Duff JM, Meyer FB, Ilstrup DM, et al: Long-term outcomes for surgically resected craniopharyngioma. Neurosurgery 46: 291-302, 2000.
 
30) Hatano N, Wakabayashi T, Kajita Y, et al: Efficacy of post operative adjuvant therapy with human interferon beta, MCNU and radiation(IMR) for malignant glioma: comparison among three protocols. Acta Neurochir(Wien) 142: 633-639, 2000.
PubMed
31) Wakabayashi T, Hatano N, Kajita Y, et al: Initial and maintenance combined therapy treatment with interferon-beta, MCNU(Ranimustine) , and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol 49: 57-62, 2000.
PubMed
32) Yoshida J, Kajita Y, Wakabayashi T, et al: Long-term follow-up results of 175 patients with malignant glioma: Impor. tance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir(Wien) 127: 55-59, 1994.
 
33) Yung WKA, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J CIin Oncol17: 2762-2771, 1999.
 
34) Wakabayashi T, Kajita Y, Mizuno M, et al: Efficacy of adjuvant therapy with procarbazine, MCNU, and vincristine for oligodendroglial tumors. Neuro Med Chir(Tokyo) 41: 115-120, 2001.
 
35) Reifenberger J, Reifenberger G, Liu L, et al: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19 q and l p. Am J Pathol 145: 1175-1190, 1994.
 
36) Kobayashi T, Yoshida J, Ishiyama J, et al: Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-cell tumours. An experimental and clinical study. J Neurosurg 70: 676-681, 1989.
PubMed
37) Yoshida J, Sugita K, Kobayashi T, et al: Prognosis of intracranial germ cell tumours: effectiveness of chemotherapy with cisplatin and etoposide(CDDP and VP-16) . Acta Neurochir(Wien) 120: 111-117, 1993.
PubMed
38) Einhorn LH and Donohue J: Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293-298, 1977.
PubMed
39) Sawamura Y, Shirato H, Ikeda J, et al: Induction chemotherapy followed by reduced-volume radiation therapy for newly diagnosed central nervous system germinoma. J Neurosurg 88: 66-72, 1998.
PubMed
40) Matsutani M, Sano K, Takakura K, et al: Primary intracranial germ cell tumors: aclinical analysis of 153 histologically verified cases. J Neurosurg 86: 446-455, 1997.
 
41) Matsutani M, the Japanese pediatric Brain Tumor Study Group: Combined chemotherapy and radiation therapy for CNS germ cell tumors: the Japanese experience. J Neurooncol 54: 311-316, 2001.
 
42) 脳腫瘍全国統計委員会・編: 脳腫瘍全国集計調査報告. vol. 9, 1996, pp 15.
 
43) 早川 徹, 平賀章壽, 青笹克之・他: 中枢神経系悪性リンパ腫, (高倉公朋・監修, 山浦 晶・編) , 篠原出版, 東京, 1994.
 
44) DeAngelis LM: Current management of primary central nervous system lymphoma. Oncology 9: 63-78, 1995.
PubMed
45) Brada M: Central nervous system lymphomas: Progress in chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 33: 769-771, 1995.
PubMed
46) Fisher RI, Gayor ER, Dahlberg S, et al: Comparison of a standard regimen(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328(4) : 1002-1006, 1993.
 
47) O'Neill BP, O'Fallon JR, Earle JD, et al: Primary central nervous system non-Hodgkin lymphoma: Survival advantaged with combined initial therapy. Int J Radiat Oncol Biol Phys 33: 663-673, 1995.
 
48) Lachance DH, Brizel DM, Gockerman JP, et al: Cyclophosphamide, doxorubicin, vincristine, and predonisone for primary central nervous system lymphoma: Short duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 44: 1721-1727, 1994.
 
49) Hiraga S, Arita N, Ohnishi T, et al: Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91(2) : 221-230, 1999.
PubMed
50) Abrey LE, DeAngelis LM and Yahalom J: Long-term survival in primary CNS lymphoma. J CIin Oncol 16: 859-863, 1998.
 
51) Ferreri AJM, Reni M, Pasini F, et al: Multicenter study of treatment of primary CNS lymphoma. Neurology 58: 1513-1520, 2002.
 
52) Sure U, Berghorn WJ, Bertalanffy H, et al: Staging, Scoring and Grading of medulloblastoma; Apostoperative prognosis predicting system based on the cases of a single institute. Acta Neurichir(Wien) 132: 59-65, 1995.
 
53) David KM, Casey ATH, Hayward RD, et al: Medulloblastoma: is the 5-year survival rate improving? A review of 80 cases from a single institution. J Neurosurg 86: 13-21, 1997.
 
54) Packer RJ, Sutton LN, Elterman R, et al: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81: 690-698, 1994.
PubMed
55) Packer RJ, Goldwein J, Vezina LG, et al: Treatment of children with medulloblastoma with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: AChildren's Cancer Group Study. J Clin Oncol 17: 2127-2136, 1999.
 
56) Zeltzer PM, Boyett JM, Finlay JL, et al: Metastatic stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer group 921 randomized phase III study. J CIin Oncol 17: 832-845, 1999.
 
57) Duffner PK, Horowitz ME, Krischer JP, et al: Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328: 1725-1731, 1993.
PubMed
58) Sawamura Y, Ikeda J, Ishii N, et al: Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor: results of a pilot study. Neurol Med Chir(Tokyo) 36: 632-638, 1996.
PubMed
59) Cottu PH, Giacchetti S, Mignot L, et al: High dose chemotherapy with stem-cell transplantation in a metastatic medullob. 1astoma in an adult: acase report and review of the literature. J Neurooncol 18: 19-23, 1994.
 
60) Rorke LB, Packer RJ and Biegel J: Central nervous system atypical teratoid/rhabdoid tumor of infancy and childhood. J Neurooncol 24: 21-28, 1995.
 
61) Committee of brain tumor registry of Japan: report of brain tumor registry of Japan(1969-1993) 10th ed. Neuro Med Chir 40(Suppl) : 25, 2000.
 
62) 野村和弘: 転移性脳腫瘍. 脳神経外科 18(5) : 407-411, 1990.
 
63) Ushio Y, Arita N, Hayakawa T, et al: Chemotherpay of brain metastases from lung carcinoma: Acontrolled randomized study. Neurosurgery 28: 201-205, 1991.
 
64) Coffey RJ, Flickinger JC, Bissonette DJ, et al: Radiosurgery for solitary brain metastases using the cobalt-60 gamma unit: methods and results in 24 patients. Int J Radiat Oncol Biol Phys 20: 1287-1892, 1991.
PubMed
65) 木田義久, 小林達也, 田中孝幸・他: 転移性脳腫瘍のガンマナイフ治療. 脳神経外科 21(11) : 991-997, 1993.
 
P.902 掲載の参考文献
1) 小原孝男: 甲状腺癌. 外科 63: 1416-1420, 2001.
 
2) 武部晃司, 伊達 学, 山本洋介・他: 甲状腺癌検診の実際とその問題点-甲状腺微小癌の問題を中心として. 外科 58: 651-654, 1996.
 
3) 甲状腺外科検討会・編: 甲状腺癌取扱い規約. 第5版, 金原出版, 東京, 1996.
 
4) 伊藤公一: 甲状腺腫瘤の診断の進め方. 外科 63: 1-5, 2001.
 
5) 飯田 太, 小林信や: 甲状腺外科の現況. 臨外 56: 1303-1305, 2001.
 
6) Candy B and Rossi R: An expanded view of risk-group definition in differented thyroid carcinoma. Surgery 104: 947-953, 1988.
 
7) 高見 博, 池田佳史: 甲状腺癌. 外科 63: 1421-1424, 2001.
 
8) 芝 英一, 米田光里, 野口真三郎: 甲状腺癌の標準術式と治療成績. 外科治療 78: 53-59, 2000.
 
9) 平井啓介, 松塚文夫, 宮内 昭・他: 甲状腺未分化癌30例の臨床的検討: 長期生存例の臨床的特徴. 内分泌外科 16: 25-30, 1999.
 
10) 木原 実, 横見瀬裕保, 宮内 昭・他: 甲状腺未分化癌の予後因子の検討. 日臨外会誌 61: 1114-1117, 2000.
 
11) 宮内 昭, 松塚文夫, 平井啓介: 悪性リンパ腫, 未分化癌. 診断と治療 89: 304-307, 2001.
Medical*Online
12) Matsuzuka F, Fukata S, Kuma K, et al: Gene rearrangement of immunoglobulin as a marker of thyroid lymphoma. World JSurg 22: 558-561, 1998.
PubMed
13) 石田常博, 横江隆夫, 泉雄 勝: 上皮小体腫瘍の全国集計(1980-1989年度症例) . 内分泌外科 8: 37-45, 1991.
 
14) 飯野佑一, 武井寛幸, 森下靖雄: 副甲状腺癌. 日本臨床 53: 111-116, 1995.
 
15) Sandelin K, Auer G, Bondeson L, et al: Prognostic factors in parathyroid cancer: areview of 95 cases World J Surg 16: 724-731, 1992.
 
16) 芳賀一徳, 篠原信雄, 野々村克也・他: 副腎皮質癌の予後規定因子. 内分泌外科 16: 177-182, 1999.
 
17) 市川智彦, 伊藤晴夫: 副腎癌. 日本臨床 59: 393-400, 2001.
Medical*Online
18) Wooten MD and King DK: Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72: 3145-3155, 1993.
 
19) 猿田享男, 鈴木洋通, 柴田洋孝: 副腎インシデンタローマ. 日本内分泌学会誌 69: 509-519, 1993.
 
20) Weiss LM: Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8: 163-169, 1984.
PubMed
21) 西古 靖, 蓑和田滋: 副腎皮質癌. 日本臨床(別冊 領域別症候群シリーズ) 1: 541-544, 1993.
 
22) Sullivan M, Boileau M and Hodges CV: Adrenal cortical carcinoma. J Urol 120: 660-665, 1978.
PubMed
23) 日本泌尿器科学会・日本病理学会・編: 副腎腫瘍取扱い規約. 第1版, 金原出版, 東京, 1992.
 
24) 三浦幸雄: 褐色細胞腫. ホルモンと臨床 49: 599-606, 2001.
 
25) Sisson JC, Frager MS, Valk TW, et al: Scintigraphic localization of pheochromocytoma. N Engl J Med 305: 12-17, 1981.
PubMed
26) Averbuch SD, Steakley CS, Young RC, et al: Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109: 267-273, 1988.
PubMed
27) Krempf M, Lumbroso J, Mornex R, et al: Use of m-[1311]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J CIin Endocrinol Metab 72: 455-461, 1991.
 
28) Kloppel G and Heitz PU: Pancreatic endocrine tumors. Pathol Res Pract 183: 155-168, 1988.
PubMed
29) 松野正紀: 膵癌全国登録調査報告. 膵臓 16: 115-147, 2001.
Medical*Online
30) 今村正之: 膵内分泌腫瘍. 第23回日本膵切除研究会アンケート集計報告, 1996.
 
31) Soga J: Pancreatic endocrinomas; astatistical analysis of 1857 cases. J Hep Bil Pancr Surg 1: 522-529, 1994.
 
32) 内藤広郎, 柴田 近, 佐々木巖: 膵内分泌腫瘍. 外科 63: 1663-1671, 2001.
 
33) 砂村真琴, 荒井浩介, 江川新一・他: 膵内分泌腫瘍, インスリノーマ治療. 内分泌外科 15: 89-94, 1998.
 
34) Slooter GD, Mearadji A, Breeman WA, et al: Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg 88: 31-40, 2001.
PubMed
35) 土井隆一郎, 藤本康二, 和田道彦・他: 膵内分泌腫瘍. 外科 63: 1672-1678, 2001.
 
36) Wiedenmann B, Jensen RT, Mignon M, et al: Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 22: 309-318, 1998.
PubMed
37) Chandrasekharappa SC, Guru SC, Manickam P, et al: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276: 404-407, 1997.
PubMed
38) Mole SE, Mulligan LM, Healey CS, et al: Localisation of the gene for multiple endocrine neoplasia type 2A to a 480kb region in chromosome band 10q 11. 2. Hum Mol Genet 2: 247-252, 1993.
 
39) 吉本勝彦: 多発性内分泌腫瘍1型および2A型. 日内分泌会誌 88: 1222-1227, 1999.
 
40) 松浦喜美夫, 荒木京二郎: 多発性内分泌腫瘍2型. 日本臨床 58: 1437-1440, 2000.
 
41) van Heurn LW, Schaap C, Sie G, et al: Predictive DNA testing for multiple endocrine neoplasia 2: atherapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 34: 568-571, 1999.
 
P.910 掲載の参考文献
1) Joseph WL, Murray JF and Mulder DG: Mediastinal tumors-problems in diagnosis and treatment. Dis Chest 50: 150-160, 1966.
PubMed
2) Cox JD: Primary malignant germinal tumors of the mediastinum; astudy of 24 cases. Cancer 36: 1162-1168, 1975.
 
3) Nichols CR and Fox EP: Extra-gonadal and pediatric germ cell tumors. Hematol Oncol Clin North Am 5: 1189, 1991.
 
4) Kuhn M and Weissbach L Localization, incidence, diagnosis and treatment of extratesticular germ cell tumors. Urol Int 40: 166, 1985.
PubMed
5) Polansky SM, Barxick KW and Ravin CE: Primary mediastinal seminoma. Am J Roentgenol 132: 17-21, 1979.
 
6) Martini N, Golbey RB, Hajdu SI, et al: Primary mediastinal germ cell tumors. Cancer 33: 763-769, 1974.
PubMed
7) Dulmet EM, Macchiarini P, Suc B, et al: Germ cell tumors of the mediastinum: a30 year experience. Cancer 72: 1993, 1994.
 
8) International Germ Cell Consensus Classification: Aprognostic factor-based staging system for metastatic germ cell cancers. J CIin Oncol 15: 594, 1997.
 
9) Hainsworth JD and Greco FA: Extragonadal germ cell tumors and unrecognized germ cell tumors. Semin Oncol 19: 119, 1992.
 
10) Knapp RH, Hurt RD, Payne WS, et al: Malignant germ cell tumors of the mediastinum. J Thorac Cardiovasc Surg 89: 82-89, 1985.
PubMed
11) Jain KK, Bosl GJ, Bains MS, et al: The treatment of extragonadal seminoma. J CIin Oncol 2: 820-827, 1984.
 
12) Luna M and Valenzuela-Tamaritz J: Germ cell tumors of the mediastinum: postmortem findings. Am J CIin Pathol 65: 450, 1976.
 
13) Nichols CR, Saxman S, Williams SD, et al: Primary mediastinal nonseminomatous grem cell tumors-a modern single institution experience. Cancer 65: 1641-1646, 1990.
 
14) Nichols CR, Heerrma NA, Palmer C, et al: Kleinfelter's syndrome associated with mediastinal germ cell neoplasms. J CIin Oncol 5:1290-1294, 1987.
 
15) Nichols CR, Hoffman R, Einhorn LH, et al: Hematologic malignancies associated with primary mediastinal germ-cell tumors. Ann Intern Med 102: 603-609, 1985.
PubMed
16) Orazi A, Neiman RS, Urbright TM, et al: Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors. Cancer 71: 3873-3881, 1993.
 
17) Bosl GJ, Ilson DH, Rodriguez E, et al: Clinical relevance of the i(12 P) marker chromosome in germ cell tumors. JNCI 86: 349-355, 1994.
PubMed
18) Garnick MB and Griffin JD: Idiopathic thronbocytopenia in association with extragonadal germ cell cancer. Ann Intern Med 98: 926-927, 1983.
PubMed
19) Lewis BD, Hurt RD, Payne WS, et al: Benign teratomas of the mediastinum. J Thorac Cardiovasc Surg 86: 727, 1983.
PubMed
20) Schneider DT, Calaminus G, Reinhard H, et al: Primary mediastinal germ cell tumors in children and adolescents: Results of the German Cooperative Protocols MAKEI 83/86, 89, and 96. J CIin Oncol 18: 832-832, 2000.
 
21) Woolner LB, Jamplis RW and Kirklin JW: Seminoma(germinoma) apParantly primary in anterior mediastinum. N Eng J Med 252: 653-658, 1955.
 
22) Bush SE, Martinez A and Bagshaw MA: Primary mediastinal seminoma. Cancer 48: 1877, 1981.
PubMed
23) Einhorn LH and Williams SD: Chemotherapy of disseminated seminoma. Cancer Clin Trials 3: 307, 1980.
PubMed
24) Stanton GF, Bosl GJ and Whitmore WF Jr: VAB-6 as initial treatment of patients with advanced seminoma. J CIin Oncol 3: 336, 1985.
 
25) Schultz SM, Einhorn LH, Conces DJ, et al: Management of postchemotherapy residual rnass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 7: 1497, 1989.
 
26) Motzer R, Bosl G, Heclan R, et al: Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J CIin Oncol 5: 1064, 1987.
 
27) Einhorn LH: Testicular cancer as a model for a curable neoplasm. The Richard and Hilda Rosenthal Foundation Award Lecture. Cancer Res 141: 3275, 1981.
 
28) Saxman SB, Nichols CR and Einhorn LH: Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J CIin Oncol 12: 1390, 1994.
 
29) Fox EP, Weathers TD, Williams SD, et al: Outcome analysis for patients with persistent nonteratomatous germ cell tumor in poat-chemotherapy retroperitoneal lymph node dissections. J CIin Oncol 11: 1294, 1993.
 
30) Motzer RJ, Gulati S, Crown Jp, et al: High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors: early intervention is better tolerated. Cancer 69: 550, 1992.
PubMed
31) Siegert W, Beyer J, Strochsheer I, et al: High dose treatment with carboplatin, etoposide, and ifosfamide followed bu autologous stem-cell transplantation in relapsed or refractory germ cell cancer: aphase I/II study. J CIin Oncol 12: 1223, 1994.
 
32) Motzer RJ, Mazumdar M, Bosl GJ, et al: High-dose carboplatin, etoposide and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14: 1098, 1996.
PubMed
33) Broun ER, Nichols CR, Einhorn LH, et al: Salvage therapy with high dose chemotherapy and autologous bone marrow support in the treatment of primary non-seminomatous mediastinal germ cell tumors. Cancer 68: 1513, 1991.
 
34) Hartmann JT, Einhorn L, Nichols CR, et al: Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis. J Clin Oncol 19: 1641-1648, 2001.
 
35) Izant RJ and Filson HC: Sacrococcygeal teratomas: analysis of forty-three cases. Am J Surg 130: 617, 1975.
 
P.928 掲載の参考文献
1) Meadows A: Lessons about cancer from pediatric oncology, (対訳: 小児がん研究から学んだ癌研究) 癌遺伝学の夜明け, (中河原章・樋野興夫・編) , (財) 日本学会センター, 東京, 2002.
 
2) Farber S: Chemotherapy in the treatment of leukemia and Wilms'tumor. JAMA 198: 826-836, 1966.
PubMed
3) Saito T and the committee for the studies of the treatments and the biological characteristics of childhood cancers: Trends in survival of childhood malignancy for the past three decades 1: leukemia, malignant lymphoma, neuroblastoma, retinob- lastoma and neoplasms of the urinary and digestive organs. Acta Pediatr Jpn 37: 479-486, 1995.
 
4) Crist W and Kun LE: Common solid tumors of childhood. N Engl J Med 324: 461-471, 1991.
PubMed
5) Bleyer WA: What can be learned about childhood cancer from "Cancer Statistics Review 1973-1988". Cancer 71(suppl 10) : 3229-3236, 1993.
 
6) 熊谷昌明, 恒松由記子: 小児悪性腫瘍. 専門医のためのがん治療学レビュー'98, (最新主要文献と解読) , 総合医学社, 東京, 1997, pp 223-227.
 
7) Rabbitts TH: Chromosomal translocations in human cancer. Nature 372: 143-149, 1994.
PubMed
8) 中川原章: ゲノム研究からみた神経芽細胞腫. ゲノム医学 1: 255-264, 2001.
Medical*Online
9) Parkin DM, Stilller CA, Draper GJ, et al: International incidence of childhood cancer. IARC Scientific Publications, Lyon, France, 1988.
 
10) 恒松由記子, 伊藤知賀子, 味木和喜子: わが国の小児がんの疫学的動向. 小児科診療 62: 1129-1136, 1999.
 
11) 味木和喜子, 津熊秀明, 大島 明: わが国における小児がん登録の実現にむけて-地域がん登録からの提言-. 小児がん 39: 150-158, 2002
 
12) Ajiki W, Hanai A, Tsukuma H, Osaka Cancer Registry, 1981-89: In International incidence of childhood cancer, (ed by Parkin DM, et al) , IARC Scientific publications, Lyon, No 144, 1998, pp 189-191.
 
13) Ajiki W, Tsukuma H, Oshima A, et al: Effects of screening for neuroblastoma on incidence, mortality and survival rate in Osaka Japan. Cancer Causes Control 9: 631-636, 1998.
PubMed
14) Smith MA, Lynn A and Ries C: Childhood cancer: Incidence, survival, and mortality. In Principles and Practice of Childhood Cancer, (ed by Pizzo PA and Poplack DG) , 4th ed, Lippincott William&Wilkins, Philadelphia, 2002, pp 2--12.
 
15) 恒松由記子: 小児がんの疫学と家族性腫瘍. ゲノム医学 1: 239-247, 2001.
Medical*Online
16) 恒松由記子: 小児がんの遺伝的リスク評価と遺伝性腫瘍症の診療. 実験医学 19: 2660-2666, 2001.
 
17) Kundson AG: Hereditary cancers disclose a class of cancer genes. Cancer 63: 1888-1891, 1985.
 
18) Li FP: Cancer families: human models of susceptibility to neoplasis. Cancer Res 48: 5381, 1988.
 
19) Narod SA, Striller C and Leoir GM: An estimate of heritable fraction of childhood cancer. Br J Cacner 63: 993-999, 1991.
 
20) Mullvihill JJ, Davis S and Fromkin KR: The Catalog of human genes predisposing to neoplasia In Familial Cancer Management, (ed by Weber W, et al) , CRC Press, New York, 1966, pp 197-237.
 
21) 恒松由記子: Li-Fraumeni症候群. 日本臨床 58: 1442-1477, 2000.
Medical*Online
22) Li FP, Gauber JE, Friend SH, et al: Recommendations on predictive testing p 53 germline mutations among cancer prone individuals. J Natl Cancer Inst 84: 1156-1160, 1992.
 
23) 恒松由記子: 家族性腫瘍における遺伝子検査に関連したインフォームドコンセントと守秘義務. 外科治療 82: 1119-1124, 2000.
 
24) Gurney JG and Bondy ML: Epidemiologic research methods and childhood cancer. In Princeples and Practice of Childhood Cancer, (ed by Pizzo, PA and Poplack DG) , 4th ed, Lippincott William&Wilkins, Philadelphia, 2002, pp 13-20.
 
25) Ji BT, Shu XO, Linet MS, et al: Paternal cigarette smoking and the risk of childhood cancer among offspring of non-smoking mothers. J Natl Cancer Inst 89: 238-244, 1997.
PubMed
26) Maruyama K, Ikeda H, Koizumi T, et al: Acase-control study of perinatal factors and hepatoblastoma in children with an extremely low birth weight. Pediatr Int 42: 492-498, 2000.
 
27) 恒松由記子: 子どものがん. 家庭の医学, 保健同人社, 東京, 1994, pp 752-758.
 
28) Teresa JV and Stueber CP: Clinical assessment and differential diagnosis of the child with suspected cancer. In Principle and Practice of Pediatric Oncology, (ed by Pizzo PA and Poplack DG) , 4th ed, Lippincott William&Wilkins, Philadelphia, 2002, pp 140-159.
 
29) Braverman RM and Parker BR: Imaging studies in the diagnosis and management of pediatric malignancies. i. bid. pp 205-236, 2002.
 
30) Triche TJ: Molecular pathology of pediatric malignancies. i. bid. pp 161-204, 2002.
 
31) 金子安比古: 小児固形腫瘍における染色体異常, がん関連遺伝子. 小児内科 30: 185, 1998.
 
32) Reaman GH and Bleyer A for the Infants and adrescents with cancer: Special considerations. In Principle and Practice of Pediatric Oncology, (ed by Pizzo PA and Poplack DG) , 4th ed, Lippincott William&Wilkins, Philadelphia, 2002, pp 410-427.
 
33) Anderson RA and Marshall NS: The importance of the pediatric oncologist-nurse partnership in the delivery of total care in pediatric oncology. Med Pediatr Oncol 34: 259-262, 2000.
 
34) 恒松由記子, 掛江直子: がんの子どもへのインフォームドコンセントとオープンコミュニケーション. 小児科 37(7) : 891-900, 1997.
 
35) 恒松由記子: 小児の患者と家族背景を考慮したインフォームドコンセントのポイント. インフフォームド・コンセントガイダンス, (月本一郎・編) , 先端医学社, 東京, 2001, pp 108-123.
 
36) 小原美江, 齋藤千恵子, 山田ことみ. 他: 小児がんにおける疼痛アセスメント. がん看護 3: 118-124, 1998.
 
37) Mc Grath PJ(co-ordinator) , Beyer J, Cleeland C, et al: Report of the subcommittee on the methodologic issues in management of pain in childhood cancer. Pediatrics 86: 813-817, 1990.
 
38) Bessho F, Hashzume K, Nakajo T, et al: Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr 119: 237-241, 1991.
 
39) Shimada H, Chatten J, Newton WA Jr, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73: 405-416, 1984.
 
40) Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J CIin Oncol 11: 1466-1477, 1994.
 
41) Nickerson HJ, Matthay KK, Seeger RC, et al: Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: aChildren's Cancer Group study. J Clin Oncol 3: 477-486, 2000.
 
42) Brodeur GM, Azar C, Brother M, et al: Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer 70(6 Suppl) : 1685-1694, 1992.
 
42) Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328: 847-854, 1993.
PubMed
43) Silber JH, Evans AE and Fridman M: Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res 51: 1426-1433, 1991.
PubMed
44) 松村隆文, 細井 創, 澤田 淳: 神経芽細胞腫. 小児科 39: 1367-1379, 1998.
 
45) Shafford EA, Rogers DW and Pritchard J: Advanced neuroblastoma: Improved response rate using a multiagent regimen(OPEC) including seuential cisplatin and VM-26. J CIin Oncol 2: 742-747, 1984.
 
46) Haase GM, O'Leary MC, Ramsay NK, et al: Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg 26: 1119-1124, 1991.
 
47) Kushner BH, LaQuaglia MP, Bonilla MA, et al: Highly effective induction therapy for stage 4 neuroblastoma in children over l year of age. J CIin Oncol 12: 2607-2613, 1994.
 
48) Kaneko M, Nishihira H, Mugishima H, et al: Stratification of treatment of stage 4 neuroblastoma patients based on Nmyc amplification status. Study Group of Japan for Treatment of Advanced Neuroblastoma, Tokyo, Japan. Med Pediatr Oncol 1: 1-7, 1998.
 
49) Kaneko M, Tsuchida Y, Uchino J, et al: Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma. J Pediatr Hematol Oncol 21: 3190-197, 1999.
 
50) Cheung NK, Kushner BH, LaQuaglia M, et al: N7: Anovel multi-modality therapy of high risk neuroblastoma(NB) in children diagnosed over l year of age. Med Pediatr Oncol 36: 227-230, 2001.
 
51) Pritchard J, McElwain TJ and Graham-Pole J: High dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 45: 86-94, 1982.
 
52) Dini G, Lanino E, Garaventa A, et al: Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases. J CIin Oncol 9: 962-969, 1991.
 
53) Mugishima H, Iwata M, Okabe I, et al: Autologous bone marrow transplantation in children with advanced neuroblastoma. Cancer 74: 972-977, 1994.
PubMed
54) Stram DO, Matthey KK, O'Leary M, et al: Consolidation chemotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: Areport of two concurrent Children's Cancer Group studies. J CIin Oncol 14: 2417-2426, 1996.
 
55) Shuster JJ: The role of autologous bone marrow transplantation in advanced neuroblastoma. J Clin Oncol 14: 2413-2414, 1996.
PubMed
56) Kletzel M, Katzenstein HM, Haut PR, et al: Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II Study. J CIin Oncol 9: 2284-2292, 2002.
 
57) Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173, 1999.
 
58) Villablanca JD, Khan AA, Avramis VI, et al: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J CIin Oncol 13: 894-901, 1995.
 
59) Klingebiel T, Bader P, Bares R, et al: Treatment of neuroblastoma stage 4 with'3i 1-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 34: 1398-1402, 1998.
 
60) Yanik GA, Levine JE, Matthay KK, et al: Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell supPort for the treatment of neuroblastoma. J CIin Oncol 20(8) : 2142-2149, 2002.
 
61) Sawada T, Hirayama M, Nakata T, et al: Mass screening for neuroblastoma in infants in Japan. Lancet 2(8397) : 271-273, 1984.
PubMed
62) 神経芽腫委員会: 神経芽腫マススクリーニングの全国集計結果. 小児がん 38: 235-241, 2001.
 
63) Murphy S, Corn SL, Craft AW, et al: Do children benefit from mass screening for neuroblastoma?Lancet 337: 344-345, 1991.
 
64) Huddart SN and Mann JR: Screening for neuroblastoma. Arch Dis Child 66: 1272-1274, 1991.
PubMed
65) Woods WG, Tuchman M, Robison LL, et al: A population-based study of the usefulness of screening for neuroblastoma. Lancet 348: 1682-1687, 1996.
PubMed
66) Schilling FH, Spix C, Berthold F, et al: Neuroblastoma screening at one year of age. N Engl J Med 346: 1047-1053, 2002.
PubMed
67) Woods WG, Gao RN, Shuster JJ, et al: Screening of infants and mortality due to neuroblastoma. N Engl J Med 346: 1041-1046, 2002.
PubMed
68) Yamamoto K, Ohta S, Ito E, et al: Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol 20: 1209-1214, 2002.
PubMed
69) 菊地正悟, 石本浩市, 福渡 靖・他: 神経芽腫マス・スクリーニングの死亡率減少効果測定方法の考按. 日小児会誌 99: 1855-1858, 1995.
 
70) Nishihira H, Toyoda Y, Tanaka Y, et al: Natural course of neuroblastoma detected by mass screening: A5-year prospective study at a single institution. J CIin Oncol 18: 3012-3017, 2000.
 
71) Hachitanda Y, Ishimoto K, Hata J, et al: One hundred neuroblastomas detected through a mass screening system in Japan. Cancer 74: 3223-3226, 1994.
PubMed
72) Green DM, Breslow NE, Evans I, et al: Effect of dose intensity of chemotherapy on the hematological toxicity of the treatment of Wilms'tumor. A report from the National Wilms'Tumor Study. Am J Pediatr Hematol Oncol 16: 207-212, 1994.
PubMed
73) Green DM, Breslow NE, Beckwith JB, et al: Effect of duration of treatment on treatment outcome and cost of treatment for Wilms'tumor: areport from the National Wilms'Tumor Study Group. J CIin Oncol 16: 3744-3751, 1998.
 
74) Green DM, Breslow NE, Beckwith JB, et al: Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms'tumor: areport from the National Wilms'Tumor Study Group. J Clin Oncol 16: 237-245, 1998.
 
75) Grundy PE, Telzerow PE, Breslow N, et al: Loss of heterozygosity for chromosomes 16 q and l p in Wilms'tumors predicts an adverse outcome. Cancer Res 54: 2331-2333, 1994.
 
76) Greenberg M, Burnweit C, Filler R, et al: Preoperative chemotherapy for children with Wilms'tumor. J Pediatr Surg 26: 949-953, 1991.
PubMed
77) Green DM, Breslow NE, Ii Y, et al: The role of surgical excision in the management of relapsed Wilms'tumor patients with pulmonary metastases: Areport from the National Wilms'Tumor Study. J Pediatr Surg 26: 728-733, 1991.
 
78) Green DM, Breslow NE, Beckwith JB, et al: Screening of children with hemihypertrophy, aniridia, and Beckwith-Wiedemann syndrome in patients with Wilms'tumor: Areport from the National Wilms'Tumor Study. Med Pediatr Oncol 21: 188-192, 1993.
 
79) 金子安比古: Wilms腫瘍遺伝子とがん. CRC 1: 82-89, 1992.
 
80) Reeve AE: Role of genomic imprinting in Wilms'tumor and overgrowth disorders. Med Pediatr Oncol 27: 40-470, 1996.
 
81) Moulton T, Chung W, Yuan L, et al: Genomic imprinting and Wilm's tumor. Med Pediatr Oncol 27: 476-483, 1996.
 
82) 岡 敏明, 金子安比古: Denys-Drash症候群. Mol Med 33: 136-137, 1996.
 
83) Huff V: Genotype phenotype correlations in Wilms'tumor. Med Pediatr Oncol27: 408-414, 1996.
PubMed
84) Li FP, Breslow NE, Morgan JM, et al: Germline WT l mutations in Wilms'tumor Patients: Preliminary results. Med Pediatr Oncol 27: 404-407, 1996.
 
85) Pelletier J, Li FP, Harber DA, et al: WT 1 mutations contribute to abnormal genital development and hereditary Wilms'tumor. Nature 353: 431, 1991.
 
86) Kumar R Fitzgerald R and Breatnach F: Conservative surgical management of bilateral Wilms'tumor: results of the United Kingdom Children's Cancer Study Group. J Urol 160: 1450-1453, 1998.
 
87) Anderson J, Slater O, McHugh K, et al: Response without shrinkage in bilateral Wilms'tumor: significance of rhabdomyomatous histology. J Pediatr Hematol0ncol 24: 31-34, 2002.
 
88) Wexler LH, Crist WM and Helman LJ: Rhabdomyosarcoma and undifferentiated sarcomas. In Principles and Practice of Pediatric Oncology, (ed by Pizzo PA and Poplack DG) , 4th ed, Lippincott Williams&Wilkins, Philadelphia, 2002, pp 939-971.
 
89) Crist W, Gehan EA, Ragab AH, et al: The third intergroup rhabdomyosarcoma study. J Clin Oncol 13: 610-630, 1995.
PubMed
90) Baker KS, Anderson JR, Link MP, et al: Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J CIin Oncol 18: 2427-2434, 2000.
PubMed
91) Pappo AS, Lyden E, Breneman J, et al: Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. J CIin Oncol 19: 213-219, 2000.
 
92) Donaldson SS, Meza J, Breneman JC, et al: Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma-a report from the IRSG. Int J Radiat Oncol Biol Phys 51: 718-728, 2001.
PubMed
93) Flamant F, Rodary C, Rey A, et al: Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT 84. Eur J Cancer 34: 1050-1062, 1998.
 
94) Newton WA, Gehan EA, Webber BL, et al: Classification of rhabdomyosarcomas and related sarcomas: pathologic aspects and proposal for a new classification-an Intergroup Rhabdomyosarcoma Study. Cancer 76: 1073-1085, 1995.
PubMed
95) Andrassy RJ, Corpron CA, Hays D, et al: Extremity sarcomas: an analysis of prognostic factors from the Intergroup Rhabdomyosarcoma Study III. J Pediatr Surg 31: 191-196, 1996.
 
96) Raney RB, Anderson JR, Kollath J, et al: Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: Report from the Intergroup Rhabdomyosarcoma Study(IRS) -III, 1984-1991. Med Pediatr Oncol 6: 413-420, 2000.
PubMed
97) Oberlin O, Rey A, Anderson J, et al: Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment-results of an international workshop. J Clin Oncol 19: 197-204, 2001.
 
98) Raney RB, Asmar L, Vassilopoulou-Sellin R, et al: Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: Adescriptive report from the Intergroup Rhabdomyosarcoma Studies(IRS) -II and-III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. Med Pediatr Oncol 4: 362-371, 1999.
 
99) Wolden SL, Anderson JR, Crist WM, et al: Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: Areport from the Intergroup Rhabdomyosarcoma Studies I to III. J CIin Oncol17: 3468-3475, 1999.
 
100) Carli M, Colombatti R, Oberlin O, et al: High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 17: 2796-2803, 1999.
PubMed
101) Urban CE, Mache CJ, Schwinger W, et al: Undifferentiated(embryonal) sarcoma of the liver in childhood. Cancer 72: 2511-2516, 1993.
PubMed
102) Bisogno G, Pilz T, Perilongo G, et al: Undifferentiated sarcoma of the liver in childhood: acurable disease. Cancer 94: 252-257, 2002.
 
103) Filler RM, Ehrlich PF, Greenberg ML, et al: Preoperative chemotherapy in hepatoblastoma. Surgery 110: 591-597, 1991.
PubMed
104) Ninane J, Perilongo G, Stalens JP, et al: Effectiveness and toxicity of cisplatin and doxorubicin(PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: ASIOP pilot study. Med Pediatr Oncol 19: 199-203, 1991.
 
105) Ortega JA, Douglass EC, Feusner JH, et al: Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: Areport from the Children's Cancer Group and the Pediatric Oncology Group. J CIin Oncol 18: 2665-2675, 2000.
 
106) von Schweinitz D, Hecker H, Harms D, et al: Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma-a report from the German Cooperative Pediatric Liver Tumor Study HB-89. J Pediatr Surg 30: 845-852, 1995.
 
107) Shields CL, De Potter P, Himelstein BP, et al: Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol114: 1330-1338, 1996.
PubMed
108) Gallie BL, Budning A, DeBoer G, et al: Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 114: 1321-1328, 1996.
PubMed
109) Greenwald MJ and Strauss LC: Treatment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy. Ophthalmology 103: 1989-1997, 1996.
PubMed
110) Friedman DB, Himelstein B, Shields CL, et al: Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J CIin Oncol 18: 12-17, 2000.
 
111) Ablin AR, Krailo MD, Ramsay NKC, et al: Results of treatment of malignant germ cell tumors in 93 children: Areport from the Childrens Cancer Study Group. J CIin Oncol 9: 1782-1792, 1991.
 
112) Meadows AT and Tsunematsu Y: Late effects after the treatment for neuroblastoma. In Neuroblsotoma, (ed by Brodeur DM, et al) , Elsevier Science, Amsterdam, 2000, pp 561-570.
 
113) Meister LA and Meadows AT: Late effects of childhood cancer therapy. Curr Probl Pediatr 23: 102-131, 1993.
PubMed
114) 恒松由記子: 悪性固形腫瘍患児の晩期障害. 小児期の悪性固形腫瘍, (山本正生・編) , 長井書店, 大阪, 1996, pp 315-328.
 
115) 恒松由記子: 小児の治療関連2次性白血病. 小児内科 28(増刊号) : 1192-1196, 1996.
 
116) 恒松由記子: 小児悪性腫瘍後の妊娠. 周産期医学 32: 1114-1119, 2002.
 
117) Mertens AC, Yaui Y, Neglia JP, et al: Late mortality in five year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol 19: 3163-3172, 2001.
 
P.942 掲載の参考文献
1) Pui CH, Evans WE and Gilbert JR: Meeting report: International Childhood ALL Work-shop: Memphis, TN, 3-4 December 1997. Leukemia 12: 1313-1318, 1998.
 
2) Kersey JH: Fifty years of studies of the biology and therapy of childhood leukemia. Blood 90: 4243-4251, 1997.
PubMed
3) Hayashi Y: Molecular genetics of recurring chromosome abnormalities in acute myeloid leukemia. Semin Hematol 37: 368-380, 2000.
PubMed
4) Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias. French-American-
PubMed
5) British(FAB) co-operative group. Br J Haematol33: 451-458, 1976. Childhood ALL Collaborative Group: Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: over-view of 42 trials involving 12000 randomised children. Lancet 347: 1783-1788, 1996.
 
6) Reiter A, Schrappe M, Ludwig W, et al: Chemotherapy in 998 unselected childhood acute Iymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM-86. Blood 84: 3122, 1994.
 
7) Kamps WA, Bokkerink JP, Hahlen K, et al: Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7(1988-1991) . Blood 94: 1226-1236, 1999.
 
8) Tsuchida M, Ikuta K, Hanada R, et al: Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 19811995. Leukemia 14: 2295-2306, 2000.
 
9) Toyoda Y, Manabe A, Tsuchida M, et al: Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 18: 1508-1516, 2000.
PubMed
10) Ribeiro RC, Broniscer A, Rivera GK, et al: Philadelphia chromosome positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts. Leukemia 11: 1493-1496, 1997.
PubMed
11) Schrappe M, Arico M, Harbott J, et al: Philadelphia chromosome-positive(Ph-) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92: 27302741, 1998.
PubMed
12) Bennett JM, Catovsky D, Daniel MT, et al: Proposal for the recognition of minimally differentiated acute myeloid leukaemia(AML-M O) . Br J Haematol 78: 325-329, 1991.
 
13) Raimondi SC, Kalwinsky DK, Hayashi Y, et al: Cytogenetics of childhood acute nonlymphocytic leukemia. Cancer Genet Cytogenet 40: 13-27, 1989.
PubMed
14) Nakamura T, Largaespada DA, Lee MP, et al: Fusion of the nucleoporin gene NUP 98 to HOXA g by the chromosome translocation t(7; 11) (p15; p15) in human myeloid leukaemia. Nat Genet 12: 154-158, 1996.
 
15) 林 泰秀: 白血病におけるNUP98遺伝子とHOX遺伝子. 日小児血液会誌 16: 39-49, 2002.
 
16) Kong X-T, Ida K, Ichikawa H, et al: Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16; 21) (p11; q22) and identification of a novel transcript. Blood 90: 1192-1199, 1997.
 
17) 気賀沢寿人: 小児急性骨髄性白血病. 小児科診療 65: 274-280, 2002.
 
18) Creutzig U, Ritter J and Schellong G: Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AMLBFM-83 as compared with study AML-BFM-78. Blood 75: 1932-1940, 1990.
PubMed
19) Woods WG, Kobrinsky N, Buckley JD, et al: Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: areport from the Children's Cancer Group. Blood 87: 4979-4989, 1996.
 
20) Michel G, Leverger G, Leblane T, et al: Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A proepective study from the French Society of Pediatric Hematology and Immunology(SHIP) . Bone Marrow Transplant 17: 191-196, 1995.
 
21) Ravindranath Y, Yeager AM, Chang MN, et al: Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 334: 1428-1434, 1996.
PubMed
22) Taki T, Ida K, Bessho F, et al: Frequency and clinical significance of MLL gene rearrangement in infant acute leukemia. Leukemia 10: 1303-1307, 1996.
PubMed
23) Murphy SB, Fairclough DL, Hutchison RE, et al: Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 7: 186-193, 1989.
 
24) Magrath I, Adde M, Shad A, et al: Adults and children with small non cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J CIin Oncol 14: 925-934, 1996.
 
25) 佐々木邦明, 大伴 寛, 川井 進・他: 小児悪性リンパ腫568例の病態と予後. 日児誌 91: 690-700, 1987.
 
26) Hudson MM and Donaldson SS: Hodgkin's Disease. In Principles and practice of pediatric Oncology, (ed by Pizza PA and Poplack DG) , 3rd ed, Raven Press, New York, 1997, pp 523-543.
 
P.952 掲載の参考文献
1) Brendel C and Neubauer A: Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions. Leukemia 14(10) : 1711-1717, 2000.
PubMed
2) 厚生省がん研究助成金「地域がん登録の精度向上と活用に関する研究」平成10年度報告書.
 
3) http://wwwdbtk. mhlw. go. jp/toukei/kihon/indexy_L2. html
 
4) 金丸昭久: 白血病. 本邦臨床統計集(日本臨床増刊号) 59(790) : 513-556, 2001.
 
5) 大野良之: 不応性貧血. 特定疾患治療研究事業未対象疾患の疫学像を把握するための調査研究平成11年度研究業績集, 2000.
 
6) Takeyama K, Seto M, Uike N, et al: Therapy-related leukemia and myelodysplastic syndrome: alarge-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 71(2) : 144-152, 2000.
 
7) Naoe T, Takeyama K, Yokozawa T, et al: Analysis of genetic polymorphism in NQO 1, GST-M 1, GST-T 1, and CYP 3 A4in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 6(10) : 4091-4095, 2000.
 
8) Jaffe ES, Harris NL, Stein H, et al: World Health Organization classification of tumors: Pathology and genetics of tumors of haematopoietic and lymphoid tissues, IARC press, Lyon, 2001.
 
9) Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103(4) : 620-625, 1985.
PubMed
10) Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2) : 189-199, 1982.
PubMed
11) Lowenberg B, Downing JR and Burnett A: Acute myeloid leukemia. N Engl J Med 341(14) : 1051-1062, 1999.
PubMed
12) Pui CH and Evans WE: Acute lymphoblastic Ieukemia. N Engl J Med 339(9) : 605-615, 1998.
 
13) Look AT: Oncogenic transcription factors in the human acute leukemias. Science 278(5340) : 1059-1064, 1997.
PubMed
14) Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92(7) : 2322-2333, 1998.
 
15) Wetzler M, Dodge RK, Mrozek K, et al: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 93(11) : 3983-3993, 1999.
 
16) Appelbaum FR: Molecular diagnosis and clinical decisions in adult acute leukemia. Semin Hematol 36(4) : 401-410, 1999.
PubMed
17) Kiyoi H, Naoe T, Nakano Y, et al: Prognostic implication of FLT 3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93(9) : 3074-3080, 1999.
 
18) Hangaishi A, Ogawa S, Imamura N, et al: Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS 1/p 161NK 4 A/CDKN 2, MTS 2/p 151NK 4 B, p 53, and Rb genes in primary lymphoid malignancies. Blood 87(12) : 4949-4958, 1996.
 
19) Ohno R: How high can we increase complete remission rate in adult acute myeloid leukemia? lnt J Hematol 72(3) : 272-279, 2000.
 
20) Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58(18) : 4173-4179, 1998.
PubMed
21) Degos L and Wang ZY: All-trans retinoic acid in acute promyelocytic leukemia. Oncogene 20(49) : 7140-7145, 2001.
 
22) Kanamaru A, Takemoto Y, Tanimoto M, et al: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 85(5) : 1202-1206, 1995.
 
23) Yoshida H, Kitamura K, Tanaka K, et al: Accelerated degradation of PML-retinoic acid receptor alpha(PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res 56(13) : 2945-2948, 1996.
PubMed
24) Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: aSouthwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96(13) : 4075-4083, 2000.
 
25) Baudard M, Beauchamp-Nicoud A, Delmer A, et al: Has the prognosis of adult patients with acute myeloid leukemia improved over years?Asingle institution experience of 784 consecutive patients over a 16-year period. Leukemia l3(10) : 1481-1490, 1999.
 
26) Sawyers CL: Chronic myeloid leukemia. N Engl J Med 340(17) : 1330-1340, 1999.
PubMed
27) Faderl S, Talpaz M, Estrov Z, et al: The biology of chronic myeloid leukemia. N Engl J Med 341(3) : 164-172, 1999.
PubMed
28) Ohnishi K, Ohno R, Tomonaga M, et al: A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86(3) : 906-916, 1995.
PubMed
29) Druker BJ and Lydon NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J CIin Invest 105(1) : 3-7, 2000.
 
30) Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346(9) : 645-652, 2002.
PubMed
31) Hotta T: Clonality in hematopoietic disorders. Int J Hematol 66(4) : 403-412, 1997.
PubMed
32) Fenaux P: Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol 73(4) : 429-437, 2001.
PubMed
33) Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6) : 2079-2088, 1997.
PubMed
34) 日本造血移植学会平成13年度全国調査報告書. 日本造血移植学会全国データ集計事務局, 名古屋, 2001.
 
P.959 掲載の参考文献
1) Thomas ED and Storb R: The development of the scientic foundation of hematopoietic cell transplantation based on animal and human studies. In Hematopoietic cell transplantation, (ed by Thomas ED, Blume KG and Forman SJ) , Blackwell, Maldon, 1999, pp 1-11.
 
2) Main J and Prehn R: Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst 15: 1023-1029, 1955.
PubMed
3) Ford C, Hamerton J, Barnes D, et al: Cytological identification of radiation-chimeras. Nature 177: 452-454, 1956.
PubMed
4) van Bekkum DW, Vos O and Weyzen W: Homo-et heterogreffe tissues hematopoietiques chez la souris. Rev d'Hemat 11: 477-485, 1956.
 
5) Barnes D, Corp MJ, Loutit J, et al: Treatment of murine leukemaemia with x-rays and homologous bone marrow. Preliminary Communication. Br Med J 2: 626-627, 1956.
 
6) Snell G: The Nobel Prize Lectures in Immunology. Lecture for the Nobel Prize for Physiology or Medicine, 1980. Scand JImmunol 36: 513-526, 1992.
PubMed
7) Lochte H Jr, Levy A, Guenther D, et al: Prevention of delayed foreign marrow reaction in lethally irradiated mice by early administration of methotrexate. Nature 196: 1110-1111, 1962.
 
8) Storb R, Raff RF, Appelbaum FR, et al: What radiation dose for DLA-identical canine marrow grafts? Blood 72(4) : 1300-1304, 1988.
PubMed
9) Storb R and Deeg HJ: Failure of allogeneic canine marrow grafts after total-body irradiation. Allogeneic "resistance" versus transfusion-induced sensitization. Transplantation 42(6) : 571-580, 1986.
PubMed
10) Storb R, Raff RF, Appelbaum FR, et al: Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. Blood 74(3) : 1139-1143, 1989.
PubMed
11) 日本造血幹細胞学会全国データ事務局: 日本造血細胞移植学会平成13年度全国調査報告書.
 
12) Mehta J, Powles R, Singhal S, et al: Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 16(4) : 499-506, 1995.
PubMed
13) Miggiano MC, Gherlinzoni F, Rosti G, et al: Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia. Leukemia 10(3) : 402-409, 1996.
PubMed
14) Gorin NC, Labopin M, Fouillard L, et al: Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation(EBMT) . Bone Marrow Transplant 18(1) : 111-117, 1996.
 
15) Meloni G, Vignetti M, Avvisati G, et al: BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplant 18(4) : 693-698, 1996.
PubMed
16) Fukushima T, Urasaki Y, Ueda T, et al: Treatment of acute lymphoblastic leukemia in adults: areview of 10 year study of Japan Adult Leukemia Study Group. Rinsho Ketsueki 38(5) : 385-388, 1997.
 
17) Ueda T, Miyawaki S, Asou N, et al: Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1year maintenance and intensification therapy: the ALL 90 study of the Japan Adult Leukemia Study Group. Int J Hematol 68(3) : 279-289, 1998.
 
18) Doney K, Buckner CD, Fisher L, et al: Autologous bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant 12(4) : 315-321, 1993.
PubMed
19) Kersey JH, Weisdorf D, Nesbit ME, et al: Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med 317(8) : 461-467, 1987.
PubMed
20) Fiere D, Lepage E, Sebban C, et al: Adult acute lymphoblastic leukemia: amulticentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol 11(10) : 1990-2001, 1993.
 
21) Silver RT, Woolf SH, Hehlmann R, et al: An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94(5) : 1517-1536, 1999.
PubMed
22) Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14) : 1038-1042, 2001,
PubMed
23) Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14) : 103H037, 2001.
PubMed
24) Gale RP, Hehlmann R, Zhang MJ, et al: Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood 91(5) : 1810-1819, 1998.
PubMed
25) Kolb HJ, Mittermuller J, Clemm C, et al: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12) : 2462-2465, 1990.
PubMed
26) Shiobara S, Nakao S, Ueda M, et al: Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 26(7) : 769-774, 2000.
PubMed
27) De Witte T: Stem cell transplantation for patients with myelodysplastic syndrome and secondary leukemias. Int J Hematol 72(2) : 151-156, 2000.
PubMed
28) Armitage JO: Autologous bone marrow transplantation for Hodgkin's disease. Ann Oncol 3(suppl 4) : 95-96, 1992.
 
29) Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341(8852) : 1051-1054, 1993.
PubMed
30) Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333(23) : 1540-1545, 1995.
PubMed
31) Martelli M, Vignetti M, Zinzani PL, et al: High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to frontline chemotherapy: aprospective randomized italian multicenter study. J CIin Oncol 14(2) : 534-542, 1996.
 
32) Verdonck LF, van Putten WL, Hagenbeek A, et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332(16) : 1045-1051, 1995.
PubMed
33) Haioun C, Lepage E, Gisselbrecht C, et al: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH 87-2. Groupe d'Etude des Lymphomes de l'Adulte. J CIin Oncol 15(3) : 1131-1137, 1997.
 
34) Pettengell R, Radford JA, Morgenstern GR, et al: Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J CIin Oncol 14(2) : 586-592, 1996.
 
35) Gianni AM, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336(18) : 1290-1297, 1997.
PubMed
36) Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325(22) : 1525-1533, 1991.
PubMed
37) Ogura M, Kagami Y, Suzuki R, et al: Phase I/II trial of cure-oriented high-dose chemoradiotherapy with transplantation of CD34+peripheral blood stem cells purified by the immunomagnetic bead method for refractory hematological malignancies. Nagoya CD34+PBSCT Study Group. Cancer Chemother Pharmacol 40(suppl) : S 51-57, 1997.
 
38) Horning SJ, Negrin RS, Hoppe RT, et al: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 97(2) : 404-409, 2001.
 
39) Attal M, Harousseau JL, Stoppa AM, et al: Aprospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335(2) : 91-97, 1996.
 
40) Moreau P, Facon T, Attal M, et al: Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99(3) : 731-735, 2002.
PubMed
41) Barlogie B, Jagannath S, Vesole DH, et al: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89(3) : 789-793, 1997.
PubMed
42) Varterasian M, Janakiraman N, Karanes C, et al: Transplantation in patients with multiple myeloma: amulticenter comparative analysis of peripheral blood stem cell and allogeneic transplant. Am J Clin Oncol 20(5) : 462-466, 1997.
 
43) Bjorkstrand BB, Ljungman P, Svensson H, et al: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: aretrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88(12) : 4711-4718, 1996.
 
44) Gahrton G, Tura S, Ljungman P, et al: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. JCIin Oncol 13(6) : 1312-1322, 1995.
PubMed
45) Badros A, Barlogie B, Siegel E, et al: Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol20(5) : 1295-1303, 2002.
 
46) Appelbaum FR: Haematopoietic cell transplantation as immunotherapy. Nature 411(6835) : 385-389, 2001.
PubMed
47) Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15(6) : 825-828, 1995.
PubMed
48) Lazarus HM, Vogelsang GB and Rowe JM: Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group(ECOG) . Bone Marrow Transplant 19(6) : 577-600, 1997.
 
49) Ho VT and Soiffer RJ: The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98(12) : 3192-3204, 2001.
PubMed
50) Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3) : 555-562, 1990.
PubMed
51) Morishima Y, Morishita Y, Tanimoto M, et al: Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood 74(6) : 2252-2256, 1989.
PubMed
52) 小寺良尚, 斎藤英彦: 感染症 造血幹細胞移植マニュアル. 第2版, 日本医学館, 東京, 1998, pp 429-500.
 
53) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 6(6 a) : 659-713; 715; 717-727; quiz 729-733, 2000.
 
54) Hughes WT, Armstrong D, Bodey GP, et al: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 25(3) : 551-573, 1997.
 
55) Korbling M, Przepiorka D, Huh YO, et al: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts[see comments]. Blood 85(6) : 1659-1665, 1995.
 
56) Powles R, Mehta J, Kulkarni S, et al: Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: arandomised trial. Lancet 355(9211) : 1231-1237, 2000.
PubMed
57) Bensinger WI, Martin PJ, Storer B, et al: Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344(3) : 175-181, 2001.
PubMed
58) Sasazuki T, Juji T, Morishima Y, et al: Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 339(17) : 1177-1185, 1998.
 
59) Morishima Y, Sasazuki T, lnoko H, et al: The clinical significance of human leukocyte antigen(HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99(11) : 4200-4206, 2002.
 
60) Cairo MS and Wagner JE: Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood 90(12) : 4665-4678, 1997.
PubMed
61) Rubinstein P, Carrier C, Scaradavou A, et al: Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 339(22) : 1565-1577, 1998.
PubMed
62) Laughlin MJ, Barker J, Bambach B, et al: Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344(24) : 1815-1822, 2001.
PubMed
63) Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3) : 756-763, 1998.
PubMed
64) Childs R, Chernoff A, Contentin N, et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343(11) : 750-758, 2000.
PubMed
65) Aversa F, Tabilio A, Velardi A, et al: Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype[see comments]. NEngl J Med 339(17) : 1186-1193, 1998.
 
66) Guinan EC, Boussiotis VA, Neuberg D, et al: Transplantation of anergic histoincompatible bone marrow allografts. N Engl JMed 340(22) : 1704-1714, 1999.
 
P.968 掲載の参考文献
1) がんの統計編集委員会: がんの統計'01. (柿添忠生・編) , 財団法人がん研究振興財団, 2001.
 
2) Lymphoma Study Group of Japanese Pathologists: The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 50: 696-702, 2000.
 
3) Lukes RJ and Butler JJ: The pathology and nomenclature of Hodgkin's disease. Cancer Res 26: 1063-1243, 1966.
PubMed
4) Harris NL, Jaffe ES, Stein H, et al: Arevised European-American classification of lymphoid neoplasms: aproposal from the International Lymphoma Study group. Blood 84: 1361-1392, 1994.
 
5) Harris NL, Jaffe ES, Diebold J, et al: The World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues. Report of the Clinical Advisary Committee meeting, Airline House, Virginia, November l997. Ann Oncol 10: 1419-1432, 1999.
 
6) Marafioti T, Hummel M, Anagnostopoulos I, et al: Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 337: 453-458, 1997.
PubMed
7) von Wasielewski R, Mengel M, Fisher R, et al: Classical Hodgkin's disease: clinical impact of the immunophenotype. Am JPahtol 15: 1123-1130, 1997.
 
8) Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31: 1860-1861, 1971.
 
9) Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convend to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J CIin Oncol7: 1630-1636, 1989.
 
10) Glatstein E, Guernesy JM, Rosenberg SA, et al: The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer 24: 709-718, 1969.
 
11) Mauch PM: Controversies in management of early stage Hodgkin's disease. Blood 318-329, 1994.
PubMed
12) Aisenberg AC: Problems in Hodgkin's disease management. Blood 93: 716-769, 1999.
 
13) Wagstaff J, Steward W, Jones M, et al: Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP. Hematol Oncol 15(Suppl 1) : 47-49, 1986
 
14) Gobbi PG, Mazza P, et al: Multivariate analysis of Hodgkin's disease prognosis: fitness and use of a directly predictive equation. Haematologica 74: 29-38, 1989.
PubMed
15) Straus DJ, Gaynor JJ, Meyers J, et al: Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J CIin Oncol 8: 1173-1186, 1990.
 
16) Specht L: Prognostic factors in Hodgkin's disease. Cancer Treat Rev 18: 21-53, 1991.
PubMed
17) Proctor SJ and Taylor PR: Classical staging of Hodgkin's disease is inappropriate for selecting patients for clinical trials of intensive therapy: the case for the objective use of prognostic factor information in addition to classical staging. Leukemia 7: 1911-1914, 1993.
PubMed
18) Hasenclever D and Diehl V: Aprognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J 339: 1506-1514, 1998.
 
19) Longo D, Glatstein E, Duffey PL, et al: Radiation therapy versus combination chemotherapy in the treatment of earlystage Hodgkin's disease: seven-year results of a prospective randomized trial. J CIin Oncol 19: 906-917, 1991.
 
20) Mauch PM, Canellos GP, Schulman LN, et al: Mantle irradiation alone for selected patients with laparotomy-staged I A to II A Hodgkin's disease: preliminary results of a prospective trial. J CIin Oncol 13: 947-952, 1995.
 
21) MacKenzie RG, Franssen E, Wong R, et al: Risk-adapted therapy for clinical stage I-II Hodghkin's disease: 7-years results of radiotherapy alone for low-risk disease-risk disease and ABVD and radiotherapy for high-risk disease. Clin Oncol 278-288, 2000.
 
22) Bursamolino E, Lunghi F, Orlandi E, et al: Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Haematologica 85: 1032-1039, 2000.
 
23) Straus DJ, Yahalom J, Gaynor J, et al: Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin's disease. Cancer 69: 1052-1060, 1992.
PubMed
24) Zittoun R, Audebert A, Hoerni B, et al: Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J CIin Oncol 3: 207-214, 1985.
 
25) Specht L, Gray RG, Clarke MJ, et al: Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: ameta-analysis of 23 randomized trials involving 3888 patients. J CIin Oncol 16: 830-843, 1998.
 
26) Longo DL, Young RC, Wesley M, et al: Twenty years of MOPP therapy for Hodgkin's disease. J CIin Oncol 4: 1295-1306, 1986.
 
27) Bonadonna G, Santoro A, Gianni AM, et al: Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. Ann Oncol 2(Suppl 1) : 9-16, 1991.
 
28) Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327: 1478-1484, 1992.
PubMed
29) Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ABV hybid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21: 607-614, 2003.
 
30) Takenaka T, Mikuni C, Miura A, et al: Alternating combination chemotherapy C-MOPP(cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd(adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: amulticenter phase II study(JCOG 8905) . Jpn J CIin Oncol 30: 146-152, 2000.
 
31) Ogura M, Takenaka T, Kagami Y, et al: Phase II study of ABVd therapy for advanced stage Hodgkin's disease(Hd) in Japan: Japan Clinical Oncology Group(JCOG) study(JCOG 9305) . Proc ASCO: 2673 a, 2001.
 
32) Glick JH, Young ML, Harrington D, et al: MOPP/ABVD hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8 year results of the intergroup trial: J CIin Oncol 16: 19026, 1998.
 
33) Viviani S, Bonadonna G, Santoro A, et al: Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J CIin Oncol 14: 1421-1430, 1996.
 
34) Connors JM, Klimo P and Adams G: Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: areport from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15: 1638-1645, 1997.
 
35) Diehl V, Franklin J, Hasenclever D, et al: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German
 
36) Hodgkin's Lymphoma Study Group. J CIin Oncol 16: 3810-3821, 1998. Sieber M, Engert A and Diehl V: Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group. Ann Oncol 11(supp11) : 81-85, 2000.
 
37) Diehl V, Franklin J, Sieber M, et al: Dose-escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: update results of German Hodgkin's Lymphoma Study Group. Blood. 968(suppl 1) : 2474 A, 2000.
 
38) Bartlett NL, Rosenberg SA, Hoppe RT, et al: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: apreliminary report. J CIin Oncol 13: 1080-1088, 1995.
 
39) Horning SJ, Hoppe RT, Breslin S, et al: Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E 1492. J CIin Oncol 18: 972-980, 2000.
 
40) Horwich A, Specht L and Ashley S: Survival analysis of patients with clinical stage I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 33: 848-853, 1997.
PubMed
41) Bonfante V, Santoro A, Viviani C, et al: Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15: 528-534, 1997.
 
42) Zinzani PL, Barbieri E, Bendandi M, et al: CEP regimen(CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease. Tumori 80: 438-442, 1994.
PubMed
43) Ferme C, Bastion Y, Lepage E, et al: The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 6: 543-549, 1995.
PubMed
44) Endlad G, hagberg H, Gustavsson A, et al: methyl-CAG, ifosphamide, methotrexate and etoposide(MIME) as salvage therapy for Hodgkin's disease: aprospective study. Eur J Haematol60: 166-171, 1998.
 
45) Gribben JG, Linch DC, Singer CR, et al: Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73: 340-344, 1989.
PubMed
46) Armitage JO, Bierman PJ, Vose JM, et al: Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 91: 605-611, 1991.
PubMed
47) Gianni AM, Siena S, Bregni M, et al: Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haematopoietic transplantation in poor prognosis Hodgkin's disease. Ann Oncol 2: 645-653, 1991.
 
48) Jones RJ, Piantadosi S, Mann RB, et al: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J CIin Oncol 8: 527-537, 1990.
 
49) Reece DE, Barnett MJ, Joseph M, et al: Intensive chemotherapy with cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J CIin Oncol9: 1871-1879, 1991.
 
50) Bierman PJ, Bagin RG, Jagannath S, et al: High-dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 4: 767-773, 1993.
PubMed
51) Horning SJ, Chao NJ, Negrin RS, et al: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford university results and prognostic indices. Blood 89: 801-813, 1997.
PubMed
52) van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: a20-year follow-up study. J Clin Oncol 12: 312-325, 1994.
 
53) Mauch PM, Kalish LA, Marcus KC, et al: Second malignancies after treatment of Laparotomy staged I A-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 87: 3625-3632, 1996. 54) Bhatia S, Robinson LL, Oberlin O, et al: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334: 745-751, 1996.
 
P.979 掲載の参考文献
1) Kadin ME, Berard CW, Nanba K, et al: Lymphoproliferative diseases in Japan and western countries. Human Pathol 14: 745-772, 1983.
PubMed
2) Devesa SS and Fears T: Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 52(Suppl) : 5432-5440, 1992.
 
3) Weisenburger DD: Epidemiology of non-Hodgkin's lymphoma: Recent findings regarding an emerging epidemic. Ann Oncol 5(SupPl 1) : 19-24, 1994.
 
4) Aozasa K, Yang W-1, Lee YB, et al: Lethal midline granuloma in Seoul, Korea and Shanghai, China. Int J Cancer 52: 673-674, 1992.
 
5) Cesarman E, Chang Y, Moore PS, et al: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332: 1186-1191, 1995.
PubMed
6) Iuchi K, Ichimiya A, Akashi A, et al: Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer 60: 1771-1775, 1987.
PubMed
7) Aozasa K, Ohsawa M, Iuchi K, et al: Artificial pneumothorax as a risk factor for development of pleural lymphoma. Jpn J Cancer Res 84: 55-57, 1993.
PubMed
8) Katsumata N, Matsuno Y, Nakayama H, et al: Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan. JPn J Clin Oncol 26: 445-454, 1996.
 
9) Yanagihara ET, Blaisdell RK, Hayashi T, et al: Malignant lymphoma in Hawaii-Japanese: A retrospective morphologicstudy. Hematol Oncol 7: 219-232, 1989.
PubMed
10) Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and descriptions of a Working Formulation for clinical usage. Cancer 49: 2112-2135, 1982.
 
11) Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: Aproposal form the International Lymphoma Study Group. Blood 84: 1361-1392, 1994.
 
12) Fisher RI, Dahlberg S, Nathwani BN, et al: Aclinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories) : A Southwest Oncology Group Study. Blood 85: 1075-1082, 1995.
 
13) The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. Blood 89: 3909-3018, 1997.
 
14) The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-994, 1993.
 
15) Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17: 3835-3849, 1999.
PubMed
16) Jaffe ES, Harris NL, Stein H, et al(eds) : World Health Organization Classification of Tumours: Pathology & Genetics: Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France, 2001.
 
17) Ichikawa A, Kinoshita T, Watanabe T, et al: Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337: 529-534, 1997.
PubMed
18) Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000.
PubMed
19) Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339: 21-26, 1998.
PubMed
20) Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002-1006, 1993.
PubMed
21) Shipp MA, Mauchi PM and Harris NL: Non-Hodgkin's lymphoma. In Cancer: Principles and Practice of Oncology, (ed by DeVita VT Jr, et al) , 5th edition, Lippincott-Raven, Philadelphia, PA, 1997, pp 2165-2220.
 
22) McLaughlin P, Grillo-Lopez, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients responded to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998.
 
23) Tobinai K, Kobayashi Y, Narabayashi M, et al: Feasibility and pharmacokinetic study of chimeric anti-CD20 monoclonal antibody (IDEC-C2 B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol 9: 527-534, 1998.
 
24) Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92: 1927-1932, 1998.
PubMed
25) Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002.
PubMed
26) Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268-276, 1999.
PubMed
27) Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory lowgrade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19: 3918-3928, 2001.
 
28) Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2 B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17: 3793-3803, 1999.
PubMed
29) Soussain C, Patte C, Ostronoff M, et al: Small noncleaved cell lymphoma and leukemia in adults: A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85: 664-674, 1995.
PubMed
30) Magrath I, Adde M, Shad A, et al: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14: 925-934, 1996.
PubMed
31) Shimoyama M and members of the Lymphoma Study Group: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. Br J Haematol 79: 428-437, 1991.
 
32) Shimoyama M, Ota K, Kikuchi M, et al: Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 6: 128-141, 1988.
PubMed
33) Shimoyama M, Ota K, Kikuchi M, et al: Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol 6: 1088-1097, 1988.
PubMed
34) Tobinai K, Shimoyama M, Minato K, et al: Japan Clinical Oncology Group(JCOG) phase II trial of second-generation "LSG 4 Protocol" in aggressive T-and B-lymphoma: A new predictive model for T-and B-lymphoma. Proc ASCO l3: 378(Abstract) , 1994.
 
35) Tobinai K: Adult T-cell leukemia-lymphoma. In Clinical Oncology, (ed by Abeloff MD, et al) , second edition, Churchill Livingstone Inc, New York, 2000, pp 2748-2768.
 
36) Tsukasaki K, Tobinai K, Shimoyama M, et al: Deoxycoformycin-containing combination chemo therapy for abult T-cell leukemia/lynphoma: Japan Clinical Oncology Group Study 9109. Int J Hematol 77: 164-170, 2003.
 
37) Yamada Y, Tomonaga M, Fukuda H, et al: A new G-CSF-supported combination chemotherapy, LSG 15, for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113: 375-382, 2001.
 
38) Gill PS, Harrington W, Kaplan MH, et al: Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332: 1744-1748, 1995.
PubMed
39) Hermine O, Bouscary D, Gessain A, et al: Brief report: Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332: 1749-1751, 1995.
PubMed
40) Tobinai K, Kobayashi Y and Shimoyama M: Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma. N Engl JMed 333: 1285, 1995.
 
41) Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333: 1540-1545, 1995.
PubMed
42) Shipp MA, et al: International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: Report of the jury. J Clin Oncol 17: 423-429, 1999.
 
43) Verdonck LF, van Putten WLJ, Hagenbeek A, et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332: 1045-1051, 1995
 
44) Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: Astudy of 464 patients. J Clin Oncol 12: 2543-2551, 1994.
 
45) Haioun C, Lepage E, Gisselbrecht C, et al: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 15: 1131-1137, 1997.
PubMed
46) Gianni AM, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336: 1290-1297, 1997.
PubMed
47) Gisselbrecht C, Lepage E, Molina T, et al: Shertened first-line high-dose chemothesapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20: 2472-2479, 2002.
PubMed
P.996 掲載の参考文献
1) Rudin CM and Thompson CB: B-cell development and maturation. Semin 25(4) : 435-446, 1998.
PubMed
2) Kyle RA and Rajkumar SV: Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am 13: 1181-1202, 1999.
PubMed
3) Nishida K, Tamura A, Nakazawa N, et al: The lg heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90: 526-534, 1997.
 
4) Avet-Loiseau H, Facon T, Daviet A, et al: 14 q 32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Cancer Res 59: 4546-4550, 1999.
 
5) Kyle RA, Therneau TM, Rajukumar SV, et al: A long-term study of prognosis in monoclonal gammopathy of undeter-mined significamce. N Engl J Med 346(8) : 564-569, 2002.
 
6) Grogan TM, Muller-Hermelink HK, Van Camp B, et al: Plasma cell neoplasms, WHO Classification: Tumours of Haematopoietic and Lymphoid Tissues, (ed by Jaffe ES, Harris NL, Stein H and Vardiman JW) , IARC Press WHO office, Washington DC, 2001, pp 142-156.
 
7) Foerster J and Paraskevas F: Plasma cell dyscrasias(Section 5) Wintrobe's Clinical Hematology, (ed by Foerster L, Paraskevas L and Greer R) , 10th edition, Williams & Wilkins, Baltimore, 1999, pp 2612-2737.
 
8) Joshua DE and Gibson J: 9. Epidemiology of plasma cell disorders. Myeloma, (ed by Mehta J, Singhal S and Dunitz M) , London, 2002, pp 139-150.
 
9) 田島和雄: 造血器腫瘍の疫学(第6章-1) 造血器腫瘍: 白血病, 悪性リンパ腫, 多発性骨髄腫, (上田龍三・編) , 南光堂, 東京, 2001, pp 179-183.
 
10) Blade J and Kyle RA: Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 30: 493-501, 1998.
PubMed
11) Rettig MB, Ma HJ, Vescio RA, et al: Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276: 1851-1854, 1997.
 
12) Drach J, Angerler J, Schuster J, et al: Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86: 3915-3921, 1995.
PubMed
13) Rao PH, Cigudosa JC, Ning Y, et al: Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 92: 1743-1748, 1998.
PubMed
14) Bergsagel PL and Kuehl WM: Chromosome translocations in multiple myeloma. Oncogene 20: 5611-5622, 2001.
PubMed
15) Avet-Loisseau H, Li J-Y, Morineau N, et al: Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Blood 94: 2583-2589, 1999.
 
16) Chesi M, Nardini E, Brents LA, et al: Frequent translocation t(4; 14) (p l6. 3; q32. 3) in multiple myeloma is associatedwith increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16: 260-264, 1997.
 
17) Iida S, Rao PH, Butler M, et al: Deregulation of the MUM1/IRF4 gene by chromosomal translocation in multiple myeloma. Nat Genet 17: 226-230, 1997.
PubMed
18) Chesi M, Bergsagel PL, Shonukan OO, et al: Frequent dysregulation of the c-maf proto-oncogene at 16 q 23 by translocation to Ig locus in multiple myeloma. Blood 91: 4457-4463, 1998.
 
19) Hanamura I, Iida S, Akano Y, et al: Ectopic expression of MAFB gene in human myeloma cells carrying(14; 20) (q 32; q11) chromosomal translocations. JPn J Cancer Res 92: 638-644, 2001.
 
20) Ronchetti D, Finelli P, Richelda R, et al: Molecular analysis of ll q 13 breakpoints in multiple myeloma. Blood 93: 1330-1337, 1999.
 
21) Avet-Loisseau H, Gerson F, Magrangeas F, et al: Rearrangement of the c-myc oncogene are present in 15%of primary human multiple myeloma tumors. Blood 98: 3082-3086, 2001.
 
22) Hatzivassiliou G, Miller I, Takizawa J, et al: IRTA l and IRTA 2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome l q 21 abnormalities in B cell malignancy. Immunity 14(3) : 277-289, 2001.
 
23) Shaughnessy J, Gabrea A, Qi Y, et al: Cyclin D 3 at 6 p 21 is dysregulated by recurrent chromosomal translocations to immunoglobulin Ioci in multiple myeloma. Blood 98: 217-223, 2001.
 
24) Corradini P, Ladetto M, Inghirami G, et al: N-and K-ras oncogenes in plasma cell dyscrasias. Leuk Lymphoma 15: 17-20, 1994.
 
25) Bezieau S, Devilder M-C, Avet-Loiseau H, et al: High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mut 18: 212-224, 2001.
 
26) Ng MHL, Chung YF, Lo KW, et al: Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89: 2500-2506, 1997.
 
27) Uchida T, Kinoshita T, Ohno T, et al: Hypermethylation of p16 INK 4 A gene promoter during the progression of plasma cell dyscrasia. Leukemia 15: 157-165, 2001.
 
28) Neri A, Baldini L, Trecca D, et al: p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81: 128-135, 1993.
PubMed
29) Iida S and Ueda R: Multistep tumorigenesis of multiple myeloma: Its molecular delineation. Int J Hematol 77: 207-212, 2003.
PubMed
30) Hallek M, Bergsagel PL and Anderson KC: Multiple Myeloma: Increasing evidence for a multistep transformation process. Blood 91: 3-21, 1998.
PubMed
31) Kawano MM, Hirano T, Matsuda T, et al: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 332: 83-85, 1988.
 
32) Klein B, Zhang XG, Lu XY, et al: Interleukin-6 in human multiple myeloma. Blood 85: 863-872, 1995.
 
33) Chauhan D, Uchiyama H, Akbarali Y, et al: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF一κB. Blood 87: 1104-1112, 1996.
 
34) Urashima M, Chauhan D, Uchiyama H, et al: CD 40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85: 1903-1912, 1995.
 
35) Dankbar B, Padro T, Leo R, et al: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630-2636, 2000.
PubMed
36) Ogata A, Chauhan D, Urashima M, et al: Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol 159: 2212-2221, 1997.
PubMed
37) Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of stat 3 signaling confers resistance to apoptosis in human U 266 myeloma cells. Immunity 10: 105-115, 1999.
 
38) Ward AC, Touw I, Yoshimura A: The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95: 19-29, 2000.
 
39) Kovalchuk AL, Kim JS, Park SS, et al: IL-6 transgenic mouse for extraosseous plasmacytoma. Proc Natl Acad Sci USA 99: 1509-1514, 2002.
PubMed
40) Tinhofer I, Marschitz I, Henn T, et al: Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 95: 610-618, 2000.
PubMed
41) Ro TB, Brenne A-T, Waage A, et al: Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 98(suppl) : 773 a(abstr 3216) , 2001.
 
42) Jelink DF: Mechanisms of myeloma cell growth control. Hematol Oncol Clin North America 13(6) : 1145-1157, 1999.
 
43) Hsu J-h, Shi Y, Krajewski S, et al: The AKT kinase is activated in multiple myeloma tumor cells. Blood 98: 2853-2855, 2001.
 
44) Derksen PWB, Keehnen RM, Evers LM, et al: Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99: 1405-1410, 2002.
 
45) Vacca A, Ribatti D, Presta M, et al: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93: 3064-3073, 1999.
PubMed
46) Dimopoulos MA, Moulopoulos LA, Maniatis A, et al: Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96: 2037-2044, 2000.
PubMed
47) Garcia-Sanz R, Orfao A, Gonzalez M, et al: Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, andcytogenetic characteristics. Blood 93: 1032-1037, 1999.
PubMed
48) Tricot G: New insight into role of microenvironment in multiple myeloma. Lancet 355: 248-250, 2000.
 
49) Choi SJ, Cruz JC, Craig F, et al: Macrophage inflammatory protein-1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96: 671-675, 2000.
PubMed
50) Croucher PI, Shipman CM, Lippitt J, et al: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540, 2001.
PubMed
51) Giuliani N, Bataille R, Mancini C, et al: Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 3527-3533, 2001.
PubMed
52) Silvestris F, Tucci M, Cafforio P, et al: Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood 97: 1155-1164, 2001.
 
53) Clark AD, Shetty A and Soutar R: Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 13: 79-90, 1999.
PubMed
54) Huang ZQ and Sanders PW: Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest 99: 732-736, 1997.
PubMed
55) Matsuzaki H, Uchida M, Yoshimura K, et al: Hyperammonemia in multiple myeloma. Acta Haematol 84: 130-134, 1990.
 
56) Krytsonis MC, Mouzaki A, Maniatis A, et al: Mechanisms of polyclonal hypogammaglobulinemia in multiple myeloma. Med Oncol 16: 73-77, 1999.
 
57) Cook G, Campbell JD, Carr CE, et al: Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T-lymphocytes. J Leukocyte Biol 66: 981-988, 1999.
 
58) Szczepek AJ, Seeberger K, Wizniak J, et al: A high frequency of circulating B cells share clonitypic lg heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 92: 2844-2855, 1998.
 
59) Greipp PR, Leong T, Bennett JM, et al: Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group(ECOG) myeloma trial E 9486 report by the ECOG Myeloma Laboratory roup. Blood 91: 2501-2507, 1998.
 
60) San Miguel J, Almeida J, Orfao A, et al: 15. Laboratory investigations. Myeloma, (ed by Singhal S and Mehta J) , Martin Dunitz, London, 2002, pp 243-268.
 
61) Harada H, Kawano MM, Huang N, et al: Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81: 2658-2663, 1993.
PubMed
62) Mathew P, Ahmann GJ, Witzig TE, et al: Clinicopathological correlates of CD 56 expression in multiple myeloma: A unique entity? Br J Haematol 90: 459-461, 1995.
 
63) Pellat-Deceunynck C, Barille S, Puthier D, et al: Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumour spreading and immortalization. Cancer Res 55: 3647-3653, 1995.
PubMed
64) Robillard N, Jego G, Pellat-Deceunynck C, et al: CD 28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res 4: 1521-1526, 1998.
 
65) Kawano MM, Huang N, Harada H, et al: Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 82: 564-570, 1993.
PubMed
66) Calasanz MJ, Cigudosa JC, Odero MD, et al: Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Promary breakpoints and clinical correlations. Genes Chromosomes Cancer 18: 84-93, 1997.
 
67) Smadja NV, Bastard C, Brigaudeau C, et al: Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98: 2229-2238, 2001.
PubMed
68) Drach J, Ackermann J, Fritz E, et al: Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92: 802-809, 1998.
PubMed
69) Zojer N, Konigsberg R, Ackermann J, et al: Deletion of 13 q 14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95: 1925-1930, 2000.
 
70) Taniwaki M, Nishida K, Takashima T, et al: Nonrandom chromosomal rearrangements of 14 q 32. 3 and 19 p 13. 3 and preferential deletion of l p in 21 patients with multiple myeloma and plasma ce111eukemia. Blood 84: 2283-2290, 1994.
 
71) Tricot G, Barlogie B, Jagannath S, et al: Poor prognosis inmultiple myeloma is associated only with partial or complete deletions of chromosome 130r abnormalities involving ll q and not with other karyotype abnormalities. Blood 86: 4250-4256, 1995.
 
72) Cigudosa JC, Rao PH, Calasanz MJ, et al: Characterization of nonrandom chromosomal gains and loses in multiple myelom by comparative genomic hybridization. Blood 91: 3007-3010, 1998.
 
73) Kyle RA and Greipp PR: Smoldering multiple myeloma. N Engl J Med 302: 1347-1349, 1980.
PubMed
74) Greipp PR and Kyle RA: Clinical, morphological and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering myeloma. Blood 62: 161-171, 1982.
 
75) Durie BGM and Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36: 842-854, 1975.
 
76) Bergsagel DE, Bailey AJ, Langley GR, et al: The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N Engl J Med 301: 743-748, 1979.
PubMed
77) Zaidi AA and Vesole DH: Multiple myeloma: An old disease with new hope for the future. CA Cancer J Clin 51: 273-285, 2001.
PubMed
78) Harousseau J-L and Moreau P: 11. Prognostic factors in myeloma. Myeloma, (ed by Singhal S and Mehta J) , Martin Dunitz, London, 2002, pp 169-183.
 
79) Bataille R, Durie BGM, Grenier J, et al: Prognostic factors and staging in multiple myeloma: areappraisal. J Clin Oncol 4: 80-87, 1986.
 
80) Greipp PR, Lust JA, O'Fallon WM, et al: Plasma cell lebelling index and β 2 M-microglobulin predict survival independent of thymidine-kinase and C-reactive protein in multiple myeloma. Blood 81: 3382-3387, 1993.
 
81) San Miguel JF, Garcia-Sanz R, Gonzalez N, et al: A new staging system for multiple myeloma based on the number of Sphase plasma cells. Blood 85: 448-455, 1995.
 
82) Liu P, Leong T, Quam L, et al: Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 88: 2699-2706, 1996.
 
83) Desikan R, Barlogie B, Sawyer J, et al: Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95: 4008-4010, 2000.
PubMed
84) Facon T, Avet-Loiseau H, Guillerm G, et al: Chromosome 13 abnormalities identified by FISH analysis and serumβ2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97: 1566-1571, 2001.
 
85) Zhan F, Hardin J, Kordsmeier B, et al: Global gene expressopn profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99: 1745-1757, 2002.
PubMed
86) Anderson KC, Bensinger W, Bernstein S, et al: NCCN practice guidelines for multiple myeloma: NCCN Proceedings. Oncology 12(11A) : 317-351, 1998.
 
87) Alexanian R, Haut A, Khan AU, et al: Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 208: 1680-1685, 1969.
PubMed
88) Salmon SE, Haut A, Bonnet JD, et al: Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: aSouthwest Oncology Group Study. J Clin Oncol 1: 453-461, 1983.
 
89) Cooper MR, McIntyre OR, Propert KJ, et al: Single, sequential and multiple alkylating agent therapy for multiple myeloma: a CALGB study. J Clin Oncol 4: 1331-1339, 1986.
 
90) Palva IP, Ahrenberg P, Ala-Harja K, et al: Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; arandomized multicentre trial. Finnish Leukaemia Group. Eur J Haemato138: 50-54, 1987.
 
91) Boccadoro M, Marmont F, Tribalto M, et al: Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 9: 444-448, 1991.
PubMed
92) Peest D, Deicher H, Cldewey R, et al: Melphalan and prednisone versus vincristine, BCNU, adriamycin, melphalan and dexamethasone induction chemotherapy and interferon maintenance treatment in multiple myeloma. Onkologia 13: 458-460, 1990.
 
93) Palvovsky S, Saslavsky J, Tezanos PM, et al: A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, meCCNU, and vincristine in untreated multiple myeloma. J Clin Oncol 2: 836-840, 1984.
 
94) Blade J, San Miguel JF, Alcala A, et al: Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 11(6) : 1165-1171, 1993.
PubMed
95) Myeloma trialists'collaborative group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6, 633 patients from 27 randomized trials. J Clin Oncol 16: 3832-3842, 1998.
 
96) Blade J, Samson D, Reece D, et al: Annotation: Criteria for evaluating disease response and progression inpatients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol 102: 1115-1123, 1998.
 
97) Barlogie B and Smith L: Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310: 1353-1356, 1984.
PubMed
98) Pulsoni A, Avvisati G, Petrucci MT, et al: The Italian experience on interferon as maintenance treatment in multiple myeloma: ten years after. Blood 92: 2184-2186, 1998.
PubMed
99) Wheatley K and the Myeloma trialist'collaborative group (MTCG) : The role of interferon(IFN) as therapy for multiple myeloma: An overview of 24 randomized trials with over 4000 patients. Proc ASCO 17: 8a(abstr 28) , 1998.
 
100) Gisslinger H: Interferon alpha in the therapy of multiple myeloma. Leukemia 11(suppl 5) : S52, 1997.
 
101) Berenson J, Crowley J, Barlogie B, et al(The Southwest Oncology Group) : Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple myeloma patients. Blood 92: 318 a(abstr 1305) , 1999.
 
102) Reichardt VL, Okada CY, Liso A, et al: Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-A feasibility study. Blood 93: 2411-2419, 1999.
PubMed
103) Gorschluter M, Ziske C, Glasmacher A, et al: Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma. Clin Cancer Res 7: 2195-2204, 2001.
PubMed
104) Attal M, Harousseau J-L, StoPPa A-M, et al: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335: 91-96, 1996.
PubMed
105) Harousseau J-L: High-dose therapy in multiple myeloma. Hematology 2001(American Society of Hematology Education Program Book) : 165-169, 2001.
 
106) Lenhoff S, Hjorth M, Holmberg E, et al: Impact on survival of high-dose therapy with autologous stem cell support in patient a younger than 60 years with newly diagnosed multiple myeloma: apopulation-based study. Blood 95: 7-11, 2000.
 
107) Barlogie B, Jagannath S, Vesole DH, et al: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89: 789-793, 1997.
PubMed
108) Palumbo A, Triolo S, Argentino C, et al: Dose-intensive melphalan with stem cell support(MEL 100) is superior to standard treatment in elderly myeloma patients. Blood 94: 1248-1253, 1999.
 
109) Moreau P, Facon T, Attal M, et al: Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99: 731-735, 2002.
 
110) Giralt S, Champlin R, Goodman M, et al: Preliminay results of a phase I/II study of multiple myeloma patients treated with 166Holmium-DOTMP in combination with high dose melphalan+/-total body irradiation(TBI) with autologous stem cell transplant(ASCT) . Blood 96: 558 a(abstr 2395) , 2000.
 
111) Goldschmidt H, Bouko Y, Bourhis JH, et al: CD34+selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: arandomized study from the EBMT. Blood 96: 558 a (abstr 2396) , 2000.
 
112) Bensinger WI, Buckner CD, Anasetti C, et al: Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88: 2787-2793, 1996.
PubMed
113) Gahrton G, Svensson H, Cavo M, et al: Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centers. Br J Haematol 113: 209-216, 2001.
 
114) Maloney DG, Sahebi F, Stockerl-Goldstein KE, et al: Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Blood 98(suppl) : 434a(abstr 1822) , 2001.
 
115) Badros A, Barlogie B, Morris C, et al: High response rate in refractory and poor-risk multiple myeloma after allotrans・ plantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 97: 2574-2579, 2001.
 
116) Fernando J-P, Ravaud P, Chevret S, et al: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment?Results of a multicenter sequential randomized clinical trial. Blood 92: 3131-3136, 1998.
PubMed
117) Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571, 1999.
PubMed
118) Munshi N, Desikan R, Zangari M, et al: Marked antitumor effect of arsenic trioxide in high risk refractory multiple myeloma. Blood 94: 123 a(abstr 541) , 1999.
 
119) Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488-493, 1996.
 
120) Greipp P, Facon T, Williams CD, et al: A single subcutaneous dose of an Osteoprotegerin(OPG) construct(AMGN-0007) cause a profound and sustained decrease of bone resorption comparable to standard intravenous bisphosphonate in patients with multiple myeloma. Blood 98(suppl) : 775 a(abstr 3227) , 2001.
 
121) Waldenstrdm J: Incipient myelomatosis or ‘essential' hyperglobulinemia with fibrinogenopenia-a new syndrome? Acta Med Scand 216: 433-444, 1944.
 
122) Herrnton LJ and Weiss NS: Incidence of Waldenstrom's macroglobulinemia. Blood 82: 3148-3150, 1993.
 
123) Iida S, Rao PH, Nallasivam P, et al: The t(9; 14) (p13; q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 88: 4110-4117, 1996.
 
124) Gertz MA and Kyle RA: Hyperviscosity syndrome. J Intensive Care Med 10: 128-141, 1995.
PubMed
125) Berger F, Isaacson PG, Piris MA, et al: Lymphoplasmacytic lymphoma/Waldenstr6m macroglobulinemia. World Health Organization Classification of Tumours. Pathology & Genetics: Tumours of Haematopoietic and Lymphoid Tissues, (ed by Jaffe ES, Harris NL, Stein H and Vardiman JW) , IARC Press, Lyon, 2001, pp 132-134.
 
126) Dutcher TF, Fahey: The histopathology of macroglobulinemia of Waldenstr6m. J Natl Cancer Inst 22: 887-917, 1959.
PubMed
127) Kyle RA, Greipp P, Gertz M, et al: Waldenstrom's macroglobulinemia: aprospective study comparing daily versus intermittent oral chrorambucil. Blood 92(suppl 1) : 279 b(abstr 4204) , 1998.
 
128) Dimopoulos MA, Kantarjian H, Weber D, et al: Primary therapy of Waldenstrbm's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12: 2694-2698, 1994.
PubMed
129) Kantarjian HM, Alexanian R, Koller CA, et al: Fludarabine therapy in macroglobulinemic lymphoma. Blood 75: 1928-1931, 1990.
PubMed
130) Frangione B and Franklin EC: Heavy chain diseases: clinical features and molecular significance of the disordered immunoglobulin structure. Semin Hematol 10: 53-64, 1973.
PubMed
131) Seligman M: Immunohistochemical, clinical and pathological features of alpha-heavy chain diseases. Arch Intern Med 135: 78-82, 1975.
 
132) Ballard HS, Hamilton LM, Marcus AJ, et al: A new variant of heavy-chain disease(mu-chain disease) . NEngl J Med282: 1060-1062, 1970.
PubMed
133) Takatsuki K and Sanada I: Plasma cell dyscrasia with polyneuropathy and endocrine disorder; clinical and laboratory features of lO9 reported cases. JPn J Clin Oncol 13: 543-556, 1983.
 
134) Miralles GD, O'Fallon JR, Talley NJ, et al: Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med 327: 1919-1923, 1992.
 
135) Watanabe O, Arimura K, Kitajima I, et al: Greatly raised vascular endothelial growth factor(VEGF) in POEMS syndrome. Lancet 347: 702, 1996.
PubMed
136) Glenner GG, Terry W, Harada M, et al: A myloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analysis. Science 173: 1150-1151, 1971.
 
137) Kyle RA and Gertz MA: Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 32: 45-59, 1995.
PubMed
138) Hayman SR, Bailey RJ, Jalal SM, et al: Translocations involving the immunoglobulin heavy-chain Iocus are possible early genetic events in patients with primary systemic amyloidosis. Blood 98: 2266-2268, 2001.
 
139) Kyle RA, Gertz MA, Greipp PR, et al: A trial of three regimens for primary amyloidosis: colchicines alone, melphalan and prednisone, and melphalan, prednisone, and colchicines. N Engl J Med 336: 1202-1207, 1997.
PubMed
140) Skinner M, Anderson J, Simms R, et al: Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100: 290-298, 1996.
PubMed
141) Palladini G, Anesi E, Perfetti V, et al: A modified high-dose dexamethasone regimen for primary systemic(AL) amyloidosis. Br J Haematol 113: 1044-1046, 2001.
PubMed
142) Gianni L, Bellotti V, Gianni AM, et al: New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxy-doxorubicin. Blood 86: 855-861, 1995.
PubMed
143) Comenzo RL, Vosburgh E, Falk RH, et al: Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloidosis. Blood 91: 3662-3670, 1998.
PubMed
144) Sanchorawala V, Wright DG, Seldin DC, et al: An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28: 637-642, 2001.
PubMed
145) Dispenzieri A, Lacy MQ, Kyle RA, et al: Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19: 3350-3356, 2001.
 
P.1010 掲載の参考文献
1) Greco FA and Hainsworth JD: Cancer of unknown primary site, Cancer: Principles & Practice of Oncology, (ed by Devita Jr VT, Hellman S, and Rosenberg SA) , 6th ed, Lippincott Williams & Wilkins, Philadelphia, 2001, pp 2537-2560.
 
2) Daugaard G: Unknown primary tumours. Cancer Treat Rev 20: 119-147, 1994.
PubMed
3) Brigden ML and Murry N: Improving survival in metastatic carcinoma of unknown origin. Postgrad Med 105: 63-74, 1999.
 
4) Hillen HFP: Unknown primary tumours. Postgrad Med J 76: 690-693, 2000.
 
5) ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP) . Ann Oncol 12: 1057-1058, 2001.
PubMed
6) Hansen HH and Daugaard G: Management of carcinoma of unknown primary site(CUP) , any changes? Ann Oncol 12: 431-432, 2001.
PubMed
7) Altman E and Cadman E: An analysis of 1539 patients with cancer of unknown primary site. Cancer 57: 120-124, 1986.
PubMed
8) Hamilton CS and Langlands AO: ACUPS(adenocarcinoma of unknown primary site) : A clinical and cost benefit analysis. Int J Radia Oncol Biol Phys 13: 1497-1503, 1987.
 
9) 万代光一, 森脇昭介, 山上啓太郎・他: 剖検例を対象とした原発不明癌症例の検討. 臨床病理 42: 75-82, 1992
 
10) Abbruzzese JL, Abbruzzese MC, Hess KR, et al: Unknown primary carcinoma: Natural history and prognostic factors in 657consecutive patients. J Clin Oncol 12: 1272-1280, 1994.
PubMed
11) Muir C: Cancer of unknown primary site. Cancer 75: 353-356, 1995.
PubMed
12) Jordan III WE and Shildt RA: Adenocarcinoma of unknown primary site. Cancer 55: 857-860, 1985.
 
13) Le Chevalier T, Cvitkovic E, Caille P, et al: Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 148: 2035-2039, 1988.
PubMed
14) Maiche AG: Cancer of unknown primary. A retrospective study based on 109 patients. Am J Clin Oncol 16: 26-29, 1993.
PubMed
15) van de Wouw AJ, Jansen-Heijnen MLG, Coebergh JWW, et al: Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in southeast netherlands, 1984-1992. Eur J Cancer 38: 409-413, 2002.
 
16) Hess KR, Abbruzzese MC, Lenzi R, et al: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5: 3403-3410, 1999.
PubMed
17) Gaber AO, Rice P, Eaton C, et al: Metastatic malignant disease of unknown origin. Am J Surg 145: 493-497, 1983.
PubMed
18) Mackay B and Ordonez NG: Pathological evaluation of neoplasms with unknown primary tumor site. Semin Oncol 20: 206-228, 1993.
PubMed
19) Leonard RJ and Nystrom JS: Diagnostic evaluation of patients with carcinoma of unknown primary tumor site. Semin Oncol 20: 244-250, 1993.
PubMed
20) Sporn JR and Greenberg BR: Empiric chemotherapy in patients with carcinoma of unknown primary site. Am J Med 88: 49-55, 1990.
PubMed
21) Abbruzzese JL, Abbruzzese MC, Lenzi R, et al: Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13: 2094-2103, 1995.
PubMed
22) Nissenblatt MJ: The CUP syndrome(carcinoma unknown primary) . Cancer Treat Rev 8: 211-224, 1981.
PubMed
23) Hammar SP: Metastatic adenocarcinoma of unknown primary origin. Hum Pathol 29: 1393-1402, 1998.
PubMed
24) Ultmann JE: Cancer of unknown primary site. J Cancer Res Clin Oncol 117: 505-509, 1991.
PubMed
25) Lenzi R, Hess KR, Abbruzzese MC, et al: Pooly differentiated carcinoma and poorly differntiated adenocarcinoma of unknown origin: Favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol 15: 2056-2066, 1997.
 
26) Bohuslavizki KH, Klutmann S, Kr6ger S, et al: FDG PET detection of unknown primary tumors. J Nuclear Med 41: 816-822, 2000.
 
27) Rades D, KUhnel G, Wildfang I, et al: Localised disease in cancer of unknown primary(CUP) : The value of positron emission tomography(PET) for individual therapeutic management. Ann Oncol 12: 1605-1609, 2001.
PubMed
28) Mendenhall WM, Mancuso AA, Parsons JT, et al: Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck 20: 739-744, 1998.
PubMed
29) Mendenhall WM, Mancuso AA, Amdur RJ, et al: Squamous cell carcinoma metastatic to the neck from an unknown head and neck primary site. Am J Otolaryngol 22: 261-267, 2001.
 
30) Greven KM, Keyes Jr JW, Williams III DW, et al: Occult primary tumors of the head and neck. Lack of benefit from positron emission tomography imaging with 2-(F-18) fluoro-2-deoxy-D-glucose. Cancer 86: 114-118, 1999.
 
31) Nieder C, Gregoire V and Kian Ang K: Cervical lymph node metastatic from occult squamous cell carcinoma: Cut down atree to get an apple? Int J Radiat Oncol Biol Phys 50: 727-733, 2001.
 
32) Hainsworth JD, Wright EP, Johnson DH, et al: Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining. J Clin Oncol 9: 1931-1938, 1991.
PubMed
33) Hainsworth JD and Greco FA: Treatment of patients with cancer of an unknown primary site. N Engl J Med 329: 257-263, 1993.
PubMed
34) Vege DS, Soman CS, Joshi UA, et al: Undifferentiated tumors: An immunohistochemical analysis on biopsies. J Surg Oncol 57: 273-276, 1994.
PubMed
35) de Braud F and Al-Sarraf M: Diagnosis management of squamous cell carcinoma of unknown primary tumor site of the neck. Semin Oncol 20: 273-278, 1993.
PubMed
36) Grau C, Johansen LV, Jakobsen J, et al: Cervical lymph node metastases from unknown primary tumours results from a national survey by the Danish society for head and neck oncology. Radiother Oncol 55: 121-129, 2000.
PubMed
37) Marcial-Vega VA, Cardenes H, Perez CA, et al: Cervical metastases from unkown primaries: Radiotherapeutic management and appearance of subsequent primaries. Int J Radiat Oncol Biol Phys 19: 919-928, 1990.
 
38) Jacobs C: The internist in the management of head and neck cancer. Ann Intern Med 113: 771-778, 1990.
PubMed
39) Guarischi A, Keane TJ and Elhakim T: Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 59: 572-577, 1987.
PubMed
40) Nicholson CP, Donohue JH, Thompson GB, et al: A study of metastatic cancer found during inguinal hernia repair. Cancer 69: 3008-3011, 1992.
PubMed
41) Sears D and Hajdu SI: The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cyto131: 85-97, 1987.
PubMed
42) DiBonito L, Falconieri G, Colautti I, et al: The positive peritoneal effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol 37: 483-488, 1993.
PubMed
43) Strnad CM, Grosh WW, Baxter J, et al: Peritoneal Carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med ll1: 213-217, 1989.
 
44) Strnad CM, Grosh WW, Baxter J, et al: Peritoneal Carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med ll1: 213-217, 1989.
 
45) Ransom DT, Patel SR, Keeney GL, et al: Papillary serous carcinoma of the peritoneum. A Review of 33 cases treated with platin-based chemotherapy. Cancer 66: 1091-1094, 1990.
PubMed
46) Fromm G-L, Gershenson DM and Silva EG: Papillary serous carcinoma of the peritoneum. Obstet Gynecol 75: 89-95, 1990.
PubMed
47) Svastics E, R6nay P and Bod6 M: Occult breast cancer presenting with axillary metastasis. Eur J Surg Oncol 19: 575-580, 1993.
 
48) Winer EP, Morrow M, Osborne CK, et al: Malignant tumors of the breast, Cancer: Principles & Practice of Oncology(edby Devita VT Jr, Hellman S and Rosenberg SA) , 6th ed, Lippincott Williams & Wilkins, Philadelphia, 2001, pp 1651-1717.
 
49) Baron PL, Moore MP, Kinne DW, et al: Occult breast cancer presenting with axillary metastases. Arch Surg 125: 210-215, 1990.
PubMed
50) Olson Jr JA, Morris EA, van Zee KJ, et al: Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 7: 411-415, 2000.
 
51) Patel J, Nemoto T, Rosner D, et al: Axillary lymph node metastasis from an occult breast cancer. Cancer 47: 2923-2927, 1981.
PubMed
52) Bhatia SK, Saclarides TJ, Witt TR, et al: Hormone receptor studies in axillary metastases from occult breast cancers. Cancer 59: 1170-1172, 1987.
PubMed
53) Ruddon RW and Norton SE: Use of biological markers in the diagnosis of cancers of unknown primary tumor. Semin Oncol 20: 251-260, 1993.
 
54) Pavlidis N, Kalef-Ezra J, Briassoulis E, et al: Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol 22: 162-167, 1994.
PubMed
55) Gamble AR, Bell JA, Ronan JE, et al: Use of tumour marker immunoreactivity to identify primary site of metastatic cancer. BMJ 306: 295-298, 1993.
PubMed
56) Panza N, Lombardi G, Rose MD, et al: High serum thyroglobulin levels. Diagnostic indicators in patients with metastases from unknown primary sites. Cancer 60: 2233-2236, 1987.
 
57) Nishiya M, Miller GJ, Lookner DH, et al: Prostate specific antigen density in patients with histologically proven prostate carcinoma. Cancer 74: 3002-3009, 1994.
PubMed
58) Ilson DH, Motzer RJ, Rodriguez E, et al: Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. Semin Oncol 20: 229-237, 1993.
 
59) Fletcher JA, Kozakewich HP, Hoffer FA, et al: Diagnostic relevance of clonal cytogenetic aberrations in malignant softtissue tumors. N Engl J Med 324: 436-442, 1991.
 
60) Delattre O, Zucman J, Melot T, et al: The ewing family of tumors-A subgroup of small-Round-Cell tumors defined by specific chimeric transcripts. N Engl J Med 331: 294-299, 1994.
PubMed
61) Bosl GJ, Ilson DH, Rodriguez E, et al: Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 86: 349-355, 1994.
PubMed
62) Feinmesser R, Miyazaki I, Cheung R, et al: Diagnosis of nasopharyngeal carcinoma by DNA amplification of tissue obtained by fine-needle aspiration. N Engl J Med 326: 17-21, 1992.
PubMed
63) Lee WY, Hsiao JR, Jin YT, et al: Epstein-barr virus detection in neck metastases by in-situ hybridization in fine-needle aspiration cytologic studies: An aid for differentiating the primary site. Head Neck 22: 336-340, 2000.
PubMed
64) Califano J, Westra WH, Koch W, et al: Unknown primary head and neck squamous cell carcinoma: Molecular identicication of the site of origin. J Natl Cancer Inst 91: 599-604, 1999.
PubMed
65) Sumi H, Itoh K, Onozawa Y, et al: Treatable subsets in cancer of unknown primary origin. Jpn J Cancer Res 92: 704-709, 2001.
PubMed
66) Farrugia DC, Norman AR, Nicolson MC, et al: Unkown primary carcinoma: Randomised studies are needed to identify optimal treatments and their benefits. Eur J Cancer 32A: 2256-2261, 1996.
 
67) Briassoulis E, Kalofonos H, Bafaloukos D, et al: Carboplatin plus paclitaxel in unknown primary carcinoma: Aphase II Hellenic cooperative oncology group study. J Clin Oncol 18: 3101-3107, 2000.
 
68) Saghatchian M, Fizazi K, Borel C, et al: Carcinoma of an unknown primary site: Achemotherapy strategy based on histological differentiation-results of a prospective study. Ann Oncol 12: 535-540, 2001.
 
69) Motzer RJ, Rodriguez E, Reuter VE, et al: Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 13: 274-282, 1995.
 
70) Logothetis CJ, Samuels ML, Selig DE, et al: Chemotherapy of extragonadal germ cell tumors. J Clin Oncol 3: 316-325, 1985.
PubMed
71) Moertel CG, Kvols LK, O'Connell MJ, et al: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 68: 227-232, 1991.
 
72) van der Gaast A, Verweij J, Planting AST, et al: Simple prognostic model to predict survival in patients with undiffer・ entiated carcinoma of unknown primary site. J Clin Oncol 13: 1720-1725, 1995.
 
73) Harper CS, Mendenhall WM, Parsons JT, et al: Cancer in neck nodes with unknown primary site: Role of mucosal radiotherapy. Head Neck 12: 463-469, 1990.
PubMed
74) Mack Y, Parsons JT, Mendenhall WM, et al: Squamous cell carcinoma of the head and neck: Management after excisional biopsy of a solitary metastatic neck node. Int J Radiat Oncol Biol Phys 25: 619-622, 1993.
PubMed
75) Colletier PJ, Garden AS, Morrison WH, et al: Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: Outcomes and patterns of failure. Head Neck 20: 674-681, 1998.
PubMed
76) de Braud F, Heilbrun LK, Ahmed K, et al: Metastatic squamous cell carcinoma of an unknown primary localized to the neck. Advantages of an aggressive treatment. Cancer 64: 510-515, 1989.
 
77) Jeremic B, Zivic L and Jevremovic S: Radiotherapy and cisplatin in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. J Chemother 4: 399-402, 1992.
 
78) Jeremic B, Zivic D, Matovic M, et al: Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. J Chemother 5: 262-265
 
79) Coster JR, Foote RL, Olsen KD, et al: Cervical nodal metastasis of squamous cell carcinoma of unknown origin: Indications for with holding radiation therapy. Int J Radiat Oncol Biol Phys 23: 743-749, 1992.
 
80) Nguyen C, Shenouda G, Black MJ, et al: Metastatic squamous cell carcinoma to cervical lymph nodes from unknown primary mucosal sites. Head Neck 16: 58-63, 1994.
PubMed
81) Wang RC, Goepfert H, Barber AE, et al: Unknown primary squamous cell carcinoma metastatic to the neck. Arch Otolaryngol 116: 1388-1393, 1990.
 
82) Lefebvre J-L, Coche-Dequeant B, Van JT, et al: Cervical lymph nodes from an unknown primary tumor in 190 patients. Am J Surg 160: 443-446, 1990.
PubMed
83) Weir L, Keane T, Cummings B, et al: Radiation treatment of cervical lymph node metastases from an unknown primary: an analysis of outcome by treatment volume and other prognostic factors. Radiother Oncol 35: 206-211, 1995.
PubMed
84) Reddy SP and Marks JE: Metastatic carcinoma in the cervical lymph nodes from an unknown primary site: results of bilateral neck plus mucosal irradiation vs. ipsilateral neck irradiation. Int J Radiat Oncol Biol Phys 37: 797-802, 1997.
PubMed
85) Davidson BJ, Spiro RH, Patel S, et al: Cervical metastases of occult origin: The impact of combined modality therapy. Am JSurg 168: 395-399, 1994.
PubMed
86) Strojan P and Ani6in A: Combined surgery and postoperative radiotherapy for cervical lymph node metastases from an unknown primary tumour. Radiother Oncol 49: 33-40, 1998.
PubMed
87) Lee NK, Byers RM, Abbruzzese JL, et al: Metastatic adenocarcinoma to the neck from an unknown primary source. Am J Surg 162: 306-309, 1991.
 
88) Bloss JD, Liao SY, Buller RE, et al: Extraovarian peritoneal serous papillary carcinoma: acase-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 50: 347-351, 1993.
 
89) Muggia FM and Baranda J: Management of peritoneal carcinomatosis of unknown primary tumor site. Semin Oncol 20: 268-272, 1993.
PubMed
90) McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
PubMed
91) Ozols RF, Schwartz PE and Eifel PJ: Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma, Cancer: Principles&Practice of Oncology, (ed by Devita VT Jr, Hellman S and Rosenberg SA) , 6th ed, Lippincott Williams& Wilkins, Philadelphia, 2001, p
 
92) Kemeny MM, Rivera DE, Terz JJ, et al: Occult primary adenocarcinoma with axillary metastases. Am J Surg 152: 43-47, 1986.
PubMed
93) Ellerbroek N, Holmes F, Singletary E, et al: Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 66: 1461-1467, 1990.
PubMed
94) Merson M, Andreola S, Galimberti V, et al: Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer 70: 504-508, 1992.
PubMed
95) Lloyd MS, Nash AG: `Occult`breast cancer. Ann R Coll Surg Engl 83: 420-424, 2001.
PubMed
96) Rosen PP and Kimmel M: Occult breast carcinoma presenting with axillary lymph node metastases: A follow-up study of 48 patients. Hum Pathol 21: 518-523 , 1990.
PubMed
97) Vlastos G, Jean ME, Mirza AN, et al: Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastasis. Ann Surg Oncol 8: 425-431, 2001.
PubMed
98) Sporn JR and Greenberg BR: Empirical chemotherapy for adenocarcinoma of unknown primary tumor site. Semin Oncol 20: 261-267, 1993.
PubMed
99) Ahlgren JD, Bern M, Booth B, et al: Protracted infusional 5 FU(PIF) : An active, well-tolerated regimen in metastatic adenocarcinoma of undetermined primary(AUP) . Amid-atlantic oncology program(MAOP) study. Proc ASCO 12: 401, 1993.
 
100) Falkson CI and Cohen GL: Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 55: 116-121, 1998.
PubMed
101) Culine S, Fabbro M, Ychou M, et al: Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy. Ann Oncol 10: 569-575, 1999.
 
102) Culine S, Fabbro M, Ychou M, et al: Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 94: 840-846, 2002.
PubMed
103) van der Gaast A, Verweij J, Henzen-Logmans SC, et al: Carcinoma of unknown primary: Identification of a treatable subset? Ann Oncol 1: 119-122, 1990.
 
104) Hainsworth JD, Johnson DH and Greco FA: Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience. J Clin Oncol 10: 91
 
105) Glynne-Jones RGT, Anand AK, Young TE, et al: Metastatic carcinoma in the cervical lymph nodes from an occult primary: A conservative approach to the role of radiotherapy. Int J Radiat Oncol Biol Phys 18: 289-294, 1990.
 
106) Jeremic B, Djuric L, Jevremovic S, et al: Metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. J Chemother 4: 41-45, 1992.
 
107) Wax MK and Briant TDR: Surgery and postoperative radiotherapy in the management of extensive cancer of the cervical lymph nodes from an unknown primary. J Otolaryngol 22: 34-38, 1993.
 
108) Medini E, Medini AM, Lee CKK, et al: The management of metastatic squamous cell carcinoma in cervical lmph nodes from an unknown primary. Am J Clin Oncol 21: 121-125, 1998.
 
109) Weber A, Schmoz S and Bootz F: CUP(carcinoma of unknown primary) syndrome in head and neck: Clinic, diagnostic, and therapy. Onkologie 24: 38-43, 2001.
PubMed
110) Piver MS, Eltabbakh GH, Hempling RE, et al: Two sequential studies for primary peritoneal carcinoma: Induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. Gynecol Oncol 67: 141-146, 1997.
PubMed
111) Kambhu SA, Kelsen DP, Fiore J, et al: Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results. Am Clin Oncol 13: 55-60, 1990.
PubMed
112) Theo Wagener DJ, de Mulder PHM, Burghouts JT, et al: Phase II trial of cisplatin for adenocarcinoma of unknown primary site. Eur J Cancer 27: 755-757, 1991.
 
113) Raber MN, Faintuch J, Abbruzzese JL, et al: Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatium in patients with metastatic carcinoma of unknown primary origin. Ann Oncol 2: 519-520, 1991.
PubMed
114) Gill I, Guaglianone P, Grunberg SM, et al: High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary. Anticancer Res 11: 1231-1236, 1991.
PubMed
115) Pavlidis N, Kosmidis P, Skarlos D, et al: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. Ann Oncol 3: 631-634, 1992.
PubMed
116) van der Gaast A, Henzen-Logmans SC, Planting AST, et al: Phase II study of oral administration of etoposide for patients with well-and moderately-differentiated adenocarcinomas of unknown primary site. Ann Oncol 4: 789-790, 1993.
 
117) Lenzi R, Raber MN, Frost P, et al: Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. Eur J Cancer 29: 1634, 1993.
 
118) de Campos ES, Menasce LP, Radford J, et al: Metastatic carcinoma of uncertain primary site: A retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide(VAC) or VAC alternating with cisplatin and etoposide (VAC/PE) . Cancr 73: 470-475, 1994
 
119) Hainthworth JD, Erland JB, Kalman LA, et al: Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 15: 2385-2393, 1997.
 
120) Warner E, Goel R, Chang J, et al: A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site(CUPS) . Br J Cancer 77: 2376-2380, 1998.
 
121) Liu JM, Chen YM, Chao Y, et al: Continuous infusion cisplatin and etoposide chemotherapy for cancer of unknown primary site(CUPS) in Taiwan, a region with a high prevalence of endemic viral infection. Jap J Clin Oncol 28: 431-435, 1998.
 
122) Lofts FJ, Gogas H and Mansi JL: Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen(CFTam) . Ann Oncol 10: 1389-1392, 1999.
PubMed
123) Voog E, Merrouche Y, Trillet-Lenoir V, et al: Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unkanown primary. Am J Clin Oncol 23: 614-616, 2000.
PubMed
124) Greco FA, Erland JB, Morrissey LH, et al: Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11: 211-215, 2000.
PubMed
125) Parnis FX, Olver IN, Kotasek D, et al: Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil(ECF) for carcinoma of unknown primary site. Ann Oncol 11: 883-884, 2000.
PubMed
126) Greco FA, Burris III HA, Erland JB, et al: Carcinoma of unknown primary site. Long term follow-up after treatment with paclitaxel, carboplatin, and etoposide. Cancer 89: 2655-2660, 2000.
 
127) Guardiola E, Pivot X, Tchicknavorian X, et al: Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site. A phase II trial. Am J Clin Oncol 24: 372-375, 2001.
 
128) Greco FA, Gray J, Burris III HA, et al: Taxene-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 7: 203-212, 2001.
 
129) Karapetis CS, Yip D, Virik K, et al: Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site. Med Oncol 18: 23-32, 2001.
PubMed
130) Greco FA, Burris III HA, Litchy S, et al: Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl cancer research network study. J Clin Oncol 20: 1651-1656, 2002.
 
131) Woods RL, Fox RM, Tattersall MHN, et al: Metastatic adenocarcinomas of unknown primary site. A randomized study of two combination chemotherapy regimens. N Engl J Med 303: 87-89, 1980.
 
132) Shildt RA, Kennedy PS, Chen TT, et al: Management of patients with metastatic adenocarcinoma of unknown origin: A Southwest oncology group study. Cancer Treat Rep 67: 77-79, 1983.
 
133) Milliken ST, Tattersall MHN, Woods RL, et al: Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 23: 1645-1648, 1987.
 
134) Eagan RT, Therneau TM, Rubin J, et al: Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. Am J Clin Oncol 10: 82-85, 1987.
PubMed
135) Dowell JE, Garrett AM, Shyr Y, et al: A randomized phase II trial in patients with carcinoma of unknown primary site. Cancer 91: 592-597, 2001.
PubMed
136) Hainsworth JD, Burris III HA, Calvert SW, et al: Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl cancer research network. Cancer Invest 19: 335-339, 2001.
 
137) Culine S, Ychou M, Fabbro M, et al: 5-fluorouracil and Ieucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res 21: 1455-1458, 2001.
PubMed
P.1021 掲載の参考文献
1) Chang Y, Cesarman E, Pessin MS, et al: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266(5192) : 1865-1869, 1994.
PubMed
2) Vincent-Salomon A, de la Rochefordiere A, Salmon R, et al: Frequent association of human papillomavirus 16 and 18 DNA with anal squamous cell and basaloid carcinoma. Mod Pathol 9(6) : 614-620, 1996.
PubMed
3) Parkin DM, Wabinga H, Nambooze S, et al: AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 13(18) : 2563-2570, 1999.
PubMed
4) Ledergerber B, Telenti A and Egger M: Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ 319(7201) : 23-24, 1999.
 
5) Beral V, Peterman TA, Berkelman RL, et al: Kaposi's sarcoma among persons with AIDS: asexually transmitted infection?Lancet 335(8682) : 123-128, 1990.
 
6) Moore PS and Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 332(18) : 1181-1185, 1995.
 
7) Whitby D, Howard MR, Tenant-Flowers M, et al: Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 346(8978) : 799-802, 1995.
PubMed
8) Gao SJ, Kingsley L, Hoover DR, et al: Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 335(4) : 233-241, 1996.
PubMed
9) Sitas F, Newton R and Boshoff C: Increasing probability of mother-to-child transmission of HHV-8 with increasing maternal antibody titer for HHV-8. N Engl J Med 340(24) : 1923, 1999.
PubMed
10) Monini P, de Lellis L, Fabris M, et al: Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. N Engl J Med 334(18) : 1168-1172, 1996.
 
11) Diamond C, Brodie SJ, Krieger JN, et al: Human herpesvirus 8 in the prostate glands of men with Kaposi's sarcoma. J Virol 72(7) : 6223-6227, 1998.
PubMed
12) Pauk J, Huang ML, Brodie SJ, et al: Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 343(19) : 1369-1377, 2000.
 
13) Brodie SJ, Johnson A, Vieira J, et al: Oral shedding and propagation of HHV-8 in pharyngeal lymphoid tissues: potential cofactor role of HIV. Program and abstracts of 5th International AIDS Malignancy Conference, April 23-25, 2001, Bethesda, Maryland, Abstract 48.
 
14) Northfelt DW, Dezube BJ, Thommes JA, et al: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16(7) : 2445-2451, 1998.
PubMed
15) Gill PS, Wernz J, Scadden DT, et al: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14(8) : 2353-2364, 1996.
PubMed
16) 菊池 嘉, 立川夏夫, 安岡 彰・他: Kaposi肉腫に対するLiposomal doxorubicinの効果. HIV感染症に関する臨床研究. 平成11年度研究報告書, 2000, pp 198-203.
 
17) Saville MW, Lietzau J, Pluda JM, et al: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346 (8966) : 26-28, 1995.
PubMed
18) Ng VL and McGrath MS: The immunology of AIDS-associated lymphomas. Immunol Rev 162: 293-298, 1998.
PubMed
19) Rabkin CS and Yellin F: Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst 86(22) : 1711-1716, 1994.
 
20) Kaplan LD, Abrams DI, Feigal E, et al: AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 261(5) : 719-724, 1989.
 
21) Kaplan LD, Straus DJ, Testa MA, et al: Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 336(23) : 1641-1648, 1997.
 
22) Sparano JA, Lee S, Chen M, et al: Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide(CDE) in HIVassociated non-Hodgkin's lymphoma. An Eastern Cooperative Oncology Group Trial. Proc Am Soc Clin Oncol 18: 12 a(abstract 41) , 1999.
 
23) Little R, Pearson D, Gutierrez M, et al: Dose-adjusted EPOCH chemotherapy with suspension of antiretroviral therapy for HIV-associated non-Hodgkin's lymphoma. J AIDS 23: A11(abstract S 16) , 2000.
 
24) Little RF, Martin Gutierrez M, et al: HIV-Associated Non-Hodgkin Lymphoma: Incidence, Presentation, and Prognosis. JAMA 285: 1880-1885, 2001.
 
25) International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92(22) : 1823-1830, 2000.
PubMed
26) Gold JE, Altarac D, Ree HJ, et al: HIV-associated Hodgkin disease: aclinical study of 18 cases and review of the literature. Am J Hematol 36(2) : 93-99, 1991.
 
27) Dolcetti R, Boiocchi M, Gloghini A, et al: Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. Eur J Cancer 37(10) 1276-1287, 2001.
PubMed
28) Diebold J, Raphael M, Prevot S, et al: Lymphomas associated with HIV infection. Cancer Surv 30: 263-293, 1997.
PubMed
29) Levine AM: Acquired immunodeficiency syndrome-related lymphoma. Blood 80(1) : 8-20, 1992.
PubMed
30) Fine HA and Mayer RJ: Primary central nervous system lymphoma. Ann Intern Med 119(11) : 1093-1104, 1993.
PubMed
31) Skolasky RL, Dal Pan GJ, Olivi A, et al: HIV-associated primary CNS lymorbidity and utility of brain biopsy. J Neurol Sci 163(1) : 32-38, 1999.
PubMed
32) Cingolani A, De Luca A, Larocca LM, et al: Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst 90(5) : 364-369, 1998.
PubMed
33) D'Amico A, Messa C, Castagna A, et al: Diagnostic accuracy and predictive value of 201 T l SPET for the differential diagnosis of cerebral lesions in AIDS patients. Nucl Med Commun 18(8) : 741-750, 1997.
 
34) Goldstein JD, Dickson DW, Moser FG, et al: Primary central nervous system lymphoma in acquired immune deficiency syndrome. A clinical and pathologic study with results of treatment with radiation. Cancer 67(11) : 2756-2765, 1991.
PubMed
35) Hoffmann C, Tabrizian S, Wolf E, et al: Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 15(16) : 2119-2127, 2001.
PubMed
36) McGowan JP and Shah S: Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy. AIDS 12(8) : 952-954, 1998.
PubMed
37) Raez L, Cabral L, Cai JP, et al: Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses 15(8) : 713-719, 1999.
PubMed
38) Carbone A, Tirelli U, Gloghini A, et al: Herpesvirus-like DNA sequences selectively cluster with body cavity-based lymphomas throughout the spectrum of AIDS-related lymphomatous effusions. Eur J Cancer 32 A(3) : 555-556, 1996.
 
39) Nador RG, Cesarman E, Knowles DM, et al: Herpes-like DNA sequences in a body-cavity-based lymphoma in an HIVnegative patient. N Engl J Med 333(14) : 943, 1995.
 
40) Pfister H: The role of human papillomavirus in anogenital cancer. Obstet Gynecol Clin North Am 23(3) : 579-595, 1996.
PubMed
41) Penn I: Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 58(3) 1611-616, 1986.
 
42) Nakagawa M, Stites DP, Farhat S, et al: Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 175(4) : 927-931, 1997
PubMed
43) Vernon SD, Hart CE, Reeves WC, et al: The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res 27(2) : 133-145, 1993.
 
44) Epidemiologic Notes and Reports Risk for Cervical Disease in HIV-Infected Women New York City. MMWR 39(no 47) : 846-849, 1990.
 
45) Henry MJ, Stanley MW, Cruikshank S, et al: Association of human immunodeficiency virus-induced immunosuppression with human papillomavirus infection and cervical intraepithelial neoplasia. Am J Obstet Gynecol 160(2) : 352-353, 1989.
PubMed
46) Maiman M, Fruchter RG, Serur E, et al: Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 38(3) : 377-382, 1990.
PubMed
47) Biggar RJ and Rabkin CS: The epidemiology of AIDS-related neoplasms. Hematol Oncol Clin North Am 10(5) : 997-1010, 1996.
PubMed
48) Sun XW, Kuhn L, Ellerbrock TV, et al: Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 337(19) : 1343-1349, 1997.
 
49) Biggar RJ and Rabkin CS: The epidemiology of AIDS related neoplasms. Hematol Oncol Clin North Am 10(5) : 997-1010, 1996.
PubMed
50) Frisch M, Glimelius B, van den Brule AJ, et al: Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337(19) : 1350-1358, 1997.
 
51) Carter PS, de Ruiter A, Whatrup C, et al: Human immunodeficiency virus infection and genital warts as risk factors for anal intraepithelial neoplasia in homosexual men. Br J Surg 82(4) : 473-474, 1995.
PubMed
52) Frisch M, Biggar RJ, Engels EA, et al: Association of cancer with AIDS-related immunosuppression in adults. JAMA 285(13) : 1736-1745, 2001.
PubMed
53) Soto B, Sanchez-Quijano A, Rodrigo L, et al: Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 26(1) : 1-5, 1997.
PubMed
54) Granovsky MO, Mueller BU, Nicholson HS, et al: Cancer in human immunodeficiency virus-infected children: acase series from the Children's Cancer Group and the National Cancer Institute. J Clin Oncol 16: 1729-1735, 1998.
 
P.1033 掲載の参考文献
1) Nathanson L and Hall TC: Introduction: paraneoplastic syndromes. Semin Oncol 24: 265-268, 1997.
PubMed
2) Henson RA, Hoffman HL and Urich H: Encephalomyelitis with carcinoma. Brain 88: 449-464, 1965.
PubMed
3) Dalmau JO and Posner JB: Paraneoplastic syndromes affecting the nervous system. Semin Oncol 24: 318-328, 1997.
PubMed
4) Gultekin SH, Rosenfeld MR, Voltz R, et al: Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123: 1481-1494, 2000.
PubMed
5) Voltz R, Gultekin SH, Rosenfeld MR, et al: Aserologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 340: 1788-1795, 1999.
PubMed
6) Trivedi R, Mundanthanam G, Amyes E, et al: Autoantibody screening in subacute cerebellar ataxia. Lancet 356: 565-566, 2000.
PubMed
7) Smitt SP, Kinoshita A, De Leeuw B, et al: Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342: 21-27, 2000.
 
8) Posner JB, Dalmau JO: Paraneoplastic syndromes of the nervous system. Clin Chem Lab Med 38: 117-122, 2000.
PubMed
9) Pranzatelli MR: The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 19: 1-47, 1996.
 
10) Connolly AM, Pestronk A, Mehta S, et al: Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 130: 878-884, 1997.
PubMed
11) Anderson NE, Budde-Steffen C, Rosenblum MK, et al: Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine(Baltimore) 67: 100-109, 1988.
 
12) Digre KB: Opsoclonus in adults. Report of three cases and review of the literature. Arch Neurol 43: 1165-1175, 1986.
PubMed
13) Telander RL, Smithson WA and Groover RV: Clinical outcome in children with acute cerebellar encephalopathy and neuroblastoma. J Pediatr Surg 24: 11-14(discussion 14) , 1989.
PubMed
14) Luque FA, Furneaux HM, Ferziger R, et al: Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 29: 241-251, 1991.
PubMed
15) Buckanovich RJ, Yang YY and Darnell RB: The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 16: 1114-1122, 1996.
PubMed
16) Hayward K, Jeremy RJ, Jenkins S, et al: Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 139: 552-559, 2001.
PubMed
17) Ridley A, Kennard C, Scholtz CL, et al: Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain 110: 1699-1709, 1987.
PubMed
18) Jacobson DM, Thirkill CE and Tipping SJ: A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol 28: 162-167, 1990.
PubMed
19) Weinstein JM, Kelman SE, Bresnick GH, et al: Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology 101: 1236-1243, 1994.
PubMed
20) Jacobson DM and Adamus G: Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma. Am J Ophthalmol 131: 806-808, 2001.
 
21) Polans AS, Witkowska D, Haley TL, et al: Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA 92: 9176-9180, 1995.
PubMed
22) Ohguro H, Ogawa K and Nakagawa T: Recoverin and Hsc 70 are found as autoantigens in patients with cancer-associated retinopathy. Invest Ophthalmol Vis Sci 40: 82-89, 1999.
PubMed
23) Ohguro H, Ogawa K, Maeda T, et al: Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci 40: 3160-3167, 1999.
PubMed
24) O'Leary CP and Willison HJ: Autoimmune ataxic neuropathies(sensory ganglionopathies) . Curr Opin Neurol 10: 366-370, 1997.
PubMed
25) Sillevis-Smitt P, Manley G, Moll JW, et al: Pitfalls in the diagnosis of autoantibodies associated with paraneoplastic neurologic disease. Neurology 46: 1739-1741, 1996.
 
26) Graus F, Dalmou J, Rene R, et al: Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 15: 2866-2872, 1997.
PubMed
27) Jean WC, Dalmau J, Ho A, et al: Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology 44: 140-147, 1994.
PubMed
28) Dalmau J, Furneaux HM, Gralla RJ, et al: Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer-a quantitative western blot analysis. Ann Neurol 27: 544-552, 1990.
PubMed
29) Chalk CH, Windebank AJ, Kimmel DW, et al: The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci 19: 346-351, 1992.
 
30) Schold SC, Cho ES, Somasundaram M, et al: Subacute motor neuronopathy: a remote effect of lymphoma. Ann Neurol 5: 271-287, 1979.
PubMed
31) Croft PB, Urich H and Wilkinson M: Peripheral neuropathy of sensorimotor type associated with malignant disease. Brain 90: 31-66, 1967.
PubMed
32) 本村政勝: 免疫性神経疾患最新の進歩Lambert-Eaton筋無力症候群 本邦110症例の検討. 臨床神経学 39: 1237-1239, 1999.
 
33) Rosenfeld MR, Wong E, Dalmau J, et al: Cloning and characterization of a Lambert-Eaton myasthenic syndrome antigen. Ann Neurol 33: 113-120, 1993.
PubMed
34) Verschuuren JJ, Dalmau J, Tunkel R, et al: Antibodies against the calcium channel beta-subunit in Lambert-Eaton myasthenic syndrome. Neurology 50: 475-479, 1998.
PubMed
35) McEvoy KM, Windebank AJ, Daube JR, et al: 3, 4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 321: 1567-1571, 1989.
PubMed
36) Ferrari P, Federico M, Grimaldi LM, et al: Stiff-man syndrome in a patient with Hodgkin's disease. An unusual paraneoplastic syndrome. Haematologica 75: 570-572, 1990.
 
37) Rosin L, DeCamilli P, Butler M, et al: Stiff-man syndrome in a woman with breast cancer: an uncommon central nervous system paraneoplastic syndrome. Neurology 50: 94-98, 1998.
 
38) Folli F, Solimena M, Cofiell R, et al: Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 328: 546-551, 1993.
PubMed
39) Mygland A, Vincent A, Newsom-Davis J, et al: Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol 57: 527-531, 2000.
PubMed
40) Odell WD: Endocrine/metabolic syndromes of cancer. Semin Oncol 24: 299-317, 1997.
PubMed
41) Kraus J, Buchfelder M and Hollt V: Regulatory elements of the human proopiomelanocortin gene promoter. DNA Cell Biol 12: 527-536, 1993.
PubMed
42) Amsler UJ, Pasi A and Qu BX: A novel hypothesis: specific oncogenes and tumor suppression genes are involved in the expression of the proopiomelanocortin gene by small cell lung cancer. Med Hypotheses 42: 397-399, 1994.
PubMed
43) Terzolo M, Reimondo G, Ali A, et al: Ectopic ACTH syndrome: molecular bases and clinical heterogeneity. Ann Oncol 12: S83-87, 2001.
PubMed
44) Howlett TA, Drury PL, Perry L, et al: Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol(Oxf) 24: 699-713, 1986.
 
45) 宮地幸隆: 診療ガイドラインレビュー, 副腎機能異常症. 日内会誌 91: 211-226, 2002.
 
46) Schwartz WB, Bennett W, Curelop S, et al: A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 23: 529-542, 1957.
PubMed
47) Vorherr H, Massry SG, Utiger RD, et al: Anti-diuretic principle in malignant tumor extracts from patients with inappropriate ADH syndrone. J Clin Endocrinol Metab 28: 162-168, 1968.
 
48) Lokich JJ: The frequency and clinical biology of the ectopic hormone syndromes of small cell carcinoma. Cancer 50: 2111-2114, 1982.
PubMed
49) Hainsworth JD, Workman R and Greco FA: Management of the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer. Cancer 51: 161-165, 1983.
PubMed
50) Barri YM and Knochel JP: Hypercalcemia and electrolyte disturbances in malignancy. Hematol Oncol Clin North Am 10: 775-790, 1996.
PubMed
51) Oikawa S, Imai M, Ueno A, et al: Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic polypeptide. Nature 309: 724-726, 1984.
PubMed
52) Kangawa K and Matsuo H: Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide. Biochem Biophys Res Commun 118: 131-139, 1984.
PubMed
53) van Oosterhout AG, van de Pol M, ten Velde GP, et al: Neurologic disorders in 203 consecutive patients with small cell lung cancer. Results of a longitudinal study. Cancer 77: 1434-1441, 1996.
PubMed
54) Ayus JC, Krothapalli RK and Arieff AI: Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N Engl J Med 317: 1190-1195, 1987.
PubMed
55) Sato K, Fujii Y, Ono M, et al: Production of interleukin 1 alpha-like factor and colony-stimulating factor by a squamous cell carcinoma of the thyroid(T 3 M-5) derived from a patient with hypercalcemia and leukocytosis. Cancer Res 47: 6474-6480, 1987.
 
56) Tashjian AH Jr, Voelkel EF, Levine L, et al: Evidence that the bone resorption-stimulating factor produced by mouse fibrosarcoma cells is prostaglandin E 2. A new model for the hypercalcemia of cancer. J Exp Med 136: 1329-1343, 1972.
 
57) Rosenthal N, Insogna KL, Godsall JW, et al: Elevations in circulating 1, 25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. J Clin Endocrinol Metab 60: 29-33, 1985.
PubMed
58) Bundred NJ, Walls J and Ratcliffe WA: Parathyroid hormone-related protein, bone metastases and hypercalcemia of malignancy. Ann R Coll Surg Engl 78: 354-358, 1996.
PubMed
59) Fukumoto S, Matsumoto T, Yamoto H, et al: Suppression of serum 1, 25-dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1, 25-dihydroxyvitamin D 3 production. Endocrinology 124: 2057-2062, 1989.
 
60) Body JJ, Borkowski A, Cleeren A, et al: Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 4: 1177-1183, 1986.
PubMed
61) Daughaday WH, Emanuele MA, Brooks MH, et al: Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med 319: 1434-1440, 1988.
PubMed
62) Zapf J: Role of insulin-like growth factor(IGF) II and IGF binding proteins in extrapancreatic tumour hypoglycaemia. J Intern Med 234: 543-552, 1993.
PubMed
63) Shetty MR, Boghossian HM, Duffell D, et al: Tumor-induced hypoglycemia: a result of ectopic insulin production. Cancer 49: 1920-1923, 1982.
PubMed
64) Frizelle FA and Pfiefer MV: Paraneoplastic hypoglycaemia treated with somatostatin analogue SMS 201-995. Eur J Surg Oncol 22: 546-547, 1996.
PubMed
65) Braunstein GD, Vaitukaitis JL, Carbone PP, et al: Ectopic production of human chorionic gonadotrophin by neoplasms. Ann Intern Med 78: 39-45, 1973.
PubMed
66) Tisdale M: Biology of cachexia. J Natl Cancer Inst 89: 1763-1773, 1997.
PubMed
67) Ballard HS and Kouri Y: The association of erythrocytosis and chronic lymphocytic leukemia. Cancer 70: 2431-2435, 1992.
PubMed
68) Blay JY, Favrot M, Rossi JF, et al: Role of interleukin-6 in paraneoplastic thrombocytosis. Blood 82: 2261-2262, 1993.
PubMed
69) Estrov Z, Talpaz M, Mavligit G, et al: Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med 98: 551-558, 1995.
PubMed
70) Sack GH Jr, Levin J and Bell WR: Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine(Baltimore) 56: 1-37, 1977.
PubMed
71) Naschitz JE, Yeshurun D, Eldar S, et al: Diagnosis of cancer-associated vascular disorders. Cancer 77: 1759-1767, 1996.
PubMed
72) Kakkar AK, DeRuvo N, Chinswangwatanakul V, et al: Extrinsic-pathway activation in cancer with high factor VII a and tissue factor. Lancet 346: 1004-1005, 1995.
PubMed
73) Pineo GF, Brain MC, Gallus AS, et al: Tumors, mucus production, and hypercoagulability. Ann N Y Acad Sci 230: 262-270, 1974.
PubMed
74) Green D, Hull RD, Brant R, et al: Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339: 1476, 1992.
PubMed
75) Gould MK, Dembitzer AD, Doyle RL, et al: Low-molecular-weight heparins, compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized controlled trials. Ann Intern Med 130: 800, 1999.
PubMed
76) Naschitz JE, Yeshurun D and Lev LM: Thromboembolism in cancer. Changing trends. Cancer 71: 1384-1390, 1993.
PubMed
77) Grainick HR and Abrell E: Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia. Br J Hematol 24: 59, 1973.
 
78) Cohen PR and Kurzrock R: Mucocutaneous paraneoplastic syndromes. Semin Oncol 24: 334-359, 1997.
PubMed
79) Schwartz RA: acanthosis nigricans. J Am Acad Dermatol 31: 1-19, 1994.
PubMed
80) Khanna SK, Agnone FA, Leibowitz AI, et al: Nonfamilial diffuse palmoplantar keratoderma associated with bronchial carcinoma. J Am Acad Dermatol 28: 295-297, 1993.
PubMed
81) Bazex A and Griffiths A: Acrokeratosis paraneoplastica-a new cutaneous marker of malignancy. Br J Dermatol 103: 301-306, 1980.
PubMed
82) Bolognia JL: Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol 14: 84-89, 1995.
PubMed
83) DiBisceglie AM, Hodkinson HJ, Berkowitz I, et al: Pityriasis rotunda. A cutaneous marker of hepatocellular carcinoma in South African blacks. Arch Dermatol 122: 802-804, 1986.
 
84) Cohen PR: Cutaneous paraneoplastic syndromes associated with lung cancer. Mayo Clin Proc 68: 620-621, 1993.
PubMed
85) Cohen PR, Grossman ME, Silvers DN, et al: Tripe palms and cancer. Clin Dermatol 11: 165-173, 1993.
PubMed
86) Dickinson CJ: The aetiology of clubbing and hypertrophic osteoarthropathy. Eur J Clin Invest 23: 330-338, 1993.
PubMed
87) Benedek TG: Paraneoplastic digital clubbing and hypertrophic osteoarthropathy. Clin Dermatol 11: 53-59, 1993.
PubMed
88) Segal AM and Mackenzie AH: Hypertrophic osteoarthropathy: a 10-year retrospective analysis. Semin Arthritis Rheum 12: 220-232, 1982.
PubMed
89) Boyd AS, Neldner KH and Menter A: Erythema gyratum repens: a paraneoplastic eruption. J Am Acad Dermatol 26: 757-762, 1992.
PubMed
90) Kurzrock R and Cohen PR: Erythema gyratum repens. JAMA 273: 594, 1995.
PubMed
91) Parker CM, Hanke CW, Madura JA, et al: Glucagonoma syndrome: case report and literature review. J Dermatol Surg Oncol 10: 884-889, 1984.
PubMed
92) Mullans EA and Cohen PR: Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonomaassociated necrolytic migratory erythema. J Am Acad Dermatol 38: 866-873, 1998.
PubMed
93) Toumbis-Ioannou E and Cohen PR: Chemotherapy-induced Raynaud's phenomenon. Cleve Clin J Med 61: 195-199, 1994.
 
94) Taillan B, Castanet J, Garnier G, et al: Paraneoplastic Raynaud's phenomenon. Clin Rheumato112: 281-282, 1993.
 
95) Sigurgeirsson B, Lindelof B, Edhag O, et al: Risk of cancer in patients with dermatomyositis or plymyositis. A populationbased study. N Engl J Med 326: 363, 1992.
PubMed
96) Amagai M: Autoimmunity against desmosomal cadherins in pemphigus. J Dermatol Sci 20: 92-102, 1999.
PubMed
97) Allen CM and Camisa C: Paraneoplastic pemphigus: areview of the literature. Oral Dis 6: 208-214, 2000.
 
98) Cohen PR, Talpaz M and Kurzrock R: Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol 6: 1887-1897, 1988.
 
P.1041 掲載の参考文献
1) Kinasewitz GT and Fishman AP: Influence of alterations in Starling forces on visceral pleural fluid movement. J Appl Physiol 51: 671, 1981.
PubMed
2) Hausheer FH and Yarbro JW: Diagnosis and treatment of malignant pleural effusion. Semin Oncol 12: 54, 1985.
PubMed
3) Leuallen EC and Carr DT: Pleural effusion-a statistical study of 436 patients. N Engl J Med 252: 79, 1955.
PubMed
4) Hirsch A, Ruffie P, Nebut M, et al: Pleural effusion: laboratory tests in 300 cases. Thorax 34: 106, 1979.
PubMed
5) Peterman TA and Speicher CE: Evaluating pleural effusion. JAMA 252: 1051, 1984.
PubMed
6) Cardoza PL: A critical evaluation of 3000 cytologic analyses of pleural fluid, ascitic fluid, and pericardial fluid. Acta Cytol 10: 455, 1966.
 
7) Winkelmann M and Pfitzer P: Blind pleural biopsy in combination with cytology of pleural effusions. Acta Cyto125: 373, 1981.
PubMed
8) Tamura S, Nishigaki T, Moriwaki Y, et al: Tumor markers in pleural effusion diagnosis. Cancer 61: 298, 1988.
PubMed
9) Roboz J, Greaves J, Silides D, et al: Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma. Cancer Res 45: 1850, 1985.
PubMed
10) D'Cunha J, Corfits AL, Herndon JE 2 nd, et al: Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer-preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg 123: 484-491, 2002.
 
11) Ahn MJ, Noh YH, Yoon HJ, et al: Detection of malignant cells in pleural fluid or ascites by CD44v8-10/CD44v10 competitive RT PCR. Korean J Intern Med 16: 30-35, 2001.
PubMed
12) Hess JL and Highsmith WE Jr: Telomerase detection in body fluids. Clin Chem 48: 18-24, 2002.
PubMed
13) Martini N, Bains MS and Beattie EJ Jr: Indications for pleurectomy in malignant effusion. Cancer 35: 734, 1975.
PubMed
14) Kimura M, Konno T, Miyamoto Y, et al: Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses. Anticancer Res 18: 2547-2550, 1998.
PubMed
15) Yamaguchi Y, Satoh Y, Miyahara E, et al: Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res 15: 2201-2206, 1995.
PubMed
16) Katano M and Torisu M: Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 50: 62-68, 1982.
PubMed
17) Rosenberg SA, Lotze MT, Muul LM, et al: Observation on the systemic administration of autologous lymphokineactivated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985.
 
18) 山口佳之, 大田耕司, 峠 哲哉: がん集学的治療におけるex vivo cell therapyの意義. がん治療と宿主 12: 172-178, 2000.
 
19) Bayly TC, Kisner DL, Sybert A, et al: Tetracycline and quinacrine in the control of malignant effusions. Cancer 41: 1188, 1978.
PubMed
20) Harley HR: Malignant pleural effusions and their treatment by intercostal talc pleurodesis. Br J Dis Chest 73: 173, 1979.
PubMed
P.1048 掲載の参考文献
1) Guberman BA, Fowler NO, Engel PJ, et al: Cardiac tamponade in medical patients. Circulation 64(3) : 633-640, 1981.
PubMed
2) Kline IK: Cardiac lymphatic involvement by metastatic tumor. Cancer 29(3) : 799-808, 1972.
PubMed
3) Roberts WC, Glancy DL and DeVita VT Jr: Heart in malignant lymphoma(Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides) . A study of 196 autopsy cases. Am J Cardiol 22(1) : 85-107, 1968.
PubMed
4) Roberts WC, Bodey GP and Wertlake PT: The heart in acute leukemia. A study of 420 autopsy cases. Am J Cardiol 21(3) : 388-412, 1968.
PubMed
5) Glancy DL and Roberts WC: The heart in malignant melanoma. A study of 70 autopsy cases. Am J Cardiol 21(4) : 555-571, 1968.
 
6) Press OW and Livingston R: Management of malignant pericardial effusion and tamponade. JAMA 257(8) : 1088-1092, 1987
PubMed
7) Sytman AL and MacAlpin RN: Primary pericardial mesothelioma: report of two cases and review of the literature. Am Heart J 81(6) : 760-769, 1971.
PubMed
8) Hancock EW: Neoplastic pericardial disease. Cardiol Clin 8(4) : 673-682, 1990.
PubMed
9) Olopade OI and Ultmann JE: Malignant effusions. CA Cancer J Clin 41(3) : 166-179, 1991.
PubMed
10) Fraser RS, Viloria JB and Wang NS: Cardiac tamponade as a presentation of extracardiac malignancy. Cancer 45(7) : 1697-1704, 1980.
 
11) Fincher RM: Case report: malignant pericardial effusion as the initial manifestation of malignancy. Am J Med Sci 305(2) : 106-110, 1993.
PubMed
12) Shepherd FA, Morgan C, Evans WK, et al: Medical management of malignant pericardial effusion by tetracycline sclerosis. Am J Cardiol 60(14) : 1161-1166, 1987.
PubMed
13) Chong HH and Plotnick GD: Pericardial effusion and tamponade: evaluation, imaging modalities, and management. Compr Ther 21(7) : 378-385, 1995.
PubMed
14) Goldberg BB and Pollack HM: Ultrasonically guided pericardiocentesis. Am J Cardiol 31(4) : 490-493, 1973.
PubMed
15) Callahan JA, Seward JB, Tajik AJ, et al: Pericardiocentesis assisted by two-dimensional echocardiography. J Thorac Cardiovasc Surg 85(6) : 877-879, 1983.
PubMed
16) Johnson FE, Wolverson MK, Sundaram M, et al: Unsuspected malignant pericardial effusion causing cardiac tamponade. Rapid diagnosis by computed tomography. Chest 82(4) : 501-503, 1982.
PubMed
17) Gouliamos A, Andreou J, Steriotis J, et al: Detection of pericardial heart disease by computed tomography. Clin Radiol 35(5) : 397-400, 1984.
PubMed
18) Silverman PM, Harell GS and Korobkin M: Computed tomography of the abnormal pericardium. AJR Am J Roentgenol 140(6) : 1125-1129, 1983.
PubMed
19) Stark DD, Higgins CB, Lanzer P, et al: Magnetic resonance imaging of the pericardium: normal and pathologic findings. Radiology 150(2) : 469-474, 1984.
PubMed
20) Moores DW, Allen KB, Faber LP, et al: Subxiphoid pericardial drainage for pericardial tamponade. J Thorac Cardiovasc Surg 109(3) : 546-551; discussion 51-52, 1995.
 
21) Hsu FI, Keefe D, Desiderio D, et al: Echocardiographic and surgical correlation of pericardial effusions in patients with malignant disease. J Thorac Cardiovasc Surg 115(5) : 1215-1216, 1998.
 
22) Posner MR, Cohen GI and Skarin AT: Pericardial disease in patients with cancer. The differentiation of malignant from idiopathic and radiation-induced pericarditis. Am J Med 71(3) : 407-413, 1981.
PubMed
23) Clarke DP and Cosgrove DO: Real-time ultrasound scanning in the planning and guidance of pericardiocentesis. Clin Radiol 38(2) : 119-122, 1987.
PubMed
24) Millaire A, Wurtz A, de Groote P, et al: Malignant pericardial effusions: usefulness of pericardioscopy. Am Heart J 124(4) : 1030-1034, 1992.
PubMed
25) Smith FE, Lane M and Hudgins PT: Conservative management of malignant pericardial effusion. Cancer 33(1) : 47-57, 1974.
PubMed
26) Sabiston DC Jr and Spencer FC: Surgery of the Chest, 5th ed, vol 1, WB SAUNDER Co, Philadelphia, 1990.
 
27) Maher EA, Shepherd FA and Todd TJ: Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 112(3) : 637-643, 1996.
PubMed
28) Vaitkus PT, Herrmann HC and LeWinter MM: Treatment of malignant pericardial effusion. JAMA 272(1) : 59-64, 1994.
PubMed
29) Callahan JA, Seward JB, Nishimura RA, et al: Two-dimensional echocardiographically guided pericardiocentesis: experience in 117 consecutive patients. Am J Cardiol 55(4) : 476-479, 1985.
PubMed
30) Gatenby RA, Hartz WH and Kessler HB: Percutaneous catheter drainage for malignant pericardial effusion. J Vasc Interv Radio1 2(1) : 151-155, 1991.
 
31) Wong B, Murphy J, Chang CJ, et al: The risk of pericardiocentesis. Am J Cardiol 44(6) : 1110-1114, 1979.
PubMed
32) Allen KB, Faber LP, Warren WH, et al: Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Ann Thorac Surg 67(2) : 437-440, 1999.
PubMed
33) Piehler JM, Pluth JR, Schaff HV, et al: Surgical management of effusive pericardial disease. Influence of extent of pericardial resection on clinical course. J Thorac Cardiovasc Surg 90(4) : 506-516, 1985.
PubMed
34) Park JS, Rentschler R and Wilbur D: Surgical management of pericardial effusion in patients with malignancies. Comparison of subxiphoid window versus pericardiectomy. Cancer 67(1) : 76-80, 1991.
PubMed
35) Naunheim KS, Kesler KA, Fiore AC, et al: Pericardial drainage: subxiphoid vs. transthoracic approach. Eur J Cardiothorac Surg 5(2) : 99-103; discussion O4, 1991.
 
36) Yim AP and Ho JK: Video-assisted subxiphoid pericardiectomy. J Laparoendosc Surg 5(3) : 193-198, 1995.
PubMed
37) Ockene IS: Pericardiocentesis. In: Atlas of Bedside Procedures, (ed by Slam TJV, Cutler BS and Wheeler HB) , 2nd ed, Little, Brown and Company, Boston, 1988, p 165.
 
38) Liu G, Crump M, Goss PE, et al: Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J Clin Oncol 14(12) : 3141-3147, 1996.
PubMed
39) Lashevsky I, Ben Yosef R, Rinkevich D, et al: Intrapericardial minocycline sclerosis for malignant pericardial effusion. Chest 109(6) : 1452-1454, 1996.
PubMed
40) Imamura T, Tamura K, Takenaga M, et al: Intrapericardial OK-432 instillation for the management of malignant pericardial effusion. Cancer 68(2) : 259-263, 1991.
PubMed
41) Fiorentino MV, Daniele O, Morandi P, et al: Intrapericardial instillation of platin in malignant pericardial effusion. Cancer 62(9) : 1904-1906, 1988.
PubMed
42) Primrose WR, Clee MD and Johnston RN: Malignant pericardial effusion managed with vinblastine. Clin Oncol 9(1) : 67-70, 1983.
PubMed
43) Ziskind AA, Pearce AC, Lemmon CC, et al: Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: description of technique and report of the first 50 cases. J Am Coll Cardiol 21(1) : 1-5, 1993.
 
44) Di Segni E, Lavee J, Kaplinsky E, et al: Percutaneous balloon pericardiostomy for treatment of cardiac tamponade. Eur Heart J 16(2) : 184-187, 1995.
PubMed
45) Palacios IF, Tuzcu EM, Ziskind AA, et al: Percutaneous balloon pericardial window for patients with malignant pericardial effusion and tamponade. Cathet Cardiovasc Diagn 22(4) : 244-249, 1991.
PubMed
46) Wang N, Feikes JR, Mogensen T, et al: Pericardioperitoneal shunt: an alternative treatment for malignant pericardialeffusion. Ann Thorac Surg 57(2) : 289-292, 1994.
 
47) 新海 哲: 心嚢炎. 臨床腫瘍学, (西條長宏, 有吉寛, 佐々木康綱, 他・編) , 第2版, 癌と化学療法社, 東京, 1999, p 1628.
 
P.1056 掲載の参考文献
1) Hall JC, Heel KA, Papadimitriou JM, et al: The pathobiology of peritonitis. Special reports and reviews. Gastroenterology 114: 185-196, 1998.
 
2) Hirabayashi K and Graham J: Genesis of ascites in ovarian carcinoma. Am J Obstet Gynecol 106: 492-497, 1970.
 
3) Negrini D, Mukenge S, Fabbro MD, et al: Distribution of lymphatic stomata. J Appl Physiol 70: 1544-1549, 1991.
 
4) Hagiwara A, Takahashi T, Sawai K, et al: Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res 54: 687-692, 1994.
 
5) Yonemura Y, Nojima N, Kawamura T, et al: Mechanisms of the formation of peritoneal dissemination. In Peritoneal Dissemination, (ed by Yomemura Y) , Maeda Shoten Co Ltd, Kanazawa, 1998, pp l-46.
 
6) Luo JC, Toyoda M and Shibuya M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an anti-vascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58: 2594-2600, 1998.
PubMed
7) Nagy JA, Meyers MS, Masse EM, et al: Pathogenesis of ascites tumor growth: Fibrinogen influx and fibrin accumulation in tissues Iining the peritoneal cavity. Cancer Res 55: 376-385, 1995.
 
8) Rynyon BA: Care of patients with ascites. N Engl J Med 330: 337-342, 1994.
 
9) Hird V, Thomas H, Stewart JSM, et al: Malignant ascites: review of the literature, and an update on monoclonal antibody-targeted therapy. Eur J Obstet Gynecol Reprod Biol 32: 37-45, 1989.
 
10) McHutchison JG: Differential diagnosis of ascites. Semin Liver Dis 17: 191-202, 1997.
PubMed
11) Runyon BA, Montano AA, Akriviadis EA, et al: The serum-ascites albumin gradient in the differential diagnosis of ascites is superior to the exudates/transudate concept. Ann Intern Med 117: 215-220, 1992.
 
12) Runyon BA, Hoefs JC and Morgan TR: Ascitic fluid analysis in malignancy-related ascites. Hepatology 8: 1104-1109, 1998.
 
13) Torresini RJ, Prolla JC, Diehl ARS, et al: Combined carcinoembryonic antigen and cytopathologic examination in ascites. Acta Cytol 44: 778-782, 2000.
 
14) Parsons SL, Lang MW and Steele RJC: Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 22: 237-239, 1996.
 
15) Mackey JR, Wood L, Nabholtz J-M, et al: A phase II trial of triamcinolone hexacetamide for symptomatic recurrent malignant ascites. J Pain Symptom Manage 19: 193-199, 2000.
 
16) Bieligk SC, Calvo BF and Coit DG: Peritoneovenous shunting for nongynecologic malignant ascites. Cancer 91: 1247-1255, 2001.
PubMed
17) Crookes P, Leichman CG, Leichman L, et al: Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: afinal report. Cancer 79: 1767-1775, 1997.
 
18) Juhl H, Strizel M, Wroblewski A, et al: Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric colorectal and pancreatic cancer experiments. Int J Cancer 57: 330-335, 1994.
 
19) Atiq OT, Kelsen DP, Shiu MH, et al: Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol l1: 425-433, 1993.
 
20) Hagiwara A, Takahashi T, Kojima O, et al: Prophylaxis with carbon-absorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 339: 629-631, 1992.
 
21) Gilly FN, Carry PY, Sayag AC, et al: Regional chemotherapy(with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 41: 124-129, 1994.
PubMed
22) Fujimura T, Yonemura Y, Muraoka K, et al: Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer; Randomized controlled study. World J Surg 18: 150-155, 1994.
PubMed
23) Sugarbaker PH: Peritonectomy procedures. Ann Surg 221: 29-42, 1995.
PubMed
24) Sugarbaker PH: Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. EJSO 27: 239-243, 2001.
PubMed
25) Reijnhart RM, Bieber MM and Teng NNH FACS analysis of peritoneal lymphocytes in ovarian cancer and control patients. Immunobiology 191: 1-8, 1994.
 
26) Yoon SJ, Heo DS, Kang SH, et al: Natural killer cell activity depression in peripheral blood and ascites from gastric cancer patients with high TGF-b 1 expression. Anticancer Res 8: 1591-1596, 1998.
 
27) Kono K, Ichihara F, Iizuka H, et al: Differences in the recognition of tumor-specific CD8+T cells derived from solid tumor, metastatic lymph nodes and ascites in patients with gastric cancer. Int J Cancer 71: 978-981, 1997.
PubMed
28) 片野光男: 癌性腹膜炎治療を通じて学ぶ臨床腫瘍免疫学. 第1版, 癌と化学療法社, 東京, 1997, pp 1-236.
 
29) Yamaguchi Y, Satoh Y, Miyahara E, et al: Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res 15: 2201-2206, 1995.
PubMed
30) Nio Y, Nagami H, Tamura K, et al: Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br J Cancer 80: 775-785, 1999.
PubMed
31) Oka M, Yoshino S, Hazama S, et al: Immunological analysis and clinical effects of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion. Biotherapy 5: 107-112, 1992.
PubMed
32) 片野光男, 森崎 隆: 免疫学を基盤とした癌性腹膜炎治療. 外科領域における癌免疫療法-その理論と実際-, (仁尾義則, 片野 光男・監修) , ライフサイエンス・メディカ, 東京, 2001, pp 44-58.
 
33) Beattie GJ and Smyth JF: Phase I study of intraperitoneal metalloproteinase inhibitor BB 94 in patients with malignant ascites. Clin Cancer Res 4: 1899-1902, 1998.
PubMed
34) Richards J, Auger J, Peace D, et al: Phase I evaluation of humanized OKT 3: toxicity and immunomodulatory effects of hOKT 3 γ 4. Cancer Res 59: 2096-2101, 1999.
 
35) Xu L, Yoneda J, Herrera C, et al: Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endotyhelial growth factor receptor tyrosine kinases. Int J Oncol 16: 445-454, 2000.
PubMed
P.1067 掲載の参考文献
1) Doci R, Gennari L, Bignami P, et al: One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 78: 797-801, 1991.
PubMed
2) Sugihara K, Hojo K, Moriya Y, et al: Pattern of recurrence after hepatic resection for colorectal metastases. Br J Surg 80: 1032-1035, 1993.
PubMed
3) Gayowski TJ, Iwatsuki S, Madariaga JR, et al: Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 116: 703-710, 1994.
PubMed
4) Scheele J, Stang R, Altendorf-Hofmann A, et al: Resection of colorectal liver metastases. World J Surg 19: 59-71, 1995.
 
5) Nordlinger B, Guiguet M, Vaillant JC, et al: Surgical resection of colorectal carcinoma metastases of the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77: 1254-1262, 1996.
PubMed
6) Rees M, Plant G and Bygrave S: Late results justify resection for multiple hepatic metastases from colorectal cancer. Br JSurg 84: 1136-1140, 1997.
PubMed
7) Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg 230: 309-321, 1999.
PubMed
8) Harmon KE, Ryan JA, Biehl TR, et al: Benefits and safety of hepatic resection for colorectal metastases. Am J Surg 177: 402-404, 1999.
PubMed
9) Minagawa M, Makuuchi M, Torzilli G, et al: Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer. Long-term results. Ann Surg 231: 487-499, 2000.
PubMed
10) 森谷宣皓, 藤田 伸, 赤須孝之・他: 大腸癌肝転移-肝切除の適応と成績-. 日外会誌 102: 385-389, 2001.
 
11) Wanebo HJ, Chu QD, Avradopoulos KA, et al: Current perspectives on repeat hepatic resection for colorectal carcinoma: A review. Surgery 119: 361-371, 1996.
PubMed
12) Jaeck D, Bachellier P, Guiguet M, et al: Long-term survival following resection of colorectal hepatic metastasis. Br J Surg 84: 1081-1084, 1997.
 
13) Jamison RL, Donohue JH, Nagorney DM, et al: Hepatic resection for metastatic colorectal cancer. Arch Surg 132: 505-511, 1997.
PubMed
14) Yasui K, Hirai T, Kato T, et al: A new macroscopic classification predicts prognosis for patient with liver metastasis from colorectal cancer. Ann Surg 226: 582-586, 1997.
 
15) Bakalakos EA, Kim JA, Young DC, et al: Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg 22: 399-404, 1998.
 
16) Cady B, Jenkins RL, Steele GD, et al: Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 227: 566-571, 1998.
PubMed
17) Elias D, Cavalcanti A, Sabourin JC, et al: Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 22: 268-276, 1998.
 
18) Okuno K, Yasutomi M, Hida J, et al: Longterm effects of hepatic arterial interleukin-2-based immunochemotherapy after potentially curative resection of colorectal liver metastases. J Am Coll Surg 187: 271-275, 1998.
PubMed
19) Yamamoto J, Sugihara K, Kosuge T, et al: Pathological support for limited hepatectomy in the treatment of liver metastases from colorectal cancer. Ann Surg 221: 74-78, 1995.
PubMed
20) Bismuth H, Adam R Levi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224: 509-522, 1996.
PubMed
21) Giacchetti S, Itzhaki M, Gruia G, et al: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, 1eucovorin, oxaliplatin and surgery. Ann Oncol 10: 663-669, 1999.
 
22) Makuuchi M, Thai BL, Takayasu K, et al: Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: apreliminary report. Surgery 107: 521-527, 1990.
 
23) Adam R, Laurent A, Azoulay D, et al: Two-stage hepatectomy: A planned strategy to treat irresectable Iiver tumors. Ann Surg 232: 777-785, 2000.
 
24) Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 107: 459-465, 1987.
PubMed
25) Chang AE, Schneider PD, Sugarbaker PH, et al: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206: 685-693, 1987.
PubMed
26) Hohn D, Stagg R, Friedman M, et al: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the northern California oncology group trial. J Clin Oncol 7: 1646-1654, 1989.
 
27) Martin JK, O`Connell MJ, Wieand HS, et al: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 125: 1022-1027, 1990.
 
28) Rougier P, Laplanche A, Huguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10: 1112-1118, 1992.
 
29) Allen-Mersh TG, Earlam S, Fordy C, et al: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255-1260, 1994.
PubMed
30) Ensminger WD, Rosowsky A and Raso V: A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res 38: 3784-3792, 1978.
PubMed
31) Weiss L, Gruneddmann E, Hartveit F, et al: Hematogenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol 150: 195-200, 1986.
 
32) Meta-Analysis Group In Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88: 252-258, 1996.
PubMed
33) Arai Y, Inaba Y, Takeuchi Y, et al: Intermittent hepatic arterial infusion of high-dose 5-FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol 40: 526-530, 1997.
PubMed
34) Okuno K, Hirohata T, Nakamura K, et al: Hepatic arterial infusions of interleukin-2(IL-2) -based immunochemotherapy in the treatment of unresectable liver metastases from colorectal cancer. Clin Ther 15: 672-683, 1993.
PubMed
35) Okuno K, Yasutomi M, Kon M, et al: Intrahepatic interleukin-2 with chemotherapy for unresectable liver metastases: a randomized multicenter trial. Hepatogastroenterology 46: 1116-1121, 1999.
PubMed
36) Okuno K, Kaneda K and Yasutomi M: Regional IL-2 based immunochemotherapy of colorectal liver metastases. Hepatogastroenterology 46: 1263-1267, 1999.
PubMed
37) Kemeny N, Seiter K, Niedzwiecki D, et al: A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 69: 327-334, 1992.
PubMed
38) Goldberg SN and Gazelle GS: Radiofrequency tissue ablation: Physical principles and techniques for increasing coagulation necrosis. Hepatogastroenterology 48: 359-367, 2001.
PubMed
39) 別府 透, 松田貞士, 前田健晴・他: 肝細胞癌の局所凝固療法-マイクロ波とラジオ波の使い分け-. 外科治療 83: 707-712, 2000.
 
40) Lorentzen T, Christensen NE, Nolsoe CP, et al: Radiofrequency tissue ablation with a cooled needle in vitro. Acad Radiol 4: 292-297, 1997.
 
41) Rossi S, Di Stasi M, Buscarini E, et al: Percutaneous interstitial thermal ablation in the treatment of hepatic cancer. AJR 167: 759-768, 1996.
PubMed
42) Shibata T, Niinobu T, Ogata N, et al: Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 89: 276-284, 2000.
PubMed
43) O`Connell, MJ: A phase III trial of 5-fluorouracil and Ieucovorin in the treatment of advanced colorectal cancer. Cancer 63: 1026-1030, 1989.
 
44) Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967-1972, 1991.
 
45) Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685-696, 1986.
PubMed
46) Buroker TR, O'connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12: 14-20, 1994.
 
47) Petrelli N, Douglass HO Jr, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7: 1419-1426, 1989.
PubMed
48) De Gramont A, Bosset F, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15: 808-815, 1997.
 
49) The Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
 
50) Vanhoefer U, Harstrick A, Achterrath W, et al: Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 19: 1501-1518, 2001.
 
51) Cunningham D, Pyrhonen S, James S, et al: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998.
 
52) Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000.
PubMed
53) Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: amulticentre randomised trial. Lancet 355: 1041-1046, 2000.
PubMed
54) Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/1eucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801-3807, 2001.
 
55) Becouarn Y, Ychou M, Ducreux M, et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients: Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16: 2739-2744, 1998.
PubMed
56) Diaz-Rubio E, Sastre J, Zaniboni A, et al: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 9: 105-108, 1998.
PubMed
57) Levi F, Zindai R, Misset JL, et al: Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 350: 681-688, 1997.
 
58) de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
PubMed
59) Giacchetti S, Perpoint B, Zindai R, et al: Phase III multicenter randomized trial on oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147, 2000.
 
60) Meta-Analysis Group In Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308, 1998.
PubMed
61) Pazdur R, Douillard JY, Skillings JR, et al: Multicenter phase III study of 5-fluorouracil(5-FU) or UFT in combination with leucovorin(LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 18: 263 a, 1999.
 
62) Ohtsu A, Baba H, Sakata Y, et al: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83: 141-145, 2000.
 
63) Twelves C, Boyer M, Findlay M, et al: Capecitabine(Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 37: 597-604, 2001.
 
64) Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-1ine treatment in 605 patients with metastatic colorectal cancer: Result of a randomized phase III study. J Clin Oncol 19: 2282-2292, 2001.
 
65) Ravikumar TS, Kane R, Cady B, et al: A 5-year study of cryosurgery in the treatment of liver tumors. Arch Surg 126: 1520-1524, 1991.
PubMed
66) Neeleman N, Wobbes Th, Jager GJ, et al: Cryosurgery as treatment modality for colorectal liver metastases. Hepatogastroenterology 48: 325-329, 2001.
 
67) Fiorentini G, Poddie D, Cantore M, et al: Locoregional therapy for metastases from colorectal cancer: The possibilities of intraarterial chemotherapy, and new hepatic-directed modalities. Hepatogastroenterology 48: 305-312, 2001.
PubMed
68) Aigner KR and Kaevel K: Pelvic stop flow infusion(PSI) and hypoxic pelvic perfusion(HPP) with mitomycin C and melphalan for recurrent rectal cancer. Reg Cancer Treat 1: 6-11, 1994.
 
69) Ku Y, Fukumoto T, Maeda T, et al: Single catheter technique of hepatic venous isolation and charcoal hemoperfusion for malignant liver tumors. Am J Surg 173: 103-109, 1997.
 
70) Starzl TE and Putnam CW: Surgical approaches to primary and metastatic liver neoplasms. Int J Radiat Oncol Biol Phys 1: 959-964, 1976.
 
71) O'Grady JG, Polson RJ, Rolles K, et al: Liver transplantation for malignant disease. Ann Surg 207: 373-379, 1988.
 
P.1076 掲載の参考文献
1) 日本整形外科学会骨軟部腫瘍委員会: 全国骨腫瘍患者登録一覧表(平成7年度) . 国立がんセンター, 1995.
 
2) Harrington KD: Orthopaedic Management of metastatic bone disease, The CV MOSBY Campany, St Louis, Washington, DC, Tronto, 1988.
 
3) 福間久俊, 館崎新一郎: 骨腫瘍の鑑別診断: 整形外科診断学, (辻 陽雄, 高橋栄明・編) , 第2版, 金原出版, 東京, 1988, pp 631-650.
 
4) 明神美弥子: 転移性脊椎腫瘍の放射線治療におけるMRI診断の意義. 厚生省がん研究助成金による研究報告集(平成7年度) , 7-18 尾形悦郎班, 1995, pp 339-342.
 
5) 木村良子, 浜本 研, 古館正従・他: 転移性骨腫瘍に伴う骨性疼痛に対する放射性ストロンチウム(Sr) 製剤のSMS. 2Pの有用性. 核医学 33(12) : 1347-1358, 1996.
 
6) 小泉 潔, アリSアルバブ, 遠山敬司・他: 骨転移の除痛を目的に投与されたSrの治療効果と副作用の検討. 核医学 33(11) : 1243-1248, 1996.
 
7) Sonoo H, Shimozuma K, Kurebayashi J, et al: Systemic therapy, pain relief and quality of life of breast cancer patients with bone metastasis. Gan To Kagaku Ryoho 22(suppl 1) : 10-15, 1995.
 
8) Shiba E, Kobayashi T, Takeda T, et al: A case of advanced breast cancer with multiple organ metastases sucessfully treated by tamoxifen, Gan To Kagaku Ryoho 19(13) : 2255-2258, 1992.
 
9) Nishioka A, Ogawa Y, Hamada N, et al: A case report of bone metastasis diagnosed by MRI and effectively treated with UFT after breast concerving therapy for breast cancer. Gan To Kagaku Ryoho 19(13) : 2251-2254, 1992.
 
10) Kubota Y, Nakada T, Imai K, et al: Chemo-endocrine therapy in patients with stage D-2 prostate cancer. Prostate 26(1) : 50-54, 1995.
 
11) Sasaki H, Minami Y, Kanetake H, et al: Chemo-endocrine therapy for prostate cancer with bone metastasis. Cancer Chemother Pharmacol 35(supp1) : S 23-26, 1994.
 
12) Fujita K, Matsushima H, Nakano M, et al: Ifosfamide in combined hormonochemotherapy on prostate cancer: Gan To Kagaku Ryoho 21(2) : 227-230, 1994.
PubMed
13) Harada Y, Arima S, Futami K, et al: A case of remarkable response of colon cancer with multiple liver metastases and bone metastasis treated with tegafur and cisplatin. Gan To Kagaku Ryoho 22(1) 123-127, 1995.
PubMed
14) Kobayashi T, Sasaki T, Ibuka T, et al: Sequential MTX and 5-FU therapy for gastric cancer patients with systemic bone metastasis and DIC. Gan to Kagaku Ryoho 19(1) : 69-74, 1992.
 
15) Tanaka S and Morikawa Y: Complete remission of bone metastasis of bladder cancer treated by cisplatin-etoposide therapy. Gan To Kagaku Ryoho 18(6) : 1039-1041, 1991.
PubMed
16) 山脇慎也, 小林昌幸, 井須和男・他: がんの骨転移の治療. Mebio 4(1) : 11-17, 1987.
 
17) Ratanatharathorn V, Powers WE, Steverson N, et al: Bone metastasis from cervical cancer. Cancer 73(9) : 2372-2379, 1994.
PubMed
18) Honda K and Simizu C: Long-term pain control in terminal care with home hospice care. Gan To Kagaku Ryoho 21(Suppl4) : 489-492, 1994.
 
19) Brescia FJ, Portenoy RK, Ryan M, et al: Pain, opioid use, and survival in hospitalized patients with advancsd cancer. J Clin Oncol 10(1) : 149-155, 1992.
 
20) 佐々木和朗, 笠井祐子: 硬膜外ブロック使用による経口モルヒネ鎮痛法とQOLダイヤグラムによる評価. 在宅癌治療 2: 45-51, 1991.
 
21) 笠井祐子, 佐々木和朗: 癌疼痛治療とQOLダイヤグラムによる評価法. 癌治療と縮主 4(1) : 86-93, 1992.
 
22) 笠井祐子: 癌患者のQuality of life(QOL) の新しい評価法. 北海道医誌 69(2) : 282-292, 1994.
 
23) 志水克時: 転移性腫瘍. 整形外科手術(9) , (富田勝郎・編) , 第1版, 中山書店, 東京, 1995, pp 178-182.
 
24) Shimizu K, Shikata T, Iida T, et al: Posterior decompression and stabilization for multiple metastatic tumors of spine. Spine 17: 1400-1404, 1992.
 
25) 山脇慎也, 敦賀 肇: 最近のがんの治療. 理学療法 16(12) : 947-954, 1999.
 
26) 大川智彦・他: 日本癌治療学会 骨転移治療効果判定基準(案) . 日癌治療会誌 32(6) : 883-888, 1997.
 
P.1085 掲載の参考文献
1) Takakura K, Sano K and Hojo S: Metastatic tumors of the central nervous system. Igaku-shoin, Tokyo, 1982.
 
2) The Committee of Brain Tumor Registry of Japan C: Report of brain tumor registry of japan(1969-1993) , 10th Edition. Neurol Med Chir 40(suppl) : 1-106, 1993.
 
3) Johnson JD and Young B: Demographics of brain metastasis. Neurosurg Clin N Am 7: 337-344, 1996.
 
4) Yoshino I, Yohena T, Kitajima M, et al: Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg 7: 204-209, 2001.
PubMed
5) 斉藤光江, 霞富士雄: 腫瘍マーカーの選択と読み方. 臨床と研究 75: 515-518, 1998.
 
6) Kuhn MJ, Hammer GM, Swenson LC, et al: MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients. Comput Med Imaging Graph 18: 391-399, 1994.
PubMed
7) Okubo T, Hayashi N, Shirouzu I, et al: Detection of brain metastasis: comparison of Turbo-FLAIR imaging, T 2-weighted imaging and double-dose gadolinium-enhanced MR imaging. Radiat Med 16: 273-281, 1998.
 
8) Lagerwaard FJ, Levendag PC, Nowak PJ, et al: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43: 795-803, 1999.
PubMed
9) Gasper L, Scott C, Rotman M, et al: Recursive partitioning analysis(RPA) of prognostic factors in three radiation therapy oncology group(RTOG) brain metastasis trials. Int J Radiat Oncol Biol Phys 37: 745-751, 1997.
 
10) Rodrigus P, de Brouwer P and Raaymakers E: Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation. Lung Cancer 32: 129-136, 2001.
PubMed
11) Chatani M, Matayoshi Y, Masaki N, et al: Radiation therapy for brain metastases from lung carcinoma: the second prospective randomized trial. Nippon Igaku Hoshasen Gakkai Zasshi 54: 1380-1387, 1994.
PubMed
12) Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29: 711-717, 1994.
PubMed
13) 松谷雅生, 中村 治: 肺癌脳転移に対する治療. 癌の臨床 41: 1504-1510, 1995.
Medical*Online
14) Ueki K, Matsutani M, Nakamura O, et al: Comparison of whole brain radiation therapy and locally limited radiation therapy in the treatment of solitary brain metastases from non-small cell lung cancer. Neurol Med Chir(Tokyo) 36: 364-369, 1996.
PubMed
15) Pottgen C and Stuschke M: The role of prophylactic cranial irradiation in the treatment of lung cancer. Lung Cancer 33(Suppl 1) : S153-158, 2001.
 
16) Prophylactic cranial irradiation overview collaborative group P: Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission. Cochrane Database Syst Rev 4, 2000.
 
17) DeAngelis LM, Delattre JY and Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 39: 789-796, 1989.
PubMed
18) Asai A, Matsutani M, Kohno T, et al: Subacute brain atrophy after radiation therapy for malignant brain tumor. Cancer 63: 1962-1974, 1989.
PubMed
19) Davey P, O'Brien PF, Schwartz ML, et al: A phase I/II study of salvage radiosurgery in the treatment of recurrent brain metastases. Br J Neurosurg 8: 717-723, 1994.
 
20) Suzuki S, Omagari J, Nishio S, et al: Gamma knife radiosurgery for simultaneous multiple metastatic brain tumors. J Neurosurg 93(Suppl 3) : 30-31, 2000.
 
21) Tanaka H, Takifuji N, Masuda N, et al: Systemic chemotherapy for brain metastasis from small cell lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi 31: 492-497, 1993.
PubMed
22) Hall WA, Djalilian HR, Nussbaum ES, et al: Long-term survival with metastatic cancer to the brain. Med Oncol 17: 279-286, 2000.
 
23) Zhang RD, Price JE, Fujimaki T, et al: Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 141: 1115-1124, 1992.
PubMed
24) Patchel RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastasis to the brain. N Engl J Med 322: 494-500, 1990.
 
25) Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al: Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33: 583-590, 1993.
 
26) Mintz AH, Kestle J, Rathbone MP, et al: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78: 1470-1476, 1996.
PubMed
27) Muacevic A, Kreth FW, Horstmann GA, et al: Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. J Neurosurg 91: 35-43, 1999.
PubMed
28) Li B, Yu J, Suntharalingam M, et al: Comparison of three treatment options for single brain metastasis from lung cancer. Int J Cancer 90: 37-45, 2000.
 
29) Patchell RA, Tibbs PA, Regine WF, et al: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280: 1485-1489, 1998.
 
30) DeAngelis LM, Mandell LR, Thaler HT, et al: The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 24: 798-805, 1989.
PubMed
31) Schackert G, Steinmetz A, Meier U, et al: Surgical management of single and multiple brain metastases: results of a retrospective study. Onkologie 24: 246-255, 2001.
PubMed
32) Pirzkall A, DEbus J, Lohr F, et al: Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16: 3563-3569, 1998.
PubMed
33) Coucke PA, Zouhair A, Ozsahin M, et al: Focalized external radiotherapy for resected solitary brain metastasis: does the dogma stand? Radiother Oncol 47: 99-101, 1998.
PubMed
34) Sneed PK, Lamborn KR, Forstner JM, et al: Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 43: 549-558, 1999.
PubMed
35) Bindal RK, Sawaya R, Leavens ME, et al: Surgical treatment of multiple brain metastases. J Neurosurg 79: 210-216, 1993.
PubMed
36) Bindal AK, Bindal RK, Hess KR, et al: Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg 84: 748-754, 1996.
PubMed
37) Grob JJ, Regis J, Laurans R, et al: Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. Eur J Cancer 34: 1187-1192, 1998.
PubMed
38) Kondziolka D, Patel A, Lunsford LD, et al: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45: 427-434, 1999.
PubMed
39) Amendola BE, Wolf AL, Coy SR, et al: Brain metastases in renal cell carcinoma: management with gamma knife radiosurgery. Cancer J 6: 372-376, 2000.
PubMed
40) Sperduto PW, Scott C, Andrews D, et al: Preliminary report of RTOG 9508: A phase III trial comparing whole brain irradiation alone versus whole brain irradiation plus stereotactic radiosurgery for patients with two or three unresected brain metastases. (Abstract) . Int J Radiat Oncol Biol Phys 48: 113, 2000.
 
P.1090 掲載の参考文献
1) Stanford W and Doty DB: The role of venography and surgery in the management of patients with superior vena cava obstruction. Ann Thorac Surg 41: 158-163, 1986.
PubMed
2) Hunter W: History of aneurysm of the aorta with some remarks on aneurysms in general. Med Obs Inq 1: 323-357, 1757.
 
3) McIntyre FT and Sykes EM: Obstruction of the superior vena cava: areview of the literature and report of two personal cases. Ann Intern Med 925, 1949.
 
4) Yuh-Min C, Shuling Y, Reury-Perng P, et al: Superior vena cava syndrome revisited. Jpn J Clin Oncol 25: 32-36, 1995.
 
5) Chen JC, Bongard F and Klein SR: A contemporary perspective on superior vena cava syndrome. Am J Surg 160: 207-211, 1990.
PubMed
6) Parish JM, Marschke RF Jr, Dines DE, et al: Etiologic consideration in superior vena cava syndrome. Mayo Clin Proc 56: 407-413, 1981.
 
7) Urban T, Lebeau B, Chastang C, et al: Superior vena cava syndrome in small-cell lung cancer. Arch Intern Med 153: 384-387, 1993.
PubMed
8) Sculier JP and Feld R: Superior vena cava obstruction syndrome: recommendations for management. Cancer Treat Rev 12: 209-218, 1985.
PubMed
9) Capek P and Cope C: Percutaneous treatment of superior vena caval syndrome. Am J Radiol 152: 183-184, 1989.
 
10) Sculier JP, Evans WK, Feld R, et al: Superior vena caval obstruction syndrome in small cell lung cancer. Cancer 57: 847-851, 1986.
PubMed
11) Gauden SJ: Superior vena cava syndrome induced by bronchogenic carcinoma: Is this an oncologic emergency? Australian Radiol 37: 363-366, 1993.
 
12) Ahmann FR: A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol 2: 961-969, 1984.
PubMed
13) Marjan J and Peter G: The role of mediastinoscopy in superior vena caval obstruction: Ann Thorac Surg 59: 453-455, 1995.
 
14) Martinoli C, Cittadini G, Gandolfo N, et al: Superior vena cava stents: Doppler US of the internal mammary veins to detect collateral flow-preliminary observations. Radiology 204: 865-870, 1997.
PubMed
15) Furui S, Sawada S, Kuramoto K, et al: Gianturco stent placement in malignant caval obstruction: Analysis of factors for predicting the outcome. Radiology 195: 147-152, 1995.
PubMed
16) Hennequin LM, Fade O, Fays JG, et al: Superior vena cava stent placement: results with the Wallstent endoprosthesis. Radiology 196: 353-361, 1995.
PubMed
17) Hansen ME, Spritzer CE and Sostman HD: Assessing the patency of mediastinal and thoracic inlet veins: value of MR imaging. Am J Radiol 155: 1177-1182, 1990.
 
18) Dyet JF, Nichoson AA and Cool AM: The use of the Wallstent endovascular prosthesis in the treatment of malignant obstruction of the superior vena cava. Clin Radiol 48: 381-385, 1993.
 
19) Gomes MN and Hufnagel CA: Superior vena cava obstruction. Ann Thorac Surg 20: 344-351, 1975.
PubMed
20) Doty DB, Doty JR and Jones KW: Bypass of superior vena cava. J Thorac Cardiovasc Surg 99: 889-896, 1990.
 
21) Graham A, Anikin V, Curry R, et al: Subcutaneous juguro-femoral bypass: a simple surgical option for palliation of superior vena cava obstruction. J Cardiovasc Surg 36: 615-617, 1995.
PubMed
22) Crowe MTI, Davies CH and Gaines PA: Percutaneous managernent of superior vena cava occlusions. Cardiovasc Intervent Radiol 18: 367-372, 1995.
 
23) Gaines PA, Belli AM, Anderson PB, et al: Superior vena caval obstruction managed by the Gianturco Z stent. Clin Radiol 49: 202-208, 1994.
PubMed
24) 森田理一郎, 赤荻栄一, 三井清文・他: 肺癌による上大静脈症候群に対する治療法の検討-上大静脈内ステント留置術の有用性について-. 日胸疾会誌 30: 1110-1115, 1992.
 
25) Rosch J, Uchida BT, Hall LD, et al: Gianturco-Rosch expandable z-stents in the treatment of superior vena cava syndrome. Cardiovasc Intervent Radiol 15: 319-327, 1992.
PubMed
26) Oudkerk M, Kuijpers TJA, Schmitz PIM, et al: Self-expanding metal stents for palliative treatment of superior vena caval syndrome. Cardiovasc Intervent Radiol 19: 146-151, 1996.
 
27) Shah R, Sabanathan S, Lowe RA, et al: Stenting in malignant obstruction of superior vena cava. J Thorac Cardiovasc Surg 112: 335-340, 1996.
PubMed
28) Stock KW, Jacob AL, Proske M, et al: Treatment of malignant obstruction of the superior vena cava with the selfexpanding Wallstent. Thorax 50: 1151-1156, 1995.
 
29) Wilkinson P, MacMahon J and Johnston L: Stenting and superior vena caval syndrome. Isr J Med Sci 164: 128-131, 1995.
 
30) Chin DH, Peterson BD, Timmermans H, et al: Stent-graft in the management of superior vena cava syndrome. Cardiovasc Intervent Radiol 19: 302-304, 1996.
 
31) Nicholson AA, Ettles DF, Arnold A, et al: Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 8: 781-788, 1997.
PubMed
P.1097 掲載の参考文献
1) 池田恭治: 悪性腫瘍に伴う高カルシウム血症. Annual Review 内分泌代謝: 1-7, 1996.
 
2) Mondy GR, Ibbottson KJ, D'Souoza SM, et al: The hypercalcemia of cancer: Clinical implications and pathogenetic mechanisms. N Engl J Med 310: 1718-1727, 1984.
 
3) Holic MF, Krane SM and Potts JT: Calcium, phosphorus and bone metabolism: Calcium regulating hormones. In: Harrison's Principles of Internal Medicine, McGraw Hill, 1991, pp 1888-1902.
 
4) Bushinsky DA and Krieger NS: Integration of calcium metabolism in the adult: In Disorders of Bone and Mineral Metabolisum, (ed by Coe FL and Favou MJ) , Ravan Press, New York, 1992, pp 417-432.
 
5) Payne RB, Little AJ, Williams RB, et al: Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4: 643, 1973.
PubMed
6) Nussbaum SR, VandePol CJ, Zubler MA, et al: Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90 mg dosages. Am J Med 95: 297-304, 1993.
PubMed
7) Fleisch H: In: Bisphosphonates in bone disease. Academic Press, San Diego, Calfornia, 2000, pp 90-92.
 
8) Mundy Gr(ed) : Bone remodeling and its disorders. 2nd, Martin Dunitz Ltd, London, 1999, pp 107-122.
 
9) 佐藤幹二: 高カルシウム血症 Q&A-悪性腫瘍による高カルシウム血症を中心に-. 医薬ジャーナル社, 大阪, 1996, pp 20-25, pp 28-29.
 
10) Burtis WJ, Brady TG, Orloff JJ, et al: Immunochemical characterization of circulating Parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 322: 1106-1112, 1990.
PubMed
11) Gillespie MT and Martin TJ: The parathyroid hormone-related protein gene and its expression. Mol Cell Endocrinol 100: 143-147, 1994.
PubMed
12) Orloff JJ, Reddy D, de Papp AE, et al: Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions. Endocr Rev 15: 40-50, 1994.
PubMed
13) Ikeda K, Ohno H, Hane M, et al: Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 79: 1322-1327, 1994.
 
14) Suva LJ, Winslow GA, Wettenhall REH, et al: A parathyroid hormone-related protein implicated in malignant hypercalcemia; cloning and expression. Science 237: 893-896, 1987.
 
15) Juppner H, About-Sammra AB, Freeman M, et al: A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254: 1024-1026, 1991.
 
16) Stewart AF, Vignery A, Silvergate A, et al: Quantitative bone histomorphometry in humoral hypercalcemia of malignancy; uncoupling of bone cell activity. J Clin Endocrinol Metab 55: 219-227, 1982.
 
17) Senior PV, Heath DA and Beck F: Expression of parathyroid hormone-related protein mRNA in the rat before birth: demonstration by hybridization. J Mol Endocrinol 6: 281-290, 1991.
PubMed
18) Kramer S, Reynords FH Jr, Castillo M, et al: Immunological identification and distribution of parathyroid hormone-like protein polypeptides in normal malignant tissues. Endocrinology 128: 1927-1937, 1991.
 
19) Morendino Jr JJ, Insogna KL, Nilstone LM, et al: A parathyroid hormone-like protein from cultured human keratinocytes. Science 231: 388-390, 1986.
 
20) Ikeda K, Weir EC, Mangin M, et al: Expression of messenger ribonucleic acid encording a parathyroid hormone-like peptide in normal human and animal tissues with abnormal expression in human parathyroid adenomas. Mol Endocrinol 2: 1230-1236, 1988.
 
21) Rodda CP, Kubota M, Heath JA, et al: Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: comparisons with a similar protein implicated in humoral hypercalcemia of malignancy. J Endocrinol 117: 261-271, 1988.
 
22) Asa SL, Henderson J, Goltzman D, et al: Parathyroid hormone-like peptide in normal and neoplastic human endocrine tissues. J Clin Endocrinol Metab 71: 1112-1118, 1990.
PubMed
23) Kitazawa S, Fukase M, Kitazawa R, et al: Immunohistologic evaluation of parathyroid hormone-related protein in human lung cancer and normal tissue with newly developed monoclonal antibody. Cancer 15: 984-989, 1991.
 
24) Southby J, Kissen MW, Danks JA, et al: Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res 50: 7710-7716, 1990.
 
25) Powell GL, Southby J, Danks JA, et al: Localization of parathyroid hormone-related protein in breast cancer metastases; Increased incidence in bone compared with other sites. Cancer Res 51: 3059-3061, 1991.
 
26) Kohno N, Kitazawa S, Fukase M, et al: The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surg Today 24: 215-220, 1994.
PubMed
27) Guise TA JJ, Yin SD, Taylor Y, et al: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer mediated osteolysis. J Clin Invest 98: 1544-1549, 1996.
 
28) Tsuchihashi T, Yamaguchi K, Miyake Y, et al: Parathyroid hormone-related protein in tumor tissues obtained from patients with humoral hypercalcemia malignancy. J Natl Cancer Inst 82: 40-44, 1990.
PubMed
29) Yoneda T, Alsina MA, Chavez JB, et al: Evidence that tumor necrosing factor plays a pathogenetic role in the paraneoplastic syndromes of cahexia, hypercalcemia and leukocytosis in human tumor in nude mice. J Clin Invest 87: 977-985, 1991.
 
30) Bertolini DR, Nedwin GE, Bringman TS, et al: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosing factor. Nature 319: 516-518, 1986.
 
31) Garett IR, Durie BG, Nedwin GE, et al: Production of lymphotoxin, bone resorbing cytokine, by cultured human myeloma cells. N Engl J Med 317: 526-532, 1987.
 
32) Kawano M, Yamamoto I and Iwato K: Interleukin-1 beta rather than lymphotoxin as a major bone resorbing activity in multiple myeloma. Blood 73: 1646-1649, 1989.
PubMed
33) Mundy GR: Mechanism of osteolytic bone destruction. Bone 12: (suppl 1) S1-S 6, 1991.
 
34) De La Mata J, Uy HL, Guise TA, et al: Inerleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 95: 2846-2852, 1995.
 
35) Sato K, Fuj ii Y, Kasano K, et al: Parathyroid hormone-related protein and interleukin l alpha synergistically stimulate bone resorption in vitro and increase the serum calcium concentration in mice in vivo. Endocrinology 124: 2172-2178, 1989.
 
36) Engelmann H, Holtmann H, Brakebush C, et al: Antibodies to a soluble form of a tumor necrosis factor(TNF) receptor have TNF-like activity. J Biol Chem 265: 14497-14504, 1990.
 
37) Okuno Y, Takahashi T, Suzukio A, et al: Coproduction of interleukin-1 and interleukin-6 in tumor cell lines elaborating colony-stimulating factors. Jpn J Cancer Res 82: 890-992, 1991.
 
38) Manolagas SC, Jilka RL, Girasole G, et al: Estrogens, Cytokines, and pathophysiology of osteoporosis. In Current opinion in endocrinology and diabetes, (ed by Kohler PO) , Philadelphia, Current Science, 1994, pp 275-281.
 
39) Singer FR, Sharp CF Jr and Rude PK: Pathogenesis of hypercalcemia in malignancy. Miner Electrolyte Metab 2: 161-178, 1979.
 
40) Myers WPL: Hypercalcemia associated with malignant disease. In: Endocrine hormone-producing tumors. Year Book Medical, Chicago, 1973, pp 147-171.
 
41) 木村 哲, 佐藤 豊, 阿部 薫: 腫瘍随伴高カルシウム血症: 腫瘍随伴症候群, (井村裕夫, 高久史磨・編) , 第1版, サイエンスフォーラム, 東京, 1987, pp 85-100.
 
42) Vassilopoulou-Sellin R, Newman BM, Taylor SH, et al: Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 71: 1309-1312, 1993.
PubMed
43) Strewler GJ and Rossenblatt M: Mineral metabolism. In Endocrinology and metabolisum, 3rd ed, McGraw-Hill, 1995, pp 1407-1474.
 
44) 木村 哲, 永田直一, 江藤澄哉・他: 癌患者における高カルシウム血症の治療に関する研究. 厚生省がん研究助成金による研究報告集, 昭和61年度, pp 264-268.
 
45) 福本誠二, 池田恭治, 竹内靖博・他: IRMA法による血漿PTH-related protein(PTHrP) 測定の基礎的および臨床的検討. ホルモンと臨床 40: 1309-1314, 1992.
 
46) Nakayama K, Fukumoto S, Takeda S, et al: Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia, J Clin Endocrinol Metab 81: 607-611, 1996
PubMed
47) Body J and Delmas P: Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia, J Clin Endocrinol Metab 74: 471-475, 1992,
PubMed
48) Pecherstorfer M, Hermann Z and Thiebaud D: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy, J Clin Oncol 14: 268-276, 1996,
 
49) 福永仁夫, 大塚信昭, 小野史磨人・他: 1型コラーゲン・Cross-linked Carboxyterminal Telepeptide(1CTP) の血中濃度の測定. ホルモンと臨床 41: 729-736, 1993,
 
50) Bouillon R, Bex M, Herck EV, et al: Influence of age, sex, and insulin on osteoblast function: Osteoblast dysfunction in diabetes melitus, J Clin Endoclinol Metab 80: 1194-1202, 1995.
 
51) Vinholes J, Guo C-Y, Purohit OM, et al: Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia malignancy, J Clin Oncol 15: 131-138, 1997.
PubMed
52) Hosking D, Cowley A and Bucknall C: Rehydration in the treatment of severe hypercalcemia, Q J Med 50: 473-481, 1981.
PubMed
53) Suki W, Yium J and Van Mundium M: Acute treatment of hypercalcemia with fluosemide, N Engl J Med 283: 836-840, 1970.
 
54) Fleisch H: Bisphosphonates in bone disease, From the laboratory to the patients, 3rd ed, The Parthenon Publishing Group Inc, New York, 1997.
 
55) Fleish H: Bisphosphonates: a new class drugs in diseases of bone and calcium metabolism, Recent Results Cancer Res 116: 1-28, 1989.
 
56) Fitton A and McTavish D: Pamidronate: a reviw of its pharmacological properties and therapeutic efficacy in resorptive bone disease, Drugs 41: 289-318, 1991.
 
57) Plosker GL and Goa KL: Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease, Drugs 47: 945-982, 1994.
PubMed
58) Jantunen E and Laakso M: Annotation: Bisphosphonates in multiple myeloma: current status; future perspectives, Br J Haematol 93: 501-506, 1996.
 
59) Russel G: Bisphosphonates inhibit bone resorption mediated by several different biochemical pathways, Int Bone Forum 66-71, 1997.
 
60) 松本俊夫, 藤田拓男, 森井浩世・他: 悪性腫瘍に伴う高カルシウム血症患者におけるPamidoronate disodium(AHPrBP) の用量設定試験. 臨床医薬 8: 605-629, 1992.
 
61) 江藤澄哉, 服部理男, 富田明夫・他: 悪性腫瘍における高カルシウム血症患者におけるアレンドロネート注射剤の有用性検討. Prog Med 14: 2869-2882, 1994.
 
62) 佐藤幹二, 服部理男, 富田明夫・他: 悪性腫瘍に伴う高カルシウム血症患者におけるアレンドロネート注射剤の用量設定試験. Prog Med 14: 2883-2906, 1994.
 
63) 松本俊夫, 武部和男, 石井 淳・他: 悪性腫瘍に伴う高カルシウム血症患者におけるYM-175の用量設定試験. 臨床と研究 71: 3263-3280, 1994,
 
64) 松本俊夫, 永田直一, 堀越 昇・他: 悪性腫瘍に伴う高カルシウム血症患者におけるYM-175とエルカトニンの比較試験. 臨床成人病 25: 383-396, 1995.
 
65) Major P, Lortholary A, Hon J, et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy-A pooled analysis of two randomized, controlled clinical trials, J Clin Oncol 19: 558-567, 2001.
 
66) 芝 英一, 井上共生, 赤澤健司・他: オクトレオチドが奏効した進行乳癌に伴う高カルシウム血症の1例. 癌と化学療法 23(3) : 343-347, 1996.
Medical*Online
67) Sauty A, Pecherstorfer M, Zimmer-Roth I, et al: Interleukin-6 and tumor necrosis facter一α after bisphosphonates treatment in vitro and in patients with malignancy, Bone 18: 139, 1996.
 
68) Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases, N Engl J Med 335: 1785-1791, 1996.
PubMed
69) Berenson JR, Lichtenstein A, Porter L, et al : Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma, N Engl J Med 334: 488-493, 1996.
PubMed
P.1105 掲載の参考文献
1) McLain RF: Endoscopically assisted decompression for metastatic thoracic neoplasms. Spine 23: 1130-1135, 1998.
PubMed
2) Viadana E: Autopsy study of metastatic sites of breast cancer. Cancer Res 33: 179-181, 1973.
PubMed
3) Sorensen S, Borgesen SE, Rohde K, et al: Metastatic epidural spinal cord compression. Results of treatment and survival. Cancer 65: 1502-1508, 1990.
PubMed
4) McLain RF and Weinstein JN: Tumors of the spine. The Spine, (ed by Herkowitz HN, Garfin SR, Balderston RA, et al) , forth edition, WB Saunders Company, Philadelphia, 1999, pp 1171-1206.
 
5) Frankel HL, Hancock DO, Hyslop G, et al: The value of postual reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia, Part 1. Paraplegia 7: 179-192, 1969.
 
6) 真鍋昌平: 他臓器転移に対する局所的治療の進歩: 骨転移-脊椎転移に対する手術法の進歩-. 癌と化学療法 17(4) : 785-790, 1990.
 
7) Tillotson CL and Rosenthal DI: Radiology of spine tumors: General considerations. In Tumors of the spine, WB Saunders Company, Philadelphia, 1990, pp 34-45.
 
8) 山下和夫, 小野啓郎: 転移性脊椎腫瘍に対するRI検査の意義. MB Orthop 24: 9-17, 1990.
 
9) Tatsui H, Onomura T, Morishita S, et al: Survival rates of patients with metastatic spinal cancer after scintigraphic detection of abnormal radioactive accumulation. Spine 18: 2143-2148, 1996.
PubMed
10) 中野政雄: 骨転移の放射線治療. 骨転移の痛みと治療, (檀健二郎・編) , 真興交易医書出版部, 東京, 1990, pp 111-128.
 
11) Seichi A, Kondo T, Hozumi T, et al: Intraoperative radiation therapy for metastatic spinal tumors. Spine 4: 470-475, 1999.
 
12) Maranzano E and Latini P: Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: Final results from a prospective trial. Int J Radiat Oncol Biol Phys 32: 959-967, 1995.
PubMed
13) Loblaw DA and Lapierre NJ: Emergency treatment of malignant extradural spinal cord compression: An evidence-based guideline. J Clin Oncol 16: 1613-1624, 1998.
 
14) Rades D, Blach M, Bremer M, et al: Prognostic significance of the time of developing motor deficits before radiation therapy in metastatic spinal cord compression: one-year results of a prospective trial. Int J Radiat Oncol Biol Phys 48: 1403-1408, 2000.
PubMed
15) Nakamura M, Toyama Y, Suzuki N, et al: Metastases to the upper cervical spine. J Spinal Disord 9: 195-201, 1996.
 
16) 徳橋泰明, 松崎浩巳, 大川章裕・他: 転移性脊椎腫瘍に対する術前予後予測と術式選択-術前予後判定点数について-. 東日本整災会誌 11: 31-35, 1999.
 
17) 富田勝郎, 藤田拓也, 川原範夫・他: 原発性脊椎悪性腫瘍に対するtotal en bloc spondylectomy(vertebrectomy) の根治性-病理組織学的検討を加味して-. 臨整外 30: 817-827, 1995.
 
18) Tomita K, Toribatake Y, Kawahara N, et al: Total en bloc spondylectomy and circumspinal decompression for solitary spinal metastasis. Paraplegia 32: 36-46, 1994.
PubMed
19) Tomita K, Kawahara N, Kobayashi T, et al: Surgical strategy for spinal metastases. Spine 26: 298-306, 2001.
PubMed
P.1114 掲載の参考文献
1) 厚生労働省: 2001年人口動態統計, 2002.
 
2) 高見 博, 高田忠敬: Oncologic emergenciesの概念と対策. 日腹部救急医会誌 15: 289-292, 1995.
 
3) 田辺 稔, 北島政樹, 露木 晃・他: 悪性疾患における治療とQOL. 外科 61: 499-504, 1999.
 
4) Turnbull ADM: Abdominal and upper gastrointestinal emergencies. In: Surgical emergencies in the Cancer Patients, (ed by Turnbull ADM) , Year Book Medical Publishers, Chicago, 1987, p 152.
 
5) Starnes HF, Turnbull ADM and Daly JM: Colon and rectum emergencies. In: Surgical emergencies in the Cancer Patients, (ed by Turnbull ADM) , Year Book Medical Publishers, Chicago, 1987, p 195.
 
6) Chang AE and August DA: Acute abdomen, bowel obstruction, and fistula. In: Clinical Oncology, (ed by Abeloff MD) , Churchill Livingstone, Tokyo, 1995, pp 583-597.
 
7) Rackner VL, Thirlby RC and Ryan JA Jr: Role of surgery in multimodality therapy for gastrointestinal lymphoma. Am J Surg 161: 570-575, 1991.
PubMed
8) 奥脇秀一郎, 鈴木博昭, 増田勝紀・他: 癌性消化管狭窄(癌性食道狭窄と癌性腹膜炎) に対する内視鏡的治療. 日腹部救急医会誌 17: 361-368, 1997.
 
9) Kozarek RA, Raltz S, Brugge WR et al: Prospective multicenter trial of esophageal Z-stent placement for malignant disphagia and tracheoesophageal fistula. Gastrointest Endosc 44: 562-567, 1996.
 
10) Adachi Y, Ogawa Y, Sasaki Y, et al: Surgical results in patients with gastric carcinoma involving the mesocolon. Am J Surg 163: 437-439, 1992.
PubMed
11) Devine HB: Basic principles and supreme difficulties in gastric surgery. Surg Gynecol Obstet 40: 1-16, 1925.
 
12) Kwok SPY, Chung SCS, Griffin SM, et al: Devine exclusion for unresectable carcinoma of the stomach, Br J Surg 78: 684-685, 1991.
 
13) 荒井邦佳, 北村正次, 岩崎善毅: 術後のquality of lifeおよび予後からみた切除不能胃癌に対する空置的胃空腸吻合術の有用性. 日消外会誌 28: 645-649, 1995.
 
14) Kaminishi M, Yamaguchi H, Shimizu N, et al: Stomach-partitioning gastrojejunostomy for unresectable gastric carcinoma. Arch Surg 132: 184-187, 1997.
PubMed
15) 梶谷 鐶: 大弯横切胃腸吻合術. 消化管癌手術アトラス, 金原出版, 東京, 1992, pp 64-68.
 
16) Macarthur DC, Nixon SJ and Aitken RJ: Avoidable deaths still occur after large bowel surgery. Br J Surg 85: 80-83, 1998.
PubMed
17) 肥田仁一, 安富正幸: 大腸癌イレウスの治療戦略. 手術 53: 331-342, 1999.
 
18) 石田康男, 幡谷 潔, 櫻井 修・他: 新しいイレウスキットによる経肛門的ドレナージ法. 手術 50: 1489-1493, 1996.
 
19) Deans GT, Krukowski ZH and Irwin ST: Malignant obstruction of the left colon. Br J Surg 81(Review) : 1270-1276, 1994.
PubMed
20) Pearce NW, Scott SD and Karran SJ: Timing and method of reversal of Hartmann's procedure. Br J Surg 79: 839-841, 1992.
 
21) Keck JO, Collopy BT, Ryan PJ, et al: Reversal of Hartmann's procedure. Effect of timing and technique on ease and safety. Dis Colon Rectum 37: 243-248, 1994.
 
22) Mosdell DM and Doberneck RC: Morbidity and mortality of ostomy closure. Am J Surg 162: 633-637, 1991.
PubMed
23) Roe AM, Prabhu S, Ali A, et al: Reversal of Hartmann's procedure. Timing and operative technique. Br J Surg 78: 1167-1170, 1991.
 
24) Dudley HAF, Radcliffe AG and McGeechan D: Intraoperative irrigation of colon to permit primary anastomosis. Br J Surg 67: 80-81, 1980.
 
25) Koruth NM, Krukowski ZH and Youngson GG: Intra-operative colonic irrigation in the managemant of left-sided large bowel emergencies. Br J Surg 72: 708-711, 1985.
 
26) Foster ME, Johnson CS, Billings PJ, et al: Intra-operative antegrade lavage and anastomosis healing in acute colonic obstruction. Dis Colon Rectum 29: 255-259, 1986.
 
27) Pollock AV, Playforth MJ and Evans M: Perioperative lavage of the obstructed left colon to allow safe primary anastomosis. Dis Colon Rectum 30: 171-173, 1987.
 
28) Tan SG, Nambiar R, Rauff A, et al: Primary resection and anastomosis in obstructed descending colon due to cancer. Arch Surg 126: 748-751, 1991.
PubMed
29) Stewart J, Diament RH and Brennan TG: Management of obstructing lesions of the Ieft colon by resection, on-table lavage, and primary anastomosis. Surgery 114: 502-505, 1993.
 
30) Meijer S, Hoitsma HFW and van Loenhout RM: Intraoperative antegrade irrigation in complicated left-sided colonoc cancer. J Surg Oncol 40: 88-89, 1989.
 
31) Saku M, Maekawa S, Ikejiri K, et al: Successful one-stage operation for completely obstructive colorectal carcinoma. Jpn J Surg 25: 284-286, 1995.
 
32) Chung CC, Kwok SPY, Kwong KH, et al: Technique of laparoscopically assisted on-table colonic irrigation. Br J Surg 84: 384, 1997.
 
33) Biondo S, Jaurrieta E, Jorba R, et al: Intraoperative colonic lavage and primary anastomosis in peritonitis and obstruction. Br J Surg 84: 222-225, 1997.
PubMed
34) Klatt GR, Martin WHM and Gillesple JT: Subtotal colectomy with primary anastomosis without diversion in the treatment of obstructing carcinoma of the left colon. Am J Surg 141: 577-578, 1981.
 
35) Glass RL, Smith LE and Cochran RC: Subtotal colectomy for obstructing carcinoma of the left colon. Am J Surg 145: 335-336, 1983.
 
36) Deutch AA, Zeilikovski A, Sternberg A, et al: One-stage subtotal colectomy with anastomosis for obstructing carcinoma of the left colon. Dis Colon Rectum 26: 227-230, 1983.
 
37) Hughes ESR, McDermott FT, Polglase AL, et al: Total and subtotal colectomy for colonic obstruction. Dis Colon Rectum 28: 162-163, 1985.
 
38) Morgan WP, Jenkins WP, Lewis P, et al: Management of obstructing carcinoma of the Ieft colon by extended right hemicolectomy. Am J Surg 149: 327-329, 1985.
 
39) Stephenson BM, Shandall AA, Farouk R, et al: Malignant left-sided large bowel obstruction managed by subtotal/total colectomy. Br J Surg 77: 1098-1102, 1990.
PubMed
40) Halevy A, Levi J and Orda R: Emergency subtotal colectomy. A new trend for treatment of obstructing carcinoma of the left colon. Ann Surg 210: 220-223, 1989.
PubMed
41) The SCOTIA Study Group: Single-staged treatment for malignant left-sided colonic obstruction: a prospective randomized clinical trial comparing subtotal colectomy with segmental resection following intraoperative irrigation. Br J Surg 82: 1622-1627, 1995.
 
42) Torralba JA, Robles R, Parrilla P, et al: Subtotal colectomy vs. intraoperative colonic irrigation in the management of obstructed left colon carcinoma. Dis Colon Rectum 41: 18-22, 1998.
PubMed
43) Eu KW, Lim SL, Seow-Choen F, et al: Clinical outcome and bowel function following total abdominal colectomy and ileorectal anastomosis in the oriental population. Dis Colon Rectum 41: 215-218, 1998.
PubMed
44) Mulcahy HE, Skelly MM, Husain A, et al: Long-term outcome following curative surgery for malignant large bowel obstruction. Br J Surg 83: 46-50, 1996.
PubMed
45) Obrand DI and Gordon PH: Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 40: 15-24, 1997.
PubMed
46) Abulafi AM and Williams NS: Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg 81(Review) : 7-19, 1994.
PubMed
47) Pain J and Cahill J: Surgical options for left-sided large bowel emergencies. Ann R Coll Surg Engl 73: 394-397, 1991.
 
48) 伊藤重彦, 大江久囲, 徳山 昇・他: 胃潰瘍および胃癌穿孔症例の検討. 日臨外医会誌 49: 844-847, 1988.
 
49) Wakayama T, Ishizaki Y, Mitsusada M, et al: Risk factors influencing the short-term results of gastroduodenal perforation. Jpn J Surg 24: 681-687, 1994.
 
50) 河村武徳, 小長英二, 榎本正満・他: 胃癌穿孔例の検討-自験例8例と本邦報告116例について-. 日消外会誌 18: 980-983, 1985.
 
51) Gertsch P, Yip SKH, Chow LWC, et al: Free perforation of gastric carcinoma. Results of surgical treatment. Arch Surg 130: 177-181, 1995.
 
52) Adachi Y, Ogawa Y, Sasaki Y, et al: Surgical results in patients with gastric carcinoma involving the mesocolon. Am J Surg 163: 437-439, 1992.
PubMed
53) 中越 亨, 猪野睦征, 橋口勝敏・他: 陥凹型早期胃癌穿孔の2例. 消化器外科 14: 233-238, 1991.
 
54) 向井正哉, 近藤泰理, 生越喬二・他: 術中内視鏡が有用であった早期胃癌穿孔の1例-本邦早期胃癌穿孔45例の検討-. 日臨外医会誌 53: 1869-1873, 1992.
 
55) Mandava N, Kumar S, Pizzi WF, et al: Perforated colorectal carcinomas. Am J Surg 172: 236-238, 1996.
PubMed
56) Kriwanek S, Armbruster C, Dittrich K, et al: Perforated colorectal cancer. Dis Colon Rectum 39: 1409-1414, 1996.
PubMed
57) Runkel NS, Schlag P, Schwarz V, et al: Outcome after emergency surgery for cancer of the large intestine. Br J Surg 78: 183-188, 1991.
PubMed
58) 須田武保, 畠山勝義, 酒井靖夫・他: 外科的救急処置を必要とした大腸癌によるイレウス, 穿孔例について. 日腹部救急医会誌 15: 313-321, 1995.
 
59) 大政良二, 鈴木博昭: 下部消化管出血に対する緊急内視鏡の適応と手技. 日腹部救急医会誌 15: 459-466, 1995.
 
60) 新美 浩, 佐伯光明, 岩崎善衛・他: 緊急血管造影. 外科診療 35: 1089, 1993.
 
P.1122 掲載の参考文献
1) Walther MM: Oncologic emergencies: Urologic emergencies. Cancer: Principles and Practice of Oncology, (ed by DeVita VT Jr, et a1) , 6th ed, Lippincott, Philadelphia, 1998, pp 2645-2653.
 
2) Morse MJ and Carroll PR: Urologic emergencies in the cancer patient. Surgical Emergencies in the Cancer Patient, (ed by Turnbull AD) , Chicago, 1987, pp 205-227.
 
3) 大園誠一郎, 岡島英五郎, 高島健次・他: 泌尿器科的緊急病態. 癌と化学療法 24 (3) : 292-296, 1997.
Medical*Online
4) Confalonieri R, Barbiano di Belgiojoso G, Banfi G, et al: Light chain nephropathy: Histological and clinical aspects in 15 cases. Nephol Dial Transplant 3 (2) : 150-156, 1988.
 
5) 岡田 定, 三好保由, 滝沢芳夫・他: 造血器悪性腫瘍に合併した急性腎不全の臨床的検討. 臨床血液 31 (4) : 431-437, 1990.
 
6) Clark AD, Shetty A and Soutar R: Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 13 (2) : 79-90, 1999.
PubMed
7) Hirota S, Miyamoto M, Kasugai T, et al: Crystalline light-chain depostion and amyloidosis in the thyroid gland and kidney of a patient with myeloma. Arch Pathol Lab Med 114 (4) : 429-431, 1990.
 
8) Cheson BD, De Bellis CC, Schumann GB, et al: The urinary myeloma cast: Frequency of detection and clinical correlations in 30 patientis with multiple myeloma. Am J Clin Pathol 83 (4) : 421-425, 1985.
 
9) Sanders PW: Pathogenesis and treatment of myeloma kidney. J Lab Clin Med 124 (4) : 484-488, 1994.
 
10) Wahlin A, Lofvenberg E and Holm J: Improved survival in multiple myeloma with renal failure. Acta Med Scand 221 (2) : 205-209, 1987.
PubMed
11) Pasquali S, Casanova S, Zucchelli A, et al: Long-term survival patients with acute and severe renal failure due to multiple myeloma. Clin Nephrol 34 (6) : 247-254, 1990.
PubMed
12) Alexanian R, Barlogie B and Dixon D: Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150 (8) : 1693-1695, 1990.
PubMed
13) Torra R, Blade J, Cases A, et al: Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91 (4) : 854-859, 1995.
 
14) Viertel A, Weidmann E, Ditting T, et al: Management of renal complications in patients with advanced multiple myeloma. Leuk Lymphoma 38 (5-6) : 513-519, 2000.
 
15) Pasquali S, Cagnoli L, Rovinetti C, et al: Plasma exchange therapy in rapidly progressive renal failure due to multiple myeloma. Int J Artif Organs 8 (Suppl 2) : 27-30, 1985.
 
16) Pozzi C, Pasquali S, Donini U, et al: Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italien Renal Immunopathology Group. Clin Nephrol 28 (1) : 1-9, 1987.
PubMed
17) Iggo N, Palmer AB, Severn A, et al: Chronic dialysis in patients with multiple myeloma and renal failure: Aworthwhile treatment. QJM 73 (270) : 903-910, 1989.
PubMed
18) Moist L, Nesrallah G, Kortas C, et al: Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series. Am J Nephrol 19 (1) : 45-50, 1999.
 
19) Weinstein T, Chagnac A, Gafter U, et al: Unusual case of crescentic glomerulonephritis associated with malignant lymphoma. A case report and review of the literature. Am J Nephrol 10 (4) : 329-332, 1990.
PubMed
20) Morel P, Dupriez B, Herbrecht R, et al: Aggressive lymphomas with renal involvement: astudy of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte. Br J Cancer 70 (1) : 154-159, 1994.
 
21) Morschhauser F, Wattel E, Pagniez D, et al: Glomerular injury in chronic myelomonocytic leukemia. Leuk Lymphoma 18 5-6) : 479-483, 1995.
 
22) Flombaum CD, Isaacs M, Reich L, et al: Acute renal failure associated with the retinoic acid syndrome in acute promyelocytic leukemia. Am J Kidney Dis 27 (1) : 134-137, 1996.
PubMed
23) Takatsuki K, Yamaguchi K, Kawano F, et al: Clinical diversity in adult T-cell leukemia-lymphoma. Cancer Res 45 (9 Suppl) : 4644 s-4645 s, 1985.
 
24) Yamaguchi K and Takatsuki K: Adult T cell leukaemia-lymphoma. Baillieres Clin Haematol 6 (4) : 899-915, 1993.
PubMed
25) Stebbing J and Smith IE: Small cell lung cancer as a cause of acute renal failure secondary to bilateral renal infiltration. Clin Oncol 12 (5) : 326-327, 2000.
PubMed
26) Rostom AY, El-Hussainy G, Kandil A, et al: Tumor lysis syndrome following hemi-body irradiation for metastatic breast cancer. Ann Oncol 11 (10) : 1349-1351, 2000.
PubMed
27) Flombaum CD: Metabolic emergencies in the cancer patient. Semin Oncol 27 (3) : 322-334, 2000.
PubMed
28) Saccente SL, Kohaut EC and Berkow RL: Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration. Pediatr Nephrol 9 (5) : 569-573, 1995.
PubMed
29) Hussein AM and Feun LG: Tumor lysis syndrome after induction chemotherapy in small-cell lung carcinoma. Am J Clin Oncol 13 (1) : 10-13, 1990.
PubMed
30) Persons DA, Garst J, Vollmer R, et al: Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin. Am J Clin Oncol 21 (4) : 426-429, 1998.
PubMed
31) Sakarcan A and Quigley R: Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol 8 (3) : 351-353, 1994.
PubMed
32) Kintzel PE: Anticancer drug-induced kidney disorders. Drug Safety 24 (1) : 19-38, 2001.
 
33) Safirstein R, Winston J, Moel D, et al: Cisplatin nephrotoxicity: Insights into mechanism. Int J Androl 10 (1) : 325-346, 1987.
PubMed
34) Decunti RC, Toftness BR, Lange RC, et al: Clinical and pharmacological studies with cis-diammine dichloroplatinum (II) . Cancer Res 33: 1310-1315, 1973.
 
34) Brock J and Alberts DS: Safe, rapid administration of cisplatin in the outpatient clinic. Cancer Treat Reports 70 (12) : 1409-1414, 1986.
 
35) 石垣 宏, 佐藤新一, 斎藤 聡・他: 総量3, 250mgのCisplatinを投与した直腸癌の1剖検例-特に臓器内残留濃度について-. 癌と化学療法16 (12) : 3805-3808, 1989.
 
35) Donadio C, Lucchesi A and Gadducci A: Prevention of cis-platinum nephrotoxicity in a high-risk patient. Ren Fail 18 (4) : 691-695, 1996.
 
36) Bekele L, Vidal Vazquez M and Adjei AA: Systemic chemotherapy in patients with renal failure. Am J Clin Oncol 24 (4) : 382-384, 2001.
PubMed
37) Corden BJ, Fine RL, Ozols RF, et al: Clinical pharmacology of high-dose cisplatin. Cancer Chemother Pharmcol 14: 38-41, 1985
 
38) Honda R, Fujita A, Inoue Y, et al: Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small lung cancer: A combination phase II study. Cancer Chemother Pharmacol 26 (5) : 373-376, 1990.
PubMed
39) Saito Y, Mori K, Tominaga K, et al: Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 31 (2) : 81-84, 1992.
PubMed
40) Goss GD, Vincent M, Germond C, et al: Combination chemotherapy with teniposide (VM 26) and carboplatin in small cell lung cancer. Am J Clin Oncol 16 (4) : 295-300, 1993.
PubMed
41) Chang A, Hunt M, Parkinson DR, et al: Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group. Am J Clin Oncol 16 (2) : 152-155, 1993.
PubMed
42) Elias A, Kantoff P, Ayash L, et al: High-dose ifosfamide, carboplatin, and etoposide (ICE) with autologous marrow support for germ cell carcinoma. Proc Annu Meet Am Soc Clin Oncol 12: A710, 1993.
 
43) Kish JA, Wolf M, Taylor S, et al: Evaluation of cisplatin+5-fluorouracil infusion for advanced/metastatic transitional cell carcinoma of the bladder: a Southwest Oncology Group Study. Proc Annu Meet Am Ass Cancer Res 34: A 1214, 1993.
 
44) Stiff PJ, McKenzie RS, Alberts DS, et al: Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. J Clin Oncol 12 (1) : 176-183, 1994.
PubMed
45) Broun ER, Belinson JL, Berek JS, et al: Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study. Gynecol Oncol 54 (2) : 142-146, 1994.
PubMed
46) Somlo G, Doroshow JH, Forman SJ, et al: High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer 73 (1) : 125-134, 1994.
PubMed
47) Nabholtz JM, Rapp E, Jha N, et al: Neoadjuvant chemotherapy with carboplatin and continuous infusion 5-fluorouracil followed by concurrent carboplatin and radiotherapy in advanced unresectable stage III and IV head and neck cancer: preliminary results of a phase II pilot study. Proc Ann Meet Am Soc Clin Oncol 13: A934, 1994.
 
48) Lee JS, Farnan N, Komaki R, et al: Promising outcome of concurrent chemoradiation therapy with oral VP-16 and cisplatin for locally advanced inoperable non-small cell lung cancer. Proc Ann Meet Am Soc Clin Oncol 14: A1077, 1995.
 
49) Crino L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC) : a Phase II study. Proc Ann Meet Am Soc Clin Oncol 14: A1066, 1995.
 
50) Mehta J, Tricot G, Jagannath S, et al: High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplant 20 (2) : 113-116, 1997.
PubMed
51) Lorusso V, Manzione L, De Vita F, et al: Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 164 (1) : 53-56, 2000.
PubMed
52) Sturn W, Sanwald R and Ehninger G: Pharmacokinetics of cisplatin in long-term hemodialysis treatment. Dtsch Med Wochenschr 114 (9) : 337-339, 1989.
PubMed
53) Chatelut E, Rostaing L, Gualano V, et al: Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron 66 (2) : 157-161, 1994.
 
54) Yanagawa H, Takishita Y, Bando H, et al: Carboplatin-based chemotherapy in patients undergoing hemodialysis. Anticancer Res 16 (1) : 533-535, 1996.
PubMed
55) Suzuki S, Koide M, Sakamoto S, et al: Pharmacokinetics of carboplatin and etoposide in a haemodialysis patient with Merkel-cell carcinoma. Nephrol Dial Transplant 12 (1) : 137-140, 1997.
 
56) 宮川政昭, 杉本健一, 大江裕一郎・他: 慢性腎不全維持透析患者におけるCis-diamminedichloro Platinumの体内動態. 癌と化学療法 14 (8) : 2491-2495, 1987.
Medical*Online
57) Richard V, Piccart M, Paridaens R, et al: Lethal aunria complicating hihg dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function. Rev Med Brux 11 (3) : 64-67, 1990.
 
58) Keizer HJ, Ouwerkerk J, Welvaart K, et al: Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol 121 (5) : 297-302, 1995.
PubMed
59) Prasad VK, Lewis IJ, Aparicio SR, et al: Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol 27 (3) : 149-155, 1996.
PubMed
60) Lhotta K, Kuhr T, Rumpelt HJ, et al: Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine hemotherapy. Am J Nephrol 19 (5) : 590-593, 1999.
 
61) Efros M, Ahmed T and Choudhury M: Cyclophosphamide-induced hemorrhagic pyelitis and ureteritis associated with cystitis in marrow transplantation. J Urol 144: 1231-1232, 1990.
PubMed
62) deVries CR and Freiha FS: Hemorrhagic cystitis: A review. J Urol 143 (1) : 1-9, 1990.
PubMed
63) 新本 稔, 松木 啓, 弘野正司: 消化器がんに合併した直腸・尿路系障害. 癌と化学療法 10 (2) : 194-197, 1983.
Medical*Online
64) Recloux P, Weiser M, Piccart M, et al: Ureteral obstruction in patients with breast cancer. Cancer 61 (9) : 1904-1907, 1988.
PubMed
65) Lopez-Martinez RA, Stock JA, Gump FE, et al: Carcinoma of the breast metastatic to the ureter presenting with flank pain and recurrent urinary tract infection. Am Surg 62 (9) : 748-752, 1996.
 
66) Dvoretsky PM, Richards KA, Angel C, et al: Distribution of disease at autopsy in 100 women with ovarian cancer. Hum Pathol 19 (1) : 57-63, 1988.
 
67) Eyre RC, Benotti PN, Bothe A, et al: Management of the urinary tract involved by recurrent cancer. Arch Surg 122 (4) : 493-498, 1987.
PubMed
68) Markowitz DM, Wong KT, Laffey KJ, et al: Maintaining quality of life after palliative diversion for malignant ureteral obstruction. Urol Radiol 11 (3) : 129-132, 1989.
PubMed
69) Desportes L, Blanchet P, Benoit G, et al: Neoplastic ureteral obstruction: drainage by percutaneous nephrostomy or double J catheterization. Presse Med 24 (29) : 1332-1336, 1995.
PubMed
70) Donat SM and Russo P: Ureteral decompression in advanced nonurologic malignancies. Ann Surg Oncol 3 (4) : 393-399, 1996.
PubMed
71) 藤元博行: 尿路への消化器がんの進展による諸症状への対策. ターミナルケア 6: 350-356, 1996.
 
72) 中川 徹, 藤元博行: 上部尿路狭窄に対するステントと腎痩による治療. 緩和医療 2: 442-447, 2000.
 
73) 斉田幸久, 角田博子, 松枝 清・他: 胃癌と閉塞性尿路障害. 日医放線会誌 50 (4) : 390-397, 1990.
 
74) Dohmen K, Mizukami Y, Tanaka K, et al: Retroperitoneal fibrosis associated with scirrhous gastric cancer. Gastroenterol Jpn 28 (5) : 699-705, 1993.
PubMed
75) Krause S, Hald T and Steven K: Surgery for urologic complications following radiotherapy for gynecologic cancer. Scand J Urol Nephrol 21 (2) : 115-118, 1987.
 
76) Ambinder RF, Burns W, Forman M, et al: Hemorrhagic cystitis associated with adenovirus infection in bone marrow transplantation. Arch Int Med 146 (7) : 1400-1440, 1986.
 
77) Ito M, Hirabayashi N, Uno Y, et al: Necrotizing tubulointerstitial nephritis associated with asenovirus infection. Hum Pathol 22 (12) : 1225-1231, 1991.
PubMed
78) Yuzawa Y, Aoi N, Fukatsu A, et al: Acute renal failure and degenerative tubular lesions associated with in situ formation of adenovirus immune complexes in a patient with allogeneic bone marrow transplantation. Transplantation 55 (1) : 67-72, 1993.
 
79) Arthur RR, Shah KV, Baust SJ, et al: Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med 315 (4) : 230-234, 1986.
PubMed
80) Deyerle KL and Subramani S: Linker scan analysis of the early regulatory region of human papovavirus BK. J Virol 62 (9) : 3378-3387, 1988.
 
81) Arthur RR, Shah KV, Charache P, et al: BK and JC virus infections in recipients of bone marrow transplants. J Infect Dis 158 (3) : 563-569, 1988.
PubMed
82) Spach DH, Bauwens JE, Myerson D, et al: Cytomegalovirus-induced hemorrhagic cystitis following bone marrow transplantation. Clin Infect Dis 16 (1) : 142-144, 1993.
PubMed
83) Burkert RE: Clinical overview of mesna. Cancer Treat Rev 10 (Suppl A) : 175, 1983.
 
84) Johnson DH, DeLeo MJ, Hande KR, et al: High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer. J Clin Oncol 5 (5) : 703-709, 1987.
PubMed
85) Stillwell TJ and Benson RC Jr: Cyclophosphamide-induced hemorrhagic cystitis. A reviwe of 100 patients. Cancer 61 (3) : 451-457, 1988.
 
86) Brugieres L, Hartmann O, Travagli JP, et al: Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: Incidence, clinical course, and outcome. J Clin Oncol 7 (2) : 194-199, 1989.
PubMed
87) Sencer SF, Haake RJ and Weisdorf DJ: Hemorrhagic cystitis after bone marrow transplantation. Risk factors and complications. Transplantation 56 (4) : 875-879, 1993.
PubMed
88) Cox PJ: Cyclophosphamide cystitis and bladder cancer: a hypothesis. Eur J Cancer 15: 1071-1072, 1979.
 
89) Brade WP, Herdrich K and Varini M: Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rep 12: 1-47, 1985.
 
90) Skinner RJ, Sharkevy IM, Pearson AD, et al: Ifosphamide, mesna, and nephrotoxicity in children. J Clin Oncol 11: 173-190, 1993.
 
91) Dean RJ and Lytton B: Urological complication of pelvic irradiation. J Urol 119: 64-67, 1978.
PubMed
92) Levenback C, Eifel PJ, Burke TW, et al: Hemorrhagic cystitis following radiotherapy for stage I b cancer of the cervix. Gynecol Oncol 55 (2) : 206-210, 1994.
 
93) Ram MD: Complications of radiotherapy for carcinoma of the bladder. Proc Roy Soc Med 63: 93-95, 1970.
PubMed
94) Adelson MD, Wharton JT, Delclos L, et al: Palliative radiotherapy for ovarian cancer. Int J Radiat Oncol Biol Phys 13 (1) : 17-21, 1987.
PubMed
95) Diamond SM and Levi M: Renal and genitourinary complications from the treatment of Hodgkin's disease. Hodgkin's Disease: The Consequences of Survival, (ed by Lacher MJ and Redman JR) , Lea and Febiger, Philadelphia, 1990, pp 306-315.
 
96) Scheulen ME, Niederle N, Bremer K, et al: Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: Results of a clinical phase II-study with 151 patients. Cancer Treat Rev 10 (Suppl A) : 93-101, 1983.
PubMed
97) Antman KH, Montella D, Rosenbaum C, et al: Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 69 (5) : 499-504, 1985.
PubMed
98) Andriole GL, Sandlund JT, Miser JS, et al: The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. J Clin Oncol 5 (5) : 799-803, 1987.
PubMed
99) Wilmer JL, Erexson GL and Kligerman AD: Attenuation of cytogenetic damage by 2-mercaptoethanesulfonate in cultured human lymphocytes exposed to cyclophosphamide and its reactive metabolites. Cancer Res 46 (1) : 203-210, 1986.
PubMed
100) Kurowski V and Wagner T: Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3-and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Cancer Chemother Pharmacol 39 (5) : 431-439, 1997.
PubMed
101) Reinhold-Keller E, Mohr J, Christophers E, et al: Mesna side effects which imitate vasculitis. Clin Invest 70 (8) : 698-704, 1992.
 
102) Meisenberg B, Lassiter M, Hussein A, et al: Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. Bone Marrow Transplant 14 (2) : 287-291, 1994.
PubMed
103) Turkeri LN, Lum LG, Uberti JP, et al: Prevention of hemorrhagic cystitis following allogeneic bone marrow transplant preparative regimens with cyclophosphamide and busulfan: role of continuous bladder irrigation. J Urol 153 (3 Pt 1) : 637-640, 1995.
 
104) Goodman TL, McKenna LM, Li JT, et al: Clinical pharmacology and efficacy of mesna given po to outpatients treated with ifosfamide for solid tumors. Proc Annu Meet Am Soc Clin Oncol 11: A272, 1992.
 
105) Briones G, Gillan E, Weinthal J, et al: Anovel method of continuous infusion of mesna in pediatric patients receiving cyclophosphamide: Significant reduction of hemorrhagic cystitis and cost of therapy. Proc Annu Meet Am Assoc Cancer Res 33: A2514, 1992.
 
106) Shepherd JD, Pringle LE, Barnett MJ, et al: Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 9 (11) : 2016-2020, 1991.
PubMed
107) Vose JM, Reed EC, Pippert GC, et al: Mesna compared with continuous bladder irrigation as uroprotection during highdose chemotherapy and transplantation: a randomized trial. J Clin Oncol 11 (7) : 1306-1310, 1993.
 
108) Goren MP, McKenna LM and Goodman TL: Combined intravenous and oral mesna in outpatients treated with ifosfamide. Cancer Chemother Pharmacol 40 (5) : 37137-37145, 1997.
 
109) Markman M, Kennedy A and Webster K: Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. Semin Oncol 23 (3 Suppl 6) : 97-98, 1996.
 
110) Brown RB: Amethod of management of inoperative carcinoma of the bladder. Med J Aust 1: 23-24, 1969.
 
111) Axelsen RA, Leditschke JF and Burke JR: Renal and urinary tract complications following the intravesical instillation of formalin. Pathology 18 (4) : 453-458, 1986.
PubMed
112) Fair WR: Formalin in the treatment of massive bladder hemorrhage. Techniques, results, and complications. Urology 3: 573-576, 1974.
PubMed
113) Donahue LA and Frank IN: Intravesical formalin for hemorrhagic cystitis: Analysis of therapy. J Urol 141 (4) : 809-812, 1989.
 
114) Kennedy C, Snell ME and Witherow RO: Use of alum to control intractable vesical haemorrhage. Br J Urol 56 (6) : 673-675, 1984.
PubMed
115) Goel AK, Rao MS, Bhagwat AG, et al: Intravesical irrigation with alum for the control of massive bladder hemorrhage. J Urol 133 (6) : 956-957, 1985.
PubMed
116) Mukamel E, Lupu A and deKernion JB: Alum irrigation for severe bladder hemorrhage. J Urol 135 (4) : 784-785, 1986.
PubMed
117) Murphy CP, Cox RL, Harden EA, et al: Encephalopathy and seizures induced by intravesical alum irrigations. Bone Marrow Transplant 10 (4) : 383-385, 1992.
PubMed
118) Perazella M and Brown E: Acute aluminum toxicity and alum bladder irrigation in patients with renal failure. Am J Kidney Dis 21 (1) : 44-46, 1993.
 
119) Kanwar VS, Jenkins JJ 3rd and Mandrell BN: Aluminum toxicity following intravesical alum irrigation for hemorrhagic cystitis. Med Pediatr Oncol 27 (1) : 64-67, 1996.
PubMed
120) Norkool DM, Hampson NB, Gibbons RP, et al: Hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis. J Urol 150 (2 Pt 1) : 332-334, 1993.
 
121) Weiss JP, Mattei DM, Neville EC, et al: Primary treatment of radiation-induced hemorrhagic cystitis with hyperbaric oxygen: 10-year experience. J Urol 151 (6) : 1514-1517, 1994.
PubMed
122) Liu YK, Harty JI, Steinbock GS, et al: Treatment of radiation or cyclophosphamide induced hemorrhagic cystitis using conjugated estrogen. J Urol 144 (1) : 41-43, 1990.
PubMed
123) Miller J, Burfield GD, Moretti KL, et al: Oral conjugated estrogen therapy for treatment of hemorrhagic cystitis. J Urol 151 (5) : 1348-1350, 1994.
PubMed
124) Levine LA and Kranc DM: Evaluation of carboprost tromethamine in the treatment of cyclophosphamide-induced hemorrhagic cystitis. Cancer 66 (2) : 242-245, 1990.
PubMed
125) 中世古知明, 王 伯銘, 佐藤 宏・他: 同種骨髄移植後遅発性出血性膀胱炎に対するprostaglandin E 1 膀胱内注入療法. 臨床血液36 (8) : 728-734, 1995.
 
126) Ravi R: Endoscopic neodymium: YAG laser treatment of radiation-induced hemorrhagic cystitis. Lasers Surg Med 14 (1) : 83-87, 1994.
PubMed
127) Gweon P and Shanberg A: Treatment of cyclophosphamide induced hemorrhagic cystitis with neodymium: YAG laser in pediatric patients. J Urol 157 (6) : 2301-2302, 1997.
PubMed
128) Quinlan DM, Naslund MJ and Brendler CB: Application of argon beam coagulation in urological surgery. J Urol 147 (2) : 410-412, 1992.
PubMed
129) Zagoria RJ, Hodge RG, Dyer RB, et al: Percutaneous nephrostomy for treatment of intractable hemorrhagic cystitis. J Urol 149 (6) : 1449-1451, 1993.
PubMed
130) Sneiders A and Pryor JL: Percutaneous nephrostomy drainage in the treatment of severe hemorrhagic cystitis. J Urol 150 (3) : 96696-96697, 1993.
 
131) Hald T and Mygind T: Control of life-threatening vesical hemorrhage by unilateral hypogastic artery muscle embolization. J Urol 112: 60-63, 1974.
 
132) Appleton DS, Sibley GN and Doyle PT: Internal iliac artery embolisation for the control of severe bladder and prostate haemorrhage. Br J Urol 62: 45-47, 1988.
 
133) Baronciani D, Angelucci E, Erer B, et al: Suprapubic cystotomy as treatment for severe hemorrhagic cystitis after bone marrow transplantation. Bone Marrow Transplant 16 (2) : 267-270, 1995.
PubMed
134) Andriole GL, Yuan JJ and Catalona WJ: Cystotomy, temporary urinary divesion and bladder packing in the management of severe cyclophosphamide-induced hemorrhagic cystitis. J Urol 143 (5) : 1006-1007, 1990.
 
135) Okaneya T, Kontani K, Komiyama I, et al: Severe cyclophosphamide-induced hemorrhagic cystitis successfully treated by total cystectomy with ileal neobladder substitution: a case report. J Urol 150 (6) : 1909-1910, 1993.
PubMed
136) Koc S, Hagglund H, Ireton RC, et al: Successful treatment of severe hemorrhagic cystitis with cystectomy following matched donor allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 26 (8) : 899-901, 2000.
PubMed
137) 長山忠雄: 泌尿器科領域における症状のコントロール. ターミナルケア 2: 123-128, 1992.
 
138) Lee SK and Jones HW 3rd: Prognostic significance of ureteral obstruction in primary cervical cancer. Int J Gynaecol Obstet 44 (1) : 59-65, 1994.
 
139) Mora Durban M, Navarro Sebastian J and Arrizabalaga Moreno M: Transurethral resection of prostate cancer: efficacy and morbidity. Arch Esp Urol 48 (8) : 829-835, 1995.
PubMed
140) Clements WD, Johnston LR, McIlwrath E, et al: Self-expanding stents for malignant dysphagia. J R Soc Med 89 (8) : 454-456, 1996.
PubMed
141) Chan PT, Begin LR, Arnold D, et al: Priapism secondary to prnilr metastasis: a report of two cases and a review of the literature. J Surg Oncol 68: 51-59, 1998.
 
142) Hettiarachchi JA, Johnson GB, Panageas E, et al: Malignant priapism associated with metastatic urethral carcinoma. Urol Int 66 (2) : 114-116, 2001.
PubMed
143) Venable DD, Hastings D and Misra RP: Unusual metastatic patterns of prostate adenocarcinoma. J Urol 130 (5) : 980-985, 1983.
PubMed
144) Puppo P, Perachino M, Ricciotti G, et al: Malignant priapism due to a huge renal carcinoma. Eur Urol 21 (2) : 169-171, 1992.
PubMed
145) Yokoi K, Miyazawa N, Muraki J, et al: Penile metastasis from lung cancer. Jpn J Clin Oncol 22: 297-299, 1992.
PubMed
146) Nelson JH and Winter CC: Priapism: evolution of management in 48 patients in a 22-year series. J Urol 117 (4) : 455-458, 1977.
 
147) Russo P: Urologic emergencies in the cancer patient. Semin Oncol 27 (3) : 284-298, 2000.
PubMed
P.1134 掲載の参考文献
1) Hughes WT, Armstrong D, Bodey GP, et al: From the Infectious Disease Society of America. guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161: 381-396, 1990.
 
2) Hughes WT, Armstrong D, Bodey GP, et al: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25: 551-573, 1997.
PubMed
3) Hughes WT, Armstrong D, Bodey GP, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730-751, 2002.
PubMed
4) American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12: 2471-2508, 1994.
 
5) American Society of Clinical Oncology: Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14: 1957-1960, 1996.
 
6) Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18: 3558-3585, 2000.
PubMed
7) Klastersky J: Therapy of infections in cancer patients. In Handbook of supPortive care in cancer, (ed by Klastersky J, Schimpff SC and Senn HJ) , Marcel Dekker Inc, New York, 1995, pp 1-44.
 
8) Yoshida M, Tsubaki K, Kobayashi T, et al: Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991. Int J Hematol 70: 261-267, 1999.
 
9) Caillot D, Casasnovas O, Bernard A, et al: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15: 139-147, 1997.
PubMed
10) Yoshida M, Obayashi T, Tamura H, et al: Diagnostic and prognostic significance of plasma endotoxin determination in febrile patients with haematological malignancies. Eur J Cancer 30: 145-147, 1994.
 
11) Obayashi T, Yoshida M, Mori T, et al: Plasma(1→3) -β-D-glucan determination in the diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345: 17-20, 1995.
 
12) Masaoka T: Evidence-based recommendations on antimicrobial use in febrile neutropenia in Japan. Int J Hematol 68 (suppl 1) : 1-40, 1998.
 
13) Yoshida M: Infections in patients with hematological diseases: recent advances in serological diagnosis and empiric therapy. Int J Hematol 66: 279-289, 1997.
PubMed
14) Iwama A, Yoshida M, Miwa A, et al: Improved survival from fungemia in patients with haematological malignancies: analysis of risk factors for death and usefulness of early antifungal therapy. Eur J Haematol 51: 156-160, 1993.
PubMed
15) Verweji PE, Stynen D, Rijs AJ, et al: Sandwich enzyme-linked immunosorbent assay compared with pastorex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol 33: 1912-1914, 1995.
 
16) Kami M, Fukui T, Ogawa S, et al: Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 33: 1504-1512, 2001.
PubMed
17) Bodey GP, Jadeja L and Elting L: Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 145: 1621-1629, 1985.
PubMed
18) Klastersky J, Paesmans M, Rubenstein EB, et al: The multinational association for supportive care in cancer risk index: amultinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18: 3038-3051, 2000.
PubMed
19) Cruciani M, Rampazzo R, Malena M, et al: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: ameta-analysis. Clin Infect Dis 3: 795-805, 1996.
 
20) Engels EA, Lau J and Barza M: Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16: 1179-1187, 1998.
PubMed
21) Uzun O and Anaissie EJ: Antifungal prophylaxis in patients with hematologic malignancies: a reappraisa1. Blood 86: 2063-2072, 1995.
PubMed
22) Goodman JL, Winston DJ, Greenfield A, et al: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantations. N Engl J Med 326: 845-851, 1992.
 
23) Slavin MA, Osborne B, Adams R, et al: Efficacy and safety of fluconazole prophylaxis for fungal infection after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 171: 1545-1552, 1995.
PubMed
24) Kanda Y, Yamamoto R, Chizuka A, et al: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 89: 1611-1625, 2000.
PubMed
25) Denning DW: Invasive aspergillosis. Clin Infect Dis 26: 781-805, 1998.
PubMed
26) 日本癌治療学会臨床試験委員会: G-CSF適正使用ガイドライン. Int J Clin Oncol 6 (suppl) : 1-24, 2001.
 
27) Heil G, Hoelzer D, Sanz MA, et al: Arandomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 90: 4710-4718, 1997.
 
28) Hartmann LC, Tschetter LK, Habermann TM, et al: Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336: 1776-1780, 1997.
PubMed
29) Maher DW, Lieschke GJ, Green M, et al: Filgrastim in patients with chemotherapy-induced febrile neutropenia: a doubleblind, placebo-controlled trial. Ann Intern Med 121: 492-501, 1994.
 
30) Yoshida M, Karasawa M, Naruse T, et al: Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Int J Hematol 69: 81-88, 1999.
PubMed
P.1148 掲載の参考文献
1) 島田安博, 下山正徳, 田村友秀・他: Japan Clinical Oncology Group (JCOG) の臨床安全性情報取扱いガイドライン. 薬理と治療 26: 263-274, 1998.
Medical*Online
2) 古江 尚: 癌化学療法のLate Effects. 癌と化学療法 14 (4) : 987-993, 1987.
Medical*Online
3) Cristy M: Active bone marrow distribution as a function of age in humans. Phy Med Biol 26: 389-400, 1981.
 
4) Tobinai K, Kohno A, Shimada Y, et al: Toxicity grading criteria of the Japan Clinical Oncolgy Group. Jpn J Clin Oncol 23: 250-257, 1993.
 
5) Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64: 328-340, 1966.
PubMed
6) Gabrilove JL, Jakubowski A, Fain K, et al: Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 82: 1454-1461, 1988.
PubMed
7) Duhsen U, Villeval JL, Boyd J, et al: Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72: 2074-2081, 1988.
PubMed
8) Welte K, Bonilla MA, Gillio AP, et al: Recombinant human granulocyte colony-stimulating factor: effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 165: 941-948, 1987.
PubMed
9) Momin F, Kraut M, Lattin P, et al: Thrombocytopenia in patients receiving chemotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) . Proc ASCO 11: 249, 1992 (abstr) .
 
10) 関野久之, 森谷和夫・他: Recombinant human G-CSF (rG-CSF) の臨床第I相試験. 診療と新薬 26: 1660-1732, 1989.
 
11) Bonilla MA, Dale D, Zeidler C, et al: Long-term safety of treatment with recombinant human granulocyte colonystimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 88: 723, 1994.
 
12) Anonymous: American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: bevidence-based, clinical practice guidelines. J Clin Oncol 12: 2471-2508, 1994.
 
13) Anonymous: Update of recommendations for the use of hematopoietic colony-stimulating factors: bevidence-based, clinical practice guidelines. J Clin Oncol 14: 1657-1660, 1996.
 
14) Ozer H, Armitage JO, Bennett CL, et al: 2000 Update of Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18: 3558-3585, 2000.
PubMed
15) Bennett CL, Weeks JA, Somerfield MR, et al: Use of hematopoietic colony-stimulating factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. J Clin Oncol 17: 3676-3681, 1999.
 
16) Spivak JL: The application of recombinant erythropoietin in anemic patients with cancer. Semin Oncol 19: 25, 1992.
 
17) Spivak JL: Cancer-related anemia: its causes and characteristics. Semin Oncol 21: 3, 1994.
PubMed
18) Goodnough LT, Monk TG and Andriole GL: Erythropoietin therapy. N Engl J Med 336: 933-938, 1997.
PubMed
19) Henry DH and Abels RI: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 21: 21-28, 1994.
PubMed
20) Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865-2874, 2001.
 
21) Quirt I, Robeson C, Lau CY, et al: Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19: 4126-4134, 2001.
PubMed
22) Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083-4107, 2002.
 
23) Ibbotson T and Goa KL: Darbepoetin alfa. Drugs 61: 2097-2104, 2001.
PubMed
24) Vansteenkiste J, Pirker R and Massuti B: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211-1220, 2002.
PubMed
25) Gmur J, Burger J, Schanz U, et al: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 388: 1223-1226, 1991.
 
26) Schiffer CA, Anderson KC, Bennett CL, et al: Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1519-1538, 2001.
 
27) Kaye JA: FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells 16: 207-223, 1998.
PubMed
28) Lok S, Kaushasky K, et al: Cloning and expression of cDNA and stimulation of platelet producing in vivo. Nature 369: 565-578, 1994.
 
29) Kenneth K, Si Lok, et al: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369: 568-571, 1994.
 
30) Francoise W, Eugene M, et al: c-Mpl ligand is a humonal regulator of megakaryocytopoiesis. Nature 369: 571-575, 1994.
 
31) Rice L, Nichol JL, McMillan R, et al: Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol 68: 210-214, 2001.
PubMed
32) Takahashi R, Sekine N and Nakatake T: Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 93: 1951-1958, 1999.
PubMed
33) Vadhan-Raj S: Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol 37: 28-34, 2000.
PubMed
34) Coates A, Abraham S, Kaye SB, et al: 0n the receiving end-patients perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19: 202-208, 1983.
 
35) Douglas EP: Oral toxicity of chemotherapeutic agents. Semin Oncol 19: 478-491, 1992.
 
36) Peterson DE: Pretreatment strategies for infection prevention in chemotherapy patients. J Natl Cancer Inst Monogr 9: 61-71, 1990.
 
37) Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325: 164-170, 1991.
PubMed
38) Gabrilobe JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414-1422, 1988.
 
39) Crawford J, Glaspy J, et al: Effect of filgrastim (rhG-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE) . J Clin Oncol 13: 442, 1994.
 
40) Chi KH, Chen CH, Chen WK, et al: Effect of granulocyte-macrophage colony stimulating factor (GM-CSF) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. J Clin Oncol 13: 428, 1994.
 
41) Maylor GD, Terezhalmy GT, et al: Oral complications of cancer chemotherapy: prevention and management. Special Care in Dentistry 8: 150-156, 1988.
 
42) Clark PI and Slevin ML: Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity. Eur J Surg Oncol 11: 267-268, 1985.
PubMed
43) 堂園晴彦, 中村和男, 本屋敏郎・他: 癌化学療法時にみられる口内炎の予防. 癌と化学療法 16 (10) : 3449-3451, 1989.
Medical*Online
44) Mahood DJ, Dose AM, Loprinzi CL, et al: Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 9: 449-452, 1991.
PubMed
45) Rocke LK, Loprinzi CL, Lee JK, et al: Arandomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 72: 2234-2238, 1993.
 
46) Gandara D, Perez EA, et al: Phase I trial of edatrexate plus carboplatin in advanced solid tumors: Amelioration of doselimiting mucositis by ice chip cryotherapy. Proc ASCO 14: 468, 1995.
 
47) Jenns K: Importance of nausea. Cancer Nurs 17: 488, 1994.
PubMed
48) Morran C, Smith DC, Anderson DA, et al: Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. Br Med J 1: 1323, 1979.
 
49) Gralla RJ, Osoba D, Kris MG, et al: Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol 17: 2971-2994, 1999.
PubMed
50) Wampler G: The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs 25: 35, 1983.
PubMed
51) Brison HL and McCarthy LE: Neuropharmacology of chemotherapy-induced emesis. Drugs 25: 8, 1983.
 
52) Akwari OE: The gastrointestinal tract in chemotherapy-induced emesis: a final common pathway. Drugs 25: 18, 1983.
PubMed
53) Ison PJ and Peroutka SJ: Neurotransmitter receptor binding studies predict antiemetic efficacy and side effects. Cancer Treat Rep 70: 637, 1986.
PubMed
54) Andrews PL and Hawthorn J: The neurophysiology of vomiting. Clin Gastroenterol 2: 141, 1988.
PubMed
55) Scogna DM and Smalley RV: Chemotherapy-induced nausea and vomiting. Am J Nurs: 1562-1564, 1979.
PubMed
56) Peroutka SJ and Snyder SH: Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet 1: 658-659, 1982.
 
57) Kris MG, Gralla RJ, Clark RA, et al: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3: 1379, 1985.
PubMed
58) Carey MP and Burish TG: Anxiety as a predictor of behavioral therapy outcome for cancer chemotherapy patients. J Consult Clin Psychol 53: 860, 1985.
PubMed
59) Wilcox PM, Fetting JH, Nettesheim KM, et al: Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep 66: 1601, 1982.
PubMed
60) Morrow GR, Lindke J and Black PM: Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. J Pain Symptom Manage 6: 2155, 1991.
 
61) Nesse RM, Carli T, Curtis GC, et al: Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med 42: 33, 1980.
PubMed
62) Morrow GR: Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 68: 585-588, 1992.
 
63) Alba E, Bastus R, de Andres L, et al: Anticipatory nausea and vomiting: Prevalence and predictors in chemotherapy patients. Oncolgy 46: 26-30, 1989.
 
64) D'acquisto RW, Tyson LB, et al: Antiemetic trials to control delayed vomiting following high-dose cisplatin. Proc ASCO 5: 257, 1986.
 
65) Ohe Y, Sasaki Y, Shinkai T, et al: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84: 972-974, 1992.
PubMed
66) Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83: 1164-1168, 1991.
PubMed
67) Rothenberg ML, Kuhn JG, Burris HA, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11: 2194-2204, 1993.
PubMed
68) Tsuji T, Kaneda N, Kado K, et al: CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 14: 341-349, 1991.
PubMed
69) Satoh T, Hosokawa M, Atsumi R, et al: Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino) -1-piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17: 662-664, 1994.
PubMed
70) Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191, 1991.
PubMed
71) Iyer L, King CD, Whitington PF, et al: Genetic predisposition to the metabolism of irinotecan (CPT-11) , role of uridine diphosphate glucuronosyltransferase isoform 1 A 1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101: 847-854, 1998.
 
72) Ciotti M, Basu N, Brangi M, et al: Glucuronidation of 7-ethy1-10-hydroxycamptothecin (SN-38) by the human UDPglucuronosyltransferases encoded at the UGT 1 locus. Biochem Biophys Res Commun 260: 199-202, 1999.
 
73) Chu X-Y, Kato Y and Sugiyama Y: Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 57: 1934-1938, 1997.
 
74) Ando Y, Saka H, Asai G, et al: T. UGT 1 A 1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9: 845-857, 1998.
 
75) Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921-6926, 2000.
PubMed
76) Paulusma CC, Kool M, Bosma PJ, et al: Amutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25: 1539-1542, 1997.
 
77) Wada M, Toh S, Taniguchi K, et al: Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 7: 203-207, 1998.
PubMed
78) Abigerges D, Guy GG, Armand JP, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210-221, 1995.
 
79) 坂田 優, 鈴木秀和, 鎌滝哲也: 塩酸イリノテカン (CPT-11) の下痢に対する半夏瀉心湯 (TJ-14) の臨床効果. 癌と化学療法 21 (8) : 1241-1244, 1994.
Medical*Online
P.1159 掲載の参考文献
1) Warren S: The immediate cause of death in cancer. Am J Med Sci 184: 610-613, 1932.
 
2) Rombeau JL, Goldman SL, Apelgren KN, et al: Protein-calorie malnutrition in patients with colorectal cancer. Dis Col Rect 21: 587-589, 1978.
 
3) Nixon DW, Heymsfield SB, Cohen AE, et al: Protein-calorie under nutrition in hospitalized cancer patients. Am J Med 68: 683-690, 1980.
 
4) Shils ME: Nutritional problems induced by cancer. Med Clin North Am 63: 1009-1025, 1979.
 
5) Souba WW: Nutritional support. In Cancer. Principles and Practice of Oncology, (ed by DeVita VT Jr, Hellman S and Rosenberg SA) , 5th Edition, Lippincott-Raven Publishers, Philadelphia, 1997, pp 2841-2857.
 
6) Nelson KSA, Walsh D and Sheehan FA: The cancer anorexia-cachexia syndrome. J Clin Oncol 12: 213-225, 1994.
 
7) Langstein HN and Norton JA: Mechanisms of cancer cachexia. Hematol Oncol Clin North Am 5: 103-123, 1991.
PubMed
8) Laviano A, Renvyle T and Yang Z-J: From laboratory to bedside: New strategies in the trreatment of malnutrition in cancer patients. Nutrition 12: 112-122, 1996.
 
9) Lind DS, Souba WW and Copeland EM: Weight loss and cachexia. In Clinical Oncology, (ed by Abeloff MD, Armitage JO, Lichter AS, et al) , Churchill Livingstone, New York, 1995, pp 393-407.
 
10) Billingsley KG and Alexander HR: Cytokines in cancer cachexia. In Protein and amino acid metabolism in cancer cachexia, (ed by Pisters PWT and Brennan MF) , Springer-Verlag, Heidelberg, 1996, pp 51-72.
 
11) Tisdale MJ: Biology of cachexia. J Natl Cancer Inst 89: 1763-1773, 1997.
PubMed
12) Daly JM, Dudrick SJ and Copeland EM: Evaluation of nutritional indices as prognostic indicators in the cancer patient. Cancer 43: 925-931, 1979.
PubMed
13) Dewys WD, Begg C, Lavin PT, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69: 491-497, 1980.
PubMed
14) Dudrick SJ, Wilmore DW, Vars HM, et al: Long-term total parenteral nutrition with growth, development and positive nitrogen balance. Surgery 64: 134-142, 1968.
PubMed
15) 倉石安庸: 栄養対策. 臨床腫瘍学, (日本臨床腫瘍研究会・編) , 第1版, 癌と化学療法社, 東京, 1996, pp 1229-1247.
 
16) Blackburn GL, Gistrian BR, Maini BS, et al: Nutritional and metabolic assessment of the hospitalized patient. J Parenter Enteral Nutr 1: 11-22, 1977.
 
17) 高木洋治, 山東勤弥, 岡田 正: 栄養評価, 最新内科学体系6, 代謝疾患1, 肥満症, 臨床栄養 (井村裕夫, 尾形悦郎, 高久史麿他・編) , 中山書店, 東京, 1995, pp 29-39.
 
18) Vitello JM: Nutritional assessment and the role of preoperative parenteral nutrition in the colon cancer patients. Semin Surg Oncol 10: 183-194, 1994.
PubMed
19) Verdery R: Perioperative total parenteral nutrition in surgical patients. N Engl J Med 326: 273-274, 1992.
PubMed
20) Baker JP, Detsky AS, Wesson DE, et al: Nutritional assessment. A comparison of clinical judgement and objective measurement. N Engl J Med 306: 969-972, 1982.
 
21) Pettigrew RA and Hill GL: Indicators of surgical risk and clinical judgement. Br J Surg 73: 47-51, 1986.
PubMed
22) Torosian MH and Daly JM: Nutritional support in the cancer-bearing host. Cancer 58: 1915-1929, 1986.
PubMed
23) Popp MB, Wagner SC, Enrione EB, et al: Host and tumor responses to varying rates of nitrogen infusion in the tumor bearing rat. Ann Surg 207: 80-89, 1988.
PubMed
24) Lowry SF, Goodgame JT, Norton JA, et al: Effects of chronic protein malnutrition on host-tumor composition and growth. J Surg Res 26: 79-86, 1979.
 
25) Hasegawa J, Okada A, Kayuyasu N, et al: Does total parenteral nutrition really promote tumor growth? A morphometric study. Cancer 54: 1739-1746, 1984.
 
26) Baron PL, Lawrence WH, Chan WMY, et al: Effects of parenteral nutrition on cell cycle kinetics of head and neck cancers. Arch Surg 121: 1282-1286, 1986.
 
27) Klein S, Kinney J, Jeejeebhoy K, et al: Nutrition support in clinical practice: review of published data and recommendations for future research directions. National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. J Parenter Enteral Nutr 21: 133-156, 1997.
PubMed
28) Bozzetti F: Effects of artificial nutrition on the nutritional status of cancer patients. J Parenter Enteral Nutr 13: 406-420, 1989.
PubMed
29) Sandstorm R, Drott C, Hyltander A, et al: The effect of postoperative intravenous feeding (TPN) on outcome following major surgery evaluated in a randomized study. Ann Surg 217: 185-195, 1993.
 
30) Shaw JHF and Wolfe RR: Whole body protein kinetics in patients with early and advanced gastrointestinal cancer: The response to glucose infusion and total parenteral nutrition. Surgery 103: 148-155, 1987.
 
31) Shike M, Russel DM, Detsky AS, et al: Changes in body composition in patients with small cell lung cancer: The effect of total parenteral nutrition as an adjunct to chemotherapy. Ann Intern Med 101: 303-309, 1984.
PubMed
32) Cheney EL, Abson KG, Aker SN, et al: Body composition changes in marrow transplant recipients receiving total parenteral nutrition. Cancer 59: 1515-1519, 1987.
 
33) Jeevanandam M, Lowry SF and Brennan MF: Effect of route of nutrient administration on whole-body protein kinetics in man. Metabolism 36: 968-973, 1987.
PubMed
34) Jeevanandam M, Legaspi A, Lowry SF, et al: Effect of total parenteral nutrition on whole-body protein kinetics in cachexic patients with benign or malignant disease. J Parenter Enteral Nutr 12: 229-236, 1988.
 
35) Copeman MC: Use of total parenteral nutrition in children with cancer: A review and some recommendation. Pediatr Hematol Oncol 11: 463-470, 1994.
 
36) Irvin TT and Hunt TK: Effect of malnutrition on colonic healing. Ann Surg 180: 765-772, 1974.
PubMed
37) Cruse PJE and Foord R: Afive year prospective study of 23649 surgical wounds. Arch Surg 107: 206-211, 1973.
 
38) Buzby GP, Mullen JL, Matthews DC, et al: Prognostic nutritional index in gastrointestinal surgery. Am J Surg 139: 160-167, 1980.
PubMed
39) 佐藤 真: 胃癌患者の栄養評価に関する臨床的研究-術前栄養状態の計量化による術後合併症発生予測指数の作成-. 日外会誌 83: 66-76, 1982.
 
40) 岩佐正人: 食道癌患者の栄養評価に関する臨床的研究-特に栄養評価指数 (nutritional assessment index, NAI) の有用性について. 日外会誌 84: 1031-1041, 1983.
 
41) Christou NV and Tellado JM: In vivo polymorphonuclear nutrophil function in surgical patients does not correlated with anergy but with "activating" processes such as sepsis or trauma. Surgery 106: 718-724, 1989.
PubMed
42) Sludley HO: Percentage of weight loss: A basic indicator of surgical risk in patients with peptic ulcer. JAMA 106: 458-460, 1936.
 
43) Fischer JE: Metabolism in surgical patients. In Textbook of Surgery, (ed by Sabiston DC Jr) , 15th ed, WB Saunders Company, Philadelphia, 1997, pp 133-175.
 
44) Archer SB, Burnett RJ and Fischer JE: Current uses and abuses of total parenteral nutrition. Adv Surg 29: 165-189, 1996.
PubMed
45) Detsky AS, Baker JP, O'Rourke K, et al: Perioperative parenteral nutrition: A meta-analysis. Ann Intern Med 107: 195-203, 1987.
 
46) Muller JM, Brenner U, Dienst C, et al: Preoperative parenteral feeding in patients with gastrointestinal carcinoma. Lancet 1: 68-71, 1982.
 
47) Bellantone R, Doglietto GB, Bossola M, et al: Preoperative parenteral nutrition in high risk surgical patints. J Parenter Enteral Nutr 12: 195-197, 1988.
 
48) Woolfson AM and Smith JA: Elective nutritional support after major surgery: a prospective randomized trial. Clin Nutr 8: 15-21, 1989.
 
49) The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group: Perioperative total parenteral nutrition in surgical patients. N Engl J Med 325: 525-532, 1991.
 
50) Brennan MF, Pisters PW, Posner M, et al: A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann Surg 220: 436-444, 1994.
 
51) Fan ST, Lo CM, Lai ECS, et al: Preoperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 331: 1547-1552, 1994.
 
52) Donaldson SS and Lenon RA: Alterations of nutritional status. Impact of chemotherapy and radiation therapy. Cancer 43: 2036-2052, 1979.
PubMed
53) Thiel HJ, Fietkau R and Sauer R: Malnutrition and the role of nutritional support for radiation therapy patients. Rec Adv Cancer Res 108: 205-226, 1988.
 
54) Rotman M and Torpie RJ: Supportice care in radiation oncology. In Principles and Practice of Radiation Oncology, (ed by Perez CA and Brady LW) , 2nd ed, JB Lippincott Company, Philadelphia, 1992, pp 1508-1516.
 
55) Valerio D, Overett L, Malcolm A, et al: Nutritional support for cancer patients receiving abdominal and pelvic radiotherapy: a randomized prospective clinical experiment of intravenous versus oral feeding. Surg Forum 29: 145-148, 1978.
PubMed
56) Pezner R and Archambeau JO: Critical evaluation of the role of nutritional support for radiation therapy patients. Cancer 55: 263-267, 1985.
PubMed
57) Solassol C, Joyeaux H and Dubois JB: Total parenteral nutrition (TPN) with complete nutritive mixtures: An artificial gut in cancer patients. Nutr Cancer 1: 13-18, 1979.
 
58) Kinsella TJ, Malcolm AW, Bothe A Jr, et al: Prospective study of nutritional support during Pelvic irradiation. Int J Radiat Oncol Biol Phys 7: 543-548, 1981.
PubMed
59) van Eys J, Wesley MN, Cangir A, et al: Safety of intravenous hyperalimentation in children with malignancies: a cooperative group trial. J Parenter Enteral Nutr 6: 291-294, 1982.
 
60) Ghavimi F, Shils ME, Scott BF, et al: Comparison of morbidity in children requiring abdominal radiation and chemotherapy, with and without total parenteral nutrition. J Pediatr lO1: 530-537, 1982.
 
61) Donaldson SS, Wesley MN, Ghavimi F, et al: Aprospective randomized clinical trial of total parenteral nutrition in children with cancer. Med Pediatr Oncol 10: 129-139, 1982.
 
62) Dewys WD, Begg C, Lavin PT, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69: 491-497, 1980.
PubMed
63) Lein S, Simes J and Blackburn GL: Total parenteral nutrition and cancer clinical trials. Cancer 58: 1378-1386, 1986.
 
64) American College of Physicians: Parenteral nutrition in patients receiving cancer chemotherapy. Ann Intern Med 110: 734-736, 1989.
PubMed
65) McGeer AJ, Detsky AS and O'Rourke K: Parenteral nutrition in cancer patients undergoing chemotherapy: A meta-analysis. Nutrition 6: 233-240, 1990.
 
66) Apelgren KN and Wilmore DW: Parenteral nutrition: is it oncologically logical? A response. J Clin Oncol 2: 539-541, 1984.
PubMed
67) Szeluga DJ, Stuart RK, Brookmeyer R, et al: Nutritional support of bone marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to an enteral feeding program. Cancer Res 47: 3309-3316, 1987.
 
68) Weisdorf SA, Lysne J, Wind D, et al: Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 43: 833-838, 1987.
PubMed
69) Bruera E and MacDonald RN: Nutrition in cancer patients: an update and review of our experience. J Pain Sympt Manag 3: 133-140, 1988.
 
70) Nelson KA, Walsh D and Sheehan FA: The cancer anorexia-cachexia syndrome. J Clin Oncol 12: 213-225, 1994.
PubMed
71) 恒籐 暁: がん悪液質症候群. 最新医学 52: 2419-2428, 1997.
 
72) Fainsinger RL and Gramlich LM: How often can we justify parenteral nutrition in terminally ill cancer patients? J Palliat Care 13: 48-51, 1997.
PubMed
73) Fainsinger RL and Bruera E: When to treat dehydration in a terminally ill patient? Support Care Cancer 5: 205-211, 1997.
 
74) Thom AK and Daly JM: Nutritional suport of the cancer patient. In Manual of Oncologic Therapeutics 1991/1992, (ed by Wittes RE) , JB Lippincott Co, Philadelphia, 1991, pp 356-370.
 
75) 佐藤忠直, 菱田 明: 栄養輸液製剤の投与基準. 癌患者の栄養管理, (漆崎一郎・編) , メディカルレビュー社, 東京, 1994, pp 230-235.
 
76) 吉田祥吾, 白水和雄: TPN管理中の代謝性アシドーシス. 医学のあゆみ 183: 617-620, 1997.
Medical*Online
77) 松本 宏, 西平哲郎: 悪性腫瘍と栄養. 最新内科学体系6, 代謝疾患1, 肥満症, 臨床栄養, (井村裕夫, 尾形悦郎, 高久史麿, 他・編) , 中山書店, 東京, 1995, pp 314-327.
 
78) Oriot D, Wood C, Gottesman R, et al: Severe lactic acidosis related to acute thiamine deficiency. J Parenter Enteral Nutr 15: 105-109, 1991.
PubMed
79) Velez RJ, Myers B and Guber MS: Severe acute metabolic acidosis (acute beriberi) : an avoidable complication of total parenteral nutrition. J Parenter Enteral Nutr 9: 216-219, 1985.
PubMed
80) McClain CJ, Baker H and Onstad GR: Biotin deficiency in an adult during home parenteral nutrition. JAMA 247: 3116-3117, 1982.
 
81) Hill GL: Nutritional assessment and intravenous nutritional support. In Mastery of Surgery, (ed by Baker RJ and Fischer JE) , Lippincott Williams&Wilkins, Philadelphia, 2001, pp 55-70.
 
82) 吉村一克, 望月英隆: グルタミン輸液. 医学のあゆみ 183: 732-736, 1997.
Medical*Online
83) Bode BP, Fischer C, Abcouwer S, et al: Glutamine and cancer cachexia. In Protein and amino acid metabolism in cancer cachexia, (ed by Pisters PWT and Brennan MF) , Springer-Verlag, Heidelberg, 1996, pp 139-170.
 
84) Ko TC, Beauchamp D, Townsend GM, et al: Glutamine is essential for epidermal growth factor-stimulated intestinal cell proliferation. Surgery 114: 147-154, 1993.
 
85) Scheltinga MR, Young LS, Benfe11, et al: Glutamine-enriched intravenous feedings attenuate extracellular fluid expansion after standard stress. Ann Surg 214: 385-395, 1991.
PubMed
86) Souba WW, Strebel FR, Bull JM, et al: Interorgan metabolism in the tumor-bearing rat. J Surg Res 44: 720-726, 1988.
 
87) Penn RL, Maca RD and Berg RD: Increased translocation of bacteria from the gastrointestinal tracts of tumor-bearing mice. Infect Immun 47: 793-798, 1985.
 
88) Lowe DL, Benfell K, Smith RJ, et al: Glutamine-enriched total parenteral nutrition is safe in normal humans. Surg Forum 40: 9-11, 1989.
 
89) Ziegler TR, Benfell K, Smith RJ, et al: Safety and metabolic effects of L-glutamine administration in humans. J parenter Enteral Nutr 14 (suppl) : 137 S-146 S, 1990.
 
90) Ziegler TR, Young LS, Benfell K, et al: Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med 116: 821-828, 1992.
PubMed
91) Schloerb PR and Amare M: Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double-blind study) . J Parenter Enteral Nutr 17: 407-413, 1993.
PubMed
92) Van der Hulst RR, van Kreel BK, von Meyerffeldt MF, et al: Glutamine and preservation of gut integrity. Lancet 341: 1363-1367, 1993.
 
93) Crosby LE, Bistrian BR, Ling PR, et al: Effects of branched chain amino acids-enriched total parenteral nutrition on amino acid utilization in rats bearing Yoshida sarcoma. Cancer Res 48: 2698-2702, 1988.
PubMed
94) Okada A, Mori S, Totsuka M, et al: Branched-chain amino acids metabolic support in surgical patients: a randomized, controlled trial in patients with subtotal or total gastrectomy in 16 Japanese institutions. J Parenter Enteral Nutr 12: 332-337, 1988.
PubMed
95) Hunter DC, Weintraub M, Blackburn GL, et al: Branched chain amino acids as the protein component of parenteral nutrition in cancer cachexia. Br J Surg 76: 149-153, 1989.
PubMed
96) Tayek JA, Bistran BR, Hehir DJ, et al: Improved protein kinetics and albumin synthesis by branched chain amino acids-enriched total parenteral nutrition in cancer cachexia: A prospective randomized crossover trial. Cancer 58: 147-157, 1986.
 
97) Cangiano C, Laviano A, Meguid MM, et al: Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst 88: 550-552, 1996.
PubMed
98) Ye SL, Istfan NW, Driscoll DF, et al: Tumor and host response to arginine and branched chain amino acids-enriched total parenteral nutrition. A study involving Walker 256 carcinosarcoma-bearing rats. Cancer 69: 261-270, 1992.
PubMed
99) Barbul A: Arginine: Biochemistry, physiology, and therapeutic implication. J Parenter Enteral Nutr 10: 227-238, 1986.
 
100) Cho-Chung YS, Clair T, Bodwin JS, et al: Arrest of mammary tumor growth in vivo by Larginine: Stimulation of NAD-dependent activation of adenylate cyclase. Biochem Biophys Res Commun 95: 1306-1313, 1980.
 
101) Reynolds JV, Thom AK, Zhang SM, et al: Arginine, protein malnutrition, and cancer. J Surg Res 45: 513-522, 1988.
 
102) Curtis EB, Krech R and Walsh TD: Common symptoms in patients with advanced cancer. J Palliat Care 7: 25-29, 1991.
 
103) Nelson KA, Walsh TD, Sheehan FG, et al: Assessment of upper gastrointestinal motility in the cancer-associated dyspepsia syndrome. J Palliat Care 9: 27-31, 1993.
PubMed
104) Nelson KA and Walsh TD: Metoclopramide in anorexia caused by cancer-associated dyspepsia. J Palliat Care 9: 14-18, 1993.
PubMed
105) Shivshanker K, Bennet RW and Haynie TP: Tumor-associated gastroparesis: Correction with metoclopramide. Am J Surg 145: 221-225, 1983.
 
106) Nelson K: Steroids and progestins. In Protein and amino acid metabolism in cancer cachexia, (ed by Pisters PWT and Brennan MF) , Springer-Verlag, Heidelberg, 1996, pp 241-270.
 
107) Lelli G, Angelelli B, Giambiasi ME, et al: The anabolic effect of high dose medroxyprogesterone acetate in oncology. Pharm Res Commun 15: 561-568, 1983.
 
108) Loprinizi CL, Wllison NM, Schaid DJ, et al: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82: 1127-1132, 1990.
 
109) Feliu J, Gonzalez-Baron M, Berrocal A, et al: Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebocontrolled study. Am J Clin Oncol 15: 436-440, 1992.
 
110) Tchekmedyian NS, Hickman M, Siau J, et al: Megestrol acetate in cancer anorexia and weight loss. Cancer 69: 1268-1274, 1992.
PubMed
111) Bruera E, Macmillan K, Kuehn N, et al: Acontrolled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66: 1279-1282, 1990.
 
112) Loprinzi CL, Michalak JC, Schaid DJ, et al: Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 11: 762-767, 1993.
PubMed
113) Simons Jp, Aaronson NK, Vansteenkiste JF, et al: Effects of medroxyprogesterone acetate on apPetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol 14: 1077-1084, 1996.
 
114) Downer S, Joel S, AIIbright A, et al: A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 67: 1102-1105, 1993.
PubMed
115) Niiranen A, Kajanti M, Tammilehto L, et al: The clinical effect of medroxyprogesterone (MPA) in elderly patients with lung cancer. Am J Clin Oncol 13: 113-116, 1990.
PubMed
116) Ettinger AB and Portenoy RK: The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage 3: 99-102, 1988.
 
117) Twycross R: The risks and benefits of corticosteroids in advanced cancer. Drug Safety 11: 163-178, 1994.
 
118) Hanks GW, Trueman T and Twycross RG: Corticosteroids in terminal cancer-a prospective analysis of current practice. Postgrad Med J 59: 702-706, 1983.
 
119) Moertel CG, Schutt AJ, Reitemeir RJ, et al: Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33: 1607-1609, 1974.
 
120) Willox JC, Corr J, Shaw J, et al: Prednisolone as an apPetite stimulantion patients with cancer. Br Med J 288: 27, 1984.
 
121) Popiela T, Lucchi R and Giongo F: Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 25: 1823-1829, 1989.
 
122) Della Cuna GR, Pellegrini A and Piazzi M: Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 25: 1817-1821, 1989.
 
123) Bruera E, Roca E, Cedaro L, et al: Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69: 751-754, 1985.
PubMed
124) Jiang ZM, He GZ, Zhang SY, et al: Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation. Ann Surg 210: 513-524, 1989.
PubMed
125) Byrne TA, Morrissery TB, Gatzen C, et al: Anabolic therapy with growth hormone accelerates protein gain in surgical patients requiring nutritional rehabilitation. Ann Surg 218: 400-418, 1993.
 
126) Mjaaland M, Unneberg K, Larsson J, et al: Growth hormone after abdominal surgery attenuated forearm glutamine, alanine, 3-methylhistidine, and total amino acid efflux in patients receiving total parenteral nutrition. Ann Surg 217: 413-422, 1993.
PubMed
127) Ziegler TR, Rombeau JL, Young LS, et al: Recombinant human growth hormone enhances the metabolic efficacy of parenteral nutrition: a double-blind, randomized controlled study. J Clin Endocrinol Metab 74: 865-873, 1992.
PubMed
128) Mulligan K, Grunfeld C, Hellerstein MK, et al: Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 77: 956-962, 1993.
PubMed
129) Wolf RF: Growth hormone/IGF-1. In Protein and amino acid metabolism in cancer cachexia, (ed by Pisters PWT and Brennan MF) , Springer-Verlag, Heidelberg, 1996, pp 201-212.
 
130) Wolf RF, Heslin MJ, Newman E, et al: Growth hormone and insulin combine to improve whole body and skeletal muscle protein kinetics. Surgery 112: 284-292, 1992.
PubMed
131) Wolf RF, Pearlstone DB, Newman E, et al: Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients. Ann Surg 216: 280-288 (discussion 288-290) , 1992.
 
132) Pisters PW, Cersosimo E, Rogatko A, et al: Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of insulin. Surgery 111: 301-310, 1992.
PubMed
133) Newman E, Heslin MJ, Wolf RF, et al: The effects of insulin on glucose and protein metabolism in the forearm of cancer patients. Surg Oncol 1: 257-267, 1992.
 
134) Heslin MJ, Newman E, Wolf RF, et al: Effects of systemic hyperinsulinemia in cancer patients. Cancer Res 52: 3845-3850, 1992.
 
135) Pearlstone DB, Wolf RF, Berman RS, et al: Effects of systemic insulin on protein kinetics in postoperative cancer patients. Ann Surg Oncol 1: 321-332, 1994.
 
P.1169 掲載の参考文献
1) Twycross R: Pain relief in advanced cancer. Churchill Livingstone, New York, 1994, pp 55-110.
 
2) 厚生労働省・日本医師会・監修: がん緩和ケアに関するマニュアル. 日本ホスピス・緩和ケア研究振興財団, さいたま市, 2002, pp 11-28.
 
3) 恒藤 暁: 最新緩和医療学. 最新医学社, 大阪, 1999, pp 47-74.
 
4) Cherny NI: The pharmacological management of cancer pain. Eur J Cancer 37 (Supp17) : S265-S 278, 2001.
 
5) Walsh D: Pharmacological management of cancer pain. Semin Oncol 27 (1) : 45-63, 2000.
PubMed
6) 日本緩和医療学会がん疼痛治療ガイドライン作成委員会: Evidence-Based Medicineに則ったがん疼痛治療ガイドライン. 真興交易, 2000, pp 38-91.
 
7) 淀川キリスト教病院ホスピス・編: 緩和ケアマニュアル. 改訂第4版, 最新医学社, 大阪, 2001, pp 31-74.
 
8) Farrar JT and Portenoy RK: Neuropathic cancer pain: the role of adjuvant analgesics. Oncology 15 (11) : 1435-1453, 2001.
PubMed
9) Mercadante S and Portenoy RK: Opioid poorly-responsive cancer pain. J Pain Symptom Manage 21 (4) : 338-354, 2001.
PubMed
10) Lucas LK and Lipman AG: Recent advances in pharmacotherapy for cancer pain management. Cancer Pract 10 (Suppl 1) : S14-S 20, 2002.
 
P.1181 掲載の参考文献
1) Foley KM: Pain syndromes in patients with cancer, International Symposium on Pain of Advanced Cancer; 1978; Venice. Vol 2, Advances in pain research and therapy, (ed by Bonica JJ and Ventafridda V) , Raven Press, New York, 1979, pp 59-75.
 
2) Daut RL and Cleeland CS: The prevalence and severity of pain in cancer. Cancer 50: 1913-1918, 1982.
PubMed
3) 西野 卓: がん性疼痛対策. 臨床腫瘍学, (有吉 寛, 西條長宏, 佐々木康綱, 他・編) , 第1版, 癌と化学療法社, 東京, 1996, pp 1176-1191.
 
4) World Health Organization: Cancer Pain Relief. WHO, Geneva, (武田文和 訳: がんの痛みからの開放. 金原出版, 東京, 1987) .
 
5) Cleary JF: Cancer pain management. Cancer Control 7: 120-1312000.
PubMed
6) Patt RB: Cancer pain. JB Lippincott, Philadelphia, 1993.
 
7) Ferrell BR, Rhiner M, Cohen MZ, et al: Pain as a metaphor for illness. Part I: Impact of cancer pain on family caregivers. Oncol Nurs Forum 18: 1303-1309, 1991.
 
8) Elliott K and Foley KM: Neurologic pain syndromes in patients with cancer. Neurol Clin 7: 333-360, 1989.
PubMed
9) Greenberg HS, Deck MD, Vikram B, et al: Metastasis to the base of the skull: clinical findings in 43 patients. Neurology 31: 530-537, 1981.
 
10) Foley KM: Overview of cancer pain and brachial and lumbosacral plexopathy. In: Management of cancer pain: syllabus of the postgraduate course, Memorial Sloan-Kettering Cancer Center, 1985 Nov 14-16. Memorial Sloan-Kettering Cancer Center, New York, 1985, pp 25-50.
 
11) Kanner R: Post-surgical pain syndromes. In: Management of cancer pain: syllabus of the postgraduate course, Memorial Sloan-Kettering Cancer Center, 1985 Nov 14-16. Memorial Sloan-Kettering Cancer Center, New York, 1985, pp 65-72.
 
12) Payne RC: Post-chemotherapy and post-radiation therapy pain syndromes. ln: Management of cancer pain: syllabus of the postgraduate course, Memorial Sloan-Kettering Cancer Center, 1985 Nov 14-16. Memorial Sloan-Kettering Cancer Center, New York, 1985, pp 73-93.
 
13) Bonica JJ: Treatment of cancer pain: current status and future need, In: Proceedings of the Fourth World Congress on Pain; Seattle, Washington, Aug 31-Sept 5, 1984, Vol 9, (ed by Fields HL, Dubner R and Cervero R) , Advances in pain research and therapy, Raven Press, New York, 1985, pp 589-616.
 
14) Cleeland CS, Cleeland LM, Dar R, et al: Factors influencing physician management of cancer pain. Cancer 58: 796-800, 1986.
PubMed
15) Ferrell BR, Cronin Nash C and Warfield C: The role of patient-controlled analgesia in the management of cancer pain. JPain Symptom Manage 7: 149-154, 1992.
 
16) Von Roenn JH, Cleeland CS, Gonin R, et al: Physician attitudes and practice in cancer pain management: a survey from the Eastern Cooperative Oncology Group. Ann Intern Med 119: 12-26, 1993.
 
17) Grossman SA, Sheidler VR, Swedeen K, et al: Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage 6: 53-57, 1991.
PubMed
18) Joranson DE, Cleeland CS, Weissman DE, et al: Opioids for chronic cancer and non-cancer pain: asurvey of state medical board members. Federation Bulletin. J Med Licensure Discipline 79: 15-49, 1992.
 
19) Shapiro RS: Legal bases for control of analgesic drugs. J Pain Symptom Manage 9: 153-159, 1994.
PubMed
20) Shapiro RS: Liability issues in the management of pain. J Pain Symptom Manage 9: 146-152, 1994.
 
21) Weissman DE, Joranson DE and Hopwood MB: Wisconsin physicians'knowledge and attitudes about opioid analgesic regulations. Wis Med J 90: 671-675, 1991.
PubMed
22) Marks RM and Sachar EJ: Undertreatment of medical inpatients with narcotic analgesics. Ann Intern Med 78: 173-181, 1973.
PubMed
23) Dar R, Beach CM, Barden PL, et al: Cancer pain in the marital system: astudy of patients and their spouses. J Pain Symptom Manage 7: 87-93, 1992.
 
24) Levin DN, Cleeland CS and Dar R: Public attitudes toward cancer pain. Cancer 56: 2337-2339, 1985.
PubMed
25) Ward SE, Goldberg N, Miller-McCauley V, et al: Patient-related barriers to management of cancer pain. Pain 52: 319-324, 1993.
PubMed
26) Cleeland CS: Measurement of pain by subjective report. In: Issues in pain measurement, Vol 12, Advances in pain research and therapy, (ed by Chapman CR and Loeser JD) , Raven Press, New York, 1989, pp 391-404.
 
27) Cleeland CS: Pain control: public and physicians'attitudes. In: Drug treatment of cancer pain in a drug-oriented society. Vol. 11. Advances in pain research and therapy, (ed by Hill CS Jr and Fields WS) , Raven Press, New York, 1989, pp 81-89.
 
28) Hodes RL: Cancer patients'needs and concerns when using narcotic analgesics. In: Drug treatment of cancer pain in a drugoriented society, Vol 11, Advances in pain research and therapy, (ed by Hill CS Jr and Fields WS) , Raven Press, New York, 1989, pp 91-99.
 
29) Joranson DE: Are health care reimbursement policies a barrier to acute and cancer pain management?Jpain Symptom Manage 9: 244-253, 1994.
 
30) Rimer B, Levy MH, Keintz MK, et al: Enhancing cancer pain control regimens through patient education. Patient Educ Couns 10: 267-277, 1987.
PubMed
31) Max MB: Improving outcomes of analgesic treatment: is education enough?Ann Intern Med 113: 885-889, 1990.
PubMed
32) Ferrell BR and Griffith H: Cost issues related to pain management. J Pain Symptom Manage 9: 221-234, 1994.
PubMed
33) Foley KM: The treatment of cancer pain. N Engl J Med 313: 84-95, 1985.
PubMed
34) 佐藤 智, 日下 潔: 癌性疼痛とPCA. ペインクリニック 21: 39-48, 2000.
 
35) Coyle N: Amodel of continuity of care. Educatiobal Booklet, (ed by American Society of Clinical Oncology) , Boston Corporation, Boston, 1986, pp 67-73.
 
36) 合田由紀子: 総合病院において在宅緩和ケアを行った症例. 麻酔科診療プラクティス, (高崎真弓, 弓削孟文, 稲田英一, 他・編) , 文光堂, 東京, 2001, pp 172-177.
 
P.1188 掲載の参考文献
1) 小島操子: 21世紀へ前進するがん看護の課題. 日本がん看護学会誌 14: 5, 2000.
 
2) Aguiera and Messick: 危機療法の理論と実際, (小松源助, 荒川義子・訳) , 川島書店, 東京, 2000.
 
3) 岡堂哲雄, 鈴木志津枝: 危機療法の心理と看護. 中央法規, 東京, 1987.
 
4) 佐藤禮子: 21世紀へ前進するがん看護の課題. 日本がん看護学会誌 13: 7, 1999.
 
5) 世界保健機関・編, (武田文和・訳) : 終末期の諸症状からの解放. 医学書院, 東京, 2000.
 
6) 説明と同意についての報告書: 日本医師会倫理懇談会. 日本医事新報, 1990.
 
7) 大場正巳, 遠藤恵美子, 稲吉光子編著: 新しいがん看護. ブレーン出版, 東京, 1999.
 
8) 的場元弘: がんの痛みとほかの痛みのちがい-わかるできるがんの症状マネージメント, (ターミナルケア編集委員会編) , 三輪書店, 東京, 1997.
 
9) 世界保健機関・編, (武田文和・訳) : がんの痛みからの解放とパリアティブ・ケア. 金原出版, 東京, 1993, pp 5-13.
 
10) 濱口恵子: 役に立つ痛みの評価とは-わかるできるがんの症状マネージメント, (ターミナルケア編集委員会・編) , 三輪書店, 東 京, 1997.
 
11) 日野原重明・総監修: がん看護マニュアル, 1改訂版. 5章がん患者のリハビリテーションと看護過程. 学研, 東京, 2001, p276.
 
12) 国立がんセンター中央病院看護部・編: がん看護看護診断と標準看護計画. 医学書院, 東京, 1998, p10.
 
13) 日野原重明・総監修: がん看護マニュアル, 1改訂版. 4章がん患者の治療と看護. 学研, 東京, 2001, p92.
 
14) 柄川 順, 山田達哉, 照井頒二・他: 放射線看護技術, 別巻4, IVターミナルケア. メジカルフレンド社, 東京, 1999.
 
15) 柄川 順, 山田達哉, 照井頒二・他: 放射線看護技術, 別巻4, V患者ケアと病歴管理A放射線の反応. メジカルフレンド社, 東京, 1999.
 
16) 西條長宏, 小島操子監修: がん治療の副作用と看護ケア, 第2版, Part3 1造血細胞移植の基礎知識. 先端医学社, 東京, 2000, pp 226-227.
 
17) 西條長宏・小島操子監修: がん治療の副作用と看護ケア, 第2版, Part3 2造血細胞移植に伴う看護. 先端医学社, 東京, 2000, p233.
 
18) 西條長宏・小島操子監修: がん治療の副作用と看護ケア, 第2版, Part3 2造血細胞移植に伴う看護. 先端医学社, 東京, 2000, p244.
 
19) 江向洋子: 国立がんセンター東病院のがん看護の現状と課題. 静岡アジア癌会議 1999記録集, pp 61-67.
 
P.1195 掲載の参考文献
1) Massie MJ and Holland JC: Overview of normal reactions and prevalence of psychiatric disorders. Handbook of psycho- oncology, (ed by Holland JC and Rowland JH) , 1st Ed, Oxford University Press, New York, 1990, pp 273-282. (河野博臣, 濃沼信夫, 神代尚芳・監訳: サイコオンコロジー(2) . 第1版, メディサイエンス社, 東京, 1993, pp 3-11.)
 
2) Kubler-Ross E: On death and dying. Macmillan, New York, 1969. (川口正吉・訳: 死ぬ瞬間. 読売新聞社, 東京, 1971.)
 
3) Okamura H, Uchitomi Y, Sasako M, et al: Guidelines for telling the truth to cancer patients. Jpn J Clin Oncol 28: 1-4, 1998.
PubMed
4) Saunders C: The moment of truth: Care of the dying person. Death and dying, (ed by Peasor L) , Case Western Reserve University Press, Cleveland, 1969, pp 49-78.
 
5) 内富庸介, 皆川英明, 岡村 仁・他: 終末期がん患者のコンサルテーション・リエゾン精神医学. 臨床精神医学 24: 149-159, 1995.
Medical*Online
6) Derogatis LR, Morrow GR, Fetting J, et al: The prevalence of psychiatric disorders among cancer patients. JAMA 249: 751-757, 1983.
PubMed
7) American Psychiatric Association: Diagnostic and statistical manual of mental disorders. fourth edition, American Psychiatric Press, Washington DC, 1994. (高橋三郎, 大野 裕, 染谷俊幸・訳: DSM-IV精神疾患の診断・統計マニュアル. 第1版, 医学書院, 東京, 1996, pp 329-336.)
 
8) Plumb MM and Holland JC: Comparative studies of psychological function in patients with advanced cancer-1. self-reported depressive symptoms. Psychosom Med 39: 264-276, 1977.
 
9) Chochinov HM, Wilson KG, Enns M, et al: Desire for death in the terminally ill. Am J Psychiat 152: 1185-1191, 1995.
PubMed
10) Akechi T, Okamura H, Yamawaki S, et al: Why do some cancer patients with depression desire an early death and others do not?Psychosomatics 42: 141-145, 2001.
 
11) Massie MJ and Holland JC: Psychotherapeutic Interventions. Handbook of psychooncology, (ed by Holland JC and Rowland JH) , 1st Ed, Oxford University Press, New York, 1990, pp 455-469. (河野博臣, 濃沼信夫, 神代尚芳・監訳: サイコ オンコロジー(2) . 第1版, メディサイエンス社, 東京, 1993, pp 165-178.)
 
12) Sheard T and Maguire P: The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer 80: 1770-1780, 1999.
 
13) Fukui S, Kugaya A, Okamura H, et al: Apsychosocial group intervention for Japanese women with primary breast carcinoma. Cancer 89: 1026-1036, 2000.
PubMed
14) Spiegel D, Morrow GR, Classen C, et al: Group psychotherapy for recently diagnosed breast cancer patients: amulticenter feasibility study. Psychooncology 8: 482-493, 1999.
 
15) 久賀谷亮, 内富庸介: 第3章 精神医学的アプローチ 2. 薬物療法. サイコオンコロジー がん医療における心の医学, (山脇成人・監修) , 第1版, 診療新社, 大阪, 1997, pp 188-196.
 
16) Minagawa H, Uchitomi Y, Yamawaki S, et al: Psychiatric morbidity in terminally ill cancer patients-a prospective study-. Cancer 78: 1131-1137, 1996.
PubMed
17) Weinrich S and Sarna L: Delirium in the older person with cancer. Cancer 74(Suppl) : 2079-2091, 1994.
PubMed
18) Morita T, Tei Y, Tsunoda J, et al: Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manage 22: 997-1006, 2001.
PubMed
19) Akechi T, Uchitomi Y, Okamura H, et al: Usage of haloperidol for delirium in cancer patients. Support Care Cancer 4: 390-392, 1996.
PubMed
20) Watson M, Haviland JS, Greer S, et al: Influence of psychological response on survival in breast cancer: apopulationbased cohort study. Lancet 354: 1331-1336, 1999.
PubMed
21) Maunsell E, Brisson J, Deshenes L, et al: Social support and survival among women with breast cancer. Cancer 76: 631-637, 1995.
 
22) Goodwin JS, Hunt WC, Key CR, et al: The effect of marital status on the stage, treatment, and survival of cancer patients. JAMA 258: 3125-3130, 1987.
PubMed
23) Temoshok L, Heller BW, Sagebiel RW, et al: The relationship of psychosocial factors to prognostic indicators in cutaneous malignant melanoma. J Psychosom Res 29: 139-153, 1985.
PubMed
24) Bleiker EM, Van Der Ploeg HM, Hendriks JH, et al: Personality factors and breast cancer development: aprospective longitudinal study. J Natl Cancer Inst 88: 1478-1482, 1996.
 
25) Levy SM, Herberman RB, Lippman M, et al: Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. J Clin Oncol 5: 348-353, 1987.
 
26) Chen CC, David AS, Nunnerley H, et al: Adverse life events and breast cancer: case-control study. BMJ 311: 1527-1530, 1995.
PubMed
27) Ginsberg A, Price S, Ingram D, et al: Life events and the risk of breast cancer: acase-control study. Eur J Cancer 32 A: 2049-2052, 1996.
 
28) Richardson JL, Shelton DR, Krailo M, et al: The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol 8: 356-364, 1990.
PubMed
29) Lyles JN, Burish TG, Krozely MG, et al: Efficacy of relaxation training and guided imagery in reducing the aversiveness of cancer chemotherapy. J Consult Clin Psychol 50: 509-524, 1982.
PubMed
30) Davis H 4th: Effects of biofeedback and cognitive therapy on stress in patients with breast cancer. Psychol Rep 59: 967-974, 1986.
PubMed
31) Linn MW, Linn BS and Harris R: Effect of counse1ing for late-stage cancer patients. Cancer 49: 1048-1055, 1982.
 
32) Grossarth-Maticek R, Schmidt P, Vetter H, et al: Psychotherapy research in oncology. Health care and human behavior (ed by Steptoe A and Mathew A) , Academic Press, London, 1984, pp 325-341.
 
33) Spiegel D, Bloom JR, Kraemer HC, et al: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 14: 888-891, 1989.
 
34) Fawzy FI, Fawzy NW, Hyun CS, et al: Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival years later. Arch Gen Psychiatry 50: 681-689, 1993.
PubMed
35) Goodwin PJ, Leszcz M, Ennis M, et al: The effect of group Psychosocial support on survival in metastatic breast cancer. N Engl J Med 345: 1719-1726, 2001.
PubMed
P.1209 掲載の参考文献
1) Mukaiyama T: Cancer palliative medicine-Turning point in palliative oncology. Jpn J Cancer Chemother 24: 776-784, 1997.
 
2) Foley KM: Controversies in cancer pain. Cancer 63: 2257-2265, 1989.
PubMed
3) Ventafridda V: Continuing care: a major issue in cancer pain management. Pain 36: 137-143, 1989.
 
4) Brescia FJ, Alder D, Gray G, et al: Hospitalization advanced cancer patients: aprofile. J pain Symptom Manage 5: 221-227, 1990.
 
5) Schipper H: Measuring the quality of cancer patients: The functional index-cancer, development and validation. J Clin Oncol 2: 472-487, 1984.
 
6) WHO: Cancer Pain Relief. WHO, Geneva, 1986, p 16-22.
 
7) Ground S, Zech D, Schug SA, et al: Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 6: 411-422, 1991.
 
8) Zech DFJ, Ground S, Lynch J, et al: Validation of World Health Organization guidelines for pain relief: a 10 year prospective study. Pain 63: 65-76, 1995.
 
9) Serafini AN, Houston SJ, Resche I, et al: Palliation of pain associated with metastatic bone cancer using saranium-153 lexidronam: adouble-blind placebo-controlled clinical trial. J Clin Oncol 16: 1574-1581, 1998.
 
10) Bloomfield DJ: Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers?an evidence-based review. J Clin Oncol 16: 1218-1225, 1998.
PubMed
11) Kern KA and Norton JA: Cancer cachexia. JPEN 12: 286-298, 1988.
PubMed
12) Morishita R, Sugimoto T, Aoki M, et al: ln vivo transfection of cis element"decoy"against nucler factor-κBbinding site prevents myocardial infection. Nat Med 3: 894-899, 1997.
 
13) Mantovani G, Maccio A, Esu S, et al: Medroxyprogesterone acetate reduce the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 33: 602-607, 1997.
 
14) Morita T, Tsunoda J, Inoue S, et al: Prediction of survival of terminally ill cancer patients-a prospective study-. JPn J Cancer Chemother 25: 1203-1211, 1998.
 
P.1221 掲載の参考文献
1) World Health Organization: Constitution in basic documents. World Health Organization, Geneva, 1948.
 
2) 第14回厚生科学審議会研究企画部会議事録, 1999. 4.
 
3) Shimozuma K: Quality of life assessment. Breast Cancer 9: 100-106, 2002.
PubMed
4) Litwin MS, Lubeck DP, Henning JM, et al: Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 159: 1988-1992, 1998.
PubMed
5) 臨床のためのQOL評価ハンドブック. 池上直己, 福原俊一, 下妻晃二郎, 池田俊也・編, 医学書院, 東京, 2001.
 
6) 鎌原雅彦, 宮下一博, 大野木裕明・他, 編著: 心理学マニュアル-質問紙法. 北大路書房, 京都, 1998.
 
7) 市川伸一・編著: 心理測定法への招待-測定からみた心理学入門. サイエンス社, 東京, 1999.
 
8) EuroQol Group: EuroQol; Anew facility for the measurement of health-related quality of life. Health Policy 16: 199-208, 1990.
 
9) Torrance GW, Furlong W, Feeny D, et al: Multi-attribute preference functions; Health Utilities Index. Pharmacoeconomics 7(6) : 503-520, 1995.
PubMed
10) Tsuchiya A, Ikeda S, Ikegami N, et al: Estimating an EQ-5 D population value set: the case of Japan. Health Econ 11(4) : 341-353, 2002.
 
11) Ware JE and Sherbourne C: The MOS 36-Item Short-Form Health Survey(SF-36) 1. Conceptual framework and item selection. Med Care 30: 473-483, 1992.
PubMed
12) Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQC30: A quality-of-life instrument of use in international clinical trials in oncology. J Natl Cancer Inst 85(5) : 365-376, 1993.
 
13) Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale; Development and validation of the general measure. J Clin Oncol 11(3) : 570-579, 1993.
PubMed
14) Shimozuma K, Katsumata N, Ohashi Y, et al: Impact of surgical adjuvant chemotherapy on quality of life(QOL) of patients with breast cancer(BC) -A phase III randomized trial comparing UFT(Uracil/Tegafur) with CMF in high-risk node negative patients. Proc ASCO 18: 579 a, 1999.
 
15) Shimozuma K, Katsumata N, Ohashi Y, et al: Impact of surgical adjuvant chemotherapy on quality of life(QOL) of patients with breast cancer(BC) for the first year of treatment-A phase III randomized trial comparing UFT(Uracil/Tegafur) with CMF in high-risk node negative patients. Proc ASCO 19: 644 a, 2000.
 
16) Shimozuma K, Ohashi Y, Yoshimura K, et al: Reliability and validity of the Japanese version of the Functional Assessment of Cancer Therapy-Breast(FACT-B) quality-of-life instrument; Women's Health Outcome Study(WHOS) -01. Qual Life Res 9(3) : 287, 2000.
 
17) Shimozuma K, Katsumata N, Ohashi Y, et al: Reliability and validity of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module(EORTC QLQ-BR 23) for Japanese breast cancer(BC) patients in a phase III randomized trial(NSAS-BC O1) comparing UFT(Uracil/Tegafur) with CMF. Qual Life Res 9(9) : 1067, 2000.
 
18) Shimozuma K, Katsumata N, Ohashi Y, et al: Impact of surgical adjuvant chemotherapy on quality of life(QOL) of patients with breast cancer(BC) for the second year of treatment-A phase III randomized trial comparing UFT(Uracil/Tegafur) with CMF in high-risk node-negative patients(NSAS-BC O1) . Proc ASCO 20: 401 a, 2001.
 
19) 江口研二, 栗原 稔, 下妻晃二郎・他: がん薬物療法におけるQOL調査票. 日癌治療会誌 28(8) : 1140-1144, 1993.
 
20) Kurihara M, Shimizu H, Tsuboi K, et al: Development of quality of life questionnaire in Japan: Quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 8: 355-363, 1999.
PubMed
21) Matsumoto T, Ohashi Y, Morita S, et al: The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD) : validity and reliability in Japanese patients with advanced non-small-cell lung cancer. Qual Life Res 11(5) : 483-493, 2002.
PubMed
22) Shimozuma K, Sonoo H, Ichihara K, et al: Analysis of factors associated with quality of life in breast cancer patients after surgery. Breast Cancer 1(2) : 123-129, 1994.
 
23) Shimozuma K, Sonoo H, Ichihara K, et al: The impacts of breast conserving treatment and mastectomy on the quality of life in early-stage breast cancer patients. Breast Cancer 2(1) : 35-43, 1995.
 
24) Shimozuma K, Sonoo H and Ichihara K: Medical economics and quality of life: Analysis of factors that influence the perception of medical cost by post-surgical breast cancer patients. Breast Cancer 2(2) : 143-153, 1995.
 
25) Shimozuma K, Sonoo H and Ichihara K: Analysis of the factors influencing the quality of life of patients with advanced or recurrent breast cancer. Surg Today 25: 874-882, 1995.
PubMed
26) Shimozuma K, Sonoo H, Ichihara K, et al: The prognostic value of quality-of-life scores: Preliminary results of an analysis of patients with breast cancer. Surg Today 30(3) : 255-261, 2000.
PubMed
27) 日本乳癌学会・編: 乳癌患者のQOL評価研究のためのガイドライン(Version 1. 0) . 2002(http://www. jbcs. gr. jp/QOL_Ver1/QOL. html)
 
28) Sprangers MA, Groenvold M, Arraras JI, et al: The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-ountry field study. J Clin Oncol 14(10) : 2756-2768, 1996.
 
29) Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC 13: amodular supplement to the EORTC Core Quality of Life Questionnaire(QLQ-C 30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30 A(5) : 635-642, 1994.
 
30) Kobayashi K, Takeda F, Teramukai S, et al: A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C 30(EORTC QLQ-C 30) for Japanese with lung cancer. Eur J Cancer 34(6) : 810-815, 1998.
 
31) Shimozuma K, Katsumata N, Ohashi Y, et al: Reliability and validity of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module(EORTC QLQ-BR 23) for Japanese breast cancer(BC) patients in a phase III randomized trial(NSAS-BC O1) comparing UFT(Uracil/Tegafur) with CMF. Qual Life Res 9(9) : 1067, 2000.
 
32) Vickery CW, Blazeby JM, Conroy T, et al: Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer 37(8) : 966-971, 2001.
PubMed
33) 福原俊一, 黒川 清: SF-36日本語版マニュアル(Version 1. 2) . (財) パブリックヘルスリサーチセンター, 東京, 2001.
 
34) Staquet MJ, Hays RD, and Fayers PM: Quality of Life Assessment in Clinical Trials-Methods and Practice. Oxford University Press, 1998, pp 227-247.
 
35) Shimozuma K, Okamoto T, Katsumata N, et al: Systematic overview of quality of life studies for breast cancer. Breast Cancer 9(3) : 196-202, 2002.
PubMed
36) Okamoto T, Shimozuma K, Katsumata N, et al: Measuring quality of life in patients with breast cancer: Asystematic review of reliable and valid instruments available in Japan. Breast Cancer(in press)
 
37) Watanabe T: Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral UFT(uracil/ tegafur) versus six-cycle CMF(cyclophosphamide/methotrexate/5-fluorouracil) in high-risk node-negative breast cancer patients. JPn J Clin Oncol 28(1) : 77-80, 1998.
PubMed
38) Fallowfield LJ, Leaity SK, Howell A, et al: Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55(2) : 189-199, 1999.
PubMed
39) Day R, Ganz PA, Costantino JP, et al: Health-related quality of life and tamoxifen in breast cancer prevention: areport from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17(9) : 2659-2669, 1999.
 
40) Day R, Ganz PA and Costantino JP: Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention(P-1) Randomized Study. J Natl Cancer Inst 7: 93(21) : 1615-1623, 2001.
PubMed
41) Fallowfield LJ and Cella D: Assessing the quality of life(QOL) of postmenopausal(PM) women randomized into the ATAC (‘Arimidex', tamoxifen, alone or in combination) adjuvant breast cancer(BC) trial. Proc ASCO No. 159, 2002.
 
42) Moinpour CM, Lyons B, Grevstad PK, et al: Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res 11(2) : 115-126, 2002.
 
43) Kosty MP, Fleishman SB, Herndon JE 2nd, et al: Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: arandomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 12(6) : 1113-1120, 19s94.
 
44) Crino L, Scagliotti GV, Ricci S, et al: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: Arandomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17(11) : 3522-3530, 1999.
 
45) The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell Iung cancer. J Natl Cancer Inst 6: 91(1) : 66-72, 1999.
 
46) Terwee CB, Dekker FW, Mourits MP, et al: Interpretation and validity of changes in scores on the Graves'ophthalmopathy quality of life questionnaire(GO-QOL) after different treatments. Clin Endocrinol(Oxf) 54(3) : 391-398, 2001.
PubMed
47) Detmar SB and Aaronson NK: Quality of life assessment in daily clinical oncology practice: afeasibility study. Eur J Cancer 34(8) : 1181-1186, 1998.
 
48) Revicki DA and Cella DF: Health status assessment for the twenty-first century: item response theory, item banking and computer adaptive testing. Qual Life Res 6: 595-600, 1997.
PubMed
49) Ware JE, Bjorner JB and Kosinski M: Practical implications of item response theory and computerized adaptive testing: Abrief summary of ongoing studies of widely used headache impact scales. Med Care 38(9 suppl II) : II-78-II-82, 2000.
 
50) Schwartz C and Sprangers MAG: Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med 48: 1531-1548, 1999.
 
51) Sprangers MAG and Schwartz C: Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 48: 1507-1515, 1999.
 

書評

最近チェックした商品履歴

Loading...